<SEC-DOCUMENT>0001829126-25-010285.txt : 20251223
<SEC-HEADER>0001829126-25-010285.hdr.sgml : 20251223
<ACCEPTANCE-DATETIME>20251223170350
ACCESSION NUMBER:		0001829126-25-010285
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		22
FILED AS OF DATE:		20251223
DATE AS OF CHANGE:		20251223

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEONC TECHNOLOGIES HOLDINGS, INC.
		CENTRAL INDEX KEY:			0001979414
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				921954864
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-287875
		FILM NUMBER:		251601566

	BUSINESS ADDRESS:	
		STREET 1:		23975 PARK SORRENTO
		STREET 2:		SUITE 205
		CITY:			CALABASAS
		STATE:			CA
		ZIP:			91302
		BUSINESS PHONE:		310 663 7831

	MAIL ADDRESS:	
		STREET 1:		23975 PARK SORRENTO
		STREET 2:		SUITE 205
		CITY:			CALABASAS
		STATE:			CA
		ZIP:			91302
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>neonctechnologies_424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML>
<HEAD>
  <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: red">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>Filed Pursuant to Rule 4<FONT STYLE="text-transform: uppercase">24(b)(5)</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>Registration No<FONT STYLE="text-transform: uppercase">. 333-287875</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: red"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: red"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: Black"><B>PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: red"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>111,732&#160;Shares</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>NeOnc Technologies Holdings, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus relates to the offer and sale from time to time by the selling stockholders identified herein of up to 111,732 of our shares (the &#8220;Shares&#8221;) of common stock, par value $0.0001 (&#8220;common stock&#8221;) of NeOnc Technologies Holdings, Inc, a Delaware corporation (the &#8220;Company&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 1, 2025, the Company entered into a securities purchase agreement with the selling stockholder. See &#8220;<I>Description of Private Placement</I>&#8221;, and the section titled &#8220;<I>Selling Stockholders</I>&#8221; for additional information regarding the Selling Stockholder. For more information on possible methods of offer and sale by the Selling Stockholder, please see the section entitled &#8220;<I>Plan of Distribution</I>&#8221; beginning on page&#160;111 of this prospectus. We will bear all fees and expenses incident to our obligation to register the offer and sale of the shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock is listed on The Nasdaq Global Market under the symbol &#8220;NTHI&#8221;. On December 9, 2025, the last reported sale price of our common stock on The Nasdaq Global Market was $8.96 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>We are an &#8220;emerging growth company&#8221; and a &#8220;smaller reporting company&#8221; as defined under the federal securities laws and, as such, have elected to comply with certain reduced public company reporting requirements for this prospectus and may elect to do so in future filings. See &#8220;<I>Prospectus Summary&#8212;Implications of Being an Emerging Growth Company and a Smaller Reporting Company</I>.&#8221;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Investing in our common stock involves a high degree of risk. See the &#8220;<I>Risk Factors</I>&#8221; section beginning on page&#160;6 of this prospectus for the risks and uncertainties you should consider before investing in our common stock.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Prospectus dated December&#160;23, 2025</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT ID="toc"></FONT>Table of Contents</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; width: 90%; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_001">ABOUT THIS PROSPECTUS</A></FONT></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: center; width: 9%">ii</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_002">PROSPECTUS SUMMARY</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: center">1</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_003">SUMMARY FINANCIAL AND OTHER DATA</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: center">4</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_004">RISK FACTORS</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: center">6</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_005">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: center">7</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_006">MARKET AND INDUSTRY DATA</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: center">9</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_007">TRADEMARKS, SERVICE MARKS AND TRADENAMES</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: center">10</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_008">USE OF PROCEEDS</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: center">11</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_009">DIVIDEND POLICY</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: center">12</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_010">CAPITALIZATION</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: center">13</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_011">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: center">14</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_012">BUSINESS</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: center">28</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_013">MANAGEMENT</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: center">80</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#a_014">EXECUTIVE AND DIRECTOR COMPENSATION</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: center">87</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><A HREF="#a_015">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</A></TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: center">92</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><A HREF="#a_016"><FONT STYLE="font-family: Times New Roman, Times, Serif">CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS</FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: center">94</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><A HREF="#a_017"><FONT STYLE="font-family: Times New Roman, Times, Serif">DESCRIPTION OF SECURITIES</FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: center">99</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><A HREF="#a_018"><FONT STYLE="font-family: Times New Roman, Times, Serif">SHARES ELIGIBLE FOR FUTURE SALE</FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: center">103</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><A HREF="#a_019"><FONT STYLE="font-family: Times New Roman, Times, Serif">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS</FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: center">105</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><A HREF="#a_020">DESCRIPTION OF PRIVATE PLACEMENT</A></TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: center">109</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><A HREF="#a_021">SELLING STOCKHOLDER</A></TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: center">110</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><A HREF="#a_022"><FONT STYLE="font-family: Times New Roman, Times, Serif">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: center">111</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><A HREF="#a_023"><FONT STYLE="font-family: Times New Roman, Times, Serif">LEGAL MATTERS</FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: center">113</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><A HREF="#a_024"><FONT STYLE="font-family: Times New Roman, Times, Serif">EXPERTS</FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: center">113</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><A HREF="#a_025"><FONT STYLE="font-family: Times New Roman, Times, Serif">WHERE YOU CAN FIND ADDITIONAL INFORMATION</FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: center">113</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><A HREF="#a_026"><FONT STYLE="font-family: Times New Roman, Times, Serif">INDEX TO FINANCIAL STATEMENTS</FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: center">F-1</TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>You should rely only on the information contained in this prospectus or contained in any free writing prospectus filed with the Securities and Exchange Commission. Neither we nor the Selling</B> <B>Stockholder have authorized anyone to provide any information different from, or in addition to, the information contained in this prospectus and in any free writing prospectuses we have prepared or that have been prepared on our behalf or to which we have referred you. Neither we nor the Selling Stockholder take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. The Selling Stockholder is offering to sell, and seeking offers to buy, shares of their common stock only under the circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of its date, regardless of the time of delivery of this prospectus or of any sale of our common stock. Our business, financial condition, results of operations and prospects may have changed since such date.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><B>For investors outside the United States: Neither we nor the Selling Stockholder have done anything that would permit the use of or possession or distribution of this prospectus or any related free writing prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of our common stock by the Selling Stockholder and the distribution of this prospectus outside the United States.</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="text-decoration: underline"><FONT ID="a_001"></FONT>ABOUT THIS PROSPECTUS</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">This prospectus relates to the offer and sale by the Selling Stockholder from time to time of 111,732 of common stock. We are not selling any shares of common stock under this prospectus, and we will not receive any proceeds from the sale of shares of common stock offered hereby by the Selling Stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">We may also file a prospectus supplement or post-effective amendment to the registration statement of which this prospectus forms a part that may contain material information relating to this offering. The prospectus supplement or post-effective amendment may also add, update or change information contained in this prospectus. If there is any inconsistency between the information in this prospectus and the applicable prospectus supplement or post-effective amendment, you should rely on the prospectus supplement or post-effective amendment, as applicable. Before purchasing any securities, you should carefully read this prospectus, any post-effective amendment, and any applicable prospectus supplement, together with the additional information described under the headings &#8220;<I>Where You Can Find More Information</I>.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Neither we nor the Selling Stockholder have authorized anyone to provide you with any information or to make any representations other than those contained, or incorporated by reference, in this prospectus, any post-effective amendment, or any applicable prospectus supplement prepared by or on behalf of us or to which we have referred you. We and the Selling Stockholder take no responsibility for and can provide no assurance as to the reliability of any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. You should not assume that the information contained in this prospectus or any applicable prospectus supplement is accurate on any date subsequent to the date set forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus or any applicable prospectus supplement is delivered, or securities are sold, on a later date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed or will be filed as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described under &#8220;<I>Where You Can Find Additional Information</I>.&#8221;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<DIV STYLE="border: Black 1pt solid; padding: 5pt; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="text-decoration: underline"><FONT ID="a_002"></FONT>PROSPECTUS SUMMARY</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>This summary highlights certain significant aspects of our business and is a summary of information contained elsewhere in this prospectus. This summary is not complete and may not contain all the information you should consider before investing in our common stock. You should read the entire prospectus carefully, including &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; &#8220;Business&#8221; and our consolidated financial statements and related notes thereto included in this prospectus, before making an investment decision.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Unless otherwise indicated, all share and per share information in this prospectus has been retroactively restated to give effect to a 1.222 for-1 forward split of our outstanding shares of common stock in April 2023 and the subsequent issuance of 10,500,000 shares of our common stock to shareholders of NeOnc Technologies, Inc. in April 2023 in a share exchange.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Unless the context otherwise requires, the terms &#8220;NeOnc&#8221;, &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221; and &#8220;our&#8221; refer to NeOnc Technologies Holdings, Inc., a Delaware corporation, and its wholly-owned subsidiary NeOnc Technologies, Inc., and &#8220;this prospectus&#8221; refers to the offering contemplated this prospectus.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our company (f/k/a NAS-ONC, Inc.) was formed in 2008, devoted to developing new drugs with new delivery modes. As a clinical-stage biopharmaceutical company, we have focused on establishing treatments for intracranial malignancies, i.e., aggressive cancers located in the brain. These cancer types include primary brain cancers, such as glioblastoma, and secondary brain cancers, that have arrived through metastatic spread from other cancers throughout the body, such as melanoma or breast and lung cancer. Brain-localized malignancies are particularly difficult to treat because the blood-brain barrier prevents efficient entry of most pharmacotherapeutic agents into the brain. As a result, these patients are faced with poor prognoses and shortened average life expectancy. NeOnc is developing novel drug delivery methods to be used in combination with novel drug candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">NeOnc has two lead products in development: NEO100 and NEO212. NEO100 is a purified form of perillyl acid (&#8220;POH&#8221;) which is administered to brain cancer patients via intranasal delivery. Ongoing activities for intranasal delivery of NEO100:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have completed human testing in a Phase I clinical trial and are currently conducting a Phase IIa trial with recurrent malignant glioma (Grade IV, IDH1 mutant and Grade III Astrocytoma, IDH1 mutant) patients.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A similar Phase IIa trial of intranasal NEO100 (NEO 100-02) for patients with malignant skull-based meningioma is also ongoing. Meningiomas are slow-growing tumors originating in the meninges, the membranous layers surrounding the brain and spinal cord. We initiated this because these patients lack effective treatment options. These tumors are notoriously difficult to access, and conventional methods like surgery often lead to significant neurological deficits. Additionally, radiation therapy has shown limited effectiveness. The trial was officially launched in July 2023. As NEO100 uses the same treatment platform as the malignant gliomas, we bypassed the Phase I trial and received FDA approval for a Phase II trial within just 30 days.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Separate from this single-drug application, NEO100 is further being investigated as a drug delivery vehicle, where the results of NeOnc&#8217;s preclinical studies suggest evidence that the combination of NEO100 with other drugs may enable a patient&#8217;s improved brain tumor delivery via the intranasal route. Intranasal NEO100, mixed with levodopa (L-DOPA), is in the planning stages for a clinical trial in patients with Parkinson&#8217;s disease (PD). NeOnc&#8217;s laboratory experiments showed that intranasal NEO100 mixed with levodopa was able to reverse PD symptoms in mice. A Phase I clinical trial is planned to study the impact on human patients.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P> </DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<DIV STYLE="border: Black 1pt solid; padding: 5pt; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our initial application for the Phase I/IIa trial for NEO 100 focused on an enrollment population with recurrent glioblastoma. Based on our Phase I results, NEO 100 showed more promise in patients with IDH1,2 mutant Grade IV astrocytomas. However, this patient population represented less than 5-10 percent of all patients with recurrent glioblastoma. As we planned for a total of 31 patients for Phase IIa in our initial analysis, enrollment of recurrent Grade IV, IDH1,2 mutants was limited due to the fact that only 5-10 percent of Grade IV astrocytomas have IDH1,2 mutations. Independent biostatistical review of clinical progression patterns of recurrent IDH1,2 mutated Grade III astrocytomas compared to recurrent IDH1,2 mutated Grade IV astrocytomas revealed that these two tumors have the same prognosis. As a result, in June 2023 we requested that the FDA not object to the inclusion of patients with recurrent Grade III IDH1,2 mutant astrocytomas in the Phase IIa trial. The FDA did not object and, as a result, the population of patients available to be enrolled is now much larger. Because the prognosis of recurrent Grade III IDH1,2 mutants is similar to recurrent IDH1,2 Grade IV astrocytomas, the number of patients needed to be enrolled in the Phase IIa trial to assess the clinical efficacy of NEO100 in the population of high grade astrocytomas did not change. The expanded patient population means that there are a significant number of additional patients that can be targeted for potential enrollment in the Phase IIa study; in an initial review, we have identified approximately 80 grade III IDH1,2 mutation-positive candidates. Patients with residual measurable disease are now followed via MRI scans to determine if there is progression, (recurrent disease), making them eligible for enrollment. We believe this targeted enrollment of both Grade III and IV IDH1,2 mutants may significantly expedite our trial process and we project that the readout for our Phase II studies with respect to NEO100 could now be feasibly delivered by the end of 2024, advancing our original timeline by a full year from 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our second lead product, NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol, has completed preclinical testing and has received investigational new drug (IND) approval from the United States Food and Drug Administration (FDA), i.e., it has been authorized to proceed to clinical testing in cancer patients. We have designed a Phase I/II trial for oral NEO212, which began in the fourth quarter of 2023. In this trial, NEO212 will be administered orally to patients with primary brain tumors (i.e., malignant gliomas) and secondary brain tumors (i.e., brain metastases derived from peripheral tumors, such as tumors of the lung, breast, skin/melanoma, etc.). Furthermore, NEO212 is undergoing development towards intranasal application specifically for patients with uncontrolled brain metastases derived from peripheral tumors (lung, breast, skin, etc.), but has not yet been studied in human patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently, none of our product candidates have been approved for sale in the United States or elsewhere. We have no commercial products nor do we have a sales or marketing infrastructure. In order to market and sell our products we must conduct clinical trials on patients and obtain regulatory approvals from appropriate regulatory agencies, like the FDA in the United States, and similar organizations elsewhere in the world.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">We have not generated any revenue from product sales and from January 1, 2023 to September 30, 2025 have only generated revenue of $39,990. We do not anticipate generating significant revenues for the foreseeable future. We had net loss of $11,898,464 and $14,921,065 for the years ended December 31, 2024 and 2023, respectively. At December 31, 2024, we had an accumulated deficit of $50,608,445. Our net loss was $46,622,106 and $9,645,482 for the nine months ended September&#160;30, 2025 and 2024, respectively. We had an accumulated deficit of $97,230,551 at September&#160;30, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Implications of Being an Emerging Growth Company</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We qualify as an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). As an emerging growth company, we are eligible to take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies and may elect to take advantage of other exemptions from reporting requirements in our future filings with the Securities Exchange Commission (&#8220;SEC&#8221;). In particular, in this prospectus, these exemptions include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">presenting only two years of audited consolidated financial statements and only two years of related selected financial data and Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations disclosure in our registration statement of which this prospectus forms a part;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P> </DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<DIV STYLE="border: Black 1pt solid; padding: 5pt; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced disclosure about our executive compensation arrangements;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">exemption from the requirements to hold non-binding advisory votes on executive compensation (&#8220;Say on Pay&#8221;);</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">extended transition periods for complying with new or revised accounting standards;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">exemption from the auditor attestation requirement in the assessment of our internal controls over financial reporting pursuant to Section&#160;404(b) of the Sarbanes-Oxley Act of 2002 (the &#8220;Sarbanes-Oxley Act&#8221;); and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the auditor not being required to comply with the requirement in Public Company Accounting Oversight Board Auditing Standard 3101, <I>The Auditor&#8217;s Report on an Audit of Financial Statements When the Auditor Expresses an Unqualified Opinion</I>, to communicate critical audit matters in the auditor&#8217;s report.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may take advantage of these exemptions up until the last day of the fiscal year following the fifth anniversary our direct listing on Nasdaq or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company if we have more than $1.235 billion in annual revenue, we have more than $700 million in market value of our stock held by non-affiliates (and we have been a public company for at least 12 months and have filed one annual report on Form&#160;10-K) or we issue more than $1 billion of non-convertible debt securities over a three-year period. We may choose to take advantage of some, but not all, of the available exemptions. We have taken advantage of certain reduced reporting obligations in this prospectus. Further, pursuant to Section&#160;107 of the JOBS Act, as an emerging growth company, we have elected to use the extended transition period for complying with new or revised accounting standards until those standards would otherwise apply to private companies. Accordingly, the information contained herein may be different than the information you receive from other public companies in which you hold stock, and our consolidated financial statements may not be comparable to the consolidated financial statements of issuers who are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies. See &#8220;<I>Risk Factors-Risks Related to Ownership or Our Common Stock</I>&#8221; which describes that we are an emerging growth company, and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make our common stock less attractive to investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate Information</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">NeOnc Technologies, Inc. was incorporated in Delaware in 2008 as NAS-ONC, Inc. In April&#160;2023, shareholders of NeOnc Technologies, Inc. completed a share exchange (the &#8220;Share Exchange&#8221;) with NeOnc Technologies Holdings, Inc. pursuant to which all shareholders of NeOnc Technologies, Inc. became shareholders of NeOnc Technologies Holdings, Inc. and NeOnc Technologies, Inc. became a wholly-owned subsidiary of NeOnc Technologies Holdings, Inc. Our executive offices are located at 23975 Park Sorrento, Suite 205, Calabasas, CA 91302 and our telephone number is (310) 633-7831. Our corporate website is www.neonctech.com. Information appearing on our corporate website is not incorporated as part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P> </DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<DIV STYLE="border: Black 1pt solid; padding: 5pt; width: 98%">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><FONT STYLE="text-decoration: underline"><FONT ID="a_003"></FONT>Summary Financial Data</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <I>The summary financial data set forth below should be read together with our financial statements and the related notes to those statements, as well as the &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; section of this prospectus. The consolidated statements of operations data for the years ended December 31, 2024 and 2023, and the consolidated balance sheet data as of December&#160;31, 2024, have been derived from our audited financial statements included elsewhere in this prospectus. The consolidated statements of operations data for the nine months ended September&#160;30, 2025 and 2024 (unaudited) and the consolidated balance sheet data as of September&#160;30, 2025 (unaudited), have been derived from our interim financial statements included elsewhere in this prospectus. The unaudited interim financial statements were prepared on a basis consistent with our audited financial statements and include in management&#8217;s opinion, all adjustments, consisting of normal recurring adjustments, that we consider necessary for a fair presentation of the financial information set forth in those statements.</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Consolidated Statements of Operations Data</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; vertical-align: top; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">For the<BR> Nine Months Ended<BR> September&#160;30,</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center; font-weight: bold; vertical-align: bottom">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Year ended<BR> December&#160;31,</B></P></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center; vertical-align: bottom">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2024</B></P></TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; vertical-align: top">Revenues:</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in; width: 52%; vertical-align: top">Revenue</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">39,990</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">63,000</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">83,000</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">70,462</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Operating Expenses:</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Research and development</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">2,390,592</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,965,726</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">3,045,239</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,534,114</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Legal and professional</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,754,287</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,652,141</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">2,000,623</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,907,687</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">General and administrative</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">2,736,732</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">973,923</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,638,410</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,488,557</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top">Share based compensation</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">25,964,096</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Advisory fees</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right">11,737,806</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right">500,000</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right">500,000</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right">500,000</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Litigation settlement expense, net</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41,250</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,100,000</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">License expense</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,737,773</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left">Total Operating Expenses</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">44,583,513</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,091,790</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,225,522</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">12,268,131</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left">Loss From Operations</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(44,543,523</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(5,028,790</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(7,142,522</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(12,197,669</TD>
    <TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Other Income and Expense:</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Interest income</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">327,377</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">12,687</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">16,133</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Amortization of debt issuance costs</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(798,311</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(145,097</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Interest expense - related parties</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(1,227,487</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(2,559,456</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(2,557,055</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(2,723,396</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Loss on extinguishment of Bridge loan</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(2,069,923</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(2,069,923</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Loss on change in fair value of derivative liability related to sales of common stock through equity line of credit</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(380,162</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; font-weight: bold; text-align: left">Net Loss</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(46,622,106</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(9,645,482</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(11,898,464</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(14,921,065</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; vertical-align: top">Loss per share:</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Net loss per share - basic and diluted</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">(2.48</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">(0.56</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">(0.69</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">(1.02</TD>
    <TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Weighted average number of common shares outstanding during the period - basic and diluted</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">18,787,603</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">17,353,327</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">17,342,755</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">14,681,111</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P> </DIV>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<DIV STYLE="border: Black 1pt solid; padding: 5pt; width: 98%">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Consolidated Balance Sheet Data</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</TD>
    <TD STYLE="text-align: center">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>As of<BR> September&#160;30,<BR> 2025</B></FONT></TD>
    <TD STYLE="text-align: center">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; width: 88%; vertical-align: top"><FONT STYLE="font-size: 10pt">Cash</FONT></TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; width: 9%"><FONT STYLE="font-size: 10pt">1,513,224</FONT></TD>
    <TD STYLE="width: 1%">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-size: 10pt">Deferred offering costs</FONT></TD>
    <TD>&#160;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right">99,302</TD>
    <TD>&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-size: 10pt">Debt issuance costs - current</FONT></TD>
    <TD>&#160;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">671,804</FONT></TD>
    <TD>&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">Debt issuance costs &#150; net of current portion</TD>
    <TD>&#160;</TD>
    <TD>$</TD>
    <TD STYLE="text-align: right">694,654</TD>
    <TD>&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-size: 10pt">Prepaid expenses and other</FONT></TD>
    <TD>&#160;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">677,246</FONT></TD>
    <TD>&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-size: 10pt">Accounts payable</FONT></TD>
    <TD>&#160;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,640,833</FONT></TD>
    <TD>&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-size: 10pt">Accounts payable related - parties</FONT></TD>
    <TD>&#160;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">499,900</FONT></TD>
    <TD>&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-size: 10pt">Litigation settlement payable</FONT></TD>
    <TD>&#160;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">4,746,250</FONT></TD>
    <TD>&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">Convertible Promissory Note</TD>
    <TD>&#160;</TD>
    <TD>$</TD>
    <TD STYLE="text-align: right">4,700,794</TD>
    <TD>&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-size: 10pt">Accrued compensation</FONT></TD>
    <TD>&#160;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">255,099</FONT></TD>
    <TD>&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-size: 10pt">Additional Paid-in capital</FONT></TD>
    <TD>&#160;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">85,414,333</FONT></TD>
    <TD>&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-size: 10pt">Accumulated deficit</FONT></TD>
    <TD>&#160;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(97,230,551</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"><FONT STYLE="font-size: 10pt">Shareholders&#8217; (deficit) equity</FONT></TD>
    <TD>&#160;</TD>
    <TD><FONT STYLE="font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(11,814,270</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P> </DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><FONT STYLE="text-decoration: underline"><FONT ID="a_004"></FONT>Risk Factors</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Investing in our common stock involves a high degree of risk. Before you invest you should carefully consider the risks and uncertainties described below and the other information in this prospectus, and under the caption &#8220;Risk Factors&#8221; in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, which is incorporated by reference, as well as the other information in this prospectus, before deciding whether to invest in shares of our common stock. If any of the following risks actually occurs, our business, results of operations and financial condition could be materially adversely affected. In this case, the trading price of our common stock would likely decline, and you might lose part or all your investment in our common stock. Additional risks not currently known to us or which we consider immaterial based on information currently available to us may also materially adversely affect us.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="text-decoration: underline"><FONT ID="a_005"></FONT>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">This prospectus contains forward-looking statements that can involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this prospectus, including statements regarding our future results of operations and financial position, business strategy, prospective products, product approvals, research and development costs, future revenue, timing and likelihood of success, plans and objectives of management for future operations, future results of anticipated products and prospects, plans and objectives of management are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In some cases, you can identify forward-looking statements by terms such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; or &#8220;would&#8221; or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements contained in this prospectus include, but are not limited to, statements about:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the timing, progress and results of preclinical studies and clinical trials for our current and future product candidates, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the timing, scope or likelihood of regulatory submissions, filings, and approvals, including final regulatory approval of our product candidates;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our ability to develop and advance product candidates into, and successfully complete, clinical trials;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our expectations regarding the size of the patient populations for our product candidates, if approved for commercial use;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the implementation of our business model and our strategic plans for our business, product candidates and technology;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our commercialization, marketing and manufacturing capabilities and strategy;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the pricing and reimbursement of our product candidates, if approved;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the rate and degree of market acceptance and clinical utility of our product candidates, in particular, and cell therapy, in general;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our ability to establish or maintain collaborations or strategic relationships or obtain additional funding;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our competitive position;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the scope of protection we and/or our licensors are able to establish and maintain for intellectual property rights covering our product candidates;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">developments and projections relating to our competitors and our industry;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the impact of laws and regulations.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we operate and financial trends that we believe may affect our business, financial condition, results of operations and prospects, and these forward-looking statements are not guarantees of future performance or development. These forward-looking statements speak only as of the date of this prospectus and are subject to a number of risks, uncertainties and assumptions described in the section titled &#8220;<I>Risk Factors</I>&#8221; and elsewhere in this prospectus. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein until after we distribute this prospectus, whether as a result of any new information, future events or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="text-decoration: underline"><FONT ID="a_006"></FONT>MARKET AND INDUSTRY DATA</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">This prospectus includes estimates regarding market and industry data. Unless otherwise indicated, information concerning our industry and the markets in which we operate, including our general expectations, market position, market opportunity, and market size, are based on our management&#8217;s knowledge and experience in the markets in which we operate, together with currently available information obtained from various sources, including publicly available information, industry reports and publications, surveys, our customers, trade and business organizations, and other contacts in the markets in which we operate. Certain information is based on management estimates, which have been derived from third-party sources, as well as data from our internal research.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In presenting this information, we have made certain assumptions that we believe to be reasonable based on such data and other similar sources and on our knowledge of, and our experience to date in, the markets in which we operate. While we believe the estimated market and industry data included in this prospectus is generally reliable, such information is inherently uncertain and imprecise. Market and industry data is subject to change and may be limited by the availability of raw data, the voluntary nature of the data gathering process, and other limitations inherent in any statistical survey of such data. In addition, projections, assumptions, and estimates of the future performance of the markets in which we operate are necessarily subject to uncertainty and risk due to a variety of factors, including those described in &#8220;<I>Risk Factors</I>&#8221; and &#8220;<I>Cautionary Note Regarding Forward-Looking Statements</I>.&#8221; These and other factors could cause results to differ materially from those expressed in the estimates made by third parties and by us. Accordingly, you are cautioned not to place undue reliance on such market and industry data or any other such estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="text-decoration: underline"><FONT ID="a_007"></FONT>TRADEMARKS, SERVICE MARKS AND TRADENAMES</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We own or otherwise have rights to the trademarks, including those mentioned in this prospectus, used in conjunction with the operation of our business. This prospectus includes our own trademarks, which are protected under applicable intellectual property laws, as well as trademarks, service marks and tradenames of other entities, which are the property of their respective owners. Solely for convenience, trademarks, trade names and service marks referred to in this prospectus may appear without the <SUP>&#174;</SUP>, <SUP>&#8482;</SUP> or <SUP>SM </SUP>symbols, but such references are not intended to indicate, in any way, that the applicable licensor will not assert, to the fullest extent under applicable law, its rights to these trademarks, service marks and tradenames. We do not intend our use or display of other entities&#8217; trademarks, service marks or tradenames to imply a relationship with, or endorsement or sponsorship of us by, any other entities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="text-decoration: underline"><FONT ID="a_008"></FONT>USE OF PROCEEDS</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Selling Stockholder may, or may not, elect to sell shares of our common stock covered by this prospectus. To the extent the Selling Stockholder chooses to sell shares of our common stock covered by this prospectus, we will not receive any proceeds from any such sales of our common stock. See &#8220;<I>Selling Stockholder.</I>&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="text-decoration: underline"><FONT ID="a_009"></FONT>DIVIDEND POLICY</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We have never declared or paid cash dividends on our common stock. We currently intend to retain all available funds and any future earnings to fund the development, commercialization and growth of our business, and therefore we do not anticipate declaring or paying any cash dividends on our common stock in the foreseeable future. Any future determination as to the declaration and payment of dividends, if any, will be at the discretion of our board of directors. Any such determination will also depend upon our business prospects, operating results, financial condition, capital requirements, general business conditions and other factors that our board of directors may deem relevant. Our future ability to pay cash dividends on our common stock may also be limited by the terms of any future debt securities or credit facility<B><I>.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="text-decoration: underline"><FONT ID="a_010"></FONT>CAPITALIZATION</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The following table sets forth our cash and cash equivalents and capitalization as of September&#160;30, 2025, as follows. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">This table should be read in conjunction with, and is qualified in its entirety by reference to, our financial statements and related notes appearing elsewhere in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">As of<BR> September&#160;30,<BR> 2025</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Cash</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">1,513,224</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Stockholders&#8217; equity/(deficit):</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Preferred Stock, $0.0001 par value per share; 10,000,000 total shares authorized, no shares issued and outstanding</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Common Stock, $0.0001 par value per share; 100,000,000 shares authorized, 19,474,303 shares issued and outstanding</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,948</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Additional paid-in capital</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">85,414,333</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.125in">Accumulated deficit</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(97,230,551</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in">Total stockholders&#8217; deficit</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(11,814,270</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The total number of shares of our common stock reflected in the discussion and table above excludes the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 0.5in">&#160;</TD>
    <TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">3,010,000 shares of common stock issuable upon the vesting of restricted stock.</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&#160;</TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">4,764,507 shares of common stock (which include the 3,010,000 shares issuable upon the vesting of the restricted stock described above) currently reserved for future grant or issuance under our 2023 Plan of which, 1,754,507 shares would be available for grants.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="text-decoration: underline"><FONT ID="a_011"></FONT>MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes thereto included elsewhere in this prospectus. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from these forward-looking statements as a result of certain factors. We discuss factors that we believe could cause or contribute to these differences below and elsewhere in this prospectus, including those set forth in the sections of this prospectus entitled &#8220;Risk Factors&#8221; and &#8220;Cautionary Statement Concerning Forward-Looking Statements&#8221;.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Overview</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our company (f/k/a NAS-ONC, Inc.) was formed in 2008, devoted to developing new drugs with new delivery modes. As a clinical-stage biopharmaceutical company, we have focused on establishing superior treatments for intracranial malignancies, i.e., aggressive cancers located in the brain. These cancer types include primary brain cancers, such as glioblastoma, and secondary brain cancers, that have arrived through metastatic spread from other cancers throughout the body, such as melanoma or breast and lung cancer. Brain-localized malignancies are particularly difficult to treat because the blood-brain barrier prevents efficient entry of most pharmacotherapeutic agents into the brain. As a result, these patients are faced with poor prognoses and shortened average life expectancy. NeOnc is developing novel drug delivery methods to be used in combination with novel drug candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">NeOnc&#8217;s lead product candidate is NEO100. NEO100 is administered to patients via intranasal delivery. We have completed human safety testing in a Phase 1 clinical trial and are currently conducting preliminary efficacy testing in a Phase 2a trial with recurrent malignant glioma (Grade IV IDH1 mutant and Grade III Astrocytoma IDH1 mutant) patients. NeOnc is also developing a second product candidate, NEO212, which has completed preclinical testing and an investigational new drug (IND) application has been filed and accepted with the United States Food and Drug Administration (FDA). The company has started Phase 1 clinical trials with patients harboring primary and secondary malignant brain cancer types. Several additional drug candidates are in the pipeline and are undergoing preclinical development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since inception, our operations have focused on organizing and staffing our company, business planning, raising capital, acquiring and developing our technology, establishing our intellectual property portfolio, identifying potential product candidates and undertaking preclinical and clinical studies and manufacturing. We do not have any products approved for sale and have not generated any revenue from product sales other than for humanitarian usage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since its inception, we have incurred significant operating losses. Our net loss was $11,898,464 and $14,921,065, for the years ended December 31, 2024 and 2023, respectively. We had an accumulated deficit of $50,608,445 at December 31, 2024. Our net loss was $46,622,106 and $9,645,482 for the nine months ended September&#160;30, 2025 and 2024, respectively. We had an accumulated deficit of $97,230,551 at September&#160;30, 2025. We expect to continue to incur significant and increasing expenses and operating losses for the foreseeable future, as we advance our current and future product candidates through preclinical and clinical development, manufacture drug product and drug supply, seek regulatory approval for our current and future product candidates, maintain and expand our intellectual property portfolio, hire additional research and development and business personnel and operate as a public company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for our product candidates. In addition, if we obtain regulatory approval for our product candidates and do not enter into a third-party commercialization partnership, we expect to incur significant expenses related to developing our commercialization capability to support product sales, marketing, manufacturing, and distribution activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private equity offerings and debt financings or other sources, such as potential collaboration agreements, strategic alliances and licensing arrangements. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on acceptable terms, or at all. Our failure to raise capital or enter into such agreements as, and when needed, could have a material adverse effect on our business, results of operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The report of our independent registered public accounting firm on our financial statements as of and for the year ended December&#160;31, 2024 and 2023 included an explanatory paragraph indicating that there was substantial doubt about our ability to continue as a going concern. See Note 1 to our annual financial statements appearing at the end of this prospectus for additional information on our assessment. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In December&#160;2022, the Company signed a Letter of Intent (&#8220;LOI&#8221;) with an investment advisory firm AFH Holdings and Advisory, LLC (&#8220;AFH&#8221;) to create a newly formed corporation called NeOnc Technologies Holding Company, Inc. (&#8220;NTHI&#8221;) to facilitate future fundraising transactions. On April&#160;7, 2023, the Company entered into share exchange agreements whereby all of the common shareholders of NTI exchanged all of their stock in NTI for a total of 10,500,000 shares of NTHI common stock in the share exchange (&#8220;Share Exchange&#8221;). At the consummation of the Share Exchange transaction, AFH and its affiliated entities, individuals, or assignees owned an aggregate of 34.4% (5,500,000 shares) of the fully diluted issued and outstanding common shares of the Company. For a period of two years after an initial public offering (&#8220;IPO&#8221;) or a direct listing, AFH will also act as an investment advisor in future financing transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> On October&#160;11, 2024, the Company entered into an agreement with RBW Capital Partners LLC, a division of Dawson James Securities, Inc. (&#8220;Broker&#8221;) to serve as placement agent and provide broker services in connection with the possible sale of common stock up to $10 million. During the year ended December&#160;31, 2024, we entered into agreements with investors to sell 624,999 shares of common stock at the private placement price of $16.00 per share for gross proceeds of approximately $10,000,000 (the &#8220;Private Placement&#8221;). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &#160; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> On October&#160;11, 2024, the Company entered into a Line of Credit Agreement (&#8220;the Agreement&#8221;) with HCWG for borrowings of up to $10.0 million. No amounts have been borrowed under the facility through December&#160;31, 2024. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &#160; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> On October&#160;22, 2024, we entered into an equity purchase agreement (the &#8220;Equity Purchase Agreement&#8221;) with Mast Hill Fund, LP (&#8220;Mast Hill&#8221;) pursuant to which the Company may sell and issue to the investor, and the investor may purchase from the Company, up to $50,000,000 of Company&#8217;s common shares. The Company cannot draw down any funds under the Equity Purchase Agreement until the Company has an effective registration statement. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2024 we issued HCWG LLC a five-year warrant to purchase up to 312,500 shares of our common stock at a per share exercise price of $12.00. In March 2025, we issued 162,500 shares of common stock to HCWG upon the cashless exercise of a common stock purchase warrant held by it. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2025, our Executive Chairman advanced the Company approximately $300,000. The advances carry a 50% (or 1 times amounts borrowed) original issue discount (&#8220;OID&#8221;) on the principal. In the event of default, interest is payable at on any unpaid balance at a rate of 10% per annum. In March 2025, further to the terms of such advance, the Executive Chairman was paid a total of $600,000 upon repayment of such advances, including OID.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2025, prior to our Direct Listing, we issued 625,000 shares of common stock to various unaffiliated third parties in a private placement at a price of $16.00 per share for gross proceeds of approximately $10,000,000. In March 2025, we issued to Dawson James 30,000 shares of common stock upon the time of our Direct Listing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 25, 2025, the Company&#8217;s common stock was listed on the Nasdaq Global Market under the stock ticker &#8220;NTHI&#8221;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2025, we issued 102,750 shares of common stock to various unaffiliated third parties in a private placement at a price of $16.00 per share for gross proceeds of approximately $1,644,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2025 we issued 162,500 shares of common stock to HCWG upon the cashless exercise of a common stock purchase warrant held by it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July&#160;2025, the Company sold 132,342 shares of common stock at $3.73 per share for gross proceeds of approximately $489,000 pursuant to Equity Purchase Agreement with Mast Hill Fund, LP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September&#160;2025, the Company sold 315,185 shares of common stock at $7.60 &#8211; 9.53 per share for gross proceeds of approximately $2,710,000 pursuant to Equity Purchase Agreement with Mast Hill Fund, LP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 4, 2025, the Company sold 76,665 shares of common stock at $9.78 per share for gross proceeds of approximately $750,000 pursuant to Equity Purchase Agreement with Mast Hill Fund, LP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 1, 2025, the Company entered into a Securities Purchase Agreement with Saad Naja pursuant to which the Company agreed to issue 111,732 shares of its common stock, par value $0.0001 per share, at a price of $8.95 per share, representing the closing price of the Company&#8217;s common stock on the Nasdaq Global Market on November&#160;28, 2025, raising a total of $1.0 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2025, the Company entered into a Share Exchange Agreement with the members (the &#8220;Members&#8221;) of JandB Holdings, LLC (&#8220;JandB&#8221;). Pursuant to the Share Exchange Agreement, the Company acquired 100% of the issued and outstanding membership interests of JandB in exchange for an amount of shares of Company common stock equal to (a) 120,000 shares of Company common stock with an attributed value of $25 per share, less (b) an amount of shares equal to (x) the aggregate transaction fees incurred by the Company in connection with all of the transactions related to the Agreement divided by (y) $25.00, rounded up to the nearest whole share. The Company remitted the cash payment for the patent on October&#160;3, 2025 and received assignment of the patent effective October&#160;8, 2025. As of December&#160;12, 2025, the shares have yet to be issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2025, 1,200,000 shares of restricted stock were granted to Amir Heshmatpour. One-half of the shares of restricted stock will vest on January 2, 2025. The remaining one-half of the shares of restricted stock will vest thereafter in twelve (12) equal monthly installments.&#160;70,000 shares of restricted stock were granted to Grace Fisher, with half vesting immediately, and the remaining shares will vest two months later with ten (10) equal monthly installments. Dr. Henry Friedman as was also granted 15,000 additional shares of restricted stock, with half vesting immediately, and the remaining shares will vest two months later with ten (10) equal monthly installments. Dr. Henry Friendman was previously granted 10,000 shares of restricted stock in September 2025, with half vesting immediately, and the remaining shares vesting in equal installments over a ten (10) month period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Components of Results of Operations</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Revenue</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We occasionally receive a fee from a patient for a &#8220;right to try&#8221; humanitarian program. Such revenues are not part of our core business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating Expenses</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our operating expenses consist of (i) research and development expenses and (ii) legal and professional expenses and (iii) general and administrative expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research and Development Expenses</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research and development expenses consist primarily of costs incurred for our research and development activities, including our product candidate discovery efforts and preclinical and clinical studies under our research programs, which include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">employee-related expenses, including salaries, benefits and stock-based compensation expense for our research and development personnel;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">costs of funding research performed by third parties that conduct research and development and preclinical and clinical activities on our behalf;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">costs of manufacturing drug product and drug supply related to our current or future product candidates;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">costs of conducting preclinical studies and clinical trials of our product candidates;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">consulting and professional fees related to research and development activities, including equity-based compensation to non-employees;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">costs of maintaining our laboratory, including purchasing laboratory supplies and non-capital equipment used in our preclinical studies;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">costs related to compliance with clinical regulatory requirements; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">facility costs and other allocated expenses, which include expenses for rent and maintenance of facilities, insurance, depreciation and other supplies.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research and development costs are expensed as incurred. Costs for certain activities are recognized based on an evaluation of the progress to completion of specific tasks using data such as information provided to us by our vendors and analyzing the progress of our pre-clinical and clinical studies or other services performed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The successful development of our product candidates is highly uncertain. We cannot reasonably estimate or know the nature, timing, and estimated costs of the efforts that will be necessary to complete development of our current or future product candidates. We are also unable to predict when, if ever, material net cash inflows will commence from the sale of our product candidates, if they are approved. This is due to the numerous risks and uncertainties associated with developing product candidates, including the uncertainty of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the scope, rate of progress, and expenses of our ongoing research activities as well as any preclinical studies and clinical trials and other research and development activities;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">establishing an appropriate safety profile;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">successful enrollment in and completion of clinical trials;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">whether our product candidates show safety and efficacy in our clinical trials;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">receipt of marketing approvals from applicable regulatory authorities;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">commercializing product candidates, if and when approved, whether alone or in collaboration with others; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">continued acceptable safety profile of the products following any regulatory approval.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">A change in the outcome of any of these variables with respect to the development of our current and future product candidates would significantly change the costs and timing associated with the development of those product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect research and development costs to increase significantly for the foreseeable future as we commence clinical trials and continue the development of our current and future product candidates. However, we do not believe that it is possible at this time to accurately project expenses through commercialization. There are numerous factors associated with the successful commercialization of any of our product candidates, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time based on our stage of development. Additionally, future commercial and regulatory factors beyond our control will impact our clinical development programs and plans.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Legal and Professional Expenses</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Legal and professional expenses consist of costs related to corporate and intellectual property legal costs and accounting and auditing fees. We also anticipate increased expenses associated with being a public company, including costs for audit, legal, regulatory and tax-related services related to compliance with the rules and regulations of the Securities and Exchange Commission, or the SEC, and listing standards applicable to companies listed on a national securities exchange, director and officer insurance premiums, and investor relations costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">General and Administrative Expenses</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">General and administrative expenses include salaries and other compensation-related costs, including stock-based compensation, for personnel in executive, finance and accounting, business development, operations and administrative roles. Other significant costs include insurance costs, travel costs, facility and office-related costs not included in research and development expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We anticipate that our general and administrative expenses will increase in the future as our business expands to support expected growth in research and development activities, including our future clinical programs. These increases will likely include increased costs related to the hiring of additional personnel and fees to outside service providers, among other expenses. In addition, if we obtain regulatory approval for any of our product candidates and do not enter into a third-party commercialization collaboration, we expect to incur significant expenses related to building a sales and marketing team to support product sales, marketing and distribution activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Advisory Fee Expenses</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The advisory fee expenses result from the advisory arrangement with AFH.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest Expense</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest expense results from the bridge loan from a related party. Borrowings under the note carry a 50% (or 1 times amounts borrowed) original issue discount (&#8220;OID&#8221;) on principal. The OID to be earned under the bridge loan is recognized ratably over the term of each draw-down under the loan through the maturity date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <I>Amortization on Debt Issuance Costs</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&#160;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Amortization on debt issuance costs resulted from the grant of warrants for a line of credit commitment. The fair value of the warrants was determined using the Black Scholes valuation method and the fair value is being amortized over the term of the line of credit commitment. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Comparison of the nine m<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">onths ended September&#160;30, 2025 and 2024:</FONT></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes our results of operations for the periods presented:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1pt solid; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the<BR> Nine Months Ended</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>September&#160;30,</B></P></TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Change</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Revenues:</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%; text-align: left; text-indent: -0.125in; padding-left: 0.25in">Revenue</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">39,990</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">63,000</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">(23,010</TD>
    <TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Cost of Revenues</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Operating Expenses:</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Research and development</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">2,390,592</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,965,726</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">424,866</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Legal and professional</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,754,287</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,652,141</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">102,146</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in">General and administrative</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">2,736,732</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">973,923</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,762,809</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Share based compensation</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">25,964,096</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">25,964,096</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.25in">Advisory fees</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">11,737,806</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">500,000</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">11,237,806</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.375in">Total Operating Expenses</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">44,583,513</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,091,790</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">39,491,723</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.375in">Loss From Operations</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(44,543,523</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(5,028,790</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(39,514,733</TD>
    <TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in">Other Income (Expense):</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Interest and other income</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">327,377</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">12,687</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">314,690</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Amortization expense</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(798,311</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(798,311</TD>
    <TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Interest expense</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(1,227,487</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(2,559,456</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,331,969</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in">Loss on extinguishment of Bridge loan - related party</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(2,069,923</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">2,069,923</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.25in">Loss on settlement of common share purchases</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(380,162</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(380,162</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.375in">Net Loss</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(46,622,106</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(9,645,482</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(36,976,624</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Revenue</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue was generated for fees for a &#8220;right to try&#8221; humanitarian program during 2025 and 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Research and Development Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the components of our research and development expenses for the periods presented:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<BR> Nine Months Ended<BR> September&#160;30,</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Research and development costs by project:</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; width: 76%; vertical-align: top">NEO100-01</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">851,664</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">693,328</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">NEO100-02</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">327,373</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">203,075</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">NEO212</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">798,997</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">549,249</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">Pediatric</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">169,663</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">103,338</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">Laboratory</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">192,377</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">362,858</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; vertical-align: top">Other</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">50,518</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">53,878</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt; vertical-align: top">Total</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,390,592</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,965,726</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<BR> Nine Months Ended<BR> September&#160;30,</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Change</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 64%; text-align: left">Clinical trial expense</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">2,147,697</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">1,548,990</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">598,707</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Research and laboratory</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">242,895</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">416,736</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(173,841</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Total research and development expense</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,390,592</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,965,726</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">424,866</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Research and development expenses were $2,390,592 and $1,965,726 for the nine months ended September 30, 2025 and 2024, respectively. A portion of these expenses amounting to approximately $242,895 and $416,736 for the nine months ended September&#160;30, 2025 and 2024, respectively are from the University of Southern California (USC), where Dr. Chen is a member of the faculty. The total increase of $424,866 was primarily due to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The addition of clinical trial sites for NEO100&#8217;s clinical trial.</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The recruitment for NEO212.</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify">The start of the clinical trial for NEO100-03for a Pediatric Indication</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increased patient recruitment efforts.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Legal and Professional Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Legal and professional expenses were $1,754,287 and $1,652,141 for the nine months ended September&#160;30, 2025 and 2024, respectively. The increase of $102,146 was primarily due to completion of the direct listing process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>General and Administrative Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">General and administrative expenses were $2,736,732 and $973,923 for the nine months ended September&#160;30, 2025 and 2024, respectively. The increase of $1,762,809 was primary due to a marketing campaign, increased employee headcount and resultant compensation and benefits, rent and travel expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Share Based Compensation</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Share based compensation resulted from the granting of RSUs and is the recognition of the expense from the grant date (which included a catch up period from the original date of issuance of the RSU&#8217;s through the Listing Date, due to the removal of the contingency which occurred on the Listing Date) through September&#160;30, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><I>Advisory Fee</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The advisory fee was earned on the Listing Date March&#160;26, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><I>Interest Expense</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Interest expense was $1,227,487 and $2,559,456 for the nine months ended September&#160;30, 2025 and 2024, respectively. The interest for the nine months ended September&#160;30, 2025 relates to the short-term loan in March from a related party in the amount of $300,000 and $146,250 interest for a litigation matter, and the accretion of the convertible note payable of $820,794. The OID interest for the nine months ended September&#160;30, 2024 relates to the OID for the related party bridge loan that was converted into common stock in June of 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><I>Amortization of Debt Issuance and Deferred Offering Costs</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The amortization of debt issuance costs was $798,311 and $0 for the nine months ended September&#160;30, 2025 and 2024, respectively. This represents the amortization of the warrants issued for the HCWG line of credit and deferred offering costs relating to the Mast Hill agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><I>Loss on Change in Fair Value of Derivative Liability </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Loss on change in fair value of derivative liability was $380,162 and $0 for the nine months ended September 2025 and 2024, respectively. The loss on settlement is related to the discount offered investors who purchased shares of common stock under the equity line of credit, which commenced in July 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Cash Flows</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes our cash flow for the periods indicated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<BR> Nine Months Ended<BR> September&#160;30,</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Change</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net cash provided by (used in):</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 64%; text-align: left">Operating activities</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">(16,772,777</TD>
    <TD STYLE="width: 1%; text-align: left">)</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">(3,259,512</TD>
    <TD STYLE="width: 1%; text-align: left">)</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">(13,513,265</TD>
    <TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Financing activities</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">18,221,108</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,562,277</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">13,658,831</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Net increase (decrease) in cash</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,448,331</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,302,765</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">145,566</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Operating Activities</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the nine months ended September&#160;30, 2025, net cash used in operating activities was $16,772,777 consisting primarily of our net loss of $46,622,106, offset by share based compensation of $25,964,096, accretion of original issue discounts of $820,794, amortization of assets of $1,161,331 and the accrued advisory fee of $3,675,569. These were offset by decreases in accrued compensation in the amount of $479,775 and prepaid expenses in the amount of $267,161.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the nine months ended September&#160;30, 2024, net cash used in operating activities was $3,259,512 consisting primarily of our net loss of $9,645,482 less the non-cash charge of the accretion of the original issue discount on the bridge loan in the amount $2,558,241, less the non-cash charge for the loss on extinguishment of convertible debt of $2,069,923 and an increase in accounts payable of $957,162.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B><I>Comparison of the years ended December&#160;31, 2024 and 2023:</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&#160;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes our results of operations for the periods presented:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> &#160; </TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"> &#160; </TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> For the<BR> years ended<BR> December 31, </TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"> &#160; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> &#160; </TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"> &#160; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> 2024 </TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"> &#160; </TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"> &#160; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> 2023 </TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"> &#160; </TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"> &#160; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> Change </TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"> &#160; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; vertical-align: top"> Revenues </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in; width: 64%; vertical-align: top"> Revenue </TD>
    <TD STYLE="width: 1%"> &#160; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD>
    <TD STYLE="width: 9%; text-align: right"> 83,000 </TD>
    <TD STYLE="width: 1%; text-align: left"> &#160; </TD>
    <TD STYLE="width: 1%"> &#160; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD>
    <TD STYLE="width: 9%; text-align: right"> 70,462 </TD>
    <TD STYLE="width: 1%; text-align: left"> &#160; </TD>
    <TD STYLE="width: 1%"> &#160; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD>
    <TD STYLE="width: 9%; text-align: right"> 12,538 </TD>
    <TD STYLE="width: 1%; text-align: left"> &#160; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top"> &#160; </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"> Operating expenses: </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"> Research and development </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> 3,045,239 </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> 1,534,114 </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> 1,511,125 </TD>
    <TD STYLE="text-align: left"> &#160; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"> Legal and professional </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> 2,000,623 </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> 1,907,687 </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> 92,936 </TD>
    <TD STYLE="text-align: left"> &#160; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"> General and administrative </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> 1,638,410 </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> 1,488,557 </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> 149,853 </TD>
    <TD STYLE="text-align: left"> &#160; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"> Advisory fee </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> 500,000 </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> 500,000 </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> - </TD>
    <TD STYLE="text-align: left"> &#160; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"> Litigation settlement expense, net </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> 41,250 </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> 4,100,000 </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> (4,058,750 </TD>
    <TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt"> License expense </TD>
    <TD STYLE="padding-bottom: 1pt"> &#160; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &#160; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"> - </TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"> &#160; </TD>
    <TD STYLE="padding-bottom: 1pt"> &#160; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &#160; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 2,737,773 </TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"> &#160; </TD>
    <TD STYLE="padding-bottom: 1pt"> &#160; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &#160; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"> (2,737,773 </TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1pt"> Total operating expenses </TD>
    <TD STYLE="padding-bottom: 1pt"> &#160; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &#160; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 7,225,522 </TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"> &#160; </TD>
    <TD STYLE="padding-bottom: 1pt"> &#160; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &#160; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 12,268,132 </TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"> &#160; </TD>
    <TD STYLE="padding-bottom: 1pt"> &#160; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &#160; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"> (5,042,610 </TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left"> Loss from operations </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> (7,142,522 </TD>
    <TD STYLE="text-align: left"> ) </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> (12,197,669 </TD>
    <TD STYLE="text-align: left"> ) </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> 5,055,147 </TD>
    <TD STYLE="text-align: left"> &#160; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left"> &#160; </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"> Other expense: </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"> Interest income </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> 16,133 </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> - </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> 16,133 </TD>
    <TD STYLE="text-align: left"> &#160; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"> Amortization on debt issuance costs </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> (145,097 </TD>
    <TD STYLE="text-align: left"> ) </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> - </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> (145,097 </TD>
    <TD STYLE="text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"> Interest expense </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> (2,557,055 </TD>
    <TD STYLE="text-align: left"> ) </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> (2,723,396 </TD>
    <TD STYLE="text-align: left"> ) </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> 166,340 </TD>
    <TD STYLE="text-align: left"> &#160; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt"> Loss on extinguishment of Bridge loan </TD>
    <TD STYLE="padding-bottom: 1pt"> &#160; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &#160; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"> (2,069,923 </TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"> ) </TD>
    <TD STYLE="padding-bottom: 1pt"> &#160; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &#160; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"> - </TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"> &#160; </TD>
    <TD STYLE="padding-bottom: 1pt"> &#160; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &#160; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"> (2,069,923 </TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; font-weight: bold; text-align: left; padding-bottom: 2.5pt"> Net loss </TD>
    <TD STYLE="padding-bottom: 2.5pt"> &#160; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (11,898,464 </TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD>
    <TD STYLE="padding-bottom: 2.5pt"> &#160; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (14,921,065 </TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD>
    <TD STYLE="padding-bottom: 2.5pt"> &#160; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 3,022,601 </TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"> &#160; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Revenue</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Revenue was generated for fees for a &#8220;right to try&#8221; humanitarian program during 2024 and 2023 and sale of product to a licensee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Research and Development Expenses</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes the components of our research and development expenses for the periods presented:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> &#160; </TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"> &#160; </TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> For the<BR> year ended<BR> December,&#160;31, </TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"> &#160; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> &#160; </TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"> &#160; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> 2024 </TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"> &#160; </TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"> &#160; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> 2023 </TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"> &#160; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"> Research and development costs by project: </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; width: 76%; vertical-align: top"> NEO100-01 </TD>
    <TD STYLE="width: 1%"> &#160; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD>
    <TD STYLE="width: 9%; text-align: right"> 1,200,624 </TD>
    <TD STYLE="width: 1%; text-align: left"> &#160; </TD>
    <TD STYLE="width: 1%"> &#160; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD>
    <TD STYLE="width: 9%; text-align: right"> 702,226 </TD>
    <TD STYLE="width: 1%; text-align: left"> &#160; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"> NEO100-02 </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> 320,987 </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> - </TD>
    <TD STYLE="text-align: left"> &#160; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"> NEO212 </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> 870,634 </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> 279,859 </TD>
    <TD STYLE="text-align: left"> &#160; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"> Pediatric </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> 191,593 </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> 169,777 </TD>
    <TD STYLE="text-align: left"> &#160; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"> Laboratory </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> 460,559 </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> 326,272 </TD>
    <TD STYLE="text-align: left"> &#160; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; vertical-align: top"> Other </TD>
    <TD STYLE="padding-bottom: 1pt"> &#160; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &#160; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 841 </TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"> &#160; </TD>
    <TD STYLE="padding-bottom: 1pt"> &#160; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &#160; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 55,980 </TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"> &#160; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt; vertical-align: top"> Total </TD>
    <TD STYLE="padding-bottom: 2.5pt"> &#160; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 3,045,238 </TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"> &#160; </TD>
    <TD STYLE="padding-bottom: 2.5pt"> &#160; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 1,534,114 </TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"> &#160; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> &#160; </TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"> &#160; </TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> For the<BR> years ended<BR> December&#160;31, </TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"> &#160; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> &#160; </TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"> &#160; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> 2024 </TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"> &#160; </TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"> &#160; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> 2023 </TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"> &#160; </TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"> &#160; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> Change </TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"> &#160; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 64%; text-align: left"> Clinical trial expense </TD>
    <TD STYLE="width: 1%"> &#160; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD>
    <TD STYLE="width: 9%; text-align: right"> 2,583,838 </TD>
    <TD STYLE="width: 1%; text-align: left"> &#160; </TD>
    <TD STYLE="width: 1%"> &#160; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD>
    <TD STYLE="width: 9%; text-align: right"> 1,207,842 </TD>
    <TD STYLE="width: 1%; text-align: left"> &#160; </TD>
    <TD STYLE="width: 1%"> &#160; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD>
    <TD STYLE="width: 9%; text-align: right"> 1,375,996 </TD>
    <TD STYLE="width: 1%; text-align: left"> &#160; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt"> Research and laboratory </TD>
    <TD STYLE="padding-bottom: 1pt"> &#160; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &#160; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 461,400 </TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"> &#160; </TD>
    <TD STYLE="padding-bottom: 1pt"> &#160; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &#160; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 326,272 </TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"> &#160; </TD>
    <TD STYLE="padding-bottom: 1pt"> &#160; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &#160; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 135,128 </TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"> &#160; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"> Total research and development expense </TD>
    <TD STYLE="padding-bottom: 2.5pt"> &#160; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 3,045,238 </TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"> &#160; </TD>
    <TD STYLE="padding-bottom: 2.5pt"> &#160; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 1,534,114 </TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"> &#160; </TD>
    <TD STYLE="padding-bottom: 2.5pt"> &#160; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 1,511,124 </TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"> &#160; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenses were $3,045,239 and $1,534,114 for the years ended December&#160;31, 2024 and 2023, respectively. A portion of these expenses amounting to approximately $460,559 and $326,272 for the years ended December&#160;31, 2024 and 2023, respectively are from the University of Southern California (USC), where Dr. Chen is a member of the faculty. The total increase of $1,511,124 was primarily due to:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="text-align: justify; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The addition of clinical trial sites for NEO100&#8217;s clinical trial.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="text-align: justify; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The completion of the IND for NEO212 and the start of the clinical trial.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="text-align: justify; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The completion and filing of the IND for NEO100-03 for a Pediatric Indication and preparation for the start of the clinical trial.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 48px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="text-align: justify; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The start of a new clinical trial NEO100-02 for Meningiomas.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT> </TD>
    <TD STYLE="text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increased patient recruitment efforts.</FONT> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <I>Legal and Professional Expenses</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &#160; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> Legal and professional expenses were $2,000,623 and $1,907,687 for the years ended December&#160;31, 2024 and 2023, respectively. The increase of $92,936 was primarily due to ending the IPO process and preparing a direct listing resulting in a writing off deferred professional fees in the amount of approximately $704,000, offset by legal expense related to litigation matters in the prior year, which were non-recurring in the current year. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &#160; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <I>General and Administrative Expenses</I> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> &#160; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> General and administrative expenses were $1,638,410 and $1,488,557 for the years ended December&#160;31, 2024 and 2023, respectively. The increase of $149,853 was primary due to the rent expense related to a new lease and advertising and public relations costs. The Company did not have a lease in the prior year. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Advisory Fee</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advisory fee expenses resulting from the advisory arrangement with AFH for the years ended December&#160;31, 2024 and 2023 were $500,000 and $500,000, respectively.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Litigation Settlement Expense</I></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Litigation settlement expense of $4,100,000 for the year ended December 31, 2023 resulted from the settlement of legal matters with two former licensees in the amount of $4,100,000, in part offset by write off of $500,000 of deferred revenue related to one of the licenses. No such settlements were incurred during the year ended December 31, 2022.&#160;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>License Expense</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the year ended December&#160;31, 2023, the license expense of $2,737,773 is equal to the estimated fair value of the shares to be issued to USC in accordance with the USC amended license agreement. For the year ended December&#160;31, 2024, no additional license expense has been incurred.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Cash Flows</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes our cash flow for the periods indicated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> &#160; </TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"> &#160; </TD>
    <TD COLSPAN="10" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> For the<BR> year ended<BR> December&#160;31, </TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"> &#160; </TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> &#160; </TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"> &#160; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> 2024 </TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"> &#160; </TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"> &#160; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> 2023 </TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"> &#160; </TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"> &#160; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> Change </TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"> &#160; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> Net cash provided by (used in): </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 64%; text-align: left"> Operating activities </TD>
    <TD STYLE="width: 1%"> &#160; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD>
    <TD STYLE="width: 9%; text-align: right"> (4,213,916 </TD>
    <TD STYLE="width: 1%; text-align: left"> ) </TD>
    <TD STYLE="width: 1%"> &#160; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD>
    <TD STYLE="width: 9%; text-align: right"> (1,880,012 </TD>
    <TD STYLE="width: 1%; text-align: left"> ) </TD>
    <TD STYLE="width: 1%"> &#160; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD>
    <TD STYLE="width: 9%; text-align: right"> (2,333,904 </TD>
    <TD STYLE="width: 1%; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt"> Financing activities </TD>
    <TD STYLE="padding-bottom: 1pt"> &#160; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &#160; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 4,246,947 </TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"> &#160; </TD>
    <TD STYLE="padding-bottom: 1pt"> &#160; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &#160; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 1,278,576 </TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"> &#160; </TD>
    <TD STYLE="padding-bottom: 1pt"> &#160; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &#160; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"> 2,968,371 </TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"> &#160; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt"> Net increase (decrease) in cash </TD>
    <TD STYLE="padding-bottom: 2.5pt"> &#160; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 33,031 </TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"> &#160; </TD>
    <TD STYLE="padding-bottom: 2.5pt"> &#160; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> (601,436 </TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"> ) </TD>
    <TD STYLE="padding-bottom: 2.5pt"> &#160; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 634,467 </TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"> &#160; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Operating Activities</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December&#160;31, 2024, net cash used in operating activities was $4,213,916 consisting primarily of our net loss of $11,898,464 less the non-cash charge of the accretion of the original issue discount on the bridge loan in the amount of $2,557,055, loss on the extinguishment of the bridge loan in the amount of $2,069,923 the write off of deferred offering costs in the amount of $703,796, and an increase in accounts payable of $1,798,583. We have primarily used the proceeds of the bridge loan to prepare the company for an offering of its securities and activities related thereto, while payment for operating activities has been deferred. During the year ended December&#160;31, 2023, net cash used in operating activities was $1,880,012 consisting primarily of our net loss of $14,921,065 less the non-cash charge for license expense payable in stock of $2,507,773, increase in the bridge loan &#8211; expenses paid by the bridge loan provider on behalf of the Company of $1,997,775, and accretion of original issue discount of $2,721,747 and an offset by an increase in accounts payable of $1,059,789, accrued compensation of $678,743 and litigation settlement expense of $4,100,000.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Financing Activities</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December&#160;31, 2024, cash provided by financing activities was $4,246,947 consisting primarily of net proceeds of $4,615,789 from the sale of common stock and $892,028 from the bridge loan, offset by the repayment of bridge loans of $791,077. During the year ended December&#160;31, 2023, cash provided by financing activities was $1,278,576 consisting primarily of net proceeds of $3,507,972 from the bridge loans, offset by the repayment of bridge loans of $2,135,277.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Liquidity and Capital Resources</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Sources of Liquidity/Going Concern</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">Since our inception, we have funded our operations through the sale and issuance of preferred and common stock and debt financing rounds from related and third parties.</FONT> </P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2025 prior to our direct listing we issued 625,000 shares of common stock in a private placement at a price of $16.00 per share for gross proceeds of approximately $10,000,000. In March 2025 after our direct listing we issued 102,750 shares of common stock in a private placement at a price of $16.00 per share for gross proceeds of approximately $1,644,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. Since our inception, we have not generated any revenue from product sales or any other sources, except humanitarian use, and we have incurred significant operating losses. We have not yet commercialized any products and we do not expect to generate revenue from sales of any product candidates for a number of years, if ever. As reflected in the accompanying consolidated financial statements, we have incurred recurring net losses since our inception. For the year ended December 31, 2024, we incurred a net loss of $11,898,464 and used cash in operations of $4,213,916 and had a shareholders&#8217; deficit of $5,504,961 as of December 31, 2024. For the nine months ended September 30, 2025, the Company incurred a net loss of $46,622,106 and has an accumulated deficit of $97,230,551 at September 30, 2025. At September 30, 2025, the Company had cash totaling $1,513,224. These factors raise substantial doubt about our ability to continue as a going concern. Our ability to continue as a going concern is dependent upon our ability to raise additional funds and implement our strategies, such as executing additional licensing contracts. The consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The ability to continue as a going concern is dependent on us raising additional capital and attaining and maintaining profitable operations in the future to meet our obligations and repay our liabilities arising from normal business operations when they come due. Since inception, we have funded our operations primarily through equity and debt financings and licensing income and we expect to continue to rely on these sources of capital in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to us. Even if we are able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing, or cause substantial dilution for our shareholders, in the case of equity financing, or grant unfavorable terms in licensing agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Funding Requirements</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We expect our expenses to increase in connection with our ongoing activities, particularly as we continue our research and development, initiate and conduct preclinical studies and clinical trials, and seek marketing approval for our current and any of our future product candidates. In addition, if we obtain marketing approval for any of our current or our future product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution, which costs we may seek to offset through entry into collaboration agreements with third parties. Furthermore, we expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on acceptable terms, we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif">We expect to finance our operations over the next 12 months primarily through existing cash balances and the proceeds from the aforementioned private placements and supplemented as necessary by funds available through our Line of Credit Agreement with HCWG and sales under the Equity Purchase Agreement, each as described below. We have based this estimate on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Our future capital requirements will depend on a number of factors, including:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the costs of conducting preclinical studies and clinical trials;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the costs of manufacturing;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the scope, progress, results and costs of discovery, preclinical development, laboratory testing, and clinical trials for product candidates we may develop, if any;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the costs, timing, and outcome of regulatory review of our product candidates;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our ability to establish and maintain collaborations on favorable terms, if at all;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the achievement of milestones or occurrence of other developments that trigger payments under any license or collaboration agreements we might have at such time;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the costs and timing of future commercialization activities, including product sales, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the amount of revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the costs of preparing, filing and prosecuting patent applications, obtaining, maintaining and enforcing our intellectual property rights, and defending intellectual property-related claims;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">our headcount growth and associated costs as we expand our business operations and research and development activities; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">the costs of operating as a public company.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through public or private equity offerings and debt financings or other sources, such as potential collaboration agreements, strategic alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interests may be diluted, and the terms of these securities may include liquidation or other preferences that could adversely affect your rights as a common stockholder. Additional debt financing, if available, may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, that could adversely impact our ability to conduct our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If we raise funds through potential collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates, or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&#160;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Controls and Procedures</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">A company&#8217;s internal control over financial reporting is a process designed by, or under the supervision of, that company&#8217;s principal executive and principal financial officers, or persons performing similar functions, and effected by that company&#8217;s board of directors, management, and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with GAAP. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness in future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with policies or procedures may deteriorate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Executive Officer and Chief Financial Officer carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2025. Based upon their evaluation, and due to material weaknesses in our internal control over financial reporting related to; controls over segregation of duties, entity level controls over the risk assessment, information and communication and monitoring process, financial controls over all significant transaction classes, controls over authorization and tracking of related party transactions and controls over information technology over user access and provisioning, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were not effective as of September 30, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We have initiated various remediation efforts, including the hiring of additional financial personnel/&#8203;consultants with the appropriate public company and technical accounting expertise and other actions that are more fully described below. As such remediation efforts are still ongoing, we have concluded that the material weaknesses have not been fully remediated. Our remediation efforts to date have included the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We have assessed our current accounting personnel, financial reporting, and information system environments and capabilities. Based on our preliminary findings, we have found these resources and systems lacking and have concluded that these resources and systems will need to be supplemented and/or upgraded. We have hired a Chief Financial Officer and implemented accounting procedures and controls, such as a two-signature policy for all disbursements and vendor invoice/contract review processes. We have also instituted procedures to store and maintain vendor invoices, contracts and agreements for efficient retrieval, and analysis of financial reporting requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We engaged external consultants with public company and technical accounting experience to facilitate accurate and timely accounting closes and to accurately prepare and review the financial statements of NeOnc Technologies Holdings, Inc. and related footnote disclosures. We plan to retain these financial consultants until such a time that our internal resources have been upgraded and the required financial controls have been fully implemented.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have also commenced remediation steps to improve our internal control over financial reporting. Specifically, we expanded and improved our review process for complex securities and related accounting standards. We plan to further improve this process by enhancing access to accounting literature, identification of third-party professionals with whom to consult regarding complex accounting applications and consideration of additional staff with the requisite experience and training to supplement existing accounting professionals. Additionally, we have initiated an accounting system migration to Oracle NetSuite, and hired a third-party consulting firm to facilitate the implementation of the new system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The actions that have been taken are subject to continued review, implementation, and testing by management, as well as audit committee oversight. While we have implemented a variety of steps to remediate these weaknesses, we cannot assure you that we will be able to fully remediate them, which could impair our ability to accurately and timely meet our public company reporting requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notwithstanding the assessment that our internal controls over financial reporting are not effective and that material weaknesses exist, we believe that we have employed supplementary procedures to ensure that the financial statements contained in this filing fairly present our financial position, results of operations, and cash flows for the reporting periods covered herein in all material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">Critical Accounting Estimates and Significant Judgments</FONT> </P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We account for stock-based compensation, including restricted stock units (RSUs), in accordance with ASC 718. RSUs are measured at fair value on the grant date based on our common stock price and expense over the vesting period. For awards with performance or market conditions, expense is recognized based on the probability of achievement and may be accelerated. We estimate forfeitures based on historical data and adjust these estimates periodically. Changes in forfeiture rates, stock price, or performance assumptions can materially affect stock-based compensation expenses. Management reviews these assumptions quarterly and updates estimates as necessary. We consider the accounting for RSUs a critical estimate due to the judgment involved and its material impact on our financial results.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Off-Balance Sheet Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the years ended December&#160;31, 2024 and 2023, and the nine months ended September 30, 2025, we did not have, and we do not currently have, any off-balance sheet arrangements (as defined under SEC rules).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Quantitative and Qualitative Disclosures about Market Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We are not currently exposed to significant market risk related to changes in foreign currency exchange rates. However, we have contracted with and may continue to contract with foreign vendors that are located in Europe. Our operations may be subject to fluctuations in foreign currency exchange rates in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Inflation generally affects us by increasing our cost of labor. We do not believe that inflation had a material effect on our business, financial condition or results of operations during the years ended December&#160;31, 2024 or 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&#160;</B></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="text-decoration: underline"><FONT ID="a_012"></FONT>BUSINESS</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: justify; width: 65%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our company was originally formed in Delaware in 2008 under the name NAS-ONC, Inc. and was renamed to NeOnc Technologies, Inc. in 2009. In 2015, the Delaware entity was merged with and into NeOnc Technologies California, Inc., a California corporation, and the surviving California corporation was renamed to NeOnc Technologies, Inc. Our company is devoted to developing new drugs with new delivery modes. As a clinical-stage biopharmaceutical company, we have focused on establishing treatments for intracranial malignancies, i.e., aggressive cancers located in the brain. These cancer types include primary brain cancers, such as glioblastoma, and secondary brain cancers, that have arrived through metastatic spread from other cancers throughout the body, such as melanoma or breast and lung cancer. Brain-localized malignancies are particularly difficult to treat because the blood-brain barrier prevents efficient entry of most pharmacotherapeutic agents into the brain. As a result, these patients are faced with poor prognoses and shortened average life expectancy. NeOnc is developing novel drug delivery methods to be used in combination with novel drug candidates.</FONT></P></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: right; width: 33%"><IMG SRC="img_001.jpg" ALT="" STYLE="height: 286px; width: 500px"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD></TR>
  </TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">NeOnc has two lead products in development: NEO100 and NEO212. NEO100, a purified form of perillyl alcohol (&#8220;POH&#8221;), is planned to be administered to brain cancer patients via intranasal delivery. <FONT STYLE="text-decoration: underline">Ongoing activities for intranasal delivery of NEO100</FONT>:</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We have completed human testing in a Phase I clinical trial and are currently conducting a Phase IIa trial with recurrent malignant glioma (Grade IV, IDH1 mutant) patients (further details are provided below).</FONT></P></TD> </TR>
  </TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A similar Phase IIa trial of intranasal NEO100 (NEO100-02) for patients with malignant skull based meningioma is also ongoing. Meningiomas are slow-growing tumors originating in the meninges, the membranous layers surrounding the brain and spinal cord. We initiated this because these patients lack effective treatment options. These tumors are notoriously difficult to access, and conventional methods like surgery often lead to significant neurological deficits. Additionally, radiation therapy has shown limited effectiveness. The trial was officially launched in July 2023. As NEO100 uses the same treatment platform as the malignant gliomas, we bypassed the Phase I trial and received FDA approval for a Phase II trial within just 30 days.</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Separate from this single-drug application, NEO100 is further being investigated as a drug delivery vehicle, where the results of NeOnc&#8217;s preclinical studies suggest evidence that the combination of NEO100 with other drugs may enable a patient&#8217;s improved brain tumor delivery via the intranasal route. Intranasal NEO100, mixed with levodopa (L-DOPA), is in the planning stages for a clinical trial in patients with Parkinson&#8217;s disease (PD). NeOnc&#8217;s laboratory experiments showed that intranasal NEO100 mixed with levodopa was able to reverse PD symptoms in mice. A Phase I clinical trial is planned to study the impact on human patients.</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">In our ongoing effort to streamline our clinical trials, we have identified approximately 80 grade III IDH1 mutation-positive patients as potential candidates for our clinical trial. We believe this targeted enrolment pool may significantly expedite our trial process. With this refined focus, we are revising our protocol inclusion criteria to include Residual Measurable Disease (RMD) grade III IDH1 mutant patients. We believe this amendment to our enrolment criteria may markedly accelerate patient accrual, enhance the efficiency of our trials and may lead to quicker results. As a result of these changes, we project that the readout for our Phase II studies with respect to NEO100-01 could now be feasibly delivered by the end of first quarter of 2026.</FONT></P></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Separate from this single-drug application, NEO100 is further being investigated as a drug delivery vehicle, where the results of NeOnc&#8217;s preclinical studies suggest that the combination of NEO100 with other drugs may enable a patient&#8217;s improved brain tumor delivery via the intranasal route. Our second lead product, NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol, has completed preclinical testing and has received investigational new drug (IND) approval from the United States Food and Drug Administration (FDA), i.e., it has been authorized to proceed to clinical testing in cancer patients. We have designed a Phase I/II trial for oral NEO212, which began in the fourth quarter of 2023. In this trial, NEO212 will be administered orally to patients with primary brain tumors (i.e., malignant gliomas) and secondary brain tumors (i.e., brain metastases originating from peripheral tumors, such as tumors of the lung, breast, skin/melanoma, etc.). Furthermore, NEO212 is undergoing development towards intranasal application specifically for patients with uncontrolled brain metastases derived from peripheral tumors (lung, breast, skin, etc.), but has not yet been studied in human patients.</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The Pipeline of NeOnc Drug</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="img_002.jpg" ALT="" STYLE="height: 317px; width: 550px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lead Product: NEO100</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: justify; width: 65%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">NEO100 is our most advanced product candidate based on perillyl alcohol (POH). This naturally occurring monoterpenoid can be found as a constituent of essential oils from various botanicals, including peppermint, spearmint, lavender, bergamot, lemongrass, sage, thyme, cherries, and others. POH has been used in cosmetics, fragrances, and some cleaning products and as an ingredient in baked goods, frozen dairy, gelatine, puddings, beverages, and candies. However, clinical trials by other companies with an oral POH formulation administered to cancer patients were not successful for two presumed reasons: (i) after ingestion, not enough POH entered the bloodstream, because the liver (portal vein) quickly metabolized and thereby eliminated POH; in fact, it was not possible to demonstrate the presence of POH in the blood of these patients; and (ii) in an effort to overcome the rapid depletion of POH, physicians attempted to administer increasing amounts of oral POH, which resulted in significant gastrointestinal toxicity that became dose-limiting. As a result, efforts to introduce oral POH into the clinic were abandoned.</FONT></P> </TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: right; width: 33%"><IMG SRC="img_003.jpg" ALT="" STYLE="height: 283px; width: 500px"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Under the direction of NeOnc, a novel manufacturing and delivery pathway was investigated which we believe may avoid the drawbacks of oral POH. Using derivatization of POH with a crystalline intermediate enabled the production of ultra-pure, pharmaceutical-grade NEO100. NEO100 received fast-track status in 2016 and orphan-drug designation in 2011 from the FDA. NeOnc&#8217;s novel approach uses intranasal, rather than oral, delivery. Our completed Phase I trial of intranasal NEO100 suggested that when given via the intranasal route: (i) the drug appeared to be well tolerated with no severe adverse effects being observed, despite consistent treatment over several months; and (ii) patients&#8217; reported quality of life was unchanged. In one patient, we were able to obtain brain tumor tissue (based on surgery immediately following intranasal delivery of a dose of NEO100), which we analyzed for the presence of NEO100 (POH). The presence of NEO100 (POH) was confirmed in the tumor tissue, thus providing proof of principle that intranasal delivery of NEO100 reaches its tumor target in the brain. This is in contrast to the above-mentioned studies with oral POH, where the presence of drug could not be demonstrated in blood or tumor tissue of any patient. Among the group of 12 patients in our Phase I trial, there were several long-term survivors: At two years after start of intranasal NEO100 treatment, five patients (37%) were still alive, which is noteworthy, because recurrent glioblastoma patients (that is, patients where the tumor has returned after one or more rounds of traditional treatment) have an average life expectancy of about six months, and 24-month survival is rare. Another result from our Phase I trial is the fact that three patients (i.e., 25% of the original cohort of 12 patients), were still alive after 3 years. These outcomes will have to be investigated with a larger number of patients to establish statistical significance. This is currently being pursued in our Phase IIa trial, where we are planning to expand our clinical trial sites and potentially enrolling the remaining Phase IIa patients. A data read out for any patient enrolled in the clinical trial is expected beginning six months from the enrollment of such patient.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="img_004.jpg" ALT="" STYLE="height: 341px; width: 600px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The above chart illustrates what is currently known about NEO100&#8217;s mechanism of action. The manner by which NEO100 may block tumor growth is thought to result from its pleiotropic (multi-faceted) impact on tumor cells. In <I>in vitro</I> tests: (i) NEO100 has been shown to inhibit the activity of the Ras protein. Ras is a (proto)onco-protein that stimulates mitogenic (growth-stimulatory) pathways inside cells. In tumor cells, it is often mutated, resulting in its increased activity and uncontrolled cell growth. Inhibition of Ras by NEO100 is thought to remove this aberrant growth stimulus from tumor cells, causing cell cycle arrest. (ii) NEO100 has been shown to block the activity of sodium/potassium (Na/K) adenosine triphosphatase (ATPase). Na/K-ATPase is an ion pump that sits in the plasma membrane and regulates the flux of ions across the membrane. In cancer cells, it can have abnormal activity and not only helps cancer cells resist chemotherapy, but also stimulates them to spread to other locations in the body. We believe that NEO100 may stunt these advantages for cancer cells. (iii) NEO100 has been shown to intercalate into the plasma membrane to disturb membrane fluidity and the function of some proteins that are located at or near the plasma membrane (including Ras and Na/K-ATPase). Among the consequences is an electrolyte imbalance that triggers endoplasmic reticulum (ER) stress. Cancer cells in general are less resistant to withstand prolonged ER stress. As a result, in combination with cell cycle arrest, they undergo apoptosis (cell death).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><FONT STYLE="text-decoration: underline">Therapeutic applications of NEO100 that are under development by NeOnc</FONT>: </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify; border-collapse: collapse">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intranasal delivery that we hypothesize may bypasses the blood-brain barrier (BBB), which could permit delivery of drugs to the brain via cranial nerves I and V, and possibly allow delivery of other pharmaceutics to the brain. Proof of this principle has been observed in animal models, but has not yet been tested in human patients.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">
        <P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">At high concentrations, we are investigating whether intranasal NEO100 may be used as a therapeutic for treating brain cancers. In a Phase I trial there were preliminary signs of activity, based on several (25%) patients who have survived for at least 4 years, but validation of activity will have to await results from the ongoing Phase IIa and possible additional clinical trials.</FONT></P> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At low concentrations, NEO100 might act as a solvent and delivery vehicle for traditional large-molecule pharmaceutics, which could potentially bypass the BBB and enter the brain. Proof of this principle has been observed in animal models but has not yet been tested in human patients.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intra-arterial delivery of NEO100 could possibly create a temporary opening in the BBB, which might allow traditional large-molecule pharmaceutics to pass through and enter the brain. Proof of this principle has been observed in animal models, but has not yet been tested in human patients.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEO100 could potentially be covalently conjugated with other pharmaceutics to create novel fusion compounds that might enable superior BBB penetration ability and, potentially higher activity against brain cancer. Proof of this principle has been observed in animal models but has not yet been tested in human patients.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><FONT STYLE="text-decoration: underline">Intranasal NEO100 for the treatment of malignant glioma</FONT>: </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The FDA granted NEO100 Orphan Drug Designation (ODD) for treating malignant glioma in 2011. Orphan drug designation qualifies sponsors for incentives including tax credits for qualified clinical trials, exemption from user fees, and potential seven years of market exclusivity after approval. Upon approval, the exclusivity granted to orphan drugs provides seven years during which FDA may not approve any other sponsor&#8217;s application for the same drug for the same designated orphan disease or condition, regardless of whether such other sponsor files an Abbreviated New Drug Application (ANDA) for a generic version of the drug, or if another sponsor files a &#8220;full&#8221; new drug application (NDA). Orphan Drug Exclusivity does not, however, prevent FDA approval of applications for the same drug for a different indication, nor applications for a different drug for the same orphan indication. In limited circumstances, such as showing clinical superiority to the product with orphan drug exclusivity, FDA may approve a competing application during the Orphan Drug Exclusivity period. However, the process of clinical development is inherently uncertain and there is no guarantee that orphan drug designation will accelerate the timeline for approval or make it more likely that NEO100 will be approved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">For clinical testing of NEO100, a combined Phase I/IIa trial was conducted, with the first patient enrolled in April&#160;2017. NEO100 was administered intranasally 4-times a day to patients with recurrent glioblastoma. Patients enrolled in this trial had already undergone standard therapy, but the disease had returned and was deemed untreatable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Among the inclusion criteria were the following: (i) Radiographically confirmed progression or recurrent grade IV glioma, and on a stable dose of steroid for at least 5 days; (ii) Patients must have failed previous radiation and temozolomide treatment; (iii) Age &#8805; 18 years; (iv) ECOG performance status of 0-2, or KPS &#8805; 60; (v) An expected survival of at least 3 months; (vi) Baseline MRI with gadolinium within two weeks of entry into the trial; and (vii) Seizures controlled on a stable dose of anti-epileptics for two weeks prior to enrollment. Furthermore, patients were screened with MR perfusion scan if there was a possibility that progression seen on a MRI scan represented pseudo-progression. Response assessment was performed by gadolinium-enhanced MRI and assessment by RANO (Response Assessment in Neuro-Oncology) criteria every two months. Adverse events were graded for severity using NCI Common Terminology Criteria for Adverse Events v.4.0.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The institutions that participated in the trial were Cleveland Clinic, University of Washington/Seattle, University of Wisconsin, and the University of Southern California. It was sponsored by NeOnc Technologies, Inc. (Los Angeles, CA) with ClinDatrix, Inc. (Irvine, CA), as the Clinical Data Management CRO (Contract Research Organization). A total of 12 patients were enrolled in Phase I, which was completed in 2020. The patients were divided into four cohorts, three patients per cohort in a dose escalating trial (384-1152 mg/day). Patients received the intranasal dosage using a nebulizer mask four times a day. The results suggested that intranasal NEO100, even at the highest dose given, appeared to be well tolerated, and there were no serious adverse events reported in any of the patients, i.e., there were only minor side effects, such as a runny nose or nasal discomfort.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Results from Phase I preliminarily suggested that intranasal NEO100 might have exerted therapeutic activity in some of these patients, although statistical analysis was limited by the small number of 12 patients, which means that statistically firm conclusions cannot be drawn. Most patients (55%) survived for more than one year, four patients (33%) survived for over two years, and three patients (25%) remained alive at the 3-year mark.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Primary endpoints for Phase I were to determine maximum tolerated dose (MTD) and progression free survival (PFS). NEO100 did not reach MTD, as results suggested that NEO100 was well tolerated by the cohort 4 patients. The recommended Phase II dose was therefore at 1152 mg/day. PFS at 6 months was 33%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Survival Data from NeOnc&#8217;s Phase I Clinical Trial with Intranasal NEO100</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="img_005.jpg" ALT="" STYLE="height: 303px; width: 600px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="img_006.jpg" ALT="" STYLE="height: 347px; width: 600px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Patient Survival: NeOnc&#8217;s Phase I Trial</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Secondary endpoints were evaluated for: a) pharmacokinetic endpoints of POH and perillic acid (PA) metabolism, b) objective tumor response according to RANO criteria, and c) adverse events.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pharmacokinetic measurements were performed in patients at the time of trial entry and used to measure the ability of patients to properly inhale NEO100. All patients had the expected rapid elimination of NEO100 within 30 minutes from serum, and elimination of its PA within 2 hours.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Objective tumor response to NEO100 was determined by RANO criteria. NEO100 performance by RANO criteria was reported as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="img_007.jpg" ALT="" STYLE="height: 402px; width: 600px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The third secondary endpoint was adverse events, as characterized by type, frequency, and severity (NCI common terminology for adverse events were reported as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="img_008.jpg" ALT="" STYLE="height: 402px; width: 600px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Moreover, our Phase I clinical trial indicated that patients harboring an IDH1 mutation in their tumor cells responded to treatment more favorably than those without the mutation. Among the 12 patients, five presented with IDH1 mutant status. Among these five, four patients (80%) survived longer than the seven patients without IDH1 mutation. As of February&#160;12, 2021 three of them were still alive four years after the recurrence of their original tumor and initiation of NEO100 treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">A potential advantage of intranasal NEO100 is that intranasal delivery via a nebulizer device does not require surgeries, infusions, or other invasive procedures that would require medical visits. Rather, intranasal delivery could be done conveniently at home (or while traveling) by the patients themselves. Compared to the well-known toxicities of many chemotherapeutic agents, NEO100 appeared to be well tolerated at the doses tested in the limited Phase I trial, and none of the typical side effects of other cancer pharmaceutics (nausea, debilitating fatigue, anemia, infections, diarrhea, hair loss, etc.) were observed. It, therefore, suggests that NEO100 may not lead to deterioration of quality of life for patients (<FONT STYLE="color: red">Sch&#246;nthal AH et al., <I>Neuro-Oncol. Adv.</I> 3:1, 2021</FONT>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeOnc Phase IIa studies describe the first time NEO100 is given to the intended treatment population. The studies are undertaken to confirm dosing requirements identified in Phase I testing (such as how much, how often and to whom the drug should be given) are correct. They are sufficiently powered (statistically) to determine how well the drug performs at the prescribed dose and for the intended outcome. Work in future trials may be needed to further understand results obtained in Phase IIa testing (i.e., dosing, effect on a patient sub-population) and randomized, controlled Phase III testing may be required prior to marketing authorization. Details regarding the ongoing Phase IIa trials of NEO100 and the ongoing Phase I/II trial of oral NEO212 are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><FONT STYLE="text-decoration: underline">&#8220;An Open-Label, Phase I/IIa Dose Escalation Study of Safety and Efficacy of NEO100 in Recurrent or Progressive Grade III or IV Gliomas with IDH1 Mutation&#8221; (NEO100-01)</FONT></I></B></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Enrollment </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of Patients to be Treated: </B>24</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patient Sub-Populations Tested: </B>Radiographically-confirmed progression of, or recurrent, primary or secondary Grade IV glioma (the original study population) and radiographically-confirmed progression of, or recurrent, primary or secondary Grade III astrocytoma.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Primary Endpoint:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. Progression free survival at six months.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NEO100 Performance</B>&#160;&#8211; Cannot be reported until completion of the Phase IIa portion of the study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Secondary Endpoints:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. Objective tumor response to NEO100 as determined by RANO criteria.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NEO100 Performance</B>&#160;&#8211; Cannot be reported until completion of the Phase IIa portion of the study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2. Progression free survival.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NEO100 Performance</B>&#160;&#8211; Cannot be reported until completion of the Phase IIa portion of the study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. Overall survival.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEO100 Performance</B>&#160;&#8211; Cannot be reported until completion of the Phase IIa portion of the study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4. Perillic acid measurement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-left: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEO100 Performance</B>&#160;&#8211; Cannot be reported until completion of the Phase IIa portion of the study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Safety Endpoint:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. Adverse Events characterized by type, frequency, severity, as graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE v. 5.0), seriousness and relationship to study therapy NEO100.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEO100 Performance</B>&#160;&#8211; Cannot be reported until completion of the Phase IIa portion of the study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2. Changes from&#160;baseline in vital signs and clinical laboratory parameters (hematology and chemistry), as well as ECOG performance status will be assessed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NEO100 Performance</B>&#160;&#8211; Cannot be reported until completion of the Phase IIa portion of the study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of Patients Currently Enrolled: </B>20</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><FONT STYLE="text-decoration: underline">&#8220;An Open-Label, Phase II Study of NEO100 in Participants with Residual, Progressive or Recurrent High-Grade Meningioma&#8221; (NEO100-02)</FONT></I></B></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of Patients to be Treated: </B>29</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patient Sub-Populations Tested: </B>Radiographically-confirmed progression of, or recurrent, WHO Grade II or III meningioma</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Primary and Secondary Endpoints:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Primary Endpoint: Progression free survival at 6 months</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Secondary Endpoint: </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Objective tumor response by RANO criteria</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Progression free survival</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Overall survival</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Perillic acid measurement and level</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of Patients Currently Enrolled:&#160;</B>6</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I><FONT STYLE="text-decoration: underline">&#8220;An Open-Label, Phase I/II Dose Finding, Safety and Efficacy Study of Oral NEO212 in Patients with Astrocytoma IDH-Mutant, Glioblastoma IDH-Wildtype or Uncontrolled Metastasis to the Brain in Patients with Select Solid Tumors (NEO212-01)</FONT></I></B></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of Patients to be Treated:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Phase I:</B> Up to 36</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Phase IIa: </B>12</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Phase IIb: </B>27 per cohort</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patient Sub-Populations Tested:&#160;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Phase I:</B> Radiographically-confirmed astrocytoma IDH-mutant, glioblastoma IDH-wildtype following previously radiation therapy or treatment with temozolomide and radiation or a select solid tumor with uncontrolled brain metastases (e.g., melanoma, NSCLC, SCLC, HNSCC, urothelial carcinoma, gastric cancer, renal cell cancer, colorectal cancer)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Phase IIa:</B>&#160;Radiographically-confirmed astrocytoma IDH-mutant, glioblastoma IDH-wildtype following previously radiation therapy or treatment with temozolomide and radiation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Phase IIb:</B>&#160;Select solid tumor with uncontrolled brain metastases (e.g., melanoma, NSCLC, SCLC, HNSCC, urothelial carcinoma, gastric cancer, renal cell cancer, colorectal cancer)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Primary and Secondary Endpoints</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Primary Objectives</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assess the safety and tolerability of increasing dose levels of orally administered NEO212 in patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype and patients with select solid tumors with uncontrolled metastases to the brain. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identify the maximum tolerated dose (MTD) of NEO212. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determine the recommended Phase II dose (RP2D) of NEO212. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Secondary Objectives</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Characterize the pharmacokinetics (PK) of NEO212. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluate anti-tumor activity of NEO212 in patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype and patients with select solid tumors with uncontrolled brain metastases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of Patients Currently Enrolled:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Phase I:</B> 12</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Phase IIa:</B>&#160;Not Open to Accrual</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Phase IIb:</B>&#160;Not Open to Accrual</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; background-color: white; color: #222222"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pipeline Product Candidates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">NEO212</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-indent: 0.5in; text-align: justify; width: 65%">
        <P STYLE="text-align: justify; text-indent: 0.5in; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEO212 (chemical structure shown on the right) was designed as a hybrid compound where NEO100 was covalently conjugated to temozolomide (TMZ), an alkylating agent that represents the current standard of chemotherapeutic care for patients with glioblastoma. Based on the recognition that amphipathic NEO100 in research has suggested it may permeate biological barriers and cellular membranes, we hypothesized that this novel covalent molecule might penetrate the blood-brain barrier, possibly enabling a dual approach against malignant lesions in the brain. Our preclinical characterization of NEO212 in various mouse tumor models suggests that this multifunctional agent may show activity against a variety of cancer types. In preclinical studies, results suggested that NEO212 demonstrated activity against primary and secondary brain cancers as well as cancer types that were chemoresistant to other commonly used cancer therapeutics <FONT STYLE="color: Red">(Chen TC et al., <I>Molecular Cancer Therapeutics </I>13:1181, 2014; Chen TC et al., <I>Cancer Letters</I> 358:144, 2015; Chen TC et al., <I>Journal of Biomedical Sciences</I> 22:71, 2015; Cho HY et al., <I>Molecular Cancer Therapeutics </I>13:2004, 2014; Jhaveri N et al., <I>Cancer Letters</I> 371:240, 2016; Marin-Ramos NI et al., <I>Oncoscience </I>5:148, 2018; Marin-Ramos NI et al., <I>Molecular Cancer Therapeutics </I>17:625, 2018)</FONT>. So far, the activity of NEO212 has not yet been studied in humans.</FONT></P></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: right; width: 33%"><IMG SRC="img_009.jpg" ALT="" STYLE="height: 148px; width: 350px"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">NEO212 demonstrates an interesting feature that its demonstrated activity in preclinical studies may be greater than the sum of its parts. That is: merely applying its individual constituents, NEO100 and TMZ, as a mix of two independent compounds (akin to the conventional combination therapy mode) may not mimic the potential of the conjugated hybrid molecule. The toxicological studies in rodents and dogs suggest that NEO212 was tolerated. When administered at the same dosages as those that suggest activity in mouse cancer models, there were no detectable side effects in mice, rats, or dogs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The demonstrated activity in preclinical studies of NEO212, along with its low toxicity profile, contributed to our IND application for oral administration that was approved by the FDA in 2023. FDA approval provides an opportunity for Phase I/IIa clinical trials, primarily focusing on patients with intracranial malignancies. We are designing clinical trials that evaluate two different modes of NEO212 delivery: oral and intranasal. Oral NEO212 during Phase I will be administered to patients with brain malignancies that include primary and secondary brain cancers (so-called &#8220;all comers&#8221;). Phase IIa will focus on newly diagnosed, primary glioblastoma. Intranasal NEO212 will be used in a Phase I/IIa trial in patients with metastatic brain cancer, i.e., where brain lesions originated from cells that were disseminated by tumors from outside the brain, such as lung cancer, breast cancer, or melanoma. All these patients represent a cohort in dire need of better therapies, and NEO212 may hold the potential that might improve their prognosis and survival.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The FDA granted NEO212 Orphan Drug Designation (ODD) for three different indications: (i) glioma (2014), (ii) brain metastases from breast cancer (2017), and (iii) nasopharyngeal carcinoma (2017). As stated above, if a product that has ODD subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusive approval (or exclusivity), which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years (except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity). However, the process of clinical development is inherently uncertain and there is no guarantee that orphan drug designation will accelerate the timeline for approval or make it more likely that NEO212 will be approved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Three Drug Delivery Pathways Potentially Enabled by NEO100</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cancerous tissue in the brain is protected from systemically circulating drugs by the blood-brain barrier (BBB), which prevents the brain entry of most pharmaceutical agents. We are using NEO100 to develop three different methods of overcoming the obstacle placed by the BBB:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify; border-collapse: collapse">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><FONT STYLE="text-decoration: underline">Intranasal delivery</FONT>: </I>As part of a direct nose-to-brain route, this pathway could potentially allow direct brain access without interference from the BBB.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><FONT STYLE="text-decoration: underline">Monotherapy with NEO100</FONT>: </I> At higher dosages, intranasal delivery of NEO100 is in clinical testing for patients with glioblastoma.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><FONT STYLE="text-decoration: underline">Combination therapy with NEO100</FONT>: </I>At lower dosages, intranasal NEO100 might be used as a carrier for the co-delivery of established therapeutics to the brain. This has been observed in animal models, but it has not yet been studied in humans.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">
        <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I><FONT STYLE="text-decoration: underline">Conjugated delivery</FONT>: </I>Stable conjugation of NEO100 to other therapeutic agents (such as temozolomide, creating NEO212) indicated a possible increase in the ability of the fused compound to penetrate the BBB and enter the brain. This has been observed in animal models, but it has not yet been studied in humans.</FONT></P> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">
        <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><FONT STYLE="text-decoration: underline">Permeable delivery</FONT>: </I></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">Intra-arterial delivery of NEO100 may create temporary (up to 4 hours) openings in the BBB, that we believe could potentially enable drugs (Adriamycin<SUP>&#174;</SUP>, Velcade<SUP>&#174;</SUP>, etc.) and therapeutic antibodies (Herceptin<SUP>&#174;</SUP>, Opdivo<SUP>&#174;</SUP>, etc.) to enter the brain and reach the tumor bed. This has been observed in animal models, but it has not yet been studied in humans.</FONT></P> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD ROWSPAN="3" STYLE="text-align: justify; width: 65%">
        <P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">All three drug delivery pathways potentially enabled by NEO100 are being investigated by NeOnc and are at different stages of development. Only one of these pathways, monotherapy with intranasal NEO100, has moved into clinical testing, where Phase I studies have been completed and Phase IIa studies are ongoing. The other pathways, including combination therapy with NEO100, conjugated delivery (e.g., NEO212), and permeable delivery have not yet reached the clinical stage and have not yet been studied in humans. In these latter pathways, preclinical studies are currently ongoing to provide further results and IND-enabling data, so that in the future these principles can be studied in human cancer patients.</P>
        <P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&#160;</P>
        <P STYLE="font: 10pt/115% Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">We believe these three delivery areas (details below) may be key to a potential shift in physicians&#8217; ability to treat brain diseases. They represent potential pathways for possible reliable delivery of pharma-therapeutics to the brain, potentially mitigating problems and side effects from current methodologies, and potentially providing an alternative treatment protocols to existing pharma manufacturers for their drugs.</P></TD>
    <TD STYLE="width: 2%; line-height: 115%; font-size: 10pt">&#160;</TD>
    <TD STYLE="text-align: right; width: 33%"><IMG SRC="img_010.jpg" ALT="" STYLE="height: 328px; width: 300px"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%; font-size: 10pt">&#160;</TD>
    <TD STYLE="text-align: right; line-height: 115%; font-size: 10pt">&#160;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%; font-size: 10pt">&#160;</TD>
    <TD STYLE="text-align: right; line-height: 115%; font-size: 10pt"><IMG SRC="img_011.jpg" ALT="" STYLE="height: 254px; width: 300px"></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; line-height: 115%; font-size: 10pt">&#160;</TD>
    <TD STYLE="line-height: 115%; font-size: 10pt">&#160;</TD>
    <TD STYLE="text-align: right; line-height: 115%; font-size: 10pt">&#160;</TD></TR>
  </TABLE>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="text-decoration: underline">Intranasal Delivery of NEO100</FONT>: Administration of NEO100 into the nose is accomplished by a standard nebulizer that aerosolizes NEO100 into fine particles that reach the olfactory mucosa and its embedded nerve endings in the nasal cavity. Uptake by these and other nerve cells enables direct nose-to-brain transport of NEO100 so it can reach the tumor sites without interference from the BBB. This direct mode of brain-targeted drug administration is thought to deliver higher levels of the drug to the brain tumor site as compared to oral delivery of a given drug, also because this route of transport avoids drug breakdown in the liver. It also lowers total drug exposure to the rest of the body; therefore, it&#8217;s hypothesized there may be fewer side effects. This principle was observed in the Phase I clinical trial with glioblastoma patients above-mentioned (<FONT STYLE="color: red">Sch&#246;nthal AH et al., <I>Neuro-Oncol. Adv.</I> 3:1, 2021</FONT>). And the actual presence of NEO100 (perillyl alcohol), along with its major metabolite, perillic acid, has been observed in brain tumor tissue (<FONT STYLE="color: red">Sch&#246;nthal AH et al., <I>J. Neurosurg. Case Lessons</I> 4:case22215, 2022</FONT>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I><FONT STYLE="text-decoration: underline">Ongoing activities for intranasal delivery of NEO100</FONT>: </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Phase IIa component of our clinical trial is ongoing in patients with recurrent Grade IV glioma (further details are provided below).</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A similar Phase IIa trial of intranasal NEO100 (NEO100-02) for patients with malignant skull based meningioma is also ongoing. Meningiomas are slow-growing tumors originating in the meninges, the membranous layers surrounding the brain and spinal cord. We initiated this because these patients lack effective treatment options. These tumors are notoriously difficult to access, and conventional methods like surgery often lead to significant neurological deficits. Additionally, radiation therapy has shown limited effectiveness. The trial was officially launched in July 2023. As NEO100 uses the same treatment platform as the malignant gliomas, we bypassed the Phase I trial and received FDA approval for a Phase II trial within just 30 days.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intranasal NEO100, mixed with levodopa (L-DOPA), is in the planning stages for a clinical trial in patients with Parkinson&#8217;s disease (PD). NeOnc&#8217;s laboratory experiments showed that intranasal NEO100 mixed with levodopa was able to reverse PD symptoms in mice. A Phase I clinical trial is planned to study the impact on human patients.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="text-decoration: underline">Stable Conjugation of NEO100 to Other Therapeutic Agents</FONT>: Many drugs work quite well for diseases in the rest of the body but do not reach the brain due to the BBB obstacle. Our pre-clinical results suggested that stable conjugation of several such drugs to NEO100 may increase their ability to reach lesions located in the brain. Temozolomide (TMZ) is widely used to treat malignant glioma&#8212;even though it enters the brain sub-optimally, its modest therapeutic impact is an expression of this limitation. However, when conjugated to NEO100, creating NEO212, the molecule may cross the BBB, and in preclinical mouse models, various types of brain malignancies have shown therapeutic activity. NEO212&#8217;s IND application was approved by the FDA in May&#160;2023. (Further details on NEO212 are provided below.)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-indent: 0.5in; text-align: justify; width: 65%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="text-decoration: underline">Intra-arterial Injection of NEO100</FONT>: Our preclinical studies in mouse models with brain cancer suggest that intra-arterial delivery of NEO100 might open the BBB up to four hours, which could allow other therapeutic agents to enter the brain from the bloodstream or a catheter in those models. The mechanism appears to be via a transient opening of the tight junctions between the brain endothelial cells. Catheters can be used to deliver NEO100 to specific parts of the brain, particularly to the sites where the tumor bed is located, so that co-delivered pharmaceutics can immediately access the malignant tissue. In this manner, NEO100 and any other co-delivered therapeutic agent might impact the tumor. While this principle has been established in our preclinical studies, it has not yet been tested in human patients., Well-known side effects of the brain cancer agent temozolomide (TMZ) are bone marrow suppression and resulting infections. We believe these side effects may be reduced or possibly avoided if the bone marrow can be spared from whole-body exposure to TMZ, as is a consequence of the typical oral ingestion of TMZ. This catheter-based approach is based on the co-delivery of another agent (as a mix). It is distinct from the above described stable conjugation of NEO100 to another compound, such as TMZ, which creates a single fusion molecule (as in NEO212).</FONT></P> </TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: right; width: 33%"><IMG SRC="img_012.jpg" ALT="" STYLE="height: 289px; width: 500px"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our Markets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">The global central nervous system (CNS) treatment market is expected to grow at 8.6% CAGR to reach $267.6 billion by 2034, and the global brain tumor drug market is expected to grow at CAGR of 9.8% reach $4.6 billion by 2032, according to Fortune Business Insights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Radiation therapy still accounts for 38% of the brain cancer treatment market, while drug treatment remains second mostly due to current inefficiencies of drug delivery, according to Grandview Research.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">We also address the malignant glioblastoma multiforme (GBM) treatment market. The GBM drug market is expected to grow at 9.8% CAGR to $4.4 billion by 2023, according to iHealthcare Analyst, with the market being driven by rising geriatric population, growing incidence cases, and a pipeline of new products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> GBM accounts for up to 54% of gliomas and 16% of all primary brain cancers, according to research published in the journal, <I>Glioblastoma</I>. By creating an alternative delivery mechanism for GBM drug therapy, we believe we can significantly impact market demand in this sector.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our Strategy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="text-align: justify">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our goal is to change the cancer therapeutic landscape by developing novel therapeutic approaches leveraging dual approaches of novel drug delivery methods in combination with novel drug candidates that potentially lead to better therapeutic results with low side effects.</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The following five clinical applications of our drugs are at different stages of preclinical or clinical development:</FONT></P></TD> </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD> </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intranasal delivery of NEO100 to patients with IDH mutant malignant glioma (Phase IIa clinical trial has started).</FONT></TD> </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD> </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intranasal delivery of NEO212 to patients with brain metastasis (IND approved).</FONT></TD> </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD> </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intranasal delivery of NEO100 alone, and in combination with doxorubicin for pediatric brain tumors (IND approved).</FONT></TD> </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD> </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intranasal co-delivery of NEO100 with levodopa for Parkinson&#8217;s disease (preclinical stage).</FONT></TD> </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD> </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intra-arterial delivery of NEO100 to open the patient&#8217;s blood-brain barrier, allowing brain entry of BBB-impermeable pharmaceuticals or biologics (preclinical stage).</FONT></TD> </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&#160;</TD>
    <TD STYLE="text-align: justify">&#160;</TD>
    <TD STYLE="text-align: justify">&#160;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oral NEO212 for primary brain cancer, including glioblastoma (IND approved).</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="text-decoration: underline">Details: <B>1. </B>Intranasal delivery of NEO100 to patients with IDH mutant malignant glioma (Phase IIa clinical trial has started)</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">NEO100 is our most advanced product candidate. Its chemical structure (<B>Figure 1</B>) is based on the natural compound perillyl alcohol (POH). We have investigated a novel manufacturing and delivery pathway that avoided the drawbacks of oral POH and capitalized on its recognized properties. The FDA granted NEO100 Orphan Drug Designation (ODD) for treating malignant glioma.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="img_013.jpg" ALT="" STYLE="height: 205px; width: 350px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure 1: Chemical structure of NEO100</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">NeOnc sponsored a Phase I clinical trial, where NEO100 was administered to patients with recurrent glioblastoma. All enrolled patients had already undergone standard therapy for this disease, consisting of radiation treatment combined with chemotherapy. Still, this standard therapy had stopped working, and patients were no longer benefiting from it. At this stage of the re-emerging glioblastoma disease, there is no clear clinical recommendation for specific further treatment because effective treatments do not exist for this patient group. Rather, the prognosis is dismal, and the average median survival is only 6-9 months.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After enrollment in our study, patients received intranasal NEO100 four times daily, using a standard nebulizer and nasal mask. After initial instructions by a nurse, patients can self-administer this treatment at the convenience of their home. Four cohorts of 3 patients each received the following dosages: 96 mg/dose (384 mg/day), 144 mg/dose (576 mg/day), 192 mg/dose (768 mg/day), and 288 mg/dose (1152 mg/day). Completion of 28 consecutive days of treatment was recorded as one cycle. Adverse events were documented, and radiographic response <I>via </I>RANO criteria was evaluated every two months. Progression-free and overall survival were determined after 6 and 12 months, respectively (PFS-6, OS-12).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The trial was completed in 2020, and after peer review, the results obtained from these 12 patients were published in 2021 (<FONT STYLE="color: Red">Sch&#246;nthal AH et al., <I>Neuro-Oncology Advances</I> 3(1):1-12, 2021</FONT>). Data analysis suggested that intranasal NEO100 may be well tolerated at all four dose levels, and even at the highest dose levels, no severe adverse events were noted. Minor side effects included a runny nose or nasal discomfort. PFS-6 was 33%, OS-12 was 55%, and of the three cohorts&#8217; median survival was 15 months (<B>Figure 2</B>, left panel). Four patients (33%) survived &gt;24 months. Thus, compared to historical controls and what is commonly observed in clinical practice, average patient survival in our clinical trial with these 12 patients might be improved (see further comparison details below). As important, there were none of the typically harsh side effects of many conventional chemotherapies, such as nausea, debilitating fatigue, anemia, infections, diarrhea, hair loss, etc.). Treatment with intranasal NEO100, therefore, did not lead to deterioration of quality of life for patients. However, further research is needed to confirm these results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure 2: Survival of all 12 patients (left) and survival in relation to IDH status (right).</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="img_014.jpg" ALT="" STYLE="height: 210px; width: 650px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From: <FONT STYLE="color: Red">Sch&#246;nthal AH et al., <I>Neuro-Oncology Advances</I> 3(1):1-12, 2021</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Detailed further analysis of our Phase I trial suggested that patients with the highest response to intranasal NEO100 were those whose tumor harbored a mutation in the gene for isocitrate dehydrogenase 1 (IDH1) (<B>Figure 2</B>, right panel). In the five patients with this mutation, 4 (80%) survived a minimum of 24 months while being treated with intranasal NEO100. In contrast, seven patients without this mutation succumbed to disease earlier&#8212;although their average median survival of 11 months was still longer than what might have been expected based on historical experience in the clinic.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prompted by these observations from our Phase I clinical trial, a Phase IIa continuation of intranasal NEO100 was started in 2021 for high-grade glioma patients with IDH1 mutations. As with Phase I, the trial is being conducted as a multicenter study. A total of 12 institutions will be recruited to enroll 31 patients for our Phase IIa trial, of which five have been recruited. The potential mechanism by which these IDH1 mutant patients may have a specific survival advantage in response to NEO100 is the subject of our current laboratory investigations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="text-decoration: underline">Details: <B>2.</B> Intranasal delivery of NEO212 to patients with brain metastasis (IND submission scheduled for late 2023)</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">NEO212 is a hybrid compound where NEO100 is covalently conjugated to temozolomide (TMZ) via a carbamate bridge (<B>Figure 3</B>). While TMZ has been widely used as the standard of care for the treatment of glioblastoma, it does not penetrate the BBB effectively; unsurprisingly, its clinical efficacy is relatively modest. Also, its activity could be further reduced when applied to tumors that are positive for O6-methylguanine methyltransferase (MGMT). This DNA repair protein protects tumor cells from killing by TMZ. Our preclinical studies suggest that NEO212 may potentially be able to overcome these drawbacks and exert its activity even against tumor cells that are positive for MGMT. The FDA granted NEO212 Orphan Drug Designation (ODD) for three different indications: (i) glioma, (ii) brain metastases from breast cancer, and (iii) nasopharyngeal carcinoma.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure 3: Chemical structure of NEO212: NEO100 conjugated to temozolomide.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="img_015.jpg" ALT="" STYLE="height: 218px; width: 450px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">NEO212 was initially designed as a therapeutic molecule with potential enhanced capability of crossing the blood-brain barrier to address the urgent clinical need for better treatments of intracranial malignancies, such as glioblastoma and brain-metastatic lesions from peripheral cancers. In mouse models data indicated that orally-administered<SUP>1 </SUP> NEO212 enters the brain in higher quantities than oral TMZ alone. While NEO212 has been investigated in multiple preclinical studies, it has so far not been studied in humans. Based on preclinical studies, the following potential beneficial features of this compound can be summarized as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEO212 might exert greater activity than the sum of its parts; i.e., a mere combination of the individual components, TMZ plus POH at equimolar ratios, does not appear to mimic the activity of the conjugated compound, both <I>in vitro</I> and in mouse tumor models <I>in vivo </I>(<FONT STYLE="color: red">Chen TC et al., <I>Molecular Cancer Therapeutics </I>13:1181, 2014; Chen TC et al., <I>Cancer Letters </I>358:144, 2015; Chen TC et al., <I>Journal of Biomedical Sciences</I> 22:71, 2015; Cho HY et al., <I>Molecular Cancer Therapeutics </I>13:2004, 2014; Jhaveri N et al., <I>Cancer Letters</I> 371:240, 2016; Marin-Ramos NI et al., <I>Oncoscience </I>5:148, 2018; Marin-Ramos NI et al., <I>Molecular Cancer Therapeutics </I>17:625, 2018</FONT>).</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In mouse tumor models, NEO212 displayed intracranial therapeutic activity not only against glioblastoma (<FONT STYLE="color: Red">Cho HY et al., <I>Molecular Cancer Therapeutics </I>13:2004, 2014; Jhaveri N et al., <I>Cancer Letters</I> 371:240, 2016; Marin-Ramos NI et al., <I>Oncoscience </I>5:148, 2018; Marin-Ramos NI et al., <I>Molecular Cancer Therapeutics </I>17:625, 2018; Minea RO et al., <I>PLoS One</I> 15(9):e0238238, 2020</FONT>) but also against brain-metastatic breast cancer xenografts (<FONT STYLE="color: Red">Chen TC et al., <I>Molecular Cancer Therapeutics </I>13:1181, 2014</FONT>) (<B>Figure 4</B>).</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-bottom: 0pt; width: 25%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>1</SUP></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Confirm oral route.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Besides intracranial tumors in mouse tumor models, NEO212 showed activity against peripheral cancers in mouse tumor models, including subcutaneous melanoma (<FONT STYLE="color: red">Chen TC et al., <I>Cancer Letters</I> 358:144, 2015</FONT>), nasopharyngeal carcinoma (<FONT STYLE="color: red">Chen TC et al., <I>Journal of Biomedical Sciences </I>22:71, 2015; Xie L et al., <I>Oncotarget</I> 7:1651, 2016</FONT>) ovarian carcinoma (<FONT STYLE="color: red">Song X et al., <I>Journal of Experimental and Clinical Cancer Research</I> 38:239, 2019</FONT>), lung cancer (<FONT STYLE="color: red">Song X et al., <I>Cell Death &amp; Disease</I> 9:202, 2018; Song X et al., <I>Scientific Reports</I> 6:22762, 2016; Chang M et al., <I>Journal of Experimental and Clinical Cancer Research </I>37:250, 2018</FONT>), cutaneous T-cell lymphoma (<FONT STYLE="color: red">Silva-Hirschberg C et al., <I>Therapeutic Advances in Medical Oncology</I> 11:1758835919891567, 2019</FONT>), and cytosine arabinoside-resistant leukemia (<FONT STYLE="color: red">Sch&#246;nthal AH et al., <I>Cancers </I>13(14):3385, 2021</FONT>).</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The activity of NEO212 was also documented with the use of primary patient samples implanted into mice, including glioblastoma stem cells (<FONT STYLE="color: red">Jhaveri N et al., <I>Cancer Letters</I> 371:240, 2016; Marin-Ramos NI et al., <I>Oncoscience</I> 5:148, 2018</FONT>) as well as xenografts of a variety of TMZ-resistant glioma and melanoma lines, where drug resistance was based on different molecular mechanisms (<FONT STYLE="color: red">Chen TC et al., <I>Cancer Letters</I> 358:144, 2015; Cho HY et al., <I>Molecular Cancer Therapeutics </I>13:2004, 2014</FONT>).</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify">
        <P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">In all tested in <I>vivo</I> models, NEO212 was administered orally in the range of 5-50 mg/kg (once per day, repeat dosing). This dose range seemed well tolerated by mice, rats, and dogs and did not result in detectable signs of toxicity.</FONT></P> </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure 4: Representative result showing survival of mice with brain-metastatic breast cancer.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;<IMG SRC="img_016.jpg" ALT="" STYLE="height: 286px; width: 550px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Source: <FONT STYLE="color: Red">Chen TC et al., <I>Molecular Cancer Therapeutics </I>13:1181, 2014</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The observed activity of NEO212, which was recapitulated in a variety of preclinical tumor models, along with its low observed toxicity profile, led to our IND application to the FDA which was approved in May&#160;2023. FDA approval allowed us to proceed for Phase I/IIa clinical trials, primarily focusing on patients with intracranial malignancies (metastatic and malignant primary brain cancer types). Although NEO212 also showed activity against peripheral cancer types (melanoma, lung cancer, breast cancer, and others) in pre-clinical studies, our first clinical trial will focus on patients with aggressive brain cancer types because the clinical need is the greatest here; due to the significant clinical need because no therapies exist. Because NEO212 was designed for blood-brain barrier penetration, we would expect that it might reveal its most valuable impact in patients with brain malignancies. However, studies with NEO212 in humans have not yet started.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="text-decoration: underline">Details: <B>3.</B> Intranasal co-delivery of NEO100 with levodopa for Parkinson&#8217;s disease (preclinical stage)</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our preclinical research in mouse brain tumor models indicated that intranasal delivery of NEO100 may facilitate nose-to-brain transport of NEO100 itself and potentially enabled co-delivered pharmaceutics to be carried along this axis and enter the brain as well. For example, intranasal co-delivery of NEO100 with bortezomib (a drug marketed under the trade name Velcade<SUP>&#174;</SUP>) seemed to allow bortezomib to enter the mouse&#8217;s brain resulting in activity against brain cancer. Without NEO100, bortezomib could not enter the brain (<FONT STYLE="color: red">Wang W et al., <I>Journal of Neurosurgery</I> 132(3):959, 2019</FONT>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Given preclinical results of NEO100&#8217;s ability to act as a vehicle to carry other pharmaceutics into the brain, we considered its application to neurological diseases, such as Parkinson&#8217;s disease (PD) or Alzheimer&#8217;s disease (AD), which are increasing in numbers as the U.S. population is aging. PD Patients are treated with levodopa (L-Dopa) pills, which must be dosed precisely. These pills have common side effects, such as hypotension, nausea, confusion, and dyskinesia. Therefore, intranasal delivery with direct nose-to-brain transport would be highly desirable because it is could potentially offer better brain-directed delivery without exposing the entire body to the drug, minimizing the undesirable side effects. As well, smaller doses can be given. In our work, we used mice with PD-type lesions in their brains and co-administered NEO100 together with L-Dopa by intranasal delivery. Our results suggest that intranasal co-delivery of NEO100 and L-Dopa suppresses PD symptoms in these mice. Intranasal delivery of L-Dopa without the added NEO100 did not achieve this beneficial effect (<B>Figure 5</B>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Figure 5: Mixture of NEO100 with L-Dopa (red underline), when given intranasally, could potentially restore healthy brain function of PD in mice as does a subcutaneous injection of apomorphine (blue underline).</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="img_017.jpg" ALT="" STYLE="height: 446px; width: 400px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From: <FONT STYLE="color: Red">Wang W et al., manuscript in preparation.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The health benefits of this approach in the mice were analyzed by determining the physical activity of the mice, in particular their ability to rotate to one side. Untreated PD mice are sick and unable to perform rotations, which is a symptom of the disease. But mice receiving intranasal NEO100 combined with L-Dopa appear to be physically active and perform rotations (bar graphs of mice in <B>Figure 5</B> with the label underlined in red). The figure also shows that mice injected with apomorphine recover from PD (label underlined in blue). However, compared to the ease of intranasal delivery, injections are invasive and do not support brain-targeted delivery due to the resulting systemic distribution of the injectate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="text-decoration: underline">Details to <B>4.</B> Intra-arterial delivery of NEO100 to open the patient&#8217;s blood-brain barrier will allow brain entry of BBB-impermeable pharmaceuticals or biologics (preclinical stage)</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">While intranasal applications of NEO100 may exploit direct nose-to-brain access routes and thereby circumvent the obstacle placed by the blood-brain barrier (BBB), an intra-arterial path of administering NEO100 has suggested that it also might directly confront the BBB and &#8220;open&#8221; it, diminishing its barrier function to potentially enable mostly unrestricted permeation of otherwise BBB-impermeable compounds. We established this procedure, characterized it in preclinical mouse tumor models, and shown that it may have advantages over the currently established clinical method of opening the BBB with mannitol (<FONT STYLE="color: red">Wang W et al., <I>Neuro-Oncology</I> 23(1):63, 2021</FONT>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We used mouse models of brain-metastatic breast cancer positive for human epidermal growth factor receptor 2 (HER2). In humans, HER2+ breast cancer is usually treated with trastuzumab (Herceptin), a humanized monoclonal antibody, and this treatment often shows success. However, HER2+ breast cancer has a propensity to metastasize to the brain, and trastuzumab may not work as effectively because it cannot effectively penetrate the BBB. Our work has established that intra-arterial NEO100 might open the BBB of mice for a few hours, potentially allowing a brain influx of therapeutic agents that are circulating in the bloodstream. In the case of mice with HER2+ metastases in their brains, a single application of BBB opening with NEO100 seems to enable brain influx of trastuzumab that had been given by intravenous injection, and this approach resulted in the recovery of several of the animals (<B>Figure 6</B>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Figure 6: BBB opening by intra-arterial (IA) NEO100 achieves the absence of brain cancer of several brain-metastatic mice treated with intravenous (IV) trastuzumab.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="img_018.jpg" ALT="" STYLE="height: 364px; width: 500px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From: <FONT STYLE="color: Red">Wang W et al., <I>Neuro-Oncology</I> 23(10):1656, 2021</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Recent cancer therapy breakthroughs have introduced immune checkpoint-inhibitory antibodies as novel tools to treat cancer. However, as with other antibody-based therapies, these biologics&#8217; applications may be limited due to the BBB, which prevents their brain entry, i.e., brain metastases and primary malignant brain tumors such as glioblastoma. Therefore, we utilized our BBB opening method with intra-arterial NEO100 to a glioblastoma mouse model, where mice received a one-time dose of a checkpoint-inhibitory antibody within the mixture of intra-arterially applied NEO100. The outcome showed that all six mice treated in this fashion showed absence of brain cancer (blue line in <B>Figure 7</B>). In contrast, all other mice died within 4-7 weeks, including those treated with checkpoint-inhibitory antibodies in the absence of NEO100.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Figure 7: BBB opening by intra-arterial (IA) NEO100 achieves the absence of brain cancer for all glioblastoma mice treated with checkpoint-inhibitory antibodies.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#160;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="img_019.jpg" ALT="" STYLE="height: 309px; width: 500px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From: <FONT STYLE="color: Red">Wang W et al., <I>Journal of Neurosurger</I>y, Feb 3:1-9, 2023 [online ahead of print]<I>.</I></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other recent breakthroughs in cancer therapy include the production of CAR T cells, where T lymphocytes are being modified to harbor a chimeric antigen receptor (CAR). While such cells have yielded impressive therapeutic advances, their activity&#8212;similar to the case of therapeutic antibodies&#8212;may be limited by their poor entry into the brain. Therefore, we applied our BBB opening method with intra-arterial NEO100 to a mouse model with intracranial lymphoma (lymphoma in the brain), where mice received a one-time dose of intravenous lymphoma-targeted CAR T cells, along with BBB opening by intra-arterial NEO100. The outcome showed that all six mice treated in this fashion showed absence of brain lymphoma (blue line in <B>Figure 8</B>). In comparison, most mice that received CAR T cells without BBB opening with intra-arterial NEO100 died within the first three weeks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Figure 8: BBB opening by intra-arterial (IA) NEO100 shows the absence of brain cancer in all brain-lymphoma mice treated with lymphoma-directed CAR T cells.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="img_020.jpg" ALT="" STYLE="height: 276px; width: 500px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">From: <FONT STYLE="color: red">Wang W et al., <I>manuscript submitted.</I></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="text-decoration: underline">Details to <B>5.</B> Oral NEO212 for advanced cancer types, including leukemia (preclinical stage)</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">NEO212 was initially designed as a therapeutic molecule with enhanced capability of crossing the blood-brain barrier to address the urgent clinical need for better treatments of intracranial malignancies, such as glioblastoma and brain-metastatic lesions from peripheral cancers. At the same time, however, NEO212 has demonstrated potential potency, along with low toxicity, against cancer types outside the brain, such as lung cancer, melanoma, ovarian cancer, leukemia, and others (<FONT STYLE="color: red">Chen TC et al., <I>Cancer Letters </I>358:144, 2015; Chen TC et al., <I>Journal of Biomedical Sciences</I> 22:71, 2015; Xie L et al., <I>Oncotarget</I> 7:1651, 2016; Song X et al., <I>Journal of Experimental and Clinical Cancer Research</I> 38:239, 2019; Song X et al., <I>Cell Death &amp; Disease</I> 9:202, 2018; Song X et al., <I>Scientific Reports</I> 6:22762, 2016; Chang M et al., <I>Journal of Experimental and Clinical Cancer Research </I>37:250, 2018; Silva-Hirschberg C et al., <I>Therapeutic Advances in Medical Oncology</I> 11:1758835919891567, 2019; Sch&#246;nthal AH et al., <I>Cancers </I>13(14):3385, 2021</FONT>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Among the most striking examples of NEO212&#8217;s potential therapeutic impact on peripheral cancer types, as established in mouse tumor models, is its effect on leukemia, particularly drug-resistant acute myeloid leukemia (AML), which in daily clinical practice remains very difficult to treat and often is fatal. First-line treatment of AML usually includes intravenous cytarabine. Still, often the tumor becomes resistant to this drug, which precludes further cytarabine treatment and generally requires subsequent hematopoietic stem cell transplantation. In our experiments, treatment of mice harboring cytarabine-resistant AML with NEO212 suggested a positive result and tolerability. Oral NEO212 was administered once daily for five days, followed by 7-14 days of a treatment holiday; this cycle was repeated twice more for three cycles in total (green arrows in <B>Figure 9</B>); there were no further treatments after week 8. All mice in this treatment group survived beyond 200 days, which might be interpreted as a positive outcome (<B>Figure 9</B>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Figure 9: Treatment of mice harboring cytarabine-resistant AML with NEO212 results in the absence of brain cancer in all treated animals.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="img_021.jpg" ALT="" STYLE="height: 196px; width: 500px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From: <FONT STYLE="color: Red">Sch&#246;nthal AH et al., <I>Cancers</I> 13(14):3385, 2021.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In light of the activity of NEO212 against a variety of tumor types studied in mouse tumor models, the initial Phase I clinical trial will be conducted with patients harboring brain cancers, including primary brain cancers (such as recurrent glioblastoma) and secondary brain cancers (metastases derived from lung, breast, and melanoma). NeOnc has received the IND approval for this Phase I trial. Phase I is expected to last up to one year, followed by Phase II, which is expected to last about two years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Extending the above, we are also designing a Phase I/IIa trial of oral NEO212 that will specifically focus on patients with newly-diagnosed glioblastoma. With current standard of care, these patients have an average life expectancy of only 15 months after initial diagnosis. Based on the encouraging results from our extensive preclinical studies, our extensive preclinical studies suggest that NEO212 may provide some benefit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Competition and Competitive Factors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">NEO100 and NEO212 address different aspects of the </FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">global central nervous system (CNS) treatment market and the brain tumor drug markets which are highly competitive, dynamic, and rapidly evolving areas of the pharmaceutical and healthcare industries. In both markets, success often hinges on a combination of clinical effectiveness, regulatory approvals, market access, pricing strategies, and effective marketing. The competition is further intensified by ongoing advances in medical science and technology, making it essential for companies to stay at the forefront of innovation and research.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our NEO100 and NEO212 candidates will need to differentiate themselves based on efficacy, safety, cost, ease of administration, and other therapeutic benefits. As we continue our research and development, we are cognizant of these competitive dynamics and are strategizing accordingly to ensure our products bring unique and tangible benefits to patients. As a clinical company, we face many of the challenges outlined below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Global Central Nervous System Treatment Market:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The competitive conditions in this market are:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Wide Range of Indications: The CNS treatment market encompasses a broad range of neurological and psychiatric disorders, including epilepsy, Alzheimer&#8217;s disease, Parkinson&#8217;s disease, multiple sclerosis, schizophrenia, and more. Each indication has its own set of competing treatments.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Established Players: Large pharmaceutical companies, such as Pfizer, Roche, and Novartis, have a strong presence in the CNS market, with well-established drugs and therapies for various conditions.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Generics and Biosimilars: Many older CNS drugs have lost patent protection, leading to the availability of generic and biosimilar versions. This has intensified competition, particularly in the treatment of common conditions like depression and anxiety.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">R&amp;D Investment: Companies invest heavily in research and development to discover and develop new CNS drugs. Advancements in neuroscience are driving innovative therapies, including novel mechanisms of action and targeted treatments.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Regulatory Challenges: Developing CNS drugs can be challenging due to the complexity of the brain and the potential for side effects. Companies must navigate stringent regulatory processes to gain approvals from agencies like the FDA and EMA.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Biologics and Gene Therapies: Emerging treatments, such as gene therapies and biologics, are becoming more prevalent in the CNS market. These advanced therapies often come with high costs and complex manufacturing processes.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Market Access and Pricing: Reimbursement and pricing challenges exist, and companies must demonstrate cost-effectiveness to secure market access, especially for novel, high-cost treatments.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Global Brain Tumor Drug Market:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The competitive conditions in this market are:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Tumor Type Variability: The market for brain tumor drugs is highly diverse due to the various types of brain tumors, including glioblastoma multiforme (GBM), meningioma, and astrocytoma, each requiring different treatment approaches.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Surgery and Radiation Therapy: Brain tumors often require a combination of surgery and radiation therapy. Competition can be intense among medical device manufacturers and radiation therapy providers, as well as pharmaceutical companies offering adjuvant therapies.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Targeted Therapies: Developing targeted therapies that focus on specific genetic mutations or signaling pathways associated with brain tumors is an active area of competition. Personalized medicine approaches are increasingly relevant.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Immunotherapy: Immunotherapies are being explored for brain tumors, and competition revolves around developing effective immunotherapeutic strategies to harness the body&#8217;s immune system against the tumor.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Clinical Trials: Companies often compete based on the strength of their clinical trial results and their ability to bring new drugs to market. The effectiveness and safety of brain tumor drugs are critical factors.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Orphan Drug Designations: Some brain tumor treatments may qualify for orphan drug designations, which can provide certain advantages, including extended exclusivity and incentives for development.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Patient Advocacy: Patient advocacy organizations play a significant role in raising awareness and influencing drug development. Collaboration with these groups can enhance a company&#8217;s competitive position.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research and Innovation: Continuous research and innovation in areas such as drug delivery, biomarker discovery, and imaging technologies contribute to the competitive landscape.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Combination Therapies: Companies explore combination therapies that can enhance treatment effectiveness. Combining surgery, radiation, and chemotherapy, for example, is a common approach in brain tumor treatment.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Global Expansion: Companies that can navigate international regulatory frameworks and secure approvals in various markets have a competitive edge.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">There are numerous other pharmaceutical and biotech companies, as well as academic institutions, involved in brain tumor research and drug development, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Bristol Myers Squibb (BMS): Makers of Opdivo<SUP>&#174; </SUP>(nivolumab) which has been explored for glioblastoma.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Merck &amp; Co., Inc.: Their drug, Temozolomide (Temodar<SUP>&#174;</SUP> in the US, Temodal<SUP>&#174; </SUP>in Europe), is a primary treatment for glioblastoma and anaplastic astrocytoma.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Roche: They have received accelerated US approval for Avastin<SUP>&#174;</SUP> (bevacizumab) for recurrent glioblastoma.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Novocure: Developers of the Optune<SUP>&#174; </SUP>device, a non-invasive treatment for glioblastoma.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">AstraZeneca are engaged in various stages of research, development, and commercialization of treatments for brain tumors.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Eli Lilly and Company: Conducting research in targeting brain tumors.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pfizer: Involvement in the development of treatments for various types of cancers, including brain tumors.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Celldex Therapeutics: Working on drug candidates for glioblastoma.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The competition in this sector extends beyond just drug therapies. Various modalities, including radiation, surgery, and newer non-drug technologies, also vie for market share in the brain tumor treatment domains.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">NEO212</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">NEO212 is a temozolomide conjugate that is given orally. Its main competitive landscape will be standard of care alkylating agents such as temozolomide and lomustine. It is intended that NEO212 will have an oral formulation for primary brain cancers and may also be used for metastatic brain cancers. These cancers are treated currently by surgery or radiosurgery only.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Future Growth Drivers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We anticipate several goals and plans that may potentially support our long-term growth, with some supported by additional high-growth global markets:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify; border-collapse: collapse">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potential commercial launch of NEO100 following FDA market approval.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify; border-collapse: collapse">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Possible clinical trials &amp; FDA approval of other POH compounds in our product pipeline.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify; border-collapse: collapse">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exploration of NEO100 pediatric indication.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify; border-collapse: collapse">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are currently investigating several additional proprietary chemotherapy agents that have shown preliminary positive effects in laboratory tests on various types of cancers, i.e., NEO212 oral and intranasal delivery for primary and metastatic brain cancer.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treatments for other CNS diseases and disorders based on our POH technology, such as Alzheimer&#8217;s, Parkinson&#8217;s and Epilepsy.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Manufacturing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We do not own or operate manufacturing facilities for the production of NEO100 nor do we plan to develop our own manufacturing operations in the foreseeable future. We currently depend on third party contract manufacturers for all of our required raw materials, active pharmaceutical ingredient and finished products for our preclinical and clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturers of our products are required to comply with applicable FDA manufacturing requirements contained in the FDA&#8217;s current good manufacturing practice standards (&#8220;cGMP&#8221;) regulations. cGMP regulations require among other things, quality control and quality assurance as well as the corresponding maintenance of records and documentation. Pharmaceutical product manufacturers and other entities involved in the manufacture and distribution of approved pharmaceutical products are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer, or holder of an approved NDA/NDA, including withdrawal of the product from the market. In addition, changes to the manufacturing process generally require prior FDA approval before being implemented and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual Property</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have exclusively licensed a large worldwide patent portfolio from USC consisting of both issued patents and pending patent applications related to NEO100, NEO212 and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions. In the United States, the Company has exclusive rights to 28 issued patents and 14 pending patent applications. Internationally, we have 65 patents issued and 28 patents applications pending.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The patent families of our product candidates are briefly described in the table below. All patents are owned by USC and exclusively licensed to us from USC. Patent Term Extension (PTE) may be available on certain patents after product approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="3" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border: black 1pt solid; text-align: left; width: 12%; font-size: 10pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Product Candidate</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; width: 30%; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title [description]</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; width: 12%; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>US Application #</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; width: 12%; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>US Patent</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; width: 12%; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expiration Date</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; vertical-align: bottom; width: 22%; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Foreign Counterparts</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: left; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEO100</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: left">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical Compositions Comprising Monoterpenes</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Ultra Pure]</FONT></P> </TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13/040,059</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13/939,834</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14/817,286</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14/843,097</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15/040,002</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15/220,135</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/575,587</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/749,293</FONT></P> </TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,507,734<SUP>1,2</SUP></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,133,085<SUP>1</SUP></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,480,659<SUP>1</SUP></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,498,448<SUP>1</SUP></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,700,524<SUP>3</SUP></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,457,618<SUP>1</SUP></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,899,691<SUP>1</SUP></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending<SUP>3</SUP></FONT></P> </TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/29/2031</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/5/2031</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/3/2031</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/3/2031</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/3/2031</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/3/2031</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/3/2031</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/3/2031*</FONT></P> </TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: left; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada, China, China, EU (France, Germany, United Kingdom, Ireland, and Italy)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: left; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEO212</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: left">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical Compositions Comprising POH Derivatives</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[POH conjugated to temozolomide (TMZ)]</FONT></P> </TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13/566,731</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14/455,371</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13/818,972</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15/408,866</FONT></P> </TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,916,545<SUP>2</SUP></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,580,372<SUP>3</SUP></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,499,461<SUP>1,2,3</SUP></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,092,562<SUP>3</SUP></FONT></P> </TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/26/2031</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/26/2031</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/26/2031</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/26/2031</FONT></P> </TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: left; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brazil, China, EU (Germany, Spain, France, United Kingdom Switzerland, Ireland, Italy, Netherlands, Sweden), Japan, Hong Kong</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: left; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEO 214</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: left">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical Compositions Comprising POH Derivatives</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[POH conjugated to rolipram]</FONT></P> </TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/123,729</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/388,535</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/306,167</FONT></P> </TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,077,104<SUP>3</SUP></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,013,804<SUP>2</SUP></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pending<SUP>2,3</SUP></FONT></P> </TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/26/2031</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/26/2031</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/26/2031*</FONT></P> </TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: left; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan, EU (Spain, France, United Kingdom, Ireland, Italy, Netherlands, Sweden)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: left; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEO 216</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: left">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical Compositions Comprising POH Derivatives and Methods of Use</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[POH conjugated to valproic acid]</FONT></P> </TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/606,520</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18/150,933</FONT></P> </TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,559,508<SUP>2</SUP></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pending<SUP>3</SUP></FONT></P> </TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/24/2038</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/18/2038*</FONT></P> </TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: left">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">China, EU</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(pending in both)</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: left; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEO 218</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: left">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Perillyl Alcohol-3-Bromopyruvate Conjugate and Methods of Treating Cancer</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[POH conjugated to 3- Bromopyruvate]</FONT></P> </TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/465,081</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,858,305<SUP>1,2,3</SUP></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/29/2037</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: left; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">China, EU, Japan<BR> (pending in all)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: left; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEO 400</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: left">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical Compositions Comprising POH Derivatives</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[POH conjugated with linoleic acid (LA)]</FONT></P> </TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/251,452</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/313,258</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/573,693</FONT></P> </TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pending<SUP>3</SUP></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pending<SUP>3</SUP></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pending<SUP>2</SUP></FONT></P> </TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/26/2031*</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/26/2031*</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/26/2031*</FONT></P> </TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: left">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">China, EU</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(pending in both)</FONT></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; text-align: left; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEO 412</FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: left">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical Compositions Comprising Perillyl Alcohol Derivatives</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Triple conjugation of perillyl alcohol, linoleic acid, and temozolomide]</FONT></P> </TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15/041,743</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/126,586</FONT></P> </TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,522,918<SUP>1,2</SUP></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,696,680<SUP>3</SUP></FONT></P> </TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/11/2036</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/11/2036</FONT></P> </TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; text-align: left; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia, China, EU (Germany, France, United Kingdom, Ireland), Japan</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify; border-collapse: collapse">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>1</SUP>&#160;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Method of making pharmaceutical composition</FONT></TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify; border-collapse: collapse">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>2</SUP>&#160;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pharmaceutical composition</FONT></TD> </TR>
  <TR STYLE="vertical-align: top; text-align: justify; border-collapse: collapse">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>3</SUP>&#160;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Method of using pharmaceutical composition</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify; border-collapse: collapse">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">20 years from the earliest filing date, subject to patent term adjustment</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our commercial success will depend in part on our ability to obtain and maintain patent and other intellectual property protection in the United States and other countries with respect to our technology, including NEO100, NEO212 and our other product candidates. We also rely in part on trade secret, copyright and trademark laws, and confidentiality, licensing and other agreements with employees and third parties, all of which offer only limited protection. We seek to protect our proprietary position by filing and prosecuting patent applications in the United States and abroad related to our technology and product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The patent positions of biotechnology and pharmaceutical companies generally are highly uncertain, involve complex legal and factual questions and have in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our licensed patents and any patents we own are highly uncertain. The steps we and our licensor have taken to protect our proprietary rights may not be adequate to preclude misappropriation of our proprietary information or infringement of our intellectual property rights, both inside and outside of the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further, the examination process may require us to narrow the claims for our licensed pending patent applications, which may limit the scope of patent protection that may be obtained if these applications issue. Our pending licensed and future patent applications may not result in patents being issued that protect our product candidates, in whole or in part, or which prevent others from commercializing competitive product candidates. The scope of a patent may also be reinterpreted after issuance. The rights that may be granted under our issued patents may not provide us with the proprietary protection or competitive advantages we are seeking. Even if patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. If we are unable to obtain and maintain patent protection for our technology or for NEO100 or our other product candidates, or if the scope of the patent protection obtained is not sufficient, our competitors could develop and commercialize products similar or superior to ours in a non-infringing manner, and our ability to successfully commercialize NEO100 or our other product candidates and future technologies may be adversely affected. It is also possible that we will fail to identify patentable aspects of inventions made in the course of our development and commercialization activities before it is too late to obtain patent protection on them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, the patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, collaborators, and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. It is also possible that we will fail to identify patentable aspects of our research and development efforts in time to obtain patent protection.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our licensed pending applications cannot be enforced against third parties practicing the inventions claimed in such applications unless and until a patent issues from such applications with a claim that covers infringing third-party activity. Because the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, issued patents that we license from third parties or own in the future may be challenged in the courts or patent offices in the United States and abroad, including through opposition proceedings, derivation proceedings, post-grant review, inter partes review, interference proceedings or litigation. Such proceedings may result in the loss of patent protection, the narrowing of claims in such patents or the invalidity or unenforceability of such patents, which could limit our ability to stop others from using or commercializing similar or identical products, or limit the duration of the patent protection for our technology. Protecting against the unauthorized use of our patented inventions, trademarks and other intellectual property rights is expensive, time consuming, difficult and in some cases may not be possible. In some cases, it may be difficult or impossible to detect third-party infringement or misappropriation of our intellectual property rights, even in relation to issued patent claims, and proving any such infringement may be even more difficult. If we are unable to obtain, maintain, and protect our intellectual property our competitive advantage could be harmed, and it could result in a material adverse effect on our business, financial condition, results of operations, stock price and prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Exclusive Patent License Agreement between USC and our Company</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On March&#160;9, 2009, Nas-Onc, Inc. (k/n/a NeOnc Technologies, Inc). entered into an exclusive, worldwide license agreement with USC, pursuant to which USC granted us a license to use certain patents and patent applications for the treatment and therapies of disease symptoms in mammals (the &#8220;USC Agreement&#8221;). The license is exclusive except for the rights granted to the US government pursuant to the Bayh-Dole Act and the right of USC and other non-profit academic research institutions to practice and improve the licensed patents for educational and research purposes. Pursuant to the USC Agreement, we (1) paid USC an upfront royalty payment of $20,000, (2) granted USC 117,236 shares of common stock, (3) will pay USC an earned royalty of 2% of Net Sales (as that term is defined in the USC Agreement), and (4) has paid and will continue to pay annual maintenance royalties of: $5,000 due January&#160;1, 2011, $5,000 due January&#160;1, 2012, $10,000 due January&#160;1, 2013, and $20,000 due January&#160;1 yearly thereafter. Annual maintenance royalties paid to USC are creditable toward earned royalties. We are also responsible for paying all reasonable patent expenses incurred by USC for filing prosecution and maintaining the licensed patents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Under the USC Agreement, payments will not be due to USC upon reaching certain development milestones. As of December 31, 2023, we have paid USC $479,621. Of the $479,621 paid to USC, $240,000 was a maintenance royalty payment. In the event of suspected patent infringement, the parties may agree to jointly institute suit, wherein the parties will share equally all costs and any recovery, with control of such lawsuit being by agreement between us and USC. Absent an agreement to jointly institute a suit, USC has the sole right to institute suit, at its option, where USC will bear the cost of such litigation and retain all recovery. In the event that USC does not institute the lawsuit, we may bring suit, at its option, and bear all such costs. Any recovery obtain by us must be shared with USC, after litigation costs reimbursement, as royalties on Net Sales for the remaining recovery. These rights and obligations were changed pursuant to the Amended License Agreement discussed below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The USC Agreement is sublicensable subject to the same terms, except that (1) sublicensees may not grant sublicenses, (2) the earned royalty may be increased as to sublicensees, (3) the sublicense reverts to USC in the event the USC Agreement is terminated as to us and, (4) additional issue and maintenance fees are owed to USC for each sublicense. These rights and obligations were changed pursuant to the Second Amendment and Restated Agreement discussed below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We may challenge the licensed patents upon 90 days&#8217; notice and payment of all royalties due. If we are unsuccessful in its challenge, the earned royalty will thereafter be increased by a factor of three. These rights and obligations were changed pursuant to the Restated Agreement discussed below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The term of the USC Agreement extends until the last to expire of the licensed patents. The Term of the Agreement was changed pursuant to the Restated Agreement discussed below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The USC Agreement may be terminated by either party upon 30 days&#8217; notice or upon material breach, wherein the breaching party is permitted 30 days to remedy such breach. USC may terminate immediately if (1) we attempt to sublicense, transfer or assign its rights contrary to the terms of the agreement, (2) we do not maintain the required insurance coverage, or (3) we are determined to be insolvent. These rights and obligations were changed pursuant to the Restated Agreement discussed below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The parties amended the USC Agreement on April&#160;5, 2023 (&#8220;Amended License Agreement&#8221;). The Amended License Agreement added NeOnc Technologies Holdings, Inc. as a licensee. The Amended License Agreement also added additional patents and patent applications to the prior license grant and requires us to obtain and record fully executed assignments of the added patents/applications demonstrating USC&#8217;s ownership in all relevant jurisdictions. Pursuant to the Amended License Agreement, we agreed to issue USC 560,000 additional shares of our common stock. The 560,000 shares were issued to USC on October 11, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In addition, the Amended License Agreement provides for an 4% earned royalty on Net Sales on licensed products protected by the newly added patents on a country by-country basis. In the event that a licensed product is protected by patents from both the USC Agreement and the Amended License Agreement, the higher royalty will apply. The Amended License Agreement also recognizes a Royalty Credit, in the event that we must obtain additional licenses from third parties in order to sell the licensed products. The Amended License Agreement also grants us control the prosecution of any patent application and maintenance of any patent included within Licensed Patents. We continue to be responsible for all costs associated with the prosecution and maintenance of the licensed patents. The Amendment also changed the parties enforcement obligations. Specifically, we shall have the first right, following consultation with USC, at our sole expense, to file suit against any alleged infringer or in defense of any Third Party claim. Any recovery or settlement in excess of litigation costs paid to us will be shared with USC as if it were Sublicense Revenue as defined in the USC Agreement. USC must consent to any settlement that is detrimental to USC or USC&#8217;s intellectual property rights. If we elect not to file suit against an alleged infringer, then upon such election, we will be deemed to have assigned to USC all rights, causes of action, and damages resulting from the alleged infringement. USC then has the sole right to institute suit, at its option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The parties further amended the USC Agreement on May 30, 2023 (&#8220;Second Amendment&#8221;). The Second Amendment revised the license agreement to permit sublicensees to sublicense the patents pursuant to specific terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif">On November 19, 2023, the Company and USC entered into an Amended and Restated Exclusive License Agreement (the &#8220;Restated Agreement&#8221;). The Restated Agreement addressed and clarified certain reporting obligations of the Company under the USC Agreement and addressed certain financial and other obligations, defaults, and deficiencies in connection with the Company&#8217;s performance under the USC Agreement. In satisfaction prior unpaid sublicense issue royalties and annual maintenance royalties due for sublicensees, the Company must pay USC $230,000 by March 31, 2024. On July 17, 2024, the restated agreement was amended to extend the payment date of the $230,000 to the earlier of September 1, 2025 or withing five days of a public offering. In connection with the Restated Agreement, the Company recorded the settlement amount of $230,000 in the accompanying consolidated statement of operations for the year ended December 31, 2023, and accounts payable to USC in the accompanying consolidated balance sheet as of December 31, 2024 and 2023.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The Restated Agreement provides for the same annual maintenance royalties of $20,000 per year above as well as the earned royalty of 2% or 4% on Net Sales on Licensed Products based on patent coverage (with the higher royalty applied when the Licensed Product is protected by patents from both the USC Agreement and the Amended License Agreement) and on a country-by-country basis. As above, the Restated Agreement recognizes the Royalty Credit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In the event that we, or our sublicensee (other than OEP (discussed below)), challenges a Licensed Patent the annual maintenance royalty, milestone payments and the earned royalty percentage rated will be doubled during the pendency of such challenge. At the conclusion of such challenge, if a Valid Claim that covers the Licensed Product, Licensed Service or Licensed Process is held valid and enforceable then such ongoing royalty payments will be tripled. We must also reimburse USC for all costs incurred in connection with such challenge. Further, we must provide USC at least 180 day&#8217;s written notice prior to our, or our sublicensee (excluding OEP) challenging a Licensed Patent. The notice is required to contain the prior art and a description of the facts and arguments that support the invalidity or unenforceability contention. We are required to discuss same with USC in an attempt to resolve the issues.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As above, we may grant sublicenses and our sublicensees may further grant licenses through one tier. By way of reference, on November 8, 2013, we entered into a collaboration agreement (&#8220;OEP Agreement&#8221;) with OEP, pursuant to which NeOnc licensed to OEP the right to commercialize NEO100 in those territories specified in the OEP Agreement. As to the OEP Agreement, the Restated Agreement waives any prior breach by us of the USC Agreement and permits the OEP sublicense despite inconsistencies with certain terms of the Restated Agreement. On February&#160;20, 2024, OEP and the Company entered into a settlement agreement whereby the Company and OEP terminated the OEP Agreement in exchange for a payment in the amount of $4,000,000 payable by the Company to OEP within ten days of the close of the Company&#8217;s initial public offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As above, pursuant to the Restated Agreement we maintain us sole control the prosecution of any patent application and maintenance of any patent included within licensed patents. We continue to be responsible for all costs associated with the prosecution and maintenance of the licensed patents. In addition, the parties enforcement obligations as described in the Amended License Agreement remain unchanged. Specifically, we have the first right, following consultation with USC, at our sole expense, to file suit against any alleged infringer or in defense of any Third Party claim. Any recovery or settlement in excess of litigation costs paid to us will be shared with USC as if it were sublicense revenue. USC must consent to any settlement that is detrimental to USC or USC&#8217;s intellectual property rights. If we elect not to file suit against an alleged infringer, then upon such election, we will be deemed to have assigned to USC all rights, causes of action, and damages resulting from the alleged infringement. USC then has the sole right to institute suit, at its option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The Restated Agreement changes the Term of the license. Specifically, the term is now tied to our royalty obligations under the Restated Agreement. We are obligated to pay royalties as to each Licensed Product, Licensed Service or Licensed Process on a country-by-country basis until (a) the last to expire Licensed Patent covering such product/service/process or (b) for 15 years after the date of first commercial sale of such product/service/process where such product/service/process is not covered by a Valid Claim of a Licensed Patent but such product/service/process was developed or made using any Licensed Process. The Term of the license ends when no further royalty obligations are due.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Last, as to termination, the Restated Agreement provides that the parties may mutually agree to terminate. Further, USC may immediately terminate if (a) we do not make payments when due and fail to cure, (b) we default on our indemnification or insurance obligations, (c) we are determined to be insolvent, (d) if any of our officers, directors or employees are convicted of a felony related to the development, manufacture use, marketing, distribution or sale of the Licensed Product, (e) if an audit shows an underpayment by us or a sublicensee of 15% or more for any 12 month period, or (f) we default in the performance of our other obligations in the agreement, and in each case fail to cure. We may terminate the license by giving 180 days advance written notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Upon any termination of the license (other than expiration of the Term), then the Restated Agreement grants to USC a non-exclusive worldwide fully paid license, with the right to sublicense to the Licensed Product Data, which includes all pre-clinical, clinical and other regulatory data generated by or on behalf of the Company relating to the Licensed Product and generated after the effective date of the USC Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Settlement Agreements with Licensees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 1, 2022, NeOnc Technologies, Inc. and Fox Infused, LLC, a Delaware limited liability company (&#8220;Fox Infused&#8221;), entered into an Intellectual Property License and Supply Agreement effective July 1, 2022 (the &#8220;Agreement&#8221;) whereby NeOnc agreed to supply certain products to Fox Infused and license certain of our patents. We terminated the Agreement with Fox Infused on April 25, 2023. On June 6, 2023, Fox Infused filed a complaint against NeOnc in the Central District of California alleging that the termination was improper (Civil Action No. 2:23-04431). Fox Infused also filed an ex parte application for a temporary restraining order and an order to show cause on a preliminary injunction against us seeking to have the court stop the termination of the contract. Fox Infused&#8217;s temporary restraining order application was denied and the case dismissed without prejudice. Fox Infused refiled the case in arbitration before the American Arbitration Association (Case No. 01-23-0002-5020). The parties engaged in settlement discussions, and agreed to settle the dispute for a $600,000 payment by us to Fox Infused within 5 business days of the closing date of the Company&#8217;s initial public offering or March 31, 2024. The Company is currently in default under the terms of such settlement agreement. The Company intends to satisfy this obligation in 2025 from sales of its securities or draws off of its line of credit. Prior to such payment, there is a risk that Fox Infused could institute default proceedings against us <FONT STYLE="background-color: white">which could result in direct and indirect costs to us </FONT>in defending and responding to such proceedings <FONT STYLE="background-color: white">and could result in operational disruptions that could harm our reputation, brand and results of operations, any of </FONT>which may affect our ability to raise additional proceeds from the sale of our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 14, 2023, the Company terminated its collaboration agreement with Orient EuroPharma Co., Ltd. (&#8220;OEP&#8221;). OEP retained counsel, who informed the Company that it believed that the collaboration agreement was improperly terminated by the Company and intended to take legal action in connection therewith. The parties engaged in a mediation on August 29, 2023. The Company withdrew its termination notice on October 31, 2023. The Company believed this would resolve the matter. However, on February 5, 2024, OEP initiated an arbitration claiming that the Company&#8217;s termination notice was invalid, the collaboration agreement remained binding and the Company breached representations in that agreement. The Company was prepared to defend the claims and assert counterclaims. Instead, the Company and OEP negotiated a settlement that resulted in the termination of the collaboration agreement and all of OEP&#8217;s license rights and resolved all disputes between the parties. Pursuant to the settlement agreement, the Company will pay OEP $4.0 million within ten days of the closing date of the Company&#8217;s initial public offering. As the Company believes its Direct Listing is not an initial public offering, the Company does not intend to make payment to OEP. OEP recently informed the Company that it believes the Company is currently obligated to pay such amount; while the Company does not agree with this assertion, there is a risk that OEP could institute additional proceedings against us which could result in direct and indirect costs to us in defending and responding to such proceedings and could result in operational disruptions that could harm our reputation, brand and result of operations, any of which may affect the Company&#8217;s ability to raise additional proceeds from the sale of its securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Government Regulation and Product Approval</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In the United States, the FDA regulates pharmaceutical products under the Federal Food, Drug, and Cosmetic Act, or the FDCA, the PHSA, and regulations and guidance documents implementing these laws. The FDCA, PHSA and their corresponding regulations govern, among other things, the testing, manufacturing, safety, purity, potency, labeling, packaging, storage, record keeping, distribution, reporting, advertising and other promotional practices involving pharmaceutical products. Consent from the FDA is required before conducting human clinical testing of drug products. FDA approval of a new drug application (NDA) or a biologics license application (BLA) also must be obtained before marketing a new drug or biological product. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the continued expenditure of substantial time and financial resources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>U.S. Small Molecule New Drug Product Development Process</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any new drug product must be approved by the FDA before it may be legally marketed in the United States. FDA approval is also required before marketing an approved drug product for a new indication or condition of use. The process required by the FDA before a new drug product candidate may be marketed in the United States generally involves the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completion of preclinical laboratory tests and in vivo studies in accordance with the FDA&#8217;s Good Laboratory Practice (GLP) regulations and applicable requirements for the humane use of laboratory animals or other applicable regulations;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: justify; width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Submission to the FDA of an investigational new drug (IND) application, which allows human clinical trials to begin unless FDA objects (issues a &#8220;clinical hold&#8221;) within 30 calendar days;</FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: justify; width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approval by an independent institutional review board (IRB), reviewing each proposed clinical trial and clinical site before each clinical trial may be initiated;</FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: justify; width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Performance of adequate and well-controlled human clinical trials in accordance with the protocol contained in the approved IND and in accordance with the FDA&#8217;s Good Clinical Practice (GCP) regulations, and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed product candidate for its intended use;</FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="text-align: justify; width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparation and submission to the FDA of a new drug application (NDA) for marketing approval that includes substantial evidence of safety and efficacy from results of nonclinical testing and clinical trials;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Review of the product by an FDA advisory committee, if applicable;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the product candidate is produced to assess compliance with current Good Manufacturing Practice (cGMP) requirements and to assure that the facilities, methods and controls are adequate to preserve the product candidate&#8217;s identity, safety, strength, quality, potency and purity;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Potential FDA audit of the nonclinical and clinical trial sites that generated the data in support of the NDA; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify">
        <P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Payment of user fees and FDA review and approval of the NDA.</FONT></P> </TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The testing and approval process of product candidates requires substantial time, effort, and financial resources. Satisfaction of the FDA&#8217;s pre-market approval requirements typically takes many years and the actual time required may vary substantially based upon the type, complexity, and novelty of the product or disease. Before testing any product candidate in humans, the product candidate must undergo preclinical testing. Preclinical tests, also referred to as nonclinical studies, include laboratory evaluations of product chemistry, toxicity and formulation, as well as in vivo animal studies to assess the potential safety and activity of the product candidate and to establish a rationale for therapeutic use. The conduct of the preclinical tests must comply with federal regulations and requirements including GLPs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrent with clinical trials, companies usually must complete some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the drug in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">A clinical trial sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. Some preclinical testing may continue even after the IND is submitted. The IND automatically becomes active 30 calendar days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to a proposed clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks, and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA also may impose partial or full clinical holds on a product candidate at any time before or during clinical trials due to safety concerns or non-compliance. If the FDA imposes a clinical hold, trials may not begin, or recommence without FDA authorization and then only under terms authorized by the FDA. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, that issues arise that partially or fully suspend or terminate such studies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Human Clinical Trials Under an IND</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical trials involve the administration of the investigational product to healthy volunteers or patients under the supervision of qualified investigators which generally are physicians not employed by, or under, the control of the trial sponsor. Clinical trials must be conducted under written study protocols detailing, among other things, the objectives of the trial, subject selection and exclusion, the trial procedures, the parameters to be used in monitoring safety, the criteria to be evaluated, and a statistical analysis plan. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further, clinical trials must be conducted in accordance with federal regulations and GCP requirements, which include the requirements that all research subjects provide their informed consent in writing for their participation in any clinical trial, as well as review and approval by an IRB at each study site participating in the clinical trial or a central IRB. An IRB is charged with protecting the welfare and rights of trial participants and considers items such as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the informed consent that must be signed by each clinical trial subject, or their legal representative, reviews and approves the study protocol, and must monitor the clinical trial until completed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Human clinical trials typically are conducted in three sequential phases that may overlap or be combined:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Phase I.</I> The product candidate initially is introduced into a small number of healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early understanding of its value in treating patients. In the case of some product candidates for severe or life-threatening diseases, especially when the product candidate may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Phase II</I>. The product candidate is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product candidate for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule.</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Phase III</I>. Phase III clinical trials are commonly referred to as &#8220;pivotal&#8221; or &#8220;registrational&#8221; studies, which typically denotes a study which presents the data that the FDA or other relevant regulatory agency will use to determine whether or not to approve a product. In Phase III studies, the product candidate is administered to an expanded patient population, generally at multiple geographically dispersed clinical trial sites in adequate and well-controlled clinical trials to generate sufficient data to statistically demonstrate the efficacy and safety of the product for approval. These clinical trials are intended to establish the overall risk/benefit ratio of the product candidate and provide an adequate basis for product labeling.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Post-approval clinical trials, sometimes referred to as Phase IV clinical trials, may be required by FDA, or may be voluntarily conducted after initial approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written IND safety reports must be promptly submitted to the FDA and the investigators for: serious and unexpected adverse events; any findings from other studies, in vivo laboratory tests or in vitro testing that suggest a significant risk for human subjects; or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#8217;s initial receipt of the information. Relevant additional information obtained by the sponsor that pertains to a previously submitted IND safety report must be submitted as a follow-up IND safety report. Such report should be submitted within 15 calendar days after the sponsor receives the information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information about certain clinical trials, including a description of the study and, in some cases, study results, must be submitted within specific timeframes to the National Institutes of Health, or NIH, for public dissemination on their clinicaltrials.gov website. Manufacturers or distributors of investigational products for the diagnosis, monitoring, or treatment of one or more serious or life-threatening diseases or conditions where no other comparable or satisfactory therapeutic options exist must also have a publicly available policy on evaluating and responding to requests for expanded access, sometimes called &#8220;compassionate use,&#8221; requests.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor that regularly reviews accumulated data and advises the study sponsor regarding the continuing safety of the trial. This group, known as a Data and Safety Monitoring Board (DSMB) or Data and Safety Monitoring Committee (DSMC), may also review interim data to assess the continuing validity and scientific merit of the clinical trial. This group receives special access to unblinded data during the clinical trial and may advise the sponsor to halt the clinical trial if it determined there is an unacceptable safety risk for subjects or on other grounds, such as no demonstration of efficacy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The FDA may order the temporary, or permanent, discontinuation of a clinical trial at any time, or impose other sanctions, if it believes that the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB&#8217;s requirements or if the trial poses an unexpected serious harm to subjects. The FDA or an IRB may also impose conditions on the conduct of a clinical trial. Clinical trial sponsors may also choose to discontinue clinical trials as a result of risks to subjects, a lack of favorable results, or changing business priorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Compliance with Current Good Manufacturing Practices (cGMP) Requirements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturers of pharmaceutical products must comply with applicable cGMP regulations, including quality control and quality assurance and maintenance of records and documentation. Manufacturers and others involved in the manufacture and distribution of such products also must register their establishments with the FDA and certain state agencies. Both domestic and foreign manufacturing establishments must register and provide additional information to the FDA upon their initial participation in the manufacturing process. Establishments may be subject to periodic, unannounced inspections by government authorities to ensure compliance with cGMP requirements and other laws. Discovery of problems may result in a government entity placing restrictions on a product, manufacturer or holder of an approved NDA, and may extend to requiring withdrawal of the product from the market. The FDA will not approve a NDA unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrent with clinical trials, companies usually complete additional preclinical studies and must also develop additional information about the physical characteristics of the product candidate as well as finalize a process for manufacturing the product candidate in commercial quantities in accordance with cGMP requirements. To help reduce the risk of the introduction of adventitious agents or of causing other adverse events with the use of small molecule products, the PHSA emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other requirements, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In relation to the clinical trials that may be conducted in other countries with a view to obtaining a marketing authorization, there are comparable cGMP requirements and other regulatory rules that are implemented nationally.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>U.S. FDA Review and Approval Process</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming successful completion of the required clinical and preclinical testing, the results of the preclinical tests and clinical trials together with detailed information relating to the product&#8217;s CMC, including negative or ambiguous results as well as positive findings, and proposed labeling, among other things, are submitted to the FDA for NDA (new drug application) approval to market the product for one or more indications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the Prescription Drug User Fee Act (PDUFA), as amended, each NDA must be accompanied by a significant user fee. The FDA adjusts the PDUFA user fees on an annual basis. The PDUFA also imposes an annual program fee for approved therapeutic products. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on NDAs for product candidates designated as orphan drugs, unless the product candidate also includes a non-orphan indication.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, under the Pediatric Research Equity Act (PREA), an NDA for a new active ingredient, indication, dosage form, dosage regimen, or route of administration, must contain data that are adequate to assess the safety and potential of the product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe. Also, applications for product candidates intended for the treatment of adult cancer which are directed at molecular targets that the FDA determines to be substantially relevant to the growth or progression of pediatric cancer, in place of the PREA investigations, sponsors must submit, with the application, reports from molecularly targeted pediatric cancer investigations designed to yield clinically meaningful pediatric study data, using appropriate formulations, to inform potential pediatric labeling. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. Orphan products are also exempt from the PREA requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The FDA reviews a NDA within 60 days of submission to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any NDA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In that event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth, substantive review of the NDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The FDA reviews the NDA to determine, among other things, whether the proposed product candidate is safe and effective for its intended use, has an acceptable purity profile and whether the product candidate is being manufactured in accordance with cGMP to assure and preserve the product candidate&#8217;s identity, safety, strength, quality, potency and purity. The FDA may refer applications for novel therapeutic products or therapeutic products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the product approval process, the FDA also will determine whether a risk evaluation and mitigation strategy, (REMS) is necessary to assure the safe use of the product candidate. REMS use risk minimization strategies beyond the professional labeling to ensure that the benefits of the product outweigh the potential risks. To determine whether a REMS is needed, the FDA will consider the size of the population likely to use the product, seriousness of the disease, expected benefit of the product, expected duration of treatment, seriousness of known or potential adverse events, and whether the product is a new molecular entity. A REMS could include medication guides, physician communication plans and elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS; the FDA will not approve the NDA without a REMS, if required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Before approving a NDA, the FDA will inspect the facilities at which the product candidate is manufactured. The FDA will not approve the product candidate if it determines that the manufacturing processes and facilities are not in compliance with cGMP requirements or otherwise are not adequate to assure consistent production of the product candidate within required specifications. Additionally, before approving a NDA, the FDA typically will inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with IND trial requirements and GCP requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On the basis of the NDA and accompanying information, including the results of the inspection of the manufacturing facilities, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If a product candidate receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing or dispensing in the form of a REMS, or otherwise limit the scope of any approval. The FDA may also require post-marketing clinical trials, sometimes referred to as Phase IV clinical trials, designed to further assess a product&#8217;s safety, and testing and surveillance programs to monitor the safety of approved products that have been commercialized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Every five years, the FDA agrees to specified performance goals in the review of NDAs under the PDUFA. One such current goal is to review standard NDAs in ten months after the FDA accepts the NDA for filing, and priority NDAs in six months, whereupon a review decision is to be made. The FDA does not always meet its PDUFA goal dates for standard and priority NDAs and its review goals are subject to change from time to time. The review process and the PDUFA goal date may be extended by three months if the FDA requests or the NDA sponsor otherwise provides additional information or clarification regarding information already provided in the submission within the last three months before the PDUFA goal date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expedited Development and Review Programs</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The FDA has a Fast Track program that is intended to expedite or facilitate the process for reviewing new drugs and biologics that meet certain criteria. Specifically, new drugs and biologics are eligible for Fast Track designation if they are intended to treat a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to both the product and the specific indication for which it is being studied. The sponsor can request the FDA to designate the product for Fast Track status any time before receiving NDA approval, but ideally no later than the pre-NDA or pre-BLA meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any product submitted to the FDA for marketing, including under a Fast Track program, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. A product may be eligible for priority review if it is intended to treat a serious or life-threatening condition and, if approved, would provide a significant improvement in safety and effectiveness compared to available therapies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">A Fast Track product may also be eligible for rolling review, where the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">A product may also be eligible for accelerated approval if it is intended to treat a serious or life-threatening condition and generally provide a meaningful advantage over available therapies. In addition, it must demonstrate an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality (IMM), which is reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. If the FDA concludes that a drug shown to be effective can be safely used only if distribution or use is restricted, it may require such post-marketing restrictions as it deems necessary to assure safe use of the product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Additionally, a drug may be eligible for designation as a Breakthrough Therapy if the product is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints. The benefits of Breakthrough Therapy designation include the same benefits as Fast Track designation, plus intensive guidance from the FDA to ensure an efficient drug development program. Fast Track designation, priority review, accelerated approval and Breakthrough Therapy designation do not change the standards for approval, but may expedite the development or approval process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Post-Approval Requirements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After approval, there also are continuing annual program user fee requirements for approved products, excluding, under certain circumstances, orphan products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rigorous and extensive FDA regulation of pharmaceutical products continues after approval, particularly with respect to cGMP requirements. Manufacturers are required to comply with applicable requirements in the cGMP regulations, including quality control and quality assurance and maintenance of records and documentation. To help reduce the increased risk of the introduction of adventitious agents, the PHSA emphasizes the importance of manufacturing controls for products whose attributes cannot be precisely defined. The PHSA also provides authority to the FDA to immediately suspend licenses in situations where there exists a danger to public health, to prepare or procure products in the event of shortages and critical public health needs, and to authorize the creation and enforcement of regulations to prevent the introduction or spread of communicable diseases in the United States and between states.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other post-approval requirements applicable to pharmaceutical products include reporting of cGMP deviations that may affect the identity, potency, purity and overall safety of a distributed product, record-keeping requirements, reporting of adverse effects, reporting updated safety and efficacy information and complying with electronic record and signature requirements. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, and potency of pharmacological products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In addition, manufacturers and other entities involved in the manufacture and distribution of approved pharmaceuticals are required to register their establishments with the FDA and certain state agencies, list their products, and are subject to periodic announced and unannounced inspections by the FDA and these state agencies for compliance with current cGMP and other requirements, which impose certain procedural and documentation requirements upon us and third-party manufacturers. Manufacturers must continue to expend time, money, and effort in the areas of production and quality-control to maintain compliance with current cGMPs. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered. In addition, changes to the manufacturing process or facility generally require prior FDA approval or notification before being implemented, and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover, the Drug Quality and Security Act imposes obligations on manufacturers of pharmaceutical products related to product tracking and tracing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Adverse event reporting and submission of periodic reports, including annual reports and deviation reports, are required following FDA approval of a NDA. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in significant regulatory actions. Such actions may include refusal to approve pending applications, license suspension or revocation, imposition of a partial or full clinical hold or termination of clinical trials, warning letters, untitled letters, modification of promotional materials or labeling, provision of corrective information, imposition of post-market requirements including the need for additional testing, imposition of distribution or other restrictions under a REMS, product recalls, product seizures or detentions, refusal to allow imports or exports, total or partial suspension of production or distribution, FDA debarment, injunctions, fines, consent decrees, corporate integrity agreements, suspension and debarment from government contracts, and refusal of orders under existing government contracts, exclusion from participation in federal and state healthcare programs, restitution, disgorgement, or civil or criminal penalties, including fines and imprisonment, and result in adverse publicity, among other adverse consequences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">A sponsor also must comply with the FDA&#8217;s advertising and promotion requirements, such as the prohibition on promoting products for uses or in patient populations that are inconsistent with the product&#8217;s approved labeling (known as &#8220;off-label use&#8221;). The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. Violations relating to the promotion of off-label uses may lead to investigations alleging violations of federal and state healthcare fraud and abuse and other laws, as well as state consumer protection laws. Companies, however, may generally share truthful and non-misleading information that is otherwise consistent with a product&#8217;s FDA approved labeling. Discovery of previously unknown problems or the failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant or manufacturer to administrative or judicial civil or criminal actions and adverse publicity. These actions could include refusal to approve pending applications or supplemental applications, withdrawal of an approval, clinical hold, suspension or termination of a clinical trial by an IRB, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines or other monetary penalties, refusals of government contracts, mandated corrective advertising or communications with healthcare providers, debarment, restitution, disgorgement of profits or other civil or criminal penalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Broadly equivalent requirements and controls typically apply in other countries to the submission of marketing authorization applications and, post-approval, to the holding of such marketing authorizations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>The Hatch-Waxman Amendments and Generic Competition</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Orange Book Listing</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Once a drug product is approved under an NDA, the product is listed in the FDA&#8217;s publication, &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; commonly known as the Orange Book. An NDA-approved drug product will be designated in the Orange Book as a Reference Listed Drug (RLD). Sponsors of approved NDAs are required to list with the FDA patents whose claims cover the product&#8217;s active ingredient, formulation, or an approved method of using the drug.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Patent Term Extensions</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Depending upon the timing, duration and specifics of FDA approval of the use of our therapeutic candidates, some of our United States patents may be eligible for limited patent term extension under the Hatch-Waxman Amendments to the FDCA (Hatch-Waxman&#8221;). Hatch-Waxman permits a patent restoration term of up to five years as compensation for patent term lost during drug product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product or therapeutic candidate&#8217;s approval date. The patent term restoration period is generally one half of the time between the effective date of an IND and the submission date of an NDA, plus the time between the submission date of an NDA and the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved product or therapeutic candidate is eligible for the extension and the application for extension must be made prior to expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we intend to apply for restorations of patent term for some of our currently owned or licensed patents to add patent life beyond their current expiration date, depending on the expected length of clinical trials and other factors involved in the submission of the relevant NDA(s).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">ANDA Approval Process for Generic Drugs</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Hatch-Waxman also established an abbreviated FDA approval process for generic drugs that are shown to be pharmaceutically equivalent and bioequivalent to drugs previously approved by the FDA through the NDA process. Approval to market and distribute these drugs is obtained by filing an abbreviated new drug application, or ANDA, with the FDA. An ANDA provides for marketing of a drug product that has the same active ingredients in the same strengths and dosage form as the listed drug and has been shown to be bioequivalent to the listed drug. An ANDA is a comprehensive submission that contains, among other things, data and information pertaining to the active pharmaceutical ingredient, drug product formulation, specifications and stability of the generic drug, as well as analytical methods, manufacturing process validation data and quality control procedures. ANDAs are termed abbreviated because they generally do not include preclinical and clinical data to demonstrate safety and effectiveness. Instead, a generic applicant must demonstrate that its product is bioequivalent to the innovator drug. In some cases involving drugs with no or limited systemic absorption, an ANDA must include clinical endpoint (efficacy) studies in order to demonstrate bioequivalence. Drugs approved in this way are commonly referred to as &#8220;generic equivalents&#8221; to the listed drug and can often be substituted by pharmacists under prescriptions written for the original listed drug.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Section 505(b)(2) NDA Approval Process</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As an alternative path to FDA approval for modifications to formulations or uses of products previously approved by the FDA under a &#8220;full&#8221; NDA, an applicant may submit an NDA under Section 505(b)(2) of the FDCA. Section 505(b)(2) was enacted as part of the Hatch-Waxman Amendments and enables the applicant to rely, in part, on the FDA&#8217;s previous approval of a similar product, and/or published literature, in support of the safety and/or efficacy of its drug product. Section 505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from studies not conducted by, or for, the applicant and for which the applicant has not obtained a right of reference. If the Section 505(b)(2) applicant can establish that reliance on FDA&#8217;s previous findings of safety and effectiveness is scientifically appropriate, it may eliminate the need to conduct certain preclinical studies or clinical trials of the new product. The FDA may also require companies to perform additional studies or measurements, including clinical trials, to support the change from the approved reference drug. The FDA may then approve the new product candidate for all, or some, of the label indications for which the reference drug has been approved or for any new indication sought by the Section 505(b)(2) applicant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">ANDA and 505(b)(2) products may be significantly less costly to bring to market than the reference listed drug, and companies that produce generic products are generally able to offer them at lower prices. Moreover, generic versions of RLDs are often automatically substituted for the RLD by pharmacies when dispensing a prescription written for the RLD. Thus, following the introduction of a generic drug, a significant percentage of the sales of any branded product or reference listed drug is typically lost to the generic product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">ANDA and 505(b)(2) NDA Patent Certification Requirements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Any applicant who files an ANDA seeking approval of a generic equivalent version of a drug listed in the Orange Book or a Section 505(b)(2) NDA referencing a drug listed in the Orange Book must certify to the FDA, as applicable, that (1) no patent information on the drug product that is the subject of the application has been submitted to the FDA; (2) such patent has expired; (3) the date on which such patent expires; or (4) such patent is, in the applicant&#8217;s opinion, invalid or will not be infringed upon by the manufacture, use or sale of the drug product for which the application is submitted. This last certification is known as a paragraph IV certification. If an ANDA or 505(b)(2) NDA is submitted to FDA with a Paragraph IV Certification, the applicant must also provide a &#8220;Paragraph IV Notification&#8221; to the holder of the NDA for the RLD and to the owner of the listed patent(s) being challenged by the applicant, providing a detailed written statement of the bases for the applicant&#8217;s position that the relevant patent(s) is invalid or would not be infringed. If the patent owner brings a patent infringement lawsuit against the applicant within 45 days of the Paragraph IV Notification, FDA approval of the ANDA or 505(b)(2) NDA will be automatically stayed for 30 months, or until 7-1/2 years after the RLD&#8217;s NDA approval date if the ANDA or 505(b)(2) NDA was filed between 4 years and 5 years after the NDA approval. Any such stay will be terminated earlier if the court rules that the patent is invalid or would not be infringed. The applicant may, in certain circumstances, elect to submit a &#8220;section viii&#8221; statement with respect to a listed method of use patent, certifying that the proposed ANDA or 505(b)(2) product&#8217;s labeling does not contain (or carves out) any language that would infringe a method of use patented listed in the Orange Book for the RLD.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The ANDA or 505(b)(2) application also will not be approved until any applicable non-patent exclusivity listed in the Orange Book for the reference drug has expired as described in further detail below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Regulatory Exclusivities</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">New Chemical Entity Exclusivity</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The Hatch-Waxman Amendments provide a period of five years of non-patent marketing exclusivity for the first approved drug containing a new chemical entity (&#8220;NCE&#8221;) as an active ingredient. An NCE is an active moiety that has not been approved by the FDA in any other NDA. A fixed combination drug product may receive NCE exclusivity if one of its active ingredients is an NCE, but not if all of its active ingredients have previously been approved. An &#8220;active moiety&#8221; is defined as the molecule or ion responsible for the drug substance&#8217;s physiological or pharmacologic action. During the five-year exclusivity period, the FDA cannot accept for filing any ANDA or 505(b)(2) NDA seeking approval of a product that contains the same active moiety, except that the FDA may accept such an application for filing after four years if the application includes a paragraph IV certification to a listed patent. In the case of such applications accepted for filing between four and five years after approval of the reference drug, the 30-Month Stay of approval triggered by a timely patent infringement lawsuit is extended by the amount of time necessary to extend the stay until 7-1/2 years after the approval of the reference drug NDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">New Clinical Trial (3-Year) Exclusivity</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">A drug, including one approved under Section 505(b)(2), may obtain a three-year period of exclusivity for a particular indication or condition of approval, or change to a marketed product, such as a new formulation for a previously approved product, if one or more new clinical trials (other than bioavailability studies) was essential to the approval of the application or supplemental application and was conducted/sponsored by the applicant. Should this occur, the FDA would be precluded from approving any ANDA or Section 505(b)(2) application for the protected modification until after that three-year exclusivity period has run. However, unlike NCE exclusivity, the FDA can accept an application and begin the review process during the 3-year exclusivity period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Orphan Drug Designation and Orphan Exclusivity Under the Orphan Drug Act</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The FDA may grant orphan designation to a drug product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States but for which there is no reasonable expectation that the cost of developing and making the product available in the United States for this type of disease or condition will be recovered from sales of the product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Orphan drug designation must be requested before submitting an NDA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years from the date of such approval, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety, or providing a major contribution to patient care or in instances of drug supply issues. However, competitors may receive approval of either a different product for the same indication or the same product for a different indication but that could be used off-label in the orphan indication. Orphan drug exclusivity also could block the approval of one of our products for seven years if a competitor obtains approval before we do for the same product, as defined by the FDA, for the same indication we are seeking approval, or if a product candidate is determined to be contained within the scope of the competitor&#8217;s product for the same indication or disease. If one of our products is designated as an orphan drug and receives marketing approval for an indication broader than that which is designated, it may not be entitled to orphan drug exclusivity. Orphan drug status in the European Union has similar, but not identical, requirements and benefits.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pediatric Exclusivity</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pediatric exclusivity is another type of non-patent marketing exclusivity available in the United States and, if granted, it provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity or listed patents. Under the Best Pharmaceuticals for Children Act, or BPCA, certain therapeutic candidates may obtain an additional six months of exclusivity if the sponsor conducts pediatric research and submits new clinical information requested in writing by the FDA, referred to as a Written Request, relating to the use of the active moiety of the product or therapeutic candidate in children. The data do not need to support a label change for pediatric use; rather, the additional protection is granted if the pediatric clinical trial is deemed to have fairly responded to the FDA&#8217;s Written Request. Although the FDA may issue a Written Request for studies on either approved or unapproved indications, it may only do so where it determines that information relating to that use of a product or therapeutic candidate in a pediatric population, or part of the pediatric population, may produce health benefits in that population. The issuance of a Written Request does not require the sponsor to undertake the described trials. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot approve another application.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Other Healthcare Laws and Regulations</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our business activities, including but not limited to, research, sales, promotion, distribution, medical education, and other activities following product approval will be subject to regulation by numerous federal and state regulatory and law enforcement authorities in the United States in addition to the FDA, including potentially the Department of Justice, the Department of Health and Human Services (HHS) and its various divisions, including the Office of Inspector General, the Centers for Medicare &amp; Medicaid Services (CMS) and the Health Resources and Services Administration, the Department of Veterans Affairs, the Department of Defense, and state and local governments. Healthcare providers and third-party payors play a primary role in the recommendation and use of pharmaceutical products that are granted marketing approval. Arrangements with third-party payors, existing or potential customers and referral sources, including healthcare providers, are subject to broadly applicable fraud and abuse laws and regulations, and these laws and regulations may constrain the business or financial arrangements and relationships through which manufacturers conduct clinical research, market, sell and distribute the products for which they obtain marketing approval. Such restrictions under applicable federal and state healthcare laws and regulations include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
        <P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">The federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in cash or kind, in exchange for, or to induce, either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers, on the one hand, and prescribers, purchasers, formulary managers and other individuals and entities on the other. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the ACA) amended the intent requirement of the federal Anti-Kickback Statute such that a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it in order to commit a violation;</FONT></P> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The federal civil and criminal false claims, including the civil FCA, and Civil Monetary Penalties Laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid or other third-party payors that are false or fraudulent, or making a false statement to avoid, decrease, or conceal an obligation to pay money to the federal government. Certain marketing practices, including off-label promotion, also may implicate the FCA. In addition, the ACA codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, therapeutic products and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare &amp; Medicaid Services, or the CMS, information related to payments and other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other healthcare professionals (such as physician assistants and nurse practitioners), and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Health Insurance Portability and Accountability Act of 1996 (HIPAA) prohibits knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, a healthcare benefit program, regardless of whether the payor is public or private, in connection with the delivery or payment for health care benefits, knowingly and willfully embezzling or stealing from a health care benefit program, willfully obstructing a criminal investigation of a health care offense and knowingly and willfully falsifying, concealing, or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items, or services relating to healthcare matters. Additionally, the ACA amended the intent requirement of certain of these criminal statutes under HIPAA so that a person or entity no longer needs to have actual knowledge of the statute, or the specific intent to violate it, to have committed a violation; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">State and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers and drug pricing and/or marketing expenditures; and state and local laws requiring the registration of pharmaceutical sales representatives and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Further, we may be subject to data privacy and security regulation by both the federal government and the states and foreign jurisdictions in which we conduct our business. HIPAA, as amended by the Health Information Technology for Clinical Health Act of 2009 (HITECH), and its respective implementing regulations imposes certain requirements, including mandatory contractual terms, on covered entities, business associates and their covered subcontractors relating to the privacy, security, and transmission of certain individually identifiable health information known as protected health information. Among other things, HITECH, through its implementing regulations, makes HIPAA&#8217;s security standards and certain privacy standards directly applicable to business associates, defined as a person or organization, other than a member of a covered entity&#8217;s workforce, that creates, receives, maintains, or transmits protected health information on behalf of a covered entity for a function or activity regulated by HIPAA. HITECH also strengthened the civil and criminal penalties that may be imposed against covered entities, business associates, subcontractors, and individuals, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. In addition, other federal and state laws may govern the privacy and security of health and other information in certain circumstances, many of which differ from each other in significant ways and may not be pre-empted by HIPAA, thus complicating compliance efforts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To the extent that any of our products are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws, and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the EU, the data privacy laws are generally perceived to be stricter than those which apply in the United States and include specific requirements for the transfer of personal data outside the EU to the United States to ensure that EU standards of data privacy will be applied to such data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Violation of the laws described above or any other governmental laws and regulations may result in significant penalties, including administrative, civil and criminal penalties, damages, fines, the curtailment or restructuring of operations, the exclusion from participation in federal and state healthcare programs, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, imprisonment, and additional reporting requirements and oversight if a person becomes subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws. Furthermore, efforts to ensure that business activities and business arrangements comply with applicable healthcare laws and regulations can be costly for manufacturers of branded prescription products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Coverage and Reimbursement</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory approval. In the United States, sales of any product candidates for which regulatory approval for commercial sale is obtained will depend in part on the availability of coverage and adequate reimbursement from third-party payors. Third-party payors include government authorities and health programs in the United States such as Medicare and Medicaid, managed care providers, private health insurers and other organizations. These third-party payors are increasingly reducing reimbursements for medical products and services. The process for determining whether a payor will provide coverage for a drug product may be separate from the process for setting the reimbursement rate that the payor will pay for the drug product. Third-party payors may limit coverage to specific drug products on an approved list, or formulary, which might not include all of FDA-approved drugs for a particular indication. Additionally, the containment of healthcare costs has become a priority of federal and state governments, and the prices of drugs have been a focus in this effort. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Further, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third-party payors are increasingly challenging the price and examining the medical necessity and cost of medical products and services, in addition to their safety and efficacy. New metrics frequently are used as the basis for reimbursement rates, such as average sales price, average manufacturer price and actual acquisition cost. In order to obtain coverage and reimbursement for any product that might be approved for sale, it may be necessary to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and rational of the cost of the products, in addition to the costs required to obtain regulatory approvals. If third-party payors do not consider a product to be cost saving when compared to other available therapies, they may not cover the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a profit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The marketability of any product candidates for which we or our collaborators receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United States has increased and we expect will continue to increase the pressure on pharmaceutical pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we or our collaborators receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. The cost containment measures that healthcare payors and providers are instituting and any healthcare reform could significantly reduce our revenues from the sale of any approved product candidates. We cannot provide any assurances that we will be able to obtain and maintain third-party coverage or adequate reimbursement for our product candidates in whole or in part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the EU, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost of a particular product candidate to currently available therapies. EU member states may approve a specific price for a product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other member states allow companies to fix their own prices for products, but monitor and control company profits. The downward pressure on health care costs has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert competitive pressure that may reduce pricing within a country. Any country that has price controls or reimbursement limitations may not allow favorable reimbursement and pricing arrangements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Health Reform</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The United States and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initiatives, including those designed to limit the pricing, coverage, and reimbursement of pharmaceutical products, especially under government-funded health care programs, and increased governmental control of drug pricing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By way of example, in March&#160;2010, the ACA was signed into law, intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add transparency requirements for the healthcare and health insurance industries, impose taxes and fees on the healthcare industry and impose additional health policy reforms. Among the provisions of the ACA of importance to our business are:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An annual, non-deductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13.0% of the average manufacturer price for branded and generic drugs, respectively;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Extension of a manufacturer&#8217;s Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Medicare Part D coverage gap discount program, in which manufacturers must now agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for a manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical research, along with funding for such research.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There have been executive, judicial and Congressional challenges to certain aspects of the ACA. For example, on June&#160;17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, on January&#160;28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, re-examining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. In addition, in August&#160;2022, President Biden signed the Inflation Reduction Act of 2022 (the IRA) into law, which among other things, extends enhanced subsidies for individuals purchasing coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost through a newly established manufacturer discount program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other legislative changes have been proposed and adopted in the United States since the ACA. For example, through the process created by the Budget Control Act of 2011, there are automatic reductions of Medicare payments to providers up to 2% per fiscal year, which went into effect in April&#160;2013 and, following passage of the BBA and the Infrastructure Investment and Jobs Act, will remain in effect until 2031 unless additional Congressional action is taken. However, COVID-19 relief support legislation suspended the 2% Medicare sequester from May&#160;1, 2020 through March&#160;31, 2022. Under current legislation the actual reduction in Medicare payments will vary from 1% in 2022 to up to 4% in the final fiscal year of this sequester.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics, also has resulted in executive orders, congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. At the federal level, President Trump used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders, and policy initiatives. For example, on July&#160;24, 2020 and September&#160;13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that attempt to implement several of the administration&#8217;s proposals. The FDA concurrently released a final rule and guidance in September&#160;2020 implementing a portion of the importation executive order providing pathways for states to build and submit importation plans for drugs from Canada. Further, on November&#160;20, 2020, the HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. The implementation of the rule has been delayed until 2032. Additionally, on March&#160;11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, beginning January&#160;1, 2024. In July&#160;2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September&#160;9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. In addition, the IRA directs the Secretary of HHS to establish a Drug Price Negotiation Program (the Program) to lower prices for certain single-source prescription drugs and biologics covered under Medicare Parts B and D, based on criteria established under the IRA. Under the Program, the Secretary of HHS will publish a list of &#8220;selected drugs,&#8221; and will then negotiate maximum fair prices (MFP) with their manufacturers. Beginning in 2026, the first year of the Program, the number will be limited to 10 Part D drugs and biologics. By 2029, and in subsequent years thereafter, the number will increase to 20 drugs and biologics covered under Part D and Part B. Agreements between HHS and manufacturers will remain in place until a drug or biologic is no longer considered a &#8220;selected drug&#8221; for negotiation purposes. Manufacturers who do not comply with the negotiated prices set under the Program will be subject to an excise tax based on a percentage of total sales of a &#8220;selected drug&#8221; up to 95% and the potential of civil monetary penalties. Further, the IRA imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. In addition, the Biden administration released an additional executive order on October&#160;14, 2022, directing HHS to submit a report within ninety (90) days on how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models for lowering drug costs for Medicare and Medicaid beneficiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the state level, individual states in the United States have increasingly passed legislation and implemented regulations designed to control pharmaceutical and therapeutic product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Some third-party payors also require pre-approval of coverage for new or innovative devices or therapies before they will reimburse healthcare providers that use such therapies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We expect that these initiatives, as well as other healthcare reform measures that may be adopted in the future, as well as the trend toward managed healthcare and increasing influence of managed care organizations, may result in more rigorous coverage criteria and lower reimbursement, and in additional downward pressure on the price that we receive for any approved product. It is also possible that additional governmental action is taken in response to the COVID-19 pandemic. Any reduction in reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from private payors. The implementation of current and future cost containment measures or other healthcare reforms may adversely affect our operations and prevent us from being able to generate revenue, attain profitability or commercialize our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Data Privacy and Security</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the ordinary course of our business, we collect, process and store confidential and sensitive information, including personal information, intellectual property, trade secrets, and proprietary information owned or controlled by ourselves or other third parties. We, and third parties upon whom we rely, use sophisticated information technology, software and services to process, store, use, generate, transfer and disclose information, as well as other sensitive information controlled by ourselves or other third parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may also be subject to federal, state, and foreign data privacy and security laws and regulations. In the United States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws and regulations (e.g., Section&#160;5 of the FTC Act), govern the collection, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners, vendors, or other third parties on whom we rely. The legislative and regulatory framework related to the collection, use, retention, safeguarding, disclosure, sharing, transfer, security and other processing of personal data worldwide is rapidly evolving. The number and scope of data protection laws and regulations is changing, subject to differing applications and interpretations, and may be inconsistent among jurisdictions, or in conflict with other rules, laws or other data processing obligations. Efforts to ensure that our current and future business arrangements, including our relationship with our CROs or other vendors who process data on our behalf, comply with applicable data privacy and data security laws and regulations will involve substantial costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For example, HIPAA, as amended by HITECH, and its implementing regulations, impose requirements relating to the privacy, security and transmission of individually identifiable health information on certain health care providers, health plans and health care clearinghouses, known as covered entities, as well as their business associates and covered subcontractors that perform certain services that involve creating, receiving, maintaining or transmitting individually identifiable health information for or on behalf of such covered entities. Entities that are found to be in violation of HIPAA as the result of a breach of unsecured protected health information, a complaint about privacy practices or an audit by HHS, may be subject to significant civil, criminal and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan with HHS to settle allegations of HIPAA non-compliance. Further, entities that knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA covered entity in a manner that is not authorized or permitted by HIPAA may be subject to civil and criminal penalties. Even when HIPAA does not apply, according to the FTC, violating consumers&#8217; privacy rights or failing to take appropriate steps to keep consumers&#8217; personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section&#160;5 of the FTC Act. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Likewise, we expect that there will continue to be new proposed laws, regulations and industry standards relating to privacy and data protection in the United States, the EU and other jurisdictions, such as the California Consumer Privacy Act of 2018 (CCPA), which has been characterized as the first &#8220;GDPR-like&#8221; privacy statute to be enacted in the United States. Although the CCPA exempts certain data processed in the context of clinical trials, the CCPA, to the extent applicable to our business and operations, may increase our compliance costs and potential liability with respect to the personal information we maintain about California residents. The CCPA among other effects, creates individual privacy rights for California consumers (as defined in the law), places increased privacy and security obligations on entities handling certain personal data of consumers or households, requires covered companies to provide disclosures to consumers regarding data collection, use and sharing practices, requires covered companies to allow users to opt-out of certain sales or transfers of personal information, and provides consumers with a private right of action for certain data breaches. The CCPA became effective on January&#160;1, 2020, and the California Attorney General&#8217;s authority to begin bringing enforcement actions began July&#160;1, 2020. As currently written, the CCPA may impact our business activities and exemplifies the vulnerability of our business to the evolving regulatory environment related to personal data and protected health information. Further, the California Privacy Rights Act (CPRA) was recently voted into law by California residents. The CPRA significantly amends the CCPA, and imposes additional data protection obligations on covered companies doing business in California, including additional consumer rights processes and opt outs for certain uses of sensitive data. It also creates a new California data protection agency specifically tasked to enforce the law, which would likely result in increased regulatory scrutiny of California businesses in the areas of data protection and security. The substantive requirements for businesses subject to the CPRA went into effect on January&#160;1, 2023, and become enforceable on July&#160;1, 2023. A similar law, the Consumer Data Protection Act (CDPA), was recently passed in Virginia and went into effect on January&#160;1, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We also are or will become subject to privacy laws in the jurisdictions in which we are established or in which we sell or market our products or run clinical trials. For example, in the EU, we are subject to Regulation (EU) 2016/679, the GDPR, in relation to our collection, control, processing, and other use of personal data (i.e. data relating to an identified or identifiable living individual). We process personal data in relation to participants in our clinical trials in the European Economic Area (EEA), including the health and medical information of these participants. The GDPR is directly applicable in each EU and EEA Member State, however, it provides that EU and EEA Member States may introduce further conditions, including limitations which could limit our ability to collect, use and share personal data (including health and medical information), or could cause our compliance costs to increase, ultimately having an adverse impact on our business. As noted above, the GDPR imposes onerous accountability obligations requiring data controllers and processors to maintain a record of their data processing and implement policies as part of its mandated privacy governance framework. It also requires data controllers to be transparent and disclose to data subjects (in a concise, intelligible and easily accessible form) how their personal information is to be used, imposes limitations on retention of personal data; defines for the first time pseudonymized (i.e., key-coded) data; introduces mandatory data breach notification requirements; and sets higher standards for data controllers to demonstrate that they have obtained valid consent for certain data processing activities. We are also subject to EEA rules with respect to cross-border transfers of personal data out of the EEA. As noted above, recent legal developments in the EU have created complexity and uncertainty regarding transfers of personal data from the EEA to the United States, e.g. on July&#160;16, 2020, the Court of Justice of the European Union (CJEU), invalidated the EU-U.S. Privacy Shield Framework, or the Privacy Shield, under which personal data could be transferred from the EEA to U.S. entities who had self-certified under the Privacy Shield scheme. While the CJEU upheld the adequacy of the standard contractual clauses (a standard form of contract approved by the European Commission as an adequate personal data transfer mechanism, and potential alternative to the Privacy Shield), it made clear that reliance on them alone may not necessarily be sufficient in all circumstances. Use of the standard contractual clauses must now be assessed on a case-by-case basis taking into account the legal regime applicable in the destination country, in particular applicable surveillance laws and rights of individuals and additional measures and/or contractual provisions may need to be put in place, however, the nature of these additional measures is currently uncertain. On June&#160;4, 2021, the European Commission adopted new standard contractual clauses under the GDPR for data transfers from entities that are subject to the GDPR to transfer personal data outside of the EEA. The new standard contractual clauses impose additional obligations, including the obligation to conduct a transfer impact assessment and, depending on a party&#8217;s role in the transfer, to implement additional security measures and to update internal privacy practices. If we elect to rely on the standard contractual clauses for data transfers, we may be required to incur significant time and resources to update our contractual arrangements and to comply with new obligations. Additionally, on September&#160;8, 2020, the Swiss Data Protection Authority (the Federal Data Protection and Information Commissioner) concluded that the Swiss-U.S. Privacy Shield does not provide an adequate level of protection for personal data transfer from Switzerland to the U.S. pursuant to the Swiss Federal Act on Data Protection. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the standard contractual clauses cannot be used, and/or start taking enforcement action, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are subject to the supervision of local data protection authorities in those EU jurisdictions where we are established or otherwise subject to the GDPR. Fines for certain breaches of the GDPR are significant: up to the greater of &#8364;20.0 million or 4% of total global annual turnover. Further, following the withdrawal of the United Kingdom from the EU on January&#160;31, 2020, pursuant to the transitional arrangements agreed between the United Kingdom and the EU, we will have to comply with the GDPR and separately the GDPR as implemented in the United Kingdom, each regime having the ability to fine up to the greater of &#8364;20 million / &#163;17 million or 4% of global turnover. Following December&#160;31, 2020, and the expiry of the post-Brexit transitional arrangements between the United Kingdom and EU, although it is likely that the data protection obligations of the GDPR will continue to apply to UK-related processing of personal data in substantially unvaried form and fashion, for at least the short term thereafter, the relationship between the United Kingdom and the EU in relation to certain aspects of data protection law remains unclear. For example, it is not yet clear whether the United Kingdom will be the subject of a so-called adequacy decision of the European Commission, and it is therefore unclear how data transfers between EU/EEA Member States and the United Kingdom will be treated. Any changes relating to the UK and EU position regarding aspects of data protection law may lead to additional compliance costs and could increase our overall risk. In addition to the foregoing, a breach of the GDPR or other applicable privacy and data protection laws and regulations could result in regulatory investigations, reputational damage, orders to cease/change our use of data, enforcement notices, an inability to process personal data or to operate in certain jurisdictions, or potential civil claims including class action type litigation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover, we use third-party service providers and subprocessors to help us operate our business and engage in processing on our behalf. If we, our service providers, partners, or other relevant third-parties have experienced, or in the future experience, any security incident(s) that result in any data loss, deletion or destruction, unauthorized access to, loss of, unauthorized acquisition or disclosure of, or inadvertent exposure or disclosure of sensitive information, or compromise related to the security, confidentiality, integrity of our (or their) information technology, software, services, communications or data, it may result in a material adverse impact, including without limitation, regulatory investigations or enforcement actions, litigation, or an inability to process data in some jurisdictions. Furthermore, applicable data protection laws, privacy policies and data protection obligations may require us to notify relevant stakeholders of security breaches, including affected individuals, customers, and regulators. Such disclosures are costly, and the disclosure or the failure to comply with such requirements, could result in a material adverse impact, including without limitation, regulatory investigations or enforcement actions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For more information on the potential impact of the GDPR, and associated EEA data protection laws, on our business, see the section titled &#8220;<I>Risk Factors-Failure to comply with health and data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation and/or adverse publicity and could negatively affect our operating results and business</I>.&#8221;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Additional Regulation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservation and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern the use, handling and disposal of various biologic, chemical and radioactive substances used in, and wastes generated by, operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. Equivalent laws have been adopted in other countries that impose similar obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>U.S. Foreign Corrupt Practices Act</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The U.S. Foreign Corrupt Practices Act (FCPA) prohibits U.S. corporations and individuals from engaging in certain activities to obtain or retain business abroad or to influence a person working in an official capacity. It is illegal to pay, offer to pay or authorize the payment of anything of value, directly or indirectly, to any foreign government official, government staff member, official or employee of a public international organization, or a political party or political candidate for the purpose of influencing any act or decision of the foreign entity in an attempt to obtain or retain business or to otherwise influence a person working in an official capacity. The scope of the FCPA includes interactions with healthcare professionals of foreign state-owned or affiliated hospitals, universities, or research institutions. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. Activities that violate the FCPA, even if they occur wholly outside the United States, can result in criminal and civil fines, imprisonment, disgorgement, oversight, and suspension and debarment from government contracts, and refusal of orders under existing government contracts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equivalent laws have been adopted in other foreign countries that impose similar or arguably broader obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 9, 2025, we had 5 full-time employees. There are also four PhD professionals and one lab technician who are paid by USC which is then reimbursed by us. None of our employees are subject to a collective bargaining agreement or represented by a trade or labor union. We consider our relationship with our employees to be good.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Properties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We do not currently own any properties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 7, 2025, we entered into an Office Lease (&#8220;Lease&#8221;) with RREF II Calabasas Park Center LLC (&#8220;Landlord&#8221;), pursuant to which we agreed to lease from Landlord, and Landlord agreed to lease to us, approximately 1,427 square feet of office space located at 23975 Park Sorrento, Calabasas, California 91302 (the &#8220;Building&#8221;). The Lease is for our new principal executive offices. The term of the Lease is anticipated to commence on April 14, 2025. Rent is payable beginning in the month of April 2025 in the amount of $6,778.25 per month; beginning in April 2026 monthly rent is $6,978.03; beginning in April 2027 monthly rent is $7,192.08; beginning in April 2028 monthly rent $7,406.13, beginning in April 2027 monthly rent is $7,634.45; and beginning in April 2028 monthly rent is $7,862.77. We must also pay 1.40% of the operating expenses of the Building, which include real property taxes, supplies, energy, water, janitorial services, maintenance and repairs, insurance, labor, legal, certain capital improvements and certain other costs and expenses. The Lease shall last for sixty-three (63) months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Legal Proceedings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">We may in the future be involved in actual and/or threatened legal proceedings, claims, investigations and government inquiries arising in the ordinary course of our business, including legal proceedings, claims, investigations and government inquiries involving intellectual property, data privacy and data protection, privacy and other torts, illegal or objectionable content, consumer protection, securities, employment, contractual rights, civil rights infringement, false or misleading advertising, or other legal claims relating to our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">On June&#160;6, 2023, a vendor filed a complaint against the Company for breach of contract in the Central District of California. The vendor alleged that the Company improperly terminated an Intellectual Property License and Supply Agreement (&#8220;IPLSA&#8221;) and that the Company also defrauded the vendor in connection with the IPLSA. This matter was settled on October&#160;16, 2023, and the Company agreed to pay the vendor $600,000 within 5 business days of the close of the date that the Company completes an IPO or March&#160;31, 2024, whichever occurs first. The Company recognized this as a litigation settlement expense in the accompanying consolidated statement of operations for the year ended December&#160;31, 2023 and a litigation settlement payable in the accompany consolidated balance sheet at December 31, 2024 and December&#160;31, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">On March&#160;31, 2024, the vendor agreed to extend the payment until May&#160;15, 2024 for payment of an additional $25,000. The Company has not made the payment as of October&#160;28, 2024 and the settlement is payable on demand. Such amount is included in litigation settlement payable in the accompanying consolidated balance sheet at December 31, 2024. On July&#160;25, 2024 the arbitrator granted the implementation of interest at the statutory rate on the unpaid balance commencing May&#160;15, 2024 until paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">On July 1, 2022, NeOnc Technologies, Inc. and Fox Infused, LLC, a Delaware limited liability company (&#8220;Fox Infused&#8221;), entered into an Intellectual Property License and Supply Agreement effective July&#160;1, 2022 (the &#8220;Agreement&#8221;) whereby NeOnc agreed to supply certain products to Fox Infused and license certain of our patents. We terminated the Agreement with Fox Infused on April&#160;25, 2023. On June&#160;6, 2023, Fox Infused filed a complaint against NeOnc in the Central District of California alleging that the termination was improper (Civil Action No. 2:23-04431). Fox Infused also filed an ex parte application for a temporary restraining order and an order to show cause on a preliminary injunction against us seeking to have the court stop the termination of the contract. Fox Infused&#8217;s temporary restraining order application was denied and the case dismissed without prejudice. Fox Infused refiled the case in arbitration before the American Arbitration Association (Case No. 01-23-0002-5020). The parties engaged in settlement discussions, and agreed to settle the dispute for a $600,000 payment by us to Fox Infused within 5 business days of the closing date of the Company&#8217;s initial public offering or March&#160;31, 2024. The Company is currently in default under the terms of such settlement agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><B>Transforming CNS Drug Development: NTHI&#8217;s AI and 3D Bioprinting Platforms for Precision Oncology and Beyond</B></P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">NTHI has strategically acquired and integrated two proprietary technology platforms that materially enhance its drug development capabilities and competitive positioning in the central nervous system (CNS) therapeutics space: (1) an artificial intelligence (AI)-powered compound modeling and sonodynamic therapy (SDT) optimization platform, and (2) a patented magnetic-field-guided 3D bioprinting technology for the generation of tumor spheroids and organoids.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">1. Artificial Intelligence for Drug Discovery and Personalized Sonodynamic Therapy</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">NTHI has acquired and operationalized an AI-driven computational drug modeling platform designed to support the rational development of sonosensitizers, including the Company&#8217;s lead assets, NEO100 and NEO212. This proprietary platform enables predictive modeling of blood-brain barrier (BBB) permeability, reactive oxygen species (ROS) generation, and drug-tumor interactions across heterogeneous CNS tumor environments, including glioblastoma, meningioma, diffuse intrinsic pontine glioma (DIPG), and brain metastases.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Key capabilities include:</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: left">&#9679;</TD>
    <TD STYLE="text-align: justify">Simulation of compound behavior, BBB penetration, and cytotoxicity (e.g., NEO100, NEO212 vs. temozolomide) across tumor types and microenvironments.</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman, Times, Serif">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: left">&#9679;</TD>
    <TD STYLE="text-align: justify">AI-guided optimization of ultrasound activation parameters to enhance SDT precision and efficacy.</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman, Times, Serif">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: left">&#9679;</TD>
    <TD STYLE="text-align: justify">In silico design of next-generation analogs and combinatorial therapeutic regimens with immuno-oncology and targeted agents.</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman, Times, Serif">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: left">&#9679;</TD>
    <TD STYLE="text-align: justify">Reduction in preclinical costs and cycle times by replacing low-throughput assays with high-fidelity computational predictions.</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman, Times, Serif">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: left">&#9679;</TD>
    <TD STYLE="text-align: justify">Personalization of treatment strategies based on patient-specific tumor biology and anatomical characteristics.</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman, Times, Serif">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The platform significantly accelerates drug discovery and improves translational predictability, offering a scalable foundation for expanding NTHI&#8217;s CNS oncology pipeline and clinical trial design.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">2. 3D Bioprinting Platform for Tumor and Disease Modeling</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">NTHI acquired exclusive rights to a patented 3D bioprinting platform developed at McMaster University (U.S. Patent No. 11,788,057 B2). This technology utilizes magnetic field manipulation to generate highly structured and reproducible tumor spheroids and organoids that accurately replicate the tumor microenvironment and neural architecture. This advancement resolves longstanding challenges of conventional 2D cultures and many 3D systems in terms of scalability, fidelity, and biological relevance.</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Applications and strategic impact include:</P>

<P STYLE="font: 10pt/115% Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: left">&#9679;</TD>
    <TD STYLE="text-align: justify">High-throughput modeling of brain tumors (e.g., GBM, DIPG, meningioma) for drug screening and mechanism-of-action studies.</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman, Times, Serif">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: left">&#9679;</TD>
    <TD STYLE="text-align: justify">Expansion into neurodegenerative disease models (e.g., Alzheimer&#8217;s, Parkinson&#8217;s) and non-CNS organoid systems (e.g., liver, lung, gut).</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman, Times, Serif">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: left">&#9679;</TD>
    <TD STYLE="text-align: justify">Alignment with NIH and international mandates to reduce reliance on animal models, positioning NTHI at the forefront of ethical, next-generation research tools.</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman, Times, Serif">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: left">&#9679;</TD>
    <TD STYLE="text-align: justify">Potential for licensing and strategic collaborations with academic institutions, biotech firms (e.g., Stemcell Technologies), and global pharmaceutical CROs.</TD> </TR>
  </TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font-family: Times New Roman, Times, Serif">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Together, these platforms provide a synergistic and vertically integrated framework that supports NTHI&#8217;s mission to deliver innovative, non-invasive CNS therapies, while opening parallel revenue opportunities in drug discovery tools, precision oncology, and disease modeling.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="text-decoration: underline"><FONT ID="a_013"></FONT>MANAGEMENT</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors, Executive Officers and Director Nominees</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our directors, executive officers and director nominees are listed below as of the date of this prospectus. The executive officers are full-time employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; text-align: left; width: 30%"><FONT STYLE="font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="text-align: center; width: 1%">&#160;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center; width: 59%"><FONT STYLE="font-size: 10pt"><B>Position</B></FONT></TD>
    <TD STYLE="text-align: center; width: 1%">&#160;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center; width: 9%"><FONT STYLE="font-size: 10pt"><B>Age</B></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt"><B>Directors and Executive Officers:</B></FONT></TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: top">&#160;</TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&#160;</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">Amir Heshmatpour</FONT></TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">Chief Executive Officer and President, Executive Chairman</FONT></TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">59</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">Dr. Thomas C. Chen, M.D., P.h.D.</FONT></TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">Chief Medical Officer and Chief Scientific Officer, Vice Chairman</FONT></TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">62</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">Josh Neman</FONT></TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">Chief Clinical Officer</FONT></TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">48</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">Keithly Garnett</FONT></TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">Chief Financial Officer </FONT></TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">51</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">Dr. Victoria Medvec, Ph.D.</FONT></TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">Director </FONT></TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">61</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">Bader Almonawer</FONT></TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">Director </FONT></TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">34</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">Dr. Steven L. Giannotta</FONT></TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">78</FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">Jim Delshad</FONT></TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">85</FONT></TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">Dr. Ming-Fu Chiang</FONT></TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">71</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each of our directors holds office until the next annual meeting of our shareholders whereby the director is up for election or until his/her successor has been elected and qualified, or until his/her death, resignation, or removal. Our executive officers are appointed by our board of directors and hold office until their death, resignation, or removal from office.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business Experience</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a brief overview of the education and business experience of each of our directors, executive officers and director nominees during at least the past five years, including their principal occupations or employment during the period, the name and principal business of the organization by which they were employed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors and Executive Officers:</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white"><I>Amir Heshmatpour</I>, has served as the Company&#8217;s Chief Executive Officer since October 2025, the Company&#8217;s President since April 2025, and has served on the Company&#8217;s Board since January 2023. Mr. Heshmatpour founded AFH Holding and Advisory LLC (&#8220;AFH&#8221;) in July 2005. Since July 2005, Mr. Heshmatpour has been the Managing Director of AFH. Mr. Heshmatpour, through AFH, his family office, has been involved in multiple biotech transactions from private to public. From 2018 to 2022, through a special purpose vehicle, Shuttle Pharmaceuticals Holdings Inc. (&#8220;SPH&#8221;), Mr. Heshmatpour restructured the board of directors, management, and recapitalized an IPO of a Georgetown phase II oncology asset. The SPV was created in 2018 and eventually was successfully listed on NASDAQ in 2022. Since then, he has been involved in NeOnc Technologies Inc., where he has provided strategic advisory services. Mr. Heshmatpour has a certification from the UCLA Anderson School of Business in corporate governance. He is also involved in the UCLA Anderson School of Business Management, Price Center, as a member of the Board of Advisors. In February 2024, Mr. Heshmatpour joined the Board of Directors of Make-A-Wish CVS in Los Angeles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Dr. Thomas C. Chen, M.D., Ph.D.</I> has served as NeOnc Technologies Holdings, Inc.&#8217;s Chief Medical Officer and Chief Scientific Officer since October 2025 and served as the Company&#8217;s Chief Executive Officer from April 2023 to October 2025. Since July 1997, Dr. Chen has worked as a Neurosurgeon at Keck Medicine of USC and a Professor Neurological Surgery at the University of Southern California Keck School of Medicine (&#8220;USC&#8221;). He has been the Director of Surgical Neuro-Oncology and Professor of Neurosurgery &amp; Pathology. Dr. Chen&#8217;s work is widely published, including 148+ peer-reviewed clinical studies. He maintains a clinical practice in both surgical neuro-oncology and spine surgery, as well as heads a research laboratory focused on glioma biology. He graduated summa cum laude from the University of Illinois at Urbana-Champaign with Bronze Tablet honors and Phi Beta Kappa. He graduated from University of California San Francisco with M.D. degree, and was in the top 10% of his class, awarded Alpha Omega Alpha. He earned his Ph.D. in pathobiology from University of Southern California where he wrote his thesis on the role of immunotherapy in malignant brain tumors. We believe that Dr. Chen&#8217;s extensive knowledge of NeOnc&#8217;s business and his extensive corporate and leadership experience as the founder of NeOnc and its Chief Executive Officer qualifies him to serve on our Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Josh Neman, Ph.D.</I> has served as NeOnc Technologies Holdings, Inc&#8217;s Chief Scientific Officer since June 2024. Since July 2014 Dr. Neman has served as an Associate Professor of Neurological Surgery, Neuroscience, and Physiology at the Keck School of Medicine of the University of Southern California (&#8220;Keck&#8221;). In addition to his academic role, he has held several key leadership positions at Keck, including Program Chair of the Cancer Biology and Genomics PhD Program since July 2019 and Scientific Director at the USC Brain Tumor Center since July 2021. In January 2021, Mr. Neman co-founded Synaptical Inc., a digital startup dedicated to providing cancer patients with guidance, education, and resources. He currently serves as its Chief Executive Officer. He also founded CNSMENDER Consulting LLC in January 2022, where he continues to serve as Chief Executive Officer. Dr. Neman earned both his Bachelor of Science and Ph.D. in Neurobiology from the University of California, Los Angeles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Keithly Garnett</I> has served as NeOnc Technologies Holdings, Inc.&#8217;s Chief Financial Officer since April&#160;2023 and served as a director from January&#160;2023 to March 2025. Mr. Garnett spent over 17 years with Ernst &amp; Young LLP in their Transaction Advisory Services practice. During that time, he specialized in business valuation modelling and strategy. His services were provided in support of audit related work for financial reporting, tax planning and management planning. His client list included companies such as Amgen, Edwards Life Sciences, Medtronic, etc. In any given year, he led over 50 transaction analyses and/or review for publicly traded companies, in connection with their SEC financial reporting requirements. From March 2017 to January 2023, Mr. Garnett was a Director at Sycamore Valuation. Since January 2021, Mr. Garnett has worked as the Chief Financial Officer of AFH Holding &amp; Advisory, a single member family office based in Malibu. From 2018 to 2022, he was involved with the Shuttle Pharmaceutical Holdings public offering, which was successfully listed on the Nasdaq in 2022. Mr. Garnett holds a Master&#8217;s in Business Administration with a concentration in Corporate Financial Management, and a Bachelor of Science degree in Business Management. He also completed the Columbia University Executive Education program with a certificate from the Chief Financial Officer program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Dr. Victoria Medvec, Ph.D</I>. has served on NeOnc Technologies Holdings, Inc.&#8217;s board of directors since March 2025. Since 1995, Dr. Victoria Medvec has been the Adeline Barry Davee Professor of Management and Organizations at the Kellogg School of Management at Northwestern University. In addition, Dr. Medvec is a co-founder and the Executive Director of the Center for Executive Women at the Kellogg School. Since 2002 Dr. Medvec has served as the CEO of Medvec and Associates, a consulting firm focused on high stakes negotiations and strategic decisions. Dr. Medvec received her Ph. D in psychology from Cornell University and Bachelor of Arts degree in Economics, Management, and Psychology from Bucknell University. Dr Medvec is a renowned expert in the areas of negotiations, executive decision making, influence, and corporate governance. Dr. Medvec&#8217;s research is published in top academic journals and she is the author of the best-selling book, Negotiate Without Fear. Dr. Medvec has served on both public and private company Boards across many industries, including banking, human resources and benefits administration. She also is a Ringleader in Ringleader Ventures, a unique venture fund matching start up technologies with corporate needs. We believe that Dr. Victoria Medvec&#8217;s extensive corporate and leadership experience qualifies her to serve on our Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Bader Almonawer </I>has served on NeOnc Technologies Holdings, Inc.&#8217;s board of directors since March 2025. Mr. Almonawer is an experienced professional with more than a decade of experience in venture capital, investment banking, and business consulting and development. Since 2013, Mr. Almonawer has served as Managing Partner for Arabian Group, overseeing its venture capital investments. In 2017, he founded Oasis Capital, a VC fund, and invested in numerous startups at their early stages, many of which have since grown into multibillion-dollar corporations. Mr. Almonawer has a background in investment banking and consulting; he has amassed valuable experience at McKinsey &amp; Company from 2016 to 2016, Citigroup&#8217;s M&amp;A advisory from 2021 to 2023, Wafra Inc.&#8217;s Alternative Investments Division from 2021 to 2021, and the World Bank from 2016 to 2017. After receiving his Bachelor in Science in Industrial Engineering and Operations Research from Penn State University, Mr. Almonawer earned a Master of Arts in Economics and Financial Policy at Cornell University earning Pi Alpha Alpha honors. Mr. Almonawer received his Master of Business Administration from Massachusetts Institute of Technology where he received the Halaby Fellowship, a Merit-based Fellowship recognizing his outstanding academic excellence and professional achievements. We believe that Mr. Bader Almonawer&#8217;s experience qualifies him to serve on our Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Dr. Steven L. Giannotta </I>has served on NeOnc Technologies Holdings, Inc.&#8217;s board of directors since March 2025<I>. </I>Dr Giannotta joined the USC Department of Neurosurgery in 1980 and has since become internationally recognized for his groundbreaking work in cerebrovascular disease, including pioneering &#8220;hyperdynamic therapy&#8221;; as a clinical approach to combat cerebral vasospasm. His research interests encompass cerebral blood flow, ischemia, and the impact of ethnic differences on cerebrovascular disorders. Dr. Giannotta&#8217;s clinical achievements include performing over 1,000 intracranial aneurysm surgeries and developing a comprehensive, multidisciplinary approach to complex cerebrovascular conditions. Dr. Giannotta earned his degree and completed his residency at the University of Michigan. He continues to serve as the Chair of Neurological Surgery at USC Keck, and as a Professor of Neurosurgery and a practicing neurosurgeon. We believe that Dr. Giannotta&#8217;s experience qualifies him to serve on our Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Jim Delshad</I> has served on NeOnc Technologies Holdings, Inc.&#8217;s board of directors since March 2025. Honorable Jimmy Delshad<I>,</I> served two terms as Mayor of Beverly Hills, starting in 2007, pioneering &#8220;Smart City&#8221; initiatives that transformed the city into a model of technological advancement and security. He holds the honorary title of &#8220;Goodwill Ambassador of Beverly Hills&#8221; in recognition of his contributions to the city. Mr. Delshad served as President of Magbit Foundation 2002 to 2006 and Chairman from 2006 to 2010. Over the past two decades he has provided management consulting services, which includes strategic advisory services across private, public, and non-profit sectors. His expertise spans government affairs, real estate, and healthcare, with a strong emphasis on non-profit development and donor engagement. We believe that Mr. Delshad&#8217;s experience qualifies him to serve on our Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Dr. Ming-Fu Chiang </I>has served on NeOnc Technologies Holdings, Inc.&#8217;s board of directors since March 2025. Dr. Chiang was a neurosurgeon and the former Vice-Director of the Department of Surgery and former Chairman of Neurosurgery at Mackay Memorial Hospital in Taipei, Taiwan from August 1991 to June 2020. Since July 2020, he is a practicing neurosurgeon at Chung-Shan Hospital and Taiwan Adventist Hospital in Taipei, Taiwan. Dr. Chiang has a Ph.D. in neuro-oncology from Free University of Berlin, Germany, and his EMBA (Executive Management Business &amp; Administration) from National Taiwan University. Dr. Chiang has also previously served as the CEO of NeuCen Biomedical, Inc. and Orio Biotech Inc. We believe that Dr. Chiang&#8217;s experience qualifies him to serve on our Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Family Relationships</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no family relationships among any of our executive officers or directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Involvement in Certain Legal Proceedings</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To the best of our knowledge, none of our directors or executive officers were involved in any legal proceedings described in Item&#160;401(f) of Regulation S-K in the past ten years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT STYLE="text-decoration: underline">CORPORATE GOVERNANCE</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Composition of our Board of Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our current Board of Directors consists of Dr. Thomas C. Chen, Amir Heshmatpour, Bader Almonawer, Dr. Victoria Medvec, Ph.D., Dr. Steven L. Giannotta, Jim Delshad and Dr. Ming-Fu Chiang.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our board of directors may establish the authorized number of directors from time to time by resolution. In accordance with our amended and restated certificate of incorporation, our board of directors is divided into three classes with staggered three-year terms. At each annual meeting of shareholders, the successors to directors whose terms then expire will be elected to serve from the time of election and qualification until the third annual meeting following election. Our directors are divided among the three classes as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt">&#160;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">the Class I directors are Dr. Victoria Medvec, Ph.D and Dr. Steven L. Giannotta, and their terms will expire at the annual meeting of shareholders to be held in 2025;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&#160;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the Class II directors are Bader Almonawer, Jim Delshad and Dr. Ming-Fu Chiang, and their terms will expire at the annual meeting of shareholders to be held in 2026; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Class III directors are Amir Heshmatpour and Dr. Thomas C. Chen, M.D., Ph.D., and their terms will expire at the annual meeting of shareholders to be held in 2027.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We expect that any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of one third of the directors. The division of our board of directors into three classes with staggered three-year terms may delay or prevent a change of our management or a change in control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Director Independence</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the listing requirements and rules of the Nasdaq Stock Market LLC (Nasdaq Listing Rules), a majority of our directors must be independent directors Bader Almonawer, Dr. Victoria Medvec, Ph.D., Dr. Steven L. Giannotta and Jim Delshad are considered independent based on the listing standards of Nasdaq. In order to promote open discussion among independent directors, our Board intends to adopt a policy of regularly conducting executive sessions of independent directors at scheduled meetings led by the lead independent director and at such other times requested by other independent directors. Executive sessions shall not include Dr. Thomas Chen, M.D., Ph.D., Mr. Amir Heshmatpour or Dr. Ming-Fu Chiang.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Committees of our Board of Directors</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors has established an audit committee, a compensation committee and a nominating and corporate governance committee, each of which operate pursuant to charters adopted by our Board of Directors. The Board of Directors may also establish other committees from time to time to assist our company and the board of directors. The composition and functioning of all of our committees complies with all applicable requirements of the Sarbanes-Oxley Act of 2002, the Nasdaq Global Market and SEC rules and regulations, if applicable. Our committees&#8217; charters are available on our website at www.neonc.com. The reference to our website address does not constitute incorporation by reference of the information contained at or available through our website, and you should not consider it to be part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Audit Committee</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audit committee consists of Bader Almonawer, Dr. Victoria Medvec, Ph.D and Jim Delshad. Our Board of Directors has determined that each of Bader Almonawer, Dr. Victoria Medvec, Ph.D. and Jim Delshad satisfies the independence requirements under Nasdaq listing standards and Rule&#160;10A-3(b)(1) of the Exchange Act. The chair of our audit committee is Bader Almonawer, who our Board of Directors has determined is an &#8220;audit committee financial expert&#8221; within the meaning of SEC regulations. Each member of our audit committee can read and understand fundamental financial statements in accordance with applicable requirements. In arriving at these determinations, our Board of Directors has examined each audit committee member&#8217;s scope of experience and the nature of their employment in the corporate finance sector.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The principal duties and responsibilities of our audit committee include, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">appointing, approving the compensation of, and assessing the independence of our independent registered public accounting firm;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pre-approving auditing and permissible non-audit services, and the terms of such services, to be provided by our independent registered public accounting firm;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing the overall audit plan with our independent registered public accounting firm and members of management responsible for preparing our financial statements;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and discussing with management and our independent registered public accounting firm our annual and quarterly financial statements and related disclosures as well as critical accounting policies and practices used by us;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">coordinating the oversight and reviewing the adequacy of our internal control over financial reporting;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing policies and procedures for the receipt and retention of accounting-related complaints and concerns;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending, based upon the audit committee&#8217;s review and discussions with management and our independent registered public accounting firm, whether our audited financial statements shall be included in our Annual Report on Form&#160;10-K;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">monitoring the integrity of our financial statements and our compliance with legal and regulatory requirements as they relate to our financial statements and accounting matters;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparing the audit committee report required by SEC rules to be included in our annual proxy statement;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing all related person transactions for potential conflict of interest situations and approving all such transactions; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing quarterly earnings releases.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compensation Committee</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our compensation committee consists of Bader Almonawer, Dr. Victoria Medvec, Ph.D and Jim Delshad. The chair of our compensation committee is Dr. Victoria Medvec, Ph.D. Our Board of Directors has determined that each of Bader Almonawer, Dr. Victoria Medvec, Ph.D. and Jim Delshad is independent under Nasdaq listing standards, a &#8220;non-employee director&#8221; as defined in Rule&#160;16b-3 promulgated under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The principal duties and responsibilities of our compensation committee include, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluating the performance of our Chief Executive Officer in light of such corporate goals and objectives and based on such evaluation: (i) recommending to the board of directors the cash compensation of our Chief Executive Officer, and (ii) reviewing and approving grants and awards to our Chief Executive Officer under equity-based plans;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&#160;</P>

<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and recommending to the board of directors the cash compensation of our other executive officers;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and establishing our overall management compensation, philosophy, and policy;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing and administering our compensation and similar plans;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and approving the retention or termination of any consulting firm or outside advisor to assist in the evaluation of compensation matters and evaluating and assessing potential and current compensation advisors in accordance with the independence standards identified in the applicable Nasdaq rules;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">retaining and approving the compensation of any compensation advisors;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and approving our policies and procedures for the grant of equity-based awards;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and recommending to the board of directors the compensation of our directors; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">preparing the compensation committee report required by SEC rules, if and when required, to be included in our annual proxy statement.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nominating and Corporate Governance Committee</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our nominating and corporate governance committee consists of Dr. Victoria Medvec, Ph.D, Jim Delshad and Dr. Steven L. Giannotta, Ph.D. The chair of our nominating and corporate governance committee is Jim Delshad. Our Board of Directors has determined that each of Dr. Victoria Medvec, Ph.D, Jim Delshad and Dr. Steven L. Giannotta is independent under Nasdaq listing standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The nominating and corporate governance committee&#8217;s responsibilities include, among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing and recommending to the board of directors&#8217; criteria for board and committee membership;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing procedures for identifying and evaluating board of director candidates, including nominees recommended by shareholders;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing the composition of the board of directors to ensure that it is composed of members containing the appropriate skills and expertise to advise us;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying individuals qualified to become members of the board of directors;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending to the board of directors the persons to be nominated for election as directors and to each of the board&#8217;s committees;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and recommending to the board of directors&#8217; appropriate corporate governance guidelines; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing the evaluation of our board of directors.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate Governance</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We adopted a written code of ethics and business conduct that applies to our directors, officers, and employees, including our principal executive officer, principal financial officer, principal accounting officer, or controller, or persons performing similar functions. A current copy of the code of ethics and business conduct is posted on the Governance Documents section of our website, which is located at www.neonc.com. The information on our website is deemed not to be incorporated in this prospectus or to be a part of this prospectus. If we make any substantive amendments to, or grant any waivers from, the code of business conduct and ethics for any officer or director, we will disclose the nature of such amendment or waiver on our website or in a current report on Form&#160;8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Scientific Advisory Board</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have assembled a scientific advisory board with expertise in oncology and clinical trials. The members of our scientific advisory board have made significant scientific contributions in their individual fields. Members of our scientific advisory board provide strategic advice to us in fields pertinent to gynecologic oncology and perform other such services as may be mutually determined by us and the scientific advisory board member. Our scientific advisory board meets on an as-needed basis, based on our need for advice in their fields of expertise from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We provide compensation for their time and on a per meeting basis to members of our scientific advisory board. We also reimburse each member of our scientific advisory board for all reasonable and necessary travel expenses in connection with the performance of his services. Our scientific advisory board includes: Axel H. Sch&#246;nthal, Ph.D. and Dr. David M. Peereboom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Board Leadership Structure</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors and management believe that the choice of whether the Chair of our Board of Directors should be an executive of our company, or a non-executive or independent director, depends upon a number of factors, taking into account the candidates for the position and the best interests of our company and our shareholders. Amir Heshmatpour serves as the Board Chair. Mr. Bader Almonawer will serve as lead independent director of our Board of Directors. As lead independent director, Mr. Bader Almonawer will preside over executive sessions of the independent directors and serves as a liaison between the independent directors and our management team.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk Oversight</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Board oversees a company-wide approach to risk management. Our Board will determine the appropriate risk level for us generally, assess the specific risks faced by us and review the steps taken by management to manage those risks. While our Board has ultimate oversight responsibility for the risk management process, its committees will oversee risk in certain specified areas.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Specifically, our compensation committee is responsible for overseeing the management of risks relating to our executive compensation plans and arrangements, and the incentives created by the compensation awards it administers. Our audit committee oversees the management of enterprise risks and financial risks, as well as potential conflicts of interest. Our Board is responsible for overseeing the management of risks associated with the independence of our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Compensation Committee Interlocks and Insider Participation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None of our officers currently serves, or has served during the last completed fiscal year, on the compensation committee or board of directors of any other entity that has one or more officers serving as a member of our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Director and Officer Indemnification Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We entered into separate indemnification agreements with our directors and executive officers, in addition to the indemnification provided for in our amended and restated certificate of incorporation and amended and restated bylaws. These agreements, among other things, require us to indemnify our directors and executive officers for certain expenses, including attorneys&#8217; fees, judgments, penalties, fines and settlement amounts incurred by a director or executive officer in any action or proceeding arising out of their services as one of our directors or executive officers or as a director or executive officer of any other company or enterprise to which the person provides services at our request. The indemnification agreements and our amended and restated certificate of incorporation and amended and restated bylaws require us to indemnify our directors and officers to the fullest extent permitted by Delaware law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><FONT STYLE="text-decoration: underline"><FONT ID="a_014"></FONT>EXECUTIVE COMPENSATION</FONT></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table provides certain information regarding compensation awarded to, earned by or paid to persons serving as our principal executive officer and our principal financial officer during the year ended December&#160;31, 2024 and 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Summary Compensation Table</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; text-align: left; vertical-align: bottom"><B>Name and Principal Position</B></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&#160;</TD>
    <TD STYLE="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><B>Fiscal<BR> Year</B></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center; vertical-align: bottom"><B>Salary<BR> ($)</B></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&#160;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center; vertical-align: bottom"><B>Bonus<BR> ($)</B></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&#160;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center; vertical-align: bottom"><B>Stock<BR> Awards<BR> ($)</B></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&#160;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center; vertical-align: bottom"><B>Option<BR> Awards<BR> ($)</B></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&#160;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center; vertical-align: bottom"><B>Non-Equity<BR> Incentive<BR> Plan<BR> Compensation<BR> ($)</B></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&#160;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center; vertical-align: bottom"><B>Non-<BR> Qualified<BR> Deferred<BR> Compensation<BR> Earnings<BR> ($)</B></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&#160;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center; vertical-align: bottom"><B>Other<BR> Compensation<BR> ($)</B></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&#160;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center; vertical-align: bottom"><B>Total<BR> ($)</B></TD>
    <TD STYLE="text-align: center; vertical-align: bottom">&#160;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD ROWSPAN="2" STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top; width: 29%">Dr. Thomas C. Chen &#8211;<BR> Chief Executive Officer<SUP>(1)</SUP></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&#160;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom; width: 6%">2024</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom; width: 1%">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom; width: 5%">212,000</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&#160;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom; width: 1%">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom; width: 5%">0</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&#160;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom; width: 1%">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom; width: 5%">0</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&#160;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom; width: 1%">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom; width: 5%">0</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&#160;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom; width: 1%">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom; width: 5%">0</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&#160;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom; width: 1%">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom; width: 5%">0</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&#160;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom; width: 1%">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom; width: 5%">0</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&#160;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom; width: 1%">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom; width: 5%">212,000</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&#160;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">2023</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">194,333</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">0</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">0</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">0</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">0</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">0</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">0</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">194,333</TD>
    <TD>&#160;</TD></TR>
  <TR STYLE="background-color: White">
    <TD ROWSPAN="2" STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">Patrick Walters &#8211;<BR> Chief Operating Officer<SUP>(2)</SUP></TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">2024</TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">195,000</TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">0</TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">0</TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">0</TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">0</TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">0</TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">0</TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">195,000</TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&#160;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">2023</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">178,750</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">0</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">0</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">0</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">0</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">0</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">0</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">178,750</TD>
    <TD>&#160;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD ROWSPAN="2" STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top">Keithly Garnett &#8211;<BR> Chief Financial Officer</TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="text-align: center; vertical-align: bottom">2024</TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">179,000</TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">0</TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">0</TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">0</TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">0</TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">0</TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">0</TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">179,000</TD>
    <TD STYLE="vertical-align: bottom">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&#160;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">2023</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">164,083</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">0</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">0</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">0</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">0</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">0</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">0</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left; vertical-align: bottom">$</TD>
    <TD STYLE="text-align: right; vertical-align: bottom">164,083</TD>
    <TD>&#160;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&#160;</DIV></DIV><!-- Field: /Rule-Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Dr. Chen served as our Chief Executive Officer until October 31, 2025 and is the Chief Medical Officer and Chief Scientific Officer of the Company.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Mr. Walters served as our Chief Financial Officer until April 7, 2023. Mr. Walters retired effective June 1, 2025.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2024, 800,000 shares of restricted stock were granted to Dr. Thomas C. Chen, M.D., Ph.D. Two-thirds of such restricted stock will be time vested; one-third (1/3) will vest seven months after March 25, 2025 and one-third will vest in equal monthly installments over a one (1) year period commencing on the eighth month from March 25, 2025. The remaining one-third will be performance-based, the vesting of which will be predicate on certain performance metrics being met as set forth in Dr. Chen&#8217;s individual grant agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2024, 300,000 shares of restricted stock were granted to Patrick Walters. Two-thirds of such restricted stock will be time vested; one-third (1/3) will vest seven months after March 25, 2025 and one-third will vest in equal monthly installments over a one (1) year period commencing on the eighth month from March 25, 2025. The remaining one-third will be performance-based, the vesting of which will be predicate on certain performance metrics being met as set forth in Mr. Walter&#8217;s individual grant agreement. Effective June 1, 2025, the 300,000 restricted stock were forfeited upon Patrick Walters&#8217; retirement from his position as Chief Operating Officer of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2024, 360,000 shares of restricted stock were granted to Keithly Garnett. Two-thirds of such restricted stock will be time vested; one-third (1/3) will vest seven months after March 25, 2025 and one-third will vest in equal monthly installments over a one (1) year period commencing on the eighth month March 25, 2025. The remaining one-third will be performance-based, the vesting of which will be predicate on certain performance metrics being met as set forth in Mr. Garnett&#8217;s individual grant agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2024, 200,000 shares of restricted stock were granted to Dr. Thomas C. Chen, M.D., Ph.D, all of which will vest seven months after March 25, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2025, 200,000 shares of restricted stock were granted to Josh Neman. One-third of the restricted stock will vest on January 5, 2026. One-third of the restricted stock will vest thereafter in twenty-nine (29) equal monthly installments. The remaining one-third will be performance-based, the vesting of which will be predicate on certain performance metrics being met as set forth in Mr. Neman&#8217;s individual grant agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2024, 1,000,000 shares of restricted stock were granted to Amir Heshmatpour. In October 2024, 200,000 shares of restricted stock were granted to Amir Heshmatpour. The forgoing restricted stock will vest one hundred percent (100%) seven months following March 25, 2025. In November 2025, 1,200,000 shares of restricted stock were granted to Amir Heshmatpour. <FONT STYLE="background-color: white">One-half of the shares of restricted stock will vest on January 2, 2025. The remaining one-half of the shares of restricted stock will vest thereafter in twelve (12) equal monthly installments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Employment Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 4, 2024, the Company entered into an employment agreement, as amended (&#8220;Employment Agreement&#8221;) with Dr. Thomas C. Chen to serve as Chief Executive Officer and Chief Scientific Officer of the Company. The term of the Employment Agreement has commenced upon the effective date of the Company&#8217;s listing of its common stock on a national securities exchange on March 25, 2025 and will continue for a period of seven months. The term will automatically renew for successive one-year periods until either party delivers written notice of their intent not to renew at least fifteen days prior to the expiration of the then effective term. The Employment Agreement provided for a base salary of $212,000. In addition, Dr. Chen shall be eligible to participate in any bonus or incentive programs established by the Company. The Employment Agreement may be terminated by either the Company or Dr. Chen at any time and for any reason or for no reason at all, subject to the terms of the Employment Agreement. Upon termination with good cause of the Employment Agreement by Dr. Chen, Dr. Chen shall be entitled to receive (i) his base salary until the end of the three month severance period reduced by any cash remuneration paid to Dr. Chen during the severance period, and (ii) benefits. Dr. Chen&#8217;s employment may also be terminated by the Company at any time, with cause, death or disability (as defined in the Employment Agreement). Upon termination without cause of the Employment Agreement by the Company, Dr. Chen shall be entitled to receive (i) his base salary until the end of the severance period, and (ii) accrued compensation and benefits. Upon the termination of the Employment Agreement due to a permanent disability, Dr. Chen shall be entitled to receive payments equal to the base salary for the severance period. On October 31, 2025 the Company entered into a Third Amendment<FONT STYLE="background-color: white">&#160;to the Employment Agreement with Dr. Chen, amending Dr. Chen&#8217;s existing employment agreement with the Company, dated as of January 4, 2024, as amended by that certain Amendment to Employment Agreement, dated as of July 12, 2024 and that certain Second Amendment to Employment Agreement, dated as of December 31, 2024 (as amended, the &#8220;Existing Employment Agreement&#8221;). Except as provided herein, all other terms of the Existing Employment Agreement remain the same. The Employment Agreement Amendment amends Dr. Chen&#8217;s title from Chief Executive Officer to Chief Medical Officer and Chief Scientific Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">On January 4, 2024, the Company entered into an employment agreement, as amended (&#8220;Employment Agreement&#8221;) with Patrick Walters to serve as Chief Operating Officer of the Company. The term of the Employment Agreement has commenced upon the effective date of the Company&#8217;s listing of its common stock on a national securities exchange on March 25, 2025 and will continue for a period of seven months. The term will automatically renew for successive one-year periods until either party delivers written notice of their intent not to renew at least fifteen days prior to the expiration of the then effective term. The Employment Agreement provided for a base salary of $195,000. In addition, Mr. Walters shall be eligible to participate in any bonus or incentive programs established by the Company. The Employment Agreement may be terminated by either the Company or Mr. Walters at any time and for any reason or for no reason at all, subject to the terms of the Employment Agreement. Upon termination with good cause of the Employment Agreement by Mr. Walters, Mr. Walters shall be entitled to receive (i) his base salary until the end of the three month severance period reduced by any cash remuneration paid to Mr. Walters during the severance period, and (ii) benefits. Mr. Walters&#8217;s employment may also be terminated by the Company at any time, with cause, death or disability (as defined in the Employment Agreement). Upon termination without cause of the Employment Agreement by the Company, Mr. Walters shall be entitled to receive (i) his base salary until the end of the severance period, and (ii) accrued compensation and benefits. Upon the termination of the Employment Agreement due to a permanent disability, Mr. Walters shall be entitled to receive payments equal to the base salary for the severance period. Upon Mr. Walters&#8217; retirement effective June 1, 2025, the Employment Agreement was terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">On January 4, 2024, the Company entered into an employment agreement, as amended (&#8220;Employment Agreement&#8221;) with Keithly Garnett to serve as Chief Financial Officer of the Company. The term of the Employment Agreement has commenced upon the effective date of the Company&#8217;s listing of its common stock on a national securities exchange on March 25, 2025 and will continue for a period of seven months. The term will automatically renew for successive one-year periods until either party delivers written notice of their intent not to renew at least fifteen days prior to the expiration of the then effective term. The Employment Agreement provided for a base salary of $179,000. In addition, Mr. Garnett shall be eligible to participate in any bonus or incentive programs established by the Company. The Employment Agreement may be terminated by either the Company or Mr. Garnett at any time and for any reason or for no reason at all, subject to the terms of the Employment Agreement. Upon termination with good cause of the Employment Agreement by Mr. Garnett, Mr. Garnett shall be entitled to receive (i) his base salary until the end of the three month severance period reduced by any cash remuneration paid to Mr. Garnett during the severance period, and (ii) benefits. Mr. Garnett&#8217;s employment may also be terminated by the Company at any time, with cause, death or disability (as defined in the Employment Agreement). Upon termination without cause of the Employment Agreement by the Company, Mr. Garnett shall be entitled to receive (i) his base salary until the end of the severance period, and (ii) accrued compensation and benefits. Upon the termination of the Employment Agreement due to a permanent disability, Mr. Garnett shall be entitled to receive payments equal to the base salary for the severance period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On June&#160;5, 2025, the Company entered into an employment agreement (&#8220;Employment Agreement&#8221;) with Josh Neman to serve as Chief Clinical Officer of the Company. The term of the Employment Agreement will commence on June&#160;5, 2025 and continue for a period of twelve months. The term will automatically renew for successive one-year periods until either party delivers written notice of their intent not to renew at least fifteen days prior to the expiration of the then effective term. The Employment Agreement provided for a base salary of $165,000. In addition, Mr. Neman shall be eligible to participate in any bonus or incentive programs established by the Company. The Employment Agreement may be terminated by either the Company or Mr. Neman at any time and for any reason or for no reason at all, subject to the terms of the Employment Agreement. Upon termination with good reason of the Employment Agreement by Mr. Neman, Mr. Neman shall be entitled to receive (i) his base salary until the end of the three month severance period reduced by any cash remuneration paid to Mr. Neman during the severance period, and (ii) benefits. Mr. Neman&#8217;s employment may also be terminated by the Company at any time, with cause, death or disability (as defined in the Employment Agreement). Upon termination without cause of the Employment Agreement by the Company, Mr. Neman shall be entitled to receive (i) his base salary until the end of the severance period, and (ii) accrued compensation and benefits. Upon the termination of the Employment Agreement due to a permanent disability, Mr. Neman shall be entitled to receive payments equal to the base salary for the severance period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">On October 31, 2025 the Company verbally agreed to the following terms of employment while a formal employment agreement is being negotiated. The Company will pay Mr. Heshmatpour $1 per year until his employment agreement is finalized. Mr. Heshmatpour is party to an indemnification agreement with the Company on the Company&#8217;s standard form of indemnification agreement entered into with each of its officers and directors. In connection with his appointment as Chief Executive Officer, Mr. Heshmatpour will be granted 1,200,000 shares of restricted stock pursuant to the Company&#8217;s 2023 Equity Incentive Plan. One-half of the shares of restricted stock will vest on January 2, 2025. The remaining one-half of the shares of restricted stock will vest thereafter in twelve (12) equal monthly installments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Non-Employee Director Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We did not pay any compensation, make any equity awards or non-equity awards to, or pay any other compensation to any of the non-employee members of our board of directors in 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2024, 50,000 shares of restricted stock were granted to Dr. Victoria Medvec, Ph.D. The forgoing restricted stock will vest one hundred percent (100%) seven months following March 25, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2024, 50,000 shares of restricted stock were granted to Bader Almonawer. The forgoing restricted stock will vest one hundred percent (100%) seven months following March 25, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2025, 50,000 shares of restricted stock were granted to each of Dr. Steven L. Giannotta, Jim Delshad and Dr. Ming-Fu Chiang. The forgoing restricted stock will vest one hundred percent (100%) seven months following March 25, 2025. In September 2025, an additional 10,000 restricted stock were granted to Dr. Ming-Fu Chiang in connection with his service on the Scientific Advisory Board. These restricted stock will vest over a 12 month period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>2023 Incentive Stock Plan</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have adopted a 2023 Incentive Stock Plan, as amended (the &#8220;2023 Plan&#8221;). An aggregate of 4,764,507 shares of our common stock is currently reserved for issuance and available for awards under the 2023 Plan, including incentive stock options granted under the 2023 Plan. The 2023 Plan administrator may grant awards to any employee, director, consultant, or other person providing services to us or our affiliates. A total of 4,345,000 restricted stock were granted to our executive officers, directors, advisory board members and employees further to the 2023 Plan as described below. The 2023 Plan is currently administered by the Board. The 2023 Plan administrator has the authority to determine, within the limits of the express provisions of the 2023 Plan, the individuals to whom awards will be granted, the nature, amount and terms of such awards and the objectives and conditions for earning such awards. The Board may at any time amend or terminate the 2023 Plan, provided that no such action may be taken that adversely affects any rights or obligations with respect to any awards previously made under the 2023 Plan without the consent of the recipient. No awards may be made under the 2023 Plan after the tenth anniversary of its effective date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Awards under the 2023 Plan may include incentive stock options, nonqualified stock options, restricted shares of common stock and restricted stock units.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Stock Options</I>. The 2023 Plan administrator may grant to a participant options to purchase our common stock that qualify as incentive stock options for purposes of Section&#160;422 of the Internal Revenue Code (&#8220;incentive stock options&#8221;), options that do not qualify as incentive stock options (&#8220;non-qualified stock options&#8221;) or a combination thereof. The terms and conditions of stock option grants, including the quantity, price, vesting periods, and other conditions on exercise will be determined by the 2023 Plan administrator. The exercise price for stock options will be determined by the 2023 Plan administrator in its discretion, but non-qualified stock options and incentive stock options may not be less than 100% of the fair market value of one share of our company&#8217;s common stock on the date when the stock option is granted. Additionally, in the case of incentive stock Options granted to a holder of more than 10% of the total combined voting power of all classes of our stock on the date of grant, the exercise price may not be less than 110% of the fair market value of one share of common stock on the date the stock option is granted. Stock options must be exercised within a period fixed by the 2023 Plan administrator that may not exceed ten years from the date of grant, except that in the case of incentive stock options granted to a holder of more than 10% of the total combined voting power of all classes of our stock on the date of grant, the exercise period may not exceed five years. At the 2023 Plan administrator&#8217;s discretion, payment for shares of common stock on the exercise of stock options may be made in cash, shares of our common stock held by the participant or in any other form of consideration acceptable to the 2023 Plan administrator (including one or more forms of &#8220;cashless&#8221; or &#8220;net&#8221; exercise).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Restricted Shares and Restricted Units</I>. The 2023 Plan administrator may award to a participant shares of common stock subject to specified restrictions. Restricted shares, or restricted stock units, are subject to forfeiture if the participant does not meet certain conditions such as continued employment over a specified forfeiture period and/or the attainment of specified performance targets over the forfeiture period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2024, 800,000 shares of restricted stock were granted to Dr. Thomas C. Chen, M.D., Ph.D. Two-thirds of such restricted stock will be time vested; one-third (1/3) will vest seven months after March 25, 2025 and one-third will vest in equal monthly installments over a one (1) year period commencing on the eighth month from March 25, 2025. The remaining one-third will be performance-based, the vesting of which will be predicate on certain performance metrics being met as set forth in Dr. Chen&#8217;s individual grant agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2024, 300,000 shares of restricted stock were granted to Patrick Walters. Two-thirds of such restricted stock will be time vested; one-third (1/3) will vest seven months after March 25, 2025 and one-third will vest in equal monthly installments over a one (1) year period commencing on the eighth month from March 25, 2025. The remaining one-third will be performance-based, the vesting of which will be predicate on certain performance metrics being met as set forth in Mr. Walter&#8217;s individual grant agreement. Effective June 1, 2025, the 300,000 restricted stock were forfeited upon Patrick Walters&#8217; retirement from his position as Chief Operating Officer of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2024, 360,000 shares of restricted stock were granted to Keithly Garnett. Two-thirds of such restricted stock will be time vested; one-third (1/3) will vest seven months after March 25, 2025 and one-third will vest in equal monthly installments over a one (1) year period commencing on the eighth month from March 25, 2025. The remaining one-third will be performance-based, the vesting of which will be predicate on certain performance metrics being met as set forth in Mr. Garnett&#8217;s individual grant agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2024, 1,000,000 shares of restricted stock were granted to Amir Heshmatpour. The forgoing restricted stock will vest one hundred percent (100%) seven months following March 25, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2024, 50,000 shares of restricted stock were granted to Dr. Victoria Medvec, Ph.D. The forgoing restricted stock will vest one hundred percent (100%) seven months following March 25, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2024, 50,000 shares of restricted stock were granted to Bader Almonawer. The forgoing restricted stock will vest one hundred percent (100%) seven months following March 25, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2024, 200,000 shares of restricted stock were granted to each of Dr. Thomas C. Chen, M.D., Ph.D and Amir Heshmatpour. The forgoing restricted stock will vest one hundred percent (100%) seven months following March 25, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2025, 50,000 shares of restricted stock were granted to each of Dr. Steven L. Giannotta, Jim Delshad and Dr. Ming-Fu Chiang. The forgoing restricted stock will vest one hundred percent (100%) seven months following March 25, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">In June 2025, 200,000 shares of restricted stock were granted to Josh Neman. One-third of the restricted stock will vest on January 5, 2026. One-third of the restricted stock will vest thereafter in twenty-nine (29) equal monthly installments. The remaining one-third will be performance-based, the vesting of which will be predicate on certain performance metrics being met as set forth in Mr. Neman&#8217;s individual grant agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">In November 2025, 1,200,000 shares of restricted stock were granted to Amir Heshmatpour. One-half of the shares of restricted stock will vest on January 2, 2025. The remaining one-half of the shares of restricted stock will vest thereafter in twelve (12) equal monthly installments.&#160;70,000 shares of restricted stock were granted to Grace Fisher, with half vesting immediately, and the remaining shares will vest two months later with ten (10) equal monthly installments. Dr. Henry Friedman as was also granted 15,000 additional shares of restricted stock, with half vesting immediately, and the remaining shares will vest two months later with ten (10) equal monthly installments. Dr. Henry Friendman was previously granted 10,000 shares of restricted stock in September 2025, with half vesting immediately, and the remaining shares vesting in equal installments over a ten (10) month period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With respect to that potion of the aforementioned restricted stock that vest based upon performance criteria, the Board determined that it would be to the competitive advantage and interest of the Company and its stockholders to grant an award of restricted stock the vesting of which will be predicate on certain performance metrics being met as a whole, as an inducement to remain in the service of our Company and as an incentive for increased efforts during such service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The number of restricted stock issued with performance criteria vesting metrics that are ultimately vested with respect to each grantee will depend upon the achievement of such performance metrics, taken as a whole, as set forth in each individual grant agreement. The actual number of such restricted stock vested with respect to each grantee will be determined at meetings of the Compensation Committee of the Board (the &#8220;Committee&#8221;) to be held semi-annually following the completion of the year ended December 31 at which time the Committee will certify whether it believes in its sole discretion that sufficient performance criteria have been satisfied to justify the vesting, in whole or in part, of such restricted stock. The Committee may certify in its sole discretion that all, none or a percentage of such performance based grants should be deemed vested and the grantee will acknowledge that certification shall be binding and non-appealable and that he/she shall have no legal right to contest such certification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Committee is permitted to waive any vesting conditions applicable to any stock award or grant of restricted stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><FONT STYLE="text-decoration: underline"><FONT ID="a_015"></FONT>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</FONT></FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&#160;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">certain information regarding the beneficial ownership of our voting securities as of the date of this prospectus by (i) each person or group of affiliated persons known by us to be the beneficial owner of more than 5% of our voting securities, (ii) each of our executive officers, (iii) each of our directors and (iv) all of our directors and executive officers as a group. Except as otherwise indicated, all persons listed below have (i) sole voting power and investment power with respect to their common stock, except to the extent that authority is shared by spouses under applicable law, and (ii) record and beneficial ownership with respect to their common stock.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 10, 2025, there are 23,970,791 shares of common stock and no shares of preferred stock issued and outstanding. In accordance with the rules of the SEC, beneficial ownership includes voting or investment power with respect to securities and includes the common stock issuable pursuant to options and warrants that are exercisable or settled within 60 days of the date of this prospectus. Shares of common stock issuable pursuant to options and warrants are deemed outstanding for computing the percentage of the class beneficially owned by the person holding such securities but are not deemed outstanding for computing the percentage of the class beneficially owned by any other person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Unless otherwise indicated, the business address of each of the individuals and entities named below is c/o NeOnc Technologies, Inc., c/o NeOnc Technologies Holding, Inc., 23975 Park Sorrento, Suite 205, Calabasas, CA 91302.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Name and address of Beneficial Owner</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock<BR> Shares</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">%</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; font-weight: bold">5% Stockholders:</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 76%"><FONT STYLE="font-size: 10pt">HCWG LLC<SUP>(1)</SUP></FONT></TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 9%; text-align: right">1,024,478</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 9%; text-align: right">4.3</TD>
    <TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Executive Officers, Directors and Director Nominees</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-size: 10pt">Dr. Thomas C. Chen, M.D., Ph.D.<SUP>(2)</SUP></FONT></TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">4,647,563</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">19.4</TD>
    <TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-size: 10pt">Josh Neman<SUP>(3)</SUP></FONT></TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">68,310</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-size: 10pt">Keithly Garnett<SUP>(4)</SUP></FONT></TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">204,953</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-size: 10pt">Amir Heshmatpour<SUP>(5)</SUP></FONT></TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">7,512,140</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">31.3</TD>
    <TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-size: 10pt">Dr. Victoria Medvec, Ph.D.<SUP>(6)</SUP></FONT></TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">50,160</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-size: 10pt">Bader Almonawer<SUP>(7)</SUP></FONT></TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">50,160</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-size: 10pt">Dr. Steven L. Giannotta<SUP>(8)</SUP></FONT></TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">50,160</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-size: 10pt">Jim Delshad<SUP>(9)</SUP></FONT></TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">55,260</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-size: 10pt">Dr. Ming-Fu Chiang, M.D., Ph.D.<SUP>(10)</SUP></FONT></TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,790,049</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">7.5</TD>
    <TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; font-style: italic; text-align: left">Directors, Director Nominees and Executive Officers as a Group (9 persons)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">14,428,755</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">60.2</TD>
    <TD STYLE="text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&#160;</DIV></DIV><!-- Field: /Rule-Page -->

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.35in; text-align: left"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Less than 1%.</FONT></TD> </TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&#160;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.35in; text-align: justify"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify">
        <P STYLE="text-align: justify; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 10pt">HCWG LLC is owned 25.1% by Amir Heshmatpour, 25.5% by Thomas C. Chen M.D., Ph.D., 7.7% by Patrick Walters, 4.3% by The Hilkiah Group LLC, of which Keithly Garnett is the sole member and manager, and 37.5% by Alan Chiang. The address of HCWG LLC is 6363 Lunita Road, Malibu, CA 90265.</FONT></P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.35in"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Represents shares of our common stock held of record by TR Chen Third Family Limited Partnership over which Dr. Chen and Dr. Chen&#8217;s spouse, Rosa Chen, exercise sole voting and investment control. The address of TR Chen Third Family Limited Partnership is c/o NeOnc Technologies Holding, Inc., 23975 Park Sorrento, Suite 205, Calabasas, CA 91302. In January 2024, 800,000 shares of restricted stock were granted to Dr. Thomas C. Chen, M.D., Ph.D. Two-thirds of such restricted stock will be time vested; one-third (1/3) vested on October 25, 2025 and one-third will vest in equal monthly installments over a one (1) year period commencing on November 1, 2025. The remaining one-third will be performance-based, the vesting of which will be predicate on certain performance metrics being met as set forth in Dr. Chen&#8217;s individual grant agreement. In October 2024, 200,000 shares of restricted stock were granted to Dr. Thomas C. Chen, M.D., Ph.D., all of which vested on October 25, 2025. Includes 261,603 shares through beneficial ownership of HCWG LLC. 888,148 common stock were held by Neucen Biomedical Co. LTD. Additionally, he purchased a total of 5,868 shares in May 2025.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">In June 2025, 200,000 shares of restricted stock were granted to Josh Neman. One-third of the restricted stock will vest on January 1, 2026. One-third of the restricted stock will vest thereafter in twenty-nine (29) equal monthly installments. The remaining one-third will be performance-based, the vesting of which will be predicated on certain performance metrics being met as set forth in Mr. Neman&#8217;s individual grant agreement.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">In January 2024, 360,000 shares of restricted stock were granted to Keithly Garnett. Two-thirds of such restricted stock will be time vested; one-third (1/3) vested on October 25, 2025 and one-third will vest in equal monthly installments over a one (1) year period commencing on November 1, 2025. The remaining one-third will be performance-based, the vesting of which will be predicate on certain performance metrics being met as set forth in Mr. Garnett&#8217;s individual grant agreement. Includes 43,601 shares through beneficial ownership of HCWG LLC. Additionally, he purchased a total of 900 between May and November 2025.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2024, 1,000,000 shares of restricted stock were granted to Amir Heshmatpour. In October 2024, 200,000 shares of restricted stock were granted to Amir Heshmatpour. The foregoing restricted stock vested one hundred percent (100%) on October 25, 2025. Includes 257,109 shares through beneficial ownership of HCWG LLC.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Includes (i) 3,714,020 shares of our common stock held of record by AFH Holding and Advisory, LLC, of which Mr. Heshmatpour is the sole member and over which he has sole voting and investment control; (ii) 550,000 shares of our common stock held of record by KIG LLC of which Mr. Heshmatpour&#8217;s spouse, Kathy Heshmatpour, exercises sole voting and investment control; (iii) 275,000 shares held by Angelina Heshmatpour, the minor daughter of Mr. Heshmatpour, and (iv) 275,000 shares held by Amir Heshmatpour. The address of AFH Holding and Advisory, LLC is c/o NeOnc Technologies Holding, Inc., 23975 Park Sorrento, Suite 205, Calabasas, CA 91302. Additionally, he received 650,000 shares that will vest within the next 60 days.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&#160;</TD>
    <TD STYLE="text-align: justify">&#160;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">In February 2024, 50,000 shares of restricted stock were granted to Dr. Victoria Medvec, Ph.D. The foregoing restricted stock vested one hundred percent (100%) on October 25, 2025. Additionally, she received 160 shares as a transfer from Dr. Chen and Amir Heshmatpour (collectively).</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(7)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">In February 2024, 50,000 shares of restricted stock were granted to Bader Almonawer. The foregoing restricted stock vested one hundred percent (100%) on October 25, 2025. Additionally, he received 160 shares as a transfer from Dr. Chen and Amir Heshmatpour (collectively).</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(8)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">In February 2025, 50,000 shares of restricted stock were granted to Dr. Steven L. Giannotta. The foregoing restricted stock vested one hundred percent (100%) on October 25, 2025. Additionally, he received 160 shares as a transfer from Dr. Chen and Amir Heshmatpour (collectively).</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(9)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">In February 2025, 50,000 shares of restricted stock were granted to Jim Delshad. The foregoing restricted stock vested one hundred percent (100%) on October 25, 2025. Additionally, he received 160 shares as a transfer from Dr. Chen and Amir Heshmatpour (collectively). Subsequently, a total of 5,100 shares between March 2025 and May 2025.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(10)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Includes 340,216 shares of our common stock held of record by Dr. Ming-Fu Chiang. In February 2025, 50,000 shares of restricted stock were granted to Dr. Ming-Fu Chiang. The forgoing restricted stock vested one hundred percent (100%) on October 25, 2025. In September 2025, 10,000 shares of restricted stock were granted to Dr. Ming-Fu Chiang. Includes 383,684 shares through beneficial ownership of HCWG LLC. 488,196 shares of common stock were held by family members. 488,148 common stock were held by Neucen Biomedical Co. LTD. And 29,309 common stock were held by Orion Biotech.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="text-decoration: underline"><FONT ID="a_016"></FONT>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other than as disclosed below, and except for the compensation arrangements and regular salary and bonus payments made to our directors and officers in the ordinary course of business as described in &#8220;<I>Executive Compensation</I>,&#8221; there have been no transactions since January&#160;1, 2022, or any currently proposed transaction or series of similar transactions to which our company was or is to be a party, in which the amount involved exceeds $120,000 and in which any current or former director or officer of our company, any 5% or greater shareholder of our company or any member of the immediate family of any such persons had or will have a direct or indirect material interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Letter of Intent &#8211; AFH Holdings and Advisory, LLC</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December&#160;19, 2022, NeOnc Technologies, Inc. entered into an engagement agreement with AFH Holdings and Advisory, LLC (&#8220;AFH&#8221;). Amir Heshmatpour is the sole member and managing director of AFH and a member of NeOnc&#8217;s Board of Directors. AFH was engaged to assist NeOnc Technologies, Inc. in connection with its intent to effect a public listing. AFH was retained to assist NeOnc Technologies, Inc. with investor presentations and decks, coordinate the retention of an investment banker for an initial public offering, identify legal and accounting professionals to assist in connection with such public offering, identify investor relations/public relations firms, advise on private capital markets activities prior to the initial public offering and coordinate the closing process for the offering, and earned $500,000 during the year ended December&#160;31, 2023. AFH agreed to advance costs of up to $500,000 for such professionals on our behalf to be to be paid off with proceeds of the short term loan provided to us by HCWG LLC. As of December&#160;31, 2023, no amounts were outstanding further to such agreement. NeOnc Technologies, Inc. also agreed to effect a share exchange with NeOnc Technologies Holdings, Inc., a special purpose entity substantially beneficially owned by Amir Heshmatpour and his affiliates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April&#160;7, 2023, NeOnc Technologies, Inc. entered into a Share Exchange Agreement (the &#8220;Share Exchange&#8221;) with NeOnc Technologies Holdings, Inc., whereby all of the shareholders of NeOnc Technologies, Inc. exchanged their stock in NeOnc Technologies, Inc. for a total of 10,500,000 shares of common stock in NeOnc Technologies Holdings, Inc. As a result, all shareholders of NeOnc Technologies, Inc. became shareholders of NeOnc Technologies Holdings, Inc. and NeOnc Technologies, Inc. became a wholly-owned subsidiary of NeOnc Technologies Holdings, Inc. At the consummation of this transaction, Amir Heshmatpour, AFH, and their affiliated entities, individuals, or assignees owned an aggregate of 34.4% of the fully diluted issued and outstanding common shares of NeOnc Technologies Holdings, Inc. For the year ended December&#160;31, 2022, NeOnc Technologies Holdings, Inc. had no operations or assets other than cash paid by its shareholders for their shares ($450 in the aggregate) and liabilities of $50,000 pertaining to an amount owing to Mr. Heshmatpour for a professional retainer paid by him on behalf of our company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, NeOnc Technologies, Inc. agreed to retain AFH as an exclusive advisor on all financing and mergers and acquisitions for a period of two (2) years from the closing of a public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 12, 2024, the Company amended the AFH advisory agreement section to allow for an upfront payment on the listing date of $2,500,000 and the remining amount of $8,828,565 to be paid in equal monthly installments for one year. AFH was paid a fee of $500,000 for the amendment. Mr. Heshmatpour was paid $2,500,000 following the direct listing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions with USC</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March&#160;9, 2009, we entered into an exclusive license agreement with USC, pursuant to which USC granted a license to use certain patented technology related to the use of monoterpenes as a solvent, specifically perillyl alcohol. This technology is the basis of the current products under development by us. We agreed to issue USC 560,000 additional shares of our common stock and issued such shares in October&#160;2023. Additionally, pursuant to the USC Agreement, we (1) paid USC an upfront royalty payment of $20,000, (2) granted USC 117,236 shares of common stock, (3) will pay USC an earned royalty of 2% of Net Sales (as that term is defined in the USC Agreement), and (4) has paid and will continue to pay annual maintenance royalties of: $5,000 due January&#160;1, 2011, $5,000 due January&#160;1, 2012, $10,000 due January&#160;1, 2013, and $20,000 due January&#160;1 thereafter. We have not paid any earned royalties date, since no products are being sold using such technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November&#160;19, 2023, the Company and USC entered into an Amended and Restated Exclusive License Agreement (the &#8220;Restated Agreement&#8221;). The Restated Agreement addressed and clarified certain reporting obligations of the Company <FONT STYLE="background-color: white">under the</FONT> license agreement with USC dated March&#160;9, 2009, and addressed <FONT STYLE="background-color: white">certain financial and other obligations, defaults, and deficiencies in connection with the Company&#8217;s performance.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the Restated Agreement, the Company recorded additional license fees in the amount of $230,000 to cure deficiencies in the existing license agreement related to unpaid sub-license fees within license expense in the accompanying consolidated statement of operations for the year ended December&#160;31, 2023, and accrued within accounts payable &#8211; related parties in the accompanying consolidated balance sheet as of December&#160;31, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> We also utilize laboratory services from USC. We have incurred approximately $461,000 and $326,000 of research and development-related costs from USC for the years ended December&#160;31, 2024 and 2023, respectively. We incurred approximately $20,000 and $41,000 of patent maintenance and legal-related expenses for the years ended December&#160;31, 2024 and 2023, respectively. At December&#160;31, 2024 and 2023, we owed USC approximately $272,328 and $277,000, respectively. From time to time prior to January 1, 2023, the Company has been unable to reimburse USC for such costs. Therefore, USC deducted certain amounts due to the Chairman for compensation for his services as faculty at USC to satisfy the amounts due from the Company to USC. In 2024, the Company reached an agreement to convert a portion of amount owed as of such date in the amount of $1,377,096 to 114,758 common shares at $12 per share (the share price of the most recent financing round) and is recorded as a portion of the common stock issued for settlement of vendor payable in the Consolidated Statements of Changes in Shareholders&#8217; Deficit for December 31, 2024. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued compensation</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The Company has incurred $785,996 and $798,743 for the years ended December&#160;31, 2024 and 2023, respectively for compensation to the management team, all of whom are shareholders. This compensation is recorded in the consolidated statement of operations as part of general and administrative expenses. The amount accrued for compensation for the management team was $693,163 and $1,091,243 as of December&#160;31, 2024 and 2023, respectively, and $255,099 as of September&#160;30, 2025. On June&#160;14, 2024<B>, </B>the Company reached an agreement with the management team to convert $412,500 of the outstanding accrued compensation to 34,375 shares of common stock at $12 per share. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term loans</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In April&#160;2023, we entered into a non-interest bearing, non-convertible promissory note with HCWG LLC. HCWG LLC is owned 31.25% by Amir Heshmatpour, 18.75% by Dr. Thomas Chen, 18.75% by Dr. Alan Chiang (a former director), 15.625% by Patrick Walters and 15.625% by The Hilkiah Group LLC (an entity wholly-owned by Keithly Garnett, our Chief Financial Officer). Borrowings under the Bridge Loan carry a 50% (or 1 times cash amounts borrowed) original issue discount (&#8220;OID&#8221;) on principal and through subsequent amendments the maximum cash borrowing was increased to $10,000,000 at December&#160;31, 2023. The outstanding amounts under this Bridge Loan are payable at the earlier of the IPO date or December&#160;4, 2024, (the &#8220;Maturity Date&#8221;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through December 31, 2024 and 2023, the Company had received under the Bridge Loan an aggregate of 7,337,408 and $5,968,987, respectively. The OID was recognized ratably over the term of each draw-down under the Bridge Loan through the Maturity Date unless settled earlier, at which point the accretion is accelerated. Accretion of the OID for the year ended December 31, 2024 and 2023, amounted to $2,557,055 and 2,721,747, respectively, and are included in interest expense in the accompanying consolidated statement of operations. Summary of the bridge loan activity for the years ended December 31, 2024 and 2023, respectively, is as follows:</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> &#160; </TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"> &#160; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> For the<BR> year ended<BR> December&#160;31,<BR> 2024 </TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"> &#160; </TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"> &#160; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> For the<BR> year ended<BR> December&#160;31,<BR> 2023 </TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"> &#160; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"> Bridge loan roll-forward </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><FONT STYLE="font-style: normal; font-weight: normal">Principal outstanding</FONT></TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> $ </TD>
    <TD STYLE="text-align: right"> 9,802,697 </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> $ </TD>
    <TD STYLE="text-align: right"> - </TD>
    <TD STYLE="text-align: left"> &#160; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; width: 76%; vertical-align: top"> Borrowings </TD>
    <TD STYLE="width: 1%"> &#160; </TD>
    <TD STYLE="width: 1%; text-align: left"> &#160; </TD>
    <TD STYLE="width: 9%; text-align: right"> 1,368,422 </TD>
    <TD STYLE="width: 1%; text-align: left"> &#160; </TD>
    <TD STYLE="width: 1%"> &#160; </TD>
    <TD STYLE="width: 1%; text-align: left"> &#160; </TD>
    <TD STYLE="width: 9%; text-align: right"> 5,968,987 </TD>
    <TD STYLE="width: 1%; text-align: left"> &#160; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"> OID </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> 1,368,422 </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> 5,968,987 </TD>
    <TD STYLE="text-align: left"> &#160; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"> Repayments </TD>
    <TD STYLE="padding-bottom: 1pt"> &#160; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &#160; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"> (791,077 </TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"> ) </TD>
    <TD STYLE="padding-bottom: 1pt"> &#160; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &#160; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"> (2,135,277 </TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> Total principal outstanding before conversion </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> 11,748,464 </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> 9,802,697 </TD>
    <TD STYLE="text-align: left"> &#160; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"> Conversion to common stock </TD>
    <TD STYLE="padding-bottom: 1pt"> &#160; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &#160; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"> (11,748,464 </TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"> ) </TD>
    <TD STYLE="padding-bottom: 1pt"> &#160; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &#160; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"> - </TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"> &#160; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt; vertical-align: top"> Principal; outstanding </TD>
    <TD STYLE="padding-bottom: 2.5pt"> &#160; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> - </TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"> &#160; </TD>
    <TD STYLE="padding-bottom: 2.5pt"> &#160; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 9,802,697 </TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"> &#160; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"> &#160; </TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt"> &#160; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"> For the<BR> year ended<BR> December&#160;31,<BR> 2023 </TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold"> &#160; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"> Bridge loan </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top"> &#160; </TD>
    <TD> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD>
    <TD STYLE="text-align: right"> &#160; </TD>
    <TD STYLE="text-align: left"> &#160; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left"> Principal Outstanding </TD>
    <TD STYLE="width: 1%"> &#160; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD>
    <TD STYLE="width: 9%; text-align: right"> 9,802,697 </TD>
    <TD STYLE="width: 1%; text-align: left"> &#160; </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt"> Less: Unrecognized OID </TD>
    <TD STYLE="padding-bottom: 1pt"> &#160; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"> &#160; </TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right"> (3,247,240 </TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left"> ) </TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt; vertical-align: top"> Total: </TD>
    <TD STYLE="padding-bottom: 2.5pt"> &#160; </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left"> $ </TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right"> 6,555,457 </TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"> &#160; </TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 14, 2024, the Company reached an agreement with HCWG to convert the outstanding principal and interest on the Bridge Loan totaling $11,748,464 to 979,039 shares of common stock at $12 per share. The fair value of the common stock issued for the conversions was valued based upon the pricing from a recent financing round which was $12 a share. The difference between the carrying value of the debt as of the date of the extinguishment of $9,678,541 and the fair value of the shares issued to settle to the debt as of the date of the extinguishment of $11,748,464 is recorded as a loss on extinguishment of Bridge Loan in the accompanying consolidated statement of operations in the amount of $2,069,923. As a result of this conversion, the Bridge Loan was terminated and is no longer available to us for borrowing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B><I>Advances &#8211; Executive Chairman of the Board</I></B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B><I>&#160;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2025, Mr. Heshmatpour advanced the Company approximately $300,000. The advances carry a 50% (or 1 times amounts borrowed) original issue discount (&#8220;OID&#8221;) on the principal. In the event of default, interest is payable at on any unpaid balance at a rate of 10% per annum. Mr. Heshmatpour is to receive a total of $600,000 upon repayment of such advances, including OID, absent default. The Company shall pay the Executive Chairman the entire unpaid principal balance on the earlier of one year following the date of the effective date of the agreement or the date of the direct listing on the Nasdaq Global Market. The Company paid Mr. Heshmatpour the unpaid principal balance following the Company&#8217;s direct listing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stock-Based Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> <B>&#160;</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> As of December&#160;31, 2022 there were 24,328 vested stock options outstanding under the 2013 Option Plan, which were cancelled in January&#160;2023. These options had a weighted average exercise price of $0.36 per share. There were no grants during the year ended December&#160;31, 2024 and 2023. As of December&#160;31, 2024 and 2023, there were no stock options outstanding. There is no further activity expected under the 2013 Option Plan. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2024, 800,000 shares of restricted stock were granted to Dr. Thomas C. Chen, M.D., Ph.D. Two-thirds of such restricted stock will be time vested; one-third (1/3) will vest seven months after March 25, 2025 and one-third will vest in equal monthly installments over a one (1) year period commencing on the eighth month from March 25, 2025. The remaining one-third will be performance-based, the vesting of which will be predicate on certain performance metrics being met as set forth in Dr. Chen&#8217;s individual grant agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2024, 300,000 shares of restricted stock were granted to Patrick Walters. Two-thirds of such restricted stock will be time vested; one-third (1/3) will vest seven months after March 25, 2025 and one-third will vest in equal monthly installments over a one (1) year period commencing on the eighth month from March 25, 2025. The remaining one-third will be performance-based, the vesting of which will be predicate on certain performance metrics being met as set forth in Mr. Walter&#8217;s individual grant agreement. Effective June 1, 2025, the 300,000 shares of restricted stock were forfeited upon Patrick Walters&#8217; retirement from his position as Chief Operating Officer of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2024, 360,000 shares of restricted stock were granted to Keithly Garnett. Two-thirds of such restricted stock will be time vested; one-third (1/3) will vest seven months after March 25, 2025 and one-third will vest in equal monthly installments over a one (1) year period commencing on the eighth month from March 25, 2025. The remaining one-third will be performance-based, the vesting of which will be predicate on certain performance metrics being met as set forth in Mr. Garnett&#8217;s individual grant agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2024, 1,000,000 shares of restricted stock were granted to Amir Heshmatpour. The forgoing restricted stock will vest one hundred percent (100%) seven months following March 25, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2024, 50,000 shares of restricted stock were granted to Dr. Victoria Medvec, Ph.D. The forgoing restricted stock will vest one hundred percent (100%) seven months following March 25, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2024, 50,000 shares of restricted stock were granted to Bader Almonawer. The forgoing restricted stock will vest one hundred percent (100%) seven months following March 25, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2024, 200,000 shares of restricted stock were granted to each of Amir Heshmatpour and Dr. Thomas C. Chen, M.D., Ph.D. The forgoing restricted stock will vest one hundred percent (100%) seven months following March 25, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2025, 50,000 shares of restricted stock were granted to each of Dr. Steven L. Giannotta, Jim Delshad and Dr. Ming-Fu Chiang. The forgoing restricted stock will vest one hundred percent (100%) seven months following March 25, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2025, 200,000 shares of restricted stock were granted to Josh Neman. One-third of the restricted stock will vest on January 5, 2026. One-third of the restricted stock will vest thereafter in twenty-nine (29) equal monthly installments. The remaining one-third will be performance-based, the vesting of which will be predicate on certain performance metrics being met as set forth in Mr. Neman&#8217;s individual grant agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2025, 1,200,000 shares of restricted stock were granted to Amir Heshmatpour. <FONT STYLE="background-color: white">One-half of the shares of restricted stock will vest on January 2, 2025. The remaining one-half of the shares of restricted stock will vest thereafter in twelve (12) equal monthly installments. 70,000 shares of restricted stock were granted to Grace Fisher, with half vesting immediately, and the remaining shares will vest two months later with ten (10) equal monthly installments. Dr. Henry Friedman as was also granted 15,000 additional shares of restricted stock, with half vesting immediately, and the remaining shares will vest two months later with ten (10) equal monthly installments. Dr. Henry Friendman was previously granted 10,000 shares of restricted stock in September 2025, with half vesting immediately, and the remaining shares vesting in equal installments over a ten (10) month period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Vesting of the restricted stock above was contingent on the completion of a listing on NASDAQ. Due to the listing condition, these restricted stock were not considered issued for accounting purposes as of December 31, 2024 and no fair value charge has been recognized in our consolidated statement of operations to these restricted stock as of December 31, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaboration and License Agreement between NeOnc and Orient EuroPharma Co., Ltd.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November&#160;8, 2013, we entered into a Collaboration and License Agreement with Orient EuroPharma Co., Ltd. (&#8220;OEP&#8221;), which is partially owned by Alan Chiang, a former director, pursuant to which NeOnc licensed OEP the right to commercialize NEO100. On February&#160;20, 2024, OEP and the Company entered into a settlement agreement whereas the Company and OEP terminated the OEP Agreement in exchange for a payment in the amount of $4,000,000 payable by the Company to OEP within ten days of the close of our initial public offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">License Agreement by and between NeOnc Technologies and Neucen Biomedical Co., Ltd</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December&#160;5, 2015, we previously entered into a License Agreement with Neucen Biomedical Co. Ltd. (&#8220;Neucen&#8221;), which is owned in part by the spouse of Dr. Alan Chiang and Thomas Chen, pursuant to which NeOnc licensed to Neucen the right to commercialize NEO212. We terminated this License Agreement on May&#160;30, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brownstone Note</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February&#160;17, 2022, the Company issued R &amp; J Brownstone Trust dated September&#160;17, 2001 (&#8220;Brownstone&#8221;) a Convertible Promissory Note (the &#8220;Brownstone Note&#8221;) in the amount of $50,000. On January&#160;31, 2024, the Company assigned the Brownstone Note to HCWG LLC (a related party). On January&#160;31, 2024, the Note was assigned to HCWG LLC (an entity owned by certain of our shareholders, directors, and officers) and the Note was amended to increase the principal balance to $62,500.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Line of Credit Agreement</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 11, 2024, the Company entered into a Line of Credit Agreement with HCWG for borrowings of up to $10.0 million. Borrowings under the Line of Credit Agreement bear interest at 10.0% per annum with interest payments due on the first business day of each calendar month, with unpaid principal due by October 12, 2027. In connection therewith, the Company issued HCWG a five-year warrant to purchase up to 312,500 shares of its common stock at a per share exercise price of $12.00. The interest rate increases to 14% if the Line of Credit Agreement is extended. In April 2025, following the cashless exercise of the warrant, 162,500 shares of Company common stock were issued to HCWG.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT ID="a_017"></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="text-decoration: underline">DESCRIPTION OF SECURITIES</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following description summarizes the most important terms of our capital stock and certain provisions of our amended and restated certificate of incorporation and amended and restated bylaws. This summary does not purport to be complete and is qualified in its entirety by the provisions of our amended and restated certificate of incorporation and amended and restated bylaws, copies of which have been filed as exhibits to the Registration Statement of which this prospectus is a part, and by the applicable provisions of Delaware law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our authorized capital stock consists of 110,000,000 shares of capital stock, of which (i) 100,000,000 shares are common stock with a par value $0.0001 per share and (ii) 10,000,000 shares are preferred stock with a par value of&#8201;$0.0001 per share. All of our authorized shares of preferred stock are undesignated. As of December 9, 2025, there are 23,970,792 shares of common stock and no shares of preferred stock issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting Rights</I></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Holders of common stock are entitled to one vote per share on all matters to be voted upon by the shareholders, including the election of directors. Such holders are not entitled to vote cumulatively for the election of directors. Our amended and restated certificate of incorporation establishes a classified board of directors that is divided into three classes with staggered three-year terms. Only the directors in one class will be subject to election by a plurality of the votes cast at each annual meeting of our shareholders, with the directors in the other classes continuing for the remainder of their respective three-year terms. The affirmative vote of holders of at least 66 2/3% of the voting power of all of the then-outstanding shares of capital stock, voting as a single class, will be required to amend certain provisions of our amended and restated certificate of incorporation, including provisions relating to amending our amended and restated bylaws and our amended and restated certificate of incorporation, the classified structure of our board of directors, the size of our board of directors, removal of directors, director liability, vacancies on our board of directors, special meetings, shareholder notices, actions by written consent, and exclusive jurisdiction.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Dividends</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Subject to preferences that may be applicable to any outstanding preferred stock, our common shareholders are entitled to receive ratably such dividends, if any, as may be declared from time to time by the board of directors out of funds legally available for that purpose. We have never declared or paid any cash dividends on our capital stock. We currently expect to retain future earnings, if any, to finance the growth and development of our business and do not anticipate paying any cash dividends in the foreseeable future. See the section titled &#8220;<I>Dividend Policy</I>&#8221; for further information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Liquidation Rights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In the event of our liquidation, dissolution or winding up, our common shareholders are entitled to share ratably in all assets remaining after payment of liabilities, subject to prior distribution rights of preferred stock, if any, then outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>No Preemptive or Similar Rights</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our common shareholders have no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to the common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred Stock</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to our amended and restated certificate of incorporation, our board of directors is authorized, without action by the shareholders, to designate and issue up to 10,000,000 shares of preferred stock in one or more series and to designate the powers, preferences and rights of each series, which may be greater than the rights of the common stock. It is not possible to state the actual effect of the issuance of any shares of preferred stock upon the rights of holders of the common stock until the board of directors determines the specific rights of the holders of such preferred stock. However, the effects might include, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">impairing dividend rights of the common stock;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">diluting the voting power of the common stock;</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">impairing the liquidation rights of the common stock; and</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delaying or preventing a change in control of us without further action by the shareholders</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible Promissory Note</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In 2022, NeOnc Technologies, Inc. issued a $50,000 convertible note to a shareholder due August&#160;30, 2023 (&#8220;Note&#8221;). The Note bears interest at 2% per annum and is convertible. The Note and all accrued interest thereon is convertible, at the option of the noteholder, into the class and series of equity securities (&#8220;Conversion Stock&#8221;) that is sold by us in its next issuance of equity securities in a Financing Transaction (as defined below), consummated after the issuance date of the note. A Financing Transaction is a sale, other than in an initial public offering, of equity securities by us to investors for cash. The Financing Transaction does not include the issuance of stock, options, or warrants to service providers in connection with the rendition of such services or to third parties in connection with the contribution of non-cash assets to us. The number of shares of Conversion Stock to be issued to the noteholder upon such conversion shall be equal to the quotient obtained by dividing (i) the entire principal amount of the Note plus accrued interest by (ii) the Financing Transaction conversion price, which shall be equal to 75% of the price paid for one share of Conversion Stock by the investors in the Financing Transaction. The entire principal amount of and accrued interest of the Note shall automatically be converted, without further action on the part of the noteholder or us, into the class and series of stock issued by us, at the closing of an initial public offering. The number of shares of stock to be issued to the holder upon such conversion shall be equal to the quotient obtained by dividing (i) the entire principal amount of the Note plus accrued interest by (ii) the initial public offering conversion price, which shall be equal to 75% of the price paid for one share of Conversion Stock by the investors in the initial public offering. On January 31, 2024, the Note was assigned to HCWG LLC (an entity owned by certain shareholders, directors, and officers of the Company). Additionally, as part of the assignment, the Note was amended to increase the principal balance to $62,500, amend the maturity date to the date that the Company completes its initial public offering, and the Note was subordinated to the Bridge Loan (defined herein).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-Takeover Provisions</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because our shareholders do not have cumulative voting rights, our shareholders holding a plurality of the outstanding shares of common stock outstanding will be able to elect all of our directors. Our amended and restated certificate of incorporation and our amended and restated bylaws provide for shareholder actions at a duly called meeting of shareholders. A special meeting of shareholders may be called by a majority of our board of directors, the chair of our board of directors, or our chief executive officer or president. Our amended and restated bylaws will establish an advance notice procedure for shareholder proposals to be brought before an annual meeting of our shareholders, including proposed nominations of persons for election to our board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As described above in &#8220;<I>Management&#8212;Corporate Governance,&#8221;</I> in accordance with our amended and restated certificate of incorporation, our board of directors is divided into three classes with staggered three-year terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The foregoing provisions will make it more difficult for our existing shareholders to replace our Board of Directors as well as for another party to obtain control of us by replacing our Board of Directors. Since our board of directors has the power to retain and discharge our officers, these provisions could also make it more difficult for existing shareholders or another party to effect a change in management. In addition, the authorization of undesignated preferred stock makes it possible for our Board of Directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change our control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These provisions are intended to enhance the likelihood of continued stability in the composition of our Board of Directors and its policies and to discourage certain types of transactions that may involve an actual or threatened acquisition of us. These provisions are also designed to reduce our vulnerability to an unsolicited acquisition proposal and to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and may have the effect of deterring hostile takeovers or delaying changes in our control or management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section&#160;203 of the Delaware General Corporation Law</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We are subject to Section&#160;203 of the Delaware General Corporation Law, which prohibits a Delaware corporation from engaging in any business combination with any interested shareholder for a period of three years after the date that such shareholder became an interested shareholder, with the following exceptions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">before such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in the shareholder becoming an interested shareholder;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon closing of the transaction that resulted in the shareholder becoming an interested shareholder, the interested shareholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested shareholder) those shares owned by (i) persons who are directors and also officers and (ii) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting of the shareholders, and not by written consent, by the affirmative vote of at least 66 2&#8725;3% of the outstanding voting stock that is not owned by the interested shareholder.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In general, Section&#160;203 defines business combination to include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any merger or consolidation involving the corporation and the interested shareholder;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested shareholder;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested shareholder;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested shareholder; or</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the receipt by the interested shareholder of the benefit of any loss, advances, guarantees, pledges or other financial benefits by or through the corporation.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In general, Section&#160;203 defines an &#8220;interested shareholder&#8221; as an entity or person who, together with the person&#8217;s affiliates and associates, beneficially owns, or within three years prior to the time of determination of interested shareholder status did own, 15% or more of the outstanding voting stock of the corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 104; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Exclusive forum for adjudication of disputes provision which limits the forum to the Delaware Court of Chancery for certain shareholder litigation matters actions against us, which may limit an investor&#8217;s ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or shareholders.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our amended and restated bylaws dictate that, unless we consent in writing to the selection of an alternative forum, the Delaware Court of Chancery (or, if the Delaware Court of Chancery does not have jurisdiction, the federal district court for the State of Delaware) is, to the fullest extent permitted by law, the sole and exclusive forum for certain actions including derivative action or proceeding brought on our behalf; an action asserting a breach of fiduciary duty owed by any current or former officer, director, employee or to the shareholders of our company; any claim arising under Delaware corporate law, our certificate of incorporation or our bylaws, as amended from time to time; and any action asserting a claim governed by the internal affairs doctrine. Any person or entity purchasing or otherwise acquiring any interest in shares of capital stock of our company shall be deemed to have notice of and consented to the provisions of our amended and restated bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">However, this provision of our amended and restated bylaws will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. To the extent that any such claims may be based upon federal law claims, Section&#160;27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Furthermore, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America will be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act, or the rules and regulations promulgated thereunder. We note, however, that Section&#160;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. There is uncertainty as to whether a court would enforce this provision and that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Delaware corporation is allowed to mandate in its corporate governance documents a chosen forum for the resolution of state law-based shareholder actions, derivative suits and other intra-corporate disputes. With respect to such state law claims, our management believes limiting state law based claims to Delaware will provide the most appropriate outcomes as the risk of another forum misapplying Delaware law is avoided, Delaware courts have a well-developed body of case law and limiting the forum will preclude costly and duplicative litigation and avoids the risk of inconsistent outcomes. Additionally, Delaware Chancery Courts can typically resolve disputes on an accelerated schedule when compared to other forums.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The choice of forum provisions contained in our amended and restated bylaws may limit a shareholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with our company or any of our directors, officers, other employees or shareholders, which may discourage lawsuits with respect to such claims. Alternatively, the enforceability of similar choice of forum provisions in other issuers&#8217; bylaws and certificates of incorporation has been challenged in legal proceedings, and it is possible that in connection with any applicable action brought against our company, a court could find the choice of forum provisions contained in our bylaws, as amended. to be inapplicable or unenforceable in such action. As a result, we could incur additional costs associated with resolving such actions in other jurisdictions, which could harm our business, operating results and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transfer Agent and Registrar</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have appointed VStock Transfer LLC, 18 Lafayette Pl Woodmere, NY 11598, telephone: (212) 828-8436, as the transfer agent for our common stock</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading Symbol and Market</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our shares of common stock are listed on the Nasdaq Global Market under the symbol &#8220;NTHI&#8221;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><FONT STYLE="text-decoration: underline"><FONT ID="a_018"></FONT>SHARES ELIGIBLE FOR FUTURE SALE</FONT></FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to this offering, our common stock is quoted on the Nasdaq Global Market under the symbol &#8220;NTHI.&#8221; Future sales of substantial amounts of our common stock, including shares issued on the exercise of outstanding options, in the public market after this offering, or the possibility of these sales or issuances occurring, could adversely affect the prevailing market price for our common stock or impair our ability to raise equity capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 10, 2025, a total of 23,970,791 shares of our common stock are outstanding. Of these shares, 111,732 shares of our common stock are registered in this Registration Statement, will be freely tradable in the public market without restriction or further registration under the Securities Act, unless these shares are held by &#8220;affiliates,&#8221; as that term is defined in Rule 144 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8,864,203 shares of common stock are &#8220;restricted securities,&#8221; as that term is defined in Rule&#160;144 under the Securities Act. These restricted securities are eligible for public sale only if they are registered under the Securities Act or if they qualify for an exemption from registration under Rules&#160;144 or 701 under the Securities Act, which are summarized below. Restricted securities may also be sold outside of the United States to non-U.S. persons in accordance with Rule&#160;904 of Regulation S.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rule&#160;144</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In general, under Rule&#160;144 as currently in effect, once we have been subject to public company reporting requirements of Section&#160;13 or Section&#160;15(d) of the Exchange Act for at least 90 days, an eligible shareholder is entitled to sell such shares without complying with the manner of sale, volume limitation, or notice provisions of Rule&#160;144, subject to compliance with the public information requirements of Rule&#160;144. To be an eligible shareholder under Rule&#160;144, such shareholder must not be deemed to have been one of our affiliates for purposes of the Securities Act at any time during the 90 days preceding a sale and must have beneficially owned the shares proposed to be sold for at least six months, including the holding period of any prior owner other than our affiliates. If such a person has beneficially owned the shares proposed to be sold for at least one year, including the holding period of any prior owner other than our affiliates, then such person is entitled to sell such shares without complying with any of the requirements of Rule&#160;144, subject to the expiration of the lock-up agreements described below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In general, under Rule&#160;144, as currently in effect, our affiliates or persons selling shares on behalf of our affiliates are entitled to sell shares on expiration of the lock-up agreements described below. Beginning 90 days after the date of this prospectus, within any three-month period, such shareholders may sell a number of shares that does not exceed the greater of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1% of the number of shares of common stock then outstanding, which will equal approximately 190,268 shares immediately after this offering; or</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the average weekly trading volume of our common stock on the Nasdaq Global Market during the four calendar weeks preceding the filing of a notice on Form&#160;144 with respect to such sale.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales under Rule&#160;144 by our affiliates or persons selling shares on behalf of our affiliates are also subject to certain manner of sale provisions and notice requirements and to the availability of current public information about us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rule&#160;701</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Rule&#160;701 generally allows a shareholder who was issued shares under a written compensatory plan or contract and who is not deemed to have been an affiliate of our company during the immediately preceding 90 days, to sell these shares in reliance on Rule&#160;144, but without being required to comply with the public information, holding period, volume limitation, or notice provisions of Rule&#160;144. Rule&#160;701 also permits affiliates of our company to sell their Rule&#160;701 shares under Rule&#160;144 without complying with the holding period requirements of Rule&#160;144. All holders of Rule&#160;701 shares, however, are required by that rule to wait until 90 days after the date of this prospectus before selling those shares under Rule&#160;701, subject to the expiration of the lock-up agreements described below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 106; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form S-8 Registration Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We filed a registration statements on Form S-8 under the Securities Act with the SEC registering the offer and sale of shares of our common stock that are issuable under our 2023 Plan. This registration statement became effective immediately on filing. Shares covered by this registration statement are eligible for sale in the public markets, subject to vesting restrictions, any applicable lock-up agreements described below, and Rule&#160;144 limitations applicable to affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Lock-up Arrangement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to that certain Share Exchange Agreement, dated April 7, 2023 (the &#8220;Share Exchange&#8221;), for a period of six (6) months from March 25, 2025, all shareholders who were issued shares further to the Share Exchange have agreed with the Company not to lend; offer; pledge; sell or otherwise transfer or dispose of, directly or indirectly, 80% of such shares; the Company has subsequently allowed such stockholders to make private transfers of such shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<!-- Field: Page; Sequence: 107; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="text-decoration: underline"><FONT ID="a_019"></FONT>MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a general discussion of material U.S. federal income tax considerations and certain U.S. federal estate tax considerations relating to the acquisition, ownership, and disposition of our common stock applicable to non-U.S. holders that purchase our common stock in this offering and hold it as a &#8220;capital asset&#8221; within the meaning of Section&#160;1221 of the U.S. Internal Revenue Code of 1986, as amended, or the Code (generally, property held for investment). For purposes of this discussion, a &#8220;non-U.S. holder&#8221; means a beneficial owner of our common stock (other than an entity or arrangement that is treated as a partnership for U.S. federal income tax purposes) that is not, for U.S. federal income tax purposes, any of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an individual who is a citizen or resident of the United States;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a corporation (or entity treated as a corporation for United States federal income tax purposes) created or organized in or under the laws of the United States, any state thereof or the District of Columbia;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an estate, the income of which is includable in gross income for U.S. federal income tax purposes regardless of its source; or</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a trust if (i) a court within the United States is able to exercise primary supervision over the administration of the trust and one or more &#8220;United States persons,&#8221; as defined under the Code, or U.S. persons, have the authority to control all substantial decisions of the trust or (ii) such trust has made a valid election to be treated as a U.S. person for U.S. federal income tax purposes.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If a partnership (or other entity or arrangement treated as a partnership for U.S. federal income tax purposes) holds our common stock, the tax treatment of a partner therein will generally depend on the status of the partner and the activities of the partnership. Partners of a partnership holding our common stock should consult their tax advisors as to the particular U.S. federal income tax consequences applicable to them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This discussion is based on current provisions of the Code, final, temporary and proposed Treasury regulations promulgated thereunder, or the Treasury Regulations, judicial decisions, published rulings and administrative pronouncements of the U.S. Internal Revenue Service, or IRS, all as in effect as of the date of this prospectus and all of which are subject to change or to differing interpretation, possibly with retroactive effect. Any change could alter the tax consequences to non-U.S. holders described herein. There can be no assurance that the IRS will not challenge one or more of the tax consequences described herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This discussion does not address all aspects of U.S. federal income and estate taxation that may be relevant to a particular non-U.S. holder in light of that non-U.S. holder&#8217;s individual circumstances nor does it address any aspects of U.S. state, local or non-U.S. taxes, other U.S. federal tax, the alternative minimum tax, or the unearned income Medicare contribution tax on net investment income. This discussion also does not consider any specific facts or circumstances that may apply to a non-U.S. holder and does not address the special tax rules applicable to particular non-U.S. holders, such as:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">banks, insurance companies and other financial institutions;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">brokers or dealers or traders in securities;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">tax-exempt organizations;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pension plans;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">persons who hold our common stock as part of a straddle, hedge, conversion transaction, synthetic security or other integrated investment or who have elected to mark securities to market;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">controlled foreign corporations, passive foreign investment companies, and corporations that accumulate earnings to avoid U.S. federal income tax;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 108; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">non-U.S. governments; and</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. expatriates and former citizens or long-term residents of the United States.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS SUMMARY IS NOT INTENDED TO CONSTITUTE A COMPLETE DESCRIPTION OF ALL TAX CONSEQUENCES FOR NON-U.S. HOLDERS RELATING TO THE OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK. PROSPECTIVE HOLDERS OF OUR COMMON STOCK SHOULD CONSULT WITH THEIR TAX ADVISORS REGARDING THE TAX CONSEQUENCES TO THEM (INCLUDING THE APPLICATION AND EFFECT OF ANY STATE, LOCAL, NON-U.S. INCOME AND OTHER TAX LAWS) OF THE ACQUISITION, OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distributions</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As discussed under &#8220;<I>Dividend Policy</I>&#8221; above, we do not expect to make distributions on our common stock in the foreseeable future. However, if we do make distributions of cash or property on our common stock, such distributions will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Amounts of distributions not treated as dividends for U.S. federal income tax purposes will first constitute a tax-free return of capital of the non-U.S. holder&#8217;s investment and be applied against and reduce a non-U.S. holder&#8217;s adjusted tax basis in its common stock, but not below zero. Any remaining excess will be treated as capital gain and will be treated as described below under &#8220;<I>Gain on Sale or Other Disposition of Common Stock</I>.&#8221; Because we may not know the extent to which a distribution is a dividend for U.S. federal income tax purposes at the time it is made, for purposes of the withholding rules discussed below we or the applicable withholding agent may treat the entire distribution as a dividend. Any such distributions will also be subject to the discussions below under the headings &#8220;<I>FATCA</I>&#8221; and &#8220;<I>Backup Withholding, Information Reporting and Other Reporting Requirements</I>.&#8221;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject to the discussion in the next two paragraphs, dividends paid to a non-U.S. holder generally will be subject to withholding of U.S. federal income tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty between the United States and such holder&#8217;s country of residence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends we pay to a non-U.S. holder that are effectively connected with such non-U.S. holder&#8217;s conduct of a trade or business within the United States (and, if required by an applicable tax treaty, are attributable to a U.S. permanent establishment or a fixed base maintained by such non-U.S. holder) will generally be exempt from the U.S. federal withholding tax described above, if the non-U.S. holder complies with applicable certification and disclosure requirements (generally including provision of a valid IRS Form W-8ECI (or applicable successor form) certifying that the dividends are effectively connected with the non-U.S. holder&#8217;s conduct of a trade or business within the United States). Instead, such dividends generally will be subject to U.S. federal income tax on a net income basis, at regular U.S. federal income tax rates as would apply if such holder were a U.S. person (as defined in the Code). Any U.S. effectively connected income received by a non-U.S. holder that is classified as a corporation for U.S. federal income tax purposes may also be subject to an additional &#8220;branch profits tax&#8221; at a rate of 30% (or such lower rate as may be specified by an applicable income tax treaty).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A non-U.S. holder of our common stock who claims the benefit of an applicable income tax treaty between the United States and such holder&#8217;s country of residence generally will be required to provide a properly executed IRS Form W-8BEN or W-8BEN-E (or successor form) and satisfy applicable certification and other requirements. Non-U.S. holders are urged to consult their tax advisors regarding their entitlement to benefits under a relevant income tax treaty and the specific methods available to them to satisfy these requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gain on Sale or Other Disposition of Common Stock</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject to the discussion below under the headings &#8220;<I>FATCA</I>&#8221; and &#8220;<I>Backup Withholding, Information Reporting and Other Reporting Requirements,</I>&#8221; a non-U.S. holder generally will not be subject to U.S. federal income tax on any gain realized upon the sale or other disposition of the non-U.S. holder&#8217;s shares of our common stock unless:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the gain is effectively connected with a trade or business carried on by the non-U.S. holder within the United States (and, if required by an applicable income tax treaty, is attributable to a U.S. permanent establishment or fixed base maintained by such non-U.S. holder);</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 109; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the non-U.S. holder is an individual and is present in the United States for 183 days or more in the taxable year of disposition and certain other conditions are met; or</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we are or have been a &#8220;U.S. real property holding corporation&#8221; for U.S. federal income tax purposes at any time within the shorter of the five-year period preceding such disposition or such non-U.S. holder&#8217;s holding period of our common stock, and, provided that our common stock is regularly traded in an established securities market within the meaning of applicable Treasury Regulations, the non-U.S. holder has held, directly, indirectly, or constructively, at any time during said period, more than 5% of our common stock.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gain that is effectively connected with the conduct of a trade or business in the United States generally will be subject to U.S. federal income tax on a net income tax basis, at regular U.S. federal income tax rates that apply to U.S. persons. If the non-U.S. holder is a non-U.S. corporation, the branch profits tax described above also may apply to such effectively connected gain. An individual non-U.S. holder who is subject to U.S. federal income tax because the non-U.S. holder was present in the United States for 183 days or more during the year of sale or other disposition of our common stock will be subject to a flat 30% tax (or such lower rate as may be specified by an applicable income tax treaty) on the gain derived from such sale or other disposition, which may be offset by certain U.S. source capital losses, if any. We believe that we are not and we do not anticipate becoming a U.S. real property holding corporation for U.S. federal income tax purposes. Non-U.S. holders should consult their tax advisors regarding potentially applicable income tax treaties that may provide for different rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FATCA</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Withholding taxes may be imposed under the Foreign Account Tax Compliance Act, or FATCA, on certain types of payments made to non-U.S. financial institutions and certain other non-U.S. entities. Specifically, a 30% withholding tax may be imposed on dividends (including deemed dividends) paid on our common stock, to a &#8220;foreign financial institution&#8221; or a &#8220;non-financial foreign entity&#8221; (each as defined in the Code), unless (i) the foreign financial institution undertakes certain diligence and reporting obligations, (ii) the non-financial foreign entity either certifies it does not have any &#8220;substantial United States owners&#8221; (as defined in the Code) or furnishes identifying information regarding each substantial U.S. owner, or (iii) the foreign financial institution or non-financial foreign entity otherwise qualifies for an exemption from these rules. Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the U.S. governing FATCA may be subject to the reporting rules of that intergovernmental agreement. Because we may not know the extent to which a distribution is a dividend for U.S. federal income tax purposes at the time it is made, for purposes of these withholding rules we or the applicable withholding agent may treat the entire distribution as a dividend. Although withholding under FATCA would have applied also to payments of gross proceeds from the sale or other disposition of stock on or after January&#160;1, 2019, proposed Treasury Regulations would eliminate FATCA withholding on payments of gross proceeds entirely. Taxpayers generally may rely on these proposed Treasury Regulations until final Treasury Regulations are issued. Under certain circumstances, a non-U.S. holder will be eligible for refunds or credits of withholding taxes imposed under FATCA by timely filing a U.S. federal income tax return. Prospective investors should consult their tax advisors regarding the potential application of these withholding provisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Backup Withholding, Information Reporting and Other Reporting Requirements</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We must report annually to the IRS and to each non-U.S. holder the amount of any distributions paid to, and the tax withheld with respect to, each non-U.S. holder. These reporting requirements apply regardless of whether withholding was reduced or eliminated by an applicable income tax treaty. Copies of this information reporting may also be made available under the provisions of a specific income tax treaty or agreement with the tax authorities in the country in which the non-U.S. holder resides or is established.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A non-U.S. holder will generally be subject to backup withholding for dividends on our common stock paid to such holder unless such holder certifies under penalties of perjury that, among other things, it is a non-U.S. holder (provided that the payor does not have actual knowledge or reason to know that such holder is a U.S. person) or otherwise establishes an exemption.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 110; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information reporting and backup withholding generally will apply to the proceeds of a disposition of our common stock by a non-U.S. holder effected by or through the U.S. office of any broker, U.S. or non-U.S., unless the holder certifies its status as a non-U.S. holder and satisfies certain other requirements, or otherwise establishes an exemption. Generally, information reporting and backup withholding will not apply to a payment of disposition proceeds to a non-U.S. holder where the transaction is effected outside the United States through a non-U.S. office of a broker. However, for information reporting purposes, dispositions effected through a non-U.S. office of a broker with substantial U.S. ownership or operations generally will be treated in a manner similar to dispositions effected through a U.S. office of a broker. Non-U.S. holders should consult their tax advisors regarding the application of the information reporting and backup withholding rules to them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Backup withholding is not an additional income tax. Any amounts withheld under the backup withholding rules from a payment to a non-U.S. holder generally can be credited against the non-U.S. holder&#8217;s U.S. federal income tax liability, if any, or refunded, provided that the required information is furnished to the IRS in a timely manner. Non-U.S. holders should consult their tax advisors regarding the application of the information reporting and backup withholding rules to them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. Federal Estate Tax</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares of our common stock that are owned or treated as owned by an individual who is not a citizen or resident of the United States (as specially defined for U.S. federal estate tax purposes) at the time of death are considered U.S. situs assets and will be included in the individual&#8217;s gross estate for U.S. federal estate tax purposes. Such shares, therefore, may be subject to U.S. federal estate tax, unless an applicable estate tax or other treaty provides otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The preceding discussion of material U.S. federal income tax considerations and certain U.S. federal estate tax considerations is for information only. It is not legal or tax advice. Prospective investors should consult their tax advisors regarding the particular U.S. federal, state, local and non-U.S. tax consequences of acquiring, owning and disposing of our common stock, including the consequences of any proposed changes in applicable laws.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 111; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><FONT ID="a_020"></FONT>DESCRIPTION OF PRIVATE PLACEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 1, 2025, the Company entered into a Securities Purchase Agreement (the &#8220;Agreement&#8221;) with Saad Naja (the &#8220;Investor&#8221;) to issue and sell 111,732 shares (the &#8220;Shares&#8221;) of Common Stock. The per share purchase price of the Shares is $8.95, which represents the closing price of the Common Stock as reported on the Nasdaq Capital Market on November 28, 2025. The Shares were sold for approximately $1 million. The Agreement contains customary representations, warranties and agreements of the Company, customary conditions to closing and obligations of the parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company intends to use the net proceeds from the offering for working capital. The Shares were issued pursuant to an exemption from the registration requirements of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) provided in Section 4(a)(2) of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing descriptions of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, filed as Exhibit 10.68 hereto and incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">&#160;</P>

<!-- Field: Page; Sequence: 112; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><FONT ID="a_021"></FONT>SELLING STOCKHOLDER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The shares of common stock being offered by Selling Stockholder are the Shares. For additional information regarding the transactions in which the shares of common stock were issued, refer the section entitled &#8220;<I>Description of Private Placement&#8221;</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are registering the shares of common stock in order to permit the Selling Stockholder to offer their shares of common stock for resale from time to time. Except for the ownership of the securities issued in the Private Placement, the Selling Stockholder has not had any material relationship with us within the past three years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The table below lists the Selling Stockholder and other information regarding the beneficial ownership (as determined under Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder) of the shares of common stock held by the Selling Stockholder. The second column lists the number of shares of common stock beneficially owned by the Selling Stockholder, based on the Selling Stockholder&#8217;s ownership of securities issued in the Private Placement held by such Selling Stockholders on that date but taking account of any limitations on conversion and exercise set forth therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The third column lists the shares of common stock being offered by this prospectus by the Selling Stockholder. In accordance with the terms of the Securities Purchase Agreement with Selling Stockholder, this prospectus covers the resale of Shares. The fourth column assumes the sale of all of the shares offered by the Selling Stockholder pursuant to this prospectus. The Selling Stockholder may sell all, some or none of its shares in this offering. See &#8220;<I>Plan of Distribution</I>.&#8221;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number of Common <BR> Shares Owned Prior to <BR> Offering<SUP>(1)</SUP></B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Maximum Number&#160;of<BR> Class A<BR> Common Stock <BR> to be Sold<BR> Pursuant to this</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number of <BR> Common <BR> Shares of Owned <BR> After Offering<SUP>(3)</SUP></B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top; font-weight: bold; text-align: left">Name of Selling Stockholder</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Percent</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>Prospectus<SUP>(2)</SUP>&#160;</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Percent</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; width: 40%; text-align: left"><FONT STYLE="font-size: 10pt">Saad Naja<SUP>(4)</SUP>&#160;</FONT></TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 9%; text-align: right">111,732</TD>
    <TD STYLE="width: 1%; text-align: left"><SUP>(5)</SUP>&#160;</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD>
    <TD STYLE="width: 1%; text-align: left">%</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 9%; text-align: right">111,732</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 9%; text-align: right">0</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 9%; text-align: right">0</TD>
    <TD STYLE="width: 1%; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&#160;</DIV></DIV><!-- Field: /Rule-Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; text-align: left">*</TD>
    <TD STYLE="text-align: justify">Less than 1%</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Applicable percentage ownership is based on 23,970,791 shares of our common stock outstanding as of December 10, 2025.</FONT></TD> </TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">This column lists the number of shares of our common shares beneficially owned by this selling stockholders as of December 10, 2025.</FONT></TD> </TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Represents the amount of shares that will be held by the selling stockholder after completion of this offering based on the assumptions that Securities registered for sale by the registration statement of which this prospectus is part of will be sold, and no other shares of common stock are acquired or sold by the selling stockholder prior to completion of this offering. However, the selling stockholder is not obligated to sell all or any portion of the shares of our common stock registered pursuant to this prospectus. Applicable percentage ownership is based on 23,970,791 shares of our common stock outstanding after this offering.</FONT></TD> </TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">4)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The business address of Saad Naja is Villa Q62, Sustainable City Sharjah, United Arab Emirates.</FONT></TD> </TR>
  </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0in"></TD>
    <TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">5)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">This column lists the number of common stock beneficially owned by this selling stockholder as of December 10, 2025.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<!-- Field: Page; Sequence: 113; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="text-decoration: underline"><FONT ID="a_022"></FONT>PLAN OF DISTRIBUTION</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Selling Stockholder of the securities and any of their pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their securities covered hereby on the Nasdaq Global Market or any other stock exchange, market or trading facility on which the securities are traded or in private transactions. These sales may be at fixed or negotiated prices. The Selling Stockholder may use any one or more of the following methods when selling securities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">block trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction;</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">purchases by a broker-dealer as principal and resale by the broker-dealer for its account;</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">an exchange distribution in accordance with the rules of the applicable exchange;</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">privately negotiated transactions;</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">settlement of short sales;</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">in transactions through broker-dealers that agree with the Selling Stockholder to sell a specified number of such securities at a stipulated price per security;</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">a combination of any such methods of sale; or</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="text-align: justify; width: 0.5in"></TD>
    <TD STYLE="width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="text-align: justify">any other method permitted pursuant to applicable law.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Selling Stockholder may also sell securities under Rule 144 or any other exemption from registration under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), if available, rather than under this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Broker-dealers engaged by the Selling Stockholder may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the Selling Stockholder (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or markdown in compliance with FINRA Rule 2121.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the sale of the securities or interests therein, the Selling Stockholder may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume. The Selling Stockholder may also sell securities short and deliver these securities to close out their short positions, or loan or pledge the securities to broker-dealers that in turn may sell these securities. The Selling Stockholder may also enter into option or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<!-- Field: Page; Sequence: 114; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Selling Stockholder and any broker-dealers or agents that are involved in selling the securities may be deemed to be &#8220;underwriters&#8221; within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. The Selling Stockholder has informed the Company that it does not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">The Company is required to pay certain fees and expenses incurred by the Company incident to the registration of the securities. The Company has agreed to indemnify the Selling Stockholder against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">We agreed to keep this prospectus effective until the earlier of (i) the date on which the securities may be resold by the Selling Stockholder without registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144, without the requirement for the Company to be in compliance with the current public information under Rule 144 under the Securities Act or any other rule of similar effect or (ii) all of the securities have been sold pursuant to this prospectus or Rule 144 under the Securities Act or any other rule of similar effect. The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; text-align: justify">Under applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously engage in market making activities with respect to the shares of Common Stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution. In addition, the Selling Stockholder will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the shares of Common Stock by the Selling Stockholder or any other person. We will make copies of this prospectus available to the Selling Stockholder and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities Act).</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 115; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="text-decoration: underline"><FONT ID="a_023"></FONT>LEGAL MATTERS</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The validity of the shares of common stock offered hereby will be passed upon for us by Manatt, Phelps &amp; Phillips LLP, Costa Mesa, California.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="text-decoration: underline"><FONT ID="a_024"></FONT>EXPERTS</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> The consolidated financial statements of NeOnc Technologies Holdings, Inc as of December&#160;31, 2024 and 2023 and for the years then ended, appearing in this prospectus have been audited by Marcum LLP, independent registered public accounting firm, as set forth in their report thereon, which includes an explanatory paragraph as to the Company&#8217;s ability to continue as a going concern, appearing elsewhere in this prospectus, and are included in reliance on the report of such firm given upon their authority as experts in auditing and accounting. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="text-decoration: underline"><FONT ID="a_025"></FONT>WHERE YOU CAN FIND ADDITIONAL INFORMATION</FONT></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the shares of common stock offered by this prospectus. This prospectus, which constitutes a part of the registration statement, does not contain all the information set forth in the registration statement, some of which is contained in exhibits to the registration statement as permitted by the rules and regulations of the SEC. For further information with respect to us and our common stock, we refer you to the registration statement, including the exhibits filed as a part of the registration statement. Statements contained in this prospectus concerning the contents of any contract or any other document are not necessarily complete. If a contract or document has been filed as an exhibit to the registration statement, please see the copy of the contract or document that has been filed. Each statement in this prospectus relating to a contract or document filed as an exhibit is qualified in all respects by the filed exhibit. The SEC maintains an internet website that contains reports and other information about issuers, like us, that file electronically with the SEC. The address of that website is http://www.sec.gov.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the information reporting requirements of the Exchange Act, and we will file reports, proxy statements and other information with the SEC. These reports, proxy statements and other information will be available at http://www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We also maintain a website at www.neonc.com. Information contained in, or accessible through, our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is only as an inactive textual reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 116; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page --> <!-- Field: Split-Segment -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT ID="a_026"></FONT>&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NEONC TECHNOLOGIES HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024 (UNAUDITED)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<!-- Field: Page; Sequence: 117; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><B>Table of Contents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; background-color: #FFFFFF; text-align: left; vertical-align: top">&#160;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; background-color: #FFFFFF; text-align: left; vertical-align: top; width: 1%">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; background-color: #FFFFFF; text-align: center; vertical-align: bottom; width: 9%"><B>Page</B></TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><A HREF="#fin1_003">Condensed Consolidated Balance Sheet (Unaudited)</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&#160;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">F-3</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><A HREF="#fin1_004">Condensed Consolidated Statement of Operations (Unaudited)</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&#160;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">F-4</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><A HREF="#fin1_005">Condensed Consolidated Statement of Stockholders&#8217; Deficit (Unaudited)</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&#160;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">F-5</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><A HREF="#fin1_006">Condensed Consolidated Statement of Cash Flows (Unaudited)</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&#160;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">F-7</TD> </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left; vertical-align: top"><A HREF="#fin1_007">Notes to Condensed Consolidated Financial Statements (Unaudited)</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">&#160;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">F-8</TD> </TR>
  </TABLE>

<P STYLE="margin: 0">&#160;</P>

<!-- Field: Page; Sequence: 118; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&#160;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><FONT ID="fin1_003"></FONT>NEONC TECHNOLOGIES HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Condensed Consolidated Balance Sheets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: bottom; text-align: left">&#160;</TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">September&#160;30,<BR>2025</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">December&#160;31,<BR>2024</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: bottom; text-align: left">&#160;</TD>
    <TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center">(Unaudited)</TD>
    <TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</TD>
    <TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center">&#160;</TD>
    <TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; font-weight: bold; text-align: left">Assets</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Current Assets</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; width: 76%; text-align: left">Cash and cash equivalents</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">1,513,224</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">64,893</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Deferred offering costs &#150; current</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">99,302</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,071,947</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Debt issuance costs &#150; current</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">671,804</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">671,804</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 1pt">Prepaid expenses and other</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">677,246</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">410,085</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; text-align: left">Total Current Assets</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">2,961,576</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">2,218,729</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Non-Current Assets</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Debt issuance costs &#150; net of current portion</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">694,654</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,198,512</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; font-weight: bold; text-align: left"><FONT STYLE="font-style: normal; font-weight: normal">Right of use asset &#150; operating lease</FONT></TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-style: normal; font-weight: normal">379,509</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; text-align: right">-</TD>
    <TD STYLE="font-weight: bold; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; font-weight: bold; text-align: left"><FONT STYLE="font-style: normal; font-weight: normal">Other assets</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-style: normal; font-weight: normal">47,177</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Assets</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">4,082,916</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">3,417,241</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; font-weight: bold; text-align: left">Liabilities and Shareholders&#8217; Deficit</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Current Liabilities</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Accounts payable and accrued expenses</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">1,640,833</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">2,917,801</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Accounts payable &#8211; related parties</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">499,900</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">628,277</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Accrued advisory fee &#150; related party</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">3,675,569</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Litigation settlement payable</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">4,746,250</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">4,641,250</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Convertible promissory notes, net of discount</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">4,700,794</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Accrued compensation</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">255,099</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">734,874</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Lease liability, current</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">69,877</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; text-align: left">Total Current Liabilities</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">15,588,322</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">8,922,202</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Long Term Liabilities</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Lease liability, net of current portion</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">308,864</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Total Liabilities</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">15,897,186</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">8,922,202</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Commitments and contingencies</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Shareholders&#8217; Deficit:</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares were issued and outstanding as of September&#160;30, 2025 and December&#160;31, 2024</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Common stock, $0.0001 par value, 100,000,000 shares authorized; 19,474,303 and 18,090,526 shares issued and outstanding as of September&#160;30, 2025 and December&#160;31, 2024, respectively</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,948</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,809</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Additional paid in capital</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">85,414,333</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">45,101,675</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 1pt">Accumulated deficit</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(97,230,551</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(50,608,445</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; text-align: left; padding-bottom: 1pt">Total Shareholders&#8217; Deficit</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(11,814,270</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,504,961</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Liabilities and Shareholders&#8217; Deficit</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">4,082,916</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">3,417,241</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">See accompanying notes to the condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<!-- Field: Page; Sequence: 119; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><FONT ID="fin1_004"></FONT>NEONC TECHNOLOGIES HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Condensed Consolidated Statements of Operations (Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; vertical-align: bottom; text-align: center"><B>&#160;</B></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center"><B>&#160;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; text-align: center"><B>For the<BR> Three Months Ended<BR> September&#160;30,</B></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center"><B>&#160;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"><B>&#160;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><B>For the<BR> Nine Months Ended<BR> September&#160;30,</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"><B>&#160;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; padding-left: 0.125in; vertical-align: top; text-align: center"><B>&#160;</B></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center"><B>&#160;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><B>2025</B></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center"><B>&#160;</B></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center"><B>&#160;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center"><B>2024</B></TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center"><B>&#160;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"><B>&#160;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><B>2025</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"><B>&#160;</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"><B>&#160;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><B>2024</B></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"><B>&#160;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; font-weight: bold; text-align: left">Revenues:</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; width: 52%; text-align: left">Revenue</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%">$</TD>
    <TD STYLE="text-align: right; width: 9%">-</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%">$</TD>
    <TD STYLE="text-align: right; width: 9%">-</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">39,990</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">63,000</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; font-weight: bold; text-align: left">Operating Expenses:</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Research and development</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: right">715,038</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: right">956,725</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">2,390,592</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,965,726</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Legal and professional</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: right">276,378</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: right">496,803</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,754,287</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,652,141</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">General and administrative</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: right">902,985</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: right">243,659</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">2,736,732</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">973,923</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Share based compensation</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: right">5,040,246</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">25,964,096</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 1pt">Advisory fees</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">500,000</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">11,737,806</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">500,000</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; text-align: left; padding-bottom: 1pt">Total Operating Expenses</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">6,934,647</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,197,187</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">44,583,513</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,091,790</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; text-align: left">Loss From Operations</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: right">(6,934,647</TD>
    <TD>)</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: right">(2,197,187</TD>
    <TD>)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(44,543,523</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(5,028,790</TD>
    <TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; font-weight: bold; text-align: left">Other Income (Expense):</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Interest and other income</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: right">6,815</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: right">12,687</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">327,377</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">12,687</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Amortization of debt issuance, and deferred offering costs</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: right">(438,111</TD>
    <TD>)</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(798,311</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Interest expense - related parties</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: right">(869,815</TD>
    <TD>)</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD></TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(1,227,487</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(2,559,456</TD>
    <TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Loss on extinguishment of Bridge loan - related party</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD></TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(2,069,923</TD>
    <TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Loss on change in fair value of derivative liability related to sales of common stock through equity line of credit</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(380,162</TD>
    <TD STYLE="padding-bottom: 1pt">)</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(380,162</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net Loss</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(8,615,920</TD>
    <TD STYLE="padding-bottom: 2.5pt">)</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2,184,500</TD>
    <TD STYLE="padding-bottom: 2.5pt">)</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(46,622,106</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(9,645,482</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; font-weight: bold; text-align: left">Loss per share:</TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD></TD>
    <TD>&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD></TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Net loss per share - basic and diluted</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.45</TD>
    <TD STYLE="padding-bottom: 1.5pt">)</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.12</TD>
    <TD STYLE="padding-bottom: 1.5pt">)</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2.48</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.56</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 2.5pt">Weighted average number of common stock outstanding during the period - basic and diluted</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">19,211,745</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">17,918,330</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">18,787,603</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">17,353,327</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying notes to the condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<!-- Field: Page; Sequence: 120; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><FONT ID="fin1_005"></FONT>NEONC TECHNOLOGIES HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Condensed Consolidated Statements of Changes in Shareholders&#8217; Deficit (Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt"><B>Three and Nine Months Ended September 30, 2024</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: left"><B>&#160;</B></TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><B>&#160;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><B>Common Stock</B></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><B>&#160;</B></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: bottom"><B>&#160;</B></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; text-align: center"><B>Additional<BR> Paid In</B></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: bottom"><B>&#160;</B></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: bottom"><B>&#160;</B></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; text-align: center"><B>Accumulated</B></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: bottom"><B>&#160;</B></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: bottom"><B>&#160;</B></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; text-align: center"><B>Total<BR> Shareholders&#8217;</B></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: bottom"><B>&#160;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><B>&#160;</B></TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><B>&#160;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><B>Shares</B></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><B>&#160;</B></TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><B>&#160;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><B>Amount</B></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><B>&#160;</B></TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><B>&#160;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><B>Capital</B></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><B>&#160;</B></TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><B>&#160;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><B>Deficit</B></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><B>&#160;</B></TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><B>&#160;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><B>Deficit</B></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><B>&#160;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 40%; font-weight: bold; text-align: left">Balance - January&#160;1, 2024</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 9%; text-align: right">16,560,000</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">1,656</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">24,720,072</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">(38,709,981</TD>
    <TD STYLE="width: 1%; text-align: left">)</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">(13,988,253</TD>
    <TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Net loss</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,938,976</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,938,976</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Balance - March&#160;31, 2024</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">16,560,000</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,656</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">24,720,072</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(41,648,957</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(16,927,229</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Sale of common stock, net of offering costs</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">141,889</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">14</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,702,654</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,702,668</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Common stock issued for bridge loan conversion</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">979,039</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">98</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">11,748,366</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">11,748,464</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Common stock issued for settlement of vendor payable</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">114,758</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">12</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,377,078</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,377,090</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Common stock issued for settlement of accrued compensation</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">34,375</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">3</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">412,497</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">412,500</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Net loss</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,522,006</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(4,522,006</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 2.5pt">Balance - June&#160;30, 2024</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">17,830,061</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,783</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">39,960,667</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(46,170,963</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(6,208,513</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font-style: normal; vertical-align: bottom; background-color: White; font-weight: normal">
    <TD STYLE="font-style: normal; text-indent: -0.125in; padding-left: 0.125in; font-weight: normal">Sale of common stock, net of offering costs</TD>
    <TD STYLE="font-style: normal; font-weight: normal">&#160;</TD>
    <TD STYLE="font-style: normal; text-align: left; font-weight: normal">&#160;</TD>
    <TD STYLE="font-style: normal; text-align: right; font-weight: normal">242,757</TD>
    <TD STYLE="font-style: normal; text-align: left; font-weight: normal">&#160;</TD>
    <TD STYLE="font-style: normal; font-weight: normal">&#160;</TD>
    <TD STYLE="font-style: normal; text-align: left; font-weight: normal">&#160;</TD>
    <TD STYLE="font-style: normal; text-align: right; font-weight: normal">25</TD>
    <TD STYLE="font-style: normal; text-align: left; font-weight: normal">&#160;</TD>
    <TD STYLE="font-style: normal; font-weight: normal">&#160;</TD>
    <TD STYLE="font-style: normal; text-align: left; font-weight: normal">&#160;</TD>
    <TD STYLE="font-style: normal; text-align: right; font-weight: normal">2,913,098</TD>
    <TD STYLE="font-style: normal; text-align: left; font-weight: normal">&#160;</TD>
    <TD STYLE="font-style: normal; font-weight: normal">&#160;</TD>
    <TD STYLE="font-style: normal; text-align: left; font-weight: normal">&#160;</TD>
    <TD STYLE="font-style: normal; text-align: right; font-weight: normal">-</TD>
    <TD STYLE="font-style: normal; text-align: left; font-weight: normal">&#160;</TD>
    <TD STYLE="font-style: normal; font-weight: normal">&#160;</TD>
    <TD STYLE="font-style: normal; text-align: left; font-weight: normal">&#160;</TD>
    <TD STYLE="font-style: normal; text-align: right; font-weight: normal">2,913,123</TD>
    <TD STYLE="font-style: normal; text-align: left; font-weight: normal">&#160;</TD></TR>
  <TR STYLE="font-style: normal; vertical-align: bottom; background-color: rgb(204,238,255); font-weight: normal">
    <TD STYLE="font-style: normal; text-indent: -0.125in; padding-left: 0.125in; font-weight: normal">Common stock issued for settlement of vendor payable</TD>
    <TD STYLE="font-style: normal; font-weight: normal">&#160;</TD>
    <TD STYLE="font-style: normal; text-align: left; font-weight: normal">&#160;</TD>
    <TD STYLE="font-style: normal; text-align: right; font-weight: normal">12,500</TD>
    <TD STYLE="font-style: normal; text-align: left; font-weight: normal">&#160;</TD>
    <TD STYLE="font-style: normal; font-weight: normal">&#160;</TD>
    <TD STYLE="font-style: normal; text-align: left; font-weight: normal">&#160;</TD>
    <TD STYLE="font-style: normal; text-align: right; font-weight: normal">1</TD>
    <TD STYLE="font-style: normal; text-align: left; font-weight: normal">&#160;</TD>
    <TD STYLE="font-style: normal; font-weight: normal">&#160;</TD>
    <TD STYLE="font-style: normal; text-align: left; font-weight: normal">&#160;</TD>
    <TD STYLE="font-style: normal; text-align: right; font-weight: normal">149,999</TD>
    <TD STYLE="font-style: normal; text-align: left; font-weight: normal">&#160;</TD>
    <TD STYLE="font-style: normal; font-weight: normal">&#160;</TD>
    <TD STYLE="font-style: normal; text-align: left; font-weight: normal">&#160;</TD>
    <TD STYLE="font-style: normal; text-align: right; font-weight: normal">-</TD>
    <TD STYLE="font-style: normal; text-align: left; font-weight: normal">&#160;</TD>
    <TD STYLE="font-style: normal; font-weight: normal">&#160;</TD>
    <TD STYLE="font-style: normal; text-align: left; font-weight: normal">&#160;</TD>
    <TD STYLE="font-style: normal; text-align: right; font-weight: normal">150,000</TD>
    <TD STYLE="font-style: normal; text-align: left; font-weight: normal">&#160;</TD></TR>
  <TR STYLE="font-style: normal; vertical-align: bottom; background-color: White; font-weight: normal">
    <TD STYLE="font-style: normal; text-indent: -0.125in; padding-left: 0.125in; font-weight: normal">Common stock issued for note payable conversion</TD>
    <TD STYLE="font-style: normal; font-weight: normal">&#160;</TD>
    <TD STYLE="font-style: normal; text-align: left; font-weight: normal">&#160;</TD>
    <TD STYLE="font-style: normal; text-align: right; font-weight: normal">5,208</TD>
    <TD STYLE="font-style: normal; text-align: left; font-weight: normal">&#160;</TD>
    <TD STYLE="font-style: normal; font-weight: normal">&#160;</TD>
    <TD STYLE="font-style: normal; text-align: left; font-weight: normal">&#160;</TD>
    <TD STYLE="font-style: normal; text-align: right; font-weight: normal">-</TD>
    <TD STYLE="font-style: normal; text-align: left; font-weight: normal">&#160;</TD>
    <TD STYLE="font-style: normal; font-weight: normal">&#160;</TD>
    <TD STYLE="font-style: normal; text-align: left; font-weight: normal">&#160;</TD>
    <TD STYLE="font-style: normal; text-align: right; font-weight: normal">62,498</TD>
    <TD STYLE="font-style: normal; text-align: left; font-weight: normal">&#160;</TD>
    <TD STYLE="font-style: normal; font-weight: normal">&#160;</TD>
    <TD STYLE="font-style: normal; text-align: left; font-weight: normal">&#160;</TD>
    <TD STYLE="font-style: normal; text-align: right; font-weight: normal">-</TD>
    <TD STYLE="font-style: normal; text-align: left; font-weight: normal">&#160;</TD>
    <TD STYLE="font-style: normal; font-weight: normal">&#160;</TD>
    <TD STYLE="font-style: normal; text-align: left; font-weight: normal">&#160;</TD>
    <TD STYLE="font-style: normal; text-align: right; font-weight: normal">62,498</TD>
    <TD STYLE="font-style: normal; text-align: left; font-weight: normal">&#160;</TD></TR>
  <TR STYLE="font-style: normal; vertical-align: bottom; background-color: rgb(204,238,255); font-weight: normal">
    <TD STYLE="padding-bottom: 1pt; font-style: normal; text-indent: -0.125in; padding-left: 0.125in; font-weight: normal">Net loss</TD>
    <TD STYLE="padding-bottom: 1pt; font-style: normal; font-weight: normal">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-style: normal; text-align: left; font-weight: normal">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-style: normal; text-align: right; font-weight: normal">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt; font-style: normal; text-align: left; font-weight: normal">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt; font-style: normal; font-weight: normal">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-style: normal; text-align: left; font-weight: normal">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-style: normal; text-align: right; font-weight: normal">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt; font-style: normal; text-align: left; font-weight: normal">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt; font-style: normal; font-weight: normal">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-style: normal; text-align: left; font-weight: normal">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-style: normal; text-align: right; font-weight: normal">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt; font-style: normal; text-align: left; font-weight: normal">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt; font-style: normal; font-weight: normal">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-style: normal; text-align: left; font-weight: normal">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-style: normal; text-align: right; font-weight: normal">(2,184,500</TD>
    <TD STYLE="padding-bottom: 1pt; font-style: normal; text-align: left; font-weight: normal">)</TD>
    <TD STYLE="padding-bottom: 1pt; font-style: normal; font-weight: normal">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-style: normal; text-align: left; font-weight: normal">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-style: normal; text-align: right; font-weight: normal">(2,184,500</TD>
    <TD STYLE="padding-bottom: 1pt; font-style: normal; text-align: left; font-weight: normal">)</TD></TR>
  <TR STYLE="font-style: normal; vertical-align: bottom; background-color: White; font-weight: normal">
    <TD STYLE="padding-bottom: 2.5pt; font-style: normal; text-indent: -0.125in; padding-left: 0.125in; font-weight: normal"><B>Balance - September 30, 2024</B></TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: normal; font-weight: normal">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-style: normal; text-align: left; font-weight: normal">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-style: normal; text-align: right; font-weight: normal">18,090,526</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: normal; text-align: left; font-weight: normal">&#160;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: normal; font-weight: normal">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-style: normal; text-align: left; font-weight: normal">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-style: normal; text-align: right; font-weight: normal">1,809</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: normal; text-align: left; font-weight: normal">&#160;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: normal; font-weight: normal">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-style: normal; text-align: left; font-weight: normal">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-style: normal; text-align: right; font-weight: normal">43,086,262</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: normal; text-align: left; font-weight: normal">&#160;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: normal; font-weight: normal">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-style: normal; text-align: left; font-weight: normal">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-style: normal; text-align: right; font-weight: normal">(48,355,463</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: normal; text-align: left; font-weight: normal">)</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: normal; font-weight: normal">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-style: normal; text-align: left; font-weight: normal">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-style: normal; text-align: right; font-weight: normal">(5,267,392</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-style: normal; text-align: left; font-weight: normal">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">See accompanying notes to the condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<!-- Field: Page; Sequence: 121; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NEONC TECHNOLOGIES HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Condensed Consolidated Statements of Changes in Shareholders&#8217; Deficit (Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Three and Nine Months Ended September 30, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><B>&#160;</B></TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><B>&#160;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><B>Common Stock</B></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><B>&#160;</B></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: bottom"><B>&#160;</B></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; text-align: center"><B>Additional<BR> Paid In</B></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: bottom"><B>&#160;</B></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: bottom"><B>&#160;</B></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; text-align: center"><B>Accumulated</B></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: bottom"><B>&#160;</B></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: bottom"><B>&#160;</B></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; text-align: center"><B>Total<BR> Shareholders&#8217;</B></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; vertical-align: bottom"><B>&#160;</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><B>&#160;</B></TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><B>&#160;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><B>Shares</B></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><B>&#160;</B></TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><B>&#160;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><B>Amount</B></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><B>&#160;</B></TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><B>&#160;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><B>Capital</B></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><B>&#160;</B></TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><B>&#160;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><B>Deficit</B></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><B>&#160;</B></TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><B>&#160;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><B>Deficit</B></TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><B>&#160;</B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; font-weight: bold; text-align: left; width: 40%">Balance - January&#160;1, 2025</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="text-align: left; width: 1%">&#160;</TD>
    <TD STYLE="text-align: right; width: 9%">18,090,526</TD>
    <TD STYLE="text-align: left; width: 1%">&#160;</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="text-align: left; width: 1%">$</TD>
    <TD STYLE="text-align: right; width: 9%">1,809</TD>
    <TD STYLE="text-align: left; width: 1%">&#160;</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="text-align: left; width: 1%">$</TD>
    <TD STYLE="text-align: right; width: 9%">45,101,675</TD>
    <TD STYLE="text-align: left; width: 1%">&#160;</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="text-align: left; width: 1%">$</TD>
    <TD STYLE="text-align: right; width: 9%">(50,608,445</TD>
    <TD STYLE="text-align: left; width: 1%">)</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="text-align: left; width: 1%">$</TD>
    <TD STYLE="text-align: right; width: 9%">(5,504,961</TD>
    <TD STYLE="text-align: left; width: 1%">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Sale of common stock, net of offering costs</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">727,750</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">73</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">10,252,425</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">10,252,498</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Common stock issued for advisory services</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">46,000</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">5</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">557,055</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">557,060</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Cashless exercise of warrants</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">162,500</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">16</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(16</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Share based compensation, as restated</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">17,397,774</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">17,397,774</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Net loss</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(32,326,016</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(32,326,016</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Balance - March&#160;31, 2025</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">19,026,776</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,903</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">73,308,913</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(82,934,461</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(9,623,645</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">Share based compensation</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">3,526,076</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">3,526,076</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top">Other</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(37,755</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(37,755</TD>
    <TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Net loss</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,680,170</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,680,170</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 2.5pt; vertical-align: top">Balance - June&#160;30, 2025</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">19,026,776</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,903</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">76,797,234</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(88,614,631</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(11,815,494</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; width: 40%; vertical-align: top">Share based compensation</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 9%; text-align: right">-</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 9%; text-align: right">-</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 9%; text-align: right">5,040,246</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 9%; text-align: right">-</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 9%; text-align: right">5,040,246</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Proceeds from sale of common stock pursuant to equity line of credit</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">447,527</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">45</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">3,576,853</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">3,576,898</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Net loss</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(8,615,920</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(8,615,920</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 2.5pt; vertical-align: top">Balance - September&#160;30, 2025</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">19,474,303</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,948</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">85,414,333</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(97,230,551</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(11,814,270</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying notes to the condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<!-- Field: Page; Sequence: 122; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><FONT ID="fin1_006"></FONT>NEONC TECHNOLOGIES HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Condensed Consolidated Statements of Cash Flows (Unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: bottom; text-align: left">&#160;</TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">For the<BR> Nine Months Ended<BR>September&#160;30,</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2025</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</TD>
    <TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2024</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; font-weight: bold; text-align: left">Cash flows from operating activities:</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; width: 76%; text-align: left">Net loss</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">(46,622,106</TD>
    <TD STYLE="width: 1%; text-align: left">)</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">(9,645,482</TD>
    <TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; text-align: left">Increase in bridge loan - expenses paid by bridge loan provider on behalf of the Company</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">476,393</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; text-align: left">Accretion of original issue discount on bridge loans - related party</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">300,000</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">2,558,241</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; text-align: left">Accretion of original issue discount on convertible promissory note</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">820,794</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; text-align: left">Write off deferred issuance costs</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">703,796</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; text-align: left">Share based compensation - restricted stock</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">25,964,096</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; text-align: left">Loss on extinguishment of bridge loan</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">2,069,923</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; text-align: left">Loss on change in fair value of derivative liability</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">380,162</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; text-align: left">Amortization of debt issuance costs and deferred offering costs</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,161,311</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; text-align: left">Amortization of right of use asset</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">36,461</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">178,869</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; text-align: left">Changes in operating assets and liabilities:</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.5in; vertical-align: top; text-align: left">Prepaid expenses</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(267,160</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(335,916</TD>
    <TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.5in; vertical-align: top; text-align: left">Other assets</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(47,177</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.5in; vertical-align: top; text-align: left">Accrued compensation</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(479,775</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(58,127</TD>
    <TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.5in; vertical-align: top; text-align: left">Lease liability</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(37,229</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(164,371</TD>
    <TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.5in; vertical-align: top; text-align: left">Accrued advisory fee</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">3,675,569</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.5in; vertical-align: top; text-align: left; padding-bottom: 1pt">Accounts payable and accounts payable - related parties and accrued expenses</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,657,722</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">957,162</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; font-weight: bold; text-align: left; padding-bottom: 1pt">Net cash used in operating activities</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(16,772,777</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,259,512</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.625in; vertical-align: top; font-weight: bold; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; font-weight: bold; text-align: left">Cash flows from financing activities:</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Proceeds from the sale of common stock</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">11,324,372</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">4,615,789</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Proceeds from related party loan</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">300,000</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">892,028</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Repayment of related party loan</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(600,000</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(791,077</TD>
    <TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Deferred offering costs</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(154,463</TD>
    <TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Proceeds from sale of common stock pursuant to equity purchase agreement</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">3,196,736</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Proceeds from convertible notes payable</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,000,000</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; font-weight: bold; text-align: left">Net cash provided by financing activities</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">18,221,108</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,562,277</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; font-weight: bold; text-align: left">Net increase in cash and cash equivalents</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,448,331</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,302,765</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; font-weight: bold; text-align: left; padding-bottom: 1pt">Cash and cash equivalents - beginning of period</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">64,893</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">31,862</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents - end of period</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,513,224</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,334,627</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; font-weight: bold; text-align: left">Supplemental disclosure of non-cash financing activities:</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Original issue discount on bridge loan - related party</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">300,000</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">1,368,421</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Right of use asset, at lease commencement</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">536,605</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Share issued in connection with advisory services</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">557,192</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Reclassified of deferred offering costs to APIC at the completion of the offering</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">1,391,580</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Increase in bridge loan payable - prepaid and deferred offering costs paid directly by bridge loan provider on behalf of the Company</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">31,346</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Conversion of bridge loan to common stock</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">11,748,464</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Conversion of accrued compensation</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">412,500</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Conversion of account payable to common stock</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">1,527,090</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying notes to the condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<!-- Field: Page; Sequence: 123; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B><FONT ID="fin1_007"></FONT>Note 1 &#8211; Description of Business and Liquidity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeOnc Technologies, Inc. (&#8220;NTI&#8221;) was incorporated on April&#160;13, 2005, as a California corporation. On April&#160;7, 2023, NTI merged into NeOnc Technologies Holdings, Inc. (&#8220;NTHI&#8221; and the combined entities &#8220;NeOnc&#8221; or the &#8220;Company&#8221;). NTHI was incorporated January&#160;5, 2023, as a Delaware Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeOnc is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The Company&#8217;s lead product, NEO100 is in clinical trials treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (&#8220;FDA&#8221;). The Company licensed the underlying technology from the University of Southern California. (&#8220;USC&#8221;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October&#160;11, 2024, the Company entered into an agreement with a broker dealer to serve as placement agent and provide broker services in connection with the proposed sale of common stock up to $10,000,000. Under this agreement, through December&#160;31, 2024, the Company closed on commitments from investors to purchase 625,000 shares of common stock of the Company at $16.00 per share for total commitments of $10,000,000, which were to be held in escrow until the Company&#8217;s registration statement was declared effective. During the three months ended March&#160;31, 2025, prior to the Company having an effective registration statement, the Company closed on an additional commitment to purchase 102,750 shares of common stock of the Company at $16.00 per share, for total commitments of $1,644,000. On March&#160;10, 2025, the Company&#8217;s registration statement was declared effective at which time the $11,644,000 in escrow was released to the Company. On March&#160;26, the Company was listed (&#8220;Listing&#8221;) on the NASDAQ global markets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying financial statements have been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. At September&#160;30, 2025, the Company had cash totaling $1,513,224. For the three and nine months ended September&#160;30, 2025, the Company incurred a net loss of $8,615,920 and $46,622,106, respectively, and has an accumulated deficit of $97,230,551 at September&#160;30, 2025. The Company has financed its working capital requirements to date primarily through the sale of common stock, shareholder loans and related party bridge loans.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company does not have sufficient available capital to fund operations for a period of twelve months from the issuance date of these financial statements. Although the Company has established agreements with several funding potential sources (see Notes&#160;6, 7 and 10), the Company does not know whether additional financing will be available when needed, whether it will be available on favorable terms, or if it will be available at all. These factors raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other risks and uncertainties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to risks common to biopharmaceutical companies, including, but not limited to, new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, product liability, and the uncertainty of market acceptance of products and the potential need to obtain additional financing. The Company is dependent on third-party suppliers and, in some cases, single-source suppliers. The Company&#8217;s products require approval or clearance from the FDA prior to commencing commercial sales in the United States. Approvals or clearances are also required in foreign jurisdictions where the Company may license or sell its products. There can be no assurance that the Company&#8217;s products will receive all required approvals or clearances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There can be no assurance that the Company&#8217;s products, if approved, will be accepted in the marketplace, nor can there be any assurance that any future products can be developed or manufactured at an acceptable cost with appropriate performance characteristics or that such products will be successfully marketed, if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 124; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>Note 2 &#8211; Basis of Presentation and Summary of Significant Accounting Policies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basis of presentation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The unaudited condensed consolidated financial statements contained herein have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;). Certain information and note disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to SEC rules and regulations, although the Company believes that the disclosures made are adequate to make the information not misleading. Accordingly, the condensed consolidated financial statements reflect all normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the results of interim periods and may not include all disclosures required by accounting principles generally accepted in the United States (&#8220;GAAP&#8221;). The information as of September&#160;30, 2025, and for the three and nine months ended September&#160;30, 2025, is unaudited, whereas the consolidated balance sheet as of December&#160;31, 2024, is derived from the Company&#8217;s audited condensed consolidated financial statements as of that date. These condensed consolidated financial statements and notes hereto should be read in conjunction with the consolidated financial statements and notes thereto included in the audited financial statements for the year ended December&#160;31, 2024, included on Form S-1, filed with the SEC on February&#160;26, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The results of operations for the interim periods presented are not necessarily indicative of results to be expected for any other interim period or for the year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Principles of consolidation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying condensed consolidated financial statements and related notes to the condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use of estimates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In preparing the Company&#8217;s financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cash and cash equivalents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company, from time to time during the period covered by these financial statements, may have had bank account balances in excess of federally insured limits. The Company has not experienced losses in such accounts. For the statements of cash flows, the Company considers all short-term investments purchased with a maturity of three months or less to be cash equivalents. At September&#160;30, 2025 and December&#160;31, 2024, the Company has money market funds in the amount of approximately $12,000 and $25,000, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Deferred offering costs</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company complies with the requirements of the ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (&#8220;SAB&#8221;) Topic 5A &#8220;<I>Expenses of Offering</I>&#8221;. Offering costs consist principally of professional and registration fees incurred through the condensed consolidated balance sheet dated December&#160;31, 2024 that are related to the planned public offering of its securities (See Note 3). These costs have been capitalized and were recognized in equity upon the completion of the securities offering. At September&#160;30, 2025, deferred offering costs consist of the fair value of shares issued in conjunction with the issuance of an equity purchase agreement. These costs have been capitalized and are being amortized over the term of the availability of the equity purchase agreement (Note 6). If planned offerings are terminated, the related capitalized deferred offering costs are written off.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 125; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Debt issuance costs</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Debt issuance costs represent costs directly attributable to warrants issued for a line of credit commitment. Such costs represent the fair value of warrants issued to the debt facility provider and are amortized to the statement of operations on a straight-line basis which approximates the effective interest rate method, over the term of the debt instrument. The debt issuance costs, net of accumulated amortization, are classified as a long-term asset until the Company begins to draw funds from the debt facility, in accordance with ASC 815: &#8220;<I>Derivatives and Hedging</I>&#8221;. At such time, the pro-rata portion of amounts borrowed as compared to the total debt facility will be reclassified as a contra-debt account.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluates the terms of warrants issued and determines if the instrument requires liability or equity accounting classification under ASC 815: Derivatives and Hedging and ASC 480: &#8220;<I>Distinguishing Liabilities from Equity</I>&#8221;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Leases</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company classifies its leases either as operating or financing lease at inception. The company has an operating lease. This lease is recorded as an operating lease, right of use (ROU) assets and operating lease liabilities on the accompanying consolidated balance sheets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease ROU assets and the related lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. The operating lease ROU assets also include lease incentives and initial direct costs incurred. For operating leases, interest on the lease liability and the amortization of ROU asset result in straight-line rent expense over the lease term. Leases may include options to extend or terminate the lease which are included in the ROU operating lease assets and operating lease liability when they are reasonably certain of exercise. Certain leases include lease and non-leased components, which are accounted for as one single lease component. Operating lease expense associated with minimum lease payments is recognized on a straight-line basis over the lease term.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fair value measurements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FASB ASC Topic 820, &#8220;<I>Fair Value Measurements and Disclosures</I>&#8221; (&#8220;ASC 820&#8221;), defines fair value, the methods used to measure fair value and the expanded disclosures about fair value measurements. Fair value is the price received to sell an asset or paid to transfer a liability in an orderly transaction between the buyer and the seller at the measurement date. In determining fair value, the valuation techniques consistent with the market approach, income approach and cost approach shall be used to measure fair value. ASC 820 establishes a fair value hierarchy for inputs, representing the assumptions the buyer and seller use in pricing the asset or liability. These inputs are further defined as observable and unobservable inputs. Observable inputs are those that the buyer and seller would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs reflect the Company&#8217;s assumptions about the inputs the buyer and seller would use to price the asset or liability developed based on the best information available in the circumstances.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&#8217;s money market funds are valued at quoted prices in active markets and are classified as Level 1 within the fair value hierarchy. The carrying value of the Company&#8217;s accounts payable approximates its fair value because of the short-term nature of these financial instruments. The note payable - related party is reported at fair value as the Company elected the fair value option for such a note (see Note 4).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value hierarchy is categorized into three levels based on the inputs as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 &#8212; Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Valuation adjustments and block discounts are not being applied. Since valuations are based on quoted prices that are readily and regularly available in an active market, the valuation of these securities does not entail a significant degree of judgment.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 126; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 &#8212; Valuations based on (i) quoted prices in active markets for similar assets and liabilities, (ii) quoted prices in markets that are not active for identical or similar assets, (iii) inputs other than quoted prices for the assets or liabilities, or (iv) inputs that are derived principally from or corroborated by the market through correlation or other means.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 &#8212; Valuations based on unobservable inputs and significant to the overall fair value measurement.</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Revenue</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized point-in-time revenue of $0 and $39,990 for the three and nine months ended September&#160;30, 2025, and $0 and $63,000 for the three and nine months ended September&#160;30, 2024, respectively, for the right to try its technology in compassion use cases where the Company has no further performance obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research and development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and development activities, including third-party contractors performing research, conducting clinical trials, and manufacturing drug supplies and materials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patent costs</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All patent-related costs incurred in filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as legal and professional expenses in the accompanying consolidated statements of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Share-based compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has granted stock options and common stock to employees, non-employee consultants and non-employee members of our Board of Directors. The Company measures the compensation cost associated with all share-based payments based on the grant date fair values. Compensation costs associated with grants of common stock are measured at fair value at the date of grant, which has historically been the most recent price paid by investors to purchase shares of the Company&#8217;s common stock prior to such grant. The Company recognizes share-based compensation expense over the requisite service period of each award, which generally equals the vesting period, using the straight-line method for awards that contain only service conditions. If the stock grant is contingent upon events that have not yet happened, then the grant is not considered issued. If an award holder leaves the company prior to vesting, and adjustment of the compensation expense will be made to reflect only those awards that vested.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes the stock-based compensation expense for the restricted stock units (&#8220;RSU&#8221;) based upon the fair value of the common stock at the date of the grant. The expense is recognized over the service period provided in the RSU awards, however expense will not be recognized until the listing date (&#8220;Listing Date&#8221;), as prior to such date it was not probable that condition to commence vesting would be met.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When the vesting contingency is met, the Company will commence to recognize expense related to the RSU&#8217;s. For time based vested RSU&#8217;s, the expense will be recognized on a straight-line basis from the grant date to the last vesting date. The expense recognized will include the expense from the date of the grant over the total vesting period and reflect the portion attributable to the service provided prior to the listing. For performance based RSU&#8217;s, the Company will determine the probability of the contingency being met each quarter end based upon an assessment of progress made under such performance criteria.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 127; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Net loss per share</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic net loss per share is computed by dividing net loss available to common stockholders by the weighted average number of common stock outstanding during the period. Diluted net loss per share is computed by dividing net loss by the sum of the weighted average number of common stock outstanding during the period. For periods in which the Company reports a net loss, the diluted net loss per share is the same as basic net loss per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the nine months ended September&#160;30, 2025 there are potentially dilutive securities outstanding of 3,010,000</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potentially dilutive restricted stock units which are not included in the diluted net loss per share calculation since their effect is anti-dilutive. For the nine months ended September&#160;30, 2024, respectively, there were <FONT>no</FONT></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potentially dilutive warrants outstanding and <FONT><FONT>no</FONT></FONT></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">potentially dilutive restricted stock units.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Income taxes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes federal, state, and foreign current tax liabilities or assets based on its estimate of taxes payable to or refundable by tax authorities in the current fiscal year. For the periods ended September&#160;30, 2025 and 2024, there is no current tax provision due to losses generated. The Company also recognizes federal and state deferred tax liabilities or assets based on the Company&#8217;s estimate of future tax effects attributable to temporary differences and carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years those temporary differences are expected to be recovered or settled.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Deferred tax assets are reduced by valuation allowances if, based on the consideration of all available evidence, it is more likely than not that some portion of the deferred tax asset will not be realized. The Company evaluates deferred income taxes quarterly to determine if valuation allowances are required by considering available evidence. If the Company is unable to generate sufficient future taxable income in certain tax jurisdictions, or if there is a material change in the actual effective tax rates or time period within which the underlying temporary differences become taxable or deductible, the Company could be required to increase its valuation allowance against its deferred tax assets which could result in an increase in the Company&#8217;s effective tax rate and an adverse impact on operating results. The Company will continue to evaluate the necessity of the valuation allowance based on the remaining deferred tax assets. The difference between the statutory and effective rates for the three and nine months ended September&#160;30, 2025 and 2024 is a result of the Company applying a full valuation allowance against any deferred tax assets as a result of net operating losses due to uncertainties surrounding the usability of such net operating losses. The ability to utilize such net operating loss carry forwards may be limited due to possible changes in ownership as defined under Internal Revenue Code section&#160;382.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows the accounting guidance related to financial statement recognition, measurement and disclosure of uncertain tax positions. The Company recognizes the impact of an uncertain income tax position on an income tax return at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it is less than 50% likely to be sustained. Uncertain tax positions are recognized in the first subsequent financial reporting period in which that threshold is met or from changes in circumstances such as the expiration of applicable statutes of limitations. The Company will recognize interest and penalties related to tax positions in income tax expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Segment Reporting</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November&#160;2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, &#8220;<I>Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</I>.&#8221; The standard expands reportable segment disclosure requirements for public business entities primarily through enhanced disclosures about significant segment expenses that are regularly provided to the chief operating decision maker (&#8220;CODM&#8221;) and included within each reported measure of segment profit (referred to as the &#8220;significant expense principle&#8221;). The standard has been adopted for our fiscal year 2024 annual financial statements and interim financial statements thereafter and have applied this standard retrospectively for all prior periods presented in the financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Reclassifications</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain reclassifications of previously reported amounts have been made to conform to the current year presentation. Such&#160;reclassifications did not impact&#160;net income as previously reported.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 128; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>Note 3 &#8211; Related <FONT STYLE="text-transform: uppercase">p</FONT>arty <FONT STYLE="text-transform: uppercase">t</FONT>ransactions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AFH Holdings and Advisory, LLC advisory agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December&#160;19, 2022, the Company entered into an advisory agreement with AFH Holdings and Advisory, LLC, an affiliate to assist the Company in connection with its intent to affect a public listing. AFH was retained to assist the Company with investor presentations and decks, coordinate the retention of an investment banker for an initial public offering, identify legal and accounting professionals to assist in connection with such public offering, identify investor relations/public relations firms, advise on private capital markets activities prior to the initial public offering and coordinate the closing process for the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July&#160;12, 2024, the Company amended the AFH advisory agreement section to allow for an upfront payment on the Listing Date of $2,500,000 and the remaining amount of the fee to be paid in equal monthly instalments for one year. AFH was paid a fee of $500,000 for the amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March&#160;26, 2025, and as a result of the listing of the Company on Nasdaq, the Company incurred $11,328,565 for the fee earned in accordance with the AFH advisory agreement which was recorded as advisory fee expense in the condensed consolidated statement of operations. In accordance with the amendment, the Company paid $2,500,000 of such fee on March&#160;26, 2025. The remaining balance of $8,828,565 is payable in 12 equal monthly installments commencing in April 2025. As of September&#160;30, 2025, the remaining outstanding accrued advisory fee totaled $3,675,569 recorded on the condensed consolidated balance within accrued advisory fee &#8211; related party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, the Company agreed to retain AFH as an exclusive advisor to the Company on all financing and mergers and acquisitions for a period of two (2) years from the closing of the private securities offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transactions with USC</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company maintains a license agreement with USC, under which the Company will pay USC an annual patent maintenance fee of $20,000 and nonrefundable earned royalties of 4% on Net Sales (as defined in the Amended Agreement) of Licensed Products covered by the licensed patents in all countries in which the manufacture, use, sale, offer for sale, or import of such Licensed Products, as such capitalized terms are defined in the Amended Agreement. To date, no sales have been made using Licensed Products, and no royalties are due to USC. In addition, the Company will assume responsibility for patent-related costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company also utilizes laboratory and patent maintenance services from USC. The Company incurred $382 and $184,449 and $98,543 and $382,858 related to such services for the three and nine months ended September&#160;30, 2025 and 2024, respectively, of which $382, $164,449 and $98,543 and $362,858 are recorded within research and development expenses and $0, $20,000 and $0 and $20,000 are recorded within general administrative expenses on the condensed consolidated statements of operations. At September&#160;30, 2025 and December 31, 2024, the Company has outstanding payables to USC for such services of $499,607 and $272,328 respectively, which is included in accounts payable - related parties in the accompanying consolidated balance sheets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accrued compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amount accrued for the management team, including related payroll taxes, was $255,099 and $734,874 as September&#160;30, 2025 and December&#160;31, 2024, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>Note 4 &#8211; Related Party Loans Payable</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Bridge Loan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In April&#160;2023, the Company entered into a non-interest bearing, non-convertible promissory note with HCWG LLC (the &#8220;Bridge Loan&#8221;). Borrowings under the Bridge Loan carry a 50% (or 1 times cash amounts borrowed) original issue discount (&#8220;OID&#8221;) on principal and through subsequent amendments the maximum cash borrowing was increased to $10,000,000. The outstanding amounts under this Bridge Loan were payable at the earlier of the date the Company completes an IPO or December&#160;4, 2024 (the &#8220;Maturity Date&#8221;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 129; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June&#160;14, 2024, the Company reached an agreement with HCWG LLC to convert the outstanding principal and interest on the Bridge Loan into 979,039 shares of common stock. As a result of this conversion, the Bridge Loan was terminated and is no longer available to the Company for borrowing. The Company has a receivable due from HCWG LLC totaling $138,247 which is recorded within prepaid expenses and other on the condensed consolidated balance sheet at September&#160;30, 2025 and December&#160;31, 2024, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through June&#160;30, 2024, the Company had received under the Bridge Loan an aggregate of $7,116,335</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The OID was recognized ratably over the term of each draw-down under the Bridge Loan through the Maturity Date unless settled earlier, at which point the accretion is accelerated. Accretion of the OID for nine months ended September&#160;30, 2024, amounted to $1,387,493</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, which is included in interest expense in the accompanying condensed consolidated statement of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 0.5pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 0.5pt solid; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For the</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Year Ended</B><BR><B>December&#160;31,<BR> 2024</B></FONT></P></TD>
    <TD STYLE="padding-bottom: 0.5pt">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Bridge loan &#8211; carrying value</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">Balance &#8211; January&#160;1, 2024</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">9,802,697</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Borrowings</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,368,422</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">OID</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,368,422</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 0.5pt">Repayments</TD>
    <TD STYLE="padding-bottom: 0.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 0.5pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 0.5pt solid; text-align: right">(791,077</TD>
    <TD STYLE="padding-bottom: 0.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 0.5pt">Total principal outstanding before conversion</TD>
    <TD STYLE="padding-bottom: 0.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 0.5pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 0.5pt solid; text-align: right">11,748,464</TD>
    <TD STYLE="padding-bottom: 0.5pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 0.5pt">Conversion to common stock (June, 14, 2024)</TD>
    <TD STYLE="padding-bottom: 0.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 0.5pt solid; text-align: left">&#160;</TD>
    <TD TITLE="Balance at end" STYLE="border-bottom: Black 0.5pt solid; text-align: right">(11,748,464</TD>
    <TD STYLE="padding-bottom: 0.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Principal outstanding &#150; December 31, 2024</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD TITLE="Balance at end" STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Advances from Executive Chairman</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February&#160;2025, our Executive Chairman advanced the Company approximately $300,000. The advances carry a 50% (or 1 times amounts borrowed) original issue discount (&#8220;OID&#8221;) on the principal. On March&#160;10, 2025, the advance and 1x interest was repaid. Interest expense in the amount of $300,000 is included in the condensed consolidated statement of operations as interest expense &#8211; related parties for the nine months ended September&#160;30, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOTE 5 &#150; <FONT STYLE="font-variant: small-caps">Convertible Debt</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 16 and July 18, 2025, the Company entered into a series of convertible promissory notes with a group of investors for the aggregate purchase price of $4,000,000 (the &#8220;Notes&#8221;). The Notes are payable three months after origination for a total amount of $5 million (20% OID). The Company may extend the payment date for up to three additional one-month periods with the OID on the Notes increasing to 25%, 30% and 35% with respect to any such monthly extensions. Further, upon the occurrence of an Event of Default, as that term is defined in the Notes, the Notes shall be convertible at the option of the holders into shares of the Common stock of the Company at a price equal to 80% of the lowest closing sale price of the Company&#8217;s common stock as reported on the Nasdaq Global Market on any trading day during the five (5) trading days prior to the respective conversion date. The Company also recorded debt issuance cost&#160;of $320,000 to be amortized as interest expense over the term of the loan using the straight-line method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASU 2020-06, the Company accounts for the convertible notes as a single liability instrument. The notes are recorded at amortized cost, and interest expense is recognized using the effective interest method. The effective interest rate on the notes is approximately 7.72% per annum, which reflects the amortization of issuance costs and original issuance discount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Through September 30, 2025, interest expense of $1,020,794 was recognized from the accretion of OID and accretion of the debt issuance cost. Subsequent to September 30, 2025, the Company exercised the first of three available extensions on the convertible promissory notes. The notes are now set to mature on November 16, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<!-- Field: Page; Sequence: 130; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes the Company&#8217;s outstanding Notes as of September 30, 2025:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: bottom; text-align: left">&#160;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>For the</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Nine Months Ended<BR> September&#160;30,<BR> 2025</B></P></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; padding-bottom: 1pt">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 85%; text-align: left">Purchase price of convertible promissory notes</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 12%; text-align: right">5,000,000</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Less: unamortized original issuance discount</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(179,206</TD>
    <TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Less: unamortized debt issuance cost</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(120,000</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt">Net convertible promissory note</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">4,700,794</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>Note </B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6 &#8211; <FONT STYLE="font-variant: small-caps">Leases</FONT></FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February&#160;1, 2024, the Company entered a 24-month lease for office space, which calls for a monthly base rent of $25,000, increasing at 3% per annum. The Company has only one operating lease and has no financing leases. The Company&#8217;s lease does not contain options to renew or extend the lease term or options to terminate leases early, except for insolvency. On November&#160;27, 2024, the Company amended the lease expiration date from January&#160;31, 2026, to January&#160;31, 2025. As of December&#160;31, 2024, the consolidated balance sheet reflects a right-of-use asset of $23,526&#160;and a lease liability of $24,722. The lease liability was computed using an interest rate of&#160;13.49%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In April 2025, the Company entered into a 63 month lease for office space which calls for a monthly base rent of $6,778</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">, increasing at approximately 3% per annum. The lease liability was computed using an interest rate of 3.72% and as of September&#160;30, 2025 the lease has a remaining 58 months. In calculating the present value of future lease payments, the Company utilized its incremental borrowing rate based on the lease term. The Company&#8217;s net lease non-lease components (e.g., standard area maintenance, maintenance, consumables, etc.) are paid separately from rent based on actual costs incurred and, therefore, are not included in the right-of-use asset and lease liability and are reflected as an expense in the period incurred. At September&#160;30, 2025 the consolidated balance sheet reflects a right-of-use asset of $379,509</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and a lease liability of $378,741</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recorded lease expense of $21,781 and $102,704 during the three months ended September&#160;30, 2025 and 2024, respectively, and $43,743 and $214,497&#160;during the nine months ended September&#160;30, 2025, and 2024, respectively, within general and administrative expenses on the condensed consolidated statements of operations. Cash paid for amounts included in the measurement of lease liability was $20,335 and $125,000 and $40,670 and $200,000, respectively, during the three and nine months ended September&#160;30, 2025, and 2024, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following are the expected maturities of lease liabilities for operating leases as of September&#160;30, 2025:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-size: 10pt"><B>Twelve Months Ended December&#160;31,</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><B>&#160;</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><B>&#160;</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><B>&#160;</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><B>&#160;</B></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">2025 (three months)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&#160;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">20,335</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#160;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">2026</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#160;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">83,137</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">2027</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#160;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">85,663</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">2028</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#160;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">88,231</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left">2029</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#160;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">90,928</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">Thereafter</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">44,944</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">Total</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">413,238</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><FONT STYLE="font-size: 10pt">Less: interest</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#160;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(34,497</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 10pt">Present value of lease liability</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">378,741</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 10pt">Less: current portion</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(69,877</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-size: 10pt">Noncurrent portion</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">308,864</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">&#160;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 131; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>Note 7 &#8211; Common and Preferred Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> NTHI is authorized to issue 100,000,000 shares of common stock, par value $0.0001 per share and 10,000,000 shares of preferred stock, par value $0.0001 per share. As of September&#160;30, 2025, no preferred shares have been issued. The board of directors is authorized, subject to any limitations prescribed by law, to provide for the issuance of shares of Preferred Stock in one or more series, and by filing a certificate pursuant to the applicable law of the State of Delaware<I>, </I>to establish from time to time the number of shares to be included in each such series, and to fix the designation, powers, preferences, and rights of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereof. The number of authorized shares of Preferred Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the Common Stock, without a vote of the holders of the Preferred Stock, or any series thereof, unless a vote of any such holders is required pursuant to the terms of any Preferred Stock Designation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the nine months ended September&#160;30, 2025, the Company sold 727,750 shares of common stock at a price of $16.00 per share for gross proceeds of $11,644,005 pursuant to a private placement of its securities, issued 46,000 shares as part of advisory services related to the listing and as part of the private placement fee for our equity line of credit, 162,500 shares were issued for the cashless exercise of warrants, and issued 447,527 shares from the sale of shares under the equity line of credit, and the release of 3,310,000 shares for restricted stock units.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Private Placement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October&#160;11, 2024, the Company entered into an agreement with RBW Capital Partners LLC, a division of Dawson James Securities, Inc. (&#8220;Broker&#8221;) to serve as placement agent and provide broker services in connection with the possible sale of common stock up to $10 million. If a sale is made between the Company and any institutional or individual third-party funding source introduced by the placement agent, the Company will pay a placement fee of 8% of the gross proceeds. In addition, the company agrees to pay; (a) 1.0% of the gross proceeds for non-accountable expenses; and (b) out of pocket expenses plus the costs associated with the use of a third-party electronic road show service up to $10,000. The agreement expired on January&#160;11, 2025 and was amended and restated on January&#160;29, 2025 to extend the term for another six months through July&#160;29, 2025 and increased the placement fee to 12% from 8% of the gross proceeds, and eliminated the 1% non-accountable expense fee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under this agreement, through December&#160;31, 2024, the Company closed on commitments from investors to purchase 625,000 shares of common stock of the Company at $16 per share for total commitments of $10,000,000, which were to be held in escrow until the Company&#8217;s registration statement was declared effective. During the three months ended March&#160;31, 2025, prior to the Company having an effective registration statement, the Company closed on an additional commitment to purchase 102,750 shares of common stock of the Company at $16 per share, for total commitments of $1,644,005, also to be held in escrow until the Company&#8217;s registration statement was declared effective. On March&#160;25, 2025, the Company&#8217;s registration statement was declared effective at which time the $11,644,005 in escrow was released to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the agreement, the Company paid $300,000 in placement agent fees to Broker for securing $2,500,000 in commitments for the Private Placement. This fee was paid when the funds were released from escrow and recorded as a reduction to additional paid-in capital on the condensed consolidated statement of shareholders&#8217; deficit as of September&#160;30, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 132; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Advisory Services</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October&#160;3, 2024, as amended on January&#160;23, 2025, the Company entered into an agreement with Broker, for financial advisory and investment banking services in connection with a direct listing of the Company&#8217;s common stock on the Nasdaq Global Market or other major US market. The agreement provides for a one-time fee of $250,000 payable three days after the direct listing and the issuance of 30,000 shares of common stock (which are restricted until the shares are registered by filing a resale S-1 within 30 days after the effective date of the direct listing). In addition, the Company agreed to pay up to $100,000 for fees and expenses of legal counsel and other out-of-pocket expenses plus the costs associated with the use of a third-party electronic road show service. Such fees were included in accounts payable and deferred offering costs in the accompanying consolidated balance sheets as of December&#160;31, 2024. The fair value of the 30,000 shares issued in March&#160;2025, amounting to $363,300, was determined using the closing day price of $12.11. This amount was recorded as an advisory fee on the condensed consolidated statement of operations for the nine months ended September&#160;30, 2025. The agreement expired on January&#160;3, 2025 and was amended and restated on January&#160;23, 2025 to extend the term for another six months through July&#160;23, 2025. This agreement expired in July 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Deferred Offering Costs &#150; Direct Listing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred offering costs relating to the Private Placement and direct listing at December&#160;31, 2024 totaled $1,071,947. At September&#160;30, 2025, this amount plus $0 and $319,633 incurred in the three and nine months ended September&#160;30, 2025, respectively was reclassified against the common stock issued in the condensed consolidated statement of changes in shareholder&#8217;s deficit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Equity Purchase Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October&#160;22, 2024, the Company entered into an equity purchase agreement (the &#8220;Equity Purchase Agreement&#8221;) with Mast Hill Fund, LP (&#8220;Mast Hill&#8221;) pursuant to which the Company may sell and issue to Mast Hill, and the investor may purchase from the Company, up to $50,000,000 of Company&#8217;s common stock. Under the Equity Purchase Agreement, the Company has the right, but not the obligation, to direct Mast Hill, by its delivery to the Mast Hill of a Put Notice from time to time, to purchase Put Shares (i) in a minimum amount not less than $50,000 and (ii) in a maximum amount up to the lesser of (a) $750,000 or (b) 150% of the average trading volume of the Company&#8217;s common stock during the five trading days immediately preceding the Put Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The actual amount of proceeds the Company receives pursuant to each Put Notice (each, the &#8220;Put Amount&#8221;) is determined by multiplying the Put Amount requested by the applicable purchase price. The purchase price for each of the Put Shares equals 95% of the Market Price, (as defined below) less the Clearing Costs (as defined below). Market Price is the lowest volume weighted average prices of the Company&#8217;s common stock on its principal market on any trading day during the Valuation Period (as defined below). The Valuation Period is the five trading days immediately following the date on which Mast Hill receives the Put Shares in its brokerage account. Clearing Costs are all the fees incurred by Mast Hill with respect to its brokerage firm, clearing firm, Company transfer agent fees, and attorney fees, with respect to the Put Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The term of the Equity Purchase Agreement commenced on the effective date of the direct listing and will terminate on the earlier of (i) the date on which the Mast Hill shall have purchased Put Shares equal to the $50,000,000, (ii) twenty-four (24) months after the date of the Equity Purchase Agreement, (iii) written notice of termination by the Company to Mast Hill, (iv) this Registration Statement is no longer effective after the initial effective date of this Registration Statement, or (v) the date that, pursuant to or within the meaning of any Bankruptcy Law, the Company commences a voluntary case or any Person commences a proceeding against the Company, a receiver, trustee, assignee, liquidator or similar official is appointed for the Company or for all or substantially all of its property or the Company makes a general assignment for the benefit of its creditors. For the three and nine months ended September&#160;30, 2025, the Company sold 447,527 shares of common stock at $3.73 &#150; $9.53 per share under the Equity Purchase Agreement, resulting in net proceeds of $3,198,735. Since the shares were purchased at a discount as a result of the five-day settlement period, the settlement feature is considered a derivative liability. The fair value of the derivative approximates the loss on the settlement of such shares or $380,162 which was recognized in the condensed consolidated statement of operations for the three and nine months ended September 30, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<!-- Field: Page; Sequence: 133; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with this agreement, we issued 16,000 shares of common stock to Mast Hill. The fair value of the shares granted to Mast Hill upon issuance was determined by using the closing day price of $12.11. Such amount net of amortization was recorded as deferred offering cost on the condensed consolidated balance sheet as of March 31, 2025. For the three and nine months ended September&#160;30, 2025, the Company reported $24,220 and $94,458, respectively as amortization expense in the condensed consolidated statement of operations, and the remaining deferred offering costs of $99,302 at September&#160;30, 2025 are to be amortized over the remaining term of the Equity Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>Note 8 &#8211; Stock-Based Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April&#160;12, 2023, the Company adopted the 2023 Equity Incentive Plan (the &#8220;2023 Plan&#8221;), which allows the issuance of up to 3,440,000 shares of the Company&#8217;s authorized and unissued common stock in the form of incentive stock options, non-qualified stock options, restricted stock units, performance share units, or other forms of equity as may be added in the future to employees, directors and consultants of the Company and its affiliates. The allowable number of shares that can be issued under the 2023 Plan increased upon the completion of the listing to 4,764,507 which represents 20% of the fully diluted capitalization of the Company on the closing of Company&#8217;s initial public price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January and February&#160;2024, 2,460,000 and 200,000, respectively, restricted stock units (&#8220;RSUs&#8221;) were granted to the executive officers and members of the Board of Directors further to the 2023 Plan as described above. Of the total RSUs granted (tranche 1) 1,686,667 vest 100% seven months from the date that the Company lists on a national exchange, (tranche 2) 466,667 will vest in equal monthly instalments over a one (1) year period commencing on the eighth month from the effective date of the listing on a national exchange and (tranche 3) 486,666 are performance-based, the vesting of which will be predicated on certain financial and operational performance metrics being met after the effective date of the listing on a national exchange as set forth the grant agreements. Since tranche 3 is performance based, it is not yet probable that all of the performance vesting conditions will be met and as such no expense has been recognized for tranche 3 as of September&#160;30, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October&#160;23, 2024, 200,000 RSUs were granted to each of the CEO and the Executive Chairman, for a total of 400,000, and 100,000 granted to two members of the Board of Directors were canceled. These RSUs vest 100% seven months from the date the Company lists on a national exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March&#160;26, 2025, 150,000 RSUs were granted to the three board members, in the amount of 50,000 each. These RSUs vest 100% seven months from the date the Company lists on a national exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior to March&#160;26, 2025, the Company determined that no expense should be recognized for the RSUs since the contingency related to the commencement of vesting (i.e., the listing) of the RSUs had not been met. On March&#160;26, 2025, the listing occurred, satisfying the contingency required for vesting to begin and defining the service period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 1, 2025, 300,000 RSUs were forfeited resulting in a reversal of $1,329,062 of shared based compensation during the nine months ended September&#160;30, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 5, 2025, 200,000 RSUs were granted to the one board member. 66,667 RSUs vest 100% seven months from the date of issuance, 66,667 RSUs vest 100% thirty-six months from the date of issuance. The remaining 66,667 RUS&#8217;s vest thirty-six months from the date certain performance metrics are achieved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company determined the fair value of all the RSUs at their respective grant dates to be $32,495,174 based on the price of the most recent sale of common stock prior to each grant date for those RSU&#8217;s granted prior to the Listing Date or the quoted market value for the RSU&#8217;s granted after the Listing Date. For the nine months ended September&#160;30, 2025, the company recognized $25,964,096. As of September&#160;30, 2025, there was unamortized stock-based compensation of approximately $9,270,400 which the&#160;Company expects to recognize over approximately 6.75 years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 134; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The activity related to RSUs is summarized as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="4" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Restricted Stock Units</TD>
    <TD STYLE="padding-bottom: 0.5pt">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Activity</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">RSUs Granted</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: center; font-weight: bold">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center">2024</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January&#160;1, 2024</FONT></TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; width: 88%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 9%; text-align: right">3,060,000</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; padding-bottom: 0.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancelled</FONT></TD>
    <TD STYLE="padding-bottom: 0.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 0.5pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 0.5pt solid; text-align: right">(100,000</TD>
    <TD STYLE="padding-bottom: 0.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December&#160;31, 2024</FONT></TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">2,960,000</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center">2025</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted during nine months ended September&#160;30, 2025</FONT></TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">350,000</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"> Forfeited</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&#160;</TD>
    <TD TITLE="Restricted stock units, granted" STYLE="border-bottom: Black 2.5pt double; text-align: right">(300,000</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance at September&#160;30, 2025</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,010,000</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Released RSUs for nine months ended September&#160;30, 2025</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September&#160;30, 2025, 1,754,500 RSU&#8217;s remain unissued in the 2023 Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>Note 9 &#8211; Commitments and Contingencies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Line of Credit Commitment &#8211; Related Party</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October&#160;11, 2024, the Company entered into a Line of Credit Agreement (&#8220;the Agreement&#8221;) with HCWG for borrowings of up to $10.0 million. Borrowings under the Line of Credit Agreement bear interest at 10.0% per annum and increases to 14% if the Agreement is extended. Interest payments are due on the first business day of each calendar month and the unpaid principal is due on October&#160;12, 2027. No amounts have been borrowed under the facility through September&#160;30, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the agreement, the Company issued HCWG five-year warrants to purchase up to 312,500 shares of our common stock at an exercise price of $12.00 per share. These warrants expire on October 23, 2029. As of December&#160;31, 2024, there were 312,500 warrants issued, outstanding and fully vested. In March&#160;2025, 162,500 warrants were exercised in a cashless exercise, resulting in the issuance of 162,500 shares of common stock. At September&#160;30, 2025, there are 150,000 shares of common stock remaining available to be purchased under the warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the warrants on the grant date was determined using the Black-Scholes valuation model, with the following key assumptions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value of common stock: $12.00</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility: 86%</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate: 4.82%</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term: 2.5 years</FONT></TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of warrants at inception was $2,015,413, which was recorded as additional paid-in capital on the condensed consolidated statement of changes stockholders&#8217; deficit for the year ended December&#160;31, 2024, and as debt issuance costs on the balance sheet. The debt issuance costs are being amortized over the term of the line of credit and amounted to $167,951 and $503,853 for the three and nine months ended September&#160;30, 2025. At September&#160;30, 2025 and December&#160;31, 2024, unamortized debt issuance costs total $1,366,458 and $1,870,316, respectively, which will be amortized over the remaining 13 months of the facility.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<!-- Field: Page; Sequence: 135; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Litigation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, the Company is involved in various disputes, claims, liens and litigation matters arising out of the normal course of business which could result in a material adverse effect on the Company&#8217;s combined financial position, results of operations or cash flows. Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that liability has been incurred, and the amount of the assessment can be reasonably estimated. As of September&#160;30, 2025 and December&#160;31, 2024, the Company had no liabilities recorded for loss contingencies, except as below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>License Agreement - Orient EuroPharma Co., Ltd.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November&#160;8, 2013, the Company entered into a collaboration agreement (&#8220;Agreement&#8221;) with Orient EuroPharma Co., Ltd. (&#8220;OEP&#8221;), pursuant to which the parties will develop certain licensed products defined in the Agreement. NeOnc will license OEP the right to commercialize the Company&#8217;s drug NEO100, a highly purified form of <I>perillyl alcoho</I>l (&#8220;Licensed Product&#8221;), in the territories specified in the license agreement (&#8220;Territory&#8221;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2023, the Company sent notice to OEP indicating their intent to terminate the Agreement with OEP, after which OEP threatened litigation. On February&#160;15, 2024, OEP and the Company entered into a settlement agreement whereas the Company and OEP terminated the Agreement in exchange for a payment in the amount of $4,000,000 payable by the Company to OEP within ten days of the date the Company completes its initial public offering. The Company has a litigation settlement payable of $4,000,000 in the accompanying condensed consolidated balance sheets as of September&#160;30, 2025 and December&#160;31, 2024, respectively. As of the date of this filing, the Company has not paid the litigation settlement amount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June&#160;6, 2023, a vendor filed a complaint against the Company for breach of contract in the Central District of California. The vendor alleged that the Company improperly terminated an Intellectual Property License and Supply Agreement (&#8220;IPLSA&#8221;) and that the Company also defrauded the vendor in connection with IPLSA. This matter was settled on October&#160;16, 2023, and the Company agreed to pay the vendor $600,000 within 5 business days of the close of the date that the Company completes an IPO or March&#160;31, 2024, whichever occurs first. The Company has a litigation settlement payable in the accompanying condensed consolidated balance sheet at September&#160;30, 2025 and December&#160;31, 2024. As of the date of this filing, the Company has not paid the litigation settlement amount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March&#160;31, 2024, a vendor agreed to extend the payment until May&#160;15, 2024 for payment of an additional $25,000, payable on demand. On July&#160;25, 2024, the arbitrator granted the implementation of interest at the statutory rate on the unpaid balance commencing May&#160;15, 2024 until paid, therefore an additional $48,750 and $146,250 of interest expense is recognized in the accompanying condensed consolidated statement of operations during the three and nine months ended September&#160;30, 2025, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At September&#160;30, 2025 and December&#160;31, 2024, an aggregate of $146,250 and $41,250 of accrued interest is included in litigation settlement payable in the accompanying condensed consolidated balance sheet.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August&#160;2025, the Company was awarded a grant totaling $400,000 in gross proceeds from the National Institutes of Health (NIH). The Company&#8217;s portion of the total proceeds made available from the NIH Grant is approximately $160,000, net of subcontractor costs, as allowable expenses are incurred. For the three and nine months ended September&#160;30, 2025 no allowable expenses under the NIH grant were incurred by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In September&#160;2025, the Company was awarded a grant totaling approximately $1,007,000 in gross proceeds from the National Institutes of Health (NIH). The Company&#8217;s portion of the total proceeds made available from the NIH Grant is approximately $245,000, net of subcontractor costs, as allowable expenses are incurred. For the three and nine months ended September&#160;30, 2025 no allowable expenses under the NIH grant were incurred by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<!-- Field: Page; Sequence: 136; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><FONT STYLE="font-variant: small-caps">Note 1</FONT><FONT STYLE="font-variant: small-caps">0</FONT> &#8211; <FONT STYLE="font-variant: small-caps">Segment Reporting</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company manages its business activities on a consolidated basis and operates as a single operating segment: Biotechnology. The accounting policies of the Biotechnology segment are the same as those described in Note 1 &#8211; Summary of Significant Accounting Policies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Chief Operating Decision Maker (&#8220;CODM&#8221;) is our Chief Executive Officer, Amir Heshmatpour. The CODM uses net loss, as reported on our condensed consolidated statement of operations, in evaluating the performance of the biotechnology segment and determining how to allocate resources of the Company as a whole, including investing in our research and development programs and acquisition/licensing strategy. The CODM does not review assets in evaluating the results of the biotechnology segment, and therefore, such information is not presented. The following supplemental information breaks down the research and development costs for the three and nine months ended September&#160;30, 2025 and 2024, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<BR>Nine Months Ended<BR>September&#160;30,</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; padding-bottom: 1pt">Revenues</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 9%; text-align: right">39,990</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 9%; text-align: right">63,000</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Less: Significant and other segment expenses:</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">NEO100</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">851,664</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">693,328</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">NEO100-02</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">327,373</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">203,075</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">NEO212</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">798,997</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">549,249</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Pediatric</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">169,663</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">103,338</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Laboratory</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">192,377</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">362,858</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Other</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">50,518</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">53,878</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Total research and development expense</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">2,390,592</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,965,726</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Advisory fee</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">11,737,806</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">500,000</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Legal and accounting</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,754,287</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,374,869</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Employee compensation expenses</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">516,428</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">331,873</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Amortization expense</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">798,311</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">178,869</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Investor relations</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">959,431</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">18,623</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Share based compensation</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">25,964,096</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other general and administrative expense</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,260,873</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">721,831</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Interest expense - related parties&#8217; loans</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,227,487</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">2,559,456</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Loss on extinguishment of Bridge loan - related party</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">2,069,923</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Loss on settlement</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">380,162</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Interest and other income</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(327,377</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(12,687</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Net loss</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(46,622,106</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(9,645,482</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<!-- Field: Page; Sequence: 137; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<BR>Three Months Ended<BR>September&#160;30,</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Revenues</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Less: Significant and other segment expenses:</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">NEO100</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 9%; text-align: right">163,036</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 9%; text-align: right">236,607</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">NEO100-02</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">125,586</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">79,644</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">NEO212</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">343,368</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">189,553</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Pediatric</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">70,653</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">34,350</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Laboratory</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">362,858</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Other</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">12,395</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">53,713</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Total research and development expense</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">715,038</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">956,725</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Advisory fee</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">500,000</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Legal and accounting</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">276,378</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">219,531</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Employee Expenses</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">182,268</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">186,149</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Amortization expense</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">438,111</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">67,076</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Investor relations</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">188,358</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">11,960</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Share based compensation</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">5,040,246</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Other general and administrative expense</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">532,359</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">253,348</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Interest expense - related parties&#8217; loans</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">869,815</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">2,400</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Loss on extinguishment of bridge loan</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Loss on settlement</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">380,162</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Interest and other income</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(6,815</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(12,687</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Net loss</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(8,615,920</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2,184,500</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><FONT STYLE="font-variant: small-caps">Note </FONT>11 &#8211; <FONT STYLE="font-variant: small-caps">Subsequent Events</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July&#160;24, 2025, the Company entered into an agreement with Dr. Ishwar K. Puri and Beth R. Levinson for the acquisition of all equity interests in JandB Holdings LLC, a California limited liability company (&#8220;J&amp;B&#8221;). J&amp;B was newly formed and held a single patented asset. No other assets, liabilities, employees or facilities were acquired. The single asset passed the &#8220;screen test&#8221; to be considered an asset acquisition. Expenses of the transaction were not significant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the terms of the asset acquisition, the transaction consideration includes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">&#160;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">(i)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">a cash payment of $500,000 and</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">&#160;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.25in">(ii)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">shares of Company common stock equal to (a) 120,000 shares of Company common stock with an attributed value of $25 per share, <I>less</I> (b) an amount of shares equal to (x) the aggregate transaction fees incurred by the Company in connection with all of the transactions related to the Agreement divided by (y) $25.00, rounded up to the nearest whole share.</P> </TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company remitted the cash payment for the patent on October&#160;3, 2025 and received assignment of the patent effective October&#160;8, 2025. As of November&#160;13, 2025, the shares have yet to be issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<!-- Field: Page; Sequence: 138; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October&#160;4, 2025, the Company&#8217;s wholly owned subsidiary, NuroMENA, signed a Master Services Agreement (MSA) with Insights Research Organization &amp; Solutions (IROS), a UAE- based contract research organization (CRO) and part of the M42 group. The MSA has an initial term of three years from the first work order executed under the agreement. The first work order to be executed under the MSA covers a multi-site, randomized Phase 2b/3 study titled <I>A Multi-Site, Randomized, Phase 2b/3 Study Evaluating Overall Survival of Intranasal NEO100 in Patients with Progressive or Recurrent Grade III Astrocytomas and Glioblastoma Multiforme (GBM), Stratified by IDH1 Mutation Status, Compared to Best Standard of Care.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November&#160;4, 2025, the Company sold 76,665 shares of common stock at $9.78 per share for gross proceeds of approximately $750,000 pursuant to Equity Purchase Agreement with Mast Hill Fund, LP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November&#160;6, 2025, the Company granted 1,200,000 RSUs to Amir Heshmatpour and 70,000 RSUs to Grace Fisher.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</P>

<!-- Field: Page; Sequence: 139; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NEONC TECHNOLOGIES HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<!-- Field: Page; Sequence: 140; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NEONC TECHNOLOGIES HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Table of Contents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<TABLE BORDER="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 90%; text-align: left">&#160;</TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: justify">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; vertical-align: top; text-align: center; width: 9%"><B>Page</B></TD> </TR>
  <TR>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; background-color: #CCEEFF; text-align: left"><A HREF="#b_001"><B>Report of Independent Registered Public Accounting Firm (PCAOB ID#688)</B></A></TD>
    <TD STYLE="vertical-align: top; background-color: #CCEEFF; text-align: justify">&#160;</TD>
    <TD STYLE="vertical-align: top; background-color: #CCEEFF; text-align: center">F-26</TD> </TR>
  <TR>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; background-color: #FFFFFF; text-align: left">&#160;</TD>
    <TD STYLE="vertical-align: top; background-color: #FFFFFF; text-align: justify">&#160;</TD>
    <TD STYLE="vertical-align: top; background-color: #FFFFFF; text-align: center">&#160;</TD> </TR>
  <TR>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; background-color: #CCEEFF; text-align: left"><B>Consolidated Financial Statements</B></TD>
    <TD STYLE="vertical-align: top; background-color: #CCEEFF; text-align: justify">&#160;</TD>
    <TD STYLE="vertical-align: top; background-color: #CCEEFF; text-align: center">&#160;</TD> </TR>
  <TR>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; background-color: #FFFFFF; text-align: left">&#160;</TD>
    <TD STYLE="vertical-align: top; background-color: #FFFFFF; text-align: justify">&#160;</TD>
    <TD STYLE="vertical-align: top; background-color: #FFFFFF; text-align: center">&#160;</TD> </TR>
  <TR>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; background-color: #CCEEFF; text-align: left"><A HREF="#b_002">Consolidated Balance Sheets as of December&#160;31, 2024 and 2023</A></TD>
    <TD STYLE="vertical-align: top; background-color: #CCEEFF; text-align: justify">&#160;</TD>
    <TD STYLE="vertical-align: top; background-color: #CCEEFF; text-align: center">F-27</TD> </TR>
  <TR>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; background-color: #FFFFFF; text-align: left">&#160;</TD>
    <TD STYLE="vertical-align: top; background-color: #FFFFFF; text-align: justify">&#160;</TD>
    <TD STYLE="vertical-align: top; background-color: #FFFFFF; text-align: center">&#160;</TD> </TR>
  <TR>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; background-color: #CCEEFF; text-align: left"><A HREF="#b_003">Consolidated Statements of Operations for year ended December&#160;31, 2024 and 2023</A></TD>
    <TD STYLE="vertical-align: top; background-color: #CCEEFF; text-align: justify">&#160;</TD>
    <TD STYLE="vertical-align: top; background-color: #CCEEFF; text-align: center">F-28</TD> </TR>
  <TR>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; background-color: #FFFFFF; text-align: left">&#160;</TD>
    <TD STYLE="vertical-align: top; background-color: #FFFFFF; text-align: justify">&#160;</TD>
    <TD STYLE="vertical-align: top; background-color: #FFFFFF; text-align: center">&#160;</TD> </TR>
  <TR>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; background-color: #CCEEFF; text-align: left"><A HREF="#b_004">Consolidated Statements of Changes in Shareholders&#8217; Deficit for the year ended December 31, 2024 and 2023</A></TD>
    <TD STYLE="vertical-align: top; background-color: #CCEEFF; text-align: justify">&#160;</TD>
    <TD STYLE="vertical-align: top; background-color: #CCEEFF; text-align: center">F-29</TD> </TR>
  <TR>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; background-color: #FFFFFF; text-align: left">&#160;</TD>
    <TD STYLE="vertical-align: top; background-color: #FFFFFF; text-align: justify">&#160;</TD>
    <TD STYLE="vertical-align: top; background-color: #FFFFFF; text-align: center">&#160;</TD> </TR>
  <TR>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; background-color: #CCEEFF; text-align: left"><A HREF="#b_005">Consolidated Statements of Cash Flows for the year ended December&#160;31, 2024 and 2023</A></TD>
    <TD STYLE="vertical-align: top; background-color: #CCEEFF; text-align: justify">&#160;</TD>
    <TD STYLE="vertical-align: top; background-color: #CCEEFF; text-align: center">F-30</TD> </TR>
  <TR>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; background-color: #FFFFFF; text-align: left">&#160;</TD>
    <TD STYLE="vertical-align: top; background-color: #FFFFFF; text-align: justify">&#160;</TD>
    <TD STYLE="vertical-align: top; background-color: #FFFFFF; text-align: center">&#160;</TD> </TR>
  <TR>
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; background-color: #CCEEFF; text-align: left"><A HREF="#b_006">Notes to Consolidated Financial Statements</A></TD>
    <TD STYLE="vertical-align: top; background-color: #CCEEFF; text-align: justify">&#160;</TD>
    <TD STYLE="vertical-align: top; background-color: #CCEEFF; text-align: center">F-31</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<!-- Field: Page; Sequence: 141; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><FONT ID="b_001"></FONT>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To the Shareholders and Board of Directors of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NeOnc Technologies Holdings, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Opinion on the Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have audited the accompanying consolidated balance sheets of NeOnc Technologies Holdings, Inc. (the &#8220;Company&#8221;) as of December&#160;31, 2024 and 2023, the related consolidated statements of operations, changes in shareholders&#8217; deficit, and cash flows for each of the two years in the period ended December&#160;31 2024, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December&#160;31, 2024, in conformity with accounting principles generally accepted in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Going Concern</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 1, the Company has a significant working capital deficiency, has incurred significant losses and needs to raise additional funds to meet its obligations and sustain its operations. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Basis for Opinion</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We conducted our audits in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit<B>s</B> to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit<B>s</B> we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0; margin-bottom: 0">/s/ Marcum <FONT STYLE="font-variant: small-caps">llp</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0; margin-bottom: 0">Marcum <FONT STYLE="font-variant: small-caps">llp</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0; margin-bottom: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have served as the Company&#8217;s auditor since 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Philadelphia, PA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">February&#160;26, 2025 </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<!-- Field: Page; Sequence: 142; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><FONT ID="b_002"></FONT>NEONC TECHNOLOGIES HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Consolidated Balance Sheets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December&#160;31,<BR>2024</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December&#160;31,<BR>2023</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Assets</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Current Assets</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left">Cash</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">64,893</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">31,862</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Deferred offering costs</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,071,947</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">970,582</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Debt issuance costs - current</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">671,804</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Prepaid expenses and other</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">386,559</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">262,932</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left">Total Current Assets</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">2,195,203</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,265,376</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Non-Current Assets</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Debt issuance costs - net of current portion</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,198,512</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Right of use asset - operating lease</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">23,526</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Assets</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">3,417,241</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,265,376</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Liabilities and Shareholders&#8217; Deficit</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Current Liabilities</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Accounts payable</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">2,893,079</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">1,565,968</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Accounts payable - related parties</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">628,277</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,390,961</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Litigation settlement payable</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">4,641,250</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">4,600,000</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Accrued compensation</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">734,874</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,091,243</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Bridge loan - related party</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">6,555,457</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Lease liability, current</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">24,722</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Note payable - related party, at fair value</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">50,000</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left">Total Current Liabilities</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">8,927,202</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">15,253,629</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Commitments and contingencies</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Shareholders&#8217; Deficit:</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares were issued and outstanding as of December&#160;31, 2024 and 2023, respectively</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Common stock, $0.0001 par value, 100,000,000 shares authorized; 18,090,526 and 16,560,000 shares issued and outstanding as of December&#160;31, 2024 and 2023, respectively</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,809</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,656</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Additional paid in capital</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">45,101,675</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">24,720,072</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Accumulated deficit</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(50,608,445</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(38,709,981</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1pt">Total Shareholders&#8217; Deficit</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(5,504,961</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(13,988,253</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Liabilities and Shareholders&#8217; Deficit</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">3,417,241</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">1,265,376</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying notes to the consolidated financial statements. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<!-- Field: Page; Sequence: 143; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><FONT ID="b_003"></FONT>NEONC TECHNOLOGIES HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Consolidated Statements of Operations</B>&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the <BR>Year Ended<BR>December&#160;31,</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Revenues:</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left">Revenue</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">83,000</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">70,462</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Operating Expenses:</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Research and development</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">3,045,239</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,534,114</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Legal and professional</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">2,000,623</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,907,687</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">General and administrative</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,638,410</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,488,557</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Advisory fee</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">500,000</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">500,000</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Litigation settlement expense, net</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">41,250</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">4,100,000</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">License expense</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,737,773</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1pt">Total Operating Expenses</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">7,225,522</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">12,268,132</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left">Loss From Operations</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(7,142,522</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(12,197,669</TD>
    <TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Other Income and Expense:</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Interest income</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">16,133</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Amortization of debt issuance costs</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(145,097</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Interest expense - related parties</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(2,557,055</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(2,723,396</TD>
    <TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Loss on extinguishment of Bridge loan - related party</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,069,923</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net Loss</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(11,898,464</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(14,921,065</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Loss per share:</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 2.5pt">Net loss per share - basic and diluted</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.69</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1.02</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 2.5pt">Weighted average number of common shares outstanding during the period - basic and diluted</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">17,342,755</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">14,681,111</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying notes to the consolidated financial statements. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<!-- Field: Page; Sequence: 144; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><FONT ID="b_004"></FONT>NEONC TECHNOLOGIES HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Consolidated Statements of Changes in Shareholders&#8217; Deficit</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Common Stock</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Additional <BR>Paid In</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Accumulated</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Total <BR>Shareholders&#8217;</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Shares</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Capital</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Deficit</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 40%; font-weight: bold; text-align: left">Balance - January&#160;1, 2023</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 9%; text-align: right">10,500,000</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">1,050</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">22,212,455</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">(23,788,916</TD>
    <TD STYLE="width: 1%; text-align: left">)</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">(1,575,411</TD>
    <TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Common stock issued for share exchange</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">5,500,000</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">550</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(100</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">450</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Common stock issued for license fee</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">560,000</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">56</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">2,507,717</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">2,507,773</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Net loss</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(14,921,065</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(14,921,065</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Balance - December&#160;31, 2023</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">16,560,000</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,656</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">24,720,072</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(38,709,981</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(13,988,253</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Balance - January&#160;1, 2024</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">16,560,000</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">1,656</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">24,720,072</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">(38,709,981</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">(13,988,253</TD>
    <TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Sale of common stock, net of costs</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">384,646</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">38</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">4,615,751</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">4,615,789</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Common stock issued for bridge loan conversion</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">979,039</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">98</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">11,748,366</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">11,748,464</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Common stock issued for settlement of vendor payable</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">127,258</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">13</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,527,077</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,527,090</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Common stock issued for settlement of accrued compensation</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">34,375</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">3</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">412,497</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">412,500</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Common stock issued for note payable conversion</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">5,208</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">62,499</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">62,500</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Warrants issued for line of credit</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">2,015,413</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">2,015,413</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Net loss</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(11,898,464</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(11,898,464</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Balance - December&#160;31, 2024</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">18,090,526</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,809</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">45,101,675</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(50,608,445</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(5,504,961</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying notes to the consolidated financial statements. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<!-- Field: Page; Sequence: 145; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><FONT ID="b_005"></FONT>NEONC TECHNOLOGIES HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Consolidated Statements of Cash Flows</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<BR>Year Ended<BR>December&#160;31,</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; font-weight: bold; text-align: left">Cash flows from operating activities:</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; width: 76%; text-align: left">Net loss</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">(11,898,464</TD>
    <TD STYLE="width: 1%; text-align: left">)</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">(14,921,065</TD>
    <TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; text-align: left">Increase in bridge loan - expenses paid by bridge loan provider on behalf of the Company</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">476,393</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,997,775</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; text-align: left">Accretion of original issue discount on bridge loan - related party</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">2,557,055</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">2,721,747</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; text-align: left">Amortization of right to use asset</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">245,945</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; text-align: left">Amortization of debt issuance costs</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">145,097</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; text-align: left">Common stock issued for license fee, at fair value</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">2,507,773</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; text-align: left">Litigation settlement expense, net</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">4,100,000</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; text-align: left">Write off of deferred offering costs</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">703,796</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; text-align: left">Loss on extinguishment of bridge loan</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">2,069,923</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Changes in operating assets and liabilities:</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; text-align: left">Prepaid expenses</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(123,627</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(24,774</TD>
    <TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; text-align: left">Accrued compensation</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">56,131</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">678,743</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; text-align: left">Lease liability</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(244,748</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; text-align: left; padding-bottom: 1pt">Accounts payable and accounts payable - related parties</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,798,583</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,059,789</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; font-weight: bold; text-align: left">Net cash used in operating activities</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(4,213,916</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(1,880,012</TD>
    <TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; font-weight: bold; text-align: left">Cash flows from financing activities:</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Proceeds from related party loans</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">892,028</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">3,507,972</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Repayment of related party loans</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(791,077</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(2,135,277</TD>
    <TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Deferred offering costs</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(469,793</TD>
    <TD STYLE="text-align: left">)</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">(94,569</TD>
    <TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 1pt">Proceeds from sale of common stock, net</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">4,615,789</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">450</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; font-weight: bold; text-align: left">Net cash provided by financing activities</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">4,246,947</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,278,576</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; font-weight: bold; text-align: left; padding-bottom: 1pt">Net increase (decrease) in cash</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">33,031</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(601,436</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; font-weight: bold; text-align: left; padding-bottom: 1pt">Cash - beginning of period</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">31,862</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">633,298</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash - end of period</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">64,893</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">31,862</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; font-weight: bold; text-align: left">Supplemental disclosure of non-cash financing activities:</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Original issue discount on bridge loan - related party</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">1,368,421</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">5,968,987</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Increase in bridge loan payable - prepaid and deferred offering costs paid directly by bridge loan provider on behalf of the Company</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">31,346</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">463,241</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Conversion of bridge loan to common stock</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">11,748,464</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Conversion of accrued compensation to common stock</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">412,500</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Conversion of accounts payable to common stock</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">1,527,090</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Warrants issued for line of credit commitment</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">2,015,413</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Right of use asset at lease commencement</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">536,605</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Decrease in right of use asset and liability from lease amendment</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">267,134</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Deferred offering costs within accounts payable</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">325,000</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">475,000</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See accompanying notes to the consolidated financial statements. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<!-- Field: Page; Sequence: 146; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><FONT STYLE="font-variant: small-caps"><FONT ID="b_006"></FONT>Note 1 &#8211; Description of Business and Liquidity</FONT></B>&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NeOnc Technologies, Inc. (&#8220;NTI&#8221;) was incorporated on April&#160;13, 2005, as a California corporation. On April&#160;7, 2023, NTI merged into NeOnc Technologies Holdings, Inc. (&#8220;NTHI&#8221; and the combined entities &#8220;NeOnc&#8221; or the &#8220;Company&#8221;). NTHI was incorporated January 5, 2023, as a Delaware Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NeOnc is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The Company&#8217;s lead product, NEO100 is in clinical trials treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (&#8220;FDA&#8221;). The Company licensed the underlying technology from the University of Southern California. (&#8220;USC&#8221;). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December&#160;2022, the Company signed a Letter of Intent (&#8220;LOI&#8221;) with an investment advisory firm AFH Holdings and Advisory, LLC (&#8220;AFH&#8221;) to create a newly formed corporation called NeOnc Technologies Holding Company, Inc. (&#8220;NTHI&#8221;) to facilitate future fundraising transactions (see Note 3). On April&#160;7, 2023, the Company entered into share exchange agreements whereby all of the common shareholders of NTI exchanged all of their stock in NTI for a total of 10,500,000 shares of NTHI common stock in the share exchange (&#8220;Share Exchange&#8221;). At the consummation of the Share Exchange transaction, AFH and its affiliated entities, individuals, or assignees owned an aggregate of 34.4% (5,500,000 shares) of the fully diluted issued and outstanding common shares of the Company. For a period of two years after an IPO or direct listing, AFH will also act as an investment advisor in future financing transactions. Except for the completed exchange transaction described above, there is no assurance of consummation of any of the transactions contemplated by the LOI. There can be no assurance that a fundraising transaction can be completed. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Liquidity</B>&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying financial statements have been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. At December&#160;31, 2024, the Company had cash totaling $64,893. For the year ended December&#160;31, 2024, the Company incurred a net loss of $11,898,464 and has an accumulated deficit of $50,608,445 at December&#160;31, 2024. The Company has financed its working capital requirements to date primarily through the issuance of common stock, preferred stock, shareholder loans and a short-term bridge loan. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December&#160;31, 2024, the Company is preparing for a direct listing on a national exchange (&#8220;DL&#8221;) of its common stock, however, there is no certainty that the DL can be completed. The Company does not have sufficient available capital to fund operations for a period of twelve months from the issuance date of these financial statements. The Company will need to raise additional funding to complete the development of its products and commence the market launch, assuming regulatory approval is obtained. The Company does not know whether additional financing will be available when needed, whether it will be available on favorable terms, or if it will be available at all. These factors raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October&#160;11, 2024, the Company entered into an agreement with a broker dealer to serve as placement agent and provide broker services in connection with the proposed sale of common stock up to $10,000,000. As of December&#160;31, 2024, the broker dealer has closed on commitments from investors of $10,000,000 to purchase common stock at $16 per share which as of December&#160;31, 2024 are being held in escrow until the Company has an effective registration statement on file with the SEC. The Company is in the process of filing with the SEC for a registration statement, however no assurance can be given that the Company will complete the process. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<!-- Field: Page; Sequence: 147; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Other risks and uncertainties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is subject to risks common to biopharmaceutical companies, including, but not limited to, new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, product liability, and the uncertainty of market acceptance of products and the potential need to obtain additional financing. The Company is dependent on third-party suppliers and, in some cases, single-source suppliers. The Company&#8217;s products require approval or clearance from the FDA prior to commencing commercial sales in the United States. Approvals or clearances are also required in foreign jurisdictions where the Company may license or sell its products. There can be no assurance that the Company&#8217;s products will receive all required approvals or clearances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There can be no assurance that the Company&#8217;s products, if approved, will be accepted in the marketplace, nor can there be any assurance that any future products can be developed or manufactured at an acceptable cost with appropriate performance characteristics or that such products will be successfully marketed, if at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><FONT STYLE="font-variant: small-caps">Note 2 &#8211; Basis of Presentation and Summary of Significant Accounting Policies</FONT></B>&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Basis of presentation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;), including all pronouncements of the U.S. Securities and Exchange Commission applicable to annual financial statements. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Principles of consolidation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements and related notes to the consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All significant intercompany balances and transactions have been eliminated in consolidation. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Use of estimates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In preparing the Company&#8217;s financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Cash</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company, from time to time during the period covered by these financial statements, may have had bank account balances in excess of federally insured limits. The Company has not experienced losses in such accounts. For the statements of cash flows, the Company considers all short-term investments purchased with a maturity of three months or less to be cash equivalents. At December&#160;31, 2024 and 2023, the Company did not have any cash equivalents. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Deferred offering costs</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company complies with the requirements of the ASC 340-10-S99-1 and SEC Staff Accounting Bulletin (&#8220;SAB&#8221;) Topic 5A &#8220;Expenses of Offering&#8221;. Offering costs consist principally of professional and registration fees incurred through the balance sheet dated December 31, 2024 that are related to the planned public offering of its securities (See Note 3). These costs have been capitalized and are expected to be recognized in equity upon the completion of the securities offering. If planned offerings are terminated, the related capitalized deferred offering costs are written off. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<!-- Field: Page; Sequence: 148; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Debt issuance costs</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Debt issuance costs represent costs directly attributable to warrants issued for a line of credit commitment. Such costs represent the fair value of warrants issued to the debt facility provider, and are amortized to the statement of operations on a straight-line basis which approximates the effective interest rate method, over the term of the debt instrument. The debt issuance costs, net of accumulated amortization is classified as a long-term asset until the Company begins to draw funds from the debt facility in accordance with ASC 815: Derivatives and Hedging. At such time, the pro-rata portion of amounts borrowed as compared to the total debt facility will be reclassified as a contra-debt account. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Warrants</B>&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluates the terms of warrants issued and determines if the instrument requires liability or equity accounting classification under ASC 815: Derivatives and Hedging and ASC 480: Distinguishing Liabilities from Equity. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Notes payable</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has elected to account for notes payable to a shareholder using the fair value option in accordance with the guidance contained in the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 825-10-25. The fair value option provides an option to elect fair value as an alternative measurement for selected financial assets, financial liabilities, unrecognized firm commitments, and written loan commitments. See Note 4 for additional information. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Original Issue Discount (&#8220;OID&#8221;) to be earned under the bridge loan is recognized ratably over the term of each draw-down under the loan through the maturity date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Leases</B>&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company classifies its leases either as operating or financing lease at inception. The company has an operating lease. This lease is recorded as an operating lease, right of use (ROU) assets and operating lease liabilities on the accompanying consolidated balance sheets. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Operating lease ROU assets and the related lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. The operating lease ROU assets also include lease incentives and initial direct costs incurred. For operating leases, interest on the lease liability and the amortization of ROU asset result in straight-line rent expense over the lease term. Leases may include options to extend or terminate the lease which are included in the ROU operating lease assets and operating lease liability when they are reasonably certain of exercise. Certain leases include lease and non-leased components, which are accounted for as one single lease component. Operating lease expense associated with minimum lease payments is recognized on a straight-line basis over the lease term. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Fair value measurements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">FASB ASC Topic 820, &#8220;<I>Fair Value Measurements and Disclosures</I>&#8221; (&#8220;ASC 820&#8221;), defines fair value, the methods used to measure fair value and the expanded disclosures about fair value measurements. Fair value is the price received to sell an asset or paid to transfer a liability in an orderly transaction between the buyer and the seller at the measurement date. In determining fair value, the valuation techniques consistent with the market approach, income approach and cost approach shall be used to measure fair value. ASC 820 establishes a fair value hierarchy for inputs, representing the assumptions the buyer and seller use in pricing the asset or liability. These inputs are further defined as observable and unobservable inputs. Observable inputs are those that the buyer and seller would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs reflect the Company&#8217;s assumptions about the inputs the buyer and seller would use to price the asset or liability developed based on the best information available in the circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<!-- Field: Page; Sequence: 149; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The carrying value of the Company&#8217;s accounts payable approximates its fair value because of the short-term nature of these financial instruments. The note payable - related party is reported at fair value as the Company elected the fair value option for such note (see Note 4).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value hierarchy is categorized into three levels based on the inputs as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<TABLE BORDER="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify">&#160;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Level 1 - Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Valuation adjustments and block discounts are not being applied. Since valuations are based on quoted prices that are readily and regularly available in an active market, the valuation of these securities does not entail a significant degree of judgment.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<TABLE BORDER="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify">&#160;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify">&#9679; </TD>
    <TD STYLE="vertical-align: top; text-align: justify">Level 2 - Valuations based on (i) quoted prices in active markets for similar assets and liabilities, (ii) quoted prices in markets that are not active for identical or similar assets, (iii) inputs other than quoted prices for the assets or liabilities, or (iv) inputs that are derived principally from or corroborated by the market through correlation or other means. </TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<TABLE BORDER="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify">&#160;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Level 3 - Valuations based on unobservable inputs and significant to the overall fair value measurement.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Licenses of intellectual property (&#8220;IP&#8221;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluates intellectual property licensing agreements in accordance with ASC 808, <I>Collaborative Arrangements.</I> If the license to the Company&#8217;s IP is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from consideration allocated to the license when the license is transferred to the customer, and the customer can use and benefit from the licenses. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measurement of performance and related revenue recognition. Determining the revenue recognition of IP licenses requires significant judgment and is discussed in further detail for each of the Company&#8217;s license and collaboration agreements in Note 5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At the inception of each arrangement that includes development or regulatory milestone payments, the Company evaluates the probability of reaching the milestones. The Company estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal will not occur in the future, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s, such as regulatory approvals, are not considered probable of being achieved until those approvals are received.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Therefore, revenue recognized is constrained as management cannot assert that a revenue reversal would not be possible. The transaction price is then allocated to each performance obligation on a residual basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such development milestones and any related constraints. The Company adjusts its estimate of the overall transaction price if necessary. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the adjustment period. To date, the Company has not recognized any milestone revenue resulting from any of its agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">When performance obligations are not required of the Company or following the completion of the performance obligation period, such amounts are recognized as revenue upon transfer of control of the goods or services to the customer. Generally, all amounts received or due other than sales-based milestones and royalties are classified as license and collaboration revenue. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Sales-based milestones and royalties will be recognized as royalty revenue at the later of when the related sales occur or when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<!-- Field: Page; Sequence: 150; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Revenue</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognized point-in-time revenue of $83,000 and $70,462 for the years ended December&#160;31, 2024 and 2023, respectively, for the sale/license of technology where the Company has no further performance obligations. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Research and development</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and development activities, including third-party contractors performing research, conducting clinical trials, and manufacturing drug supplies and materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Patent costs</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All patent-related costs incurred in filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as legal and professional expenses in the accompanying consolidated statements of operations. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Share-based compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has granted stock options and common shares to employees, non-employee consultants and non-employee members of our Board of Directors. The Company measures the compensation cost associated with all share-based payments based on the grant date fair values. Compensation costs associated with grants of common shares are measured at fair value at the date of grant, which has historically been the most recent price paid by investors to purchase shares of the Company&#8217;s common stock prior to such grant. The Company recognizes share-based compensation expense over the requisite service period of each award, which generally equals the vesting period, using the straight-line method for awards that contain only service conditions. If the stock grant is contingent upon events that have not yet happened, then the grant is not considered issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Net loss per share</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic net loss per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the sum of the weighted average number of common shares outstanding during the period. For periods in which the Company reports a net loss, the diluted net loss per share is the same as basic net loss per share. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the year ended December&#160;31, 2024, there are potentially dilutive securities outstanding of 312,500 warrants and 3,060,000 restricted stock units, which are not included in the diluted net loss per share calculation since their effect is anti-dilutive. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the year ended December&#160;31, 2023, there are no potentially dilutive securities outstanding. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Income taxes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes federal, state, and foreign current tax liabilities or assets based on its estimate of taxes payable to or refundable by tax authorities in the current fiscal year. The Company also recognizes federal and state deferred tax liabilities or assets based on the Company&#8217;s estimate of future tax effects attributable to temporary differences and carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years those temporary differences are expected to be recovered or settled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<!-- Field: Page; Sequence: 151; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Deferred tax assets are reduced by valuation allowances if, based on the consideration of all available evidence, it is more likely than not that some portion of the deferred tax asset will not be realized. The Company evaluates deferred income taxes quarterly to determine if valuation allowances are required by considering available evidence. If the Company is unable to generate sufficient future taxable income in certain tax jurisdictions, or if there is a material change in the actual effective tax rates or time period within which the underlying temporary differences become taxable or deductible, the Company could be required to increase its valuation allowance against its deferred tax assets which could result in an increase in the Company&#8217;s effective tax rate and an adverse impact on operating results. The Company will continue to evaluate the necessity of the valuation allowance based on the remaining deferred tax assets. The difference between the statutory and effective rates for the years ended December&#160;31, 2024 and 2023 is a result of the Company applying a full valuation allowance against any deferred tax assets as a result of net operating losses due to uncertainties surrounding the usability of such net operating losses. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the accounting guidance related to financial statement recognition, measurement and disclosure of uncertain tax positions. The Company recognizes the impact of an uncertain income tax position on an income tax return at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized if it is less than 50% likely to be sustained. Uncertain tax positions are recognized in the first subsequent financial reporting period in which that threshold is met or from changes in circumstances such as the expiration of applicable statutes of limitations. The Company will recognize interest and penalties related to tax positions in income tax expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Segment Reporting</B>&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November&#160;2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, &#8220;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.&#8221; The standard expands reportable segment disclosure requirements for public business entities primarily through enhanced disclosures about significant segment expenses that are regularly provided to the chief operating decision maker (&#8220;CODM&#8221;) and included within each reported measure of segment profit (referred to as the &#8220;significant expense principle&#8221;). The standard has been adopted for our fiscal year 2024 annual financial statements and interim financial statements thereafter and have applied this standard retrospectively for all prior periods presented in the financial statements. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><FONT STYLE="font-variant: small-caps">Note 3 &#8211; Related party transactions</FONT></B>&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>AFH Holdings and Advisory, LLC advisory agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December&#160;19, 2022, the Company entered into an advisory agreement with AFH to assist the Company in connection with its intent to affect a public listing. AFH was retained to assist the Company with investor presentations and decks, coordinate the retention of an investment banker for an initial public offering, identify legal and accounting professionals to assist in connection with such public offering, identify investor relations/public relations firms, advise on private capital markets activities prior to the initial public offering and coordinate the closing process for the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NTI agreed to affect a share exchange with a special purpose entity (NTHI) substantially owned by AFH, whereby AFH retained approximately 34.4% of the shares of the combined entity after the Share Exchange. The Share Exchange occurred on April&#160;7, 2024 (see Note 1). The Company has accounted for the Share Exchange transaction as a reverse recapitalization with NTI as the accounting acquirer. At the time of the Share Exchange, NTHI had no operations and did not meet the definition of a &#8220;business&#8221; as defined under U.S. GAAP. Since NTI is the accounting acquirer, its historical financial statements became the Company&#8217;s historical financial statements, and such assets and liabilities continued to be recorded at their historical carrying values. The historical common and preferred stock of NTI have been retroactively adjusted for all periods presented to reflect the conversion of preferred stock of NTI to common stock of NTI prior to the Share Exchange and the exchange ratio from the Share Exchange (0.1465 shares of common stock of NTHI for 1 share of common stock of NTI). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<!-- Field: Page; Sequence: 152; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July&#160;12, 2024, the Company amended the AFH advisory agreement section to allow for an upfront payment on the listing date of $2,500,000 and the remaining amount of $8,828,565 to be paid in equal monthly installments for one year. AFH was paid a fee of $500,000 for the amendment and the fee is included in advisory fee expense in the December&#160;31, 2024 consolidated statement of operations. For the year ended December&#160;31, 2023, AFH earned a fee of $500,000 for its advisory work, which is included in advisory fee expense in the consolidated statement of operations. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, the Company agreed to retain AFH as an exclusive advisor to the Company on all financing and mergers and acquisitions for a period of two (2) years from the closing of the private securities offering. Further to the advisory arrangement, AFH shall be paid an aggregate fee in an amount equal to 2% of the post-money valuation of the Company immediately after the effective time of the public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Further, AFH agreed to advance costs of up to $500,000 to the Company for fees paid to service providers related to a financing transaction and were repaid out of proceeds from the short-term loan provided to the company by HCWG LLC. As of December&#160;31, 2024 and 2023, no amounts were outstanding further to the agreement. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Transactions with USC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March&#160;9, 2009, the Company entered into an exclusive license agreement with USC, pursuant to which USC granted a license to use certain patented technology related to the use of monoterpenes as a solvent, specifically <I>perillyl alcohol</I>. This technology is the basis of the current products under development by the Company. The Company granted USC 117,236 shares of common stock in exchange for the license. Additionally, the Company is required to pay an annual patent maintenance cost of $20,000 and a 2% royalty on all net sales, as defined. The Company has not incurred any royalties through December&#160;31, 2024, since no products are being sold using such technology. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April&#160;5, 2023, NeOnc amended the license agreement with USC dated March&#160;9, 2009 (&#8220;Amended Agreement&#8221;) to include all of the worldwide patents developed by the Company related to the biotechnology under development by the Company. The Amended Agreement also had added the Company as an additional licensee. In addition, the Amended Agreement contained the following provisions: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<TABLE BORDER="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify">&#160;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify">&#9679; </TD>
    <TD STYLE="vertical-align: top; text-align: justify">The Company issued 560,000 shares of common stock of NTHI on October&#160;11, 2023 to USC. The Company had not issued such shares within 15 days of the effective date of the Amended Agreement, as required by the Amended Agreement, and received a waiver from USC to forgo any material breach of the Amended Agreement for such failures. The fair value of the common stock was issued for the license was valued based upon the pricing from a recent financing round adjusted for the dilution from the Share Exchange. The Company recorded license expense in the amount of $2,507,773 in the accompanying consolidated statement of operations equal to the estimated fair value of the shares to be issued to USC. </TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<TABLE BORDER="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify">&#160;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">The Company will pay USC nonrefundable earned royalties of 4% on Net Sales (as defined in the Amended Agreement) of Licensed Products covered by the licensed patents in all countries in which the manufacture, use, sale, offer for sale, or import of such Licensed Products, as such capitalized terms are defined in the Amended Agreement. To date, no sales have been made using Licensed Products, and no royalties are due to USC.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<TABLE BORDER="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify">&#160;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">The Company will assume responsibility for patent-related costs.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November&#160;19, 2023, the Company and USC entered into an Amended and Restated Exclusive License Agreement (the &#8220;Restated Agreement&#8221;). The Restated Agreement addressed and clarified certain reporting obligations of the Company under the license agreement with USC dated March&#160;9, 2009 (&#8220;Amended Agreement&#8221;), and addressed certain financial and other obligations, defaults, and deficiencies in connection with the Company&#8217;s performance under the Amended Agreement. In connection with the Restated Agreement, the Company recorded additional license fees in the amount of $230,000 to cure deficiencies in the March&#160;9, 2009 agreement related to unpaid sub-license fees which is recorded as license fees in the accompanying consolidated statement of operations during the year ended December&#160;31, 2023. On July&#160;17, 2024 the restated agreement was amended to extend the payment date of the $230,000 to the earlier of September&#160;1, 2025 or within five days of a public offering. Such payable is included in accounts payable - related parties in the accompanying consolidated balance sheets as of December&#160;31, 2023 and as of December&#160;31, 2024. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<!-- Field: Page; Sequence: 153; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company also utilizes laboratory services from USC. The Company has incurred approximately $461,000 and $326,000 of research and development-related costs from USC for the years ended December&#160;31, 2024 and 2023, respectively. The Company incurred approximately $20,000 and $41,000 of patent maintenance and legal-related expenses for the years ended December&#160;31, 2024 and 2023, respectively. At December&#160;31, 2024 and 2024, the Company owes USC $272,328 and $277,344 respectively, which is included in accounts payable - related parties in the accompanying consolidated balance sheets. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From time to time prior to January&#160;1, 2023, the Company has been unable to reimburse USC for such costs. Therefore, USC deducted certain amounts due to the Chairman for compensation for his services as faculty at USC to satisfy the amounts due from the Company to USC. In 2024, the Company reached an agreement to convert a portion of amount owed as of such date in the amount of $1,377,096 to 114,758 common shares at $12 per share (the share price of the most recent financing round) and is recorded as a portion of the common stock issued for settlement of vendor payable in the Consolidated Statements of Changes in Shareholders&#8217; Deficit for December&#160;31, 2024. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Accrued compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has incurred $785,996 and $798,743 for the years ended December&#160;31, 2024 and 2023, respectively for compensation to the management team, Chairman, COO and CFO, all of whom are shareholders (the &#8220;Employees&#8221;). This compensation is recorded in the consolidated statement of operations as part of general and administrative expenses. On June&#160;30, 2024, the Employees converted $412,500 of their accrued compensation into 34,375 shares of common stock at $12.00 per share (the share price of the most recent financing round). On June&#160;30, 2024 and in light of the current macro-economic funding environment, the Board of Directors of the Company resolved to reverse their 2023 decision to provide bonuses to certain members of management, and accordingly $251,576 was recorded as a reduction of compensation expense in the year ended December 31, 2024. The amount accrued for the management team, including related payroll taxes, was $734,874 and $1,091,243 as of December&#160;31, 2024 and 2023, respectively. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><FONT STYLE="font-variant: small-caps">Note 4 &#8211; Related Party Loans Payable</FONT></B>&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Note Payable</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In 2023, the Company issued $50,000 of convertible notes to a shareholder due August 30, 2024 (&#8220;Note&#8221;). The Note bears interest at 2% per annum. This Note and all accrued interest thereon is convertible, at the option of the noteholder, into the class and series of equity securities (&#8220;Conversion Stock&#8221;) that is sold by the Company in its next issuance of equity securities in a Financing Transaction (as defined below), consummated after the issuance date of the note. A Financing Transaction is a sale, other than an initial public offering (&#8220;IPO&#8221;), of equity securities by the Company to investors for cash. The Financing Transaction does not include the issuance of stock, options, or warrants to service providers in connection with the rendition of such services or to third parties in connection with the contribution of non-cash assets to the Company. The number of shares of Conversion Stock to be issued to the noteholder upon such conversion shall be equal to the quotient obtained by dividing (i) the entire principal amount of this Note plus accrued interest by (ii) the Financing Transaction Conversion Price (as defined below). The Financing Transaction Conversion Price shall be equal to seventy-five percent (75%) of the price paid for one share of Conversion Stock by the investors in the Financing Transaction. The entire principal amount of and accrued interest on this Note shall automatically be converted, without further action on the part of the noteholder or the Company, into the class and series of stock issued by the Company, at the closing of an IPO. The number of shares of stock to be issued to the holder upon such conversion shall be equal to the quotient obtained by dividing (i) the entire principal amount of this Note plus accrued interest by (ii) the IPO Conversion Price (as defined in the Note). On January&#160;31, 2024, the Note was assigned to HCWG LLC (an entity owned by certain shareholders, directors, and officers of the Company). Additionally, as part of the assignment, the Note was amended to increase the principal balance to $62,500, amend the maturity date to the date that the Company completes its initial public offering, and the Note was subordinated to the Bridge Loan (defined below). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has elected to account for the Note under the fair value option (See Note 2). The fair value of the Note (classified within Level 3 of the fair value hierarchy) approximated the face amount of $50,000 at both December&#160;31, 2024 and 2023. As such, no adjustment was made to the carrying value of the Note. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<!-- Field: Page; Sequence: 154; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June&#160;30, 2024, the Company and noteholder entered an agreement with HCWG LLC to assume the Note. As part of the agreement, an outstanding interest of $2,250 at the time of the assignment, plus an additional interest charge of $10,250 upon assignment of the loan, was converted to principal, for a total principal balance of $62,500. The additional interest of $10,250 is recorded as an interest expense in the accompanying consolidated statement of operations. On July&#160;23, 2024, the note was converted into 5,208 shares of common stock. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Bridge Loan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In April&#160;2023, the Company entered into a non-interest bearing, non-convertible promissory note with HCWG LLC (the &#8220;Bridge Loan&#8221;). Borrowings under the Bridge Loan carry a 50% (or 1 times cash amounts borrowed) original issue discount (&#8220;OID&#8221;) on principal and through subsequent amendments the maximum cash borrowing was increased to $10,000,000 at December&#160;4, 2023. The outstanding amounts under this Bridge Loan were payable at the earlier of the date the Company completes an IPO or December&#160;4, 2024, (the &#8220;Maturity Date&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Through December&#160;31, 2024 and 2023, the Company had received under the Bridge Loan an aggregate of $7,337,408 and $5,968,987, respectively. The OID was recognized ratably over the term of each draw-down under the Bridge Loan through the Maturity Date unless settled earlier, at which point the accretion is accelerated. Accretion of the OID for the year ended December&#160;31, 2024 and 2023, amounted to $2,557,055 and 2,721,747, respectively, and are included in interest expense in the accompanying consolidated statement of operations. Summary of the bridge loan activity for the years ended December 31, 2024 and 2023, respectively, is as follows: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<BR>year ended<BR>December&#160;31,<BR>2024</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<BR>year ended<BR>December&#160;31,<BR>2023</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Bridge loan - rollforward</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Principal outstanding</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">9,802,697</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">-</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Borrowings</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,368,422</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">5,968,987</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">OID</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,368,422</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">5,968,987</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Repayments</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">&#x202f;(791,077</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,135,277</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Total principal outstanding before conversion</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">11,748,464</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">9,802,697</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Conversion to common stock</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(11,748,464</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Principal; outstanding</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">9,802,697</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<BR>year ended<BR>December&#160;31,<BR>2023</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Bridge loan</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">Principal Outstanding</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">9,802,697</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Less: Unrecognized OID</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,247,240</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Total:</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">6,555,457</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June&#160;14, 2024, the Company reached an agreement with HCWG LLC to convert the outstanding principal and interest on the Bridge Loan totaling $11,748,464 to 979,039 shares of common stock at $12 per share. The fair value of the common stock issued for the conversions was valued based upon the pricing from a recent financing round which was $12 a share. The difference between the carrying value of the debt as of the date of the extinguishment of $9,678,541 and the fair value of the shares issued to settle to the debt as of the date of the extinguishment of $11,748,464 is recorded as a loss on extinguishment<I>. </I>As a result of this conversion, the Bridge Loan was terminated and is no longer available to the Company for borrowing. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has a receivable due from HCWG LLC totaling $148,705 which is recorded within prepaid expenses and other on the consolidated balance sheet at December&#160;31, 2024. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<!-- Field: Page; Sequence: 155; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><FONT STYLE="font-variant: small-caps">Note 5 &#8211; Leases</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February&#160;1, 2024, the Company entered a 24-month lease for office space, which calls for a monthly base rent of $25,000, increasing at 3% per annum. The Company has only one operating lease and has no financing leases. The Company&#8217;s lease does not contain options to renew or extend the lease term or options to terminate leases early, except for insolvency. In calculating the present value of future lease payments, the Company utilized its incremental borrowing rate based on the lease term. The Company&#8217;s net lease non-lease components (e.g., standard area maintenance, maintenance, consumables, etc.) are paid separately from rent based on actual costs incurred and, therefore, are not included in the right-of-use asset and lease liability and are reflected as an expense in the period incurred. On November&#160;27, 2024, the Company amended the lease expiration date from January&#160;31, 2026, to January&#160;31, 2025. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December&#160;31, 2024, the consolidated balance sheet reflects a right-of-use asset of $23,526 and a lease liability of $24,722. The Company recorded lease expense of $245,944 and $0 during the year ended December&#160;31, 2024, and 2023, respectively, within general and administrative expenses on the consolidated statements of operations. Cash paid for amounts included in the measurement of lease liability was $275,000 and $0, respectively, during the year ended December&#160;31, 2024, and 2023, respectively. The lease liability was computed using an interest rate of 13.49% and as of December 31, 2024, the lease has a remaining life of one month. Future lease payments under non-cancellable operating leases are detailed as follows: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December&#160;31,<BR>2024</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Future Operating Lease Payments</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">2025</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">25,000</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Total lease payments</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">25,000</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Less imputed interest</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(278</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Present value of lease payments</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">24,722</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Less: current portion</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(24,722</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Lease liability, net of current portion</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><FONT STYLE="font-variant: small-caps">Note 6 &#8211; Common and preferred Stock</FONT></B>&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>NeOnc Technologies Holdings, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The total number of shares of common stock available for issue by NTHI is 100,000,000 shares of common stock at $0.0001 par value per share and the total number of shares of preferred stock is 10,000,000 at a par value of $0.0001. See Note 1 for discussion of the issuance of common shares pursuant to the Share Exchange. As of December&#160;31, 2024, no preferred shares have been issued. During the year ended December&#160;31, 2024, the Company sold 384,646 shares of common stock at a price of $12 per share for gross proceeds of $4,615,789. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The board of directors is authorized, subject to any limitations prescribed by law, to provide for the issuance of shares of Preferred Stock in one or more series, and by filing a certificate pursuant to the applicable law of the State of Delaware<I>,</I> to establish from time to time the number of shares to be included in each such series, and to fix the designation, powers, preferences, and rights of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereof. The number of authorized shares of Preferred Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the Common Stock, without a vote of the holders of the Preferred Stock, or any series thereof, unless a vote of any such holders is required pursuant to the terms of any Preferred Stock Designation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<!-- Field: Page; Sequence: 156; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><FONT STYLE="font-variant: small-caps">Note 7 &#8211; Collaboration and license agreements</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>License Agreement - Orient EuroPharma Co., Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November&#160;8, 2013, the Company entered into a collaboration agreement (&#8220;Agreement&#8221;) with Orient EuroPharma Co., Ltd. (&#8220;OEP&#8221;), pursuant to which the parties will develop certain licensed products defined in the Agreement. NeOnc will license OEP the right to commercialize the Company&#8217;s drug NEO100, a highly purified form of <I>perillyl alcoho</I>l (&#8220;Licensed Product&#8221;), in the territories specified in the license agreement (&#8220;Territory&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the terms of the Agreement, OEP will bear the cost of, and be responsible for, among other things, developing pre-clinical materials, conducting the clinical studies and other developmental activities for the Licensed Products, and bear the cost of and be responsible for, among other things, preparing and filing applications for regulatory approval in the Territory and for commercializing Licensed Products in the Territory, and will use commercially reasonable efforts to commercialize Licensed Products and obtain pricing approval for Licensed Products in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As part of the Agreement, OEP agreed to compensate the Company as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.25in"></TD>
    <TD STYLE="width: 0.25in; text-align: left">&#9679;</TD>
    <TD STYLE="text-align: justify">Reimbursement of the costs related to an Investigational New Drug Application filing with the FDA, which was received in 2014 and 2016.</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify">&#160;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">$200,000 paid upon signing the agreement in 2013, and</TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify">&#160;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify">&#9679; </TD>
    <TD STYLE="vertical-align: top; text-align: justify">Specified clinical milestone payments of up to $1,900,000. The Company received a milestone payment of $300,000 during the year ended December&#160;31, 2020 upon completion of the first phase of clinical trials. The Company has received no other clinical milestone payments through December&#160;31, 2024. </TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has determined that the arrangement is within the scope of ASC 808, <I>Collaborative Arrangements,</I> as both NeOnc and OEP are active participants in the activity, and they are both exposed to significant risks and rewards dependent on the commercial success of the activity. The Company has determined two performance obligations under the arrangement &#8211; the scientific development phase and the clinical trial evaluation phase. The Company had deferred recognition of revenue on the $200,000 paid upon signing the agreement and the $300,000 milestone payment received in 2020 as the clinical trial evaluation phase had not yet been completed at that time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If, after completion of Phase II clinical trials, the Company enters into one or more agreements to license any of the patent rights or Licensed Products to a party other than OEP, then the Company will reimburse specified amounts based upon amounts paid by OEP to the Company, not to exceed $3,000,000 to be paid as various milestones are met.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In 2023, the Company sent notice to OEP indicating their intent to terminate the Agreement with OEP, after which OEP threatened litigation. On February&#160;15, 2024, OEP and the Company entered into a settlement agreement whereas the Company and OEP terminated the Agreement in exchange for a payment in the amount of $4,000,000 payable by the Company to OEP within ten days of the date the Company completes its initial public offering. As part of the settlement, the license was terminated and all rights in the underlying licensed territories have been returned to the Company. The Company recognized $4,000,000 as a litigation settlement expense in the accompanying consolidated statement of operations during the year ended December&#160;31, 2023, and had recorded an associated litigation settlement payable in the accompanying consolidated balance sheets as of December&#160;31, 2024 and 2023. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>License Agreement &#8211; Neucen Biomedical Co., Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December&#160;5, 2015, the Company entered into a license agreement with Neucen Biomedical Co., Ltd. (&#8220;NB&#8221;), a shareholder of the Company, in which NeOnc will license to NB the right to commercialize the Company&#8217;s drug NEO212, a conjugate of perillyl alcohol and temozolomide (&#8220;NB Licensed Product&#8221;) in the territories specified in the license agreement (&#8220;NB Territory&#8221;). </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<!-- Field: Page; Sequence: 157; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the terms of the Agreement, NB will bear the cost of, and be responsible for, among other things, developing pre-clinical materials, conducting the clinical studies and other developmental activities for the NB Licensed Products, and bear the cost of, and be responsible for, among other things, preparing and filing applications for regulatory approval in the NB Territory and for commercializing NB Licensed Products in the NB Territory, and obtain pricing approval for NB Licensed Products in the NB Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NB must pay the Company tiered royalties of 1-5% on net sales of NB Licensed Products in the NB Territory. The Company received no sales milestones or royalties through December&#160;31, 2024, as no commercialized products are using such technology. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June&#160;2023, NB and NTHI mutually agreed to terminate this license agreement, and no consideration was paid or received related to such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><FONT STYLE="font-variant: small-caps">Note 8 &#8211; Segment Reporting</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The company manages our business activities on a consolidated basis and operates as a single operating segment: Biotechnology. The accounting policies of the Biotechnology segment are the same as those described in <FONT STYLE="text-decoration: underline">Note 1 &#8211; Summary of Significant Accounting Policies</FONT>. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Chief Operating Decision Maker (&#8220;CODM&#8221;) is our President and Chief Executive Officer, Dr.&#160;Chen. The CODM uses net loss, as reported on our Consolidated Statement of Operations, in evaluating the performance of the biotechnology segment and determining how to allocate resources of the Company as a whole, including investing in our research and development programs and acquisition/licensing strategy. The CODM does not review assets in evaluating the results of the biotechnology segment, and therefore, such information is not presented. The following supplemental information breaks down the research and development costs for the years ended December&#160;31, 2024 and 2023, respectively. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the<BR>Year Ended<BR>December&#160;31,</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; padding-bottom: 1pt">Revenues</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 9%; text-align: right">83,000</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 9%; text-align: right">70,462</TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Less: Significant and other segment expenses:</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">NEO100</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,200,624</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">702,226</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">NEO100-02</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">320,987</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">NEO212</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">870,634</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">279,859</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Pediatric</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">191,593</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">169,777</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Laboratory</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">460,559</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">326,272</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Other</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">841</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">55,980</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Total clinical trial expense</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">3,045,238</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,534,114</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Legal and accounting</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,178,812</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,907,687</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Offering costs</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">821,812</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Employee expenses</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">686,131</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">798,743</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Advisory services</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">500,000</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">500,000</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Lease amortization</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">245,944</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Advertising</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">349,278</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">141,109</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">General and administrative expense</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">357,057</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">550,354</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Litigation settlement expense, net</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">41,250</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">4,100,000</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">License expense</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">2,737,773</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Interest expense - related parties and loss on extinguishment of bridge loan</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">4,626,978</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">2,721,747</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Amortization expense</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">145,097</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">-</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">Interest income</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(16,133</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 2.5pt">Net loss</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(11,898,464</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(14,921,065</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<!-- Field: Page; Sequence: 158; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>Note 9 &#8211; Stock-Based Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April&#160;12, 2023, the Company adopted the 2023 Equity Incentive Plan (the &#8220;2023 Plan&#8221;), which allows the issuance of up to 3,440,000 shares of the Company&#8217;s authorized and unissued common stock in the form of incentive stock options, non-qualified stock options, restricted stock units, performance share units, or other forms of equity as may be added in the future to employees, directors and consultants of the Company and its affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January and February&#160;2024, 2,460,000 and 200,000, respectively, restricted stock units (&#8220;RSUs&#8221;) were granted to the executive officers and directors further to the 2023 Plan as described above. Of the total RSUs granted 1,686,667 vest 100% seven months from the date that the Company lists on a national exchange, 486,667 will vest in equal monthly installments over a one (1) year period commencing on the eighth month from the effective date of the listing on a national exchange and 486,666 are performance-based, the vesting of which will be predicated on certain financial and operational performance metrics being met after the effective date of the listing on a national exchange as set forth the grant agreements. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October&#160;23, 2024, 200,000 RSUs were granted to each of the CEO and the Executive Chairman, for a total of 400,000, and 100,000 granted to the Board of Directors were canceled. These granted RSUs vest seven months from the effective date the Company lists on a national exchange. As of December&#160;31, 2024, 380,000 common shares remain unissued in the 2023 Plan. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Since the terms of the grants are not fixed due to the uncertainty of the timing and completion of a listing on a national exchange as of December&#160;31, 2024, the RSU&#8217;s are not considered issued and outstanding, and no expense related to such instruments is recognized. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><FONT STYLE="font-variant: small-caps">Note 10 &#8211; Commitments and Contingencies</FONT></B>&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: underline">Contingent Fee Arrangements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Placement Agent </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October&#160;11, 2024, the Company entered into an agreement with RBW Capital Partners LLC, a division of Dawson James Securities, Inc. (&#8220;Broker&#8221;) to serve as placement agent and provide broker services in connection with the possible sale of common stock up to $10 million. If a sale is made between the Company and any institutional or individual third-party funding source introduced by the placement agent, the Company will pay a placement fee of 8% of the gross proceeds. In addition, the company agrees to pay; (a) 1.0% of the gross proceeds for non-accountable expenses; and (b) out of pocket expenses plus the costs associated with the use of a third-party electronic road show service up to $10,000. The agreement expires on January&#160;11, 2025 and was amended and restated on January&#160;29, 2025 to extend the term for another six months through July&#160;29, 2025. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December&#160;31, 2024, we entered into agreements with investors to sell 624,999 shares of common stock at the private placement price of $16.00 per share for gross proceeds of approximately $10,000,000 (the &#8220;Private Placement&#8221;) which are currently being held in escrow until the Company has an effective registration statement on file with the SEC. In connection with the Private Placement, the Company incurred placement agent fees from Broker of $235,000 of which $225,000 is payable upon the release of the Private Placement funds from escrow. Such amounts are recorded within deferred offering costs on the consolidated balance sheet at December&#160;31, 2024. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January&#160;29, 2025, the Company amended the agreement with RBW Capital Partners LLC, a division of Dawson James Securities, Inc., increasing the placement fee to 12% from 8% of the gross proceeds, and eliminated the 1% non-accountable expense fee. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<!-- Field: Page; Sequence: 159; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Advisory Services </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October&#160;3, 2024 as amended on January&#160;23, 2025, the Company entered into an agreement with Broker, for financial advisory and investment banking services in connection with a direct listing of the Company&#8217;s common stock on the Nasdaq Global Market or other major US market. The agreement provides for a one-time fee of $250,000 payable three days after the direct listing and the issuance of 30,000 shares of common stock which are restricted until the shares are registered by filing a resale S-1 within 30 days after the effective date of the direct listing. In addition, the Company agreed to pay up to $100,000 for fees and expenses of legal counsel and other out-of-pocket expenses plus the costs associated with the use of a third-party electronic road show service. Such fee and expenses of legal counsel in the amount of $100,000 is included in accounts payable and deferred offering costs in the accompanying consolidated balance sheets as of December&#160;31, 2024. The agreement expired on January&#160;3, 2024, and was amended and restated on January&#160;23, 2025 to extend the term for another six months through July&#160;23, 2025. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended December&#160;31, 2023, the Company incurred $475,000 in fees with service providers which were payable upon completion of a previous planned offering, and are included in accounts payable on the December&#160;31, 2023 consolidated balance sheet. As a result of the termination of the previous planned offering during the year ended December&#160;31, 2024, such amounts became immediately payable and are no longer payable contingent on completion of a planned offering. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Deferred Offering Costs </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December&#160;31, 2023, the Company had recorded deferred offering costs of $970,582 related to a previous planned offering. During the year ended December&#160;31, 2024, the Company terminated the previous planned offering and determined that some of those costs no longer met the criteria for capitalization as they were specific to the previous planned offering. As a result, the Company wrote off $703,796 of such costs, which was recorded within legal and professional expense on the consolidated statement of operations for the year ended December&#160;31, 2024. Total deferred costs relating to the Private Placement and direct listing at December&#160;31, 2024 totaled $225,000 and are recorded as deferred offering costs on the consolidated balance sheet at December 31, 2024. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: underline">Line of Credit Commitment</FONT>&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October&#160;11, 2024, the Company entered into a Line of Credit Agreement (&#8220;the Agreement&#8221;) with HCWG for borrowings of up to $10.0 million. Borrowings under the Line of Credit Agreement bear interest at 10.0% per annum and increases to 14% if the Agreement is extended. Interest payments are due on the first business day of each calendar month and unpaid principal is due on October&#160;12, 2027. No amounts have been borrowed under the facility through December&#160;31, 2024. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the agreement, the Company issued HCWG five-year warrants to purchase up to 312,500 shares of our common stock at a per-share exercise price of $12.00. These warrants expire on October&#160;23, 2029. As of December&#160;31, 2024, there were 312,500 warrants issued, outstanding and fully vested. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of the warrants on the grant date was determined using the Black-Scholes valuation model, with the following key assumptions: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify">&#160;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify">&#9679; </TD>
    <TD STYLE="vertical-align: top; text-align: justify">Fair value of common stock: $12.00 </TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify">&#160;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify">&#9679; </TD>
    <TD STYLE="vertical-align: top; text-align: justify">Expected volatility: 86% </TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify">&#160;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify">&#9679; </TD>
    <TD STYLE="vertical-align: top; text-align: justify">Risk-free interest rate: 4.82% </TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify">&#160;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify">&#9679; </TD>
    <TD STYLE="vertical-align: top; text-align: justify">Term: 2.5 years </TD> </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of warrants at inception was $2,015,413, which was recorded as additional paid-in capital on the consolidated statement of stockholders&#8217; equity for the year ended December&#160;31, 2024, and as debt issuance costs on the balance sheet. At December 31, 2024, unamortized debt issuance costs total $1,870,316 on the balance sheet. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<!-- Field: Page; Sequence: 160; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: underline">Equity Purchase Agreement</FONT>&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October&#160;22, 2024, we entered into an equity purchase agreement (the &#8220;Equity Purchase Agreement&#8221;) with Mast Hill Fund, LP (&#8220;Mast Hill&#8221;) pursuant to which the Company may sell and issue to the investor, and the investor may purchase from the Company, up to $50,000,000 of Company&#8217;s common shares. Under the Equity Purchase Agreement, the Company has the right, but not the obligation, to direct Mast Hill, by its delivery to the Mast Hill of a Put Notice from time to time, to purchase Put Shares (i) in a minimum amount not less than $50,000.00 and (ii) in a maximum amount up to the lesser of (a) $750,000.00 or (b) 150% of the average trading volume of the Company&#8217;s common stock during the five trading days immediately preceding the Put Date. The Company cannot draw down any funds under the Equity Purchase Agreement until the Company has an effective registration statement. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The actual amount of proceeds we receive pursuant to each Put Notice (each, the &#8220;Put Amount&#8221;) is determined by multiplying the Put Amount requested by the applicable purchase price. The purchase price for each of the Put Shares equals 95% of the Market Price, (as defined below) less the Clearing Costs (as defined below). Market Price is the lowest volume weighted average prices of the Company&#8217;s common shares on its principal market on any trading day during the Valuation Period (as defined below). The Valuation Period is the five trading days immediately following the date on which Mast Hill receives the Put Shares in its brokerage account. Clearing Costs are all the fees incurred by Mast Hill with respect to its brokerage firm, clearing firm, Company transfer agent fees, and attorney fees, with respect to the Put Shares. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The term of the Equity Purchase Agreement will commence on the effective date of the direct listing and will terminate on the earlier of (i) the date on which the Mast Hill shall have purchased Put Shares equal to the $50,000,000, (ii) twenty-four (24) months after the date of the Equity Purchase Agreement, (iii) written notice of termination by the Company to Mast Hill, (iv) this Registration Statement is no longer effective after the initial effective date of this Registration Statement, or (v) the date that, pursuant to or within the meaning of any Bankruptcy Law, the Company commences a voluntary case or any Person commences a proceeding against the Company, a receiver, trustee, assignee, liquidator or similar official is appointed for the Company or for all or substantially all of its property or the Company makes a general assignment for the benefit of its creditors. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-decoration: underline">Litigation</FONT>&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From time to time, the Company is involved in various disputes, claims, liens and litigation matters arising out of the normal course of business which could result in a material adverse effect on the Company&#8217;s combined financial position, results of operations or cash flows. Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred, and the amount of the assessment can be reasonably estimated. As of December&#160;31, 2024 and 2023, the Company had no liabilities recorded for loss contingencies, except as below. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June&#160;6, 2023, a vendor filed a complaint against the Company for breach of contract in the Central District of California. The vendor alleged that the Company improperly terminated an Intellectual Property License and Supply Agreement (&#8220;IPLSA&#8221;) and that the Company also defrauded the vendor in connection with IPLSA. This matter was settled on October&#160;16, 2023, and the Company agreed to pay the vendor $600,000 within 5 business days of the close of the date that the Company completes an IPO or March&#160;31, 2024, whichever occurs first. The Company recognized this as a litigation settlement expense in the accompanying consolidated statement of operations for the year ended December 31, 2023 and a litigation settlement payable in the accompany consolidated balance sheet at December&#160;31, 2024 and 2023. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March&#160;31, 2024, a vendor agreed to extend the payment until May&#160;15, 2024 for payment of an additional $25,000. The Company has not made the payment as of October&#160;28, 2024, and the settlement is payable on demand. Such amount is included in litigation settlement payable in the accompanying consolidated balance sheet at December&#160;31, 2024. On July 25, 2024, the arbitrator granted the implementation of interest at the statutory rate on the unpaid balance commencing May&#160;15, 2024 until paid, therefore an additional $16,250 of interest expense is recognized in the accompanying consolidated statement of operations during the year ended December&#160;31, 2024. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<!-- Field: Page; Sequence: 161; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><FONT STYLE="font-variant: small-caps">Note 11 &#8211; Income Taxes</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has no significant current income taxes due because of the losses generated each year. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and those used for income tax purposes. The Company&#8217;s deferred tax assets relate primarily to its net operating loss carryforwards and other balance sheet basis differences. In accordance with ASC 740, the Company recorded a valuation allowance to fully offset the gross deferred tax asset because it is not &#8220;more likely than not&#8221; that the Company will realize future benefits associated with these deferred tax assets at December 31, 2024 and 2023. The valuation allowance increased by approximately $2,700,000 and $4,200,000 for the years ended December&#160;31, 2024 and 2023, respectively. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Significant components of the Company&#8217;s deferred tax assets at December&#160;31, 2024 and 2023 as follows: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the <BR>Year Ended<BR>December&#160;31,</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Deferred tax assets:</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Net operating losses</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">8,398,192</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD>
    <TD STYLE="width: 9%; text-align: right">5,452,848</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Share based compensation</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">2,405,371</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">2,405,371</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Interest expense</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">87,260</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">849,349</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Deferred research and development costs</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,230,953</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">614,609</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Accrued wages</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">205,765</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">305,548</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Accrued litigation cots</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,299,550</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">1,288,000</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Deferred revenue and other</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">37,940</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">37,940</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Total deferred tax assets</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">13,665,031</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">10,953,665</TD>
    <TD STYLE="text-align: left">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1pt">Valuation allowance</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(13,665,031</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">(10,953,665</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 2.5pt">Deferred tax asset, net of valuation allowance</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">&#160;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The difference between income taxes at the statutory federal income tax rate and income taxes reported in the consolidated statements of operations is attributable to a full valuation allowance recorded in all periods since inception.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The provision for income taxes for the taxable years ended December&#160;31, 2024 and 2023 differs from the statutory federal income tax rate for the years ended December&#160;31, 2024 and 2023 as follows: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the <BR>Year Ended<BR>December&#160;31,</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">&#160;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</TD>
    <TD STYLE="padding-bottom: 1pt; font-weight: bold">&#160;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 76%; text-align: left">Tax benefit at the federal statutory rate</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 9%; text-align: right">21</TD>
    <TD STYLE="width: 1%; text-align: left">%</TD>
    <TD STYLE="width: 1%">&#160;</TD>
    <TD STYLE="width: 1%; text-align: left">&#160;</TD>
    <TD STYLE="width: 9%; text-align: right">21</TD>
    <TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">State tax, net of federal benefit</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">$</TD>
    <TD STYLE="text-align: right">7</TD>
    <TD STYLE="text-align: left">%</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">7</TD>
    <TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Permanent differences</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">0</TD>
    <TD STYLE="text-align: left">%</TD>
    <TD>&#160;</TD>
    <TD STYLE="text-align: left">&#160;</TD>
    <TD STYLE="text-align: right">0</TD>
    <TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Change in valuation allowance</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-28</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">%</TD>
    <TD STYLE="padding-bottom: 1pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: right">-28</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt">Effective income tax rate</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">%</TD>
    <TD STYLE="padding-bottom: 2.5pt">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&#160;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: right">0</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<!-- Field: Page; Sequence: 162; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December&#160;31, 2024, the Company had Federal net operating loss carryforwards of approximately $30,000,000 which will begin to expire in 2035. Of the total Federal net operating losses, the amounts incurred after 2017 of approximately $22,800,000 will carry forward indefinitely. Sections&#160;382 and 383 of the Internal Revenue Code, and similar state regulations, contain provisions that may limit the NOL carryforwards available to be used to offset income in any given year upon the occurrence of certain events, including changes in the ownership interests of significant stockholders. In the event of a cumulative change in ownership in excess of 50% over a three-year period, the amount of the NOL carryforwards that the Company may utilize in any year may be limited. Although the Company has not undertaken a formal analysis, it is likely that such an ownership change occurred prior to 2020. The years 2021 through 2024 are subject to examination by taxing authorities. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company&#8217;s financial statements as of December&#160;31, 2024 or 2023. The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date. No tax audits were commenced or were in process for the taxable years that ended December&#160;31, 2024 and 2023. No tax related interest or penalties were incurred during the years ended December&#160;31, 2024 and 2023. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><FONT STYLE="font-variant: small-caps">Note</FONT> 12 &#8211; <FONT STYLE="font-variant: small-caps">Subsequent Events</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has evaluated subsequent events through February&#160;26, 2025, the date these financial statements were available to be issued and determined the following subsequent events have been identified and would require adjustment to our disclosure in the financial statement except as disclosed in Note 10: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February&#160;2025, our Executive Chairman advanced the Company approximately $300,000. The advances carry a 50% (or 1 times amounts borrowed) original issue discount (&#8220;OID&#8221;) on the principal. In the event of default, interest is payable at on any unpaid balance at a rate of 10% per annum. The Executive Chairman is to receive a total of $600,000 upon repayment of such advances, including OID, absent default. The Company shall pay the Executive Chairman the entire unpaid principal balance on the earlier of one year following the date of the effective date of the agreement or the date of the direct listing on the Nasdaq Global Market. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</P>

<!-- Field: Page; Sequence: 163; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#toc">Table of Contents</A></FONT></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</P>



<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="border-top: Black 2pt solid; font-size: 1pt; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>111,732 Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NEONC TECHNOLOGIES HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>December&#160;23, 2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>



<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</P>

<!-- Field: Page; Sequence: 164 -->
    <DIV STYLE="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</P></DIV>

    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>img_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &S O@# 2(  A$! Q$!_\0
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M9VC_ . H.5#OM-Y_S]3?]_#1]IO/^?J;_OX:;11_K%C.T?\ P%!RH=]IO/\
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M_P"_AIM%'^L6,[1_\!0<J'?:;S_GZF_[^&C[3>?\_4W_ '\--HH_UBQG:/\
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M-WUZU>TW7?"FB?&"\UQ/$,4UC?6\DDDNQ@L4C,,)P.>!G-3[RU\BM/Q.2O\
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M@E?NL#R&'L16=71>.O$4?BKQA>ZM!&T=O)MCA###%%& 3Z$]:YVMU>VIF]]
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MLKJL1DQT,1"_GG^E<GK&@ZAH4XCO8L*WW)%.5;Z&K<?C+Q!'<B?^T9'.<[&
M*'VQ7HT;V_C/P@6DC"M*I&/^><J]Q^/Z&ARG#XMC*T9;'CE%=GX+\,Z?K=O>
MMJ"2EX)0@V/M['-8OB7P_-X?U(PG+VTGS02D=1Z'W%:*:<N4CE=KF-17:Z5X
M8TV[\$3ZK*LINDCE8$/@97..*I^$?"?]O%[J[9H[&,[?EX,C>@/8#N:.=:OL
M'*SEJ*])>7P!;3_8FAA8@[3)M9@#_O5S7B_3=&TZ[@_LFYW^:N]H@VY4!Z$-
M[^E)3N[6!QL<RO\ Q]1_[P_G10O_ !]1_P"\/YT5^IY=_N-'_#^K,'NR2Y_Y
M"-S_ -=&_G5_1-"U+Q%J/V#2K?[1<["^S<%^4=3D_6J%S_R$;G_KHW\Z]$^"
M/_)1%_Z\Y?YK7Q_$KMB[_P!V/Y&E-7T,>Z^%_C.SMGN)=$D9$&YO+D1SCZ Y
M-<C7T;X1;0X/%^H#3O&EYJFHR><%TZYD98PVXD@9'.,8XZ"N!\-^%['7['QC
MI.HZ=%'XGLWDGAD1CP<G*@9P1N&.G1J^:C4WN:N'8\PHKTCQ%X:T?P]X1\*6
MLU@O]NZE(DMS*S-N6,D97&<#[P'3L:[#4]#^'FE^/+3PJ_AIVEU",?OQ,^V$
MG.T 9SSCDU7M%V%R'@]%>H>'?!NF6WC[7](NM%OM<6Q.+6*-@L?/(,K$C!Q@
M?F<5:^)/@_0],T+1-6@T^/2)+BY$%W%!/YR*ISD@]"1CJ*/:*]@Y':YY+17T
M/=_#[PPNGD:?X534M/-ON2\LK[-PS^P) /KG/X5QGPO\+:!K-AJ[W=G#?ZQ;
MR[(+"\G,.%]3C)SU!.#C%)55:X<CO8\KJ>SLKK4;N.TLK>6XN)#A(HEW,Q^E
M=K\4- LM#U.S-EH-SI(FC/F*T@DA=AC_ %;9/3/.<=N!6A\#IK5/',D4ML9+
MF2V?R)MV/*Q][COD8_*J<_=YD+E]ZQQ6E^&-8UJZO;6PLS+/9*S7"%PI0 X/
M4^HK(!R,U[GX!NM+O/B)XPDL[!K*R%JR2Q!]Q+!R'8'W.3BN>U72O">N?"J_
M\1Z)HKZ7/IUQY0S,7,B@K][)YR&_ U*J:V:[#Y=-#@M!\2:OX8O6N](O&MY6
M7:XP&5QZ$'@U=\1>.O$7BJ".WU>_\V!&WB*.,(N[U('4UZWH_P -=#L-&T:*
MZ\._VM)?1A[V]>[$?V8$ _*I89 SV]*\@\::%#X:\7:AI5M*9;>%@T3$Y.QE
M# $]R,X_"B,HREMJ#32':%X(\1>)K-[O2-/^T0)(8V;S%7#8!QR?<4FN>"/$
M?ANV6ZU72Y8+<L%\T,'4$] 2"<5Z5\-EM&^#^OB^U.;3+8W1\R\ASOB&$Y&.
M?;\:OZE';W'P:UFU\.ZY+XA1'WW$UW(2\2 AB%!'8#('N34NH^:WF/E5CQJZ
M\/:I9:%::W<6NS3KMMD$V\'<>>W4=#697JVNV[7GP4\$VJ, T]\(E)Z L9!G
M]:V;K0OA_H7BC3O!-UH4UW=W2*'U RD,KMG;T/MVX''6J]I^HN4\0HKU?0/A
MQI,'C+Q+%K#R7.E:$GFB,'#2J5+C=CT4'IC)J+4-'\*>+?A[JGB/P_I,FCW>
ME-^\A,A99%P#SSCH>W<=Z?M%<.1GEZ(TDB1J,L[!5'J2<"M#7- U/PY?BQU:
MV^SW)02!-P;Y3T.1]#7I\FC^#?!FA^&4U?19-2O]7V227(E*F'.TY49[%AQW
MP:/B?X:U'Q5\4TT[2UB:X&G+*?-?:-H8@\_B*7M-?(.30\QT/P_J?B2_:RTF
MV^T7"H9"F\+A00,Y/U%;5[\,O&-A:27,^B2F*,%F\N17( ZG .:[CX7^&=2\
M*?$^73]46);AM-:4>4^X;2ZCK^%=-X+;1;?7M272/&5WK.HR12;+"[D98PP.
M>X['C(Z"IE4:>A2@FM3YTHKU3P%X:T.;2_%UYXJTL3RZ5.2Z*[ H0&+*N"!R
M1BH?"UIX9\4>+M2N;/PA>SV:0(;:PCD C1\<M(Y8 9/3G'M5\ZU\B.4\SCC:
M65(D&7=@JCU).!5_6]!U+PYJ'V'5;;[/<[!)LW!OE/0Y'T->F?$/P?H^EZ5X
M>U:RTR/3;FYO8X+BW@N#*G.3PWJ,=1BM#5?#.D7GQVLM(N[9KBQDL"[Q2S.^
M2%8CYB<]O6E[1;CY#Q*@G S7M,?A_P $:[8>+--TW0Y+.YT1)&2\,S,TC*&Y
MZ],KC![5XH3F//J*N,N835CLK?X6^,[JVBN(='W12H'1O/094C(/6N>UC0]3
MT"^^QZK926MQC<%?^(>H(X(KW?Q3'HSZ%X8.J^+;[02+)/+%L6'F_(N2< ]/
MZUS'QFBDO+KPQ<J?M.D21".&ZA;?+,6VD_4E0"/4DUE&HV]2Y121Y!17T3I_
MP]\-:DC6,OA!].MVMP8KNXN@+EG[G8"<8]3^5<9X.T3PI!\--1\1^(-)^W26
M5\\8VNP9P-@5<9 ZM5>U1/(SRFM32?#FK:Y:WUSIUH9H;%/,N&W ;%P3GGKP
M#T]*]'\)Z9X,U/0O%/B2_P!"/V&RN/,MX!(VY(PH(3[W<_SH\)1:)KMMXYO=
M.TZ6PLX[-6M[=9W78?+?.[#8.2,X.10ZF^@*)Y(#D9HKVCP9X TM? FFZQ<^
M'_[=O=18,R-<B%8(B3R,D G SZY/:JZ_#_0[/XSV>BF$7.CW=J]RL#R$["%;
MY<@YX(R/K1[57:#D9X_17:_$"3PPE]_9?AW16LI+&XDBGN6<GS@.!C)/?/7V
MJ?X9Z'IVK7]\;[0KS69(HP888V"0ACG_ %C$C'M^/%7S>[S$VUL<'17K7Q)\
M&Z/IFCZ'JECIL>G3W,XAN+>"<RQ\^A]1C&1BNEOO#7@#3?'5CX:;PUYDNHP[
MO-\]]D77&!G.3@\_2H]JK7*Y-3P"M2W\.:K=:!<:[#:EM-MG\N6;<!M;CC'7
MN/SKT7PSX&T'_A+/%C:E%)<Z9H+-L@+'+_>(R1UP%_.M>>]T34?@?KMWH>F-
MIL#W $EL9"X#ADY!]",4.IV\@4>YXK;VLMU<16\2[I97"(OJQ. /SKKG^$WC
M5$+'1F..RS(3_.L'0B/^$CTOC_E\A_\ 0Q7I7Q,\1:SHWQ3B_L[4+F(+% 1"
MDAV,23D%>ASTIR;O9"25KL\SL_#VJ7^N#18+1_[2+,GV>3Y&! R0<].!56\T
M^XT^^GLKM/+N()#'(F<[6!P17NGB73+.X^.>@AD*M=6A><1N4)(#@'*D'H,?
MA61X;\->'M1\3^.6UJR-Q;:=.[IND?<J@N3SG).!WI*II<?+K8\;\OCK2%#]
M:];\(^'_  SXZ\3ZAJ%IHKVVDV%LA&G^;@S2G/4YX''J/>G^.? ^G1>&;/5[
M+25T34&NDMYK(7(F4AVVAL@D9Z'CWI^T5[,7([7/'R"*M6>FWVH)</9VDTZ6
M\9EF9%R(T'4L>U>P:UI_P\\'ZG!X<U70[BY9K7S)M1#L7#'.,*#[=N!Q4OPV
MN=#MO!/B]5T^6ZM8&9IFD;:UU"0VQ2,_*0 1^-)U-+I#4=;-GD=KX>U2]T*[
MUJWM=^GV;!9YMX&T\=NIZBLRO5M ,<GP4\:O;Q>5"]UNBCSG8I*87/? P*LR
M> M(\1VW@S4]#L!;VE]((]2CC9B!@98\DX^ZX_$4>TLW<.6^QY!73:/\/O%&
MOZ;'J.F:9Y]K(2$D\U5S@X/!/K2>/H=)MO&=_::):);6-JP@"HQ8,Z_>.23W
MR/PK2^%NI7Z>/=%LEOKE;0RMF 2G8?D8_=Z=:IM\MT))7LS,UKP#XF\/:<VH
M:IIOD6JLJ%_-5L$G X!KFZ[/XAZA>W'Q UFPFO;M[,7H @$A8 87[J],^E>J
MZ7\/O#.HJ+&7P=)8VSVVZ.[NKH"Y9^_R DC&<Y/Y5/M.5)R'RW=D?.]%>K^#
MM!\*V_@'6M>U_2S?MIMZ\8(=@SJ"H5>"!R33/#>D>$[O2_$WC6\T9WTJSDVV
MFF^8<*,#J<]22/8<T_:+4.4\KHKU3Q-H/AB\^&6G>(- T<V%S?7Z0X>5G*9+
M KR<$9 KM4^%_ANS>VT>;P\UQ;O 3/K#7@1TDQV3.?R&!D=:3JI!R,\ L=,O
MM3:86-I-<>3&99?+7(1 ,EB>PJKVS7N7PWBTW0]/\<:7<61N7T]G%Q,'Q]IA
M ;:GMP&Y_P!JO%+V6WGOKB:TM_L]M)(S0P[MWEH3PN>^!Q51E=M":LCN=-\+
M_$'4O!<6FV-D)-"NF%RB;XP6).<Y)S^%<]<:=XB\!ZY:75U:/8WL3>;;NZAU
M;'''4'KTKUVXCTJ3X5^$AJOB6[T)/)79+;;LRG9]TX'XUE?%>,W?A#PM/8W(
MU+1XY!&;]Y-TDC$8&>.X!R?6LXS;=BW'2YYAXB\4ZSXJNX[G6+OSWB7;&JJ%
M5 >N /6L>O7OB58>"/"=L^E6GAX_VI=VHEAG$C%8#G /+>QKH/#7@?PY>V6G
M03>#9EM[B#,M]J%P(YF?&?EC#9.>O;%/VB4;V%R-NUSQ72/#FJZ[#>S:;:F>
M.RC\VX.X#8O)SSUZ'\JRP<C(KUGP9X?LH;WX@6),S1V$3I"1,R' \S&[:1NZ
M#K4&@Z5X3T_X1V_BC6M$.H72W+1[4F9#(=Q !YQ@#V[57M-1<IY;17H7Q3\/
M:-I$FAZAHEJ;2WU.U,S0;B0I&T@C/3AOTKSVKB^97):L[!1113$%%%% !5BP
M_P"0A;_]=!5>I[$A;^!F( #C)-9U?@EZ/\CIPCMB*;?\R_-'0W%ZMM>112<)
M(OWO0U%%8"WU/SHA^Z=3D?W35#6Y$DFBV.K *<[3FI]*U(%/L\[@%1\K,>H]
M*\;V,XT%.'56:_4^W^OT:N8/#XAJT9)PEIH[+2_9_P!=".?_ )&./ZK_ "J]
M?P6<TB&ZDV,!\OS8XK/FD0Z^D@=2F5^;/'2KUW!97KJTEPH*C VN*J=U*FW=
M>[T1GAVIT\3&*C)NIM)I)_B06AL=/US3;B&7<J3J7^;.!FNU^(^GRW6CV]W"
M"ZVTA+@?W6'6O/-0M;:W$?D2[]V<_,#BNU\,>.K=;..PUEBI1=B7!7<K+Z-_
MC7?"[A&<6WZ[GRN-7+7E"45';2+NMNC//,\9KUWP7:OI7A%9+H&/<7N"&XVK
MCC]!FD$?@J"7[>ITP-U#!@1GU"],_A7->+?&T>I6SZ=IFX6S<2S$8+CT ["M
M)-U-$CB24-6S5^&\GFV^K2#@/<!A^(-6K&]L_&^CW.FWH5+R%CG'4$' =?ZU
ME?#F^M+.QOUN;J&$M(I42.%SP?6N,M]0GTW6#>VDFV2.5B#V89Z'V-')>3#F
MLD>E6>G7&E?#_4+*Y $L44XR.C#G!'L:ATKS!\+'^Q9\[[-)C;USD[OQQFK-
MQXET[5O"%Y*MS%%-);.I@=P&#8Z =_:N.\(>+1H6ZTO%9[&1MV5&3&>YQW!]
M*E1DTWUN4VDT<J.G'2BO29+/P!=3?;#=0IN.XQ"5E!_X#U_"N:\7:KH^I7,"
MZ3:"-85V&8+L#CL OMZULIW=K&3C;J<RO_'U'_O#^=%"_P#'U'_O#^=%?J>7
M?[C1_P /ZLP>[)+G_D(W/_71OYUT7@;Q4O@WQ&-6:S:[ A>+REDV'YL<YP?2
MN=N?^0C<_P#71OYUN^%O"&I>+[BY@TU[9'MT#OY\FP$$X&.*^0XDM];U_EB:
M0OT.UMOBMX?TR\EU#2O EM;:B^[_ $@S@G+<DG"YY]J3X46VN:SX[N/%(F@%
MNLLG]H.[[<[P3@+]<?3%4)_@MXIMH7EDETT*JEC_ *0>0!GTKSQ9&4%5=E!Z
M@,1GZU\THQ:?*:MM/4[CQYXB3Q'\3OM$,H>TMIXK:!@>"JL,D>Q8DUZ)X\\>
M:/X;\<(\_AR'4-1MK57M;T3;2F[<"#P>G]:\"R.U!;<>6)/N<TW33MY"YWJ=
M]X<^)LFF7VORZOIPOX-;8O<I')Y;*<$8!],''KQ2>(?B)9:OX<T_1[#P^FGQ
MZ==+/;#SO,0*N?E92.<YYYK@L@]Z,CUI\D;W%S/8]7M?B]I5C*=0M/"26^JF
M'RBT-R4@/OL Q^F?>N=\.>.[/3X=1MM<T&WU.*^G:X:5"(ID=CDX<#.,\@ C
M%<51D>M'LXAS,['QSX\;QA'I]I!8?8K"P!$4;RF5R2 ,LQ]A6=X+\3MX0\3P
M:N+;[2J(R/%NVEE88X/K7/@@]#13Y5:PKN]ST.Q^(^FZ5XFUG5-/\/&&#4K7
MR#;K.!M<DEI"<<Y)Z5BZ?XP6Q^'6I>$S8M(U[/YOVGS,!/N\;<<_=]>]<M11
MR(?,STK3_BCI[Z7ID'B'PU'JEWI:[;6X\[;P!@;E(.> /4<=*X36M4;6M9NM
M1:V@MO/?<(8%VH@Z  50HH44M4)ML[SPA\0+#P[X7O=!U'0/[4MKN8RR*TP5
M2,+P1M.>5S5G5?B=9MX8N]"\.^&;?1H;S(G=) Q(/7& .2.,FO.J*7)&]Q\S
MM8ZS4?&AO? VB>'8K-H)=+F\Y;KS<[B"Q&%QQ][U[5U*_%_3YYK75=1\)6]S
MX@M8]D5X)=J_7&,CJ?S.,5Y510X18<S.TT#XD:GI'BG4=:NH([U-3XO+=CM5
MAVV]<8''?BK.O_$.SNO#,WAWPYH$6C:?<OON</N:3H<=.!P/P&*X*BCDC>X<
MS/1[#XH6?]@:;9:YX;AU6\TK'V*X>7:%Q@*6&.V![' K"\:>-9?%7B1=8MH9
MM.<6ZP[4G)/!)^\,<<]*Y6BA0BG<')M6.L\%>-I?"GB-]7NH)M29K<P;7G(8
M9(.=Q!].E=-:_%;0=(GFO-$\"VMGJ$BL!<&8'KUSA<_K7EM%#A%N[!2:.OT?
MQW)IVA>)K"YM&NKC76+O<"0*(V(.3C'/)]J?X%\<Q>$K;4[&\TW[?8:B@65$
ME\MQ@$<'T()KC:*;@F+F9WOB'XAV&L>'=-T>S\/_ -GPZ==I/;A+C<H52?E(
M(SDYZYZU/-\4(YOB5;>+O[(<+#;&W^R^>,G((SNV^_I7G=%+DB/F9VNB>/DT
M>Y\43'36E_MQ74 3 >3NW=>/F^][=*XG;\FW/;%+15));";N>I3_ !3\/ZCI
MVGVNK^"H]0:R@6&-Y;@'&  2!MXSBL7Q/\2;K7M2T>:UTZ"QL](D66VM0=PW
M C&3@<8&,"N'HJ53BA\S9Z\OQFTJ+73K4?A(_P!H30B&XF-WR5'0+Q@#/M7'
MIXTBB\ ZGX7CTYP+R\:Y2<S#]V"RD*1CG[O7-<D%8]!3UCSUH5.*!S9TVB>+
MAI7@G7/#GV%I6U3I<"3 CX ^[CGIZU)X2\7+X7TK7+%K(W)U2#R0XEV^7PPS
MC!S][]*YD8 HR.PI\J)YF=SH/Q"LK3PS;>'_ !!H*ZM:6<@DM6$NQDP20#ZC
MD_AQS3+3XA+!\0H_% T6&*&*)HDL[=A& "I&2V.3SDG%<2.:0\4<D0YF7-3O
M/[1U:\O?+V"XF>79G.W<<XSWKI_!7C>'PO9:GIU[IGVZPU!0)$23RV'!!Y]"
M#7& Y[YI"3G@4W%-68)V=SN_$WCZQUSPYI^CVFA?V?%87"R0;)]RA!GY<8SG
MGKGK3]2^)":C\0=-\4#2GC6RC"&V,X)?[W.[''WO3M7 Y/I2J<#-+DB/F9W6
MC_$272O&.LZS_9RS6.KL3<63OV/3#8QD9(Z<YJQJWQ&TRY\'WWAG2O#2Z;9S
ML#&4GSM.X$EACDG'K7G^2>](?K2Y(WN',R>PN19:E:W>S?Y$R2[<XW;6!Q^E
M>G7?Q:T&]U5=5E\$0RZD@ CN);A6*XZ?P]J\I((YHIR@I;@I-;'80?$&\;X@
MP^+-1MQ<21Y5;:-MBJFTJ%!.>F<^_-6=-^("6%UXKF.FL_\ ;PD 43 >1N#=
M>/F^][=*X;'(.*-W/2CDB+F9TW@OQC+X-OKAQ:I>6=U%Y5S;NVW>OJ#V/)_.
MKGB3QCIFI:1;:7H?AZ#2K>&03>:2))2P.0 V,@9]ST%<82">E/XHY5>X7=K'
MJ,?Q>L9)+;4[_P +07.O6T)BCO/-P/KC&1UZ>YQ6)X5^(B:-/KIU72UU&#66
MWSQHPC /S9&,8VD,17$$?E32N#D4O9QV'SL["V\:6]IX0U_0(-,,<6ISF6)A
M+Q N00N,<X QVKT;P7/J'@'X7:A?ZO-;B.4?:-.B63<S%T&!^)P<=N:\)R :
MD,CN K.S*O0%B0/I1*FFK I-#79I7:21MTCDLS'N3R36IX7UA?#GB:QU@VYG
M^RN6,0;;NRI'7!QUK*(I!P>:MJZL3MJ:^KZ_)?\ C.?Q'!;B%Y+M;I(7.X*1
MC )XSTKT$?&;2X]=76U\)$ZD\(@GF-WSL'9>,#G':O*"::0#VJ7"+*4VCJX_
M&\47@G7/#D>G.!J5V;A)C,/W0+JVTC'/W<9XZUU/P>>ZGTW7-/C_ +.O;>4#
MS-+NWV--E>JM@C!Z'(].E>4%/2D!96#*2K#H0<$4G!--(:EK<]M^*-TNG_#7
M2M)FMK/3;\7BR1V%I)O$*)NQS^(Y]36'_P +:TV[-O?ZOX2M[W6[> PK<M+^
M[8>I0C_'J<8KRYF9VW,S,WJQR:2DJ:M9C<W<[;P=X^C\-WVLR7VE)>VVK+B:
M")A&%Y;@#&-N&(Q]*Y+4)K>YU&YGM+46MM)*S16X;<(E)X7/?%5J*M12=R;O
M8]+M?B;HC>%]+T36/"":FFGQA$>6X&"0,;@-O%9?B[XB'Q'IMAI-AI,.EZ59
MR+(MO&^[<1TY   &3V[UQ%%2H13N/F9U/CKQ@/&6NVVIQV1L_(MUA"-)YF2K
M%LYP/7I78GXR:?+?Z?JUSX56;5[2+R?/^U$*JG[VP8X)R>O2O):*'"+5@YF=
MWIOQ$ATW4_%5VFE.R:ZK!4\\?N"0W4X^;EO:LQ_%ZM\,X_"'V%@R7/G_ &KS
M.#\Q.-N/?UKEZ*?(@YF=5XO\8KXIT_0[5;%K8Z7;& L9=_F<*,]!C[OZURM%
M%-))60F[A1113$%%%% !4UI]G^VP?:PQMO,'F[3@[<\X/TJ&B@#H6MO#&V(I
M=3C*(9 6.5)8[\?+R0,8'N:E^R>$?EQJ%Y_K)0V5_@ _=GIU)ZUS-%3;S'<Z
M*VL_#!V?:+^<9D3=M!X4H">W][<,^PZT6]IX7+ 3WD^/-4$C(^3#;CT]=OYU
MSM%.WF%S:TRW\/O"AU"[GCE^T[6"#Y?)P?FSCKG%30VGAKRG,U]/N_=[ H.1
M\Q#9&/3!_&N?HHL%SH#:>%_LJLE]<_:/LJLRLO'G;OF4''3'2JLUKI*:R56[
M+:8QDV,I)=0%.W/'=L?A63118+FWJMIX>6/_ (E5Y+(Y6/FX!&#M)<8 YYP*
M]1LO"WPDDL;=[C6(5G:)3(/M^,-@9X^M>)T5+BWU&I6Z'N7_  B?P=_Z#,'_
M (,*7_A$_@]_T&H?_!A7AE%3[-_S,?.NQ[G_ ,(G\'O^@U#_ .#"N1^(6B^!
M=,T:UE\+7\=S=M<!956Z\W$>UCG';G'->=44U!IWN#DGT&K_ ,?4?^\/YT4+
M_P ?4?\ O#^=%?J>7?[C1_P_JSG>[)+G_D(W/_71OYTTLRJ=K,O'8XIUS_R$
M;G_KHW\Z81D8KY'B+_?%_AC^1<=CU?XSNXB\*X=AG3^<,>>%K.UW3+"'X%:'
MJ,5E E]+>%9+A8P)&'[S@MU/0?E7/>*O&%YXN&FI<VD,!L8?(C\DD[QQUSWX
MKH-*\8>(_"OA1=*U'PLEUI\4GF02:A;.%B8G([8/)R/K7S"344C:Z;9TWB'0
M=)M_B5X&LXM,M([>Y@!GA6$!9#@_>'?\:V[*'PKJ?B/Q3X?E\)Z<EGI:";S$
M0!Y&ZMR.GM@UYIK?Q!UN]\4:%X@O])AM[BQBWP(0ZI.IS\W/;Z57LOB-J%CK
MVNZLEA:M+K$9CEC9FVQC_9_^O4\DFOZ[CYE<Z7Q)'I'B3X26WB.VT2RTN]6^
M%NGV9=HV%]N#CKP0?J*W=5_X1KP-K'A_PH/"UIJ"7Z)]HNIT#2,6;9D9')SS
MCTQBO*_^$MNO^$#'A+[+#]D$_G^?D[\YSC'2NHLOB]K%G:6<&H:)87U[:(!;
M7=S&1*H(P#]<8Y&,TW"0*2.GT#P7HFG_ !EU?1GLH;K3Q8">*&=0XCW%>!GT
MYQ[&L/1M=\(^)/B'9+J&@V.FZ;;1211(%!263=\ADP!V!X/&:RM/\3^+_#GB
M2_\ %=_HMQ//=1F.5[J"1(U!(QC'0#  KG/"_BG4/">M_P!J6 B=V4I)%*,K
M(I.2#W'..:?*W?T%S(]3^(^@*?!D]_!H>BS+#)N74-*;R_*CR -RX.[T//?-
M>(UWNJ?$#4M>T&\T/2/#]II]I,#/>+8QEBRC!8GC@=,FN"JJ::5F*33>@45)
M!!-=3I!;Q/+,YPD<:EF8^@ I)8I()GAFC:.5"5='&"I'8BM"!E%%% !1110
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MD,WRX&,9YKAF)4[2"".H/%4G<35A0!WH('K30YI213$!.!3<9Y%/ZB@].*
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MZ;;ZOI5[+-=-&69KHEIKH@@;>.Z]"YPO09.,UYR^Y6*D8(.#6T7=&30K9_\
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MJ75S)I\2D!UDDR%('#97/TYK'^)%S9+XC71-,!&F:0IMXE!S\[,7D/UR<?\
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M;DJ&.]6:/=RN]0<IGMD"K^G^!=3UGPO;:OI2?:99+B6%X-Z(1L (VY(+$Y/
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MFN47$C[?O'\:>D7?<AN[&:Q+_9MG=:C9V"W%\$"_*GS,/<CD@=<5FW&O'3M
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M,H(93[?-Q6CJ7AK0]&\,^)[6*XFO-7T][:.=Y8 J1,6^;RCG)'8YQTJIX0\
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M.,KN,ER?;I22LK%SES2<NY;"!>!C\*J23B14PX 8;J)+B*")I9MJ(@W,Q;
MK+TV3%N)I\*6SY<8'W4R2,^^,47UL)1]UR9?P<$AR?K5.XLW#^?;S.LP.X!W
M.S&?F&!V(_I5G[0C1]3SP>.E,DE#C:N=O<GO3M<49N+NCQSXBE1XK;_K@G'Y
MUR><UTGCN9;CQ?>;6R(PL?Y#_P"O7-CK7?#X4<4MV,/WJ<?N4AX:G'E*L!%/
MRT$YXH4?+3>] "=Z<>5H(YI>] A#TI!T-+M)H"T@$/*?2E4Y I=ORT<*,^E
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MN62&_5(W4G<VUC@ $')QCZ$UIIX9T[^R8X&\.QK8/HC7TFM9<-%<[2=F[.T
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MJ8S?0;24ZBMC,::81FI":2@!JCM2-Z4^FD4 ,'6GXHQQ1R30 ;:0BG4>YZ4
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MGM#J]E);3:?=J8FNHHT$[%RJ^3MW,W3#D^F*.=]@Y4>6:AX9U33+%KR[@18
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MH **** "BBB@ HHHH *;3J* &THI**!CJ*04M @HHHH **** "BBB@ HHHH
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MWI+(ZU_;5Y]L6$:=_P NY4C)]/?USFM0:5X@QC;IG_?U_P#"C^RO$']S3/\
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M)?\ (WZ3_P!?2?SKZH/WC]:XZ_Q'12^$2J6KZM9Z'I5QJ5_(4MH "Q49)).
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MT5JJR2B(@HKMU900.*5IA>)U"?#"#4YKN[-Z]FEUJ%W#9I'&GE0K'(RCS"S
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MVR\LH+2UGMX8+G!5YF92I<K\R@KD' R*S]<\):5IGAZXUZ*2=K*\BMO[*5I
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MVZZG;>P9LR,=Q'0GU(['M2/=RRJ5DN)74N7(9R06/5N>_OUIQRS&1_Y=2_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH W/!ME;ZCXSTBSNXQ)
C;S72+(A)&X9Z<4445\!Q5B*U+$4U3FTN7HVNIUT$FG<__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (W ]D# 2(  A$! Q$!_\0
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M *-2O?P<YYK]!SK.L3@,2J%!1Y>6+UBNQR4Z:DKL\+'P>\:'IJ-E_P"!;_\
MQ-+_ ,*<\:_]!"R_\"W_ /B:]SWXIXD->,N*L=VC_P" K_,T]A$\)_X4WXV_
MY_[/_P "W_\ B:/^%-^-O^?^S_\  M__ (FO?(I,\9JQ3_UHQ_:/_@*_S%[&
M)\^?\*;\;?\ /_9_^!;_ /Q-)_PIOQM_S_V?_@6__P 37T)11_K1C^T?_ 5_
MF'L8GSW_ ,*;\;?\_P#9_P#@6_\ \31_PIOQM_S_ -G_ .!;_P#Q-?0E&:/]
M:,?VC_X"O\P]C$^>_P#A3?C;_G_L_P#P+?\ ^)H_X4YXV_Z"%G_X%O\ _$U]
M"9HS1_K1C^T?_ 5_F'L8GSW_ ,*<\;?]!"S_ / M_P#XFC_A3GC;_H(67_@6
M_P#\37T)1FC_ %HQ_:/_ ("O\P]C ^>_^%.>-O\ G_L__ M__B:/^%.>-O\
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M&BC_ %HQ_:/_ ("O\P]C$^?O^%/>-?\ H(6?_@5)_P#$T?\ "G?&O_00L_\
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M_P!G_P"!3_\ Q-?0!8 4PGFC_6C']H_^ K_,/8Q/!!\'/&Q&?M]G_P"!;_\
MQ-'_  ISQK_T$+/_ ,"W_P#B:^@TQMI#]ZE_K1C^T?\ P%?YC]C$^?#\'?&H
M_P"8A9_^!;__ !-)_P *>\:?]!"S_P# J3_XFOH0\K4/>C_6C'=H_P#@*_S#
MV,3P+_A3WC3_ *"%G_X%O_\ $T?\*=\:_P#00L__  +?_P")KZ  S0PH_P!:
M,?VC_P" K_,7L8GS_P#\*=\:_P#00LO_  +?_P")H_X4]XT_Z"%G_P"!;_\
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MV]31_K/C_P"[_P" K_,/91/!O^%-^-O^?^R_\"W_ /B:3_A3GC4?\Q"R_P#
MM_\ XFO>O,;UHWT?ZSX_^[_X"O\ ,/90/ S\'_&@ZZC9?^!;_P#Q-)_PJ#QG
M_P!!"S_\"I/_ (FO>V.>](#1_K/CNT?_  %?YB]E$\%_X5!XS_Z"%G_X%2?_
M !-+_P *?\:?]!"S_P# J3_XFO?!2%CCBC_6?'?W?_ 5_F'LHG@G_"G_ !I_
MT$++_P "Y/\ XFE_X4]XT_Z"%E_X%O\ _$U[QACWIZ9%'^M&/[1_\!7^8>RB
M>"?\*>\:_P#00L__  +?_P")H_X4[XU/_,0L_P#P+?\ ^)KZ HH_UHQ_:/\
MX"O\P]C$\ _X4YXU_P"@A9_^!;__ !-)_P *=\:_]!"R_P# M_\ XFOH+'%&
M*/\ 6C']H_\ @*_S#V,3Y]_X4[XU_P"@A9?^!;__ !-'_"G?&O\ T$+/_P "
MW_\ B:^@\"@"E_K1C^T?_ 5_F/V,3Y]_X4YXU_Z"%G_X%O\ _$T?\*<\;?\
M/_9_^!3_ /Q-?0>*6C_6C']H_P#@*_S#V,3Y\_X4WXV_Y_[/_P "W_\ B:3_
M (4WXV_Y_P"S_P# M_\ XFOH2BC_ %HQ_:/_ ("O\P]C$^>_^%.>-O\ H(6?
M_@6__P 31_PIOQM_S_V?_@6__P 37T'2BC_6C']H_P#@*_S#V,3Y[_X4WXV_
MY_[/_P "W_\ B:/^%-^-O^?^S_\  M__ (FOH2BC_6C']H_^ K_,/8Q/GO\
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M*?\ ^)I/^%/>-?\ H(6?_@4__P 37T'SCKFFD<T?ZT8_M'_P%?YA[&)\_?\
M"GO&O_00L_\ P*?_ .)H_P"%.^-?^@A9_P#@6_\ \37T 1S3@M/_ %HQ_:/_
M ("O\Q^QB?/P^#GC8]+^S/\ V]O_ /$U&?A%XR!(_M&SX_Z>I/\ XFOHF-3D
MT_R4)^XII?ZTX[M'_P !7^8>QB?.\?P<\;2KE+^S(_Z^W_\ B:<?@SXW7K?V
M?_@6_P#\37T4J", *H H89'2E_K3CNT?_ 5_F/V$3Y.\4^&/$7@F6S.H7PWW
M&YHFM[AR1MQGL,?>%:G_  G_ (K_ .@[>?\ ?==5^T&NV?P__NW'\XZ\QK[3
M SCC\'3KUXQ<G?HN]CGE[LFD=3\+?^2CS?[K_P#HU*]]'#"O ?A;_P E'F^C
M_P#HU*]_/+ 5\5Q5_OR_PQ_)G30^ 1N&]J0'G%+)U(I,=#7RQN2(</5U7!QF
MJ SO%6 U4F2RWP>E)BH%EP?>K 8,,XP:H0E&,TM% "4F*=0: &XHQ2T4"$YH
MI:0T )BC%+10 E&*6DI@)BBEHI )24[%&*8#:*6BD E%%% !FDI:#0 W-+GF
MG[?ES3*8#@21Q2\XYH4$4K=.E(!O>FGBG'BFGF@!,TAHHQ3 ::3-.9<#-,SD
MTQ"9HS2&@=* ),T TE%(!:,TW-&: '$TV@FC-,">,\4YN#44+=JF8< U(Q.J
MU 1AJLH>,5'*N#FF BT,10M-(I .'2H)/O=:L?PU6?K3$1THZ4E&:8#Z*;D4
M;J 'B@4S<:,YH DXI,BFY-'- #MP]:0MQ28HH -U)FEQ10 E/&::.M2"@  .
M*7;2BG=S0 @ IP% I:0Q>U+1BB@!>U%':EQ0 "BBAF"T@%HJ/SEIRN&- QU+
M11D4 -[TX<4F11F@!:1FQ1F@@D4 0F5B< 4FYS4P3VI=GM0*PU2<<TZC I<4
M#$S2<T[%)0 G-)@TZB@!N*7 I:,4 -Q13L4F*!"4&EQ1BF VD/2GX/I32.:
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M'-$U.1II3YTM[<RDM"@&" QSC)QTKT;P?X?\/Z+X-\0R^'-5FU&VGAE5Y7
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M?05:L,36EAJNC3]U_H'@9U_X3&$>TE7?B6^-9M0>\!_G63X"8GQA;DGDH_\
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M>-Y5MY=J,Q49..WX5T/B?P'H/C"XMY]8AGDD@0I'Y4Q3 )SS70V\"6MK#;1
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MVUQ8FQN(4FM3&(FCD&X,H&.:XF?X&>"KJ=I5M[V ,<^7%<?*/ID&O088R[#
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MJ$R/_=/Y4@>0_P !_*@":BD .,D&EP?2@ I*7\#2$^Q_*@=@HIN3Z'\J"_\
MLG\J!#JC=]O04&0_W3^5,+'^XWY4Q#?-<]C2!W]*4L0.$;\J;N?^XWY4P)U.
M1S3L@=ZJ[I/[C?E329?[I_*D!:W"FEL56_>?W6_*C;*?X&_*GH*Y8\P T]9
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MR6D<=J_^CEETMCA@#\^1C/O0)+68-/(+</)I9+;0!\^?3UI\GF9^WT^#\/\
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MS_K'_P"^S2[W_OO_ -]&J]B^XG4\CZ'&W^^G_?0HR/[Z?]]"OGC>_P#ST?\
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MJ?SO_P >,G\1]10Z5NH^<]H*'/\ #_WT* ASU7_OH5X$'?'^L?\ [Z-&]_\
MGH__ 'T:/9/N+G/H92 .67_OH4A(_O+_ -]"OGOS'_OO_P!]&CS'_OO_ -]&
ME[+S'[3R/H/C^\O_ 'T*CD7=W7_OH5\_^:_]]_\ OHT>8Y/^L?\ [Z-/V/F'
M.NQ[YY1]5_[Z%.$/<L@_X$*\"\U_[[_]]&C>_P#ST?\ [Z-'LGW%SH^A%"XP
M77_OH5'+&K?Q+_WT*\ WO_ST?_OHTAD<?QO_ -]&E[)]Q\Y[PT;9[?F*9Y3=
M@/S%>$%Y ?\ 6/\ ]]&CS)/^>C_]]&G[%]Q<Y[P(FST'_?0JY"B!?F*Y_P!X
M5\]^9)_ST?\ [Z-'F/\ WW_[Z-#H^8>T/HH%%/#)_P!]"GF51_$O_?0KYS\R
M3'^L?_OHTGF/_P ]'_[Z-+V/F/VA]%FX4=Q^8J+SR#QC_OH5\\[W_P">C_\
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M3QRX6?[C9QRE<#6[\1AA]-^DG_LM85?KF0RYLKHOU_\ 2F?.8RBJ->5-=/\
M(Z'X>?\ (Z:C_P!>\W_H:U=7[HJC\/?^1TU'_KWF_P#0UJ^OW17S/$?^_?\
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MI9&*G:<C(]Z9BI9T6.XECCD$J*[!9!_$,]:CK8S$Q1BEHH 2M.W_ .19O?\
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MT<[#ZK2[&])XC=GLVCM @M9C*H:0L6SU!)^M,776B6=;:U6+S)EG'SEL,/\
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MX_[]-1]@O?\ GSN/^_35[29I?^>C?G2>=+_ST?\ .E[1ARH\7^P7G_/G<?\
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MI/.E_P">C_G1]6\Q_P!LR_E/._L=S_S[3?\ ?LT?9+G_ )]IO^_9KT/SI?\
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MM6E4:M<ZCX7?\E&G_P!U_P#T:E>[&O"?A=_R4:?_ '7_ /1J5[K7R7$W^_\
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M_P!\T<R'["IV)L-_SSH^?^X*A_M6V]9/^^:3^UK;/_+3_OFCF0?5ZG8GVO\
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M12T4 (.M2W/_ !\O]:CJ6Y_X^)/K_2@?0AHHHIB"FMUIU,/+4"'CI2T@Z4M
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MH&)!IM.PKEC_ $;/_+7\Q1BV'_/7\Q56ESF@+EH"W/\ #+^8IV+?TE_,5"O
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MN7_=_K0P&;(/^FOYBE\NW_Z:_F*:*7\* N+Y=O\ ]-?S%&RW_P"FOYBFT=J
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M:^XK..*UM)T@W)%Q<J1#_"G][_ZU.GS7T(Q,J:IOVATJLKHKH=RL,@^M+2*
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M>"V4&1DMF/.=NT>ISVJI:>$M1TW7M-U.TU"VQ#IJ:?=1R1D[U7NA[$^]5O\
MA [O_A";/0(]1A$]K=_:=S(WE2C>6V.!R1SS1J+0U9/B!H/]D1ZGY]P+=[DV
MFWR#YBRX^Z5ZYJ2V\9Z3<Z)-JD(O)(H)O(EB%N?.1_0IU%8=M\/KJU@AB%_:
MC9K*ZF1'$44 #!11V]J74/ -[=2WDL6H6VZ?5O[1$4T;&)UV[=D@!Y]:-1Z&
MJ_Q!\/BPL[I)+J;[8[QPP16Y:4LGW@5[8J?5?&.DZ*UN+X7<23HL@E^SDH@8
MX&X]OI7-/\-[X>&SI$5WI;YNI;@326[JT)<\&,J<J1^5&L_#2^U22XSK$$RS
MVL,)ENXF>1'CQRAS@!N_>B['H=%HVL7=]XP\1Z=*Z-:V/D&W 7!&]<G)[UT7
M6L32/#\FF>(M9U1[B.1-06!5C4$%/+7!S]:W<"FB6-J:#_EK_P!<S4>*E@'^
MMY_Y9FF!":2G;:0B@0E.'2DP:7I0!QNO^"KO6-:O[ZVUB*TCOK1;2>)[02G8
M/[I/0\U>TSPA%I6KO>17DC1'2X]-$9'S!5S\V[UYKH^]+2LAW.!T;X:G2;NU
MG.K+*+6&>! +8*660'EF!RS GJ:N:7X&&E/92?VB9/LNE2:;_JL;MY)W]>V>
ME=EFHY.E%D%V9&@:3_87A^RTH3>=]EB\OS-N-WOC\:Q&\#LGA.TTF'4S'<V=
MZ;V"Z\K(5]Q8 KW'-=:.M/? %)H+G%Q_#^5[>47&LF:>;58]3DE, &YE'*X!
MX!_2KMWX*-W;ZK$-0*_;]5CU+/EYV;,?)UYZ=:ZF,_(*D%%D%V<5/X"\S4)D
M&K2+HL]^-1ET_P H;C,.>).H7(Z5;L_"LUCHFJ6$%_&7O[N2YWRVX=%#')4H
M>&%=.W6D )/%%D%V8OA'PT/"^E267VK[09)VF)";$3/\*+DX7VK>/%*H I#2
M 3&>M,"#-/I-V!2 L6X43Q_6J\A!X'K4EN<W*>F:A'^LQ56!DG3BD84M**H0
MS%,8\U/QCI3<#TI6+YB"F-5L8QTIN!Z46*YRGGBD)[5> &>@_*@A?0?E2Y2O
M:%.'&X\C[IJ$GCK6M J^8WRC[I[5$54@?*/RI<NH_:^1F$\TF:U-J_W5_*G!
M$Q]U<_2CE*]MY&/[YIAZUL[%Z;%_*CRU_N+^5'(-8A=C%)&.HIA(K=\M/[B_
ME1Y:'C8OY5/(5]978P:1N*WPB9^XOY4[8AZHOY4>S']978YHD&G1']\O(KHC
M''_<3_OD4^WBC^T+^[3KZ"E[,KZVNQRWXTTXR.E=2(X\?ZM/RI#%'_SS3_OF
ME[+S']<78Y3(SU%)GWKJ_)B_YYI_WR*7R8O^><?_ 'R*/9>8_KJ['(EAWII(
MQU%=AY,7_/*/_OD4GDQ?\\H_^^12]D4L?Y'&DCU%(6'K79&*+_GE'_WR*/)A
M_P">2?\ ?(I>R\Q_V@OY3BRP]:8Q&.M=L8(?^>,?_? I#!%C_4Q_]\BCV/F5
M_:*_E.&+#U%)(1LCY_AKMC##G_4Q_P#? J26"+RX?W,?W/[@]:3H^8UF7]TY
MK2M',VVXN%Q&/NH?XJZ,<    #L*.WM16\8J*T/-K5I5I<T@HHH[51@)113&
M-)C'T5%11<+$PIZ#FJU2)+MQGD4 6#4L1_=S?[O]:BZU+$/W<W^[_6@9'GUI
M:;S1F@0ZBDS10 [-%)2T#$(I!3C3>AH$.Q24M)WH&%23_P#'P_\ GM4?>I+C
M_CX?_/:@"*BBB@!<9%)O"\4H^Z*:R[J8A0XI=XJ I@TA6@18#BC<*K\[*.?6
M@"<-\U.W"H>?+S49)[4 6LCUHR*J!R.].$C=J +51R)GO4.]A0)3BF ;6!J=
M3A:@WT"3VH \C^.)S/HG^[/_ #2N KO?C<<S:)_NS?S2N"K]3R3_ )%M+Y_F
MSFG\3.H^%W_)1I_]U_\ T:E>\5X/\+CCXC3GKA7X_P"VJ5[O]K'_ #PB_6OD
M.)_]^_[=C^3-J?PBTHIOVH?\\(OUH^UC_GA%^M?-:FF@X4\'(J+[8/\ GA%^
MM+]L'_/&+]:>H]"0]*:>13?MG'^HB_6D^U_],(OUI:AH!44=*/M8_P">$7ZT
M?:O^F$7ZU-AW'+3CQ3/M8_YX1?K1]K_Z81?K32%H/ZBD%-^V?],(OUI/M?\
MTPB_6GJ&A(#4H/\ H[_[PJO]K_Z81?K4B7.;:0^3'PP&.:-0$X/6BD^U#'^H
MC_6D^U#_ )X1_K3U$/XQ013?M?\ TPC_ %I?M7_3"/\ 6C4-"-OO4+]ZE-R,
M_P"HB_6D%R!_R[Q_K1J+0'ZTM!N03_J(OUH^TC_GA%^M ] -(.M+]I7_ )]X
MOUH^TC_GA%^M :!WHH^TC_GA%^M+]J'_ #PC_6@-!*F@(Q+_ -<S4/VI?^>$
M?ZU+!<!O-_<QC$9/&:3&K$0)[TK'BD^TC_GA%^M(;H'_ )=X_P!:>HM!0U+F
MD^U#'_'O'^M'VD?\\(OUH 7/-%)]I'_/"+]:7[2/^>$7ZT!H&*AE/.*F^U#_
M )X1?K49N5)_X]XOUH%H1H.:63I4@N%S_P >\7ZTUIT_Y]XOUHU'H$1^6I :
M8MPH'%O%^M/^TC_GWB_6C4-!IZTY3BFFX7/^HC/YTOVE?^?>/]:6H:#^M(:;
M]J'_ #PC_6@W8_Y]X_UI6"X$X%-W>U*;H?\ /O'^M'VA?^?>+\S32"Y+:D?:
M$^M1+R[&I+:<-<QCR(QD]1FFK< ?\N\77WH'T'4M-^TC_GA%^M'VD?\ /"+]
M:8M!Q'%-/ I?M6/^6$7ZT?:_^F,?ZT!H-YIPQBC[6/\ GA'^M'VL8_U$7ZT
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M)Y?\&>*4QA5-)]LYSY,?ZTC7@(P8(_UHU#0KG[U*.*?]H7_GWB_,TGVA<_\
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MU_"JY6E<2DF:%%%!Z5!08HHH/M0 5/;_ /+;_KD:@J:WZ3?]<C0!#11FCO0
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M-M "[J0L>W%&VC;0 Y?F-*4'I30"#Q3]U #=@]Z<  .*,BDX- "U-!_JY_\
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MMM&T4 -HIV*,4 -HIV*.W% 'D7QJ_P!;HO\ NS?^R5PM=U\:_P#7:+_NS?\
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MV5$([<1A&&0,;R",;L=ZZ2UA>WM8H9;B2YD1<--)C<Y]3CC-24M KABC%%%
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M0A@M\_ZR7\A1Y%M_?E_(4PG'6C> >M,!WDVW]^7\A3?+MA_'-^0I=ZTPE#0
M\0VYZ-+^0I_DV^0 \OY"F#"KQ2I][- #V@@_OR_D*;Y$']^7\A2N>:;S0 OD
MV_\ ?E_(4OD0?WY?R%,QEJDVT )Y$']^7\A2>5;9QOE_(4N,=Z0]:0"^1!UW
MR_D*#!!_?E_(4J\4N,T#&^3;?WY?R%--M;]?,E_(5)@4WI0 ZW@A6XC*F4G/
M<#%0-%;@GYIOR%6K;_7)]:CQWHN!7*6P/WYO^^11MM?^>DW_ 'R*L;0>HI#$
MA[4"(-ML/XYOR%*!;?WYOR%/:!3T)%1FW(Z&BX"YMA_%-^0I<VO]Z;_OD5'Y
M+XZ4PHPZ@T7 L?Z*>-\O_?(IVRU(XDD_(54Q10!HP1P;SM>0G:>H%1^3;XY>
M7\A4-JQ\T_[C?RJ(.P'!H0V7/(M_[\OY"CR+?^_+^0JL)F'O3A/ZBF(G\FV_
MOR_D*/(M_P"_)^0J+SE-.$BG^(4 /\FW_P">DOY"CR(/^>DGY"D!![BEH /(
MM^[R?D*/(@_OR?D*** #R(/[\OY"I+>&$3H5>3/N!3*DMS^_7_/:@9%Y%OC[
M\OY"CR(/[\OY"ES0<8H$)Y%O_?E_(4>3;_WY?R%+10 GDV_]^7\A1Y$']^7\
MA2XI* (Y8[90 7EY] *CV6O]^;\A23G,GT%1XSBD!;C@MRH/F2_B!3_(M_[\
MGY"FKP@HW4#'&W@_OR?D*DEBA,<(+OPO' ]:BW>]22G]W#S_  _UH 9]G@_O
MR_D*3R(/[\GY"DS[T9% "^1;_P!^7\A1Y%O_ 'Y?R%)D49H$-:WM^H>4_@*9
MLMNS3?D*ES3'C#<@X-,!OEVW]^7\A32EJ/XIOR%(59>H)II(- AP6U/\4WY"
MGA+;^_+^0J%5[TN:!DWEVP_CE_(5)$EN(YL/+]SG('K5?.:FA_U4_P#N#^=)
M@1E;4#[\WY"FXM?[TWY"F,>*90,FQ:_WYO\ OD4;;7^_-^0J#%*:5P)MMK_?
MG_(4HCMB?O3?D*C0<9-.JA#RMLO\<WY"G*ML_1Y1_P !%1>U-!V/0!;\BV_O
MR_D*!#;X)WR_D*3(*Y!S0O7%(8>5;Y^_+^0J:XA@,[EGD!SV J \&K-QCS6^
MM %<P6X_CE_(4ODV_P#?E_(4]A0%H 9Y-O\ WY?R%'D6_P#?E_(5)@4A H 9
MY-M_?E_(4GDV_P#?E_(4XK1M- #?)M_[\OY"CR;?^_+^0IVWFC% ">3;X^_+
M^0I/)M_[\OY"E Q1B@!/)MO[\OY"E\FV_OR_D*3%&* %:W@'\<OY"D\FW[O+
M^0J3((ZBFD#UH 3R+?'WY?R%)Y-O_?E_(4M(.<T"/'OCDD:3:'Y98Y6?.X?[
ME>?5Z!\<O]=H?^[/_-*\_K]5R3_D6TOG^;.6?Q,ZGX6_\E'F_P!U_P#T:E>[
MGK7@_P +?^2CS?[K_P#HU*]X/6OD.)_]^_[=C^3-J?PA2YI**^9-!<4F**6@
M!.E+FBB@84M)10(6C)I** #-%%% "XR#42'%K(>_F+_6I1TJ(?\ 'K+_ -=%
M_K0-$98L>324VCF@0[.*<,&F@X[4XL,\"F(7 K-U757T\PV]K$9[ZX.(HLX
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ME?JF2?\ (MI?/\V<D_B9U'PM_P"2CS_[K_\ HU*]X/6O"/A;_P E'F_W7_\
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M3F=-/OK*[D0;W$#J[ >IQ_.BP^;R/)K*]FTKP3KPM-7OX]:35@LB-(Q,2&;
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MXK:WFC/W8&'1<CIWI9[K6].&I7">)=1E32]<BL8HY64B2-B-V_CD\UZJ(8,
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M8XUVJHP .U+D^M !IWR]ZZK'AMZZCHSP:DS35"XI>*9# @4S8<T\\<4A/I0
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M@4H4 YS2YHS3 4GTI*,T4 2VW_'PG7K46>:EMO\ CXC^M1=S]: 84'BCM10
MF>*!00#Q1M]Z!$T/.34N:JQDJX'2K$C[,<4F4AQ)]:0G!IGFJ>#D4NX'H<T!
M<F@/[P_[IJ+/'>I81^\;_=-0TACBV1WIOYT44"#MWIQ/R=:;FC/&* $R3W-
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M_P#9*X&O0/CD/WVA_P"[/_-*\_K]4R3_ )%M+Y_FSEG\3.H^%W_)1I_]U_\
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M1L;>U $>7]#3U=J;@>HI4.#UXI@.Y)S3E'K3\#M3<XI !HS2$BBD,#24II*
M"BBB@0AHHHH&>/?''_7:'_NS_P#LE>?UW_QQ_P!=H?\ NS_S2N K]5R3_D6T
MOG^;.2?Q,ZKX5C/Q)E'J&_\ 1J5]%-80$DX?/^]7SK\*_P#DI4OT;_T:E?2A
M^\:^.XH_W]?X8_DSHH_"9YMH <%'_P"^J0V\ _@?_OJK[Q*XJLR-&<$<5\P:
MD'D6_P#<?_OJE%O;_P!U_P#OJI"O&167K6N6>@6B7-Z7".X1=J$\DX[=/ZT
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M)C.0.XQ1I8G4MFVM\?=?_OJD^SV_]U_^^JIVFNZ;J#1?9;I'6:-7B;(P^<X
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MLEXZW,<SVL/G20Q."^WZ?C6@FIV+77V07D(N?+\PP&0;PN,\B@"4V=N.F_\
M[ZIK6L '"N?^!5736=)DBFECU.U>.#B9A*,)GIDTVVUK2KV=8;34[:>5U+JD
M<@)*CJ: 9/\ 9H!_RS?\Z:8( P&QB3VW4Q==TS[-)<C5+4P1ML>3>-JMZ$^M
M)!X@TJ?4K:QCO8);BXB,T(0YWH#C(-,FQ=^QP8'#_P#?5--G!Z/_ -]5;:F$
M5)5B'[%!Z-_WU2?8[<=G_P"^JLTA'% RO]CM_1_^^J3['!_=?_OJK.WWIN*
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MW$9;S)5)8[<'C W<'K3H?!UV\8CNYK(I%%%;Q+'$?G1'#;GS_%Q]*[,$"EH
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M83;]>*ZT*,4U8@"302SSBX\':H\-O9KJ</V2(YV89=I\TOD =<@@<],5J_\
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MRW*EEVC(R.QZ4 >\0S13Q[H9$D7.-R,&'YBH;C4;:"WN95ECD:WC:1XT<%L
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MB>Y-;?;/]: 021G% 7(;>UCM+6.VMH8X8(E"I'&,*H'8"GD/GTJ3( ZTAE%
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M444?V9@?^?,?_ 5_D'/+N'_"WO'7_0<'_@'!_P#$4?\ "W?'/_0;'_@'!_\
M$444?V9@O^?,?_ 5_D'/+N'_  M_QT.FN#_P#@_^(I?^%P>._P#H._\ DI!_
M\1111_9F"_Y\Q_\  5_D'/+N'_"X/'?_ $'?_)2#_P"(H_X7!X[_ .@[_P"2
MD'_Q%%%']F8+_GS'_P !7^0<\NX?\+@\=_\ 0=_\E(/_ (BC_A<'CO\ Z#O_
M )*0?_$444?V9@?^?,?_  %?Y!SR[A_PN#QW_P!!W_R4@_\ B*/^%P>._P#H
M._\ DI!_\1111_9F!_Y\Q_\  5_D+GEW#_A<'CO_ *#O_DI!_P#$4A^+_CH]
M=<S_ -ND'_Q%%%']F8'_ )\Q_P# 5_D'/+N)_P +=\<_]!L?^ <'_P 12_\
M"W?'/_0;'_@'!_\ $444?V9@?^?,?_ 5_D/GEW#_ (6]XY_Z#8_\ X/_ (BC
M_A;WCK_H-C_P#@_^(HHH_LS!?\^8_P#@*_R#GEW#_A;WCG_H-C_P#@_^(H_X
M6[XY_P"@V/\ P#@_^(HHH_LS _\ /F/_ ("O\@YY=P_X6[XY_P"@V/\ P#@_
M^(I/^%N>./\ H-C_ , X/_B***/[,P7_ #YC_P" K_(7/+N)_P +;\<?]!H?
M^ <'_P 11_PMOQQ_T&A_X!P?_$444?V9@O\ GS'_ ,!7^0^>7</^%M^./^@T
MO_@'!_\ $4O_  MWQS_T&Q_X!P?_ !%%%']F8'_GS'_P%?Y!SR[A_P +=\<_
M]!L?^ <'_P 11_PMSQQ_T&Q_X!P?_$444?V9@O\ GS'_ ,!7^0<\NXG_  MO
MQO\ ]!I?_ .#_P"(H'Q;\;CIK2_^ <'_ ,1111_9F"_Y\Q_\!7^0<\NXX?%[
MQT.FN#_P$@_^(I?^%P>._P#H._\ DI!_\1111_9F"_Y\Q_\  5_D'/+N'_"X
M/'?_ $'?_)2#_P"(H_X7!X[_ .@[_P"2D'_Q%%%']F8+_GS'_P !7^0<\NX?
M\+@\=_\ 0=_\E(/_ (BC_A<'CO\ Z#O_ )*0?_$444?V9@?^?,?_  %?Y"YY
M=P_X7!X[_P"@[_Y*0?\ Q%'_  N#QW_T'?\ R4@_^(HHH_LS _\ /F/_ ("O
M\@YY=P_X7!X[_P"@[_Y*0?\ Q%'_  N#QW_T'?\ R4@_^(HHH_LS _\ /F/_
M ("O\@YY=P_X7!X[_P"@[_Y*0?\ Q%'_  N#QW_T'?\ R4@_^(HHH_LS _\
M/F/_ ("O\@YY=P_X7!X[_P"@[_Y*0?\ Q%'_  N#QW_T'?\ R4@_^(HHH_LS
M _\ /F/_ ("O\@YY=P_X7!X[_P"@[_Y*0?\ Q%'_  N#QW_T'?\ R4@_^(HH
MH_LS _\ /F/_ ("O\@YY=P_X7!X[_P"@[_Y*0?\ Q%'_  N'QY_T'?\ R4@_
M^(HHH_LS _\ /F/_ ("O\A\\NX?\+A\>?]!W_P E(/\ XBC_ (7#X\_Z#O\
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MX[_Z#O\ Y*0?_$4?\+@\=_\ 0=_\E(/_ (BBBC^S,#_SYC_X"O\ (.>7</\
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)M:QM2CSW;/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>img_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &N O@# 2(  A$! Q$!_\0
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M[V**_=[IFDE9IIF P&_'UZ5K_P#"N/%G_/[!_P"!+_X4?#C_ )'V[_ZY2_\
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MU"CY_>>.?\*V\6?\_L'_ ($O_A1_PK7Q;_S^P?\ @2_^%>RT4?ZUYAVC_P"
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M%G_/[!_X$O\ X5[**0T?ZUYAVC_X"O\ ,/J%'S^\\<_X5MXM_P"?V#_P)?\
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M+?\ G]@_\"7_ ,*]EHI_ZUYAVC_X"O\ ,/J%+S^\\:_X5MXM_P"?V#_P)?\
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M^ K_ ##ZA2\_O/ +^VUWPAK]I'-?NET LR/!,QP-Q'M_=-%;GQ3_ .1RLO\
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M6?QGX9C6%FUVQ"S9V'S1SV_"II/$^@Q:DNG2:O9K=L0!%YHSD]!Z9.:\9LM
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M@CGMY4EAD7<DB'*L/4&I0,D5Y_\ "[4;6S^'-@U]>0P*T\L<9FD"@_-T&:]
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M/KFMW:3T!H'6B['R1['*Q_#GP['::=;"*Y,>GRM-!F<Y#L023Z\J*G\1^!-
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M.Y_L\FQ6/KCH/PK;T#PQI'ABU:WTJT$(<YD<G<[_ %)K2MIQ<VD%P%*B6-9
M#VR,XJ7:2. :+LM0BG=(Q==\+Z7XCELY-1CE=K-]\.R0K@\'GUZ"I]:T33_$
M.GO8ZG;B:!CN S@J?4'L:K^*->;PWI/V]=/GOCYJQ^3!][G//0\<5IVDQNK2
M"?RV0RQJ^QNJY&<&@/=;:,+PWX'T+PK-)/IML_VB0;3+*^]@OH/057UKX;^&
M=?U-M0O+21;ASF0PR%!(?4CU]ZFNO%\-MXZMO"QLY#-/%Y@GW@*O!.,?A73*
M">0#BB[)48-62V(K.SMM/LH;.TA6&WA4)'&@X45FWWA?2]1U^RUNXCE-]9 "
M%ED(48)/([]:V@,].:"".HQ2+LGH<9J7PN\+ZEJ$MZUM/;R3$F5;>8HKD]>.
MV?:NETG2+#0M.CT_3;=8+:/D*#DDGJ2>YJ[13N)1BG=(P_$GA+1_%=O%%JMN
M7:(DQRQMM=,]0#Z>U4-+^'?AO1M2L]0L;66.ZM,[',Q.XG.2WJ>375FDHNQ.
M,6[V.-U+X7>%=4U"2\EM)HGE;=(D$I1'/T[?A6KJ'@W0-3T2#1[C3T%G;_ZA
M8R5:/W!Z\]_6MVBB[%R1['+:%\/?#WA[44U"U@FENXQB.6XE+^7_ +HZ"K-G
MX7M- M-7ET.#-[?*TA6Y<O&\G) ([ DFN@HHN"C%;(^?9=*9K6^MV^'=Y%K4
M^8XI(O,-O%G^(*<C/7'.*],TCP#93>%- LM;BD-UIH,BB.7:$=FW$''7&!7;
M[CC&324W(B-)(QM7\+Z7KFJ6.HWT<K7-BVZ I(5 .0>1WY%4O$'@#P_XFO?M
MM];2)=D8::"387'^UZ^E=-2BE<MQ3W1AV7@_0M/T";0X+!/L$_\ KD<Y:0^I
M;KGT]*PH_A'X02"2(VEP^\@[FG.Y<=@>U=S11=@X1?09!"EO;Q01@B.)%1<G
M/ &!_*GDT4TFD:(0\TS%.S10 VBG44 8OBK_ )%F^_W5_P#0A7$^']8GT.=9
M75FLISM<=LCN/<9KM_%7_(LWW^ZO_H0K%\.:7!J_A&2VG&/W[E''5&P.:YYI
MNHK;V/:PE2$,)+VBO%RL_FM_D1>.Y8[BVTZ6)@\;[BK#H1Q4OC#_ )%G3OJO
M_H-<KJ4=[8M_9EV3MMV)0=L'N/8UU7C#_D6=.^J_^@U'-S<S.E4E2=""=U=Z
M^1GV.C>&IM/@EN=1,<[H#(OF@8/TQ72M'!;Z79P6DGF6RK\CYSD?6N;L+#PI
M)I\#W=UMN&0&0>81AN_:NKBM;=M'@2P;?!&O[HYSD5M1LGT/,S5RE!J\GKU6
MGR_K8N6:*EJF.XR:6[0/:R ]AD51M;[R$\N120.A'4475_YR>7$I /4GJ:Z+
M.YXGM8>SL%BQ^SW"]MN:K02O;N)%!VYPWO6A;P&&RD+##,I)'IQ4-A&LL$R.
M,@D4[[F?)+W5U'W\BRV2.ARI:F2S-%IT*J<%AC/M56>.2W)A8Y0G</>K,L)E
MTZ%E&2@Z>U&@<TI.3ZV)+?3X_*#2Y9B,]>E306202LZDG(P >U16^H1>4%E)
M5@,=.M2P7J3S&-5; '!I.YK#V6EMRS1114G0>.?%/_D<K+_KTC_]&/11\4_^
M1RLO^O2/_P!&/17[)E/_ "+J'^']6?.5_P"++U&_#C_D?;O_ *Y2_P#H8KL_
MB=8M>>!KUUNI81;8E*QGB7MM;VYS^%<9\./^1]N_^N4O_H8KU+7]*&N:!?:6
M9/*^TQ% ^,[3U!Q]:^%XJ_Y&"_PQ_)GI8-7H->IY+:WU]X/^%$&HV.H7#W&J
MR"*-7.5M0-V2GH35C6](U[P1H=CXEM_$EY<W+.GVF&9RT;;AG !/([<_A6_8
M?#K4)?"=QX?US58YK=2K6)A3FW8%LGD#(.>E5_\ A7/B'4TM-/U_Q(MSI%HP
M*0QJ=S # &<>G'.<5\Q=&W)*VQZ)IMV-1TVTO NT7$22;?3<,XKRS3[;5/B-
MX@UR677+S3[:QD,5M#;L0 <D D9'IR>O->LQ1I!%'%$H2.-0J*.P' %>?WO@
M+6['7+[4/"NN)I\=_P SPNN<$\G!P>Y)'<9J4:S3=NID^)-2\5>$_"%AI-SJ
MD<^H7MP8X[R)B62( ?*6(ZY/7TJOK]AK7PU_LS5[?Q!=WR2R^7=07#$JQQDX
M!)X(SSUK?_X59;2>#QI$VH2/?B;[0+PY(5\8P 3]W'^-11_#S7=7O;(^*O$"
MWUC9',<$:D%\>IP.N.3R:=T9N$NWIY&5XD&JZW\5XM'L=7N[&VNK2-F\N1L*
MICW'"YQFHM;L=8TWQQX=\-6/B"]0O;!'N#(QSN+[FVDXSCI]!7<MX/N&^),7
MB@74(MT@\KR-IW?<*]>E+JO@^XU'X@Z7XD2[A2"RC"-"RG<V-W0]/XJ5RG3;
MN_/\#CM+EU'P=\3;C1O[5N]0L6LWG*W3EB2(RX^AR.HKE(M?NM7L;W5[SQ'K
M,6M;RUI;VT;&'C^$D<#T_GFO6[KP7-=?$5/$CW,)M/LY@>W(.]@4*GGIWKGT
M^'/B72H+K3-"\3);Z1<R;BCH?,0>Q Z_0BFFA2ISV6VO];F/XL\2ZSJ'@+PM
M?QW-Q::A-<O%,T;&/>RX ) ]>#BO0_"/A>Y\.171N]8N=2FN2KEIB<(<<X!)
M[FLOQ#X#NM8T?0["+4]SZ;-YLD]UEFFZ9Z5W)J6]#6$'S7EY'F7Q%F@_MVS@
MO_%-S96?EY_L_3XV,[GGYN..??TK(^'VLZB\/BW3WOKZ6VM;.26W^UDB6,C(
M'NIQCCU%=1X@\$:O<>-$\3:#JL%K=&,1NMQ'N XVY'![5'H'P_U32-0UVYN=
M8AO#JMH\3R,A#^8W.X]L9S3NK$.,N>]CAM)T[7-:^&U]K\_B;4D-@SFWA65L
M'&"Q9LY/7CTJ[J?B[7=1\%>%-/BOY(;O5)'BGNE)#LJN$&2/KD^N*[;1O ]U
MI?P\O_#+WL#SW/F;9E4[5W8ZCKVK-G^%\EQX*TS23J$<>IZ;*\D%TBG;\S9P
M>_ISZBG=$^SFEIV.4\7>&[CPSXL\+6SZQ=ZC;O<JR?:CEHV$BAL>QXKV^^N%
MM+2YN2NX0QO(1ZX!/]*\TN?AUXFU75-+U/6?$D%W<6<JML,9 "!@<# ZG!R?
MI7ITB+,KHZ[D<%64]P>HJ6S6G%IO2QXQX?T77OB!H]]XAD\27=M>^>R6T,<A
M6),8.#@\#G''ZUH^--7\2Z/H^@>'FU&/^U;]C'/>P$C<H8*,'@@\\GVJ9OAG
MXBTZ.]TW0?$B6VBWK$O!(IW*#P1P/3C@C-:^J?#"UOO"FG:5!?2QWNGDO#>/
MDDL3ELCL,XQCIBJNC)1ERM6U]3E=7MM8^&6LZ1<PZ[=ZC9W<GE7$-RQ()!&[
M R?7@]>*98V6J^*/B#XGTO\ X2#4+.QA=W*Q2'/#851D\#GG%=!;?#W6]2UF
MROO%NNKJ,5B<PP1K@$@YY.!Z#/<UJ^'_  C<Z-XPUS6I;J&2+4MVR-5(9,MN
MYHN'(V]M#SC0;37?$/AC6I+GQ)?QQ:*K_9TC<@NX!;YFZD<?AFDU_5;S6/@O
MI%S>S--<+J)B\QN2P56QD]S[UW_AWP/=:)H6OZ?+>P2OJF_8Z*<)N4CG\ZS)
M_AG>S> +3PW_ &C;"6"]:Y:;:VT@@C [YYHNKB]G+E^1A^)]/USP18:5XD@\
M1WMW<R2(MQ%*_P"[)*[L =-O!&*M^,KNWO/$:_;O%-]%"\"M#IFEQ,948J"-
MW.,]^>>E7Y_AOKNJSV-GK7B,7FBV3 QQ;,2,!Q@^^.,Y/%6KSP'K=MXQN]<\
M/:S!9"\4K()8MS1@@9V\>W'2BZ!QET6G]>9QVC76HZ_\,/$UM>:G>%=.=98R
M[$NRX;,;$G.#CI78_"+2FM/"B:B;ZXE6[! MG/[N':QY7Z]Z?X?^'=WI.D>(
M=,N=3BGAU5-JRJA#JW/+ \=ZT/ GAG6O"]G+9:CJ<-U9J,6T42D>6<Y)R1WH
M;*A!IIM'%_%+2'F\=Z"PO[A/MS+&H4_\>^&5<ISU.<_6M?Q"U[H_CWP7I4>I
M7<D*QB.5FE(\_#$9<9P3]:V?'7@V]\37&EWNFWT=K>6#DJ9 2#D@@_4$57\2
M>"-6UN#1;Z/5XTU[35PUR5^24YSD#'!S[47!P=VTNQ4U>_NT^.&CV27<ZVK6
MX+0"0A&.U^J]#VKD]"T_6?$FC^);J;Q)J,,.GR.\422D[G )Y.<XP.E=CIW@
M+6H_&MAXEU77(KVXB'[X>65[$ )CC !'ZU>\->";K0M%U^QEO()7U-G*,BD!
M,J1SGZT7%RR;U7?\CSN*/7M6^&\_BBY\2Z@)K!Q%;PI(5!4$ EB.2?FZ^U;&
MM^+-=U+0_"6DVEZUM=ZO$IN;I?E8_-L'(Z="3BNELO -W:_#:[\+&^MVGGD+
MB<*VP LIZ=>U1ZA\-3?^%M&LEOU@U725Q#=HIVGG.".O7!S1="Y)VT[&#J$>
MK?#3Q/HWE:W=ZEIU_)Y<T-TQ/.0#@9/KD$54L]+UGQ;X[\2Z8OB*^LK.UN'?
M"2,W.\A0!D8'6NFL/ &L7^OV>K>+M;74?L1!@@C7 R#D$\#N ?>MCPUX2N-#
M\4Z]J\UU#*FIR;TC12"GS$\Y^M%RE!M[:7_0\Q\37E]9>++VV\2WNNV]E&!'
M8R6;X7:/NL<_>XY/.<YKT[X>7HO/#"G^W?[8\MROG-&4>/C[C DDGWK+U/P;
MXG36+RZT;Q"C6EWG?:Z@OFK'GLH((P.W2MCP/X/3P?I4UN;G[1<W$GF32!=J
MYQ@!1Z4FU8<(R4SA_C%I3-JNCWOV^X N9A (0?DBQCYU]SG]*@\3V&L67CG0
M?#%CXBU$":V"-</*VYMS/N8@'DX_D*[KQMX2N/%7]E_9[J&#[%/YK>8"=PXX
M&/I1JWA&XU'XAZ7XE2ZA2"RC"-"P.YL;NAZ?Q4TPE3;;:\O^"<9K<6KZ7J.B
M> ;'7+H&[<RW%\S'>P9CA1SD !>@/)J8?VI\//'NCZ:-9NM2TK4R%:.Y)+*2
MVW(Y.""0>*ZOQEX*;Q)/9ZC87QL-6LC^YGQD$9S@_0]ZH:-X#U63Q+;Z_P"*
MM874KJU ^SQ1KA5(Z$\#IUP!UH3!PDI:?TCF+"PU;Q1X\\5:6?$&H6EE;O(Y
M2*4G)#$*HR>!ZXK,T"WU[Q'X.UF[NO$NH1QZ*C&WCCD(WL 6.YLY(XX]*]*\
M.^#[G1?%>O:Q+=PRQZGNV1JI#)EL\U4\-^ KO0_"^O:3+?6\LFI[]DB*VU,J
M5YS]:=Q>S?7S_P" 7OAIJUYK/@6RNK^9IKA7>(R-U8*<#/J<=ZYWXBS0'Q#:
M07_BJZLK/R\_V=I\;&=CS\QQQR?7L*Z[P3X=F\*^&8M*GN(YY$D=]\8(!W'/
M>L+7O ^L3>-1XGT#5H+6Y>,(ZW$>X+\NW(X/8"EU+DI>S2.&T'5KZX\)^.=,
MGN[R>TM[7? +S/F)\^.<].,<4[7/^2!Z'_U]_P!7KJ['X:ZK:IXC6?68+IM9
MMO+::2-@PDW!MQ]NOZ58U#X=7MY\.=/\,+?VZSVL_FM,5;:PRW '7^*BZ,N2
M=MNGZG;Z5_R"+#_KWC_]!%>":KJ=]'KVI1^*]1UZPO/-/V62V.(4&3CY<C*]
M/NU[_:0&VL;>W8AC%$L9([X %>>7G@/Q4DE];6/B2*XTZ\)S'J$?FO&#Z$@\
M^XQ23-:L6TK&?XIU>Z3X/V5W9Z_+>S?:40WT.Z%V'S?*W.<CH<]<5%KU]JOB
M#Q3X=\*0:G<65M+9137$L3$/(2FXDGOP/S-;=W\,V/P\A\,V=_&)A<BXEN)5
M.UFP<@ =.H_*I?$/@"\OYM(U/2-26RUC3H$A\TJ=L@48!]N_X&G=$.,W^!QR
M6-QX;^,=I#=:A/J*6MJ\D4LYRYC$3L%)_ UB0^(+C6[:_P!6OO$6LP:N')L[
M>TC<PC'(!(X [?SS7H6G?#S5HO&5MXAU;6HM0DV,MRK1D%LJRX7' &"/UJLG
MP[\2:3'>:?X?\21VVDW4FXQR(?,C^A Z]L@BBZ(<)=M#/\1>(?$^J_#C1-0A
M%Y&K2M'J;VH*R':< \= 1D^F:/A[JUC)XJCCL/%&HB"52#INIKO:1L'[K@[0
M>_K77ZOX,U&[T+3K73?$=[;WUCS]HD=B)SG)W@>_3KZ5GZ1\/M5?Q;:^(?$6
MI6D\UK@QQVD C#D9P6( ]<T75BN6?,GZ'H=%<_HFDZY8ZWJ=UJ6L?;+.X8FU
MM^?W W$XY]L"N@J#H3N+10**"D%%%% PHHHH #24II*!,****!"BEI!030,1
MNE,-.)IE A*6D[TM !1110!3U9;9]+N!>H[VVT>8J Y(R/2LJRU70M)L'6W,
ML5NKDMN4G!W!#^O%= RAE*L 0>H-1?9;;_GWB]?N#ZT66Y7//EY4].QSU_?^
M&M8D"W6Z1XF:/(5E((7<1D>U2WMYX?U!8M/N6=UCD"(HR.=I(Y^@-;OV6WSG
M[/%G_<'IC^5)]DMA@BWBR#D?(.N,9_*CECV&JM56M+;;R.5MM+\*WEQ'!#!*
M7D9D7+, 2H!/Z$5H6>O:+:P16MO,RQH&505/&TX/)]S6R+>!'#)#&K Y!"@$
M&D-K;'K;Q'J.4'?K0HQ6R'.M6J*TY7]3'NM?T-4EEG<@1NR.P0\$$ ]/<BI[
M34M)>[6W@;]\7= 2IZI][DUH_9;?:5^SQ8/4;!2&TMFSFWBR223L'4]357,.
M36^A0O=>TVSN?LES,RR-N&-A.<*&//T-9>M^,-$\)+:_;%N +M2Z"--V,8Z\
M\'FND:"%VW/#&S>I4$U1O_#^CZIY?V_3+:X\K(3S$SM^GY"@))[K<X^7XM^$
MIE"R+?$#I^Y_^O3D^+WA6- BB^"CI^Y_^O71?\(1X6_Z %A_W[H_X0CPM_T
M+#_OW3NB.6I>]T<R_P 5_![MEHKS/KY'_P!>M/0?B+X=UK58-+T]+E9YL[=\
M6T< DY.?:M/_ (0CPM_T +#_ +]U/9>%M TZ[2[LM(M+>XCSLDC3#+D8.*+H
M%":=]/N->BBBI-CQSXI_\CE9?]>D?_HQZ*/BG_R.5E_UZ1_^C'HK]DRG_D74
M/\/ZL^<K_P 67J-^''_(^W?_ %RE_P#0Q7L=>.?#C_D?;O\ ZY2_^ABO8Z^%
MXK_Y&"_PQ_)GJ8'^%\V%%%%?*G<%%%** !1S4@% %+292'4E)BEI#%S124M!
M5A:*2B@3%I":*#0(4<T8I!2T# <FG"FBEIB%H'6BCM0)@1FHF7%3"FM0(@[T
MM+C!HH **** "BBB@ HHHH **** %HH%**  4M)10-"TE%% PHHI10 E+0>E
M IH!:6@44 %%%%  *#0:2D 4444 )24M)0 AIM/--H$QRFGU&*>IH 6BES10
M(!11104%%%% !1110 &DI324"84444""D-!IIH 7--H-)0 =Z6DHH 6BDHH
M6BD%+3 *#12&@!#24M% "44II* $HI:#0 E%%% !1110 4444 >.?%/_ )'*
MR_Z](_\ T8]%'Q3_ .1RLO\ KTC_ /1CT5^R93_R+J'^']6?.5_XLO4;\./^
M1]N_^N4O_H8KV.O'?AO_ ,C[=_\ 7*7_ -#%>Q5\+Q7_ ,C!?X8_DSU,#_"^
M;"BBC%?*G<%/44W%/6@!V*6BBDRD%%%%(I"T449H*"BCK102PH-%!H$ I:04
MM P%+24N:8A:#THS1GB@3#-&,TE.% B-Q@4RII!E<"HL$4 )12XI* "BBB@
MHHHH ***!S0 HI128I0*!A12X-&*!H2BBDS0 M**2E% "GI6?K<CPZ'?2Q.4
M=(2593@@UH55U.U:^TNZM495::,H&;H,T/8NFTIIO:Z..&OW;^'OL\LTD=]%
M-%\^<-)&QZU8U2^*^);R"XU&^MX$12BVREN<#/%7M2\+&]M=/$<L:7-JBH[D
M'#J*FGTG54UNYU#3[NUC\]54K*A8X%8VD>FJM"]XV6_WW7D_R*4]].FF:?:Z
M=?7#O?7#)]HN%PZ@=>*EF%YX>U.PSJ$]W:W4GE2)-R0?45:NM'OM2L(UO+R)
M;Z"7S()H4PJ^Q%)%HVH76HV]WJ][%,ML=T44*;06]33LS-5*=M6K:W7?M9V_
MR,^UO=:?QY;V^H;;>"2WD:.VC?(V@X#-[FLF[UC5BM_KL6H2)#::@MLEH /+
M:/(!S[\UUT^E2R>*K75Q*@BAMFA,9!W$DYSZ8K$N?!]Y-=7%O'?1+I-S=+=2
MQ%#Y@8<X!Z8KHNCQ)1E;3N4-5U75)GUK5K7498(M+EC2*V4#8X.,[O7K7>6\
MOGVT4V,>8BOCZC-<IJ?A*]NKN^CM+Z&'3=0D22YC9"7!7^Z??%=;&JQQI&@P
MJ*% ]A29I34DW<6DI<TF:DU"D-*#030(04H--I:!#LTH-,%.!H <*6D!I<T#
M"BBCI0,****  TE!-)F@3%H-)F@F@0A---+FD- "4444 %%%% !12XHQ0 @I
M:04M, I#2TC'% "44F:,T *:2BC% !0:*2@ HHHH **** "@T4&@#QOXI_\
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ME'B32?\ GY/_ 'Z;_"CF7<?L*O\ *_N-2G"LG_A)-)_Y^3_WZ;_"E'B72?\
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M)=)_Y^6_[]-_A2_\)+I/_/RW_?IO\*?,NYG["K_*_N-8TE91\2Z3_P _+?\
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MYTFKEQG**:74?G% IFY?[R_G3@RX^\OYU1%B0&D;I4?F*#]Y?SIQ=2/O+^=
MK"BES3-Z_P!Y?SI0Z_WE_.@+"FD%!9?[R_G29!'!S0 $TVG4AH$)12;E'5A^
M=&Y?[R_G0 II*-R_WE_.C<O]Y?SH&%%&Y?[R_G2%E_O+^= "T4FY?[R_G1N7
M^\OYT"*L^FV]QJ5M?2+F:W!"^^?7Z5<IH9?[R_G2[E_O+^=(IN3LGT%HI-R_
MWE_.C<O]Y?SIB%IX%1[E_O+^=/5U_O+^= #\8HI-ZG^)?SHW+_>7\Z!BTAHW
M+_>7\Z6@!M)3B*,4 (*6D I: "D/%+2&@ !IV*0"ES0 @&**0FC.:0!28S3L
M4'Y: $(XJ-NM2DY%1L,F@!AI*5ABDJA,****!'CGQ3_Y'*R_Z](__1CT4?%/
M_D<K+_KTC_\ 1CT5^R93_P BZA_A_5GSE?\ BR]1/AO_ ,C]=_\ 7*7_ -#%
M>R5XW\-_^1^N_P#KE+_Z&*]DKX7BO_D8+_#'\F>K@/X7S84445\J=P4444 %
M)2FDH <*<#3*<IYI#'4M(*<!2&&*,4I'%% !B@BEHQ0 W%.I** &SRB"WDE8
M$A%S@=ZM0Z)!)&&OB\\K %EWE44^B@8X]ZS=2/\ Q+IOJG_H:UT['YC]::5W
MJ14DXQ3B9IT'2O\ GS'_ '\?_P"*I#H.E?\ /F/^_C__ !57+FZ@M(&FN)4B
MC4<LYP*I6>MV5Y*8=YAGP&\J7@E2 0?3D'-5:)FIU6KIL/[!TK_GS'_?Q_\
M&C^P-*_Y\Q_W\?\ QK1K*U/Q-H>BW*6^IZK:VDSKO5)7P2O3/THY5V)]M/\
MF?WDG]@:4?\ ES'_ '\?_&C_ (1_2O\ GS'_ '\?_&I6U?38[BR@:^MQ+? F
MU3>,S #.5]>*A7Q)HCZP=(75;0ZB"1]F$@WY]/K[=:.5=@]M/^9_>+_PC^E?
M\^8_[^/_ (TO_"/Z4/\ ES'_ '\?_P"*I-3\1Z+HLT4.IZI:VDLO*)-( 2/7
MZ>]::G>@9"&4C(8<@BCE78?MI_S/[S-_L#2O^?,?]_'_ /BJ/[ TK_GS'_?Q
M_P#XJM/!QG'%(5/H:.5=@]K4_F?WF;_8&E_\^8_[^/\ _%4G]@:5_P ^8_[^
M/_C6H%.<8--<A(R[D*BC)8\ #UHY5V#VM3^9_>9O]@:5_P ^8_[^/_\ %4O]
M@:5_SYC_ +^/_P#%5?B=+B%)86$D;@,KJ<A@>A!J.SN[?4(3-9S+/$'9"Z<C
M<IP1^!HY5V#VM3^9_>5#H&E?\^8_[^/_ /%4G]@:5_SYC_OX_P#\56D:*.5=
M@]K4_F?WF9)H5LD;&R+VTV/E(<LI/H02>*IV\WGVZ2%=K$?,OH1P1^== .H^
MM<Y;_=D_Z[2?^AFI:ML;4YN2?,3'&"3VJ[I^F6\MI'/=1+-+*N\[QD*#T '3
MI5(_<;Z&MNQ_Y!UM_P!<E_E1%:BJR:CH1_V7I_\ SX6W_?I?\*/[+T__ )\+
M;_OTO^%6ZH:IJUOI<(,AW3./W<0ZN<@#GL,D<FKT1@I3;LFR3^R]/_Y\;;_O
MTO\ A1_9>G_\^-M_WZ7_  JI:Z_;22^1=C[)<!VCVN?D9E."%;HW45K4:,'*
M:W;*G]EZ?_SXVW_?I?\ "C^R]/\ ^?&V_P"_2_X5#<:[IMKK":3-<JE\]NUR
ML1!^:-<Y(/X'CVJ>PU&UU33K:_M)A);7*!XG/&X'IP:+(GVDN_XB?V7I_P#S
MXVW_ 'Z7_"C^R]/_ .?&V_[]+_A52\\2:5I^I+I]S<[+EFB4)L)YD)"#/N5/
MY5/IFMZ?K#W:Z?/YZVLIAED53LWCJ W1L=\460>TEW_$D_LO3_\ GQMO^_2_
MX4?V7I__ #XVW_?I?\*BN-=TRTUNST:>Z5-0O$9X(2#\X'7GIV/Y5E'Q]X=&
MJMIANIQ>*Q#1FUDXP<9SC&,@\]*+(/:2[_B;7]EZ?_SX6W_?I?\ "C^R]/\
M^?"V_P"_2_X5EZ)XTT#Q'=?9M,OO-G\OS51XFC+ITW+N R/I6[O7;NWKM/?<
M,?G19![27?\ $K?V7I__ #XVW_?I?\*/[+T__GQMO^_2_P"%6LC.,C.,XSS2
MT60^>7=_>5?[+T__ )\+;_OTO^%9^J6%O:6K7EM&(6C(+JG"LN<'(Z9]ZVC6
M?K7_ "!;O_<_J*&E8JG.7.DV9H&#2I"+J[AMB<(X9GP<$J!T![=12G[Q^M26
M/_(8@_ZY2?\ LM0;WLFR_P#V78 8^PVQQZQ@G\S2_P!EV'_/A:_]^A_A5R@
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MG.2.H%.R#VL^[^]GI_\ 9>GYQ]AM<^GE+1_9>G_\^-K_ -^EKS%?"'BI=?\
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M%V\LA"QA"VWKZYK1'+-:NYYA<>$?%>HB+4[/3(].;1[:WBTVTN7W3 Q89MC
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M%&**7-(!,4=*7-(: "BE!H)H 3-)0:!3 6D)XI33&- AAI*#0*!"FDI2:2@
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MU;_G[M/_  &/_P 72TTF@-.R^X9.;V\C\JZO 8C]Z.&/RPX]"<DX]J>
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ME=A?>,XSG%.\^'_GM%_WV*$K&LY<UK+9)#Z":C\^'_GM'_WV*#-%_P ]H_\
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MIEL;4?XB_KN:AZFDH)Y-%,@!2T@HH 6@TE% "4H%%% "D<449HH 0TVG&DH
M=;0)>7ZV\N3$L9D=<XW<@ 'VYK9%A9@8%I;_ /?I?\*R]+_Y##_]>Q_]#%:.
MIW\>EZ;/?3([QP+N94&3BJC:US"JY<RBAYL;/_GTM_\ OTO^%'V&S_Y]+?\
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M:=U]Y'2&I?L>H_\ /DG_ ($#_"D-GJ7_ #Y)_P"! _PH#3NOO(J2I?L6I?\
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M=_\ 7&;_ -#6O9MM?"<5_P#(P7^&/Y,]; ?P?FQF:3%2;: M?*G<,"YJ54%
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M?[C?]_&_QH^S0_W6_P"_C?XU+118.>7<A^RP_P!UO^_C?XTOV:'^ZW_?QO\
M&I*446#GEW(A:0G^%O\ OXW^-/%G!_=;_OXW^-24!N:+!SR[D9LX/[K_ /?Q
MO\:3[+ /X6_[^-_C4I:FDT6#GEW&&V@/\#?]_&_QI/LL/]UO^_C?XU)FC-%@
MYY=R/[)#_=?_ +^-_C3!!;,S*I)9#A@)6R/KS4^:S=._Y"NK?]=4_P#0:3+B
MVTW?;_,N_9H?[K?]_&_QH^S0_P!UO^_C?XU+118GG?<B^RPG^%O^_C?XTOV6
M'^ZW_?QO\:E%+18.:7<A^RP_W6_[^-_C1]EA_NM_W\;_ !J:BBP<TNY#]EA_
MNM_W\;_&C[+#_=;_ +^-_C4U%%A<\NY#]DA_NM_W\;_&D^RP_P!UO^_C?XU/
M1BG8.:7<@^S0_P!UO^_C?XTGV:'^ZW_?QO\ &K&*3I19!S2[D'V6+^ZW_?QO
M\:!;0JZMY>64Y!8EL?3)J?-+UH#FEW&&DI[CBF4R HHHH ***7% "44I&*2@
M I:2EH !3P<4RG4%(D4YIV*C4T[-)C'8I#Q1FCK2&)FC-+10 4444#"D(I:*
M /%_BM_R.EE_UZ1_^C'HI?BM_P CI9?]>D?_ *,>BOV;*?\ D74/\*_-GS&(
M_C2]1/AI_P C_=_]<9O_ $-:]HKQ;X:_\C_=_P#7&;_T,5[.*^$XL_Y&"_PQ
M_)GK8#^#\V.%+24M?*G>+2YIM% [#LTAI**0"&DS3L4A% " TX4F*7% "]J*
M#TIF33 <:2@4M !BEQ0*#0 HI<TS-127$41P\@!].I_*@5FWH6<T9JJ+ZV_Y
MZ_\ CI_PIWVZU_YZ_P#CI_PI70<LNQ/14'VZV_YZC_OD_P"%+]NM?^>H_P"^
M3_A1=!RR[$^*,5!]NM?^>O\ XZ?\*/M]M_SU_P#'3_A3N@Y9=B?%8OB7[6+6
MU^RP++_I,98$D8.>/P]:T_M]M_SU_P#'3_A2&^M3_P M1_WR?\*3LU8NGS0D
MI6N38..<9[XI,5#]NMO^>O\ XZ?\*:;VV_YZ_P#CI_PIW1')+L3DTTU#]LM_
M^>G_ (Z?\*0WEO\ \]/_ !T_X470^278D(IN,5$;R#_GI_XZ?\*!>6_>3_QT
M_P"%*Z#DEV)13J@^V6__ #T_\=/^%*+NW)QYH'U!'\Z+CY)=B:BBBF2%(:*3
M- "T4F:3- A32444Q!13))8XL;W"YZ>IIGVN#_GI_P".G_"E<:BWLB:BH?M<
M'_/3_P =/^%'VNW_ .>G_CI_PHNA\DNQ,!FEZ5#]LM_^>G_CI_PI/M<'_/3_
M ,=/^%%T')+L3YHJ#[7;_P#/3_QT_P"%+]K@_P">G_CI_P *+H.278FHQ4/V
MR#_GI_XZ?\*/MD'_ #T_\=/^%&@<DNQ-BC%0_;(/^>G_ (Z?\*/MEO\ \]/_
M !T_X47#DEV)L5CZ5]K_ +8U3SH52,R+A@?O''&/PK2^V6__ #T_\=/^%'VR
MW_YZ?^.G_"D]2X\T4U;<GHJ#[9;_ //3_P =/^%'VRW_ .>G_CI_PHNB.278
MG%+5?[9;_P#/3_QT_P"%'VR#_GH?^^3_ (47#EEV+%%5_MD'_/3_ ,=/^%*+
MR#_GI_XZ?\*+CY)=B>BH?MEO_P ]/_'3_A1]LM_^>G_CI_PHN@Y)=B=:=BJX
MO+?/^L_\=/\ A2_;+;_GI_XZ?\*+H.278FQ0%S4/VRW_ .>G_CI_PH%[;_\
M/3_QT_X47'R2[$A7% %*DB2KN1@PZ9!IV*";#&Z4VI&Z4S%,EB48I<4G-,+
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M*!W1TVYO[Q_.C<W]X_G7.KX[\,/%>RKJT6RS&Z5BK $;MN5X^<;N/ESS4/\
MPGNC2ZKH]A;M-,=4,BQR")E$93J&!&0<\>U 71U&YO[Q_.F.!(I20!U/56&0
M:<:::0SF5C$,UQ "2L4S(N?3@@?AG'X4ZE?_ )"%]_U\'_T%:7%9GH,924_:
M3T%(5/H:"1AHI<'TIK$(,L0H]2<4Q"T444 :&A(I6YGP/,\XQANX4 <#\ZU]
MS?WC^=96A?\ 'K<_]?+?R6M2J6QRU?C8N]O[Q_.H+N]%G!YTA8KN"G!YY]!W
M/M3YI4@A>60[412S'V%8P>6XU!3>0RPEX2\$@Y2WSP,G_GH<_ATH;%&-]66$
M\01_O%E22&2-]A1FSSQGD9  R,_E5NVU!KBZN(&BFB,385GZ2#U'M7/SZ4]G
M/!$?M%P?*8':Q2)B2,A\<!1C)SR<U)HS3OKLT[JTJSJW[Y#M3:,;?EZ@''&?
MZTDW?4U=.%FT=/O;^\?SHWM_>/YTT#)P*Y30_'=EK6M:Q8>0\$5@K217#'*W
M,:,5=UXZ*PQWJSGT.MWM_>/YT;V_O'\ZYRR\<^&;^UN[FWU:+R;2(33.ZL@5
M#P&&1R,\<=^*:?'GAD:>E\=37R'F^S@>4^\28SM*8R#CD<<T!='2;V_O'\Z-
MS?WC^=<M_P )]H3:O86,5P7BO;22[6[ (B1$SD,>QX.?3'-30^._#,^G7-_'
MJB&WMV19,HP8%_N84C)W=L#F@+HZ/<W]X_G1N;^\?SKFI_&NE0R6,WVB(:?<
MVTURUS(Q0H(R ?D(SU.*T]+US3M8T^2^LK@O;QDB1GC9"F!DY! /3FD&AI;F
M_O'\Z-S?WC^=<Q'XGOK[R(=+TE)[F2U%XRS7'E+'"S$1Y.#\S $XQ@=S5T^)
M]-@>T@U!WL;NX1':WE0DP;CM D(R%RW )/- 71M;F_O'\Z-S?WC^=<_H7B8:
MW/=Q?9##]GC\S._.[]Y(F/\ R'G\:JZ7XLN[I-+N-0TN.TLM4R+:>.Y\S:V"
MP#@J-N0IY&>E KHZK<W]X_G2AF_O'\ZPH?%VAW%M//%>EHX0K']T^65CA608
MRX)X!&<UG:A\0-,M8V>VCFN<6LUR3L9 IB(#(V1\K<]_ZT#NCKMS?WC^=.W-
M_>/YUSZ>*]/G@BN;9FDM_M26MP61D:!G V$JP!P25_!LUOXQQ0-6%#-_>/YT
M;F_O'\Z2EH&&YO[Q_.C<W]X_G244 8>K1K'JL$BC!FB</COM(P?KR:@JUK/_
M !_V7_7.7_V6JM9O<[8_"OZ[A1BBBD F*3%+2&F%A<4A%*#2T@L1T4K4VJ 2
MBBB@0E%%% A11244 .S1FFT4#'9HS3:*!#LT9IM% #LTF:2B@#Q[XI_\CE9?
M]>D?_HQZ*3XI_P#(Y67_ %Z1_P#HQZ*_9,I_Y%U#_#^K/G:_\67J+\-O^1^N
M_P#KC+_Z&*]EKQOX:#/C^[_ZXS?^ABO9]M?"<6?\C!?X8_DSUL!_!^;$%+BC
M%+BOE#O$HQ3L48H*0F*7% '-.IB8@%+110(**** "BBDH *,TE% !112XH C
ME'[I_P#=/\JU[**.;1K6*5%>-[= RL,@C:*RW4LC*.I! K6TM@^DVA4Y B53
M]0,']136YG5^!>OZ&$VFF\U.XM%E$D.G(C117)W*Y.3A_4 <#/2GQB#Q%#)+
M;V\=G]F4[)54"590,Y!'\'OT:K>K:-+<W0O;-U\PH(Y[>1BJ7" Y )'((_7H
M:6;3I=7LYDN+=M-G>,P"2&8,VP^F/TSTHL+F5D[_ / _S+^F7;7NE6ETX >6
M)68#IG'.*P-4\'37>JZA?:;KUWI1U*.-+U8(U8OLX#*QY1L<9%=+;P):VT5O
M'G9$@1<]< 8J2K1RR2;.,'PYLE\5_P!MB^F8-,EP\$B!R9%3:#O/(]3QG/>K
MGAOP5!X;OK2ZBOI9VMK%K(*Z !@TIDW<=\G&*Z>C-,5D<I:^");&^_T/Q!>V
M^E?;C?&PC51\Y.2OF==A/.VL73/A\]]=^*[G5(7L(M49HK.%)%D-NA8.[C'
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MD- H-4@&&DI324$L2BBB@04444 %%%% !1110 48I110(3%&*6B@#QWXI_\
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M_D/RJ9[&TEC$<EO&R!@P4KQD# /X"OG#_A)_$'_0<U/_ ,"Y/\:/^$H\0?\
M0=U/_P "Y/\ &C_4K$?\_H_=(7]HP_E_(^C'TK3W:)GLX6:)=L9*_='7 _.G
M2V%I-&(Y;>.1!T#C=CD'O[@?E7SE_P )1X@_Z#NI_P#@7)_C2?\ "4>(/^@[
MJ?\ X%R?XT?ZE8C_ )_1^Z0_[2A_+^1]#C2=.1U9;* ,IRIV]*1=+T]'#+9P
MAAR#M]\_SKYY_P"$GU__ *#FI_\ @7)_C1_PD^O_ /0<U/\ \"Y/\:/]2L1_
MS^C]T@_M&'\OY'T0-)T[(/V*'@Y'R]#3WTNPD=7>SA9E.X';SG.<_GS7SI_P
MD^O_ /0<U/\ \"Y/\:/^$H\0?]!W4_\ P+D_QH_U*Q'_ #^C]T@_M&'\OY'T
M8VFV+0+ ;6+RE<.$Q@!@<@_7-,72=/CE\U+.%7VLNX#LW4?0U\[?\)1X@_Z#
MNI_^!<G^-'_"3^(/^@[J?_@7)_C1_J5B/^?T?ND']I0_E_(^C9+2VF1TD@C9
M74(P(ZJ.@_"DCT^TA25(K:-%E&) !PP]Z^<_^$GU_P#Z#FI_^!<G^-'_  D_
MB#_H.:G_ .!<G^-'^I6(_P"?T?ND']I0_E?X'T1_9-@%=?LD>UW+NO.&8\Y(
M]:>NGVRHBB(80@K[8;<!],\XKYT_X2?Q!_T'=3_\"Y/\:/\ A)_$'_0=U/\
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M2Z]_T&]2_P# N3_&C_4O$?\ /Z/W2#^T8?RO\#Z.HKYQ_P"$EU[_ *#>I?\
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M_P# M_\ &E_J7B/^?T?ND']HQ_E?X'T;17SE_P )+KW_ $&]2_\  M_\:/\
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KFO9)KF>584EN9&?:,^IR<<FBOJ8U:&68>EAL142:CYZZLX)7J3<TMS__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>img_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -'!<0# 2(  A$! Q$!_\0
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M*\0_\_47_?\ ;_"O1<'UHP?6CZG3\_O#_6'&]H_^ H\Z_P"$*\0_\_<7_?\
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MFO\ PA'B+_GZB_[_ +?X4G_"$>(O^?J+_O\ M_A7I631R:/J=/S^\/[?QO\
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MPA'B+_GZA_[_ +?X4?\ "$^(O^?J+_O^W^%>DXI11]4I^?WB_P!8<;VC_P"
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MV_PH_P"$(\1_\_,7_?\ ;_"O3OFH^;UH^J4_/[Q?ZQ8WM'_P%'F7_"#^(_\
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M5Z/QZ4<>E'U.GY_>'^L.-[1_\!1YQ_PA/B'_ )^X?^_[?X4?\(3XB_Y^X?\
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M_A"O$(_Y>X?^_P"W^%'_  A7B'_G[A_[_M_A7HS9Q311]3I^?WA_K#C>T?\
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M-1;U^\UHY_C)U8Q:C9M+X5U://M'\3:U861AMM3N8X]Y.T.<#@45E6?^I/\
MO45Y\:DTMSZZKA,/*;;IJ_HO\C?\&_\ (VW/^Y)_Z$*]&KSGP;_R-MS_ +DG
M_H0KT:O2P?\ #^;/C>(?]\7^&/Y!11176?/W"BBB@+A1110%PHHHH"XZDHI!
M0%Q:*** N%%%% TPHQ1105<*,444"N%'-%+0*X@I:** N%%%% 7%%% Z4M Q
M*#110.X"BEXI: N)11FBD(*3;2T9I@)C%%*:2@+A1110*X4T]:=10 "BBB@
MHHHH **** "EI*6@+A2BDI10%PHHHH"X9]J,^U&:* N&?:DI:3O0%QV****
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MBG4A@*6D'6EH **** "BBB@ I#2TAH **** "BBB@ H-)FB@ I: ** "BBE
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M ***.@S0-)/<*,4H4G'%!XZD"GRD7BF--%+QGGD>U)WYHL%T%%+24B@HHHH
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M48I ?;-.S0B=4[#32'I3C24QZB#I12TV@0M%&.,T=:8PHHHH **** "E%%%
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M<'\^U!X]"/:HS=68;R_MD9F_YY9&:ED:.! \TT<0]"0*JP<R$R#T.#[TF#N
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M=OS=,5[$US9R. E[$[$ [%8=:=B(U+LRM=\3Z5X95&U.3:7^XH[U8T?6]/\
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MA5$C'&['(JC+DYIV/+]:TGQ+X4NU^VR3PL>1)N.#7L/PJ\63Z_I<MK?'S;B
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M7- N)KO18Y9_]9WS5J>V6X0Y(#]C7736A\UBJ3YM3/M+WR7*MRE:B31NF[>
M/2L22VF@ZK^-1AO7=GTK2QQJ3B;,U[%&A"<M6--*TCEC2A2[':#FKMMI[,P,
MHP.M!5W4W)],MS'&7?\ BJ#5,G;6H1RJJ,(O6LO4V#. *135E873!\QJ:_ME
MD&^,5%IGWB._I6GP6VG@4[CIQNCG5D=<ITI(AF5,GO5W4+0HWF(..^*I1C,R
M=>#1<YG"2GH:]]"9+8;3T%9=N[02*1V/-;FU6CQG@CI6==6;;MT8X]*5S:<)
M:,T5E6X(96' YH=TC&685@[KB(X0,*0M/,=IS2:+521M1W$<C;5;K4Q&UQSF
MLNTL9%()Z5I[0 .>E)FL&WN+1112-0K/U[_D7]1_Z]I/_036A6?KW_(OZC_U
M[2?^@FHG\+]#;#?QX>J_-'E-G_J3_O446?\ J3_O45X2V/U2I\3-_P &_P#(
MVW/^Y)_Z$*]&KSGP;_R-MS_N2?\ H0KT:O5P?\/YL^#XA_WQ?X8_D%%%%=9\
M^%&>112&@!ZD!9/]TU\SZBP'Q <]OM(_G7TJISQCKQ7,2_#WP_<:@=0>-OM.
M_=CMFFG8QJ0<FCJ8&V00OC(,0!'MBO"?BIX4_L;6/[0M%_T6?YLCLU>YG$:A
M><* H'M5/5=(LM:L18ZA'F'J#CI3N.4;QL?+UE,TFK6K2/DB1<DGWKZMA_Y!
M48)_Y=\C\JY./X9^&8I4GCB;<IS@UU@3$0@ (C"[<D\XIMD4Z;C<^6M6G\GQ
M3<S#G;<%OUKTR#XV""W@B-@',2A<^M=?/\-?#5W=23S1,'8Y/UJ+_A5GA;.2
MC &BYFH3CL)X/^( \87KV_V41[><BH_B;X0?Q#I9N[4%[JWX"CJ16WH/A#2?
M#4S2V (=AUK=B8HQ(/7K[U'-J;J$I1LSYH\.^)=6\$ZBS(K+SAXVKM;GXWW3
M6K?9[-4N6&-_I7INH>$]!UAV^TV*"0\LP7K65'\+/"RS>8T)?'.WUJ^9&7LI
MK1'AEK::OXSUXOLDDGG?YY,<**^D="T>'P]H=MIL)#-$H,A]ZFT[2=/T9-NG
MVB0@]\<U;Q\Q]6Y)J6S>C3<7=B+@/Q_$>*\/^-__ "'[;_<KW D9  P16%KW
M@[1O$MU'-J2-O08R*2>H5H.5[&#\'0'\&N.V_K6QX_T)]?\ "LD,0WSQ<J*U
M-%T6R\/61L]/!$3')!K2#&/H,YIWU'RWA8^:/"/BF]\!ZW(SPG:WRR1MWQ4W
MCCQO=>.;^+9"4CCX2(=Z]QUCP1X?UR3S;JU42'JRCFHM.\!>&]*G26&V#NO3
M<,U5^IS^REM<SOA7X??P]X=-Q=(1/<CE#V!KS'XG^%[O1?$<E]'&QMYCO5U[
M&OH1B&D&5V@#  J&^L[34+8P:C;I-$W0$9Q2YC:=%N-D>*VOQDNH/"XTO[./
M,2+8).]<UX*T&\\2>*89C"S0"7S)&_&O93\+_"K3^886 )SLKI-,TNPT:W,&
MFP) .A(')I<QFJ4GN7-JIA%^ZB@"E'+*1ZTF/?-(0>@J3IZ6/$?CB<:];J.?
MDZUV?P9E*>$74'^+M6]KO@W2/$UTDVI(PVC (J]HNAV7AVU:SL%VQ9S]:NYA
M[/WN8TV+R !V/6FD+EE8Y5Q@_2EIC+EL5F[FBCN?.?CWPU>^'/$TMY#$WD22
M>9&X' KJ]-^-[VNBPVUQ:"2YA7:&]:]<O;*SU*$V][ DR8Q\PSBN6D^&'A62
M4R>0RD]0!Q5\QBZ33NCPX1ZGXZ\4-,D+-)._S$#A17TIHVEIH^B6^F0@,$CP
MWUQ4>DZ#I>A1[=-MD1\8+;>36B W9L/US3N5"D[:GR[XLM9=)\871FC8#SMZ
MY[\UZ+IWQC\V.PL!:?.N(RU>B:QX6T;Q ,W]N#)_? YK,L?AMX:TVX\Z&!F=
M3D;N>:+B5*47HS&^)OAN;Q#X>@O[2,F>)=Y4#DUYUX(\>W?@F>6SN+<-;L?G
M1EY%?0:_(%53\O381VK!U/P5X=U>5GGL@DK=64=:=QSI/>YR-S\;M/CB+6M@
M&DQ\H*]*[+P3K]SXFT;^T;F%8\MPJBLZ#X9>&;60/]F\PCMVKI[*UAL(!!8Q
M+#$/X0*+BBI+4^>/BDP_X36Z^@KVOX?\^!=/^E1ZK\/M"UZ_>[NT;SC]XUNZ
M?80:7IT=E9@B&/[H-)L(QDI79XU\;"!KEL/]BNP^#A'_  B,G/1ZZ'7?!ND>
M))4FU%6W)WJ[HFAV/AZS:TT\$1'DYHYAQIM.YY)\:=/N/[5@O0I\C;MS[U4\
M'_%)?#6BM826HF ^Z37M=_IMEJUL8+R%9H^^X9Q7-+\+_"JS&58BX/5>PHN0
MZ;4KHN6VM'Q#X N=3>+RRT9POI7@GA-L>-K0@X_?_P!:^E(-,L[?2_[,MXMM
MIC:5]JP+/X<>'+#4%OH5;SE.X>QH3'*#DU<Q_C/83W>@VT]NC.D>-X%><_#K
MQI:>#[V>2ZM1*)1C)&2*^A94CN(##-&)(2,%7&:Y:?X9^%;B<S/ RESGY> *
M+BG19YIX\\;WWCBTVVEDRZ=;<EP.!6C\"\?VI?C_ &17J<7AK1[;2WTB*W1+
M9QAB%^]4.A>$=*\+S22:9&PEDX.>E/F)C2:E<\Y^.(_TFS^E;'P3(_L"Z'^U
M77ZYX4TOQ,T9U-6R@Y([5+H>@:=X<M7M],1@A/);O2YC90]ZYJ$[0,U'=C_B
M7W1_Z9'^52%E:AE$D4D;YV.,''I4IFTHZ6/F?P\1_P +#@/_ $\G^=>K?&G1
MS>Z#!J$2_O(/O?2MJU^'N@6FJ#4H(SYX;< >QKH;^Q@U6S>RO$S$XP:KF.=4
MM&CY;TB.XUS5[&Q+%\N !GH*^AO&]NME\.)K2,@+'"%(]\4:1X \/Z-J"WMC
M$6FCZ;NU;>HV$.K6,MK>*3%)U I\PHT6D>&_!KGQ@/79P*]*^*'AN3Q#H9DM
M5WW4#$[16AHW@C1/#]U]KT]9%G]ZZ,.0Q) RW7W^M3<N-)VLSYR\&>-+SP+J
M$D4MOE"<.CBN^NOCC8"/=;Z>IDQTV]Z[+5_!?A[5SONK-/,/)*K@UFQ?##PO
M;.LJ6[$CLW-/F,E3DG9%WP-XGN/%6FRWMU L8)VA0.U>/?$_PU=:5XAEODB;
M[-*=RD#I7O%E86NG6_DV,(BC'8<4^\L[34+7R;^%)D;@;AG%%S1TVT>,^&?C
M%)I.C)87EKYQB&$:NF\(?$2^\7>)TM/)$%L%R2!6Q+\,/"LTID:%L^B\ 5LZ
M/X8TGP\C-80*DC# ?'-%T*%.:>YYK\=0%O;/!SQU]:U_@H WA^Y&?XZZ_7O"
M6E^)W3^T58LHX(J?1/#VG^&[5K>P1E!//O1<I4I*=SC?C.5_X1BW&?XZP/@8
MP&J72^V:]2UO0=/\16Z6U^,QKS@57T/PGI'AJ22320=[]=U',#I/FN>,?%FP
MN8/%<ETZ-Y,OW6[5O>#OBQ8>'?#RV+6(\^(?(P7DFO5=4T;3]>MC%J,".!W(
MY%8-K\,_#%O<B<6Q<J<A6'%$63*D[GAOC'4M3UW4SJ^H6S0I-_J\C'%>]?#$
M_P#%$6P7T-6]9\*:1KT,-M=P*L$?"[1R*T-+T^#0K,6=G_J%X'J*;=QPI.+/
MFOQL0/&][_UUKZ0\.9/AS3/^N8K$OOAQX=U'4&O[F)VFD.21TS736UNMG:Q6
ML+?NXAA?7%%PITVI6/ /C$?^*S;_ ':]:^%W_(EVOT-3ZYX%T+Q!?+=W\3EQ
MU(-;&EZ;;Z)8"QL!^Z'3/:E<<*;4V?-7CG_D=[WG_EK_ %KWV.^DTOX;VM_"
M-[PPY _"H=0^''AS4;]KZZ5C.QR<=S70Q6-M%I8TXQ;[<# 4^E-L4:3BV>8Z
M;\<87B$>JV ;UXS7!>._$>G>)]5CFTFR%N,89%7&XU[1=?#3PQ>,6>T\LDY.
MVI[#X?>&M,D66&S#NO(W#-+F(=%M[E#X6:9<:=X&N/M.Z-I5)5"*\(ORO_"9
M.0<C[3_6OJS^#9M"#;M"*. *Y&3X9^&Y;R2^,3&9GWGTS23&Z4G8ZK3@3IMH
M>WD?TKY<\2_\CK>'_IY_K7U+&5BCC@BR$1-O/I7*7/PT\.W.HM?3*S32-N([
M9IW-)PYK'1Z'SH-E_P!<!_*OFCQL?^*VN_\ KK_6OIVW06MLEO&,(B[5'M7,
M7_PV\/:E?&^G1VG8Y(!HN$Z?,DC7\-'/A:P_ZYBM+&0%]>]16]LEI:I:0 A(
MQ@5-][D\>U2S:G%I'$?%#PQ+XA\.K/:*6N+?G8.K5Y)X,\:WG@6_F1X"4?Y9
M(V'2OI+=MZ<^U8.J^"O#NM,9[BU5)6^\5'6FF85(.]T>.>./B9-XLLTT^W@\
MJ ')"]ZZKX.>%IK".77+N,HS#;$K#J*ZZQ^''AC2YUD2W\P]1O&1FNG4*H6)
M$$<:#" # HN3&G)OF9Y_\93CPDF3_'7,? _F]O/I7JNLZ%9>(;,6NH@F->PJ
MKH?A+2?"Y8Z<#NDZFFI6*<7[3F-H]6IT>U27<_*HS^5,Y)Z4DB!X61@=CC:2
M#TJ6;2V/F_XB:S_;GB^X:-MT:-L49[UZ9X7^&.AS^'+6>_@+7$JAC6O_ ,*Q
M\-&Y-RR.SE]_XUUD*K'%'!$"JQ# JKG.J>MV<5J?PM\.'1[J2TA87"H2@%>,
M^&+]O#WB^&1R5$<NQL?6OJ!7*AB!D,-K+7*3_#+PU=W;W31NLTC;CCH#3;!T
MM;F=\7-"?Q)X:M-5L%\QHU!95],5Y3X*\=7G@J\D7R2\;</&:^D[2WCL[*.T
MC3?"!A@W<5SNI?#[PSJTSS2V@C<MSM&*28I4FW='!W/QKN+N2&WTZQ6-G<!O
M>O4+J)]1\)R@@K<30Y*^^*Q]/^'7AK2YQ-%;"1@<C<*ZC/E%3QM PJCTHN:*
M,FK,^4K:YF\-^*?/EB(>"4G:?K7LVB_%T:]K%IIZ6F"^%+8KIM8\#>'=<G-Q
M>6>R8]67O1I7@30M%G6YLH/WB\AB.10W<F%*4>IYY\>/EO[-/]G-;/P08+X?
MNB1D;N0*[+7_  II/BIT?4T;*C ([5-H'A_3_#EJT&EJ0A/)--,%3?/S'C/Q
M:\(W5CKIU:VB9[6?DLH^Z:M>%OC')HFE1V-[:>?Y0PC>E>US007$+6]S$)XV
MZJPR!7+3_#'PK=3F4P[&;DA1@4<R(=)IW3/#=>U?4?'?B+S5C9F=L(H&=HKZ
M&\%Z'_PCOANWM",3&/+C\*DTKPIHFAD-86:&0='QS6LK[F+9.XC'-3S&D*=G
MS,^6O%^!XVNL'CSL_K7TOX=_Y%W3L=/+'-8-Y\-_#FH:DUY<*WG.<G XS73P
M0+9VJ6\!_=PC"BCF"$.5ML^>?BX0?&LN/[HKV'X<$?\ "$6@]JDU;P%H6OWO
MVR]1O-/)/K6SIFFVVDV0M+12L*] :+A&G:5RT>M*.M%'>I-[#C24=J2@8M%%
M%  *6DHH$+124N: "BDHH 6BBB@ -)3CTII]: &-UII.33CS3#UH&+12]J2@
M HI*=VH 2BEI*8!11128I*]A,$G/'%5[R*RFA47VSDX :K2@$D^@K&\1:7)J
MEI L9(VMSMH>JL/G<9<R+-M8Z7:2DP+$'7G(-7!-&X\Q)$.>.M<6F@ZG'?7N
MT2%'CPF3TIE[H.LWEO9):.;<PX\[G[PII)$SJ.;O([@/&1L$D;;N",UGR:5H
M[NS".(L&YQZURI\-ZT=<2[CG9;15P4SU-+!H>KQ?:V+-R^X#-+E74<:LX[/0
M[8-#'M@#*)"/ND]JI_V3I,SN[1QLX^]7-SZ1K%SK,%V&8!HPO7I4=CH>NPSW
MD<KX5VX8FAI JLU+F3.E_LO0QTCB#=Z>NC:.X+I;QE%Y)KEH="U2/4+II"QC
M,>$R>];.A:?>P^&Y[2?/GMDACUI<JL7]8K7UD;2"T@A^1T6,=LTH:,D%&4AA
MG.>E<!!X;UR.RG1IG=F8[2QZ5I6>F:O:/;HQ+1^7B3)Z&J6BL8SG*3NSK%E@
MD3 D1MO7GI3 ELSX5T\P=17&:=H&L1&X:21@K297GM1%X=UI/$3W7VA_L;QX
M SWIW9E9';+-9J-X= !P3[TX$M%N5L@G(Q7 PZ%K8TN[BD9MWF$Q'/)KJM&G
MNHH[>PN(CN2/,CTM2DDMC3:6-6!>90O>F.;-F!DD4 _</K7):WH6JWJ7J6DK
M*'.4.>GTHL]&U6T^PBY)F\H?-D]:6HWL=3<75AIRA[N98,_=8G&:KCQ#HA.X
MZE%_WU7%?%.VU#6-)@^RVLF4."$KR,^&O$/_ #YW'ZU:U,%/EZ'TDWB/0V&W
M^T(2#[BH?[8\/APW]H0Y'N*^<O\ A&O$/_/G<?K2?\(SXA_Y\[C]:JQ#FWK8
M^E/^$AT+_H(Q#_@5'_"1:)GC4H<?[U?-?_"-^(?^?.Y_6@>&O$/_ #YW/ZTK
M%.K)]#Z3;7] [ZA#^8IO]O>'P>+^'/U%?-__  C7B$_\NEQ^M'_"-^(,_P#'
MG<?K5:$\[['TD/$&CN1''J$1+<  U?&T(N#N5NAKYKTGP[KR:M:L]K.JB09)
MSQ7TG  +6W4C!6,9'O6;.FF^9#O;THI!TI:1J%9^O?\ (OZC_P!>TG_H)K0K
M/U[_ )%_4?\ KVD_]!-1/X7Z&^&_CP]5^:/*;/\ U)_WJ*+/_4G_ 'J*\);'
MZI4^)F_X-_Y&VY_W)/\ T(5Z-7G/@W_D;;G_ ')/_0A7HU>K@_X?S9\'Q#_O
MB_PQ_(****ZSY\*"*** $QQZ4H.!C'XT44 ( %Y R>^:/FSG=N'H>U+10 G.
M>>:,+G)!)^M+11<.9H.>YXH]NJT4X#-"&F-(!X P*>1C&*7;3RO2I'=@N=IH
M"A5XSNI>E%.XTV& 1R"3]:4\C/>DHS2;*NQIQ^--QVZ TXTAH0:"CG&>,4HX
M;/:D%+3:):U%)_N\4<CGJ?6BBE=C:T#)[G=1PO(7GW-%%%Q)R%QN.X\$4K$9
MZ?C3"V!B@&@=A02>N*#G.:444"L-R2NW)QG.*=W)SUI *6G<JR"D/7-+24B6
M@[YQDT<^N?:BB@%8!D'GD>E*!@'G%(#3L4)B>@A&Y<']*  #G)&.E+28YJK@
M*.I8X)/;%-88Z<5*!37%%QO4K@!?7\Z7D]\4I'-)THN+5:"EB0-IVD=?>D)!
M.[;SV&:**07#_)%!/S;NOM110 AZY7@=Q2\ _*NVBB@30 #<3R": ".1Q13N
MU%R;"9PVX<FD*CW.?TI:*=RDV!P0 ><4H)/WCGT%)0*15T.[=Q[4AYX(R/2E
M-)0*PF!Z4$>]+10 '!]J0\\X.1[]:6B@%H'<$# [B@D;6 !!['-%%%QW0N6Q
M@D$?2DX ('>BB@.9AGC!&?>D(ST8XI:*!:MB$#' /YTO48QC'2BBE9A83&<9
M_2G =_3I2=Z=3"[0G0Y'!H/)SGFBD-%PNV ) X !]:",X.>1Z=Z!10.PK88=
M,'N/6@9' ;\*2E[T" C!7;P>](2V3@#)[TXTE.Y6@=L-DY]#BA1C'/2BE%%Q
M.R5Q,  ]6S[TI;(X&#10!1<:M:XHX(!.11@;B>1^-%%%RM&&.^2?QIRGTR#3
M:4=:1.@I.1R/F_O4A )[T&B@ XQTH "Y '6BBBX!TX'YT84>N?7-%%%R6)EN
MF>!2]2>,44HHN5'80 +2<;LXI324 P[8/-'..NZBE'2@+H9\P;Y6X/6C)P0<
M'T-%% K(,Y'--Y'OFE[T4Q[B 8&U3Q2G+ <X(HHH)L.!&>%Y]<TN2%*YSGO3
M**+BL2C '?\ .@^BGBF@TX"E<+!B@ #J,^]+247&+D ]"3ZDTF>:**=P%X+
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M_P#0A7HU>K@_X?S9\'Q#_OB_PQ_(****ZSY\**** "BBB@ HHHH **=BD-2
ME/7-(HJ0"@L4#BEHHH 0DYH!S2'K2B@H#0.:#29H 7%-(Q2Y--R2:!#A2FDQ
MBD)H&.'UI<4P?6G<B@!:*.M% #3UI*4]:6@!5Z4M-Z49]Z '"E--%*30(*,4
M44 )2L..**44"&#-/[48HI@ I1UI!3@.: %Z4-S2&E[4"(F S49Q4Y6HRM [
MC***,4""BBB@ I*6EH !111B@ HHHH *44E /- #J2EIIS0 M%(*7- !111F
M@ HHHH ****"@HHHH!A1110(*6@44 !H[4&CM0 E%'>B@ I124X=* $HHHH
M!2T"@T %+24M (****!BT4"@\4""BBB@ HHHH **.E&: 84444 MA#10:* "
MBBB@!IZTE.I#0 E%%%,04444@"@4"G'% #@.*=VJ-6XIX.1B@8M%%% @I*6D
MH ****!BYHIM% ,=13:,T"'44VB@8N!1@4E% "X%%)2YH **,T4 %%%%  :3
M-!H% !0*** '&DI329H *;GFE)XJ/G- AY--/6D)H% !1113 **** "BBB@
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MH3-+NI!UI: $ZTZDHH #S2"E-% !3?XJ?BF@9.:!"]Z:PS3\44#&@4I/%%%
M"CI1VH' HH 2C-+BDQ0 'I31UIW:D H =1VH-&:!"KUI:0<4M  :3-*:3B@0
M[M10.E%,!13L\4T4IH ,THYIM**!"D4PBGDTTB@"(FDSFI"H-,(Q0 E%%% !
M1WH[T'K0 M%%% "'K11BB@ I%^]2T <YH =WI&Z4O>D;I0 E%%% !2=Z6B@!
M>M!% .#03F@ HH[T4#"E%)2B@ HHHH **** $I?X:2ESQB@!*,444 &*<.E-
M)IPZ4 )2XI.]/% #<44XTV@ IW>FFF"XA+[1/'N'49YH+C!O8>3AJ=N&*3 (
MW9POJ::DD4V?*E5MO4 T$VUL2#'7-# $=:A:XME.UIT4^A-*+B!GV1SQL3T
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M%%%% !1110,*44E.% #U-/S48-.J2A2<TQA3J#3*&KQ3J04M( HHHH ****
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MBU6S7P:VG$GSP<D9ZUBVSTY4TE%P8>#]:DT^\6"20^2XY+'I7H+:CIY;'VI
M#SG->:>&]'?6KQ4<%(DZGUKM&\&:8!CS'QZ9K2+=CGQ4:2G8V!J&G#_E\C_.
MG#4]/[7D?YUA_P#"%Z8?XY/SI?\ A"M,_OR?G579Q^SI=S<.I6!'_'Y'^=-7
M4=/S_P ?D?YUB?\ "%Z9_P ])/SI?^$,TP?QO^=%V'LZ7<VCJ&GY_P"/R/\
M.C^T-/\ ^?R/\ZQ?^$,TS_GI)^='_"&:9_STD_.B[#V=+N;?]IV(_P"7V/\
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M@8I0,"G#% #2:4'B@XS1VH 7.133UI100":!" T&BB@8E***!0 H-*:3BEH
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M(3FBE[4E.QR>04<^M%%,=D'6C!I4!J55YYH%9#%4]ZD"T[ Q3"U TD/ %#8
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M<M.- ""@FBD:@!V>*3--HS0 [-+D4T=** '9HS28HH **** "BBB@ HS10:
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MX% A%4"E9L"BD/O0 F\&F$T'&:4#- "=J4]*:3@XIPY% Q ,BEZ4F#2X/K2
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M%%%% !1110 4444 %&:** "@]:*3O0 N*7;2XI0*  #%+2XH H ::.M*124
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MI<TF** %HHH/% !2$T['%,(H 44ZD%+F@!C"E6@T#B@0ZDHZTN* $Q1BEHH
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M#3P: &,*9CFI3S2;:  'Y:C/6GG(IIZT )2@DTE*M,844_%,(H 5:#0*,\T
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ME%1@\U(O2@=P:CFCK3J &XI0*6B@!,48I:* &X]J44M'>@!:*** "BBD)Q0
M&@444""G!MN68=!FFFDD/[F4]PAI%(K>&K;[3=7.H2G<0Y6(&NGR"2_\9ZBL
M3PL,:4<?WS6UA<<=:T1R57J* ,=:#@#@TW/%!/RFG8@"3ZTF3ZT*I==W0=Z
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M&1N^[WKR/XP7UY?:[H_AR&9H8;AP)"IQN%!+5CT.T\7>'+^[^RV6J0S3DX"
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M[_D7]1_Z]I/_ $$UH5GZ]_R+^H_]>TG_ *":B?POT-\-_'AZK\T>4V?^I/\
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M6GQ):NNS&0,\FK/;)KF)[$:3J5EY%P2&;!7-=4_WL4C"6XS^ FN!^*'CJ_\
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MQ?X8_D%%%%=A\^%%%%  .M*>M(.M*>M !VIRTVG"@!#]ZE[TW^*G4AA110:
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MMB]!QR!UHR=V!TH[8HH)N-*IYF_RTW]-X'-* J.2$4,?X@.3]:4"C'.: N(
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M]\U$MCIH%SL:4=*:&X%%0C=B]Z*2EIL04444@%QQ3:=GBFT % HI: "BBB@
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MRD=!G-+^%<\/$UW_ - ]J!XGNB>;!A1SH7LI'0_@:*Y\^);K_GQ:C_A);O\
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M]ZBBS_U)_P!ZBO#6Q^IU/B9O^#?^1MN?^N<G_H0KT:O.?!O_ "-MS_USD_\
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M)2B@!<48HHS0 4444 %&:** #-%%% !112XH ;UHQ2T4 )0:0T&@!PHH[44
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M[*_E2<0]N<E]IE/_ "ZO^5*+J8?\NK_E76=/X!^5&1_<'Y4N47MSDS=2@?\
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MU/UJ6=L?A"BBBD 4444 %%%% !1110 4444 %%%% !1110 N:0TE% PHHHH
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M77L:Z70;U]1\/6=P3EC& 6]:R_'M\EIX4ELU!>6[(1%'<FM+0+'^S/#>GV;
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M2[23@4 MSG=<XUB ^U,/!/UI^MG?K42^BTUN7:I9VQ^$2BBBD 4444 %%%%
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MIQ% % #*6@BB@048.**">* $')YH[T#K1WH 0T"@T"F(**** "BBB@ HHHH
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MH&*WK2#FEI<4 (128I2*04"#%,VU*#2-0 P#FGXXI *4\B@!A'-*.!3L4W-
M"$9H QWI:* #\:0GFC% % "T4M)B@!PZ4M(.E+0 AIE24R@!!UIW:@=:0XH
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M4M$@=]07;.,@@YH%SLZ1>3@=?>A<D\G#=L"H[:>&]MXIK:17@D&5<'J*\_\
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M+>PP+<#H,4#Y3RK6_#NC1?&W3=.AM!%9R("\(Z,:T?#=E:Z5\:=8L;!%@M3
MQV#IG%>C7'A33+KQ-%XAF4_;XAA/:EB\*Z7!X@N-=B4F]F4JYH#E/'M!EN(_
M#_C8V/F&X\Q@2O4#VKHOAA:>"SX0L[B[-LVI>9\V\CS-U=[H_A/2=%^V-!&3
M]M8M,IZ5CP_"OPQ;ZU_:ENCK-NW[ ?ES0'*=7>L5T>];;E?)./IBOFVR/BB/
MP]K$^DSG^R3.5N$ Y SR:^F)562)XI,B-TV8QVK'TCPGI6AV5Y96R$P7F3,A
MY'/>D-H\M\4);6WP0LE\/RE[61P;G9UW=\UE6OAW4-;TW0IK22QLXH65@\;
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MBBB@ HHHH **** %!I::*>*0(<*7-(*<!F@T#-%%%(!12'%&:2@84&BD/2@
M%+BD7FGF@!M%%% !1110 4444 %%%% !1110 E9VO_\ (O:C_P!>TG_H)K2K
M.U__ )%[4?\ KVD_]!-3/X6;X;^-#U7YH\DL_P#4G_>HHL_]2?\ >HKPUL?J
M%3XF=!X,_P"1MN?^N<G_ *$*]( ]:\W\%_\ (W7'_7.3_P!"%>E8S7J83^'\
MV?"\0_[XO\,?R#%&*<.E%=9\^1FDP:>>M(>M,0RBANM H **4TE "J*=112&
M*.M.!IE.6@"44\=*C!IX/% !10*6@+"4E!-)F@+ :::7-(:0P/2@=*** '4"
MD%** '<TAIU-Q3$)11BB@0QJ9BI&I * &4H%(!\U/7O0 ;:-M.-+0"&8/I2@
M4ZB@8PTF*>1Q3!UH 0TPG Q3VZTTB@0RBCO10 44H-+F@!M%.X]**!C<&BG?
MPTE K"44G\5+5(+!7->*/^0OIG^_72US?B?_ )#&F?[]9R.C#O<Z9N@^@I#U
MI6Z#Z"FU43*IN%%%%!(4444 %%% H *<IQ244 2!N:>.:@SBG!J )N/6DP*A
M)YZT;O>@"88I<CUJ#=2;S0,L9HS5?<:=F@"4G-%1AL&I>,<4K (::>:<128H
ML S%/ HQ0":+ .HIP Q3">: #O1WH!S2GB@92U'_ %<7^_74Q_ZF/_=%<IJ!
M_=Q?[]=5'_J(_P#=%4C&MJ/S0SC[P/"CYLTE&<#.,AN#5-',MSA=7ET*ZNW8
MQ2&<-]U1]ZC3]/GU.Y6XN+<6VG0#*1XP6Q6KXE>UTFT\Z"W3[1*VU21WK U6
MTU+3]-6:6_'F3@;(E/K4,ZXRNK&EIL7]MZX]W(";:'Y(U(J?Q7I-I;V0U"$^
M1<QGC'&ZLW3(?$6C6@\F$2>8-QJTFD:QKEU%)JC[(%.2E"(E+4Z31KF6YTJW
MFE!!VXP>]7R,4B1);Q"*,?NT&!2C&*T,6[NXHIW;/%-I<TB;B'#>H^@HR <$
M9]NU - 89Q3%<:\R*H:618US@;NA- FBEEV1S O_ !*O:N5U^66_\7Z;I:,1
M$#O<>M+X>4CQ]J4:@[%4  F@5SIUFB,S6ZNOFCMGFI&! .0<^F.M<*U[+9>)
M];N@2TD,642HK;6/$D>F6FN7#HT4K[/+] :!7.PO]7TW2[E+:<JLTF J1BKR
MJ9(P57 ZY[UYN]E=7OQ(-U-*&ACM_-*GH.*T?[8U_4[>ZUJR9(K6S.T1?WP*
M!7.OEO[6*\2RF?$THRH/4U--*EK:M)<';%&>7K@[C5H]0UW2M99=I$1+@=,U
M#JMWK^M>'+_45F L0V%C[L,T#N>AP/'=0K- 0\;?=;UI67!(^9F'7/:O/Y/$
MLEAI.EZ/;2&.:2(,6'6GVOCB]32[B.6)OM:/LB=A]\T!<[>[O[:P,*W+;6E.
M$SU-33216JEYI!%#C<7:O-M5AUF/6]#EU2;?YS!MH_A/I75?$([?"S;F.-P+
ME>PH%S&M;:EIU\V+6\C=_P"Z#UJV YXQ^0XKS"*.QO;W1V\.K,C* 9CV-:VF
MZ[KFJZCJ5S(ZQ6.FD@C^]B@.8[ABPX()ST&*15)7EN3Z5PO]MZ_<:2_B&.11
M:H_^J]5S39)=9UOQ9IUS9W@AM)8@\D/8"F%SO@C,H8\*.F.]5IKZ"WG2"8D/
M)RHQ7!ZEXPNI=4N;6SDV_8#SMYW&KD?B>XOI-+N);<;WSN+"D',=R8W;!"@^
MAIAR20IZ=?:N#AU/Q-J5MJ%_#*J0VLAVKZ@5V.BWQU70HKYAM+(0_N: Y@?6
M-*B?RI+Z(/G!YYJ]GS%4HPD4\@BO'%OM-M_[6CN;*:2YDD*1SGHI)XKH)=:O
MO#VE:;H?G;KJ==XEZX6@=ST,*?ND?,>E!5D'S=<]:X&W\6ZF^DW\:VK33VYP
ML@!_.KNFZMJ$/AZ\OFOTN)XTW>0>JF@+G9&-LAGR3VS3 I.2,Y'0CH*\_BUC
MQ';Z1::_<2@P2OAH3V&:T9=7U77M4:TT20011Q!WSWH'S'7D.HZX8<D^M*P(
MZ@AC^5<'<^+]1AT%EBC#:A#,(F)Z'FKD6H:[I6J6R7\BSP7,>]<=0?2@5SL<
M.5RW"CN* I_AY^M<1I6KZIJ6M3)=W7V7RV.;=^,J*H:CXUNY]1N_L<K1QV9^
M6-1G?B@+GH7FPB80^;^]/(6GG![].X[UP.L7LUU::-XB4/!<,X1T/&:[XN)(
MTD[LH)_*@=Q&R>1V[>M'1ACCZ48(^E% 7%X_^O2-T&#GZT44 (!SD8S[TOXD
M^M%% K"4M%% P-)2FDH 0TY>A^E)VI4Z'Z4F-?$<A!_Q]W7^_5FJ\'_'W=?[
M]6#UJ#L:T"BBBF-!1110(**** "BBB@ HHHH **** "BBB@ HHHH **** "G
M C--H%($2@4\=*8IS3AUH+N)WI:#29I#"BBB@84AZ4II* !*=FFKQ2T %%%%
M !1110 4444 %%%% !1110 W-9VO'/A[4>?^7:3_ -!-:#5G:\/^*>U'_KVD
M_P#034S^%F^&_C0]5^:/)[/_ %)_WJ*+/_4G_>HKPUL?J%3XF=!X,_Y&ZY_Z
MYR?^A"O3%Z5YGX,_Y&ZY_P"N<G_H0KTH&O4PG\/YL^%XA_WQ?X8_D.HIN:7.
M*ZSY\0CFD(H+<TTG-,0A'-'2B@T &<TN*;3Q0 9I12XHQ2&&*<#0!3L"@! :
M>#Q30!2GI0 M+30>*6@8#FFGK3UIAZT )1112 7.:*2DH <*=313J 'TE+24
MQ!BD(Q2T-TH$,/6DZ4=Z#0 T#YJ<*:/O4^@JP4M)2T""@\"B@]* $HQ103@4
M 1L*:33SS32N#0 W'-+2TE [!BEVT &G8- AM(13\4AH :>E-IQIIH ;WI:2
ME%-"8'IFN;\4<:SIH_VJZ4_=_&N9\4?\AO3?]X5$C?#]3IST'T%-[TYN@^@I
MM5'8SJ;A11102%'-&:4&@ Q1110 4444 %%%% "Y]J3%%% !BBBB@ HHHH&&
M*D1L5'1B@"QG-&.*A#8J19,G!H 6BER*-PH 3-)BG$C%1EJ0$@]:1B348DHW
MT 4]08>7&1V<9KK(P1#'Z;17)ZDK?9=Z#*HP9JZ6PNH[RSBEC;JH!'I5(RJE
MGF@&EP:0*WI5LY3/UG28M9LS#)PR\H?0UB67A&<7,<FI7!E2(_(":ZO#9Z4%
M03W)]Z5BU)@AQD X':E8!EY/-.VGCC&*1@<YQQ18EW8A.<#C [4W&*7'^S2X
M]J8),;2YI<4G/I2$T)SVHW;?O"EP3VH(Q]X9IBL<IXFBFLO$^FZO#$TBC"MC
MTI^H:#J-OKAUO190#<)\Z/VKJ&7> 9%#+V4BG894.U<9Z"@+'*V7A>[CL=0E
MO)0VH7JX!'05.WAZ=_#%II?F#S8W#,?I71$%0%P6)ZGTH'S,1@XZ9H#E9@6F
M@30^(9+V1P87@\IQ^%9)\,:S9I<:;ITRC3KEB7)/S 'TKM?F="N.>E*@8#()
M 7C% 6.67PAY5_9")A]EMX]K _Q&L^X\+Z\+6?3+:Y L)FRF>HYKN,$*2 >#
MT]:/GR1D@8_*@+'(7_@Z4PV,MF$>\M4"Y?H:M3>'KO5-#DM[L10WBD-$T0[B
MNF!;L,>]!#DCU[&@.4XI_#>O7][83WUPI2TP#COBNA\1::VLZ5]CB(7)^;WK
M2)?<<$[?XJ "PY!7WH%R%73;"VTS38X8X(XY43;N4<YK*T/P^=/AU&"Z.Y+T
MDG\:W]K @@9Q2G< 1C.?TH#D.(;POK45I)H\-PHTQGW$?Q8]*T+SP_>VNI:9
M<Z1,HC@4)(C="*Z<;C@X.X=12;,$X!&>M*X6..N?"M]8:Q+?Z:D+O=G,H<9
M/M5^]\/7-Y>V4V]$>),.B\*372#?MP,X%-93@D9SUS3&D8&GZ!-9Z/J-GYN7
MN&)Y/3Z5HZ+9-INCQV+,. >M7]I! (.,9)I,;B=R_2@?*<Q9^$L:7J=I>;'D
MN7+0OW4U3NO"%_+9V<N]6U"TX0GH17:8.<L,_P!*0;LY.?K0+E,*QMM6@TV9
MC! ETXY51\K?6N?D\-WMKI^IZG>L(Y)8ROE)]W/K7>G?GHV?6DEC2>,PRH77
MN#0'*>=Z'H.NZKX>LK.[N -/#[B/X@,]*W+WPYJ-CJ#7F@2K'O01LK=,5TZ1
M+$BI&NU!T44\EFZKM^E <K..;P;,-'V><3=22^9*PK8U'19;FZTZ:-Q_HB#(
MSU-;:;E.0O'>FA=N?+!R>N:!<IQU]X?U;6M8BGF$<,,;9,B<,P]#23>%;ZPU
M"6;2EA>*; 82#.#7:$MMP2?I33N3[HP*!\K.-\2P7%]=:5H\<67C8/*RCY17
M8E=B)'_= %&P!@50;F_Y:$<TJH0.#GW- N5@3T%)2[6/)I=IH&D-HI=IHVGT
M- "44[8?0T;3Z&@!M ^HIV#Z&@*?[M #3]12?B*<5/\ =I-A]* L)VI5P ?I
M0%XZ4R:5+:W>5R %'>AE)>\<I!Q>70/7?5D]:J61,LTUP>DC\5:SDFLSL>P4
M444Q(**** "BBB@ HHHH **** "BBB@ HHHH *3-+24 +10** "@44"D"'IU
MJ45$M2B@H0BDQ3C12*0VB@]:!UH&%(>M/Q28H 2BBB@ I,TII* %HIM+0 M%
M H/6@ HHHH **** &8K/U\?\4]J/_7M)_P"@FM&L[7O^1>U'_KVD_P#034S^
M%F^&_C0]5^:/)K/_ %)_WJ*+/_4G_>HKPUL?J%3XF=!X+_Y&ZY_ZYR?^A"O2
M*\W\%_\ (W7/_7.3_P!"%>D5ZF$_A_-GPO$/^^+_  Q_(7-!/%)176?/@>E-
MI<YIM,0M*",4G6G!<4 )CTI0*=BE H <HIQ%(M/I#&@48I^:0T (*:>M/SFF
MGK0%@HI,TM(=@-)0310,*3%+10 E**,9H'7% @IW:DQ1GB@!])FC-)3 =FFD
MT4E "=Z:U.)II.: $%2"F 4Z@8M+2 TM F%%&**!!BDQ2@Y-+0 W%(4R:?3A
MTS0!$%P*.*>W/:FX]J!W$QZ4A%/ H*YH"XS%(13\4A% B,BFXJ0BDVT ,Q28
MI^VC:::$Q@'!^M<UXG_Y#>G?[U=1MX_&N8\4\:WIO^]6<C?#[,Z9N@^@IM/<
M8P/84SO51V(FAII0.*7;FE"TR 7'>EXI0M+M% #<48I:,T )BFT[-(>M "44
M44 %%%%,84444 %%%%( HHHH *,XHHH 4-2$T4'F@0H;BDS28H H 6CI11F@
M D("@'E&^\M55@N+:0O9R[%/:K &"3W/6E/W<#%,;0P7.K;?EF4M1]KUC_GJ
MM.QR#WI<F@FR&?:]7[RJ*476JG_ELM.Z]:*=PL N=6_Y[+2&YU;_ )[+3@V*
M"<T7'RH9]JU;_GLM(;K5@,^<M/R:.:0<J&+=:L?^6RT[[5JW_/9:7FEW&@.5
M#1=:M_SV6C[5JW_/9:7)-%.X<J$-WJW_ #U6F_:]6_Y[+4F[Z49SZ4KARHC^
MU:M_SV6GK<:J?^6RT\+GTI^W%+F#E0SSM4Q_KUJ(W.K X\]:L'I3< GI1S!R
MHA^T:M_SV6@7.K$X\Y:GVTG'MFCF#E0S[1JW_/9::;G5?^>ZU*<XJ,YS1S!R
MH07&J_\ /9:7[1JQ_P"6HI0<=JF1^.@IWN.T>I7-QJP_Y;"D%SJW_/=:ED))
MIG- 6B)]JU4?\MEH^V:MVF6G#)STXHXW*K%0Q[47L"46-^U:L?\ ELM+]JU;
M_GLM!X) //I1R.HHN2[;(;]JU8'_ %RT?:M5/_+9:>"<]*,GVIW"PS[3JO\
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M)H *4]*04N: "BBBD,<M2@U"#BI V: '&@4A-**1:88YH-+WI#S0,3-%&**
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MH;D4I6@=Z L1CBE[TG>EIA86FFEHH 2BER:.M A*6B@4 %%&*,@4 %%&<T4
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M43^%G1AE^_AZK\T>4V?^I/\ O446?^I/^]17AK8_4JGQ,Z#P9_R-MS_N2?\
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M //%?RJ4],@4'I18?.R+[-;_ //)?RH^S6__ #R7\JE[=*..U%@YV1?9K?\
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M?XET^=HXPZF9 >,5V=M<K>V4%VGW94#4 F28XI,4YCC&*2@L.E%%% !1110
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MDVCL6I?$EFL3VRDR2(N 2.&-)X9U6^OX9S?V_DPQ'Y68=JQ27GTQ--AL"E]
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M"BBB@ HHHI %%%% !1113&%!I>U-H **** "BBB@04444 %%%!H ,TAYHHH
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M4"(?P ]:M!B>YHP,Y[T7&N5[(2-$CC"(-JKVI<Y-+UHVT!L-/6BG$4W'- 7
M8HXS2[:-M 7$X-1MU-2E:8RT 1F@$4$<4E,0I--S2]J;WH 4FDH)I!0 M(<$
M'<,[N#110%TMRO$;O39C]F/F1M_#Z5<'B"]7@V>3ZU&.*7>: ]UDO]OW?_/K
M1_;]W_SZU"7HW&E<+0)O[?NO^?2C^W[O_GUJ+)QUHR?6G=A:)+_;]W_SZT'Q
M!=_\^E19-&X^M%PY8DG_  D%W_SZ4?\ "07?_/I4>31DT78<L27_ (2"]_Y]
M!1_PD%YWM*CY]:.?6IN'+$D_X2&[_P"?2D_M^\_Y]*9S_>I>?[U%PY(CO^$@
MNQ_RZ4O_  D%U_SZ4SGUHY]:+ARQ'_\ "077_/I1_P )!=_\^E,Y]:.?6BX^
M6([_ (2&[_Y]*7_A(+O'_'I3,'UHY_O478N6([^W[O\ Y]*/[>O/^?6F\^M)
MS3N*T%T'_P!O7?\ SZTG]OW8_P"76DSP:9SFBX>YV)#X@O/^?2E_M^[Q_P >
MM1@GUH)/K3N%H=B3^W[O_GUH_P"$@O/^?2HLFEY]:+BM#L2?\)!=_P#/I2_\
M)#=_\^E1\^M'/]ZB["T.Q)_PD-W_ ,^='_"0W?\ SZ5'EAWHRWK2NPM$D_M^
M\_Y]*4:_>?\ /I40)]:3)SUHNRN6),?$%W_SZ4G]OW?_ #Z4S)]:4,32N/EB
M._M^[_Y]*<->NS_RZ5'EO6GJQ]:+ARQ%&NWF?^/2E_MV\_Y]#29/K2[F]:+A
MR1#^W;W_ )]#1_;E[_SZT;FHWMZTKL.2(?VY>_\ /K1_;M[_ ,^AHWMZT;F]
M:=V+EB']O7O_ #Z&C^WKW_GT-(2W7-&X^M%V'+$4Z]>?\^M)_;UY_P ^E-+-
MZT@9A1=CY8D@UV\_Y]:#KU[VM*3+$4A+CO1=ARQ(YM4U&YC\N&+RV;JQ]*;;
M6QMU)8YF/WF]:ERW<T=:+LM<J#(]*7CTI,T4 +124O:@!IZTG4TIH H =VI!
M2DXIH;VH 4"C%)N- :@!2*2EI#0 "G<4VE% "X%&!2$XIN_GI0 I%-VG%/!!
MI3TIDL@(I,5(:;BF2QO2E/2BB@044@HH&)2T44 %%%% !1110(**** "BBEH
M 0TE%% !1110 4444 %%%% !1110 5GZ[_R -0_Z]Y/_ $$UH5GZ[_R -0_Z
M]Y/_ $$U$_A?H;X;^/#U7YH\KL_]2?\ >HHL_P#4G_>HKPEL?JM3XF=%X)_Y
M&^Y_ZYR?^A"O2J\U\$_\C?<_]<Y/_0A7I5>GA/X?S9\/Q!_O:_PQ_(,T9I**
MZSP!<TH--ZTHXH =FBFYIU @H S12@&@ HI<4$4"$II%.I&Z4#&8H%**.] [
MA0>E%% "9IR\TW%*.*!$E%(#FB@!:7BFT9H$!IO%.--H ,"CI12$T#%I#2J:
M#UH 04N:2B@8[- .#3<THH$/!YHW4S-+3$.S2&DI10*PF#2BG8%% "8]J,>U
M+10 F/:C%+10,:W2F"I&Z4S&!0*["BBBD5KW"@CTHHS0&H;>.:4#%)FC- :D
MG%(>M(II3UH#4****8A,4N !THH- QN**#10(3H:6D/6CO2&!Z4<T44P#FGC
M.*93@: %Q2XI!UIU!(#/K1110 4N:2BF(6F]Z6@=: %I#2T4 ---S3R.*8:!
MD;<TWI4A%,(H$-S1VI"*3F@ HHHH **** "C%%% 6$Q1S2T4"L':BBB@+!11
M10,*,4HHHN,,48HHI %%%% !^-%%% !1110 4444"#-'-)WI:  9I2*04I-,
M!*#24IH 2EQ24M !BBBB@ HHHH%8!P:,'-!/-+2&&*50:44"@8X"G 4F<4H;
MVI#%Q13L@TAH ;^-(:*#0 4F32CI10-"9:CFEHH&(128]Z4TE "C([TIR>]
MHH!H3GO10:7M0 E%%% !124M !1110 4"BB@!".U-P14A^]33UH  :0FBDH
M>*#2#I2T -S1CF@\4#F@!1@4N:2CO3$T-<U'DT]J:13(8#)HI>@I":!""BBB
M@84444 %%%% !1110(**** "E-)2F@!M%%% !1110 4444 %%%% !1110 5G
MZ[_R -0_Z]W_ /035F2Z$4RH1UJMKO.@:B>G^C/_ .@FHG\+]#?"_P >'JOS
M1Y79_P"I/^]119_ZD_[U%>$MC]5J?$SH?!7_ "-]S_USD_\ 0A7I5>:^"O\
MD;[G_KG)_P"A"O2J]/"?P_FSX?B#_>U_AC^04445UG@ .M+31UIU !1DT44"
M'KTI<XI@Z4M #J#110(2D-/IK4 -Q3>].IIZT#"BBB@8&C/%!I* 'J:=S4:T
M_- A:,4F:-U A33:=3:  =*::>/NFF4#'+0<4F>* :!BT444 )B@4[BDH$&*
M*** "G"FTH-,0\<T4BTXT Q****"0HHHH&&,TTTZFFD F*2GFFT%!28%+10
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M "GBF"GT -;I302*?3#P: %S1FDII/-,) U)03FBF9!1BBB@!****!A1110
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M$U\0G_F(?^08_P#XFBBCVM3^9A_9^$_Y]1^Y!_PFOB'_ *"'_D&/_P")I/\
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M !-%%'M:G\S#ZAA/^?4?N0?\)KX@_P"@A_Y!C_\ B:/^$U\0?]!#_P @Q_\
MQ-%%'M:G\S%]0PG_ #ZC]R#_ (33Q!_T$/\ R#'_ /$T?\)IX@_Z"'_D&/\
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M (FBBCVU3^9_>']GX3_GU'[D'_";>(?^@A_Y!C_^)H_X3;Q#_P!!#_R#'_\
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M /Y!C_\ B:/^$RU__G__ /(,?_Q-%%'MJG\S^\/[/PG_ #ZC]R#_ (3+7_\
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M_A,M?_Y__P#R#'_\3111[:I_,_O#^S\)_P ^H_<@_P"$RU__ )__ /R#'_\
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M8_\ XFC_ (3'7O\ G_\ _(,?_P 3111[:I_,_O#^S\)_SZC]R#_A,=>_Y_\
M_P @Q_\ Q-'_  F.O?\ /_\ ^08__B:**/;5/YG]X?V?A/\ GU'[D'_"8Z]_
MS_\ _D&/_P")H_X3'7O^?_\ \@Q__$T44>VJ?S/[P_L_"?\ /J/W(/\ A,=>
M_P"?_P#\@Q__ !-'_"8Z]_S_ /\ Y!C_ /B:**/;5/YG]X?V?A/^?4?N0?\
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.\50Q=2E%*R;6S_S/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>img_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +I!<0# 2(  A$! Q$!_\0
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M5_Y^?_(K4?V3JO\ S\_^16KHZ*/[,H>?WE?ZVYAVC_X"O\SF_P"R]4_Y^?\
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M.T?_  %?YG/_ -EZI_S\_P#D5J/[+U3_ )^?_(IKH**:RVCY_>'^MF8=H_\
M@*_S.>_LO5/^?G_R*:/[,U3_ )^?_(IKH<9HQ1_9E'S^\/\ 6S,.T?\ P%?Y
MG/?V9JG_ #\_^131_9>J?\_/_D4UT/-*,TO[,H^?WA_K9F':/_@*_P SG?[+
MU3_GY_\ (K4?V9JG_/S_ .1371<TF*?]F4?/[P7%F8=H_P#@*_S.>_LS5/\
MGY_\BFE_LO5/^?G_ ,BM70!:*/[-H^?WC_ULS#M'_P !7^9S_P#9>J?\_/\
MY%-']EZI_P _/_D5JZ"BC^S:'G]XO];,P[1_\!7^9S_]EZI_S\_^16H_LO5/
M^?G_ ,BM7044?V;0\_O#_6S,.T?_  %?YG/_ -EZI_S\_P#D4T#2M5/_ "\_
M^16KH@*>J\4?V;0\_O#_ %LS#M'_ ,!7^9S?]DZK_P _/_D5J/[(U7_GY_\
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MH_\ @*_S.?\ [+U3_GY_\BM1_9>J?\_/_D5JZ"BC^S:'G]X?ZV9AVC_X"O\
M,Y_^R]4_Y^?_ "*U']EZI_S\_P#D5JZ"BC^S:'G]X?ZV9AVC_P" K_,Y_P#L
MO5/^?G_R*U']EZI_S\_^16KH**/[-H>?WA_K9F':/_@*_P SG_[+U3_GY_\
M(K4?V7JG_/S_ .16KH**/[-H>?WA_K9F':/_ ("O\SG_ .R]4_Y^?_(K4?V7
MJG_/S_Y%:N@HH_LVAY_>'^MF8=H_^ K_ #.?_LO5/^?G_P BM1_9>J?\_/\
MY%:N@HH_LVAY_>'^MF8=H_\ @*_S.?\ [+U3_GY_\BM1_9>J?\_/_D5JZ"BC
M^S:'G]X?ZV9AVC_X"O\ ,Y_^R]4_Y^?_ "*U)_9>J?\ /S_Y%-=#1G%']FT/
M/[P_ULS#M'_P%?YG/?V7JG_/Q_Y%-+_9>J?\_/\ Y%:N@W4#I1_9M#S^\/\
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M7^9SXTC5C_R\_P#D5J>-$U<_\O(_[^M72)G-3KG-8RP%%=_O-%Q3CWTC_P"
MK_,Y8:#K!_Y>1_W]:I%\-ZVW2Y7_ +_-_A75J*MPCBL_J=+S^\K_ %HQ_:/_
M ("O\SCE\*:ZW2Z3_O\ -_A3QX.\0-TNH_\ O^W^%=Y *NIC%;1P%!]_O,I<
M5Y@ME'_P%?YGG(\%>(3_ ,O47_?]O\*4^"?$0'-U%_W_ &_PKTI3BG,<BM8Y
M;AWW^\YWQ=F2Z0_\!7^9YC_PAGB#_GZB_P"_[?X4W_A#O$'_ #]1_P#?]O\
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M*7%']ET//[P_UMS#^[_X"O\ ,YP:5JI_Y>?_ "*:7^R-5/\ R\_^16KH^E.
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M<3%*HI:515)!<4BEQ3P*"*JQ#D,VTT\5-M.*8RT["3$C&35N-3^%01+S5Z,
M@5SU-$=,!P3/04]8\4Y1Q4J D]*\RI,ZHH9L)%*(O459"$=J7;7-[1W-&BFT
M9K.UA#_8U[_UP?\ D:V6%9FM8_L2^_ZX/_(UHYMP?HS;"+_:*?\ BC^:/.+/
M_4G_ 'J*+/\ U)_WJ*\%;'[54^)G8_#/_D=[[_KUF_\ 0EK0F&;J?_?-9_PS
M_P"1WOO^O:;_ -"6M.4#[3/_ +YKZ'*O@^;/R[B[_?E_AC^3("*85J8CBF$5
M[+6I\>WH0,O-)BI"*3%.*);&XI<4[%)3L3<3%&*<!2XIV07&XH(XIVTT%31R
MAS# .*3%2!::PP:.4.8 .*1EIZBE*T<H<Q&J\4F.34F,"FX-*P7&XHQ3L"@K
M2:&F,P*#BE(I,4K#YA>*,4@I<4#YANR@K3J0B@+C"*:14A6F,.*AC3 'BFFG
M <4$4BT- XI"*7..*0FI9:$(I*>.:0BBPKC:***3&@HHHI#"BBBBPKAVI5'%
M(.:>!@4TA-BXI0M I:M(7,&*,4X=*3-.PKB8HQ2T46"XE-SS3Z:10T1?43 I
M"*6BE8T0SH33@N5)H(IRC J6BAR+4@7FD05*JU+0T/5>*>%H45(.M(8!:0J*
M=2=:  "@BEZ49H 3%-*T\'F@@4 0E33&6IR*:RB@"L5XJ!UZU;85 XIB*Q%)
M3V&*90 4444"N!I>U)10,**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "B@4F><4 +10>M% !1110 4444 %%%
M% !1110 4444 %%%% !1110 448HH **** L%%%% !1110 4444""BBB@844
M44 %%%% !1110 4444 %%%% !1110 444A-*P7%HSBDS28)HU'="[OEI5/2D
M"4_;BKY0NB9#Q5B,'%54JU&>*PJ4[EJ2)DS4RYQ4:=*F7&*YG0-5-#E'>IE;
M'>H<TFX]C35*S!M%L2D#K2&7CK54N1WIIDSWKJC&QD[6++2<=:@>49ZU$\N!
MR:J22GL:Z$<LTB26;!ZU6>4DTQG.>:9R:M&?+8E'-/Q34&*D JDB;A@XHVT_
MM0",56P7(]O--=<"I>]-<9%2PN0 4X+1MIX'%"15Q-HH"\TNVG*,4[$W&[>:
M<BTN1WJ1%%-(EL-E*$J7;D<4H7 JTB;D06FLE3[>]-84- F(B\5/%N!Z<5%&
M,&K ..AKFJPT.JG(F0GN*GCQ5<?=//-2(3BO)K0:.N#+:D&EX%0*V*5GZ5Q*
M+N;W0Y\9K'US_D#7W_7!_P"1K4=JRM:;.C7O_7!_Y&M.5J#]#HPK7UBG_BC^
M:/.K/_4G_>HHL_\ 4G_>HKQEL?LU3XF=C\,_^1WOO^O:;_T):U)0?M,_^^:R
MOAI_R.U]_P!>TW_H2ULS?\?4O^^:^ARGX/FS\LXP?^W+_#'\F0$<4PBI.U-/
M2O;ZGQ[V(F%)BGD4TU:(;$I".:<!S3L46)N, I:=MHVTK!<3!I0*6B@FXT\4
MTC)J1AFF]Q0%PQS05-.HZT6"Y&0:0+FI"*,<4[#4B(C%'6G'K1BBQ8S%--2X
MII6LV!&*6E(Q246 ****120$\4WK3L4F*EEI#,4AJ3%-*U):1&1S2$5+BFL*
MALT2&B@TM%.XN49BDI^*::38)"44@I:0PHI*<!D4T2"CFGTT'%/%4D3+84=*
M,&G 4M6C.XSD4HI32BF%QN**=10.XV@BE(HQ0%AAI*<1S2$4K#3#'%.44T=*
MD6I:-$R1!4H%,2I0:EE(>HIPZTT&G"H&!I!3C24 +24F#3L&@ '6@]:*#0 '
MI36Z4[M33WH A8<U"XYJ:2HFS0! XS41&*G<U ^.I-5830F**0D,/E-*<TB;
M!11VYH'/>F,**3O3J07$HHP:*!A1128YH 6BCM0* "BBB@ HHHRI[T %% ^M
M!H !0>M"D9ZT$<^U ["]J04I.13<8H$*:*7M28H ****!!10*!CO2"X44G4X
M!I1D=:87"BC()]Z*!A11C-)F@!:*2E&: "B@@XQ1WH%<**0]:=TZT!<2BC(%
M'TH&%% &:4C:* &GI2A?>DSFI0.*=F2V1E3ZT;34H'%&*+,.8B(-)R*GP*;@
M>E.P<Q%2TI0]J"*EZ#YA****5R@HHHH$%%%%, HHHH **** "BBB@ HHHH *
M*** "BC%. S3L*XVBG;>:<%'>GRBN1XS2[*E&!1UZ4["N,V"C%.VD'FE-4B6
MR,@@T]1Q3BM*JXJK$W$ J>/I48%2 FCEN+GL3J<"IE;CK58&GJV*.0M3)\TA
M.*C\SFFM(:GD*]H.9\U&SE34;L<U$TC$\T*(G4)'<M4)!IRY-+BM.4R>I&5S
M3D7':G[0!2;J+";) HI2.*04^K(&[>* N!UI^.*,<4,",G!H)XIVVFM0*XS(
MI0:9CFE[4#N/S2YJ,$TX<BF(=MS4Z"H5-6(B-M4B62*< TH&12@ BG@<51)&
M.>,4,E/ YI6'-,"N,@U("*".:3I431<)69.I&*E5JJA^:D#UPU*5SLA,LAN*
M-V:KESVH\PUR>QLS=3)I":R]8;_B3WH_Z8/_ "-6VG/>J&KN#H]YC_GB_P#*
MG.G:$O1_DSIPDO\ :*?^*/\ Z4C@K/\ U)_WJ*+/_4G_ 'J*^66Q^VU/B9V'
MPT_Y'>^_Z]IO_0EK8EYN9O9S61\,_P#D=[[_ *]IO_0EK7D_X^)_]\U]%E/P
M?-GY7QA_OR_PQ_)D6*0CBG]J:37N6U/C&]",YI,4\FDZFJ2);$ XI0N>]*1B
MG 55B;C,8HQ3\48HL*XS%&*?BC&*5AB%>*9M.:DW48HL S:31@T_&*.]%@&$
M&D XJ0]*;FG8",K2 5)32*0TQM-*^]/Q3346U*N,(IM/- %)EH9BEQ3\48J#
M5(:!2[:=BBI9HD,/I33GI4F.]-)&:1:1'MI"*FQD9I"M9,M(@Q28S4Q6FE:F
MXVB/'O3<5(13<<4T0T1XYHIV.:0BF%A*<O6FXI1P::,Q<<T]:CSS4BU:)EL2
M \44"EQ6B1FPVYHQ3L4N*=A#,4N*=BC%%@&44N*"*+"N,QDTA%.I#28TQIXI
MZTPT]>E0S1,E2I1UJ%#S4PK-FJ'BGTP5)CBI&-W>U&:,44 *#3JCI<T .I":
M3-**  &@@8ZTI&!FF%J &-TJ*0U(QJ"4\4 0N>:@N'2"$S2G$2_>/I4K&J&L
MG_BG[W/]S@4V[(:5V4AXMT')476.W-6[36M+OWV6]VK-]:\Q\'>'[77M2F@N
MB0$YXI_BG0CX6U.-K.9@I.5YK'FU+Y3TS5M331=-:\GCW ' %5] U^#Q!;RR
MQ1-&4. /6L7Q'<R7OP\AN)N9> PK"\(>)K3P_HUQYJEYG/RJ*?-J'*>DYX!X
MSW%.^]G;TKD]+\>6.HW213P^1(3@>]=1<S"U@>=D)C W9'I5IDN(\9'7K2DC
MG!R17&7'Q'M8W*V]F\@'!.*U-"\6:=KK^3S!<_PH>]%Q6-\G: 3SGTHR<\UE
M:WK]GX=0BX&9SSL]:Y]?B3;EP7L'52<;L4FPY3M3S]WMUIH89]JAL[Z"[L?M
MJDK#C))KF;WXA6L$QAL[8W 4\D#-*X<IUWU!_"EQ\I-8&B>++#6YO*PT5Q_<
M-;S ARA!'')-7'5"EHR&[NX+"'SKE]L7<BH[#4['55+6#^9CKFLOQBJ_\(I-
MDY-8?PQ^6WNV)/2H;U+2T.Z!YQW[U%<W5M90^;=3"-:E R$!&23FO-/B#=3/
MKJ6;LR0 CI52T1,5=G7CQEH)D"&? '!-;$%U;7D>^VE$D9Y!6N3M_A_HU]I<
M;P7'[QE#%P>E;^F:;%X=TF2*#+;1DL>]0I%-&B,<<]:0G.3^E8.B^+(-:OVM
M$AVNAQNJSX@UV/P]$DLB;RYQ5W)L:P*GH>.]'W2,]#Z50TS58M3T?^T%BPHY
M(K*L_&NG71N5F_<F'.,]Z+BY3I0.<9S2>W.:Y2S\=QW;2F.S8I%GYAWK0T#Q
M);^(7D5(V1TI7'RFWT0L> .QK/UC5X-%L%O)U+ G  J+7_$4'AY8I9X_-9Q]
MVJ&H:U9WWAK[??69:W<_*F*+CL:FC:Q;Z[8FZA0IM.,5H8QR6'/2N;T;5K&+
MPW-?V%HR0Q'YHQWJUH'B:U\0%XXXRCISBA,+&T,=^#03MX/6LC7M?@\.QI)*
MOF,_1:DL]:2XT=M6>(K&!G%#8K&FK9''4]J;C&X8.?2N,G^)%L'(AL7;GAP.
MM;&A^*++7R(HPR7/]T]Z7,%B37_$D/AWRA/"7,G2M#3[Q=1T^&\52BR#.#7%
M_$_(^R#!)'4FNJ\.+N\+V0!S\HJD[C:LC5VY?DX %9$GB?18+AH9KO:R\&MJ
M-"<CVKQJZM(;WQH]M)N"/+@TI.Q,%<]+MO%&B7!(%V,'@&M1=K1I(C^8K>E<
M;JGPXM$M9&T^9S,J[@#67X,U^[LM3.E73EE)V_-VIIE\IZ.>>HQ1G YP/K5#
M6M6AT6U\^XC8^E<P?B5#O#'3W,?J11<FQVP.1T^E&!_$ZK]35'2M:L]9LVNK
M1\!!F1/2N \8^)UO=1ACT^214@.&QQNQ1S6"USU!44<]:E&.F.:Y/P_XSMM5
MFM=/6W=9MN"Q%:/B#Q19^')5M9('DG89XK=-6,W$W0H]<>M!3'(Y%<1!\3[5
MIU2>R:./."2*[>TG@O+5;NVDS#(.!34DR'!H ,CI2;0*FVX%)MJ^70SN5F&*
M:1FIW6F$8%9-%ID)&*2GG@TTC-18T3$HHHHL4%%%%( HHHH **** "BBB@ H
MS12XIH3&YI>M+MW4]4Q3L*XW%/44[;Q3@O%6D0V-V]Z,4_'%-(YJ[6(N)@4$
M8Z4NV@"D%P&3UH(S3A1BF*XF.:>HXI ,T&J)' 4\"F(:E!%4F0UJ'4<4E.W
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M]^7^&/Y,3%':G;:-M>[U/B5L-XI#BI-HI"M,!@I<4F* IH$+C%%&WU-&WWH
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MJGQ,['X9_P#(\7O_ %[3?^A+6S)_Q\S?[YK&^&?_ "/%[_U[3?\ H2UMN/\
M2IO]\U]+D_\ #?JS\IXR_P!^7^&/Y,"*,4K8I%^]7N+X3XE;!MHXQS1NY]J1
MB#PHS]*;:125R,D9XIPS3<CNI_*EW#^ZWY4N:(.+'$>U)CVI-_H#^5&X^A_*
MCFCW%:78:<T9I3NS]T_E1DX^Z?RHYH]RN5]A,GTI >>E.!/]P_E1@_W3^5'-
M'N+E89XHS[TAR!]T_E1N/]T_E1S1[AR,7D_2D)I&9L<*?RIHSW!_*CFCW#D8
MM+U/)I"Q'53^5)O']T_E1S1[BY6../6@4P/_ +)_*G!O]D_E2<H]RHI]A_&*
M4=.*0<@_*?RIPX'W3^53>/<WBF)1P:-S'^$_E1S_ '3^5)N)HDP()IA Q4@S
MZ'\J/JI_*HT'9D) VGUI@6I6]D/Y4W=_L'\J3L.S&%>>M)BGEAG[I_*DW#^Z
M?RI:%),;@TN/6ER/[K?E1GT5ORI7068W;01[5(#ZJ?RII/L?RHNAZHCVTA%2
M<_W3^5,;=_=/Y471+N,(IN!4ASC[A_*HVS_<;\JT3B9-,3'/6G*!30&)^XWY
M5(H('W#^55>)DXL< *7 % S_ '#^5._X ?RHNNY+@P7 %..*08_NG\J4X_NG
M\JKF7<CDD&?>C H_X"?RHSC^$_E3YH]PY)!^- 'O0&']T_E2[O\ 9/Y4<T>X
M<LNP'BF$C-/W<?=/Y5&Q_P!AORHO'N%I"TQA2[F'\)_*FEFS]P_E4WCW*2D&
M*3&33@2>J'\J7..BG/THO'N4XL84Q3=I'>I=V?O*1]108]HR#D4770FS1$5-
M)MQ4IIIIV"Y$133Q4A&7'%-9E#8QGVJ'H4FV,P*8V*DW'.#&P_"ANO\ JS^5
M9W1K9D)'%-/UJ;D_\LV_*F,"/^6;?E4-HM7(_P :6CYO[C?E1AO[C?E4%V8#
MFC!SUI0&'\#?E2@MGE&_*C0+,3;[T8I^3_SS;\J.?[C?E0(CQS2X-*0?[C?E
M1M/]QORIW0#?QH_&E(;_ )YM^5-P_P#SS;\J5T.POXT?C2?/_P \V_*E 8_\
MLV_*A- DQ1C-/7':D7.>4;\J?G'_ "S;\JM- TQ103SP:3<3_ WY4GS$_<;\
MJM-&+BRU&2%J52.]0(0$^ZWY4A<@\*WY5?.C+E998CL:1L8SFH5<G^$_E4I8
MX^X?RI^T0<K*KG#5$Z]Q4LF<_<;\J:6;'^K;\JRE)&L4RN#S@FE[]:1@V2?+
M;\J0%O\ GFWY5E=&HX_6BEY_YYM^5* W_/-ORIW0[L3%/5<]:<%./]6WY4X;
MO^>;?E5JQ+;&[!1M]Z<2?[C?E1\W_/-ORJ[HC40TE/8-G_5M^5)@_P!QORHN
MA68RG4N#_<;\J.?[A_*E=!9B \TY 2U-()_Y9M^521C'\#?E35B'%EA.,U8A
MZ$]ZJJ3D_(WY58A8@?<.?I6Z:MN9.$B9SM&>]"/GJ:CE<E>A_*HDD(?!4_E1
MS1[ARR[%F0CUIA/'6FR/DC"G\J-_'W3^5'-'N+EEV(68AL4QCCO3VR>BG\JB
MVOG[I/X5+<>Y2C+L)G)XIVPFG*O/W3^52@9'W3^53SHOD9"(SZ4A3FK&WV;\
MJ,#^Z?RHYT4H,@"X%,=B*L'@\*?RJ)P3_ ?RH]HA\A7#TX,2,]:4H<_<;\J<
M#M',;?E0FGU(E%B %AF@YI"1][:P'TIP8'&!P>]7=$V?4C)R,5'C%66 J!AS
M4-7&AG.:#G-/P>"!29.[H?RJ;61:8N!Z4_ Q3?F_NG\JD3)XV'\J:L*5Q-E/
M5.*>H_V#^5/!Q_ ?RJUR]S/WB/R^:=MJ3<,_=/Y4$C^Z?RI^[W!J1& !1MSW
MIW_ 3^5)N/\ <;\J+Q[BY9#&7!HQD=:=G/5#^5+T'W3^5%XARR&;!CK2$ &I
M.WW3^5,8G/W#^5)R2&E(:2 :>O/>HF))^XWY4]&(_@;\J.=#Y9$ZXQ3A]:C5
MO53^5+N_V3^55>/<GDEV'''K3&P!2,WL?RIA<XQM/Y477<:C)",1CI3#TZT2
M.?[I_*F;B1]QORI.4>X[2[$F*<%%("<?<;\J>N3_  -^5'-$:@Q *=L!I?\
M@!_*E!_V3^5'-$KD8)'SUJ;9GK3$.#]T_E4HSZ'\J.>(_9C2N*814A..JG\J
M83_LG\J.:/<7LAA%1,>*GY/\)_*D,9Z[3^5'-'N2XM%1@#SBF\[JN;/]D_E0
M(\-]P_E4^[W(O(JF,FI8[<]ZL\#^ _E4Z#*]#^5.\0U*!C8-[5+$ 6Y%663
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M:M"(@JOJG_((O/\ KBW\JMA:JZK_ ,@F\_ZXO_*MJS_=R]'^3'@H_P"U4O\
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M(?#T'A5+:YLP^HF$[Y"?X\5B6O@'Q&/AQ?\ AF9U<&4M;ENP[4PN>@_#X;/
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MS'^,5Z'X#\)WOA3P5=P.%_M:968N>I;'%8G@[X2VBPW=WXJB\^^N92QYX -
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M>FG_ %;_ $KS/4AC49S_ +5=%'<YJVQ1;K4;GI3VZU"YR0*ZY/0Y8HN:.?\
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M%% !0>E%(30,2BBBCH!0UH?\2F2N 45WVMG_ (E,E< ,@9KKPYS52052U?\
MY U]_P!<'_D:M]JIZMSHUZ?^F#_R-:UOX<O1_DRL%_O-/_%'_P!*1P%G_J3_
M +U%%G_J3_O45\(MC]\J?$SL/AI_R.]]_P!>TW_H2UI2_P#'U/\ [YK.^&?_
M ".]]_U[3?\ H2UI2_\ 'U/_ +YKZ3)_@^;/RGC+_?E_AC^3$SBC=SBDIO\
M$*][J?$]"6+_ (_(O]X5Z?'Q:Q'_ &17E\7_ !]Q?[XKU&(9MH_]T5PXG<[:
M 'A:,YPJCGN32C.. ">V:ANLM8W"I*J2,A"NW0-7,=0?;+,7'D_;8?,[QEAU
MJ<J5;!&0>F.E>-Q:6NGJT?B*WN$NWFW+JD3$KC-=]I&ORSZN^DQ,+BW@M?,2
M;NU0RD=/'D]C3^>P.[M7G,GC?79[BTL[&WB$L\QC8M_"*T8O&5_96^IP:G"B
MW]JP6$?\],^E(#L@\;MM5P9!]Y:=N'4 UYK;^)-1MI+BY2T!N8R&F^AK:?Q=
M=W%])'IJ0F". 2.[]F]* .P.$!=SM4<DFFAU=0T;"2-^C"O-G\:ZC-)<:7?A
M'-S 6C>/HG%=3X%+-X4A#.6?>1DT7 Z(Y'!IH-*1Q2#K1<!:*7BDXI@.[4#I
M1Q1F@!#24II*: ****HE@324&@4"%QQ24[K2$<T  %+F@=** "EQ2C&* : $
MHHHH ****!A12T47 2BEI#0 4F*7FB@!,48I:#2EL4AM!HHQGMQ68P'/-&=H
MY'-9VHWEQ%-':6FWSI!P34-MJ%Y#++;WZAIE7*E: -?MD@T;L\'(K&TJ^OK\
MRM))$H4D",_>I8;S48=56SN_*>*3D.O5:8&QTX[>M&*QKC5;A-7BM8(]\!;#
M.>U;.59SM((% !1VHH/2@&"GFN$U_P#Y#,GTKNEZBN%U_P#Y#,OTKJH_$8U/
MA,X4"EQ0!7H/<Y.@Q^?SKT'2CC2XOI7 $<?C7?Z4,Z;$/:N7$&E%%P<K4,EU
M:PLJ37D,;Y^Z6&:F!.PG.QL8'H/>O(KS3&M=3OGUZTN+M))"T-Y"Q(C'KQ7"
M=5CUPG<=P8-&>C"E;.!@&N+T?7&M[[2M(LI_M=I.I)G?D@]A5/4/'>J6MS=V
MD-NC2I.(4/89HN.QZ!S@<$8Z^](94+;"XWGHG>N,MO%6JZ?J%S9Z['$K)#YL
M+CHQ]*R!XHU1[T79M%%T4+HOJH]J+CL>F<] .:?M88PO'<^E<8OC&YN;NPM[
M.%6FE0M/GHAK);QWJMMJT4=VD3V\[F,*G6@+'HJ2(Q?9(LI[D'I3ZY#P&7!U
M59&) F) )R0*Z_(IHEA1FD)H%,0IIIHR:2@ HQ110 8HHHH&!Z4T=:=2 <T
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MMO8V\?VBXF,89N@I#1Z V PX.[TI%=&<Q1N"Z\L*XR'QC?6<6H6VJQH-1MF
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MUH8LW&,#UH YZZT;4DU*.2UG46P;+ ]370@?(, #'6@ ],\4I&* $H/2BBF
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M_P#0EJ[,?]*G_P!\U2^&O_([7W_7K-_Z$M6IC_ID_P#OFOI,G^#YL_*^,?\
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MW/Y4AV.P'T-.X]#7''QSJ Z>';G\J/\ A.M1_P"A=N?RIW"QV/X&C\#7'_\
M"=:A_P!"]<_E2_\ "<ZC_P!"]<_E1<+'7$>QH)Y'%<C_ ,)OJ)_YE^X_*H9O
MB#<VY43:!<J6.%XZT".S/)Z4AX[&N0_X3C4.H\/7/Y4I\<ZAC_D7KC\J .L'
M3H:7\#7(_P#"<ZC_ -"]<_\ ?-'_  G.H?\ 0NW/_?- '7Y&,<TW(SWKD?\
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MRNB?]RGSH+'3C/M0<URS?$+2HV"-;7'F'^$+3CX]TPY_T2Y(_P!RGS(DZ?\
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MI_*DS]*YG_A/=-_Y\KK_ +XH_P"$]TW_ )\KG_OB@#ILY]*7\17,?\)[IO\
MSY7/_?%!\>Z;C_CRNO\ O@T7$SI^!W%&17+?\)]IO>RN?^^*</'FF]K*Y_[X
MHN*QU.0>]-*UA:9XOT[5[_['#%+'+C.'7%;[#:Q'I33"PVBEZTE, HHHH **
M** "BBB@ '6G=:1>HI[<"@J)FZR,:9)7%1Y*UVVLC.EO7'PQD*.,UO2U,*K(
MP#Z52UL?\22^X_Y8/_(UJ[&/:J&N)C0;_/\ S[O_ .@FKJQ_=R]'^3-\"_\
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MJVEZO[J50?[K=:O 988K%GT;3;^-;NRE$9;D21G@U66YU319,7,?VBV[2+U
MK)SJ1?O&B4)+W1R8_P"$Y?\ ZYUOD\FN8L;Q=0\8--;G=%Y?S \$5U##FMX5
M%+8S<6MQ*6FTHYK7<0=Z7/O0>G:F\YH 4'K4=T?^);<_[AIX[TRZ(&F77^X:
M3 S?"W_( 0?[9_G6O65X7 _L"/\ WC_.M8BA )UH'%&!1Q3 4<4X&F9I-V*
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MTO\ 85E_>D_.J$7O/@_Y[I^='G0?\]D_.J/]AV7K)^=']AV7K)^= %[SX/\
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MU0U@'_A*M*QQ@<&LK&G0Z-^9#3>].?\ UC4WO6B,T%!I#1FBX,<O6N+UH_\
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M)]ML\_\ 'TE $XZTN>:@^W6>/^/I*!>69'-TE RUFJ6LG_B27?TIWVZTR/\
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MT_\ L73_ /GD:N#@]:?D^M*Q5SEY["VM?&5B8E(^0UU3<L?K7/7P'_"8V/\
MN&NC(^8T@8SI01BEI&ZTT2(:2E/2DI@!%)0329H 6F]Z7M0!3&*!2]*4 4IQ
M2; S=9_Y!CG%<4' &*[;6CC2Y*XF,*Q%=N&..N-W,>M4-9_Y M]Q_P L'_D:
MU0G%9^MIC1+[_K@_\C6];^%+T?Y,6!_WJE_BC_Z5$\UL_P#4G_>HHL_]2?\
M>HKX%;'] 5/B9V'PU_Y':^_Z]9O_ $):T)!_I,_^^:S_ (:?\CM??]>TW_H2
MUHR?\?,_^^:^DRCX/FS\KXQ_WY?X8_DR+&.:,T$Y%-![5[KW/BGL21'_ $R+
M_?%>J1'_ $>/_=%>4Q?\?D/NPKU6+_CWC_W17#6W.RCL/S124N:YD=(&A>M'
M6@<4F ^-=[8/:I1@D[JC7Y67)QGO4O&^D%A2H"9%8_BGCPGJG_7!OY5KE@HY
MX!K(\5_\BGJG_7!OY4"1C?#$;O -I_O&NID&#7+?"_\ Y$&T_P!XUU;\F@9%
M13B.<TFW-,0N.*6D.1Q2@9[TF H^^OUK"A_Y'J?_ *Y5NK]X'WK"@.?'4_\
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MU91YG^K_ +U;A\/:>2>).O\ >I 7O.B_Y[Q_G1YT/_/>/\ZH_P!@6 _YZ_\
M?5(= L/^FO\ WU3"Q?\ .A_Y[Q_G1YT/_/>/\ZSQH-AGD2_]]4\:!IQ[2_\
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M\,!CX?VG^\:ZW!]* #)HHHS0 449I,T .'45@0?\CU/_ -<A6\N21]:P8/\
MD>IO^N0H WF'SXI#UIS [Z0@YIB"FGK3J:>M #J81\U/%-(;/ H IZN!_8=Y
M_N5#H@_XD-F.VVI=7W?V)=Y!^Y46AC.@VA[;: -#&**,<452 ***.?2@09HX
MRI%+@^E)CE<"DP,2?/\ PFD)_P"F=;Q_UAK G/\ Q6L*GKY=;Y'[PT(!IIR#
MFF@BGJ>:8"GK2CI33UIPH *JZI_R![O_ *YFK55=4!_L>[_ZYFD]@*/AC_D6
M[;ZFM<]ZR?#'_(MVWU-:Q[TH@&*3I2T4V4)2$ ]:6E(XIW$Q.#@>E<_K./\
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MU_6@!G XIN:>4/\ DTA0C_\ 73 0&H[S_D'7'^X:E ^GYU%>#_B77'(^X>]
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M6:(Y)'%(I!)SC%9YU>S6U6<G 8X)-/EU.TCN(H2<&09%9_6*/<7LI%T-\Q'
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MY<DT <=+=:NWBN(&W0R"/O6Z;G7,Y%K'G-5YSGQG![1UNLY\QN: ,K[1K?\
MSZQTGVG7!_RZQUJ@G'4TX,1WIV Q_M6N9_X]4IXN]<_Y]4K5W&GJYQ]ZBP&1
M]JUPG_CU6JVH7.L_V5>![1,>6:Z NQ'WC535"W]CW?/_ "S-(#G_  Y<:O\
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M-HI0@Q2THH)(F6F,,%<U8(%1LN0/K0,YZ<C_ (3.''_/.MQOOM6'.,>-8O\
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M@CCXE^(_K2 ](S_.EW5'OYYINZJ)L2'DTUN*,]*":8"4444,9B^*Q_Q)HO\
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MZT@ "D/6C-!Z52 3-%-YHYI@.S5+61G1+OZ5;)/Z52UD_P#$CN?I4L!="_Y
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M#TS7J,0Q:PX_NBN'$2U.ZBM!Q'-*O!H_BI=N#7+>YN+(<8IHQC.*63M2?PT
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MB? QK_UXH_X1GQ/_ -!_]*=P.Q$;^E+Y;^E<;_PC/B?_ *#_ .E'_",^)_\
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M&/3DUR>DZ%X@&N1WVK7<<J1KCBNKE&)#TP>F*I"L(M.Q[TBTI-,!#24'FC%
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MO- !N-&ZBBI8!NH[TE*!30QPZ4#K2X^6D7@TFP,[7O\ D#2UY];']W7H6O\
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M%T.J^*M0T-8RKVHW*W8TQ'3JS@$ @[>F: 2#D=#U6FC.Y22 QY(%*PP<]S0
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MS'_:KHP^YSUGH0J AZ9H.YCTJ54.>:<@ '2O0Z',F2Z:F-0A^M=^.%'TK@[
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M=XZ&GXQT.?7ZU5B6,W8-+0115"#%&*44O% ""EQQ36I-QHL*S'=Z"*%YIQ%
MQ@ZT[M33Q2C)% "YIII0*4CBA#0PC$;_ $K@[I?]-EQ_>KO&;*M]*\_NY?\
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MGP99Z5="[EF:YEC.(B?X:Z-AD%7565NJD=:FXSR?3BTFLB+PJUV]A)$?M"7
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MM:0I$GEIU]:PM60OIMV6)RL3?RKHK_PY>C_)CP+_ -JI?XH_^E1.,L_]2?\
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M9MQ2]J=BEQQ1S7*L1[<GFC&*=BD-%Q,2D-+VIASFJ6PNHG\+_2O.+PYU.?\
MWJ]&8D(W':O.[Q,:E,?]JNK#[G-B&+&N1FIE&*CBX6I"V*[WL<:99M0/ML/^
M]7<#T]JX.R?=?0C_ &J[OO\ @*\W$;G?0%P*.E+2&L.AMU'"FGUIU(<8I (*
M4&FTIH&!/%-W&@GB@4 !YQGM2$9/:EH'/>D ;<G)I>A)P*4#WH-- -(&,4O0
M @#BFFI/X:>@#&SBE7#8R,$>E!/:F=*!"L.3[T@'%.&"*:P- !P#D#FCG)]Z
M13ZT[%)@)VP>E/4\8S3:0&F@)#@CM2C'7 S4>>*>#Q4R*%"C &3@=J7I0*#6
M=@ >O>FOG!'K2Y %,9JN*$Q.U&:!THK0D.^:3\!2TAI +FE'!^M-'6G'K3&.
M;&S%1CC@=*<3P*11S0 M'I113 .X..E-P!C'8YIU)4W 7(/4#UI&!_"BE)XI
M@-!_6G#BF#BGBI  ?FI&)'2@?>H;I3 <G2D)I >*#1<! :<*8.M(2:5P)#BD
MIF:4&F@) :#S3,T#)IM FQ] ^:@#UI5X-*RL.YGZY\VDR!NE<,LZ^6JJ>E=Q
MX@;_ (DTV/2O-H,F/).#FNK#G'B&6GZ[N]9FK'=I=V<_\L6_E5J5GQP:S=02
M=M,NSM.T1-G\JWQ'\.7H_P F5@/]YI?XH_\ I2.1L_\ 4G_>HHL_]2?]ZBO@
MUL?OU3XF=E\,?^1ZO/\ KVF_]"6NNE.+IP!N.XUR/PQ&?'5X,XS;S?\ H2UV
M3R102R8Y;<>:^CRC^'\V?EO&#MCE_AC^3&>0SG+C:.]#3K&I2(<^M,9VE'WS
MBHBI7ITKW;,^.3T)HF+3(6;O7=0_\>Z?2O/HB1<1_6O0(<>1'C^Z*\^OHSJI
M:D@%% Z45S&X8SS0*4="!UQFJUQ>V]E;FYNY5BA'\3&@"9L]:B)(&*R+?QCH
M]Z)A#*Q,0)Y'6K>F:C'K-HMU;*=A.W!JKDLN*23S2[N:,;@^,87CGUIOEO@9
M4[L\CVIW%8=@4FW--D9(<&65(U)PNXXS3AQ@$@D],=Z5Q6$*X%.&> *4H=I/
MH,U0TO5K;6%G-F21 ^QB?6C09I$X7!'-(00.:;\Y;:0<YI65E0%N?ITH8 1D
M<4A4CM3L8SU 7J:55).&/)Y 'I1<!@Y[8I"*<21GY>!TQWI R%U0RH)&YV$\
MT[@&:4\BL_3M7MM5N[JWMLDVS;7)]:O[6! &-WH:+@-)-"G%/9=@+'&.WN:,
M=RI(]NU%Q"$X%/.,@B@KSG X'/-"*<%N_P"E%PL-8=QUIOOWIX#;Q\OW@>M
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MC-9W*L&*0XI<Y[CCK2'#G (JHL5B,A3TIP*]Z81@\'KQ2A,>^*JX[ 1SQTI
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MSC6K+4SXUTNTM9PMP;<![H]>E31>)=0\--JEKJDOVJ2!-T4OO[TQ-'>L'/S
M';ZT @J22 !_&>!7E]AXKUV*XL;UDGNH[UP#$%.$![UT_P 18[EO"FVVNFMW
M9@=R]LU7,2=2%<KP,MGC'<5!<7UM;74-I,^V>;[HQFN&U2ZU_1-'T6RLKOS+
MB[VJ9&[ U=>2_P!+\1:19WLBW$LHR\I'W:0SM!&ZL05^IJ@FJV;ZF^FI)FY
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MTO3@L:+:($B.Y5QP#7/:KXTMH]%M-0TIUECEE"2./X17066K:=>X6WNTDE*
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M.&Y/4T^4FY6N[1+K2I-.ZQR1>7N/TKD;;X>K:^"[S0DNSY]PQ83'JOL#7;9
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MM..*WH+WC"O\)5_LTD<'%"Z3+GAA599[EN6)'I3S<3+_ ,M"*]);GEMZ$_\
M9DB+DR \UWNEQE=.B4GH*\X2YF/!8GFO1M)).FQ$^E<6(.S#%XCCK3=O?-*_
M J,GBN1;':..1C:><UY_X]NG\-Z_:^(=Q\J1/LY7W/&:[[/RYZFJVHZ39:Q
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M0&.Z7P_::C(XTR126+'@MZ&N^D\.Z6U^^H>1BX==KA3@./>I9M"TV[L/L$T
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M_BQ30I!I[>M(#FF 8SBG9QTI,$THXH :IIW4TA8#H*0L3TJ0%;@X'2D5MII
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M4S1;+Q/96[Z/>K%)9)&4BF!^8^E=<F95R'$BCHZGBF+=0^:84O(FD'5 V32
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MO)<:S/M!"AL9KJH+4YJZNBHP&#SS3XH99_E5#]:O+;06P)D<$TJW,TQ\JWC
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M<W#R0!M_DL<@'VH F\57]Q8^"[F\LFPQ0;&]%K@-:T*TM="T745U!WFGF1I
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M^UDM[R'5580*Y\@N<DK0!U6X E2>3T-&<4P?< [$\4IH #S28H%+3 ,4444
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M=[I;IXU>X' <= *Q?&-K?W.@7*V%UY!CC+,X%9%E>7B_";SE=WNMA4N/O=:
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MO6DRDC'?PQ9O<W\\S$B\7:P':J-OX*A2Q@L;B\DDBADWQ GI73XY&3\HZ"D
M(7&:ALM(SKS0K6[U2SU%S^]M%PM)K6CVNO6?V:ZR"QW(X_@/K6GGM39""<XX
MZ4(3.4M/!-O#J$%[=7TEQ<0*55B>BU/_ ,(L(K*2#3KY[5GD,N\>]=!@8]^@
MH."> ,'J*T(,"S\&Z;;V=S!<,9Y;GF2?OFDT[PO)IY>.;4I;BSD4H(R?NK70
M  #%*#T!^Z.U%@.2/P]LFB%HUY(+%9/-2'/&:NZGX4DU*8 ZC(EB4$9M\\8%
M=#VXZ4O8CMVI6'<Y^\\(65S;VRV4SVDUJ-J2+U-7])TZ32K8P2W37+YR7:KY
MIN/EQW[F@!>F?>B@\XHI@%%%% @H%%% "T8I <FG]* $[4C4II#S3"YGZ_G^
MPI_I7E,9!7FO5?$'_(#G^E>4KC:*WIF%1DF%"U6OA_Q++K_KDW\JF-1W_P#R
M"[G_ *Y-_*M:K_=R]'^3+P?^\T_\4?\ TI'*V?\ J3_O446?^I/^]17Q*V/W
MBI\3.R^&7_(\WO\ U[3?^A+72W3_ +^3_>-<S\,O^1XO?^O:;_T):V[A\2S\
M_P 9KZ+*?@^;/S#BYVQR?]V/Y,BD?BH"<J33&DS0""N#7OK<^&EKJ20_\?4'
M^^*]3C'[F/\ W17E=ON^V18(QN%>J0_\>\1_V17%B'=G50V'8--)(%.W4T\F
MN8Z18\DL>IQ@"N<\3Z==7NJ:4\"[XXVQ.?05TJ^M)C (]:D#S^R\*ZI'XNOE
M?']CQH9+=3T+D56O/".I7WAV"5K;_2[:Z,@BS@%:],4X3!Z4GF,?XC2&<);:
M,FN6=[$VD-83-'@3$\LPK,NK?Q/?>';703IVUK>929NS*#7IF]B<;J<)'QC=
M0!Q$FBZP+S4)K,>5(]L$1L\@@5B6F@ZS>S:49+)EEM9=]Q,[<O\ 2O3R7_O<
MTOF,[=2,4 <KHFE7UO%KXEC"FZ),/J>.]7O!=A<:3X=%O?+MDWMG'<&MXL3M
MQ0^2W/*^E '"I9ZQX.UF]EL;3[9IUV_F>6/X31I>FZS?ZY+XGU*'R9(8BMK:
M#KFNW#,"<$@>].C9BQ9FR>QH \VUBWU7Q3+!;?V&+&=)0[W:C'0UUOB:UU2X
M\,O:Z3<;;V- -Y_B%;1DE"D \$T# .13 \SL-"U.\UC2K@6#V_V<8GDD_B/<
MUO\ AN+5-'U^_P!.GM6:SG<R1S8XKK]S,1\QP.N:168!@7R.U%@*FIQ//H]]
M#$/WDD17'O6+H-O>Z/X)2(VWFWB9/DD?>YKI-Q+"AMWF!@>:+ >>7-GJOBK5
MK /I:Z<EM()))5&"?:NC\:V$^K^'Q;VR%Y%D4A<<8%="S.3@=^OO0N]9,[N/
M2@#C]:TB_NM6\.7,40>.UP)^/N\5#JGAF[UC7]5WILMYH (9<]6'8UVRL5WX
M!R:3!X(;\*5@//VC\1ZGIUEX?DTX1Q1,!),>FT=Q6QX;TJZTS7K]Y$7R"@2.
M0GDGTKK"Q:/EL5&#T4CCM18#SN3PYJO_  CVHA8\W8NQ,B@<,N:T8X-0U/7=
M$U&>S,0MH]LBM_"?6NURP.10Q+<=SUIV$<E<:;?Q^,;[4DM1/;M!@*3P]9&D
M:?J_]N_;M-LY+&W12TULY^5V]J]%#L%V"G$LR#FD!FZ1=7M[:/+?6_D2[R-@
M/&*O]13B3NQ2'I5("/!H'!IW%!Q3 1C@@4XCBF]ZD/W:!6(\TTC-.HI#&\CB
ME!QUI<<TA6BP[CA@TA3TIN*>M%@N 7%/%%-JD2P[TY3Q2 4HZT@%QGFD(XH-
M)GB@ Q2%>E+FD+8% [CU^_7 ^(Y$75)0Q!-=VK<UYWXDC!UR5CTQ6]#XCGK?
M"4556?)Z5;5HE'052!48H9UKT+ZG!T+KW:QKP.]=YI;[]+B?U%>9.<@_6O2M
M('_$G@^E<F).K#%\'Y:::=_ *8:XD=S$.<8QR>!7&^*[V]N?$FG>'+.Y-K%*
M,SN.K?2NRX[DC/ /I6+X@\,1ZX]O="<V]_;']W,IZTF(XN"&;PYX[U*?SS=-
M;6A,8?[QXJII^IZS=)9ZQ8O<SWT\^)4.?+5<UVFF^"X;/4[C5+Z\DN[JXC\I
M^. *33?!]WI-XHL]5*V 8N8BOZ4BC"\C4O$.OZO')J,L%O:1^9'&AZ.!6?;-
MK=WX5;Q$^IM]JM)=@0'Y74''/O7?VGAV&SO]1NQ.2U\A5@.PZ53B\&V\/A>;
M0A*WE22;]^><YS0!A?:KWQEKL6G_ &M[*&*W$A$9Y9O6L^YUW6;31M1TG[6'
MN;68)'<Y[9KJ-0\&^?):7-A>&TO(8_*9A_$/>E7P/:+I+6+SEIY7\R24]S2$
M<_=1:AX;FTG4/[2FN#>X62)SQD]ZBA>ZA\3,?$EW<VVZ0&W9?N$=@:[75/#<
M&K6]A%)*46R((;UQ65J'@^?5KK%WJGG6(</Y9'S#'8&F,PM+T3[3\1-3O#J4
MQ*1[E0'@C%2^$(=0U:6^UC5-3=+:WE947/&T=ZWKGPD#KBZE87AMOW7ELG]X
M5:TWPY;V&DW>G;S)#=$^9Z@F@#A=6U=;2_MM4TK4;E_,FV$MG81GM5S3-),O
MQ$O]2:]FW16_F^5GC./2M"'X<Q_9DLY-0S90R>9'$!@@YK6NO"@/B&#6+*],
M+J@CFCZAQTH X(:YJFN?;-0MI+HW=M/LAC7.WKWK=AN]6\6:]#I-U<OIYMXA
M)(J<,QK6D\%RVVHO/I.I"TAE;?*F,[C4^J^$C?ZA;W]M?-:W\2[7D'_+0>]
M&+\/[=[/Q;K]K/)YK C]X._UKF_B)9W.H?%W1;*TG\F9HB!-W%>A^'/"T/AN
M]N[M;EII;MMTC'GFHM4\&VVI^-+/Q.UR0]JNT1^M(#@=%U;6].NO%7AS5+XW
M9@A+Q39R1QT-9<7BC6[?P!I+B806EQ<&.YGCX*#->D'P!;G7-7U/[60=2C,;
M#^Z#7 >-/#C^'](TSPR(YY='\WS9KE%S@T +HZ:M<)XA9[^>\T"&V+12R='.
M*Q--MO$>G?#^V\0V>KM%:QW'$ X!&:W_  9I^K7FJ76B6SROX:GB*^8R[<5W
M#?#VT_X0D^%%NF"+)O60_6F!PWB[QMJ6IZUI&D03/:P3VX>62+[Q;':EM?%'
MB2#P7K"W0FB>S;%K</\ >?GO79ZO\,].U.TL8XKMH+^T0*EPHZXJ4?#]I?"U
MSHUWJ;W$T[9,I'04 4_AS8>(9;:/7==U1IX[F,;;<=%]ZQ/BE=^)H-<MF@F>
M/15'[R6+JOUKTK2+!=%TBUTU',HMU"[C_%7-^*_ D_B*[,R:R]K#(,-!_"10
M!QFO>(KJUTOPPVDZR]Q;7-R$EDS[]#6[K&L7Z?%RQTZ"\)MFMLM&IXSCK6A=
M_"[1IO"D6@P.T31MO$_HWJ*;HOPOM=*UB'5VU.2XO(H_++.<Y% ')>&5\4^,
M_$&K6YUAH+*SG95"GGK4$/CC4?#^E:[X?OKMY-6639;2-][!Z5Z9X5\'0>$;
MO4+F"<RM>R&1U]ZSM;^&NF^(/%]MXAF<1R0D$QX^\1ZT <=*^J6.M>%K&_N#
M+<W4>9&<<JQZ5"?&NH^'++Q)I&IWC/J7F;+(GOGIBO1M:\&0:SXET_6C,4-B
M %3U JCXC^&VG>(?%5IK\DP1K<@E".&QZT <GJUY>6?A;1M+N]8F36;I/-*H
M?FYK'T3Q%JNI^%?$^CZG(95M$.PR?>/UKT;Q;\/++Q/JMIJB7;6=];J%0KTV
MU4L?A?865OJ2)J#R_P!H)LD=NN: -#X51A?A[8G@Y#8QT%<%H+^*O%'C?5;&
MWU=K>RL;C+_[0STKU3PUHL?AC1(='AE+QQ9^;ZUF^'O!D'AK6=3U&*X,KWQ)
M9#VH \Y\;Z[-/?7DFB:Q<E]/3$B)T#"JOB[4M3\2_#;P]>379B:681N5."3Z
MUV5S\)+"?4KRZ@U![>&^!\Z,=<UHW7PZTVZ\%KX:>=DCB;=#<#J#0!R/BS6-
M4\ ^%-)T:VOY+J>^VAK@\E%/I5CP!K'B"V\7-IUPT\^E21Y\Z?J#71)\-K6X
M\*KHFIWTES*G,5V>2N.E3:#X$N-+M;F.YUJ2Z\V,QHQ&#&*5QG8?NFR8I RY
MYQ3V7* UD^%_#I\.Z4+)KM[DEBQ>0Y-;/.W&.*7,%B+;SUHRH]Z?Y8.:84 I
M\UQ- 6'84F_VIIHS3$.R3WI.1WH_"C\*!AR:7D#I28^M.VF@!.IZ4+P:"K8I
M%4YYH 5_O\=:4#(^:E. :C<D]*& [>2KKVQ7EMX=FLS@'JU>H@$*W^[7DNI,
M5UNX)_O5I EFQ;ME.HIK@@U3M9P5ZU?#*RC-<E6#N=5*2':=_P A.#_>KT9O
MO_@*\^L$4ZG#CLPKT%OO$>PI1057J- P:?D,I3&<\4E-X!!]#6Z,#A=;75=2
M\>PZ3;W[6UAY>Z0+U)K(U#59[WQ)=:*);D06$7R-'G+M[UW;Z#$WB-=;\P[U
M&"N:H:MX5%[J1U/3+S[#>/\ ZQMN1)3).7FNO%%YX8A,D$BQQOB;;]\Q^M37
M>I6UOX8B;2]0>X+3J&$WWDYY%=//H>H'3XX+;5&BG3EY2.&K/M_ -I':-#+-
MOF>7SGD' S3 Q=6:_364FUR:XBTPA3;S0$@ _P"U2S:/'J7Q&L)8M2E:,0[@
MZO\ >XKH-6\*W6JDQ?VEBQ8 20D>GI27?A"%I[*?3KMK6:T4*#V=>] &-XHO
MK.>2ZN+*_N3-9KAMF=H8>M02:CJ^MW6@6Z79A2YC_?LG\0K8E\!(7NEAOQ'9
MWG,ZXR2WM6A;>%+>UN].FBFP;)=JJ3]X4@.<_M._\)W&LVHN&N88TS"7.2AK
M0TK3+JUTAO$USJ,EQ<>09!$#\@K:D\,6<^J7E[,V];I=LD9[52TSPE/I<S0C
M4I)--(.;4\\&@#B;;5]6O;&+6K)KJ6^DFVM" ?+V9KUJ!W:UB>10CE 6C7UK
ME[;PC<Z;>&2QU(QV!DW^1C]*U[729+;7)]1:[:2!TPL6>AI@:0.<\4T<YIQ.
M22.,T4 -HI2*3%- %%)@TM.XA.]//2FCK3Z5QB4&@=:1NM($% -)10-C\Y%)
M313LT"Y0HHS1F@!#UI*?Q1@4"!33Z9BDS2DAHDHIJG'6EW"LVBKBD#-1OBG,
M:C[U2"X448I:T3$)2BBE%%Q"]J.U**3UH$--)3V^[3* 044J@5( #4W*(P,T
MN*E""FE*+CL145(5%,(HN*P@ZTZF#@T^F(*2G#I3?X33 S?$'_(#N/I7E"GY
M1]:]7\0?\@&X^E>3(>M;09E-$A-1WW_(+N?^N3?RI^:AOC_Q+;G_ *Y-_*KJ
M?PY>C_)FF$TQ-/\ Q1_]*1S-G_J3_O446?\ J3_O45\8MC]UJ?$SL/AH<>-[
M[_KVF_\ 0EK4G8M//P<;S67\-!GQO>C_ *=IO_0EK5NHVBFF+9QO/2OH\H^#
MYL_*N,I6QR_PQ_)E4KWINV5SMB7<QJQ;PS7+;8T(0]S6A]F%HFU7 <_Q>E>_
M8^+OH5[:WCMYH6F?YR1P*]*BR;>+']T5YQ$+5;R(NY=RU>DQ'%M'Q_"*X*^Y
MUT-AP0XYHRHH+'%,)S7,= [=V%(S8(I!]X4/UH*0[G%-)P*12:",T@%!]A3B
M1QQ4?2ES0 I;YN*<" <TRDH$/&*4$XR#S35YI1QFG8!"2>M.0>@IIIT>:+ #
M+\U)S[4\]:;18 [=*3 S03BB@ '%*">])10 H6E]\<TM%%@$R<\4 8/ YI<8
MYIV1BGL A3<.>/I2%AC&.E.S\M1D47 7.13<G-*#1CFACL. '6E^E)TH!J08
MO2D/(I6'%-)^6J0A,9HVTBFES0 8YIYZ5&#S3R>* &4444@$.<T9S0:513 ,
M&E%+2B@!>U&*7C%)F@0O2F]Z":!UH 4\BF8-2$X%(&S0 W%(0:?N%(6H 11S
M7GOB<L-8D"KSBO0U?D5P/B*Z1-;DW+VK6D_>,:OPF!NDSC::<-YZJ:M?;HB_
MW!4PNXL?<KT5N<-M"B5;;G!Y->F:1_R!H/I7 BZB*[=G>O0=+V_V9$>V*Y,2
M=&'+6-R@"D*$=2*7BFL37(CM#.*0]C@9'2FY-+GBDP#DMN8Y(Z>].7 Y QGD
M@=S3*4&D,D&#SW(P:4XS@\BF9HS0 XDDG)SFD/S#!/ Z4F:3-%@ D\DGGL.U
M-//X\GB@]:*0Q&&[.3CW%*><CU[T44 )C@+V]>YH (^8':>F*6B@ XZ8SWI"
M#UW<GKQ2T4 *#M/R]#U!I.N>WI110 'D '\?>D=4D3RYHTEB_NL,TIZT'I0
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M110FA:B#.:D_A]Z:!3@*>@:C0.*,4\D#J:8QI:"NPI13 <BG*:- U%HHHJM
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MC/BK_IS_ /(O_P!:N=HI?VGBOYOP7^0_]5<I_P"?7_DTO\SH3XHS_P N>/\
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M^;\%_D'^JF4+_EU_Y-+_ #.H'C#'_+A_Y&_^QH_X3#G/V'_R-_\ 8UR]%/\
MM3%_S_@O\@_U4RC_ )]?^32_S.K'C, Y_L__ ,C?_8U:7Q^JK@:5SZ_:/_L:
MXJBG_:N+_G_!?Y"_U3RC_GS_ .32_P SLY/'S/\ \P[ _P"N_P#]C34\=A1S
MIF?^V_\ ]C7'44?VKB_Y_P %_D'^J>3_ //G_P FE_F=E_PG:_\ 0,_\C_\
MV-,_X3HYXT__ ,C_ /V-<A11_:N+_G_!?Y"_U2R?_GS_ .32_P SKG\<,W_+
MAC_MM_\ 8U6D\7-(>;/'_;7_ .M7-44O[4Q?\_X+_(:X3RA;4?\ R:7^9T(\
M4X_Y<_\ R+_]:@>)\'_CS_\ (O\ ]:N>HI?VGBOYOP7^17^JN4_\^O\ R:7^
M9T1\4_\ 3G_Y%_\ K4W_ (2;_IT_\B?_ %JY^BI_M'$_S?@A_P"JV4_\^O\
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M&7^9OCQ-C_ET_P#(G_UJ</%'_3G_ .1?_K5SU%5_:6)_F_!"_P!5\J_Y]?\
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*>SORNV__  #_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>img_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (Y ]D# 2(  A$! Q$!_\0
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M'E'_  K3Q3_T%++_ ,"W_P#B:/\ A6GBG_H*67_@6_\ A7J]&*7^L6._N_\
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M&/\ X5Z@:3%5_K)CO[O_ ("O\R'&)YC_ ,*V\4?]!6R_\"W_ ,*/^%:^*/\
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M_P#"O2Z*/]9,=_=_\!7^8>SB>:?\*X\3?]!:Q_\  Q_\*/\ A7'B;_H+6/\
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MQ-_T%K'_ ,#'_P */^%<>)O^@M8_^!C_ .%>ET4O]9<=_=_\!7^8_9Q/-/\
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M;_\ Q-'_  K3Q3_T%++_ ,"W_P *]8XIAH_UAQO]W_P%?YBT['E7_"M?%/\
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M %CQW]W_ ,!7^9/+$\Q_X5MXH_Z"ME_X&/\ X4?\*U\4?]!6R_\  M_\*]/
MJ1137$>._N_^ K_,5HGEO_"M?%/_ $%++_P+?_XFC_A6GBG_ *"EE_X%O_A7
MJ@H-5_K%CO[O_@*_S%H>5?\ "M?%/_04LO\ P+?_  H_X5MXH_Z"ME_X&/\
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MB6QZKQ3L4)TI^*T2,FR,K44@YJR14+CDBE)#BR"BE]J2LC8**** "BC%."T
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MR_\ LE<A78_%\8FTC_=F_P#9*XZOTC*/^1?2^?YL:.@^'?\ R/EW_P!<I?\
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M;JX-Q+HUJ9"<DJNT$^X%#I[- I]&<=\+SIM[=W5]8Z"]B8H_+-Q]H9U;)^Z
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M>?UK-P+YB^D9C8G=GBE8YZ\UDZK8WEUIB6]N5#J5/#D?7FL'_A&]9/\ $/\
MO]32MT!NYT[VOSY5L#TIQ&>#7+?\(SK/]X?]_J8WAG6?[P_[_5:=NAG)7ZG3
MFV1CD'%21VB \DFN0_X1O65/WA_W^J1?#FL?WA_W^I_(CYG;*H P!3Q6;H=G
M<66G>3=',F]F^]NXX[UIU9)Y1\9?]=HW^[-_[)7$UVWQE_UVC?[LW_LE<37Z
M1E'_ "+Z7S_-C1N^ /\ D>;O_KG+_P"A"O7(UR>E>2_#T9\=W?\ USE_]"%>
MPHN*^5XD=L8O\,?R+BKBJM2 4JK4@45\US&O*1%::PXJ<K49%-2$XD.WFG!:
M=BE H<@41-M/"\4H6I,4*0W$BQ2$4]A3#6J9FT,[T9H--)JC,=FC-,S3N] A
MPIP&::!4@%,+B;:-M/%* * (\<4X+3MM*!4E#,4E2%32;:0QF*,4[;1MYH&-
MI#3C330 TTTBG4WK28QAIAJ0BF'I4W*2&&D%.)I *FY=APJ0"F*,4\52):%I
M*6EJ[D-#:::?3",TR&@I,4[% ZT$B8J2-:0+4J"BPKDJ#I4RD"HU%.!YIM")
MQ@BF,*0/Q36:DK@12=*JRU:>JLG-4,A)I.M*114%"8HIV*0B@+BJ*=GYJ$7B
MG;?GI@(1Q4#CFK>WM4+J,FAH$R&BEQS2@5)5Q ,FG8Q3EQ3L4["N"CBDQS4J
MCBDQAJ8B)QQ46*LNO%,"9I,I$>*"<"I-A%-*\4AV(CR:>B\TNVG"A(3)T&!3
M0O)J2,9%*!@FK(*K(=QIRC J5ADDU&3BI9I%$BFI U5MQS3U:HN:)$^_%.1S
MFH">*56YH0,LEZC8]:1CP*;G(-:)&+8UFRN*@8=:FSBHY/6F1<A:HR>:>U1,
M>:S9K$7-)29I14E#EJ>/I4*U+&:H2W+"TZH@U/W5FSLA8&&:813B:3O674T=
M@Q4L2<TU5R15A>&P*TB<\V* !VI0H/:D)YIR538DAP3BG!:44Z@30S;2XXIQ
M%&.*9FQHI0* .:<.M2RD1L.::14C]:9BH-"(BF,!4Q6F%:M"9 0*8U3,*B85
MJF82(S3X^AIC+3XAQ33U):&S]*A6K$XXJ 4/<5M"1&(.*LKR*J=:M0G( H!#
MPIS4RI[4 <U.BU#-$1E..E1.E72O%0.*$P:*3)S0O!J1ZBSS5HS:)1135/%.
MIDGE'QE_UVC?[LW_ +)7$UVWQE_UVC?[LW_LE<37Z1E'_(OI?/\ -C1T'P[Y
M\>7?_7*7_P!"%>QH/:O'?AS_ ,C[=_\ 7*7_ -"%>RI7R7$O^^K_  Q_(VI[
M%F*VFE7='$[C_9&:E%E=#_EUF_[X-;ND?\@R+\?YFKU?)N3.I11RAL[K_GVF
M_P"^#4;6-V?^767_ +Y-==24E-ARHY#[!=_\^LO_ 'S2_8+O_GUE_P"^:ZZB
MGSL.5')BRNQ_R[2_]\FG?8KK_GVF_P"^#7549IJ;%RHY,V5V?^767_O@TPV%
MY_SZR_\ ?-=A25:K2)=),X[^S[W_ )]9?^^:3^SKW_GUE_[YKLJ*KV\B/8Q.
M-_LZ]_Y]9?\ OFE&G7G_ #ZR_P#?-=B**/;R#V,3D187G_/K+_WS2BQN_P#G
MUE_[Y-==11[>0>QB<F+&Z_Y]IO\ O@TOV*Z_Y]IO^^#75T4>WD'L8G*_8[K_
M )]I?^^#1]CNO^?:;_O@UU5+1[>0_8Q.5^QW7_/M-_WP:7[%<_\ /M-_WP:Z
MFBE[:0_91.5-E<_\^TW_ 'P:3[#<_P#/M-_WP:ZNBCVT@]E$Y,V-U_S[3?\
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MQYTZ\(_X]9O^^:4:==X_X]9?^^:["BCVTA^RB<<=.O#_ ,NLW_?-1G3+T_\
M+K+_ -\UVM)2]M(/91.*_LR^_P"?27_OF@:9?9_X]9?^^:[6BG[:0.E$Y)+&
M\4?\>LO_ 'S2_8;OG_19O^^*ZVBG[>0O8Q...GWI/_'K-C_=IITV\_Y]9?\
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MP/9L8[45YI\-Y6O;\3O?^+)76U#.FK0E+=BV.4/<^GL:]+I@%+3:* '44E%
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M2VDN+B18H(U+/(YPJ@=233U8.H92"K#(([B@!:**6F(2BEHH 2BBB@ HHHH
M**** "BBC- !1244 +FEI** %HS244 +1110,6BD%+0 E%+10 E%%% !37_U
M;?[I_E3J:_\ JV_W3_*@#B.U1D<U)Z4!:[DM#D9L>'!^_G_W!_.NAK \/#%Q
M/_N#^=;5Q<06EO)<7,T<,$:[GDD8*JCU)/2N2I\3.B'PHEHJCIFM:9K43RZ7
M?V]XD9VN89 VT^_I5[!]*@H2BHI;F"&6&*65$DG8K$K'!<@9('KQ4N": "BH
MA<P&[:T$R?:%02-%GY@I) ./3(/Y5+0 444M !1BEHQ0!QOQ&T^_U'1[6*VT
M&VURS$X-Y9N=LI3'WHFR-K"N#M/ _B.]\'^*M/M[&\L+"Y,+Z7INH7(D=61@
MS<Y.T'& *]NHI6'<\L@MO$GBCQAH^IWGARYTFWTFPGC?[1(I,TKQE,( >F3W
MKE[#X9ZMI7A;P]K$6EW%WJEE/OO=&N)=R2KNX95SM##@U[U118+GDGQ$\'Z[
MK'B6VO-"MI5MM:M4LM6Z Q('!RW/7''&?NUMW/A2:;XEH?L+?V$= ?3S+QL&
M3C9Z]/:O0**+!<\A^'_A?Q)H=YJ.IZU92S2Z18M8:1$,$S(&9LKSWXZXZUCK
M\.O&EMX>M=;2Z235H;[^U?[.$($OG,?F7S,\_+VZ<5[M246"YY;I-SXC\.^+
MO$^H?\(;JE[!JLT,T1A>-=NU""#EO4_I6O\ $G2=1\4>![.VM-.G:XDO+::6
MV##?&H.6R<XR,]J[NBBP'ENE^%M0\">.;Z\T[2;G6-.N[-OL]PS^9/:R 9\K
M+'[K$#]*YU?AUXT@\.V^MI=1OJ\5]_:O]G"$"7SB?F7S,\_+VZ<5[K118+G$
M>)-,U/5O&'@?4X=/E$-K+)+=YQ^XW(.&Y]>.*YKQEX9GO/B7=:G=^$]2UK3G
ML8HHC9W/D[9 3G)W*3Q7KP-+18#R?6](N[SPKHEK'X$DN-'MWD6?3)YMU[#U
MVO')O[D^N:VOA?I&LZ1IVI)J,%W:6$ESNT^RO)_-E@CQR"V>Y[5WU-)H"XVB
MDHH <*2E%%,0E)2FFT#'44VE%(8M%%% Q1249HQ3$<EJ7_(2N?\ ?-4ZNZBN
M=3N3_P!-#58H<9KLA\*.>6Y>T#_D)_\ ;-OZ5TU<UH0QJ?\ VS;^E;&IZQIN
MC0+/J=];VD;MM5IG"[CZ#UKGJ?$:PV+M%16MU;WMK'<VDT<\$@W)+$P96'L1
M4V#Z5F,**C6YA:Z>U65#.B!VC!^8*>A(]#@U+@GM0 +PP^M>2>#_ (6V]U97
M,OB:#4$?^TI9DLGN"(77=E6*#KFO5+>ZM[N-GMYDE17:-BC9 8'!'U!J6@#Q
MW4? /B;Q?JGB;4;B=-*AO/\ 0[>VN( [/!'@H0<_)DC/YUH:UIOB;7_A)I-E
M<Z3<#68+JW$\!*[BL;8WYSC!&#7J5+2L.YYA\0_#FL:OXIGNM/L);B!O#MS:
M!TQ@S,Q*IR>IK+\(^'O[,>R4^ =:M=0%NT,E])>[HE8H06V;R,'TQ7L6*446
M"Y\_WGPR\0P^#]%N=-L)H]0DQ!JUB"N7592R.><9''YBO3-=TC4+KXF>$M2@
MM)'LK.*=;B88Q&67 SSGFNUHHL,\9\;^'-7U'7M5D;P?+=7KX_LO5]*G\AEX
MX\[YN2#WQ7I^F:=>R>$+;3=:F$]Z]F(+J3KN8KAC[UKBEHL!X%I'PY\2Q^"]
M<ENK.5=;MIK==*1BI8I V5V\]#G]*WH?!NL6GA;P);+82R7=KJJWNH@$9BW-
MN9FY[=.,]*]>-)181QDVD7[?&.#6!:N=.72'@-QQM$A<';ZYQ7.GX=Q:WXR\
M8ZAK6EW+1R[#ITBW#1B0[&S@(PSSMZUZI118+G*_#33+W1?A]I5AJ-L]M=PA
MQ)$^,KER1T]J\]D\,>)+/2+>1-"NKB:W\5R:CY"%0SPY!##)QSBO;3TI* /,
M#H_B#Q%K^N^)+W1I=,#:-)I]G9R2*TLK-R2<' Z8'UK ;X7/:>$/"MS9Z-=?
MV]'=6[WRFX9MB@DL=I;:.W05[?1189Q_B[1[R^\5^$KRRLS)#:ZBTUU(@ V+
ML(#-ZU8^(NG7FK_#_6+#3[=[B[FC01Q)C+$2*3U]@:Z?%+BBPCY\U'X:^)#+
MKT<>G32VD"HVF1@K\SRRQO+MYZC:U=?K/A#Q+XL\<75SYJZ7865B+&VDN(%E
M$X=3YI5<\>F:]4Q118=SQ1_"/B6_\&^'O#NI:9=2?V5K7EO*CA=]H V)%(.0
M.<>O%7(/!>J^'+GQ?I5IIDVHVFIV$ALM29@\JG:<0.2<]>GX5Z^>E%%@/'/#
MO@K6? 4OAW6M%L+JY>Y@6#7;$N"_/.\9./E/&!Z>]4[GPG(/%?B.YU7P-K&K
M1W=ZTMM/:7GDKY>!V#C->WT46 \LUKP5<>*_&^F7%U8ZAI^FC0_*\U)MKVTV
MX[4)!Y(!'J#6U\,=+U+0-#NM$U/2Q:RVMPVV[3&V]!Z29SG=QSGVKN:2BP@I
M124X4Q"&B@T4 *.HKB[E<W4Q_P"FC?SKM!U%<=/_ ,?,V?\ GHW\ZZ,/\3,*
M_P )Y'\8!B;2/]V;_P!DKCJ[3XQ#]]H_^[-_[)7%U^IY3_R+Z7S_ #9RHW/
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MM%)0(6BBB@84444 !Z44'I24"%HHHH ****!A2TE.H 2DQ2FB@ '45QMP?\
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M3D<FD!R5MXE\/W-H3>$R.[L&\RT8Y"N=O\..!C%7_P#A,-#_ .?F7_P&D_\
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M:^K_ /0M7/\ X$Q?XUM'J:,BCFCW$8IU?5_^A:N?_ F+_&C^U]7_ .A;N?\
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M8]G=NW^<]:WQU%8%D &TC&W'FW/W6+#JW<U+W1K'^%+U7ZF_2XHHJC$*:_\
MJW_W3_*G4C_ZM_\ =/\ *@#D0/D7Z4F*>H^1?H*,5W)G(T:.A_\ 'S-_US'\
MZW*Q-$_X^IO^N8_G6W7+4^)G1#X4)1167XCU9M"\/W>I)$LI@ .';:HR0,L?
M09R?I4%FI7/^.?\ D1-;_P"O1_Y5C:?XUU+6(X;;3K;3IKR2:=1/YK?9W2(*
M2R\;N2VW!Z$&K6O:FNM?"G4-26(Q?:+!V,9.=AZ$9[X(-(#I-*_Y ]C_ ->\
M?_H(JW67I>HV*Z19 WMN"+>,$>:/[HJW_:=A_P _UM_W]%,"S256.IV'_/\
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M15A4$E 2OH,#CFNTT."]DUG5=5N[-[-;OR(XH)'5GQ&IRQVD@9+<<]!6]BD
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M9$NO,N+,9N9"N[;TSQ6Z+2V_Y]H?^_8_PJAI-M;LEYNMXCB[D R@]:OW//\
M GW_ "#^T=!_Y^;'\UIPOM#(S]IL/^^EJ]]DMO\ GVA_[]C_  IG]GV6?^/*
MV_[]+_A3]SS_  #W_+\2K]NT/_GXL/\ OI:/MVA_\_%A_P!]+5K^S[+_ )\K
M;_OTO^%']GV7_/E;?]^E_P *7N>?X![_ )?B8UI>:.-4U(M/9!"T>PDK@_+S
MBKWV[1/^?BP_[Z6HK*RM#JVIJ;2 A6CP#$N!\OTJ_P#V?9?\^5M_WZ7_  H_
M=^?X![_E^)5^VZ)_S\6'_?2T?;M$_P"?BP_[Z6K7V"R_Y\[;_OTO^%']GV7_
M #YVW_?I?\*/<\_P#W_+\2M]MT3_ )^+#_OI:K*]K=:E=K8-!)FQV_NB,9);
M .*T_P"S[+_GRMO^_2_X536.&TUJ9H840"S#%8U SACZ4>[TO^ >]U.>TSP[
MJMO<Q>8-B0V\D$+;P=@92><'^\<?A3_[$O9+.6.+3UM2+,0,HD4^>^X'=^&#
MR?6M[2M4GU.RED\B.*=#@1,S @D9&[(R*S7\1W<-G%<36]M&LL[1 F1B%VYR
M3Q[5V^TK2D]%<Y>2FH[NQ3ET&^CC>(6_F_Z6LN^,1@,FTCA#P"._K6Q=:>US
MX7DM/LH,_DD1QNJ ANQXX!^E54\2W$LMO&MI&AEA64[V8]6(XV@^F><=:MQ:
MX+C6KG388TW1J?*=GX=Q]X''(QD?K43=5V;6VI453UL]]#.O]#NY/M0M%\F-
MK6-!%&%"R,#D@^GUJ0Z?JO\ ;PU01)M#"'R]_P QAQC/7'7GUI6\2W,%K#<W
M-I"L4ER8"4D)V@$AF/'M4:>+)9DC:.UC7S)9$4NS$;5 (/ )YS5)5K;+L2W2
MON+H&C:AIU_;F<9MDMWQE@3&[$$K].,UU%<\WB;R[]K.2W EWQ(C;CM?=C=C
MCJ,]*O:=?7EU>W<,\$$:6S[&9')); (ZCI@UC6C4D^>2-:;A'W8E"^_X^KC_
M 'C5!ABM"^_X^[C_ 'S5$UZF"_AG+6^(NZ)_R$_^V;?TKHZYO1#_ ,3/_MFW
M]*Z2IK?&SHH_ A*Y3Q)X3N=:U)[F"33RL]LMLYO(#(]OAB=\)!X;G\U4]JZR
MBL34Y>U\,7\&I01O>V[Z3;7KW\2^6WGM*V[AFSC +L>F>@IFIPQS?$S1%E17
M7^S;HX89YW)75UR]]_R4[1/^P9=?^A1TAHWO[/L_^?6+_OD4?V?9_P#/K%_W
MS5JDIB*W]GV?_/K%_P!\TO\ 9]G_ ,^L7_?-6** ,B:QM/[=LQ]FBP;>;/RC
MU2K_ /9]G_SZQ?\ ?(J";_D/V7_7O-_-*OT 0?8+,#(MHL_[M-^Q6W_/"/\
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MTG5GW'[./8P?^$0TW_GK??\ @2U5-0\*:=#;HRR7A)EC7YKACU8"NJJCJO\
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M_K6/.P#2>N\_SHH)>ULBYMN%V>/?&9-LNC>ZS?\ LE<37;_&9BTVC9_NS?\
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MG_STM/\ OEJ-NH_Q/:_@K5G5^!C19I5^\/K57;?_ -^V_P"^6I0M_D?/;?\
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M3CKFNKW+OWG_ %\OZN<_OV6@MMIVC32HMI))O$(9?*G<?NR3CH>F<\4RV;0
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M9MO&Y*0SK**J>;J'_/G#_P!__P#ZU)YVH?\ /G#_ -__ /ZU,"W255\W4/\
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MX5TD#,Q7:_W@%)PN>^T"K.EZ18:/&\5A;B)9'WN2[.S'&.68DGCCK5VE'44
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M:=%%_;VM?NH^'A_A']RM7R8O^>4?_? K8Q*O]K:;_P!!&T_[_+_C2_VMIO\
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MFC_LZZ.R1<C.Y.:0SKZ2L[^P-&_Z!5G_ -^11_8&C_\ 0*L_^_*TQ&A16?\
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M+/\ Q)['_KWC_P#015NJ>E?\@>Q_Z]X__015R@04E%% %74_^03>_P#7!_\
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M+XF:GA]BVIG/_/-JZBN9T$8U+_MFW]*Z:N2K\1T4_A"BBEP>PK,T "N7O_\
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M17$7./ML_P#UT;^==N.HKB[D@7<W'_+1OYUO1^(RJ['D_P 7_P#6Z1_NS?\
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M&L ,C_?:JG_"9Z!_S^M_WXD_^)J*TU.TUO7;K^SYV8?8 GF&-E"L6;U J9;
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M^&B>9X_O /\ GC-_Z&M>R%(XQW=O3L*\=^& S\0;O_KC-_Z&M>SLM?*\1/\
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M.U(#3.BZ3_T"K'_P&3_"F_V+I/\ T"K'_P !D_PJ_24P*/\ 8ND_] JQ_P#
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M9H 6E%-%/%)C08HI:*FXQM%*:2J$SB]5/_$UN?\ ?-50,U?U)5;4KG/7S#4
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M?(BVJ"%&P8 /4#ZTD%M;VL/DV]O##%S\D:!5Y]A4M&: &JB)&(U150# 4
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M4?G^;.*M_$9T/PY&?'EV/^F4O_H0KV9(Z\;^&X+>/KL 9_=2_P#H0KVE=JC
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MBPKG"Z=X1NK.;2KC[';I<0ZQ<W<\BLNXQ2"3'/4YW+Q4GBGPQ?:KK-Q=VMM
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M(ZUZ1246 \V7P!?QZ-J=M+!;7-T^D6UI;S,P)\Q-Q(!/*@$C!]JNR>%+^;Q
M[3:=;O9'6(M0,I=#O00E2"O7(;GWS7>GK24 >9ZEX,U7[+BTT]&D2YO3!Y,\
M:A(Y7W*&1P49#W'4=JZ?7M$U#4_!$&G*EL][$+=Y(0=D,QC96:/V4X(KI<TN
M: . A\*ZC<Z@=1ETNULDFU:WNC9"1&$4<<;*S''R[F)' ]!6WXMTF\U"?2KF
MRM([IK6:7>CNJD*\3IN!;T)!Q729HH \ROOA[J,N@V-E8P6UM+'H_P!EN"CA
M?,D$D;A"1U!VMSSUKI/!6A7>E7&IW=Y;26QO&CQ#),DA^5<9.P!1UQQV'-=5
M1FBP7/,;7P/J/EZG'<:7:!AIUW:VCET;<\DS.K#^[E6')Z8JMJ?@WQ'=7+!+
M&$A;F&9'CEBC1E5 IW<;VDX/).,=*]7).:.O0T6"YB^&K>^T_1K+3;RU6,6M
MI$GFK*&WOC## Z8P.>^:V<T9-&XT &:3(]*=DTF?84P#CUI0.#29]A3E.3TH
M ;R*,FC<:-QH .:7\!2=?6C'O0 O%(^/+;_=/\J7%-?[C?[I_E0(XM1!@<G/
MN:GB5-A 48JFJ<59MQPX]J[YZ0//ZFIX>\O[3/L7'R#/YUO\5SWAU<7%Q_N#
M^==#C'6N2JK39V4_@08J.XN(+2W>XN)DBAC&7DD;"J/4FI,UB^+=*GUOPEJ>
MF6RHTUS#Y:K(V%/(ZGZ5F:$D'B?0;J6**#6K"229S'&BSJ2S#L!4T6NZ1-=W
M%I%J=H]Q; M/$LP+1@=21[=_2N2U#P3<S3ZW+:VMG&]W-8/;L"%*B$KO[<=.
M/6LR#P/K?V2RTY[2RB33(KQ4O4FR]X9595!&,KG=ELD\BD,[*]\:^'[/2+W4
MUU.VN8+,+YPMY5<C<<#OWS2Z?XPT?4-5N=-%Y#%=13^1'&\J[I_E5@R#/0AO
MT-<OJ7@:_ETTP6=M9HPT"*QV[@H:='#8/'3@_-[U8D\):A<QW]PUG:PW=SK5
MM?I^\!*1H(\C=CJ-K8'^- '86VM:7>WLUE:ZA;3W4.?,ACD!9<<'(K/MO%>E
M3Z]>:-)<Q6]];SB%8I9%#3$J&RHSGOC\*P/#?A?5])\6&Y-O#;Z:HN-R^>)0
MQ=LJ8@5WQCNP)(S535?"6M7NLZW%%I]B+;4]0M[I-1:8>9 L03/RXSG*D#![
MF@#M$\1Z))/<0)J]DTMLI>91,N8U'4GV'>F'Q+H8T[^T3J]D+/?Y?G><-N[^
M[]?:O-SX \17<L/VRRM)$BM[F*16NE2)S)@KY:1J"BY'<DY.>U3?\(/XE:XM
M;]U+BVN9&2T-W&)RCQA=S3!-K,".,C.T]:+@=WKGB_1M!TLWEQ?6[EH?.AA2
M9=TZ_P"QSSFM"_UC3=*MHKC4KZWLXI,!&GD"Y.,X&:\OD^'FNV6@ZAIMII]A
M>'4[..(M/<_\>;J[,0"5RR_-QC'(]*Z_Q%HNI2:[IFKV-C:ZE]GLY;22UN)0
M@!?:=X)!'\.#[&BX6-RZ\0Z+8RQ176K64,DH4QJ\R@N&Z$>H/K4]_JFGZ5;K
M-J%[!:QL2%:9PH)QG SUXKSZV^'M_;Z+J%G(EG<32:''80R%N!*&D8@9&0HW
M* ?:NJU+0I[^\\,2/%#+%ILQDN!(<X_<E 0.YW&BX&I#JEA<+&\-[!(LD1G0
MI("&C'5A[#UJ"7Q)H<$L44VKV,<DRJT:O.H+!AE2,]CZUQ4'A7Q!I,<+V-E9
MW#FVOK1HC<",1":8NC XY '4"F-X U";0]0M9[6RDN)]/TZU0LX(W0D&09QP
M/3UI#.KO/&>AV@T^7[?;R6=Y,\/VI)5\N-E4L=Q_#'XU>N-?T:SM;>ZN=5LX
MK>Y_U$KS*%D_W3WKD-0\*:M#XE.J6>F65W;IJGVM+9YA&&3[/Y>1D8#;N?PK
M)?X?:W!%9SI'%.[6]U%-:0W0A6 S2F0!692&49VG !XXI@>EG5]-&HQZ<;^V
M^VR+N2W\P;V&,Y ],4DVLZ7;ZE%IT^HVL=[+REN\H#MZ<5@^%?"TN@ZE=3SQ
M0.#9VEO#*&WL/+1@PR1D#)'UK)U;PEJ]WJ6L6\-I9R6NJWMO=?VC)+B6U";,
MJ%QDD;/EP?XC0(Z'2/%]EK UB:% EEIDC1O<&13O*#+':.0/0GK4^G>+M#U*
MRTZXCU&",ZBH:VAED D?/8#UR"*@T+1)]/TS5[:=(E:\O+F5-I!!1_NY_P *
MP="\':C&MJ=0MK6WD@T)M,61'$A23>?G7C@$8/KVH ZVWUO1;U[A[;4K&9K0
M'SV2528AWR>PX^G%4;OQKH%IIRWZZE!<6[7,=KNAD#;7<X&?0=_I7#Z;X UZ
MUTJ6'[/;I=P:8;&%I[E9HYB64_<V@*N%S\V<$U-!X-\0)_:5RUG&\DMS8W,,
M-Q>([OY+'<K,%"@D'C QVH [R7Q3X?@FEAEUK3TDB!,BM.H*X.#G\>U27&OZ
M+:I;/<:K9Q+=8,#/,H$H]5YY'O7*6/@N>._TRXN;*S/DZQ>7TW(8[)0^SMR<
MD<=L5S\OPZUQ88T\F.X66P>R>)+P1+#^]=AR5.Y"&&0,$$4 >F2ZYI$.HKI\
MFJ6B7KL%6!I@')(R!CW!%1Z-K]AKT=W)8R[UM+A[:4D]&4X)^GI7)W'@B]-K
MJJ1Q6SSSW=C)!*S_ #%(5C#9)&0?E;'K^-:MEH%^-%\4:5*L5L-0N;I[6XC<
M'*S9() Y4C.* -JTU_1[^58[/5+.XD9S&JQ3!B6 R0,>P-$WB+1H'6)]4LQ,
MY94C,RAF*\$ >N>/K7GNM66HZ;X;BNI]+TS3-4L1;1:8;8^9)<W"'&W*C[C
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M;ICYGV<VF'V@?P8QLVXYS0!WL'A;0;2UNK6#1[2.WNUV3QB/B1?[I]O:IY-
MTB9;H2:9;.+M$CGS&/WBH,(#].WI7)^$-,O--U32"6U!DNM%\R\-S([@SADQ
MG=]UL%ACC@5FZDFI'Q+>X75O[;.JQ?863S/LXLOEW9Q\FW;OSGG- '9Z3)X>
MCLK^PTM(%M+-V2[1(SL#8.X$G[QX.>M<U/JOPOL;!;6632X[6]5;E5*-AU!(
M5\XR "#CTK0\,Z7_ &?X3UJ&.WGC>6ZO2J2%B6&]]I /J,?6O/?"TTOAJ_TZ
MXU30M6GB?P^MOLBT]Y2)/-<[6&../6@#U+3#X6L[^PMM*6QCN;BW>6T%N/OQ
M$@N5(XP2 3]*A&H>#K?1[C5!)816%I>M++-MPJ7(.&;_ '\UYSX?\):_%JGA
M2V,M[I$B6-T[30Q!_LX>3<L1)!4'!Z4A\)RW'PB\0QWNG75UJ=M>73VGF0L)
M'9G'[P(.I(Z$#Z4AGJ&IVWANPT.^NM1M[.+3+AA<W;LGRR,V,.V.<].:0Z?X
M9\,K#?"SM+'=((XYEC.2[C:.?4\#-9/Q$M;J[^%&HVMK;RS7+VL2K%&A9R<K
MP .<UP<<6L,;O^RH?$ TG[;I^U+Y9#)YH;]\0#SMQC)Z4P/9+C2-/NOM7VBQ
MAE^UHL=QO3/FJOW0?IVJG'X2T"&!H8]'M51G21@$Y+H<JQ/7(]:\P*^)/^$K
M.%UW^WO[7<NQ#?8OL'. #]WICCKFJNF^']8N%T/[5-KX^VVM^U\#-*N"F3"I
M_N\XP.,T"/8;'P_H^GWTM[9:9;P74N=\L:8)SR?ID]<54URQ\-VLT6N:U:V:
MRQ,B)=3)DAB?D'OR>,]*\8O[KQ9-8:5(]MKJ7]K96K+)MG8R$-\_RJ,*0.&W
M9)]*U=9T#5[[0_$NH[=4EU ZUY=G#+YC1K%YBD,L?=<\Y]J /:;:U@M&E-O
ML1FD,TFT8WN>K'WX%8.C>"=&TF.=FLH+FYG:4RSR1#+K(Q)4_@<>^*\MU"'Q
M-'H5G:7:ZKYD&I3KK$P$SB=BN8I%V?-Y?H%X!ZUN^&]&UK4?%&B+KMSJS06N
MC+,7R\*R3";Y1)ZMM/(/- ';Q>&/"JS3:;'I%IYCQ*\D?EG)0-\N3[,..>*M
M7/A;0KN""WN-(M9(K<L8D9.$W'+8]B3DCO7,>,H-4N-7O8[7[<L$EM9J&M]P
MP3<'?@CH=O7T%:N@VL^EOXFLT^TBRAF!M//=GP#$"VUFY(W9[]: -W^QM."2
M(;" +)*DSKLP&=,;6^HVC'T%9EUX8\*Q-!]ITJQ0O.?*WIC=(YS@>N3SCI7F
MVCW%^WAZ&YTF/7;@MI+?VD9))5+REEV%&(/(&XY0?=]Z=:65S+=AKF"^ETVV
MU>SGB,<5P$52I#L@?YR-V,_G@4 >JRV>D^)M.07-M#>V@?*"1#A67(R!V(YJ
M"3PCX>F@MX)-%M&BMU*Q)Y?"@G)'N">>:\RO8M?>WLEO&OX[7[-<^41'.S"X
M\YL<1X.[;MV[OEK5;3-89=0U*ZDU1]3M;BP$!5G52"L8E(0'!!RV[KWH [6U
MT'PU/<Q7]II]D\MJ?)CE1?N&/Y0/3*]/:I8?"NA6QN3#H]FGVI2DP$7#J3DC
M'H3S@5@^$[1=.\,Z_;I#/;S17EXS"4..I8HRENHQ@Y%</IT-YJ6F:,FFOKWD
M7$-L-5ED:4%I#*G*D_[._)7C;B@#U[2]"TS1(Y%TVPAM%D(,GE+C>1T)/>N=
ML)? EW<7,UC!8M)>2?997$# 3,^<J"1@AL'IP<5S$EA>1:G+8Q)K']K+J?EQ
M$O*8/[/Z8W9VE=F>OS;JSM/TO6;73M/@LK.]5XA9R0K*CE4EV3Y//3DKGTR*
M /8(["VAN3<QVT:3F)83(%P2B\A?H*GQ7E_@B;4=/O#>7DFH/"MD!?1-;SL3
M<%@ 3OSE^3G9QCFO42#0 ?PTIHQ\M!Z4P$ P:X2^5VO9^I'F-C\Z[D$YKAKN
MX9+^X7 ($C?SK:CN8U;V/*?BR")=)S_=E_\ 9*Y.NO\ BY(LDND%1C"RY_\
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MNKR"[GBW3P)(D;9(VJX 88]\"L^7PAH<]I%:R:>'ABMOLL:EV^6/<& !SU!
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M-J[I&V#T[U;U:;R]6N511OW]:J+&2=]PY'HO<UVQ:44<DE>3-CP^Z'4ML:X
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M#3)X9['1[.WE@+M$\<8!0L,,1]0!FM;-&: ,U_#VC2-J#/IEJ3J0"WI*<W
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MGC7Q:C\N;2A[2_\ LE<E7:?&1=L^D?[LW_LE<77ZODKOEM+Y_FS@J*TVC?\
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MY#_"I5U>^/\ R\M^0_PI/[&OO^>(_P"^Q2?V-?CI"/\ OL5'N&NMB0:K??\
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M_L#4_P#GW'_?:_XT?V!J?_/N/^^U_P :+1#W@_X2#4_^?C_QT4O_  D&I_\
M/S_XZ*3^P-3_ .?<?]]K_C1_8&I_\^X_[[7_ !I6B'O"_P#"0:G_ ,_'_CHH
M_P"$BU3_ )^?_'12?V!J?_/N/^_B_P"-']@:G_S[C_OXO^-/W0U'?\)#JG_/
MS_XZ*/\ A(=4_P"?G_QT4W^P-3_Y]Q_W\7_&C^P-3_Y]Q_W\7_&E[H:B_P#"
M0ZI_S\_^.BC_ (2#4_\ GX_\=%)_8&I_\^X_[[7_ !H_L#4_^?<?]]K_ (T6
MB'O"_P#"0:G_ ,_'_CHJQ9ZWJ$LNU[@X]E%5O[ U/_GW'_?:_P"-/AT/4XI
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ME;TVLZ?:1VIO;VVM'N0#&DTJJ6)'09ZT@.1TKX66%C%K0N]1FNY=5M/L<KK
MD 6/UVH,%LX.32:?\,A:WJ7=WXCOKZ5--DTV/S844)$RD#&.XSWZUV-YJ^FZ
M<VV^U"UMCLWXFE"_+G&>>V:S=>\8Z-X>@TZ:\NE*:A,L5NT; @Y_C)S@*.YH
M R+?X=QV4WAR:SUFZ@DT6W-MN6)3]HB)R5;/W<],BH=.^&-M9>*+36Y]8NKQ
MK.1Y($EA0."W]^4#<X&> :ZZ;6=+M[^.QFU*TCNY<&.!IE#MGI@9JOXDUR+P
MUX=O=8FA>:.T3>T:'!;D#@GZT 4O&/A-/%^GV=JVH36+VEVMW'-"@8AU! X/
M'?/X56T7P+!I^IWFJ:GJEWK6HW5N;5KB["KLB/5%5>!FJ6F_$9KC5M*L-4\.
M:CI0U7BSGF9720X! XZ<$?G76IJFGR:@VGI?VS7J#+6XE!D _P!WK0!R7AGX
M:VOAG5(+F+5KJXMK7?\ 9;5XD41[L_><#<^,\9IT'PVL[>RTZV74K@BQU@ZL
MK&-<NY.=A]![]:ZL:IIYU Z>+^V^V@9^S^:/,Q_N]:5=4T]]1.G+?VQO0,FW
M$H\P#_=ZT <X?A]ILND^(--NKB>:#6KLW<AP%:%^,;?7! /-,T7P$FFZA<ZE
MJ&LWFJZA+9FQCGN$5?)AQT '4^]:NE>)+?49KF&9%LY8KMK6))9E)G*@'*@?
M7IUI=4\26^GW%I! BWDDUXMI*L4R@P$@G+ _3IUH R=/^'UII]IX9MUU"=QH
M$SS1%HU'G%L\-Z=>U4[[X86VH^(X]4NM9NY88[L7:V[Q(65@<A1+]\)_LYKK
M?[<TC[4MK_:EEY[N8UB\]=Q8=1C/6G76LZ78W M[O4K2WG*E_+EF56V^N">E
M &%+X)5O$NM:O%JMQ%'J]MY%U:B-2I(4J&!//&2<>]1WW@&TOO -EX4:^G2*
MS$?E7(12Q*'(+*>"/8UUBNCQB174QE=P<'C;C.?IBN3\'?$+3/&=_J=I90R0
MO8MP9"#YR9(WKCMD?J* *EE\-+>VTGQ%83ZO<W(UU$$\A@1#&RC@J%X_"FZA
M\-5U&RT?S-=N1J6F1-!'?&VC<R1G^%D(V\#@'KQ6OXJ\:Z5X5TZXN)I8KBY@
MV;K..91+AB!G'XUI:KKNG:-:&:\NX(I#$TD<,DH5I,#.%!ZF@!VAZ3%H.C6V
MFPRR3+ N/-EQN<]23BN8O_AUYFH:A<Z/XAU#1HM2;=>6UNBO'(Q&"PW?=)]J
MOZ;XUAU.#P]<)8R1PZQ%)+O>51]G" GYO7IVJ*+X@Z9?>&[K6M+B>\CM[H6S
M0^8J,<OMW<G@=QGJ* $B^'NFVVF>'=/M;JXC@T2Z-U%NPQE8YR&/;DD\5'XH
M^'EMXCUP:O#J=QIUV\'V:9HX4D$D>>,!A\K#U'-=-=ZKIVGF%;V^MK5YL>6L
MTH4L?;/6EO-4T_3\?;;^VMLH7'G2A<J.I&>U '*ZW\.+75I]+G@U2YLI=/M3
M:*PB27?&>IPPP&Y/S"F'X;QIH&@:;;:W=03:).9K:[6%"QSG@J>.]=:^J:?%
MIXU"2^MDLB,BX:4",C_>Z5E:]XNL-%T"'68MM_:RW$<"-;R @EVVYS[4 8FH
M?"^SO/$-UJD6JW-M'>RI-=VR0QMYKKW#D;DSW ]:Z&T\.0V?BZ_\0I<2&6\M
MH[8P%1M0(<@@]:D\1:M>:)8"YL]'N=5??AXK=U4HN,[CGM6)X1\=R>*[9KYM
M"NM/TSRWD6]N)5,9VG!''3H?RH U?%7A>W\5Z9%:37,]I-!,MQ;W-N</%(O0
MCU^E9&F_#R&&;5KO5M7O-6O]3M/L<US,JH5B]%"\=A^5=+%K6E303SQ:E:/#
M;@&:19E*QYY&XYXJ2+4K"XL?MT-[;R6>,F=904 _WNE '&:5\,1I]Y97-QXB
MOKW[%92V-NDL**J1.I4 8[C.<GKQ6O;^";&'X??\(?+/)/:>0T/G,H#<DL&Q
MTR#@_A5V^\5Z)8^'KK7?[0@GL+89>2W</D_W1@]3Z4^V\2Z//I5IJ+:C:PP7
M47G1F695X[]^W0T 8*_#;3X_".E^'H[V=(K"^2^,^P%YI%)/S#WS^@JW-X#T
MR;XA1>,6D<7<<87R-HV,X!42$^H!K<AUG2[FXCMX-2M)9Y4\R.-)E+,OJ!GD
M4Y]4T^+4$L)+^V2]<96W:4!R/9>M '#7GPEM+G5;F\36[N&*>_74#!Y"-B4'
M/+GYBO'3.!75:)X<BT35-;OX[F29]6NA<R*R@",@8P,=1S5NZUO2;&5HKO4[
M.WD4J&2695()Z<$]ZI:GXMTG2?$&EZ+<W %WJ.3%R-J@="QSW/ ]: *X\%Z>
M^N:_J-U(US'K5NEO/;.@V*JC'!ZUAO\ "V,Z1I%B/$%X6TB=Y+.:2!'*(V/D
M*MD-C'!/2NS76-,?4FTY-1M&OE^];"93(/\ @/6H?$&O6/AK1+C5M09A;P@?
M*@RSL3@*H[DF@#DT^%T4&@6.FVNO7D4UCJ+:A;W?DH75VZ@CH>N:?!\+K*UU
M]M0@U6Z2T>Z^V260BCPTO?Y\;@I/.WI5K1?'S7^L)INJ^']0T62: W$$EU@H
MZ 9.2/NG'8UU U*Q9+9UO+<K='%N1(,2G_9]?PH XV_^&%MJ7B--4NM9NY8$
MNQ=K;O$A96!R%67[X3_9S76:[I%OX@T*^TFZ)6&[B,3,HR5ST(]QUJ2+5M.N
M)[BWM[ZVGN+<$RPQRJSKCU K(T+QII>L>%[/7KB6+3;>[9E1;J90<@XQGO0!
MBZ3\)]&TC5M!U&*YF>32(BBJ4 $S$L0[>A!8_D*W#X1MF\1:UJ[W4K-JUD+*
M6': $4#&0?6M2]UC2]-2)[[4;2V2;_5-+,JA_IGK5P,K('5@5(R&!X(]<T <
M3;_#E(_#>D:+/K=U/%I5_'>6\C0J#A#D1\=NO/7FMW2?#D.D:]K>K1W,DDFK
M2I+)&R@",J,8![U>L]7TS4)98K+4+6YDA_UBPRABGUQ3+?6])N[E+:VU2SFG
M==R1QS*S,/4#- %*]\,6U_XLL=?FF8M:VLMK]F* I(LG7)_&N7B^$.E6WAO6
M]"MM1N8K75+E)\^6I,.TDA1ZCG'-=#XI\::7X6T^>>:6*XN86C#6<<RB7#L%
MSCVSFM?4;R>TTF6\M;&6]F6,.EM$0&D)QP">._Z4 8>E^%M5M+@_VEXMO]6L
MFB:)[.XMXU1P1CDKS6&/A/#]D726\2ZJWAU9?,&E';MZYV[^NW/:I]$^(]WK
M6HW5JOA/4(4LI&CO)GF0B!@I."/PK=\+^,-+\4Z79W4$T4-S<QF4633*954$
MCD#Z9H&.\2>%K;Q'IUA9-.]K%9745S&(D!_U?1>>@K)\3?#BU\2:S<Z@-5N[
M%+Z)(=0MX%4K=(ARH)/*] ,BNI_M73AJ']G_ &^U^VXS]G\U?,_[YZTW^V-,
M&I?V;_:-I]N_Y]O.7S/^^>M CEO$7PTLM=U&2YAU2[T^&YMX[6]MX%4K<1(0
M5!)Y4\ 9%;>EZ=J-GXEU"1IV&C?9H8;*V+ A&4'<0.PQ@<UHMJNG)J"Z>U_;
M+>L,BW,H\PC_ '>M32W5O!+#%-/'').Q6)'8 R'T'J: )J2J@U;3B@<7]L4,
MOD!A*,&3^Y_O>U8]SXSL]/BU^XU"![:UT=E5Y-ZL9LCC:!T/;!IB.CI:Y6Y\
M=Z9 /#LHPUMK98).95"P@+N.X]..A]ZZ.TO+6_MDN;.XBN('^[)$X93^(H&3
MTM<G>^.[:QO?$UJUE,QT&T6ZE8./WH8$X'ITK/TGXFQWE[ID.I^']1TF#5,"
MRNIRK12L1D#(Z$T7$=Y25S]AXK@O]9\0Z:EK*CZ)M\URPQ)N0MQZ=*S5^)&D
M)X"M_%EVDEO!<A_)MB=TDCJ2-HQU)VY]A0!V-+6;X?U=/$'A^PU>*)H4O(A*
ML;')4'L37,:?\3M,O-;\0Z9):RV[Z+%)-)([@B54.#CT[?G0,[FBN7\&>.++
MQCX<GUM8&L+>&=H7^T2#C 4Y)Z ?-6W;ZQIEW8O?6VHVLUI'G?/'*"BX]3VH
M$7:7-<UK/C73-*M[&:W=-06ZU"*P/V:56\MW!()_ =/>MQ-1L9EN'BO;=TMB
M5F99 1&1U#'M0!8HS5.WU73KRR>]MK^VFM4SNFCE#(N.N2.E+9ZE8ZB)#8WE
MO<B,@.89 ^TD9&<>U %NBDHH&+1110(6DI110 E)3B*3% Q**6DH *6BDH =
M1113)&T4M)2*%'45P%V/]-G_ .NC?S-=^.HK@;K_ (_)_P#KJW\S6M+=F538
M\N^*W^MTKZ2_^R5RU=5\5_\ 6Z5])?\ V2N5K]4R?_D74OG^;.1[G3?#,X\?
MWO\ UPF_]#6O5)3F0UY3\-O^1^N_^N,W_H0KUEQ\QKY?B)?[;_V['\@4M+'9
M:?\ \@VU_P"N2_RJSFJU@/\ B76W_7)?Y58KX][G<MAU%)FEH 2BG4F*!@.E
M)3ATIM @I*6BD,***7% "44M%,0O\--IW\-)0 E<%\0_#=]XBUOPHELMXEO#
M=R-<W-HVUH%*\-N[5WV*0FD,X'5?!4?AWP-KT'AZQ?5M2O@K2_;W,KW!!'7I
MG R0.YKCO#WAG7(8/&9.B:A"NHZ.L=NLMM'#YL@!!4(G // ZXKV_-&:0SQW
M6/ OV;X7^'(K+PUYNH6UQ;7%_;Q0@S/C_69]3V-:>K^'=9U3Q%XGFT^QFLH[
M_P .QVUJ[@(!)NR8LCH<<>U>GTH4FG85SR[P7HTIC:!/!#Z)+'H_V.:]G<(T
MTN,$!1PP)YW'FLCPWI7B)K_X?6=SX:U"TCT"2X2ZN9E782PX*X.<>]>UXH/%
M%@N>+OH'B&V\#ZU;IX?-Q+/XB>X\J: 2MY!(_>HA.&/H#60O@_7Y/ ?BC3O[
M$U />:M!<00R0JCR1Y^9MJ_*"!U Z5[Z332<T6"YP>J^&3:^+?!']CZ4(M-L
M)IVG\A $AW1XR?J:Y'1=#DG^+#^&HY(IM TB]?6D",&"NZC8AQP,,2<?6O:J
MS]*T'2=$:X;3-/@M&N7WS-$N#(WJ3WZFBP7.7^*&@3:_9:$MMIAOI(=5B>4!
M Q2'^//^STS7+^,_#%ZOBW7KA_"DVO6NHZ>EMICPA2MDX7&""?D&?FR*]BS0
M318+GE,/@:\N-?\ !,&O:>-1MM/TF2*[ED&^-9?X5)[X[?2NJ^(^G7>J?#W5
M[#3[9[BYEB58X8ADM\PX ^E=4324#.+\+_#ZPT:>QUB:?4+S58;01Q_;K@N(
M"5&Y5';N/:O/M"\.>(E\=:#J-SX<N+,6NHRM<F"T2."-&S@A@2[@]26KW6DI
M >*7'A34H=!^(FE6WANX%S?7(ELIHHALFB,JD(I]N3CVIGCCPCKMWXA-R-)O
M+^TNM)BM(A;P1RF&0* RG?\ ZOGG<.:]NHI6&>73>#+F[\8Z&=2TQ[ZSM/#C
M6SS3J'43Y;"D]"V#6'-X4U9?AIX.2Z\/7-W=:9J327-GY8:40%F^7!/0_+Q]
M*]MHH \/\6>&-<?QK>7^D>'[R5KJ>"5$N((Y[:3  R6.&B*^@S7I/Q#L+S5?
MA]J]C96[W%W- %2&(9+'(X%=/13$>1:;X*OO"OB_PWJ\5C?:M8O;I%/',[2R
M:;,5 +J">!_+!]JQ] \$^(+7QA:)>:=?)+;ZL]X^H)%$(F0D_-YWWVR.-M>Z
MT4K#/'M!\.W^G:]):7_@M[^_.M/>#6Y)-L:Q$Y#!QR2/[N,5EZ5X)\00^-(4
MN].OA+%K37QU&.*(1F/.=QF^^<CC97NM%,#QYO!^M/X>\1W4&GS0ZO:^(&U3
M3 R\S 8^[ZAAD?E3XO!^L1:#X7N);"675;CQ -4U0*N3#N#?>] HP*]>HH \
M2N/ VH-H6KW*Z!(=6?Q0+B"3RQYAMPX.Y3_=ZUD^/X$MM0\=K<Z5#J4UR898
M=0\Y,V8 &58$Y!] .O%?0=8NH>#_  YJNI#4;_1+*XO!C,TD0+''3/K^-*P7
M,;7FU>/X516^BV<UQJ5Q806\:1#E-R*&8^F!FN1TCP5XH\%>)_#FI*T.IVL4
M0TZYCL;?8T<)R=S\_-@G.?85[#T&!THIB/ ?$?@_6FA\2:?_ ,(E=:CJ=UJW
MVRWU:-59?(R/E#$YSU&WW/I71^,_#U_)XNU*\D\+SZ]!?Z0MI9-&%86LP'\6
M3\O/.17K=%(9Y/HGAG5HI_AJ+K2YQ'I]M<QWV].(-R$ /Z9S63!X7U6/X8ZU
MH4/AJZAU!=6CE#"( 7$?G;@5(/(51^M>W44!<\?\8>'-0;Q5KEW<>%I]?@U+
M38[;3WB 86<H4 YR?E^;YLBKL/@J_DUSP/#K5A_:$&G:7+%=RN/,C27'RJ2>
MOH/I7J=%,1XI'X>\06/PWTC3O^$>DF,&KRR2Q-;+--;Q;CM>.-CM/!/6H[#P
MKX@3X97>EMH]\EU_;\=Q' Z ,8MRG< .,>N.*]OHH&1W8+VUPJ#):-@ .YP:
M\\\,:'JMG\#;G1[BPGBU)K.\1;5E^<LQ?:,>^1^=>CT4"/'M6\!WJ?"#1['2
M=),5^DMO<ZC:QQKYLY4'<&!X9@3T/I4-MX;UVW\ ^(3;:#-*]_?1RQV%[;Q@
M[01ND6%#M!_V<XXKV>B@9XAI/A'6)/#/C^TET2\0ZA%#+8)<P)&9'4-G"K\J
MMTX'2M:'PQ+JNI> &G\,S0Z?8VLZ7<%Q"H6)\<%AT^9AN'UKUFBD%SQ'PWX'
MU+3+?P=<C09H+VWUF>2\?RP'2 \+N/\ =Q4&J^"O$$_C74UETV^G-WJD=U!?
MP11;%C!&"9F^9-O]T=:]UHHL%SR?Q'X-NM5\3^.[Z716NOM&F0QZ=,T8.^4(
M VS_ &LBENO#]_%J_P .M3N/#]Q>_8K,6]\%C#/$^%VE\G^$Y.>V#7J]%,#Q
M"P\+Z_I_Q#AFL]"NO(.JO<2M>PQR0I&QYECG&&!(Z+BO0_B/X?O?$?A&2VTT
M*]Y!/'<Q1,<"4H<[<^XKK**!'&:3X@\3>(=<2"Z\,2Z5H@MV%\VH#YY'(^['
M@_=^O:N#\$:'>WWBV_TD7,<EAX72YBTZ=&W#S)R2AR.Z@GZ5[:Z+)&T;@,C
MJP/<'J*I:3HFEZ#:M:Z3806<+-O9(5QN;U/J: /,O 6A7>FRZ797/@>2VO[&
M*X6ZUB5PH<MNP4(_UF[('/2N6'@KQ+;Z+X9EN=%O9HK:SN+>6UCMHYI(9&=B
M"8W.,$$?-U%?0M%(9X1KG@G6K?1] \O2M5GNK?36MR42*[5<L2(9(VP.^-P/
M\J]1L+;58OAK':RZ;:C5%TXQ_81Q%OVX"<=!VP#7344Q'BWP_P##VMV?C:VU
M&[T.\LH#I,EO*6M$@C67CY5"'D>A;DTSPYX'U#3=+\!SC098-1M=5>34)!&!
M(D1/5S_=QBO;**5AW/ ]?\(:T8_$%@?"=UJ.IW6KB\M]6C56409!P&)SG&1C
MW->]0@K#$#P0B@CTXIU%,1P?A/1]1LKOQTUU931+?7SR6I<8\Y2C#*^O:N6\
M.>";[2[?X>7,>AR6U];7-PVIRB,!XU;(4N?3'2O9:* /"CX-ULR_V5_PC,_]
MM?VU]L_X2'</+\G=NSOSG..-M3W/A?7;7XBO=:?H5U)'+JPN6-W!'-;E21F5
M9LAD/^S@XXKVZB@=SPFZ\$^(7\;7ZS:=?2FXUE;V#4(8HMBQ;L@F8_,N!QL'
M%>B_$O1]0U/PW#>:-"TVL:9=1W=HJ#+,P.& _ Y_"NQHH$>)>#? /B#3_%^D
MV^I03-I$&-7ED=?E-XT8!3Z@]O8ULW_A;5+VV^)L1TN1SJ,B26&]1B9E4\I[
M@UZK118#RIO#<VKVGP\AD\-SP65E,WVZVGA $6%QN<#C#,,^^:Z#X;:->:):
MZ_;7-D]G"^L3RVL;+A3$3\I4>F,5VM+18#RW6?#VKW&L_$:6+3IWCU'2XX;-
M@O$[A2"%]35*/3_$/BBQ\(:#+X;O]+MM'GAN+J\O-J@^6N,( <G->OTM%@N>
M4M\/UUKQMXTO]6L;](I3&UA)%.\2S'R\'&TC=R!UK3\*Z#?6OP8BTN]TUTU.
M.SN42"1!YBNQ?&/0D$?G7H=)3L%SGO 5E<Z;X#T*RO8'@N8+54EB<89#D\&O
M(-;\ ^);G4M0NK/3KI&OM:N+>8A?OV<JI\_^[E3S[U] 48I6"YX[#X;UO3?A
MKXBTV#0/M$LFMO)#;3PA]\'RXD1,@-TR :K:)X:UR/POX^M3H^H1-J,"M9QS
M0)&TIVD$!$^4'/85[52BBP'DOB7P+<-\./#&D:'IDEG=F\M);UK>/YX6\HAY
M6YZJ34$GA7Q WP@U3PK!I31:A9W8PZ*%&HQA]V\'^)B.H/I7L-+3L*YXYX>\
M,:LGAOQE*-+U"V;4+(106D\$<)E<)C*Q)POIGOUKO/ 6@0>'O!NF6Z:>EG=O
M:Q->*$PS2[?FW>IR373FDI6'<2BBB@ I:2EIB%%.I!2T#$(I,&EHI%#:*4TE
M F%%%%,D**** "BDI:  =17 W7_'[/\ ]=6_F:[\=17!W2YO)_\ KHW\S6U)
M:LRJ[(\L^*_^MTKZ2_\ LE<K75_%@8ETKZ2_^R5RE?J>3_\ (OI?/\V<KW.E
M^&G_ "/]W_UQF_\ 0A7K;E=QKR/X;?\ (_W?_7*;_P!"%>N,GS'FOF>(O]\7
M^&/Y$FA:ZY/:PK#Y22*O"DG! J8^))O^?6/_ +Z-9VGV\=Q>B.=F$84L2OMZ
MGL/>K\VAN'8Q.%1O]6K\EL#)Y'%?,25.^ING.V@'Q+./^72/_OHTY?$LQZVL
M?_?1J/\ L60>87F151F4D@]L?XT]-"D>1D6:/*<-P>&]/_KTN6F/FJ$P\12D
M?\>T?_?1H/B*7_GVC_[Z-9\5LIOH(&?(=@&VC&/45?DT L 895P6)WL>"O&V
MFU36XDZCV)%U^4QD_9X_^^C4)\13?\^L?_?1IMOI$S H9$!V@GKQDD?TJ,Z3
M(8PT4J2$C<JC(RI.,\T<M(5ZA(?$DP_Y=8_^^C0/$LO_ #ZQ_P#?1H.D0[%A
MD\T7#PF7>,;%QVJ%M"D0%OM,6Q<AVP?E(QQCOU%3:F5>H3_\))-_SZQ_]]&E
M_P"$DE_Y]H_^^C4$.BL7C,DJE2075<Y"DX!I!HD[GY98\@!G!S\BG)!]^!VI
MVIA>H3_\)++_ ,^T?_?1I#XFE _X]H_^^C5:7194B:7SHS&J[F8 \#&1Q[U3
MT^WCNKU8IRZIM)..V/7T'O2M"UT@O.]F;0\12>5N^SQ_]]&D7Q#*1DVT8_X$
M::VA.!(8F C !0.<YXSU':FMHA_>JUROR*P&U3]\8X/MS3_=6#]Y<23Q1*IP
M+6,_\"-1CQ3,?^72+_OLU&_AR99=KW,2C@9P>I.,?G3T\/9@8_:$,A=5C8 [
M3G.1^8J&H%IS'?\ "43_ //I%_WV:D7Q),?^76/_ +Z-0CP]*B!Y)XT7878\
MG;T_/K3;"QAN%F\TR (,[U^Z!ZG_  JE&&Y#E.]B]%KTTC8^S1_]]&KJZK(<
M 0IGZFL6PA'GJKACDXPHYK=^PPJKD.W&??& ,BHJQBFHHF,IO5,4ZF^/]4OY
MFHFU609_<)^9J8643,.9!D#Y3C()Z9JB47STCW [L XJ$H-IH'*HMV0R>(ID
M8C[-'_WT:C_X264?\NL?_?1JU-HUM^\DDD)0;BI#X! QU/;G-4ETVR8H6\YA
M-+Y2>6P8)P.2<<UK^[[%?O.K%/B>;/\ QZQ_]]&G?\)+-_SZQ_\ ?1J"/2;5
MDC;SW?#2B3:,9V#.!4EQH\$%M.XED+H&92<8P,<'WYH]R^PWSVW'_P#"2S?\
M^L?_ 'T::?$\P_Y=8_\ OHU4MM*FN[/[2DD:KNP >IYP?YU*OA^628(ES&P(
M/S '&0<$?G3:IH2<R7_A*)B?^/2+_OLTT^*9A_RZ1?\ ?9H_L*,2(?.RIC!=
M>X8J3UZ8R*A_X1RX,T4;3PJ74D]>",<>_6LWR&BYR3_A*YO^?2+_ +[-'_"5
MS?\ /I%_WV:H6>GI/<W=O-)L,$;-NP>""!R.M61X=E\Q8VN8P[%L *3P.I_4
M4K1*O(F_X2N;_GTB_P"^S1_PE<W_ #Z1?]]FHFT @*K3I&RYWLV2"=^T8%4;
M?3FFO)X&E1!!GS&Y/0XXQ1:(79I_\)7-_P ^D7_?9H_X2N;_ )](O^^S2OX:
M,=ZH,H^SF8)MS\VTG&?3K5>30BR"2&51&$W2;CG;QD'\>E'N#]XG_P"$KF_Y
M](O^^S1_PE<W_/I%_P!]FH)?#TENCO/=0HB)N9L$X.<8_6J=_ITFGM&DKH7D
M)VJ/3. ?QH2BQ79I_P#"5S?\^D7_ 'V:/^$KF_Y](O\ OLTR/08X1/)=W"E(
M8V+!,@AP!QTZ<U5L]+6]TWSTE"R^:RA3T8!=V/8]:+1#4N_\)7-_SZ1?]]FC
M_A*YO^?2+_OLU%-X><S.MO*G)/EHY.6 QDYZ#K21^'G,R[[F,PA@K, <YW;<
M8QZ]Z/<'[Q-_PE<W_/I%_P!]FC_A*YO^?2+_ +[-11:#YBW19_+59 D+$Y!R
MQ'('/I38O#TDLB1?:8Q(R;RNTG:,X&3]:+0%[Q/_ ,)7-_SZ1?\ ?9H_X2N;
M_GTB_P"^S41T L8PLZ1LRJ,-D[G()X].E4M-LHKW[2'E\LQQ[@W4 Y YQ1:(
M79I?\)7-_P ^D7_?9H_X2N;_ )](O^^S40\,W.W+31J0^T@@\#U]Z;'H:-&V
MRZ25WB\R(+D<;L9.>U%H![Q/_P )7-_SZ1?]]FC_ (2N;_GTB_[[-5;K0GLX
MII)KJ()&!R ?F)SQ^E,M-+6\L$G$RQ'<^YFY&!CL/K1:(79=_P"$KF_Y](O^
M^S1_PE<W_/I%_P!]FH3X=D&XF[AV*=K,%)PV<8_44?\ "-7(6,O-"NXX/7Y1
MSS[]*+0#WB;_ (2N;_GTB_[[-'_"5S?\^D7_ 'V:@30/,5&2^A(?:5^4\[LA
M?SQ2KX;N28=TT0WC)P"=O&:+1#WB;_A*YO\ GTB_[[-'_"5S?\^D7_?9I%\.
M@M AF&_<?-7GD!L$J?QJG?:-+9VANC(ACWX"YY R0/Y46@'O%W_A*YO^?2+_
M +[-'_"5S?\ /I%_WV:B@T6WFL(IOM6V21%8%AP"6QCWI#X:N$4-+<0HNTLY
MY.T 9_'BBT ]XF_X2N;_ )](O^^S1_PE<W_/I%_WV:A'AV0PK-]IC$94L25;
M@ 9Z?2E7PS<L,^?#@OM'7D<<_KTHM ?O$O\ PE<W_/I%_P!]FC_A*YO^?2+_
M +[-1V>@I)&LD\Q!9P%11C.21U_"HX] DDG6'[3$)",LI!^7C(^O6BT!>\6/
M^$KF_P"?2+_OLT?\)7-_SZ1?]]FL.>%K>=XGZHQ7IC.*CJN6(N9G0?\ "5S?
M\^D7_?9H_P"$KF_Y](O^^S7/T4<B#F9T'_"5S?\ /I%_WV:/^$KF_P"?2+_O
MLUS]%+E0<S.@_P"$KF_Y](O^^S1_PE<W_/I%_P!]FN?HI\D0YF=!_P )7-_S
MZ1?]]FC_ (2N;_GTB_[[-<_11RQ#F9T'_"5S?\^D7_?9H_X2N;_GTB_[[-<_
M11R1#F9T'_"5S?\ /I%_WV:/^$KF_P"?2+_OLUS]%'(@YF=!_P )7-_SZ1?]
M]FC_ (2N;_GTB_[[-<_12Y$',SH/^$KF_P"?2+_OLT?\)7-_SZ1?]]FN?HHY
M8AS,Z#_A*YO^?2+_ +[-'_"5S?\ /I%_WV:Y^BGR1#F9T'_"5S?\^D7_ 'V:
M/^$KF_Y](O\ OLUS]%+D0<S.@_X2N;_GTB_[[-.'BF8_\ND7_?9KG:4'%'*@
M;9T7_"43?\^D?_?9I?\ A*)O^?2/_OLU@ TM7R1[&;E(Z)?$LQ _T6/_ +Z-
M+_PD<O\ S[1_]]&L%.%%29K3V<.Q//+N;!\2RC_EUC_[Z-,_X2B;./LL?_?1
MK&:HB.:ETX]AJ<NYO_\ "33?\^L?_?1I?^$FF_Y]8_\ OHU@#-/Q1[./87/+
MN;?_  DTW_/K'_WT:/\ A)IO^?6/_OHUB[: M/V4>P>TEW-P>)9C_P NL?\
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M"2*V@HOF,I8K=G)"]!]RJ_\ PN>47+7":*4E8D[EN\=?^ 5Y910N'\N6U/\
M%_Y@YR>[/6#\;[LA@=*<[OO9O.O_ (Y23_&^]GN&F.F,I.0 MWP >P^2O***
M/]7\N_Y]_B_\PYY=SU-OC3>,VYM-D)X_Y?/3D?P4^/XVW<:E5TR0*>,"\_\
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M_"-VF",$>>>?_':\:HH_U<RS_GU^,O\ ,/:S[GLK?M 7; AO#=H0>H,YY_\
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M?03G'_H->-T4?ZN99_SZ_&7^8>UGW/9A^T%>#IX<M1GGBX/_ ,32?\- W?\
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M>GW_ ,8YM1N3/-HPSV5;KA1[?)57_A:G_4&_\FO_ +"O.J*K_5[+?^??XO\
MS)]I+N>B_P#"U/\ J#?^37_V%'_"U/\ J#?^37_V%>=44?ZO9=_S[_%_YA[2
M1Z+_ ,+4_P"H-_Y-?_84?\+4_P"H-_Y-?_85YU11_J]EW_/O\7_F'M)'HO\
MPM3_ *@W_DU_]A1_PM3_ *@W_DU_]A7G5%'^KV7?\^_Q?^8>TD>B_P#"U/\
MJ#?^37_V%'_"U/\ J#?^37_V%>=44?ZO9=_S[_%_YA[21Z+_ ,+4_P"H-_Y-
M?_84?\+4_P"H-_Y-?_85YU11_J]EW_/O\7_F'M)'HO\ PM3_ *@W_DU_]A1_
MPM3_ *@W_DU_]A7G5%'^KV7?\^_Q?^8>TD>B_P#"U/\ J#?^37_V%'_"U/\
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M9<O^7?XO_,AR;W/41\8@/^8#_P"3G_V%'_"XA_T ?_)S_P"PKRZBJ_L'+_\
MGW^+_P Q7/4#\8<_\P'_ ,F__L*8WQ=W?\P/_P F_P#["O,J*7]@Y?\ \^_Q
M?^87/2#\5_\ J"_^37_V%(?BKG_F"X_[>O\ ["O.**7^K^7?\^_Q?^8^9GHO
M_"U/^H-_Y-?_ &%.'Q6(_P"8-_Y-?_85YQ12_P!7\N_Y]_B_\PYV=)XL\5_\
M)0UHWV+[-]G#C_6[]V['L,=*9]EN/^>$O_?!K'T__D)VO_79/YBOLNN+-,=#
3*(4Z-*G>+OUVU^?<TIPY[G__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )[ [0# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#BM-TWQ#X[
M\77MI:W[/>,9)F:XG91@-CMGU'%=/_PI;QS_ ,_UG_X%O_\ $T?!7_DJ%Y_U
M[3_^AK7T::_0<ZSK$X#$JA04>7EB]8KJCDITU)79\X_\*6\<_P#/]9_^!;__
M !-'_"EO')_Y?K/_ ,"W_P#B:^BV95'S$ 5 U]"O\6?I7B/BK'+^7_P%?YFJ
MPZ9\]_\ "EO'/_/]9_\ @6__ ,31_P *6\<_\_UG_P"!;_\ Q-?07]H0^I_*
MC[?#GJ?RI?ZV8W^[_P" K_,KZLCY]_X4MXY_Y_K+_P "W_\ B:/^%+>.?^?Z
MR_\  M__ (FOH/[?#ZG\J3[?#ZG\J/\ 6S&_W?\ P%?YA]57F?/O_"EO'/\
MS_67_@6__P 31_PI;QS_ ,_UG_X%O_\ $U]!_;X??\J#?P^_Y4?ZV8W^[_X"
MO\P^K+S/GS_A2WCG_G^L_P#P+?\ ^)H_X4MXY_Y_K+_P+?\ ^)KZ"^WQ>]+]
MOB]_RH_ULQO]W_P%?YA]57F?/G_"EO'/_/\ 6?\ X%O_ /$T?\*6\<_\_P!9
M_P#@6_\ \37T%]OASW_*E_M"'U-'^MF-_N_^ K_,/JR\SY\_X4MXY_Y_K/\
M\"W_ /B:/^%+>.?^?ZR_\"W_ /B:^@_M\7J?RI/M\/O^5'^MF-_N_P#@*_S#
MZLNS/GW_ (4MXY_Y_K+_ ,"W_P#B:/\ A2_CC_G^LO\ P+?_ .)KZ"^WP^_Y
M4?;X?>C_ %LQO]W_ ,!7^8?5EYGS[_PI;QS_ ,_UG_X%O_\ $T?\*6\<_P#/
M]9_^!;__ !-?0?V^'W_*C[?#ZG\J/];,;_=_\!7^8?5EYGSY_P *6\<_\_UG
M_P"!;_\ Q-'_  I;QS_S_6?_ (%O_P#$U]!_;X?4_E1]OA]Z/];,;_=_\!7^
M8?55YGSY_P *6\<_\_UG_P"!;_\ Q-'_  I;QS_S_6?_ (%O_P#$U]!?;X??
M\J/[0A]_RH_ULQO]W_P%?YA]57F?/O\ PI;QS_S_ %G_ .!;_P#Q-'_"EO'/
M_/\ 6?\ X%O_ /$U]!_;X?4_E1]OA]31_K9C?[O_ ("O\P^K+S/GS_A2WCG_
M )_K+_P+?_XFC_A2WCG_ )_K/_P+?_XFOH+[?#ZG\J/M\7O1_K9C?[O_ ("O
M\P^JKS/GW_A2WCG_ )_K/_P+?_XFC_A2WCG_ )_K/_P+?_XFOH/[?#ZFC[?#
MZG\J/];,=_=_\!7^8?5EYGSY_P *6\<_\_UG_P"!;_\ Q-'_  I;QS_S_67_
M (%O_P#$U]!_;XO?\J/M\/J?RH_ULQO]W_P%?YA]57F?/G_"EO'/_/\ 67_@
M6_\ \31_PI;QS_S_ %G_ .!;_P#Q-?07V^+U/Y4?;X??\J/];,;_ '?_  %?
MYA]57F?/O_"EO'/_ #_6?_@6_P#\31_PI;QS_P _UG_X%O\ _$U]!_;X<=_R
MI/M\/J?RH_ULQO\ =_\  5_F'U9>9\^_\*6\<_\ /]9?^!;_ /Q-'_"EO'/_
M #_6?_@6_P#\37T']OB]3^5 OX?4T?ZV8W^[_P" K_,/JR\SY\_X4MXY_P"?
MZS_\"W_^)H_X4MXY_P"?ZS_\"W_^)KZ#^WP^IH^WP^_Y4?ZV8[^[_P" K_,/
MJR\SY\_X4MXY_P"?ZS_\"W_^)H_X4MXY_P"?ZR_\"W_^)KZ"_M"'WH^WP^_Y
M4?ZV8W^[_P" K_,/JR\SY]_X4MXY_P"?ZS_\"W_^)H_X4MXY_P"?ZS_\"W_^
M)KZ#^WP^I_*C[?#ZFC_6S&_W?_ 5_F'U9>9\^?\ "EO'/_/]9_\ @6__ ,31
M_P *6\<_\_UG_P"!;_\ Q-?0?V^'U-'V^'U-'^MF._N_^ K_ ##ZLO,^?/\
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M=7UY]/U*&*#2U1TM9( 1+\NX@MU%;O\ PD&G1Z;8WM[>16@O8U>-9&]1R/\
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M/2@#1T__ %!^M9?CK_D0O$'_ &#I_P#T UJ:?_Q[GZUE>.?^1!\0'_J'3_\
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M_P"?R+_OL5Y!M'<4%1CI3^N-NUA?V*OYSV#^TK$_\OD7_?0H_M&QQ_Q^0_\
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M[Z%>/#:2.:?)&8F"NI#$;L>HI_6Y=@_L>'_/P]>_M*P_Y_(O^^Q2_P!I6/\
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M;'_G\B_[[%']HV/_ #]P_P#?8KR#CTS_ %IIV9Q@4?6WV!Y-%?;/8?[2L?\
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M/7_[2L/^?N+_ +[%+_:-C_S^1?\ ?0KR (".@HVC'3OCK1]=\A_V*OYSU_\
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MY5/B9X"/0O@Q_P E/O/^O:?_ -#6NN\>_P#(UR_]<EKD?@Q_R4^\_P"O:?\
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M_+&3_O@T>7+_ ,\9/^^#7YQROL?H'M(?S+[QM%.\J7_GC)_WP:/*E_YXR_\
M?!HY7V%[2/\ ,OO&T4[RI?\ GC+_ -\&CRI?^>,O_?!HY7V#VD.Z^\;13O*D
M_P">4G_?!H\N3_GE)_WP:.678?M(?S+[QM%.\N3_ )Y2?]\&CRY?^>,G_?!H
MY9=@]I#^9?>-HIWER?\ /*3_ +X-'E2?\\I/^^#1RR["]I#^9?>-HIWER_\
M/&7_ +X-'ER_\\9?^^#1R2[#]I#^9?>-HIWER?\ /&3_ +X-'ER?\\I/^^#1
MR2[![2'\R^\;13O*D_YY2?\ ?!H\J7_GE)_WP:.2787M(=U]XVBG>7+_ ,\9
M?^^#1Y4O_/&3_O@T<DNP>TCW7WC:*=Y<O_/&3_O@T>7)_P \I/\ O@T^278:
MJ1_F0VBG>7)_SRD_[X-'E2_\\I/^^#2Y7V#VD/YD-HIWE2_\\9?^^#1Y4O\
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M+#N3CM7I6P_W6YHV-_=:GJ3:)7M;=+.SM[6/[D$:QJ?4 8J:EV/_ '#1L?\
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M&C8_]PT68<T1**78_P#<-+L?^Z:+#YD3V_W/QK&\=?\ (@^(/^P?/_Z :VH
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M7_Y*?>?]>T__ *&M?0,P_>&OG[X+?\E0O/\ KVG_ /0UKZ"F_P!8:_,>+/\
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MFF!Z2"#2U0TFX>[TNTN'FBG:2(,981A'/J/:K] !1110 4444 %%%% !7/\
MCK_D0?$'_8.G_P#0#705S_CK_D0?$'_8.G_] -=.$_WBG_BC^:)ELSY.T_\
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MYT<R%RL6[MHKRUEMIUW12H4<9QD$<UA:+X0M-$NC<K=W=W*L9A@:YDWF"/\
MNK_C6[]H'=3^='V@?W#1SH?*S*L_"^GVOAZ716#S6TQ=I6<_,[,<DD^N:31/
M#-OHLSW!NKF\NF01>?<ON98QT4>U:WVD=-AH-R,?<-',A<K+ HJM]I_V3^='
MVK_9/YT<R'RLLT56^T_[)_.C[3_LG\Z.9!RLLT56^T_[)_.C[3_LG\Z.9"Y6
M3LH(.><C&*Y>S\#:?9:C%.MS=O;02&:"RDDS#%(>K ?C70_:?]DTOVD8^Z:.
M9!RLYRS\"Z=9ZE'<BXNY+:&4SP64DN8HI"<E@/QX]*ZH=_>J_P!I']VC[3_L
M'\Z.9#Y66:*K?:?]D_G1]I_V3^=',@Y66:*K?:?]D_G1]I_V3^=',@Y66:*K
M?:?]D_G1]I_V3^=+F0<K+-%5OM7^R?SH^T_[)_.CF0<K+-%5OM/^R?SH^T_[
M)_.CF0<K+-0W5O%=V\EO.@DBE0HZGH5(P13?M Q]TT?:0/X33YD'*SG-.\#6
M.GW5LYO+ZYM[,[K2UGEW1P'U'KCMGI5:;X>VTTUV'U?4Q8WDQFFLDE"QL2<D
M=,X-=9]I']TT?:1_=-/F0<K'001VT$<,*".*-0B(O0 =!4U5_M(_NFD^T_[)
MI<R#E99HJM]I_P!D_G1]I_V3^=',@Y66:*K?:?\ 9/YT?:?]D_G1S(.5EDUS
M&K^"[+5M2DO?M=Y:M<((KI+>7:MP@Z!A_45OBY']TT?:!_=-',A<K.=U#P/I
MU]<^;%<7=DCQ+!/#;2[4GC7@*P^G'%=);V\=K;QP0H$BC4(BCH . *;]H!_A
M-'VD?W33YD/E98HJM]I_V31]I_V3^=+F0<K+-%5OM/\ LG\Z/M/^R?SHYD'*
MRS15;[3_ +)_.C[3_LG\Z.9!RLLT56^T_P"R?SH^T_[)_.ES(.5EFBJWVG_9
M/YT?:?8T^9!RLLT56^T_[)_.C[3_ +)_.CF0<K+-%5OM/^R?SH^T_P"R:.9!
MRLJZCI$.I7=A<3,X:QF\Z,*>"V,<UDIX(TN.TU6VC,RQZG<BYF.[D-D'"^@R
M*Z'[0.?E-'VA.NTT<R#E9SVJ>"[/5KNXG>[O+<74(AN8X)-JS*!@$^XJPWA6
MT:]L[D3SJ+>T-F\0/RS18QAA6Q]H '*&@7 _N&CF0N5F!IG@NSTV[M[@7EY<
M&WC>&%)I,JD;#[@'MZTV+P5:V^F6]G#?WL;VDK26EP''F0ANJ ]U]C71?:!_
M<I//&/NFGS(?*S#D\(63V-K"EU=QW%K(9HKOS,RAF^\23V/I5W0M MM!%V+>
M660W4YGD:5LDL1SS5_[0/[OZT"X _@-+F0N5EFBJWVG_ &31]I_V3^=',@Y6
M6:*K?:?]D_G1]I_V3^=',A\K+-4=7TV/5]+N-/EDDCBN$V.T9PV.^#4OVG_9
M-'VG_9/YT<R#E9G:CX=L-2T7^R73RX J!&C #)M(P0?PJK)X1L9?M&Z:?,UY
M'>L<_P :  ?AQ6Y]H&/N&D^TC^Y1S(.5F9=^&[*\\2V6O2AQ=V<;1HH/RMGN
M1W([5!=>$[:ZU"6X%Y=V\=PRO<V\,FU)F'0GN/?'6MK[0/[A_.@7('\)HYT+
ME9.J[0 .@IU5OM/^R?SH^T_[)_.CF0^5EFBJ_P!H_P!D_G2?:.?N_K3YD'*R
MS15;[0/[IH^T_P"R:7.@Y66:*K?:?]DT?:?]D_G1S(7*RS15;[3_ +)_.C[3
M_LG\Z.9#Y66:H:KIL.KZ9<V%P6$5PFQBIY J;[3_ +)H^T@_PFCF0<K,K4/#
M<-Z+-XKJXM;FTC\J.X@.&V8P0<]0<55N_!MK/;VL4%_J%JT$;1&2.;)E1OO!
M\]<^M;_VD#^ TOV@8SM-/F0K,9IUC;Z98065HFRW@0)&OH!5NJWVC_9-'VG_
M &3^=+F0<K+-%5OM/^R?SH^T_P"R?SHYD/E99HJM]I_V3^='VG_9/YTN9!RL
MLT56^T_[)_.E^TC^Z:?.@Y66*Y_QU_R(/B#_ +!T_P#Z :W(Y-XSTK#\=?\
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M/RK-X>TZ5;9[9&MU(@D8EHQZ9/6M*I9:"BBBD,**** "BBBD!9M_N5B^.?\
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M/04>4GI1[,/:#+?[IK&\<_\ (@^(/^P?/_Z :WE0*.!6#XZ_Y$'Q!_V#I_\
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M\<0ZEIVF7MG+)"PU;[3&0N['RJ">^?3BF!Z(.E+2"EH **** "BBB@ HHHH
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M2=#OI+NWO%TJ=96MX+8B0ASA^<\_>_2K5_:74C:JRVT[;]>MY$PG50 =WTH
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M:3>W]X_G2]IY!R,O9HS5'<W]X_G1N;^\:?M Y&7@<U@>.O\ D0?$'_8/G_\
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M)U*3]V?*FMK?;CR(V&0"?7'-=D#FN-\-^&]5TKQ3JE[>:I/=VT\<:QB0*-Y
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M@^?([=,46?A_4H=/\(PR0KNTZ8O<@-]T8(&/7K0!W .12TBG(I<T %%)FC-
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MG]X4>:G]X52VBC:*/:,/9HN^8G]X4>:G]X53HP*/:,/9ESS4_O"DWQ_WA5/
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M"EW1XQD>]4\#TS2XH]HP]FBWNC_O"C?'_>%4^*0X&.5YX SU-'M&)P1>WH.
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MJUJP?#7A_P#X1R34;>W=!ILT_G6L(SF+(^8?G6]4.QK$****104444 %%%%
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M*7D2>GZT>1)Z?K5W%&*7(@YV4O(D]!^='D2>GZU=Q3)9(X(FEE<)&@W,S'
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M *W(XSV]?6O0JY[1?#4FGZE)J5_J,VHWS1"!974($C!S@ =SW-=%3 *2EHH
M****0!1110 4444 %%%% !5#6;=[O2;RVCG$#RPLBRDXV$C&:OU4U&RAU&RG
ML[@$P3QF-P#@X-,#S[2(H=*O-"L-=\-K93P2".TU*T<-'))C'S$<_-UP:FTG
M0],U/P=KHN[.'<;NZ;S=@#J020P/48K7L/!DEO=69OM:N[^TL&#6EM*H 4@8
M4L1RQ';-56\!WCK>6G_"2W2:7=SO-+:QQ*I.XY*[^N#0!M^#[R>]\(Z3<W.6
MF>W7>QZMCC-;U06MK#9VD-M;H$AA0(BCL ,"IZ0!1113 ****0!2-TI:0]*
M/*?%<(@U#Q#+?Z9=W-W)$LNEW2 E8PHY 8?<(/)]:])TF=[G1[*>0YDD@1F/
MJ2!FL35?"4FI7UQ)_;%Y#97>T75FN"LF/0]5SWQ720Q+%&D:+M1 %51T ' %
M,"6BBB@ HHHH **** "BBB@ HHHI %%%% !0:** .0\4A;#Q!X?UDX58IGMY
MG]$=3_45R-I(='74K\?++KMA+/D]6EW[1_XZ17H?B;P_#XGT"XTJ>:2%)L$2
M1_>4@YR*I:MX.M-6&B"29XUTJ59%"#_6@#&UO;@&@#GKK_0+'4=$$$*I;>'P
M?-"?O"><@GT]JM0:EK%U;P:5I!M85L]+BFG:9"WF%DX0>G3K6[J'AJ/4-0U"
M\:Y=&O+'[$5"\*,YW?6JTWA$B:*:TU.>V?[(MG<%5!\Y%& ?9O<4 4?#WVD?
M"B$VLJVUP+.0AS\P0\DU!X>UO4M-MM @U2ZCGM+RP9_/*[6\Q1NP3[K72:5H
M4&F>&8M$6226!(6A\QQAB#GGZ\US.O\ A6X_X1#3= 6>>]=;R,1W&T*T40/.
M2.V./QI@26^O^([]M'AM_LD4FI1SS;W0D1(I^3CN<=:@F\:W\-A;VER]K::B
MUY):3W)0M$NP9+!1SR,<5I:[H]W<^*=$;3Y)K2.WMI5%Q&@94.  &!X(J9?!
MD4=E;):WTT=];S-<"\90Y=W^_N!X(/I0!;\)ZU/K>E/-<*OFPSM"9%0JDH'1
MU![$5T-9FD::^F6?D/=RW4A<N\TG!)/H!T'M6G0 4444@"LGQ-SX8U48_P"7
M23_T$UK55U&S74-.N;-F*+/$T98=LC&: //=6TVTL_A]HFK6EO%;W]I]F>&:
M)0K98@$''4$&IKWQU>)J]T+:2W\FUNUM39>4S2RY(#,&' QGI[5I67@:Y5M/
MCU77KC4+.P*O!:F)8T++PI;'WL>E79/"K+J,L]MJEQ;6D\XN)K:-1EI.^&Z@
M'N*8%:VU;7=3U&>YL([4Z;;79MGB?B1U7[SANQ'I638>.KF\U:V=98)+:YNS
M;?8XX6\R)<D!RW3J.:W&\(A=6>YAU.YAL9+C[5)8H %:7UW=<'N*=8^%&L;Q
M#'JD_P#9T<K31V80##-G(+=2O/2@#+B\6WR^*[>R>>UN+>YN7M_*@C;$6 2#
MYG0GCD4S2/%^H7.J7*WKVL?DK,\VGNA2>()G:5)X<'';UJ]9>!Q9W=HXU6XD
MM+*Y:>VMB@PNX'(8]6ZG!/2I+?P;C4$N+_5+F_@@$@MHIE&Y X(8%^K#!P,T
M 8VC>.KJXN8);F6"YMKFWDG,<$3*UKM&0&8\'/3ZU&]QK>HZEX4O]3%H;>ZN
M_.BCB!#0 H< GOQUKHM.\)M98BGU.XNK**)H8;9E"@(PP0Q'+8' J"T\%M!<
MZ4\FL7,T&ER%[6%E& I&-K'O@=#0!UR]*6D7I2T )2T44 %%%%(!#7GOCG3)
M-3\5Z;]E&+^TLY;JS?TD4CC\1Q7H=9<^D+-X@M=7\U@]O"\(C X8-W/Y4P.1
MTW6XKS5=4UN+CS-)B)7NLF2"I]PW%4/$:Z;)'H_A74KN"W@-H]Y/YS[<OCY/
MQ#G/X5T5OX%M+75-5NX;N98]1DCDDM\#:A4Y(7V8]:T(O#%G_;%_J=VJ7DET
M4"K/&&$*J,!5S0 SP3JXUOPE87GF+(^SRI&!R"R':3^E=%6+H?A^'0KC46M9
M2+:[G\];? "PL1\VWV/6MJ@ HHHH #1110 4E+10 8KG_'7_ "(/B#_L'3_^
M@&N@KG_'7_(@^(/^P=/_ .@&NG"?[Q3_ ,4?S1,MF?)VG_ZAO][^@HHT_P#U
M#?[W]!17[34^)GG(]#^"_P#R5"\_Z]I__0UKZ$DNTBD*L#D5\]_!;_DJ%Y_U
M[3_^AK7O%W_Q\GZ5^8\6NV.3_NQ_)GH86/,K%DZA'_=;\J/[1C_NM^59XZ=:
M/QKX_P!LST/81+_]H1_W6_*E_M"/^ZU9_MFC\:/:R%[")H'4(_[K4?VA'_=:
ML_\ .C\Z/:R#V,30_M"/^ZWY4?VA'_=:L_)HS1[60>PB:']H1_W6I/[0C_NM
M^54*/SH]K(?L8FA]OC_NM1_:$?\ =;\JSN/>E_&CVL@]C T/[1C_ +K?E1_:
M$?\ =;\JS_QH_&CVK#V$30_M"/\ NM^5']H1^C5G].]%'M9"]A$T/[0C_NM1
M_:$?]UORK/HR:/;2#V$30_M"/^ZWY4?VA'_=;\JS\GUHR:/:R#V$30_M"+^Z
MWY4?;X_[K?E6?D^M&3ZT>UD'L(F@-0CZ[6_*C^T(_P"ZWY5GY/K1D^M'M6'L
M(FA_:$?]UORI/[0C_NM^54,GUHR?6G[60>PB:']H1_W6_*C^T(_[K?E6?SZT
M9-+VT@]A$T/[0C_NM1_:$?\ =;\JS\T9-'M9![")H?VA'_=;\J/[0C_NM^59
M^31D^M'M9![")H?VA'_=;\J/M\?]UORK/R?6C-'M9![")H?VA'_=;\J/[0C_
M +K?E6?D^M&31[60>PB:']H1_P!UORH_M"+^ZWY5GY-&:/;2#V$30_M"/^ZU
M']H1_P!UORK/S1DT>UD'L(FA_:$?]UJ/[0C_ +K?E6?FER?6CVL@]A$O_P!H
M1_W6H_M"/^ZWY5GY/K11[60>PB:']H1_W6_*C^T(_P"ZU9^31D^M'M9![")H
M?;X_[K4?VA'_ '6_*L_)]:,GUI^UD'L(FA_:$?\ =;\J/[1C_NM^59]'XTO;
M2'[")H?VA'_=;\J/[0C_ +K?E6?D^M&3ZT_:R%[")H?;X_[K4?VA%_=;\JS\
MGUHR:7M9![")H?VA'_=:C^T(_P"ZWY5GY-&31[60>PB:']H1Y^ZWY4?;XR?N
MM^59^3ZT9/K1[60>PB:']H1Y^ZWY4?VA'_=;\JS\GUHR?6CVT@]A$T/M\?\
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MQ7,CI**0'*@@Y!&0?44M(I!1110,**** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *0]Z6D- C2L/]0?K67XZ_Y$'Q!_V#Y_\
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MXWY4>5)_</Y4<C#G0S-%/\J3^XWY4GE2?W&_*CED'/$2C-.\J3^XWY4>4_\
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M_P E)_\ XBOE6BC_ %0P/\TOO7^0?6)'U5_PN'P'_P!!W_R4G_\ B*/^%P^
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M .@[_P"2D_\ \17RK11_JA@?YI?>O\@^L2/JK_A</@/_ *#O_DI/_P#$4?\
M"X? ?_0=_P#)2?\ ^(KY5HH_U0P/\TOO7^0?6)'U5_PN'P'_ -!W_P E)_\
MXBC_ (7#X#_Z#O\ Y*3_ /Q%?*M%'^J&!_FE]Z_R#ZQ(^JO^%P^ _P#H._\
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MT4?ZH8'^:7WK_(/K$CZJ_P"%P^ _^@[_ .2D_P#\11_PN'P'_P!!W_R4G_\
MB*^5:*/]4,#_ #2^]?Y!]8D?57_"X? ?_0=_\E)__B*/^%P^ _\ H._^2D__
M ,17RK11_JA@?YI?>O\ (/K$CZJ_X7#X#_Z#O_DI/_\ $4?\+A\!_P#0=_\
M)2?_ .(KY5HH_P!4,#_-+[U_D'UB1]5?\+A\!_\ 0=_\E)__ (BC_A</@/\
MZ#O_ )*3_P#Q%?*M%'^J&!_FE]Z_R#ZQ(^JO^%P^ _\ H._^2D__ ,11_P +
MA\!_]!W_ ,E)_P#XBOE6BC_5# _S2^]?Y!]8D?57_"X? ?\ T'?_ "4G_P#B
M*/\ A</@/_H._P#DI/\ _$5\JT4?ZH8'^:7WK_(/K$CZJ_X7#X#_ .@[_P"2
MD_\ \11_PN'P'_T'?_)2?_XBOE6BC_5# _S2^]?Y!]8D?57_  N'P'_T'?\
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MKY5HH_U0P/\ -+[U_D'UB1]5?\+A\!_]!W_R4G_^(H_X7#X#_P"@[_Y*3_\
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@P;J1=[.PX 7 X-%1B^(,/0KSI2B[Q=NG^8XTFU<__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )[ [0# 2(  A$! Q$!_\0
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M_A2WCG_G^L__  +?_P")H_X4MXY_Y_K/_P "W_\ B:^C,T9H_P!:<?\ W?\
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M^L__  +?_P")KZ,S1FC_ %IQ_P#=_P# 5_F'L(GSG_PI;QS_ ,_UG_X%O_\
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MEO'/_/\ 6?\ X%O_ /$U]&TE'^M./_N_^ K_ ##V,3YS_P"%+>.?^?ZS_P#
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MK3C_ .[_ . K_,/81/G/_A2WCG_G^L__  +?_P")H_X4MXY_Y_K/_P "W_\
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M(GSG_P *6\<_\_UG_P"!;_\ Q-'_  I;QS_S_6?_ (%O_P#$U]&T4?ZTX_\
MN_\ @*_S#V$3YR_X4MXY_P"?ZS_\"W_^)H_X4MXY_P"?ZS_\"W_^)KZ-R*3-
M'^M./_N_^ K_ ##V$3YS_P"%+>.?^?ZS_P# M_\ XFC_ (4MXY_Y_K/_ ,"W
M_P#B:^C,T9H_UIQ_]W_P%?YA[")\Y_\ "EO'/_/]9_\ @6__ ,31_P *6\<_
M\_UG_P"!;_\ Q-?1F:,T?ZTX_P#N_P#@*_S#V,3YS_X4MXY_Y_K/_P "W_\
MB:/^%+>.?^?ZS_\  M__ (FOHVDH_P!:<?\ W?\ P%?YA[&)\Y_\*6\<_P#/
M]9_^!;__ !-'_"EO'/\ S_6?_@6__P 37T92YH_UIQ_]W_P%?YA[")\Y?\*6
M\<_\_P!9_P#@6_\ \31_PI;QS_S_ %G_ .!;_P#Q-?1F:,T?ZTX_^[_X"O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %!QD&BD;I0(NZ>_WDS[XK/\ '/\ R(/B'_L'S_\
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MI3_E']7Q/_/W\$=#_P (S:?]#'8T?\(S:?\ 0Q6-<]M3T'Y4NQ/0?E2YZ?\
M*'U;$?\ /[\$=#_PC-F?^9CL:3_A&;/'_(QV-<_L3'0?E4]EI\M_*T=O&FY5
MW'<0H ^M-3A)V4/Q(G2KTX\TJVGHC;'AFT/)\1V((IJ^&;,@_P#%1V/T-9BZ
M+<-.T -KN SGS1M/XT]]"O8[D0-#$'9/,R&&T+ZDU22>T/Q,>:=_X_X(T?\
MA&+3OXDL>:7_ (1BT[>)+"L&YLY+27RIHPK8SQR"/4&H0B_W14.<%IRF\:.(
MDN:-;3T1T?\ PC-GW\1V-!\+V>,_\))85SVU/[J_E2;$]!1ST_Y2OJN(Z5?P
M1T7_  B]F<9\26% \+V6?^1CL*YW8GH/RHV+Z"CVE/\ D#ZOB%_R]_!'1_\
M"+V1)_XJ&QH_X1>S'_,QV-<YL4=A0RJ!G Q]*;JP_E)6'Q"VJO[D='_PB]GC
MCQ'8XH_X1>RR#_PDEA6;'H%Y/#YD:V[*%W\2#./I42Z/=/:_:5@79MW@$C<5
M]=O<4_=M_#,'*7_/_;R1K+X7LSD?\)%88_G1_P (O:?]#)85E-HMXEH;AH%V
MA=^T,-X7UQVJEMC(X _*E-P3UA^9I3IU9J\*U[>2.B_X1FS_ .ADL:/^$9L_
M^ACL:YW8OH/RI=B_W5_*IYJ7\GXLU^KXG_G[^".B_P"$9L_^ADL:/^$9M/\
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M'_X1C1/^@9;_ /?%'_"+Z)_T#;?_ +XK8I*/90[![>K_ #/[V9'_  B^B?\
M0,M_^^*/^$7T3_H&6_\ WQ6QBBCV4.P>WJ_S/[V8_P#PC&B?] VW_P"^*/\
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M^B?] R#_ +XH_P"$7T3_ *!EO_WQ6Q11[*'8/;U?YG][,?\ X1C1/^@9;_\
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MHYQ^S+6%]O?WHPF .,#H!53)]:*/:"]F6\+[<T *.]5.:/<T_:#]F6PJC@8
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M</RWRJN<GT ]15O2/$XBT 7.JS/+<27LL$$<4>YY-K<  =<"GJ*Z['6>8_\
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M1YC_ -\TVBB["R'>8_\ >-'F/_>--HHNPLAWF/\ WC0)'_OFFT478K(?O?\
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MV9B"<C%8_CG_ )$'Q#_V#I__ $ UKV_WS]*R/'/_ "(7B#_L'S_^@&N_!/\
M?T_\4?S1A4ZGR?I_^H;_ 'OZ"BC3_P#4-_O?T%%?M=3XF>8CT/X+?\E0O/\
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M$\FG#D5Q.M:;'!\1- U#SIVFG:6/:SG8BA.@6NU0$#!YH =BC%%% !BC%%%
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MS!C\$V"6U[";BZ:2ZN5NVG9_G24=&4]JU=)TA=+68FZN+J:9MTDL[9)/; Z
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M!_V#Y_\ T UK6WWVK)\<_P#(@^(/^P=/_P"@&O0P/\>G_BC^:.:KU/D[3_\
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M,/:%&CFKV%]!1A?04_9H/:%>V^^?I63XY_Y$'Q!_V#I__0#6\,=L9K!\<_\
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MP:[GTF'3-->Y;4HFE!9P@B"G#!OI63KOB:ZU3PKKLL%E+:V]FYB^TB3YG=6
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MM,A>ZN/+83./X0#T 'I0!V2]*7-(IXI:!!1110 4444#"BBB@ )Q5:XO+:V
M\^XAASP/,<+GZ9JS5"_T;3M5\O[?907/E_<\Q<[:+@6+>[M[I=UO/',H."T;
M!@#^%3U4L-,LM,A,5C:Q6\;'<5C7 )]:MT %%%% !1110(**** "FL<=J=2$
M ]:+@5/[5T_?L^W6N[.-OG+G/IC-6P<BL?\ X1701/YXTFT$N[?O\L9W>M;"
MC H 6BBB@84444 %%%% !1111<"EJ,-U/8S165PMO<,,),5W;/?%8G@&:ZG\
M+1&]NWNYTFEC::3J^&(KIFK(\-:1)HFE?8Y95E;SI)-RC PS$X_6@#9HHHH
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M&M[2"ZDO5\FX4O$54L2HZM@=O>M6WGCG@2:*17BD4,K*<@@]"*+(+L=Y,?\
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M '14M%%@NR+R(_[HH\B/^Z*EHHL%V1>1'_=H\B/^[4M%%@NR+R(_[M'V>/\
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M]OXKT:Z2Y>&^1H[8%I9,$*F#@C/KGM6?JOBV+_A'I;[1YDDFBFCC=9$(*AF
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M@Z?_ - -;JNK' (-8/CG_D0?$/\ V#Y__0#73@W_ +13_P 4?S0I;,^3]/\
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MC\31[0/9LOY'K1D>M4,T9]S^=/V@>S9?R/6C(JAD^IHH]H'LV7L@]Z0*J_=
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MW1;6^L;@P7LCP1WKN"2X)/S#J!@<&K.AZ'JEU8Z'-JEW$T%A;[X85C(=I&7
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M1118 HHHHL 44446 ****+ %%%%%@"BBBBP!11118 HHHHL 44446 ****+
M%%%%%@"BBBBP!11118 HHHHL 44446 ****+ 36_WOPK)\<_\B#X@_[!\_\
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M\(Z.UA!9M:L8[?/EGS6W $\C=G)!]*FNO#&DWL5I'-8H$M1B (2I0>G';VH
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MQ/<TZ7P_ILS3M):*YN)DGE.3\TB_=/X4 <;K^NW\&L37>G7ETT5O>QVKYVK
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M6_FL#QS_ ,B#XA_[!T__ * :Z<)_O%/_ !1_-$RV9\G:?_J&_P![^@HHT_\
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M7$4BQ.C$Y5CTS[>]6-4\3:)HLL,6I:E!;R2C<BDY)7^\<=![TKR'[IL^<_\
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MJ.BE=CY46(9&=CDUC^.?^1!\0?\ 8.G_ /0#6M;??/TK)\=?\B#X@_[!T_\
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MYKP,D5KH0L8-$O=*AMFP%O,%YB>KDCN373TAD!/+4F]?[PH<K@HV'44W>O\
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MT%%&G_ZAO][^@HK]LJ?$SRT>A_!;_DJ%Y_U[3_\ H:U]&U\Y_!7_ )*A>?\
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M2D__ ,11_P +A\!_]!W_ ,E)_P#XBOE6BC_5# _S2^]?Y!]8D?57_"X? ?\
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M'P'_ -!W_P E)_\ XBOE6BC_ %0P/\TOO7^0?6)'U5_PN'P'_P!!W_R4G_\
MB*/^%P^ _P#H._\ DI/_ /$5\JT4?ZH8'^:7WK_(/K$CZJ_X7#X#_P"@[_Y*
M3_\ Q%'_  N'P'_T'?\ R4G_ /B*^5:*/]4,#_-+[U_D'UB1]5?\+A\!_P#0
M=_\ )2?_ .(H_P"%P^ _^@[_ .2D_P#\17RK11_JA@?YI?>O\@^L2/JK_A</
M@/\ Z#O_ )*3_P#Q%'_"X? ?_0=_\E)__B*^5:*/]4,#_-+[U_D'UB1]5?\
M"X? ?_0=_P#)2?\ ^(H_X7#X#_Z#O_DI/_\ $5\JT4?ZH8'^:7WK_(/K$CZJ
M_P"%P^ _^@[_ .2D_P#\11_PN'P'_P!!W_R4G_\ B*^5:*/]4,#_ #2^]?Y!
M]8D?57_"X? ?_0=_\E)__B*/^%P^ _\ H._^2D__ ,17RK11_JA@?YI?>O\
M(/K$CZJ_X7#X#_Z#O_DI/_\ $4?\+A\!_P#0=_\ )2?_ .(KY5HH_P!4,#_-
M+[U_D'UB1]5?\+A\!_\ 0=_\E)__ (BC_A</@/\ Z#O_ )*3_P#Q%?*M%'^J
M&!_FE]Z_R#ZQ(^JO^%P^ _\ H._^2D__ ,11_P +A\!_]!W_ ,E)_P#XBOE6
MBC_5# _S2^]?Y!]8D?57_"X? ?\ T'?_ "4G_P#B*/\ A</@/_H._P#DI/\
M_$5\JT4?ZH8'^:7WK_(/K$CZJ_X7#X#_ .@[_P"2D_\ \11_PN'P'_T'?_)2
M?_XBOE6BC_5# _S2^]?Y!]8D?57_  N'P'_T'?\ R4G_ /B*/^%P^ _^@[_Y
M*3__ !%?*M%'^J&!_FE]Z_R#ZQ(^JO\ A</@/_H._P#DI/\ _$4?\+A\!_\
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M_P E)_\ XBC_ (7#X#_Z#O\ Y*3_ /Q%?*M%'^J&!_FE]Z_R#ZQ(^JO^%P^
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ES4=.2XN#=2+O9V' "X'!HJ,7Q!AZ%>=*47>+MT_S'&DVKG__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #* =\# 2(  A$! Q$!_\0
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M?\*X\7?\_*?]_I/_ (FOJ/:/04;1Z"C_ %IQ_:/_ ("O\P]A$^7/^%<>+O\
MGY3_ +_2?_$T?\*X\7?\_*?]_I/_ (FOJ/:/04;1Z"C_ %IQ_:/_ ("O\P]A
M$^7/^%<>+O\ GY3_ +_2?_$T?\*X\7?\_*?]_I/_ (FOJ/:/04;1Z"C_ %IQ
M_:/_ ("O\P]A$^7/^%<>+O\ GY3_ +_2?_$T?\*X\7?\_*?]_I/_ (FOJ/:/
M04;1Z"C_ %IQ_:/_ ("O\P]A$^7/^%<>+O\ GY3_ +_2?_$T?\*X\7?\_*?]
M_I/_ (FOJ/:/04;1Z"C_ %IQ_:/_ ("O\P]A$^7/^%<>+O\ GY3_ +_2?_$T
M?\*X\7?\_*?]_I/_ (FOJ/:/04;1Z"C_ %IQ_:/_ ("O\P]A$^7/^%<>+O\
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ME/\ O])_\37U'M'H*-H]!^5'^M./[1_\!7^8>PB?+G_"N/%H&3<IC_KM)_\
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M:_XQN;(-IZLMI:V0)7<W5F)[TD!Z(O7%.IB9).<=:?0 4444P"BBB@ HHHH
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MHBCRKD]<./ZCFC3O$X^TBQUJS;2[XC(\QLPR'_8DZ$^U '2T4S?R!CK0SX-
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MSS0;=L;'@DG%<W:_$R2]\):/K%O:)Y]U>I9W4+''E,3SBA:@>DT4TMBG YH
M*0G%+5>]O(;"SGNYR1#!&9'/H ,T 2ECZ5Q&M:E:ZV+PWD@C\/Z;,%G(^]=3
M @A%_P!D''U-9_A_QEXP\175OJEOX=MU\-7$FU':7$Y3IYF/2NKF\.I<ZC#Y
MIC72[<[X;*-,*TO4L_K@]!0!%H&FW+W=QK.J)B^N2?)C;DVT/:/TSW/UKH@O
M.:-HSFG4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!'+_J9/\
M=/\ *ODKQ=_R/U]_O+_Z+%?6LO\ J9/]T_RKY*\7?\C]??[R_P#HL5]?PE_O
M=3_ _P T<]?X4:OPX_Y*!/\ [LG_ *&M?4:_='TKY<^''_)0)_\ =D_]#6OJ
M-?NCZ5AQ3_OZ_P ,?R8Z'PBT445\N;A1110 4444 %%%% !1110!C>(-=MM
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ML5]?PE_O=3_ _P T<]?X4:OPX_Y*!/\ [LG_ *&M?4:_='TKY<^''_)0)_\
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M[''O5;2_#+>'K_Q#J<,\MW+J;^=Y*J%92!C"FLWX?:3J.FW&MSW=M=V]M=W
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M Q]6\*Q^#?A]XF&F:E?O$]JS(D\Q8Q,!U5NO-<1=>/5U3PQX2TNW35(+Q+B
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MK'BG_?U_AC^3'0^$6BBBOES<**** "@C-%% ";12;%]*=10 W:/2C IU%(
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M_P#OTO\ \77A5%8?ZJY;VE_X$_\ (KV\SW7_ (7Y;_\ /A/_ -^E_P#BZ/\
MA?EO_P ^$_\ WZ7_ .+KPJBC_57+>TO_  )_Y![>9[K_ ,+\M_\ GPG_ ._2
M_P#Q='_"_+?_ )\)_P#OTO\ \77A5%'^JN6]I?\ @3_R#V\SW7_A?EO_ ,^$
M_P#WZ7_XNC_A?EO_ ,^$_P#WZ7_XNO"J*/\ 57+>TO\ P)_Y![>9[K_PORW_
M .?"?_OTO_Q='_"_+?\ Y\)_^_2__%UX511_JKEO:7_@3_R#V\SW7_A?EO\
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MC_57+>TO_ G_ )![>9[K_P +\M_^?"?_ +]+_P#%T?\ "_+?_GPG_P"_2_\
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M2_\ "_+?_GQG_P"_2_\ Q=>%44?ZJY;VE_X$_P#(/;S/=/\ A?EO_P ^,_\
MWZ7_ .+I?^%^6_\ SX3_ /?I?_BZ\*HH_P!5<M[2_P# G_D'MYGNO_"_+?\
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F-I#=013Q>5*=DJ!AG8>QK>GE>#RJ%3$T4[J+ZWTW["<Y5&HL_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (+ =\# 2(  A$! Q$!_\0
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MT4?ZTX_M'_P%?YC]A$^>/^%->-_^?ZS_ / M_P#XFC_A37C?_G^L_P#P+?\
M^)KZ'HH_UIQ_:/\ X"O\Q>PB?/'_  IKQO\ \_UG_P"!;_\ Q-'_  IKQO\
M\_UG_P"!;_\ Q-?0]%'^M./[1_\  5_F'L(GSQ_PIKQO_P _UG_X%O\ _$T?
M\*:\;_\ /]9_^!;_ /Q-?0]%'^M./[1_\!7^8>PB?/'_  IKQO\ \_UG_P"!
M;_\ Q-'_  IKQO\ \_UG_P"!;_\ Q-?0]%'^M./[1_\  5_F'L(GSQ_PIKQO
M_P _UG_X%O\ _$T?\*:\;_\ /]9_^!;_ /Q-?0]%'^M./[1_\!7^8>PB?/'_
M  IKQO\ \_UG_P"!;_\ Q-'_  IKQO\ \_UG_P"!;_\ Q-?0]%'^M./[1_\
M 5_F'L(GSQ_PIKQO_P _UG_X%O\ _$T?\*:\;_\ /]9_^!;_ /Q-?0]%'^M.
M/[1_\!7^8>PB?/'_  IKQO\ \_UG_P"!;_\ Q-'_  IKQO\ \_UG_P"!;_\
MQ-?0]%'^M./[1_\  5_F'L(GSQ_PIKQO_P _UG_X%O\ _$T?\*:\;_\ /]9_
M^!;_ /Q-?0]%'^M./[1_\!7^8>PB?/'_  IKQO\ \_UG_P"!;_\ Q-'_  IK
MQO\ \_UG_P"!;_\ Q-?0]%'^M./[1_\  5_F'L(GSQ_PIKQO_P _UG_X%O\
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MY59O05(2JKECM ZDT#%HJA)K5C$V"[-]!3X-4L[@X20JW^U0!<HHZ]/S]:*
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M6,?:I'K5)X"W(BR_B>W2_2Q:VN#.R>8PQ_JU[YJ&'QGILLKATEBAP6CE8<2
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M988 S00<WISF'4(CD]<'W%6_$ W7L9_V:J:9$TVH1 CON/M5SQ"?]-CQT"T
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M559%W;5VY/I3$L;:+:(H]FT8!![58HH S)O#VF7$QFE@)D;J<U'_ ,(QI/\
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M:7^U[GN%IZZ++WDP?2E_L20_\M*/>"\1!K,V0&0<D5X/\2CN^*NJ'&,F(_\
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M"J^,58LO^/E:]"6S)I_$:>.E%%%<)ZH4444 %%%% !110>G% !SWHI%SWI:
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M-<QXZTR[U+PW<V=C")7F92(^F2#2D5$S/#WC._U/7(M,U2&TE5X#/Y]JVXH
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M_P#T-:^AZPXI_P!_7^&/Y,=#X0HHHKY<W"BBB@ HHHH **** "BBB@ HHHH
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M.*?]_7^&/Y,=#X0HHHKY<W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ***,4 174Z6EK-<R [(D+MCJ0*Y;1/B/H?B#0M2U6T:7R].!:>)Q\P
M[BM_7<_\(]J)')^SOT^E> 2:9>^'O =IXHTJWD*7D$EIJ5OM/()P'QZU(SWK
M3O$6G:EH=KK*SI#:W"[D:=MO'IS5'6O"_AS7+J'4-06/[3LVI<1S>6SIZ9'4
M5XQK$%S]D\&"^;R]%^P'#3JQB5_]H#O5F_T=V\->%-.;4YM1M)M28>?"&7:A
M/W?I6G*KHD]NT.VT?3;/['HQME@3.5B<$Y[DU<>^M4@,[WD(@SM,A<8SZ9KQ
MOQQILGPXU:VU+PY:R_9KVU:RDB4EOG/1C[UF>+/#]WH&B^$+&9W&F#,E[))N
M9/-;G+XYQ4]"K:IGO<<R30J\4JR1M]UT;(-/W$ \Y]JX'X4V'V+0KP1:HE_;
M/<LT)12%0>@S77ZQJ]GH&ES:EJ$C1VL."[ 9(_"BUA%_)SGG/;VHR0,9/YUE
MZ-XCT;Q#;+/I.HP7",,X5OF'U%:94CJ#Q0 I/'?GKS24<D'':@'- !2.XB1G
M;HHS2U5U)B+/:/XSCCTI-V0UN5+8$JTS$EI&)Y]*I:S)BW2,<9Y-:(&U !T
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MX2!NY*DU6,MU(<Y$:^F,T?Z0#_KOTH LQS*S!3\K9Z'O7B?Q+_Y*MJGUB_\
M1*5["97RBW #+GB0=17CGQ(_Y*GJ?.?]5SZ_N$KZ_A+_ 'NI_@?YHYZ_PHVO
M@U_R4Z\_Z]I__0UKZ'KYX^#7_)3KS_KVG_\ 0UKZ'K#BG_?U_AC^3'0^$***
M*^7-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "C'&:** (KFWC
MO+.>UER(ID*,0><&J'AW0++PUHD>E6(<VJEB/,Y//6M3'M1[YYI=0.!_X5%X
M>,LO^D7@MVN/M MP_P BR9SD"M2X\!:9-XK3Q#'<7=O>>7LE6-\)* ,#<*ZJ
MC/'2F@9R(^'&A?\ "/W6B?O_ +)=77VN3YN=^<\&K.H^!M%U36=+U6Y25KG3
M%"0X;@@=,^M=+U%%-@CE[+P#H5A=ZU/%'*SZN"MR&/&#UQ6;IWPOT;1Y[.\@
MGOKB73B7M$>3A/\ 9%=U12$>:>$/#&HW?Q!U/QEJ^F#3FD7RK>W)!8_[9^M>
ME_C023WHH'U#\:*** !MK(0X#(>"K#(KCM?^%_A?Q"YF>Q^PWG:XM#Y;?7BN
MQH[T >0PZ/\ $7PGO_L?4H]=L8FP;:Z.'QVP:B?XF6+7BP:_IMUHMZ.&\Y"4
M/T->H2J(M3<#&74'ZUC>)K*RU.VBBO;6*X0\8D4''XUQU&MFCHA<Y'6TAU;3
M$N].GCN?*PW[ILY%<['<<]3[@\$5<N_AS!;3M=>']3N=+N 2?+#9C/X5AWZ^
M)-&R=7T@7T"];JSZ_4BL'!2^%GHT<3RJTC7M)G?5K=8S\V[]*[LAE;<&PP[U
MP_A/6/#5W/NCU#;>XQY-P-A7Z9KN "1D#<#_ !#H:GD<=PK5(S?NFI<*+[35
MG!S)".?6LA9%)7GYFS\M6;6Z-M*IY\OHR>U<OXHOUT#Q!;?8KB*YEO.?LLC8
M9*Z:=916IY]2#OH=%TJ"^3SM,D !S$=PJK_:%Y&%%SILJNPR!'\U/CU2WN8I
MK<B2*4H<HZXQ75AL52G47)+4XZ]*2I-R0S17#PSPL-P W8J34BMM:".,!7G/
M/L*A\/CS)Y@IXV<GVJM>RM?:@=G(!V*!Z5[/L^:MS'E^TM0Y>I;TI([:UEU"
M<;4'RH/[U5)IKG5+D(%XZ+&.B^YIU]*9'ALXCE(?E '=C6I;VB6EN80,R,,R
ML.QIU91A[SW(I0=2T5MU&VUA;V8!VB:4_>8_=%6IA%*-JQ@1XY7T/K50.\'$
MAW1=F]/K5G<" P_ CO7FRJRD[GK0I0@K(K*SVQ6.4[HC]V3_ !JT>0#Q^%-*
MAPP89![5"$DA7,7S+W#5BS0GHSSUJ#[6G\2LI],5&]T7<0PJ?,;N1TI 6\X]
MZ3*G@$$^F:A%N"H+2,WJ13TA1#E:!M6'. WRD<9%>-?$@ ?%/4P.@\K_ -$)
M7L^"6!SW'7ZUXS\2?^2JZI_VR_\ 1"5]APE_O=3_  /\T<U?X4;/P:_Y*=>?
M]>T__H:U]#U\\?!K_DIUY_U[3_\ H:U]#UAQ3_OZ_P ,?R8Z'PA1117RYN%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 % H'6L^ZNS*S6]N<@</(.WTI2:0TKC)"LU\9U.54;!
M[UC:M*'N1'V0=*UI)8+*$<X4#@5SDCF29Y&ZL>*\^<E)Z'53C;<3.0/6@,1P
M.GI4T%K+<'"#&.YZ4VY.GV/_ !^7\2G^Z#6:3[&Z:9@ZQX2T+7<F]L(Q+VFB
M^5Q^(KG?^$2\3Z 3)X;UMKF '<+6\_EFNDN_&GA"QSY^J'([*,FL&Z^*FB$[
M=)TO4;]^G(PN:VCSD63Z&IX;U[5=5NIK'5-%DLKF(9:0'*/]*Y?Q%#I]QKFI
MZE-'N,2JD4F[!1QW%-F\3^,]620QFSTJ$C:JO\SD>U<G<Z%;EX/M>K3W4\CY
MF0'"J:F:BGO87O(ZNT^)7]B*L%W=K?1%1]WEUJU-\4GU)EMM-T&0B5@KSW'R
MX&>>:PK?1])L0XMTM_,8A%+<\'TK6T^$K>06L+1R[I\?,. HKFI86C[3FA'4
M55OD][8]+@MK4:>/L\@B$@ WYZFJ4>FBPG:9+J"29<A$9@,^N:RI)#)<%8S\
MJM\B@\<5C:VIAO\ 52T$GF;(V#;N *]JK'$8:"?/=L\JE[/$3:ML=6ELNG2M
M?MBX3'R",YPQZY%+'K%C*V&E9']'7%<-%-&E_'<2/-';BY1&"N<8(KT.YT72
MY@?(N9(]W(+_ #*:Y98JHW[QVPPT::]WJ*K)< +&R2 ]D((J,VES"=UN-X/\
M#'I56+1)(+M701L N<P.5_,51::\B9CNE4;CUKT,/&-;=G+B*CH]#8#W(X:W
M(8=<&F3W1@ :9HHEZG<W/Y56M)'O+<1WEQ+;VZG(N%]:N0V_A^S#.LPN;@#*
M-.2PS659>RE8TI-SC=DMCNU)&DMXR(1_%(,9^E0_:+?3[B1YI5>4<!5K,F.K
M7\GF7&KVD4"'*6\(('XU/-:6]Q,LKWD$8(^?:.]:X?V<G[YEB.>*]PL6VJ0W
M4@BDA,;LWRD=*O,H25AC.._:JT-I96 \Z*[2XD;IM_AJ589;C[X,4/4 ]6-.
MLX7]T5!3:]XCRURZQPGY<_,_:O'OB.NWXI:FH.<>4/\ R E>XI&L:HJJ N>E
M>'_$K_DJNJ?6+_T2E?4<)?[W4_P/\T*O\*-GX-?\E.O/^O:?_P!#6OH>OGCX
M-?\ )3KS_KVG_P#0UKZ'K#BG_?U_AC^3'0^$****^7-PHHHH **** "BBB@
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M:3PUJ;W,BP1#?&N7F;HQ[@5Z)DYYXI<G:>.O7%)Q2(<+GFFH6EQ:7D,=Q:K
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M->37D%G=D1:@@^5^@<5<9-=2:F&NN9HNF5_*$7R^7_<(XJA=ZM863[)C$#W
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MJ-VUU<OOE<]_X?:M&TLM_.#M%-L[42-TPHZUL *B@*"J_P ZA1<MSTI2Y59
M$"* *<>O%)DXSM8CZ4\HZ@;D90>F16Z3['.Y+JQM%)U.!U'>I4C0VSSR.1M/
M(%$8N3LB)R4%S-D1."<U+' 6.]F\N/KGUJ,WML@S%"TA]6[5$?M6HN.<@=@,
M**].E@7O4=D>17S-6<:6K'7-T9D$%O'B,'H.K&K(MA;63@RHSOR5'\-(J168
MVQX>8]6[#Z5$22>>3WHQ.)BH^RICP>$G*7MJVX#I1117E]+'M:W"CUYZT44A
MD4L:RIAP&^M8E[;2V=Q'<0$B2,[D8=JZ BH+B$30L".>U2UU'&71G0VM_'K&
MEPZBG^L'R2CWKBKR+R-=D7@!FS4WAW4#I6J26DI/V>X."#T#5:\36[1W4-VJ
MX4<-47NR81Y*C19*!T(8 C'6KFBR-;$PL<JI^4U0@<30(V>U2AFC8.IY!K1+
MJ357,K'2L,?,#PU(>E5[:\)C&1N0^G6K >$J#N(]C75&HK69Y,Z3OH)-(T<L
M3J<#&"*\/^)1S\5=4/O%_P"B4KVJ>19)%VYP,=:\4^)'_)4]3_[9?^B4KZ_@
MV5\94_P/\T<V+C:"-KX-?\E.O/\ KVG_ /0UKZ'KYX^#7_)3KS_KVG_]#6OH
M>GQ3_OZ_PQ_)F5#X0HHHKY<W"BBB@ HHHH **** "BBB@#!\6>%;7Q9I45K/
M-);3P2B:VN8_O1..A%9.E>![I/$$&N>(=;DU>^M$*6J^6$2('^+'K[UVE!^8
M\\^U ' I\,UCT2ST[^U&/V;5#J6_;]XDYVFJOB/X4C7=7U2\AU@P0:EM:6-H
M0[!E_NL>0*](_GZT?TH XB[\ W:ZY'J^C:_+IUQ);1VUWLC#"54Z8ST-33^!
M3+XJO=7&IN+74K46U]:E,^<H7&0>QKL>O!- SCK0!Y]IOPQ>WN=-AO\ 79[W
M2-*E\VQLF0+L/;<W?%=!X>\,1Z$VM-)<&Y34[AIW4KPH(P1[UT/;':ESSF@#
MRWX0^&FTRXU_4Y8)H5ENF@LUG&"(@2>/:NON/"J7'CJ/Q*]RQ"636;6VWAP>
M]=$3GK1Z9YQ0!Y[8?";3[33_ !!I\M]+-9ZL054C!@P<C'TJ;3?A[=6^F7]E
M>:S'.)[,VD)CM@FQ3_$V.IKO,=/;I28YS0!RE[X(@OOAY!X4DNV_<1(D=T!\
MRLO1JSG^%MC)X&MO#K7T@N+>?[4MX5R6ESU(/45WOT]<T@8Y(.<T 8/ACP]<
MZ"MP][?)=W$Y&3% (U '08%=!N)'!_.F]^>32TM030?2BBBF "JE]<M"BQ1\
MS2<*,=!5B:5((C(Q^5>?K66@E.Z[<$RO]P'^$5G.=D5!7=A-PMHUAC&Z1N@]
M_4T?N;&WDGG<#C,CG^E2Q((P68@OU9O05YYXR\0F^NCI]HQ\B(_O"/XC7$Y6
M.VC2=25D9GB#6Y=>U%B&(MHSB(#O[U7MX"^U<>U0V\><$#'H*V[2#RH@W\?:
MLM]3V+*FN5$\$!.(HURP[U)+<6]K\J?Z1*.I/W5I]SNBT\>0I97_ -8XZK[5
M#;VJ)&LUR./X(C_%[FO;PU"E&'M*C/FL9BJU2K[*FA8Y[^X/[M%QVXP*LE[_
M (WSP,!_"U123O*< A$'15Z5%C:>345<:KVC%&M/+I[U)NY=>)/)9I@L<F,J
M%.0:J02&-LXRI'SJ>](1_/-&.<YYKBE4?-='I0H\D.23N2*;9,[+?)/=J'G>
M1=APJ?W5XJ( FEP, ^OI3G6J2TD3##4X/1"8%+1TZT#GI6)T-6"BCO2@<\GB
MD4)10,XZ44""CFBEQ0#,;5;-O]?$#D$'CUKH1LUG15!P21AB>S"JKE0"7QLQ
MSFL^TUVTTZZ**6DMY.&X^Z:RT0YJ4HW0VQE:TG>RN>'4X&>XK2YZ&K=WI]IJ
MUN'1P6Q\LZ=1]:PY/[3TU]D\?GQ@\.G/%6I=!<R>C-BTD,4H4G@FM(]:P;*Z
M-U*@6%U]216_CC!ZBAI'-45F .,?45XQ\2/^2IZG_P!LO_1*5[..WU%>,?$C
M_DJ>I_\ ;+_T2E?;\%?[Y4_P/\T>5COA1M?!K_DIUY_U[3_^AK7T/7SQ\&O^
M2G7G_7M/_P"AK7T/6G%/^_K_  Q_)G-0^$****^7-PHHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *.]%17%Q':PM+*P"KZGO5+>PI
M24=69NH3WMM>(UOAU(^:.K=EJ$5X"HRD@^\C=15".4S/]I8[BWW<=JI7;O#>
MPW*'#C@@=Q74J?,K=3S/K#C4OT.H/TH';U_E4<$OG0)(.]07UQY,8C3_ %DI
MP#Z"N*7NW1Z4'S*Z*UQ*+RYV#_CVC/S>YJ7D^PQP*9"BQ1!.N.2?4T_K7'*6
MITI66ARWC;7GTFP2U@&)K@$!O05YM K$@DY;JQ]:[KXCV<CVMK>(NY(VPWL*
MXF <9SQ7)/<]K"1BH71I6D6]ER.!WK:CB>0GRT.P< GBJ>CJ3.IV[AGI[58U
M"[>:Y=$<B->%"\<UZ.$PKK:G!F&.5"RZDP,EI*5[?W>QILDC3MN?&>@'H*DN
MD=1"67:VP9S4 Z=,5%2\6X7-:2C**J6W.<\8>(KKPY;VDMK LKS.0RGT%(WB
MKS[G1%LHUD@U$?.>Z$=14GB73;J_U#17MX/.A@FWS<\ 5@#PKJ>G^,XWLXS)
MI:R--&V>(V(Z?G4PM8*G.I'3MXKT=-4_L]Y)8YB_EJ6CPI;TS1-XJTB'5#IQ
MEEDN P4B-"0I/8FN)GT'Q!?W2/=6<[SQ7@D:8M\A3/&!ZUHZEI6JMXJ6ZTK3
M9K6?>/.N&;,3K]/6GRQW$JD[['2WGBO2;"_%G=R3(^X(7*$+GZU!9:U=7/C6
M_P!+9U-I%"KQ[1SS7):OH?B35)KQ+BTEGE\Y6AD# 1A!Z>]=)HVDW]IXQN;^
M: K;M:H@<GJP'-"C$?/-LEUKQ!?QZU!HFBVT<]\\>^1W/RH*L_VU/I>EI<>(
M(=DY8KMMUW9]ZS-9L-4TSQ6GB#3+/[8DD7E30@X/X5!K9\1ZI'I\_P#9LL5O
MD^?;1$;QZ<TDHM%-R4F;:>*]%DLX+I+DB.>3RE)7[K^A]*CUOQ';V<-];6MX
MB7T"JS%URJ@USNF>$[U_"NK6-U;F&X:;S[9203D'CFB#PSJS^$-4:X@+ZQ?.
MH*YYVBGRQ6MQ*I/:QMR^,[*UU*SL9UDDDGB5VDC7(!/M5Y?$^D/87-Z+DB"U
M?9-E>0?I6#<Z?J>G^(M'U.#3?M*I:K#,BX^1O4UDZOIBW7CR/3K.9#:WS+<7
M<2'.PKR0:%%$^TFMSTB"6.XACFC;*2*&7(QD&G-DG%!"J-HZ)PH'&!2],_3B
ML6[-G1%W6I@:W>&2;[*C$*O7%48HPPQMSGM1+^]O9'Q]YB#5R",Y&!7.]6=J
MM%7&VMS>:=)FVD8#^[VK<M_%2,H2\@ /=EZ54;3R\.[/S>E4FMRC8*XQ3LS+
MEA(ZRWU"QN0/)F12>S<5=VMC(&1UR#Q7">1DGKGMBM?2[ZXA4Q!V..FZJ6IS
M3H6V.BSRH]Z\9^)'_)5-3_[9?^B4KUM-3+;1-$&^;J*\D^(Y!^*6ID=/W7_H
MA*^ZX*C;%U/\#_-'BY@K17J;7P:_Y*=>?]>T_P#Z&M?0]?/'P:_Y*=>?]>T_
M_H:U]#UIQ3_OZ_PQ_)G+0^$****^7-PHHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH%TN(2%RS=!7$^+;^X,9948VXZ8[^]=+J$S2.+
M:-O=V':JDD22)Y;INCQ@BNNC%+5GGUZUW9'GNE>(+O3I=Y8R0MU4]JZ\WL%_
M%#<0_=;/'H:R=1\'-)*7LI0H8Y*GM5^VTP:39PQ9WL6^8UV+EO=')6MRG5:2
M^_3XCZ<5 Y\W4)F/1!A13-!DQ;RIG[CT]U,6I2J?XQD5Y&(5FSUL([P1*.E%
M'6BO.ZG?U(;FUAO;>2"= T;K@BN"O/ EW:S%[&19(R> W45Z'2'KU-#2>C-*
M5:=+J<%9:/J=E;2YMBT[_*".U)::5>0S&26TD;9T[Y->@<XZ\4F<5TT\3*E'
MEB85H1KS52?0X&>&]8[IX)0>OW>@JONR=I/S>C"O1NW(##WJAJ&D6M_&RF,+
M(1\KKP0:P;N[L[:>(25CB@>&ZKZXH]AT/44LB/#))#)_K$;:32=2<=!4M'8I
M7#+>M*&..^._/-)104.)XX)XZ<TA.>YXZ9]:2B@0<CI^= 8Y)!()ZT#VHH0,
M,DX!))[9I>YSSGMGI244 .#LOW3BL^TT?3M/N9;FTM5CN)23)*>2U7J*:8G9
MA_6D8?(WT.*6C.5Q^%2QG*1*6F<D?Q&MJQM_XSVZ5E(I2[E4GO\ UKH8$V0K
M[UE%:F]1VB2\X]#37B5ARH)IQ[45M8P(Q%&I^Z*?M&00H!]J6B@ Q\P_WA7F
M'Q%_Y*AJ7_;+_P!$)7IXZC_>%>8?$7_DJ&I?]LO_ $0E?;\&?[W4_P #_-'C
MYG\,?4V_@U_R4Z\_Z]I__0UKZ'KYX^#7_)3KS_KVG_\ 0UKZ'JN*?]_7^&/Y
M,X*'PA1117RYN%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %5KVX^S0LPY<\*/>K-8UQ*;B\8@92'@#MFM*4;LY<34Y8V0V-2J_-]YN6-.
MSFCMFBNQ'F7"J]ZI:W) Y7D58H(R"#WXJEH)JY5TB<)?@9^25>_K6S>6S3JK
M)@31\KGO7-;"CNJ_>B.Y:ZBTN1<VB2="PY]JY\336YVX2I;W2E#.LHQC;*.&
M5JESD\U-<6<5R2W^KD[2+51X[NV'S+YZ8^\*\N=.VJ/64KJQQ_C'Q-J6B:G;
MQ6@01D9(8?>K9T;Q)%J-O%]J3R)W&=IZ&EURQTS5]/9KU<&#YAG@@^E<8JM>
M74<<8P20J ?PBNC#X1U%>6Q.)Q4::4$M3T[' (Y!Z$4@KA+J7Q9I%XWV> S6
ML8 VGG-:VB>*9M0NA:WFG3V\Q'4C KBE[LFCH4&X*3.F'/%&<#(I.1GK@=,T
MIP.W/I2(2..\0P^5K#LN )%S663ZX_.NMU.QT^YNEENI6WJ,;5-4_L6BJ<")
MV^II7.Z%515CG=ZCJP'XT;T_OC\ZZ,+I*<"RW'WIZR:8/^8<@_"DF7[==CF-
MZ^HI=X]173M<V ^Y8)GW%)]JM,_\>$-%T+VWD<R)%#8R!1O4'EEKI_M-D>#I
M\>/I2>9IK'YM.0_0470O;^1S/F)_?7\Z-Z?WUKIP^D]].2G!M&_Y\4'X470>
MW\CE3)'GEUI3(H_B6NL T0GFTC'X5(%T; (@C_$470>V\CC_ #$_OJ* P'.\
M&NO,>B'EK>+\J<-,T>Y^[$G/3::5[B]NNQYGJ=LT5V;F,90]<5JVERMQ NT_
M,!R*["?PM82@A3(@QT)K-/@6)'+6]\4R>F*+6-OK,6K,R2<]J*V3X6O8UPEP
MCX]:SKK3KVS!::W;9TWKR*=P52+V*]%(K!QD$$>HI:9H ^\/J/YUYA\1?^2H
M:E_VR_\ 1"5Z>.H_WA_.O,/B+_R5#4O^V7_HA*^WX+_WNI_@?YH\?,_ACZFW
M\&O^2G7G_7M/_P"AK7T/7SQ\&O\ DIUY_P!>T_\ Z&M?0]5Q3_OZ_P ,?R9P
M4/A"BBBOES<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH C
MN'\NVD<]E-8EN!Y /]X[C6IJ>3ITP YVFLVWYMXP#_#BNJBK(\S%-\UB8\+G
M%-IZG*8/6FL,'VK>YR"44?2B@"G=#RI8IA@!CM:KVDR%)9[<G@?,HJ"YC$EN
MZ@<]:@@G=6CGCZLNW/O1*/,K#IRY)W.E8X&2=H]ZR=1\1Z?IHP\HDD/14YKB
MKO5=8O))(?,D<!L80$5+9^%M2N\NRB)3_$YYK*.'A'6;.Z>(FW:*(=9UR;5[
M@93RXE/"#JWUK5\/:3/:+_:5Q =H^ZI]/6MC2?"MII["64^=-U!/05OD9!7
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MX]2U#5;F^N;Z'SF,H_U?'0"O.M.O]8O[;0K!-2N+1;W59XIY(5VDH.E>Y1F
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MF_T6\P\$@P&;JI^M<IJ^GOI-\]N067JK>HKDE'J>I3FMF4J*.M%9G1<****
MN X-%%% @HHHH *.U%':@!*GL[AK2]AF5L%6&?I4%/BC::=(D^\Y II:BE:S
M/2[E/MUBNTX+ ,I]ZR$SE@W##@BMNWC,5M&A_A4#Z$5F7X"7Y8# =<UU/8\Z
M-KV(!S2T=>:#4I%!_$#_ +0KS#XB_P#)4-2_[9?^B$KT_N/]X5YA\1O^2HZE
M_P!LO_1"5]OP9_O=3_ _S1Y&9_#'U-OX-?\ )3KS_KVG_P#0UKZ'KYX^#7_)
M3KS_ *]I_P#T-:^AZKBG_?U_AC^3."A\(9Q45U*+>UGG(W"*-I"/7 SBI:"
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M_>Q0Q]3D6\>>)[SQDVCV0M5=;L12VS1DLD6,[\UN^.=0EL_$WAB&.))&EF<
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MC0Y2%=OXTFQX9-RNC&HI!TZ\TOYU)ZH4444 %%'/I10 4444 %%%% !1110
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M^2D__P 17RY11_JA@?YI?>O\@^L2/J/_ (6[X&_Z#G_DI/\ _$4?\+=\#?\
M0<_\E)__ (BOERBC_5# _P TOO7^0?6)'U'_ ,+=\#?]!S_R4G_^(H_X6[X&
M_P"@Y_Y*3_\ Q%?+E%'^J&!_FE]Z_P @^L2/J/\ X6[X&_Z#G_DI/_\ $4?\
M+=\#?]!S_P E)_\ XBOERBC_ %0P/\TOO7^0?6)'U'_PMWP-_P!!S_R4G_\
MB*!\7? W_0<_\E)__B*^7**/]4,#_-+[U_D'UB1]0O\ %OP)(,/K*M];2?\
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M-O\ "N%HH_U&R_\ GG]Z_P#D1_VS7[+\?\SNO^$ATK_GZ_\ (;?X4'Q#I?\
MS]?^0V_PKA:*/]1LO_GG]Z_^1#^V:_9?C_F=U_PD&EDC_2\#O^[;_"NEM?&?
MANWM8X5U'&WK^XD_^)KR"BFN",O7VY_>O_D2)9O7ENE^/^9[/'X[\-K.C'4N
M P)_<2>O^[7F&I74-[XIO+FW??#+.[HV",@YQP>:QZ['X7Z58ZSXZM;/4(!/
F;M'(Q0L0"0IQT-=^$R3"9-&IBJ;D[1=[VVW[(Y:V*GB+1DD?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img_011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &5 =\# 2(  A$! Q$!_\0
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M0(-3/_+T_P#W]:M0+Q2[>:/[;Q/:/W![61E_9]3_ .?I_P#OZU'D:G_S]/\
M]_6K7 ..E+M/I1_;>)[1^X7M9F/]GU/_ )^G_P"_IH^SZG_S]/\ ]_36SMHV
MT?VWB>T?N%[:9C?9M3_Y^G_[^M2_9M4_Y^G_ ._K5L;<4;0:?]M8GM'[A.M(
MQOL^I_\ /T__ ']:C[/J?_/T_P#W]:MC;1MH_MK$]H_<)UYF/]GU/_GZ?_OZ
MU'V?4Q_R]/\ ]_6K7VXH9:?]M8GM'[B?K$S'\C4_^?I_^_K4OV?4_P#GZ?\
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M #1V87XCT3X,?\E/O/\ KVG_ /0UKZ*KYU^#'_)3[S_KVG_]#6OHFOF^*?\
M?U_AC^3/>H?"+6=JVK1Z9;%NLQ'RIWJ:_OX--LI;JX<+'&,G)Z^U>2W_ (CD
MU&YGNIB8SNVJ!S@=J^2J5%'0]C+\#+$SVT1OR:U(6>5Y&Y/S$]?PIZZ[<(,[
MMRGI7(-?GHTJNG<CM2+=21XPYV-TS7%[1MZGT[P,+62.S>^AN0!/;VTK-V=!
M69J?A^UO8O/T^-+*^52H*?ZM_J*RK>Z"@C)R?7K6U9RDR+'YAP1D@U7,F83H
MNBU*#.'EAGMYVAN$!N5'SHYR&QW'M6K;ZA;+&6+!I) ,JG(]*Z34]$M=52=Y
M%)>&/<KKQD^E<CH]K';*X$.V1VRQ/\ ':LG!IGI4\1"O#S1T^GQLY1F;Y1U7
MM6I?>4$2>&'SIXON*.^>U8UNTWVNU@MU.9#\ZGD@>M=9:V"V-F[2MF8\Y/85
MO!::GCXN:C)$,;2PVZ-(H$[+\R#HOL*H3W222;?,5F'\(85R7CKQ#=Q2KIUG
M(8Y)%W2R+U ]!7GS0W43><+B993R'W')KV:&63K4^<TH8237,T>S3\1 E3N'
M8=JK_: %SN 'O7->&/$5Q?Z9=6E\X:XMAE9#U9?>MO3K*;4R6R8X5ZN1][Z5
MY5:C.%3D94JL*<'SNS1<M87U"X 4YA3[YKH(XAA5  5>F.U16MLEK L48P@Z
MGN3[U;12,#&/>NNG!16I\MB\0ZTK+8,' '8=*X+QWKL=V@T2V*2\YF<#I]*U
M/%WBB+3;-[&UD#7THP ISL'K]:X33;-F<LQ=W8Y9NY)K*K4L/#47=2,AM FN
MKN.W5,,_(EZ!5'4GZ55U>7)CM+1<Z?:@K$1U=N[M]:]5.F)_9;6!&)IE_>..
MJ#L*X*]T>2UGDA( D0X(QUHHXV=/0[JV7TZZNU9G,HV>>WM4ZGBK,UCR<#8X
MZG'%5BK1':X_&O>H8VG4TZGS&*RVM0N[71,H^6IU&<5 AS]*M1#-=G-=7/,B
MM;$\<?2K21\4R-<XJY&O Q6<F=U. J1\5:CB]J6.($U;CCXY%<\IGHTZ:&QQ
MY[582+VJ2*/VJTD0QDUS2F=].F0+%[5<LQY5W"X!X;MZ=ZT]-T.XOB& \N(=
M9&KI;73;+3AF.,/(/XVY-9<S9I*<(:'.1>&[RXNI,((H@Q^=^XK9M?#>GVV&
MFS</Z,?EK4N+@Y!!ZBJ;7!)PH)-4HM[G.Y3EL6T:.W79$B1@=E%1-/D]<GZU
M$L$K?-*X5>P[T]8H>F"3ZYJTHF3IM[D;38/7GZU$T_N?RJV((H^B FE=LC"Q
MJ/;%7S+L8N"1GF<D]#^55KJ^%K$9)3L0< CDM[ 4Z_U:*S@=V0<'8 .K-Z"J
MMA9M/*+^\<&;^",](Q5<U]$92AV*;"]U-OWXDM+/^&//SR?4UK630V4:QPH$
M4?W:NF0%1YBJ5'3-*'C<9CVY],52LE9HYI\PR6>WO8S#=P1S1G^^,FN<U+P+
M97H:32Y_L\G_ #R?[I_&N@D:(MLFCVGL141BEC;,!,B]_:B/NN\79G-/56EJ
M>4ZGI-]I,_E7UNT9/W6QE3]#68P .#7M[O97=L;6_1+E&X*'G'XUR7B#PK#I
M\1NM,TN*ZM5Y=2YWI_C792Q37NU#S:^$TYH'G1Q2 E75U&65@P'J16K]OM",
MC1X/^_C4W^T+/OH]O_W\:NSFYEJCSTK/0OZF^AZIJ!U=M0EC>3:9;01_,7'!
MPW85IW.OZ3;Q6:6EP72*^6?"!MRQXP2Q/4USGV^RQ_R!K?\ [^-2'4+//_(&
M@X_Z:-7-[!6L[V.Q5VNQHSZO;6MM)!;:C+*SZFMSYBY7,?O]/2M,>)]/97^S
MW,-M+#=O,CS1L1(#W&._UKF#?V9S_P 2:#/KYC4TZC9Y_P"0+ ._^L:CV$2O
MK$NYMZ?X@L88])N;JZ<R65S*TEO@X</T8#I@4_\ X2*WMM2M\:A!);PI.T;0
M1LI1G'&2>IK _M"S .-$MQG_ *:M3/[1LL$'1;?_ +^M2^KQW*]O*UKF0S.[
M,\CL[,<EF.2::W7C]:V#J-C_ - 6W_[^M44E_9M&RKH]NK$8#"1B16Z=C+S,
MDCBL:3_D,G_/\-;A7!K$E_Y#3?Y_AKW\D_C2_P +_-'7A'[[/0O@Q_R4^\_Z
M]I__ $-:^B2,U\[?!G_DIUY_U[3_ /H:U[SKNI)I.BW-ZYQY:''U[5\UQ4[8
MZ_\ =C^3/HL-%S2BNK/._B%XACN[YM(MWWBV&9%[.WI7(%V-K T)PZ<.#UJB
M[I=RS32S,+AR9"<=>?6I4G=4VL05/\?<?6O@ZD^>1^FX+"+#T8P1.I=F+/$H
M#=<5/&$DC CF+ '&TCD&J]J^Z,JHW;3SDUHV\.^19+=2&Q@L!Q4HZ*C2T)+?
M"E=_KR:VK=) [,,$'!4BJ<5F=_SE=Q_(UKZ9&@D R0PXP1Q6B1YE>:2;.AT*
MT6XLIMP^^#D>E8%UH_V5Y&>)=K EU ZGM7;:; MM;E3PK\YH6RB)E>7YUW;L
M'^5=;A>*N?,QQ<H5)-;&%HFF&QA^WW2@7+CY1Z#M3]5N5AL7,AY;'XFKES+)
M)*7;  X4#L*QM4"S;1P2O.">]*7NJQO34JE13GN>?Z_:J/$-M?7"DVK@+(?0
MCUK5\7?V'_8:-;>6)  1MQS5Z2.%XGCG :/^+=TSZ5SUWI6F ,4M7DD"DA68
MX%>KALSC3A%3O[I[D8<W*T]C \)J?[9,J7L-LP&W]YT?V->JZ3KEC>2&R#1Q
M7,7!CSP?=3W%>1>'=>M-%^V)=V*W#2@J,C[IJ*TN"\3RCY)"Q*8."![5SU<R
MC7D[Q/&Q^3U*E=UXRWM_2/>F981\Y"]^3UKE_%OB^/2;+[/92+)>S<?*<[!Z
MGTKS[^V]9$'V=;Z4QL._4?C4%K9,7+-DECDD\YKEGB+HX(Y<XSU)+6W>>9II
MBTDCG+,>]=QHMBMK"MZZY_@@C(ZGUK.T;3%EDS(=L2C=(W3 KI1F9]V-J ;4
M7T%<4ZAZ5.BEHA\$>3N<DL>3]:R_$FG>="+R)?GC^_[BMI$(P>U3^4LJE&&5
M<;6'M64-6=,K1V/,WMXY!AL'WQ6?/IK*,H P]*Z*\LC97DL!'"-QGT[5!L_.
MNI>Z[B:C-')O:[&)7Y6_NGI3H6*L PVFNEFLHI@05Z]ZS+C3WCSQN45Z%#'S
MAI+4\;%95"?O0T81$$@5?@7/X5DINB/J/3N*T[696 (.?:O3CB(S5T>1]6G2
M=I&G$A.#BKL46<55MSP.?PK2@&1G^593D=M*))'$1VKIM)T$*JW-ZN%_AC[U
M)HVD+"JW=TH+GF.,]O>M:6;/?\ZQ5WN7.HV^6(LDP50J@*HZ*.@JH\Y/4X--
M=BS8 )/H*E2%8QF0;F/0>E-RMHBX4HK5[BI"]S;H?N[6ZGN*F6."W  )+>M,
M:9_+D15).,Y[9J&W25GRR$#KDU'/<M0NM1\L+%\O)\I].M$90-@(23_%45P9
M/-(VG%*95@BP.7/>G[2QI[+W="Q++''@*,GO67=WQBWYD"!%W2.3]Q?6LSQ3
M%JT^@7!T>79>@@I_M>U<+9>*+Z_U32M"FT>]QO\ ^)BTBXW/['^Z*'4:T,94
M8I6ZG:10S:GC5'4B./B"$CH/[WU-2[Y5/*.OX&M2:Z^S<1*%C7@8'3Z>U,M[
MYYI=@ <GVR*Z(-+4R=%QCL58#),0N3D]JMQZ?<*_#<>E:GE06T>X(,D98+W-
M94^H.\FU3M7T7^M;QFY;'F5(EW9&$\NX/F-V"]OJ:JM=31L4("H#C:O3%6+5
M0]N9G;:HJK=W$<DG[NB*O(X*BL0/:AMSVQ 8<M'ZU)9ZD\3;2"#T.15>[+Q:
MA'(O&%&<5;6X0L//B#1N,;P.A]ZV>L=5='#;WO==F<[XJ\(QW4<NJZ0@$H&Z
M:W4?>'JM>?%0PR/Y5[8J/9D2Q,6B;I_LUQGC7PU''G6]/3$+'_2(E_A/]X#T
MJL/7<9<C>ASXK#W7/'<X3MBF'-3$9.1T/2F$<UZAY-R(\&F&IB!32*-2TR%N
MM-/7I4A'--(YI:EID1^@I#]*>13#UH+1&16%-_R&V_S_  UOD5@3_P#(;;_/
M\->UDO\ &G_A?YH]#!?&_0]!^#/_ "4Z\_Z]I_\ T-:] ^*VM1P06FEE=YE.
M]ESV'K7GWP9&?B?>#_IVG_\ 0UK8\=S3ZEXPO3$R%+=!&%)Y/KBOD^,)<N,_
M[=C^3/O.':"JXE-[+4PHVM&E(FD982,8/K]:?' EO,K!O]';[I8=:8MH Z.F
M .KQGD?A5Z<I)!$BHP\G[H(X.:^$6Q^ART>@^"2-;@[(]R_WAWJ_#,RQLA)/
MSY4 8XK*29R1&%VM_#BM+3S*\@B(W$<-FJB<]6UC2LCY\Q5F#.WW!CBN@TBT
M9KI P(YP:PK%3')\N 4?!'H*[C0K39F0G@?,?K733C=G@8^MR1=C9E7Y(H0,
MG/-5-2NE11"C$'T'>K-Q<) A<@[GX6N:N[IE5@" 3SN/:NJ3LCP,-2=25V,G
MNE##>_)[5FRS>;NDQ\J]/6L2^\5Z7!*T33L\@.&*+D"I[75H+^)7M9TD3H>Q
M'X5%6E5BN:478^CIT.5(BNYTE5S'( RG<1V/M7.WMZUO:FY8L=QX#'!-:NI1
M,I!'"9W8 YKD=4O(VC*3A_-ZH@[5EAZ;JU5$ZZ\:D</)TOBMH$MG/>0->O9I
MMW!=R#G)Z#ZU4FGDMIQ;7ELUNXZ<=*MP>)KR+34M$B $<HE4^XJKJU[?^(=3
M%Q<Q+%P!QTQ7;FF'5&I[JLC@R.GB_8/ZYJVW\C1MH6?8.IZ_6M^RLB[JJ+EF
MP *R;)%2,1S<G'!!_*NQLU%G9K*PQ-(N /[H]:\:39ZV*I1@M-V61&EO&MJG
M*J<R$?Q-_A5R!>U5+<9Q6A"N#4*[9Y\DH*Q,@W BK2Q8_#K38X>AJY'&9&"+
M^)KMI4SSZE2QRGBBSP\-V%^\"C'^5<]LYZ5Z+XCLXWT.51]Y,./PK@0G'I6M
M2-BJ%3FBT0;#FD,>>U6=A]:/+]ZRL;W[F;/I\<O(&T]JS9;26W?/S$#H:Z3R
M_>FM&&X/(JHMIW1E.$9Z-&1::AL 67C'\==OX=MHY0M[-@PC_5CU-<E/I:M\
M\7RMZ&HK6^O](DQ&YV#^ _=KKA7Z2/.K85I>X>M&ZW<YJ$R[OY5R>G^)K>[Q
M'+^XE[ ]#73V# *)GQG^$>M=$JD6K(YH4^3XMS5MHDA7>^-YIDUP < UGWFH
M1QPLRM\X&2,]JY*7Q+YD37";FC!VK[GVKEG6458]+#X.=74[V"XC63YVR344
M]TP+!2>M>8R^,+F*XQM1 OWB[5I3^*)K*Z\V09MGC$FY><9K+ZS='6\JJ1DC
MK9)I7./FID09GYYYJ'2=:CU2)6A8,"*UKG9;VX* ">3A?;WK6E>6MSEK2='W
M9+4R=1N_(7Y>7SY<8'=S_A4T99(8X5Q),!\S@?,3]:@T^&PU'S;R>8C[*3'%
M'GC/=OQJ&6_.2L:[!ZCJ16CJJ.YAAJ3JMRMJ:?V"/RR9Y /]A355XB(_+BN(
MXD_NH/YFL[SI')()(]:8)&)/6MX5$S>>&DEJS;GF>#3%3<&([U@+=?OLDXK7
M<9T=&')SP:Y>9RLS >M=L)6V/(=%2YCH[R]?^S8F5ALW8;%48+@LXS5;>9M*
MN$&<@;@*JV=SN 8G\*ZJ31Y%>E9&_?SJK1LW0I3+>Y(QW5NH/I5'5Y,Z?;RC
MHK%34EJROI<KY^:,9!K56Y;,\>K%HZ>Q.]&B#%HV&>:B@*Q2RVLJAX'!4@]P
M>U9&D7[RJ\2M\VT[:?!>&ZMRQ&)H6PP]JYW2=VA>UT5SA/$VAMH6KO"N3:R_
M/ WMZ?A6*5ZUZWK^F?\ "0>&Y$50US /,B/\Q7DY&0<\8/2N_"UG)<LMT>7B
MZ7)+F6S(2.:814I%,QUKJ.1,B9::5Q4I%,(YH-$R(CBF$<U*::>M(T3("M<_
M<?\ (<?Z_P#LM=&U<[<_\AU_K_[+7MY+_&E_A?YH]+ O]X_0[_X-''Q,OC_T
MZS_^AK6GJEI+?ZW<7;,JE9#U^M9'PB.WXB:D1VL[C_T):M7'VJZGD",N6+9!
MX[U\;QD_]N7^&/Y,_2^&(Z3D7$>WABY<G:>'QQ4\]LEW;^9%(%F4?*0>&]JR
M#NMU1$5AOZ#J 14L-TPN6C+N3C\ :^+O9GV,Z;W3+8C\XPIY:B=3\_M5ZP!%
MU.V".>M+"J2X4-MEQRV*T+>$K($:/+8[=&JTK['%5G969?TZW0N65.-W)_O5
MW=G$(+;<>%[YK T6P4-'@8'7%;>IW0BA$(/;YOI7;!**NSY7&U'4J*",V^NQ
M,2=P"J<"N%\97QBMH88V:**XEV,W?'>H_'WB.XTO3D%GA9KAM@D_NBN&N;?Q
M%/I=O=WKO/;RO^[+\G-7AZL/K$>;8]3"87DCSR=D=SK.AZ'!X96:!E$H7((/
M4UYYIUV]GK,+1$X=MK@=P:BN+R\C/V>82Y7C8>U3Z39.;M+RX!0*<QKW)]:^
MIQ56G3P[C-WOL=U"49PY82YM=SMKM]Z",N5 .3SSCTKS^X<S:K<,X.=Y&#V%
M=BBF971V)+Y.X=5KF[JP=LW4.YL\'</O^]?-Y5B*=&KS36YWRI]%T.UT+PAI
MM[H#7,T@\QESUZ5Q4MN(;F>*-\F%LY/.15JPFU00^1',887!.2W:IKC3(X;8
MW$4K%2,,&ZL:[\WQ-.5/V:E>^WD&$IRA4<IO1FEX>U"SMM;@O;RV\RW9<%,9
MY]:Z>>[AU&^EN((S'$Q 53Z"N1LX-D:0$;3C<%[J*Z738V\A=V,@U\PW>/*+
M%4H<_M>NQJ0*=P&.*U+>/YC5.V4,0?2M*W4OPM:TH=SP\1.Q9AC,C%!6B-EN
MG &ZH4"P1CNU022DDDUWIJ"/*=YOR&WA\^VE4\AD(Q7!B, 8/4<&NVD?*D>H
MKDFCQ(WUK"3N=E&/*5]@]J3;["K&RC94&Q!L]A1L]A4^RC90!!LJ*2W60$,
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M';MSQ6CK.EK]K%T@"HX_>X]:R+RY 4PQ#D#UKXWDY'<^K6*EBH(6]OF?)WJ
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M6)29+QPHZ CDUZ#P<7*_4YJ>-E&-D5+2VN$8%QL4')+<8%22ZD+J5XQ%F)>
M_K3&E@N)-KO,PSC+&I)8K> 84@>E=4(<NAS5*O,[O<@;:HRK8^M58H(HI6ED
M'RDY^II[RQ@Y9MJ=L]ZP=4U!C(\:N&'<CICVKI2.9R98UN82V\4JON21L<=%
M]JH6LUN 8YOEST85#'('MW@)X/S*#V-4F<\K73")QU9I*QHW%OL.4P0>]5?+
M.>.14<5TT? .1Z&H[B]<G X^E=D4>36F69KG9&(0Q!SDU!)-D9S50R9/7-(3
MN'6NB"/'KSN7XGR ?2KT4P"<'!-8HD(& <>M33ZK:Z59?:KPE@?]7$/O-_\
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M_P"RU]+DO\:7^%_FCJP"M4?H=O\ "3_DI%Y_U[S?^AK7O>37@GPE./B1>?\
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MTIE% #^:3I3:* '9/I02:9THS0 [)HR:910 [FDW&DI*.H'B_P 4S_Q6K?\
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MKY7BG_?U_AC^3/M*'PDE%1_C1^-?+FY)3<TW\:* '9HS3:* '9%+D4RC/TH
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MSP:YY5DCMCAVS4:Y IGVGWK)-QDXS1YQ8@#K6?M[FZP]C6$Y=@!UKH=-@\M
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5TG@7P\OB?Q7;Z8]R;=71V,@3<>%)Z9%%%<.8U)4L)5G!V:BVBH*\D
#C__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img_012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &X O@# 2(  A$! Q$!_\0
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M /X5%XT_Y_K3_P "G_\ B:/^%0^-?^?ZT_\  I__ (FO?C2$T_\ 6;'=H_\
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M_/\ 6O\ X%/_ /$TO_"HO&G_ #_6G_@4_P#\37OM%'^L^.[1_P# 5_F"I1/
MO^%1>-/^?ZT_\"G_ /B:/^%0^-?^?ZT_\"G_ /B:]^HSBI_UHQW:/_@*_P R
MO8Q/ ?\ A4/C7_G]M?\ P*?_ .)I?^%0>-?^?ZT_\"G_ /B:]\W4N:/]:,=V
MC_X"O\Q>QB>!?\*@\:_\_P!:?^!3_P#Q-'_"H/&O_/\ 6G_@4_\ \37OO-!)
MH_UHQW:/_@*_S#V,3P'_ (5%XT'_ "_6G_@4_P#\32?\*C\:?\_UK_X%/_\
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M^M?_  *?_P")I?\ A47C3_G^M?\ P*?_ .)KWVBC_6?'=H_^ K_,/9Q/ O\
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M.[4O]9\=VC_X"O\ ,7LT?/W_  J#QK_S_6G_ (%/_P#$T?\ "H/&O_/]:?\
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M_P"%0>-?^?ZT_P# M_\ XFC_ (5!XU_Y_K3_ ,"W_P#B:]_S1FE_K/CNT?\
MP%?YA[-'@'_"H/&O_/[:?^!;_P#Q-'_"H/&O_/\ 6G_@4_\ \37T!FD-'^L^
M.[1_\!#V:/G_ /X5#XU_Y_K3_P "G_\ B:/^%0^-?^?ZT_\  I__ (FO?Z*K
M_6;'=H_^ K_,?LT> ?\ "H?&O_/]:?\ @4__ ,32_P#"G_&O_/\ 6G_@6_\
M\37OU/!I/B?'=H_^ K_,7LT?/Q^$'C4?\OUI_P"!3_\ Q-)_PJ+QI_S_ %I_
MX%/_ /$U]!'FHR.:%Q/CNT?_  %?YA[-'@/_  J+QI_S_6G_ (%/_P#$T?\
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M4+*9HB+="SA&&0<#G@C]:\^\0^ =9TGPCX9NM+T^[:]N+:6.^CAA8NI<Y 8
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M(9O"DNFJR8@MXC))/<*"2!L.3UP,\=^U*[N.RL9?_"[]6ATV?3Y]'0>)TNQ
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M.'R<G*YQU]J5BCYVT])+GX7BVFUCP]:Z<T^&22 M=K)NZY'/X^E=UX_M?+^
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MW_P-E_\ BJ?,.Q:VGT-."GT-4_\ A&M-];W_ ,#9O_BJ3_A&M.];W_P-E_\
MBJ7,+E+V#Z&D(/H:I?\ "-:=ZWO_ (&R_P#Q5'_"-:=ZWO\ X&R__%4^8.4M
MX/H:3!]#57_A&M-];W_P-E_^*H_X1K3?6]_\#9?_ (JCF"Q:P?0T8/H:J_\
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MH-O=6<%Q>3WDUQ+&KNRW,B#)&<!5( '-2W8:5R_@^AI0#Z&JO_",Z;_T^?\
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MN"?^@BLS5Q_Q(]0_Z]I/_036G8?\@VT_ZX)_Z"*B142Q1114%!1110 4444
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M=OM[QX9E98=H'D;-A YS\WO77>+OB/H>HS>'[W2KDRW.F7OVIXI[>9%;Y"N
MVT]S1<9Z3I7B?2-7TXWL%TL42R-"ZW/[IXW'56#=#5BQUFSU!YTB<JT,K1E9
M,*6V]67U7WKP^+7?#=W=VEWJ]XD[2ZR^I7UN+.8QJICVJJY7YN@SFH=2UO1)
MK.[>PU=[;4'U*>2*06LN!:S#:RGY>#CG'M1<1[^E[:/+'$EU TDJ[HT$@)<>
MH'<4QM3T]4=VO[4+&0'8S+A<],\\5X$=4\-6_CBUO[74I?[,AEMI(V^S2K)
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M1043^XG_ 'R*44ZD(9L3^XG_ 'R*-B?W$_[Y%*>.XHI@(,#@ #Z"EI#QUH%
M"T44HH **,CIFD% Q:***!A1110 4449I %+24M,5Q*7-(0<T &FD2V.S332
MT9%58FYGS_\ (R:-]+C_ - %;E8=P?\ BH]&^EQ_Z *W,U#W*6P8I:3-%(84
M444""BBB@ HKG/$EKJTT\;V$4LR"(A$CG\L)+N!#-\RY&..^/0UFW,'C#R);
M>(/M;+*R.A(&[/#$YW>@Z8ZT =K17&3#QI//'"T8%NT0WNK1J=VX$'@\''!Q
MQ6SJTFH2I97=A:W# >:)+<,J/\R$*3D@<-@]: -K!]*,&N".D^(XYI!(E[<1
MGRO-*W0!< KD(=XZ@-U"D>IS5[4-/UR7PQ:V\7VG[0MTS,BRAI%A^;:&;>NX
MC*Y^;\Z!G845PC:?XM+1M\Y*QJ"/M PQV@$GGGG-7E/C%YB241$8G!6/YSD?
M*.?N8S@]?6@#JI)$B0O(ZH@ZLQP!3JP=.M-3U+1[JTU] ':8^6P"Y* @@X&0
M.16]0(**** "C-%% !39?]3)_N'^5.ILO^ID_P!QOY4 8V@$?\([IW_7NG\J
MT,9K-T$_\4]IW_7NG\JT@>*TMV(*>KK_ ,234/\ KVE_]!-:-A_R#;3_ *X)
M_P"@BLW6#_Q)-0_Z]I?_ $$UI6'_ "#;3_K@G_H(J9%1+%%%%04%%%% !111
M0 44ASM.W&['&?6N)ANO%"/E+6_ED78TPG "%_FW*O ^7IR">,=Z .WHKC$U
M;Q5]L$G]G2/$8C^[-L5#8W?-RWR-PORGKFKWAO4]9NIV.MV<UL90$A3RBJD@
MN2WME0O7VH Z6BN-O[CQ"ZS6\"W\30O,7F2'<&0NOE[/[WRY^[R*9ILWB%]0
MM?/34T??&&65083%@[RQP/FZ8Z'VZT#.VJ.:*.XB>&:-)8G&&1UR&'H0:XRY
MG\3)XAU'R([R2U^<1+L(3'R;2IQC^]T.?6FVVH>+K6-C+8SS$[>9(MQSMZ!0
M1U; )[9S0!V-I8VFGP>196L-M%G.R% HSZX%39&2,C(ZC/-<C/JWBV%0XTM)
M-TP^1(22J;F&,YY. ISP.:WH-->+7+K46EC99HU18UCVE0/4Y^;\J!&C1110
M 4444 %%%% &)<#/BQ?^P?\ ^U*N&JD__(V#_L'_ /M2KC#FM(D2W/ /C-_R
M/]G_ -><7_HQZ*/C-_R/]G_UYQ?^C'HK]<RS_<*'^']6<DOB8OPB_P"2DWG_
M %[S?^AK7OM>!?"+_DI-Y_U[S?\ H:U[[7Q?$W^_+_#'\F;4_A$?=L;9C?@[
M<],]JS= ;6FTE#KZ6J:AO;<+4DIMS\O7OBM2D-?-&@J]:\7\9RVL6M>))-<@
MDGU%)8SI4;W$L0\C;_RP* C?NSGBO9Q6$?&&BMXF&@EY#>B3R@QA)C$FW=LW
M?WL<U+0T>?W>NZMINIZO?6XDM7F@TU)IID,OV1&4[W([D=_UJG>^(]3O?^$=
MOKO5Q:QP:C>PQ:N+;Y981&-LICZ<]/3O7IVK^*M)T;4X-.NVE:YG4,5BA,FQ
M2=H9\=!GBJI\;:$9KZV#2/)9.L31B'/F,S^6 GK\P(_"BWF.YYYJ/Q&\2P:9
MHL_F?9[N2UCN)HFM0$G!F*9&>>5 . !C.<UV?A@W9LO&9M2QN?[2N/L^[^]L
M&W&?>NJU*^L]*T^?4+]TBMK="TCL,[1_GM6?H7BS3-=DN(;>.ZMIK=!+)'=0
M&)MAZ.,]11;41YWX6?PZ+6W^S?VHWB4Z;<'42&? DVG=Y^[C.?NXK+\)OK5G
MJ?A73M0-U+:C3KJ\M+B,$N4D@.8\=V5@<9]17JFE^,=!U?1;[6;6Z5;*T=EN
M)9%V[=O<^H]/6JUGX\T6\6Z/E7MN;:U:\Q<6K1EX5&2R9Z_2E8=S@OA>\-OX
MLCM[9A>"2Q<RW4)EC92&'%S&V5\SW!JUX@UG6])\8>(Q9:NR3R-9);0R0[U5
M';:S*/;//UKMM#\::1K=]'9VT-W;7%Q#]HA%S;&+SD[LI[]16_/+;VZ>;</#
M$O3?(0!^9IVT"^IYG-XI\46/Q!AT)[A)H8IH82KP!3=(RY>08Y!!Z8X&.:YZ
M_P#&GB'5[7Q%9Q:A*L']G33Q;8!'+$T<RKM '*Y4GJ2>_%>UK<VKSM&L\#3(
MNXJ'!95]?4"FI>6#P/<)<VK0J2'E#KM![Y-*P7/+YO$_B8SE=.UN-[2&73[:
M-S9AA*)TPSD^QYQ4.J>./%-EHMD!<HDGVR[MY;XP* YB.(P0>!N]NO:O4DUC
M36U)M.$\*SK&DB@E0'#9V[3WZ'I3EU*Q=#YDL4/[TQA9BJEF!QD ]>:5@N>;
MZEXL\51RW5TEQ';I96^GS26HM@PE:8@.NX\@=ZVO!5Q>)+XS2ZU*2YN;;4IB
MD4B8,:[?E(]CC@=/E]Z[-KFV6X%NT\ G(!\LN-Q]..M8FL>,](T+7++2;D3O
M>7@#8AA+[%.0&;';((I-#3N>=+XM\:+I:WK:M&Q_LF+4RGV)>6,NPQ_3')/6
MM:\\<:Q'\0X-.@N,61N!!+;R0!< Q;MP/WCS_%P.V*ZY/&V@R:S+I?FNDL?F
M+YCPE8F,8RZJQ&#@<U#!XZT6[T^6_M[>^FCC95(2S8NP;.U@,<KQUI%'GFIZ
MQXNDT+PMKR3?;]4FGNI(;=8 BQ*(B.0/O' S@]3Q6E?^.-?3Q#I=MIMVLUI+
M;6LD3S0!?MID.)">X(Z87H1S7H&F>)M*U7PZ^NPNT6GQAV:2:/9M"?>.#VX-
M.T/Q%IWB"TENK))E6 \B> QL 1N! /8CGBBP'+>"[FZ;PUXG6[OWO+J"\N@8
MYEYCZXSZ@^E1:)XBU,>)--L)KD&TFCC1;>&)?D!B#?,#AAS_ !#*]JZVQ\3Z
M3?Z')J]I*)(%C:5T4#S-HR.5Z]N]5?\ A,]%_M!+7]Z+AI8K<?NNC2(749^@
MI@8VO^(]1LO%%Y:6VI1H]NEHUMI_DAC=F1B'&>O3TZ=:K2:YK*".6\UT6-G<
MW=U']H-JI$ B9@B GNV.I]..M=9I]UI,Y&M1E8);\*@:X(1FV94  GKR>E:+
MW5F)A;R3VXE)P(F=<D]>GK0!YI/XIUR-!<;([:>Y2S6YN @4QJP?YOFX7.!C
M/3-78?%.K/%8F_U2+3\VWFI(MMYHO'\TKM _W<'"^N1Q742W>BZ-X@,%P_EW
MNJH96>9LH5CP,9/  SP/>M=KBU )::#$1&26'R$]/IFD!Y;+XAUG2E>U@U)@
MK7U^TMQ,$!C=&!CB^88P02V.I P*MZGKFI7US9P7]\MI*+JQ*:?'#_KPVUFD
M#'G ;(]L8/6NP\0^*=(\-^4-1$K-*K2[88#(0B8W.V!P!D<U&WC303KMOI?G
ML]Q,$V2B(F,%UW(I?L2.0*!W,CQ=J-_I7B=KFTNW0_V:WEQ%-R9\T!GQW*J2
MWX5I>'=6O;JTU@B[&K16CXM+L1A/M'R;BO'!PW&15K2?%VC:UJ-S96SRK/;(
M9"9X2@9 2I=2>JY!&:98>+M$U6QM9[-I)+6[NVLHF6(A2XSGZ+[T <9%XLUJ
M9)8[;7([B=[*VF?_ $0#[)-)<+&Z8[@*3P>?6M(ZSKB:TVGIJXDO5O39"S>V
M4$P[,BX)'OS_ '>U=?I?A[3M(EEEM(G\R11&7ED:0A <A06Z $]*TR%#;MHW
M8QG'./K32%<\WT/Q;X@U77+2SDA\J&Z<!7,.-@AXGS]6QBK/C?Q3J.C:N8K"
MY,8@BBE,31IMEW/@C)^9N.RXQU)KON/0?E3&56()521T)&:=B6SE_#]U-;6G
MBEY+R:YFM]1N65&3<T:X!4!1U!'05#X)UK6-2U"^@U)Y)8DMX9HGDC52"V=P
M^7CTXY([FNIN5'V:;Y)#E3D0G#GZ'UK*TJ)4O5*VFL1<'YKJ;<GY9ZUK"G>+
ME?;^NYFY:V-XFFYI33:@91G/_%1Z-]+C_P! %;M84W_(R:/]+C_T 5NU#W*6
MP4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !39?\
M4R?[C?RIU-E_U,G^XW\J ,/0?^1>T[_KW3^5:2UFZ#_R+VG?]>Z?RK2'6M2"
MGK/_ "!-0_Z]I/\ T$UI6'_(-M/^N"?^@BLW6!_Q)-0_Z]I/_036E8?\@VT_
MZX1_^@BHD5$L4445!04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 8L_\ R-J_]@__ -J5>-49_P#D;!_V#_\ VI5ZKB1+<^?OC/\
M\C_9_P#7G%_Z,>BE^-'_ "/]G_UYQ?\ HQZ*_7<L_P!PH?X?U9R2^)A\(O\
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MD_\ 036C8?\ (-M/^N"?^@BHD5$L4445!04444 %%%% !1110 4444 %%%%
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M?^@BHD7$L4445)04444 %%%% !1110 4444 %%%% '!?$+_C]L?^N3?SKG]
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MEE/'=[A9QMT41A>2Q W-G-2V'AOQ3;:;JUS+9Z;)>ZAY$$MC]J8(T$<6PXE
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M9>K_ /($U#_KVD_]!-:EA_R#;3_K@G_H(K.942Q1114%!1110 4444 %%%%
M!1110 4444 <KXIT=]5U&T/F!(HXR'/?D]J?9:?;6$6RWC"^K'DGZFM34/\
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M]Y<,MMO$_ER!5QZ;@1G'OBM _"K2"I4ZUXDVGJ/[3.#^E*/A7I ((UOQ*,#
M_P")F?\ "BS#0@^&WBK5_$%QJ%OJLOGR0QI('BB C7)((##G_@+ $5Z!7(:3
M\.=+T?4X+^#5==DDA?>(Y[\O&Y_VEQS77U2OU$PI0*2E&:8A0*4T=J3O2$%
M7-+MIW2D F,"FDYI2>:3&: $Q3P* *,XH 7 %(32%J:30 I--S115#"BBB@
MI:2C- "T&B@T )1110 X'B@C--IP-(#/G_Y&/1OI<?\ H K<K$N/^1CT;Z7'
M_H K;K.6Y2V"BBBD,**** "BBB@ HHHH **** "H[C_CVD_W:DJ.X_X]I/\
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M_P"1>T[_ *]T_E6A6R(*>K_\@34/^O:3_P!!-:EA_P @VT_ZX)_Z"*R]7_Y
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M2HXKV63<B6T1Q&FW[A;^)CUK/WK7N=B>'<^3V:WMT^\SO^$QUS_G\'_?M?\
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MM)3 Q+G_ )&Q?^P?_P"U*N53N?\ D;%_[!__ +4JY6D=C.6YX%\9O^1_L_\
MKSB_]#>BCXS?\C_9_P#7G%_Z&]%?K>6?[A0_P_JSDE\3%^$7_)2;S_KWF_\
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M/#:1Q/\ :5/ROOSP 1D8Q7+6OPEBB&HPS:F)+>X@FA@(B;S(A(VXDDL0<'L
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M2N(2BE[4A.* $--S2DTE4,**** *$_\ R,>C?2X_] %;E84__(QZ-]+C_P!
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M2M4U.W?1YI;;39TAN+A+B,'+ $%4)W-U[4F[!8[P4E99\2Z*FK1Z4^HP+?R
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M*5E3>O12Q8#@@"GH&H[4_!UWJ'B0:E_:2"!;J*Y2)E;*[!C: #MYZY(S3(/
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MWRW=O).TB@J [ CG\*W:Z*<7%69XN.KPKU>:&U@HHHK0X3%G_P"1L7_L'_\
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MIAIQIM,0E%%%4,*2EI* "BBB@!<4ZDI,T /W8I":;2U(@)I,TM-IH8M%)13
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M-RBL/;KO_04M/_ $_P#Q=&W7?^@K:?\ @"?_ (NCE871N45A[==_Z"MI_P"
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MVPE!D4:4@)3;@CIZ\UUEWH_B&XNYKF*W2"68G)2ZZ#C@?E3/[&\5[B0Y )?
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MHHH **** "E%)0* %S2YI** %S2@TVB@!X-/'2HP:<#6=K !%-J0'-(132U
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MY>)O^?'2/^_,G_QRBBC^Q,N_Y\Q_'_,.>7</^%Y>)O\ GQTC_OS)_P#'*/\
MA>7B;_GQTC_OS)_\<HHH_L3+O^?,?Q_S#GEW%_X7EXF_Y\=(_P"_,G_QRC_A
M>?B;_GQTC_OS)_\ '***/[$R[_GS'\?\PYY=P_X7GXF_Y\=(_P"_,G_QRD_X
M7EXF_P"?'2/^_,G_ ,<HHI_V)EW_ #YC^/\ F/GEW#_A>7B;_GQTC_OS)_\
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M^/\ F'/+N'_"\?$W_/AI'_?F3_XY1_PO'Q-_SXZ1_P!^9/\ XY113_L3+O\
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A-\V&)'!).?F-%%%>-G&9O+)4Z%""Y;>>FIK3ASIML__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img_013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $< >8# 2(  A$! Q$!_\0
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MX\9:G^=)_P *OU3_ *''4OSKQO\ 6G']H_\ @*_S-/81//?^%+^./^?^R_\
M Q__ (FC_A2_CC_G_LO_  ,?_P")KT/_ (5=JG_0XZE^='_"KM4_Z''4OSH_
MUIQ_:/\ X"O\P]A$\\_X4OXX_P"?^R_\#'_^)H_X4OXX_P"?^R_\#'_^)KT/
M_A5VJ?\ 0XZE^='_  J[5/\ H<=2_.C_ %IQ_:/_ ("O\P]A$\\_X4OXX_Y_
M[+_P,?\ ^)H_X4OXX_Y_[+_P,?\ ^)KT/_A5VJ?]#CJ7YT?\*NU3_H<=2_.C
M_6G']H_^ K_,/81///\ A2_CC_G_ ++_ ,#'_P#B:/\ A2_CC_G_ ++_ ,#'
M_P#B:]#_ .%7:I_T..I?G1_PJ[5/^AQU+\Z/]:<?VC_X"O\ ,/81///^%+^.
M/^?^R_\  Q__ (FC_A2_CC_G_LO_  ,?_P")KT/_ (5=JG_0XZE^='_"KM4_
MZ''4OSH_UIQ_:/\ X"O\P]A$\\_X4OXX_P"?^R_\#'_^)H_X4OXX_P"?^R_\
M#'_^)KT/_A5VJ?\ 0XZE^='_  J[5/\ H<=2_.C_ %IQ_:/_ ("O\P]A$\\_
MX4OXX_Y_[+_P,?\ ^)H_X4OXX_Y_[+_P,?\ ^)KT/_A5VJ?]#CJ7YT?\*NU3
M_H<=2_.C_6G']H_^ K_,/81///\ A2_CC_G_ ++_ ,#'_P#B:/\ A2_CC_G_
M ++_ ,#'_P#B:]#_ .%7:I_T..I?G1_PJ[5/^AQU+\Z/]:<?VC_X"O\ ,/81
M///^%+^./^?^R_\  Q__ (FC_A2_CC_G_LO_  ,?_P")KT/_ (5=JG_0XZE^
M='_"KM4_Z''4OSH_UIQ_:/\ X"O\P]A$\\_X4OXX_P"?^R_\#'_^)H_X4OXX
M_P"?^R_\#'_^)KT/_A5VJ?\ 0XZE^='_  J[5/\ H<=2_.C_ %IQ_:/_ ("O
M\P]A$\\_X4OXX_Y_[+_P,?\ ^)H_X4OXX_Y_[+_P,?\ ^)KT/_A5VJ?]#CJ7
MYT?\*NU3_H<=2_.C_6G']H_^ K_,/81///\ A2_CC_G_ ++_ ,#'_P#B:/\
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M_.C_ %IQ_:/_ ("O\P]A$\\_X4OXX_Y_[+_P,?\ ^)H_X4OXX_Y_[+_P,?\
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M[+_P,?\ ^)KT/_A5VJ?]#CJ7YT?\*NU3_H<=2_.C_6G']H_^ K_,/81///\
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MX4OXX_Y_[+_P,?\ ^)KT/_A5VJ?]#CJ7YT?\*OU3OXQU+\Z/]:<?VC_X"O\
M,/81///^%+^.?^?ZR_\  Q__ (FD_P"%,>.,X^W6><9Q]K?_ .)KJ?%?@K6/
M#GANYU2+Q?J#O;@,58\$9Z5Z=X:FDN?#6FW$S;Y9(%9F/?(H_P!:<?VC_P"
MK_,/81/EO3M6U[PQKM]:P:G<0W$+/!*8Y25)5L'K[BBF:]_R/>O_ /7]<?\
MHTT5^@2H4:RC4G!-M+HNR\CENUHF=C\%_P#DI]Y_U[3_ /H:UZ!J8_XOKIO_
M %YFO/\ X+_\E/O/^O:?_P!#6O0M3_Y+IIO_ %YFOS_BG_?U_AC^3.JA\)Z5
M2XI:*^7-PP*,"BB@ P*,"BB@ P*,"BB@ P*,"BB@ P*,"BB@ P*,"BB@ P*,
M"BB@ P*,"BB@ P*,"BB@ P*,"BB@ P*,"BB@ P*,"BB@ P*,"BB@ P*,"BB@
M P*,"BB@ P*,"BB@ P*,"BB@ P*,"BB@ P*,"BB@ P*,"BB@ P*,"BB@ P*,
M"BB@ P*,"BB@ P*,"BB@ P*,"BB@ P*,"BB@ P*3%+10!QOQ2_Y)WJO^X/YU
MK^$\GPAI./\ GV3^59'Q3_Y)WJG^X/YUK^$_^10TG_KV3^5 'RWKO_(]:]_U
M_7'_ *--%&O?\CWK_P#U_7'_ *--%?ML/X</\,?R1YO4['X+_P#)3[S_ *]I
M_P#T-:]"U+_DNFF_]>9KSWX+_P#)3[S_ *]I_P#T-:]"U+_DNFF_]>9K\ZXI
M_P!_7^&/Y,ZZ'PGIE%%%?+FX4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1FBD.,^] !FC=Q4?\1_O4N#CC\: '[AC-('!Q
M[UE:MKVF:#;?:-2NXH(LXZYYK*T+QK8ZU>2VA4VSG+0&3@2I_>% '5!P?K2Y
MJ)<M'\S ^XIZ\-B@!]%%% !1110 4444 %%&:0F@!::6 .#3<9;(-<WKWC?2
MM$E>R607.J;<QV<?+O\ 2@#IMPI<BN6\,^,(==#6]S;MIVHJ-S6TIPV/6NDR
M"_([=<T 2Y]**08[=*45/4 HHHI@%%&:,T %+29% - "T444P"BBB@#C?BI_
MR3O5?]P?SK8\)_\ (H:3_P!>R?RK'^*G_).]5_W!_.MCPG_R*&D_]>R?RH ^
M6M>_Y'O7_P#K^N/_ $::*->_Y'O7_P#K^N/_ $::*_;8?PX?X8_DCS>IV/P7
M_P"2GWG_ %[3_P#H:UZ%J7_)=--_Z\S7GOP7_P"2GWG_ %[3_P#H:UZ%J7_)
M=--_Z\S7YUQ3_OZ_PQ_)G70^$],HHHKY<W"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHICL10 XFFDBF%P 0>@&<]L5R.L_$72
M=,4)8I+JDVXH8[0;BA_VO2@#J;F[M[*T>[NI5@B09:1S@ 5Q.H_$%KRZ6P\-
M6<M\UP-L=Z@S$C>]16NB>(_%4_F>*3'#I8.^*WB."P/9Q7;:7IEEI-M]GT^U
MCMK<G(2,8&: .5T7X=6MO.]]K=S)J5U/S)%,<QJQ]!6KX@\':;XAT^.TE5K4
MQ#;%+ =K(OH#72;132" ,<D&@#S@-XJ\%2KY[+J'AZ#Y% &9@/4FNTT?Q!I>
MNQ,^G7L4^S&\*>5/H:T&19$:-@'0@AE/.?:N+U?X<:?=,LVDW$VE3 EB+8X6
M1NVZ@#N!Z=J4<5Y_IWCN?2KM-'\264T-Q'\K7H7]R0.A)KM;'4+74K9;JRN$
MG@?[LB'(H N9I,BF*V\G' '>C<3T[4 /R!1VJ,C)S^E5[_4K/2K8W-]<QV\
MX+R' S0!;XS65K'B/2="1#J%[% TF1&K'ESZ"N2U'QO=ZU>3:-X:M)6F8X%Z
MR_NMO<@U;T;X<:;:%I-6FEU6<D.#<G(C;_9H S)/$WBOQ;YL'AVQ.FI$<23W
M:_?![I72>'_!NGZ-'%/-$MUJ1^9KN5<N&/7'H*Z5$5455&U5& !Z4[&* .8\
M3^#-/\3!6GDDM9U/-Q =KL/3-<]'?^*/!UPO]KLM[H:L(HWC'[Q%_O.:]$=0
M1DTVXBCN;=X9HQ)'(-K*>XH I:3K>F:W TNFWD5S&IP2AZ'TK3Z5PFJ?#NU,
M\=UHEW+IDD7S)!"<1R/VW5'I'BK6=*U!=-\8QQ0R3_ZBXB'R'V)]:0'?YS25
MQ_C[QQ;^"M#^TDK)<N,11G^*O*K?5_BEXE@&MVL0AMQDK%C&10]KC/H0XQ2
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M7_)=--_Z\S7YUQ3_ +^O\,?R9UT/A/3****^7-PHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ IK_=IU!&: /.?C ,^%[+_ *_8_P"==];#
M%K!_US7^5<#\8^/#-C_U_1_SKT"U_P"/2'_KFO\ *@!W0\]^GM3E'J:=1B@
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MM=0V<L0>>U $E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ME*$R>]<GXA7Q?9ZT=1TRYBFTN)<O98^=S[&G8!VF_$OP[?75O927+07\GR-
MZD;&[@FNKBN(I6*+/%(_4!6!.*\P'B71=02Y'B3PTVB0R@@7<D8#%O8@4S2O
M"UF;5]6\!>(6%T6\MGNW+*1]#0!ZUCZTZO,V\1>-/"RBWU/36UUY/F2:S7
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MF_\ 7F:_.N*?]_7^&/Y,ZZ'PGIE%%%?+FX4444 %%%% !1110 4444 %%%%
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MO/\ KVG_ /0UKT+4O^2Z:;_UYFOSKBG_ ']?X8_DSKH?">F4445\N;A1110
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MW_(]Z_\ ]?UQ_P"C311KW_(]Z_\ ]?UQ_P"C317[;#^'#_#'\D>;U.Q^"_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\U_X65KW_0DZA^='_"RM>_Z$G4/SH ]*HKS7_A96O?\ 0DZA^='_  LK7O\
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MZP^Q]B_\)KX6_P"AFT;_ ,#HO_BJ/^$U\+?]#-HW_@=%_P#%5\=44?ZFT/\
MG[+[D'UA]C[%_P"$U\+?]#-HW_@=%_\ %4?\)KX6_P"AFT;_ ,#HO_BJ^.J*
M/]3:'_/V7W(/K#['V+_PFOA;_H9M&_\  Z+_ .*H_P"$U\+?]#-HW_@=%_\
M%5\=44?ZFT/^?LON0?6'V/L7_A-?"W_0S:-_X'1?_%4?\)KX6_Z&;1O_  .B
M_P#BJ^.J*/\ 4VA_S]E]R#ZP^Q]B_P#":^%O^AFT;_P.B_\ BJ/^$U\+?]#-
MHW_@=%_\57QU11_J;0_Y^R^Y!]8?8^Q?^$U\+?\ 0S:-_P"!T7_Q5'_":^%O
M^AFT;_P.B_\ BJ^.J*/]3:'_ #]E]R#ZP^Q]B_\ ":^%O^AFT;_P.B_^*H_X
M37PM_P!#-HW_ ('1?_%5\=44?ZFT/^?LON0?6'V/L7_A-?"W_0S:-_X'1?\
MQ5'_  FOA;_H9M&_\#HO_BJ^.J*/]3:'_/V7W(/K#['V+_PFOA;_ *&;1O\
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MU11_J;0_Y^R^Y!]8?8^Q/^$U\+?]#-HW_@=%_P#%4H\9^%<?\C-HW_@?%_\
M%5\=44?ZFT/^?LON0?6'V.@UB:*X\::W-#(DD4EY.Z.C!E93(2"".H(HK=^%
M7A;3_%6MWMOJ#3JD-MO7R6"G.X#G(-%>EC,VPN"J+#U&[Q2Z>7KY$QIRDKH_
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img_014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $^ ]D# 2(  A$! Q$!_\0
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M  I7QS_S_6?_ (%O_P#$T?\ "E?'/_/]9_\ @6__ ,37T9FC-'^M./[1_P#
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M_P#Q-'_"E?'/_/\ 6?\ X%O_ /$U]&T4?ZTX_M'_ ,!7^8>PB?.7_"E?'/\
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MFOHVBC_6G']H_P#@*_S#V$3YR_X4KXY_Y_K/_P "W_\ B:/^%*^.?^?ZS_\
M M__ (FOHVBC_6G']H_^ K_,/81/G+_A2OCG_G^L_P#P+?\ ^)H_X4KXY_Y_
MK/\ \"W_ /B:^C:*/]:<?VC_ . K_,/81/G+_A2OCG_G^L__  +?_P")H_X4
MKXY_Y_K/_P "W_\ B:^C:*/]:<?VC_X"O\P]A$^<O^%*^.?^?ZS_ / M_P#X
MFC_A2OCG_G^L_P#P+?\ ^)KZ-HH_UIQ_:/\ X"O\P]A$^<O^%*^.?^?ZS_\
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MS_WS7J ^E>7ZYX'\33^,+W6=(O8+438"-NPV,=ZB_P"$3^(N<_\ "0)_W\-
M'JU4-3UFPT:**74;J.WCED$2,YQN8]!7G'_")_$7/_(P)C_KH:S=:^''CC7K
M:*WO]:CECBE65 SYPPZ&@#V<4M>4_P#"*?$4_P#,?0?]M#1_PB?Q%_Z&!/\
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MQ6EON\J,87<<D#TJW2 "EH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?PPPC;ARD3;@.^*].\,S33:!://#+#(5Y24?,/K6J0?>E P* %HHHH ****
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M2<4 >9Z,,?'_ %__ +!D7\Q7IPZ5YAHCJ_Q^\0%6##^S(AD'/>O3Q0 M%%%
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M<0203?9UWI(<L#CJ?K7 ?#>/7-+U]]&US5?[4@N]/COX/-^8QDG!'->L*,#
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MY*[_ "R -G)'UJVW4\<XJF8F.K0RYEVK$RD?P]>_O0!?HHHH **** "BBB@
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M33-5GG2YE@+*$A+#!! Y%-^%!W?#G2V4_*P=A]"QQ0!VU%%% !1110 4444
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M] N?^N+_ ,JY/X4C_BWFG#.>9/\ T,T =K1110 4444 %%%% !1110 4444
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M U_G_F&1?S%>FCI7F.C$_P#"_P#7\_\ 0,B_F*].'>@!:*** "BBB@ HHHH
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M^:T 0L)?FQ_N>GO6RIXQ6%&DQ\82LSQ>3]GX3RCO!]=_I[5O+TYZT +1110
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M*HR3.-6@A"R;&B9B0/E!]_>KYZ52D:,:I"I"^8T;%3NY ^E %Q>E+2*.*6@
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /"_VA_\
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M?]>T_P#Z&M?1M?'\4_[^O\,?R9O0^$****^7-PHHI#TH 6D/2FY_&C.>#WH
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M8]JOMSQQBJ<DL@U>&$"38T;,< ;?Q/K0!>HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBFMTH 4UFZUHMCX@TJ;3-1B,EK-C>H;!/XU?R0?Z4Z
M@#Q_P1H.G^&_C5KNFZ7$T5JFG1L$9B<$D=S7L(ZUYCHP_P",@-?_ .P9%_,5
MZ<* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *2EHH YGQRC2>$[E8T=VRN%09/6MS3E9=,M5;J(ES^55==
MU5-$TF6^DC,JQD94=\FK]M*)[6*8# D0,!]10!+1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!X7^T/_K_  ]_NW'\XZ\MKU+]H?\
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M/^_ZTW_A,/#7_0=T_P#[_K_C7*_\*.\$?] ^3_OZ:/\ A1_@?_H'R?\ ?TT
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MUX=T[XK^'M#M[5UL+R(F5-QR2#US7H__  H_P1D_Z!+_ -_30!UG_"8^&_\
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M%L^"_P#H,I_WPW^%=1_8^F?] ZS_ ._"_P"%']CZ9_T#K/\ [\+_ (4 <O\
M\+9\%_\ 093_ +X;_"C_ (6UX+_Z#*?]\-_A74?V/IG_ $#K/_OPO^%(='TP
M?\PZS_[\+_A0!RY^+?@H?\QA/^^&_P *0?%OP63C^V$ZX^X:ZD:3I?;3K3_O
MPO\ A7F/@2QL9/BKXZC>TMF2.6/:AC!"_0=J .F_X6WX*_Z#*?\ ?#?X4?\
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M"4]EWCI6K\'+K00FK6&GZ?<Z=J4,H%Y:SSF7!'&5)[4 >KBBFC[U.H ****
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MN]*WK^S6_L)[-WD1)D*,T9PP!ZX->#^-/".C16=OX'\)6<E]K NA<W-PHW/
MG?>_]* /5KS5O!W@>XD-U/9Z9-J#>=)ZRG^\:Z*QO[34K2.YL;F.X@< J\;9
M!%>+VFA6MW\=/[+U4_;4LM(1%\X9#'9C.*V/@9&EO8^);:(_N8=39(QG@*!T
M% 'K0Z4M(O2EH **** "L?7O$^B^&XHWUC48+-93A#(>IK5+')';UKA/&^F^
M%=/OHO%_B3]Z;2$PPVS_ #+(3T"IW:@#;M;_ ,->+K:+4[::TU"*R<O',.?)
M8=3[57L?B'X3U"^BL;37;2>\F;8D2DY9O2O,M$T36SX3\7ZWIVD-9#7L)8V(
M81M$G(W'/ S3M*,_@!/#;:_X.TN.&5DA.I0G=-'(>A;WH ]U&<<TM(IRH.<^
M]+0 4444 %%%% !1110!X7^T/_K_  ]_NW'\XZ\MKU+]H?\ U_A[_=N/YQUY
M;7ZQD7_(LH_/\V<-7XV=S\%?^2H7G_7M/_Z&M?1M?.7P5_Y*A>?]>T__ *&M
M?1M?'\4_[^O\,?R9O0^$****^7-PHHHH **** .,\?>$+OQ-%I]WI5U';:MI
MLXFMI91E!Z@BJGA;PAK4/C*]\4^);JUEOY8%MX4M00B(.N<]Z[PK\V<T!2#G
M.: '"BBB@ HI,XI-PH =13=V1Q1NH 9(N^-DSC<",CM7E6J^"/'VLZ9-H%[K
MUC)I,MQO:9D/G>7G(2O6-H/XTA7H,XH K:;9IIUA;V4(_<P1K&I^@Q5RF9 .
M.U.#9- "T444 %%(3B@-F@ "XKB?!W@ZY\/ZCXEFO9H9H=6NS,BIG(4@\'\Z
M[>F%<\]: /&KCX6>)QI=]X;MM6L4\-W=WY^UD)EB7=D@&O7K"V2SLK>T0ED@
MB6-6/4@#%3A,?7UI57#9SQ0 ZBBB@ HHI#0 IY%<)XY\%WWB?7O#U_:W$,4>
MF3F219,Y8<=/RKN21GK0%SUH XWQ-H?BF?6[75O#VM1QK%A9+"Y'[IQW.1SF
MJ'P^^']UX:U?5M<U>X@GU34'))@R$12<D8/O7H.V@_** % YI:8'SSVH+C.*
M 'T4F:,T #=*\T^)_@CQ+XT-M:Z;JUO;:8@S-!+D;WSU..HKTEC@48R "* /
M-K#P1XBO/"NI>'?$E[ITME);"*S2TBV>2PZ-5+2_A]XHGUK0)_$FK6<MIH>3
M;?9D(>0]MV?I7JA[]L\9%*.2.YQ0 Y,D$D8)IU,7CBGYH **** "LGQ!!J5U
MH-[!I%S';7\D96&:09"'UK6IK*&&* /%_"'PW\=>$[YY[76=*;[5*KW4KQEY
M'7.2 QKK-:T;QTFOW]WH.KV1LKN((D%VI/V=N[+ZUW80@ 9I=O% ',^!/"@\
M(>'4L7E$UU+(TUS*.CR-U('85TXH I: "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ -9NKZ;;ZQI-UIUV@>"XC,;@C/7O6E3-IS[4 >1>&_A'J&EZW8#
M5=76]T/2Y&ELK4+SO/=OI7KJG/(Q1M/3M2JN.: '4444 %%)GBC- "TAZ4 Y
MI3TH \W\6^ =<OO$*Z_X9UPV%Z\9BFCERT94C&0.QK:\ ^"+;P1H\EJD[7-W
M</YES.PP7;_"NK(HS@\C\: ' <4M(#2T %%%-).>* '4C=*%.>U!&10!QOC/
MPA<^)M2\/75O<QQ)IEX+B0-G+#T'O4'C_P %WWB:33M0T;4%L-6T]RT,K#@@
M]0:[?80>*-IW9S0!Q/PZ\"'P5873W5T;O4KZ3S+F4?=)]OSKN!U-)M^7&:7I
MS0 M%)NYI: "D(S2;^2*-WM0!'/%OMI(QP70J/Q%<?X5\%3:%X.O-"N;W<UT
M\I\V'@QA\]/>NUSFFE,D<X_K0!Y#8_"KQ$UQI^GZUXB6[\.Z=-YT-N%.^3G(
M#^M>OQ@*H50 HX  Z4FW\J4<<4 .HIN[G%+D]Q0 M%)FD#B@"CK,%Y<Z1=V^
MGSB"[DC*Q2L,A">]>)V7P7\;6$MQ/:>+DAFN6W3NF[+GW->\GZ<4$ ]>* /*
M?$7PNUF]O[#6]'UP6NNQ6JV]U*^2LN!@FNJ\!>"8/ ^B/91W+W%Q<2>;<2O_
M !/CM[5U04'(/^13L #_ !H <*6FCBE#9.* %HHHH 8PKR[XE_#36?&VN6=Y
M9:O':V]M& D3@G#Y^]7J14T@3GK0!Y=I'PTUR30-5TGQ)XDGNQ=!/(DB<@P%
M>XS571OAAXA;6M.?Q/KZ7^FZ40;6V4'#$?=W@UZWMYHV\8ZYH <O2EI ,#%+
M0 4444 %%%% !1110!X7^T/_ *_P]_NW'\XZ\MKU+]H?_7^'O]VX_G'7EM?K
M&1?\BRC\_P V<-7XV=S\%?\ DJ%Y_P!>T_\ Z&M?1M?.7P5_Y*A>?]>T_P#Z
M&M?1M?'\4_[^O\,?R9O0^$****^7-PHHHH **** "BBB@ HHHH C;J!@_45R
MVN_$/P]X<U^#1M3N9(KJ<*R80E<$X&376UX#\4=,@U3XHW,<T+S/!HC7$2)U
M+H<B@#TW6_B1X=\/:_%HNH7$RWDH1E5(RRX;IS76!@0&X^8<<XKY=D%SXHM;
M;QUJ6%F?5K:RMHUZ!%P"*Z^W2;Q=J?BV[UCQ!?64NBSM]AABN!&(P%)''?D"
M@#W;(&!W]*@NKF"TMI;FXF2*"-2SR,?E4#J37A&CZSK?BN?P/;WFL7EL]]%<
M">:!]KRA>A_^O4%SILIE\?\ AM]8U"33=+MOM,*/-EBY&3N/<>U 'KUWXYT.
MSU'2;%YY6EU7_CUV)E6'J3Z5THX88.?QKYKO-%MTU#X=6,&H73I=JK-*)07B
M)QE5/85I6=]K&G0^/="L==FC2RD"VCW,FY\YY4,>A/K0!]";@1P01TX-!.!D
MG ]<UXC\,]5_LGQ5#I&H66JV-Q?6Y=%N;KSHYF'5@.U7_C'_ &N^HZ-!87\C
MPS,1+ID$OERS =6!]* /2/$7B'3_  SI#:IJ+NML'5"T:[CEC@<5I0RI+$DR
M?<=0PSZ$9'TKP*[UQ_\ A3VJP6WVVWFLM3AA>*\E$S1 L. W<4^S@O\ Q5\3
M-=T>ZUN_ATZ*U64Q6\NS>P0$?2@#W_- .0,'(]J^:QXQUY_!>@:=)K4\$-]J
M$MO<7Q/SK&K!0N[MQ77ZVP\#>#_$UEH7BF:]DBBCDB@>3S);3<<,V[T/I0![
M*"#T(-&X ')  ZFOG_X;ZGKT'CS2K,)J$-C>6QFN8[JY$PE;'^L']T9[5UOQ
M?_M.8Z-::?+-+&\S-<Z?;3>5+<(.X;VH ]'U'5;'2+3[7J%W%;09"^9(V!D]
M!5B*=)84F4CRW&02>HKYF\27EOJGPSN[-VU*WNM)U)$>UNI_-VJ_3YN^*W?%
M/V>WFTGPY87&KZI)%8_:)+>&]$:QY7(8M[>E 'T!GCK6?=:WIUKJUKIDMU&M
M]= F*'/S,!U/TKPDZWJ]Y\*?#&_5[J.:YU@VKSJ_SB/)&,_2M"^\(V>C_&KP
MO8)J-_(AMVE\R:?+Y7.%SZ'TH ]>T+Q'8>(?MK6!D(M)S;R[T*_..N,]16N&
M&3SGUKYQUO7M4B\":W<0:A)%,OB)HE:+Y"%]*U1?:GX,^(#V>G:A?7J76CF[
MDBN9/,+R[<@KZ8H ][W#D9''6LS7-;LO#^CW&JZ@[+:VXRY5<D#ITKP:YC^S
M> ]-\5VWBN^DUC4+J);I/M&58EOF39VQ7J'Q9)_X53K'][R%S^8H V-/\::+
MJ?A:7Q):W#-IT2LTAV?,NWJ"*S-9^*/AG07LDO);G=>0+<PK# 7)0],@5XG!
M>W/@'P=D":ZT7Q)IYV@<+;W'3\>*Z:^M;NX^(O@^*RU"WL;@:$A$\R!UZ=,&
M@#TO0OB5X=\1/<I9R7,0MHC-+)<P&-54=\FLV/XT^"WN1$+NY$9?9]H-NWE
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MK%_K,\-K!?6<1L+B8_*_3.TU5OKZU\0?'_2I?#]W#.(K1DNY8AD <Y!/K@T
M>BVGCO1-0\6_\(Y8W(N;U8VD=HN43'4$^M4-:^*'A_0]3FLK@74RVI"W5Q!$
M7CMV/0,?6N9L/#VE^&OCAIEGI5NL$<FFS22'.6D8GJ37)7NH66G6?Q4M;Z>.
M*6YG"PQ.<,['I@4 >K:W\3/#^BW-O;;I[RXGA%PL5I&7(CQG<?3CFN@TK7+'
M6]'CU73IA<6TB;D*=?\ =QZUX7H%W8:9XW9]2=8/,\,(L#2_+DF/D#\*ZWX
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M878^QJ*^.?\ A-/%7_0S:S_X'R__ !5'_":>*O\ H9M9_P# ^7_XJC_4VO\
M\_8_<P^L+L?8A/45ER>'],FUP:S+;*U_Y)@\P_W#U%?)_P#PFGBK_H9=9_\
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M^BMI<3V#.TOEL,X=NI![&FZ7X&\.:/I%QIEMID9MKGB<2_,TOIN)Y.*^7_\
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M=?Q>=:R*%=#_ !8KY(/C/Q2<9\2ZP<=/].E_^*I?^$T\5?\ 0S:S_P"!\O\
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M1-I>"/(;H._\Z^5O^$S\5?\ 0RZS_P"!\O\ \51_PF?BD_\ ,RZS_P"!TO\
M\51_J;7_ .?L?N8?6%V/J'1O!'A[0;"XL[#3(EBN4*3%_F,J^C$]14>@> O#
MOAF]EO-*L!%<."-Y8L4!_A7/05\Q?\)IXJ_Z&;6?_ ^7_P"*H_X33Q5_T,NL
M_P#@?+_\51_J;7_Y^Q^YA]878^OY(5FA>*0!D<%6![@CFLNS\,Z7I^@/HEI
M8K!PVY%./O'FOE3_ (33Q5_T,VL_^!\O_P 51_PFGBK_ *&;6?\ P/E_^*H_
MU-K_ //V/W,/K"['U&?!7A[R-.A738HTTY_,M=@P4/UKHATKXZ_X3/Q3_P!#
M+K/_ ('R_P#Q5'_":>*O^AFUG_P/E_\ BJ/]3:__ #]C]S#ZPNQ]C45\<_\
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MC&/RKY5_X33Q5G/_  DNL_\ @?+_ /%4?\)IXJ_Z&;6?_ ^7_P"*H_U-K_\
M/V/W,/K"['T]=^ _#5YH%OHD^FQO8VY)@3O&3U(-2Z?X*T#2M#GT:ST^..SN
M4*SCJT@/]X]Z^7/^$T\5?]#+K/\ X'R__%4?\)IXJ_Z&;6?_  /E_P#BJ/\
M4VO_ ,_8_<P^L+L?5O\ PC>D^3IL1M5\O32&M?\ IF16=<> ?#MUJ&HWLFGK
MYFHQ^5= '"R#.<X]:^8_^$S\4_\ 0RZS_P"!TO\ \51_PF?BK_H9=9_\#Y?_
M (JC_4VO_P _8_<P^L+L?5-UX5T:]M]/MY[-9(]-96ME/\!'2LFX^&'A*ZU4
MZC+I">:S;I(U8A'/JR]Z^;/^$T\5?]#-K/\ X'R__%4?\)IXJ_Z&;6?_  /E
M_P#BJ/\ 4VO_ ,_8_<P^L+L?7D]C:W-DUE/;QR6K)L,3+E=OIBN<TGX=>%M#
MU+^T++2T6=6W1EB6$1_V!VKYF_X33Q5_T,VL_P#@?+_\51_PFGBK_H9M9_\
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M //V/W,/K"['V-17QS_PFGBK_H9M9_\  ^7_ .*H_P"$T\5?]#-K/_@?+_\
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4X6GA\145U?OKK?\ 4Q=ZDFTC_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img_015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $; D<# 2(  A$! Q$!_\0
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M/_@*_P P]A$\:_X4MXY_Y_K/_P "W_\ B:/^%+>.?^?ZS_\  M__ (FO9?\
MA'_$O_0W2?\ @&E'_"/^)?\ H;I/_ -*/]:<?VC_ . K_,/81/&O^%+>.?\
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M?\(_XE_Z&Z3_ , TH_UIQ_:/_@*_S#V$3QK_ (4MXY_Y_K/_ ,"W_P#B:/\
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M#=)_X!I1_P (_P")?^AND_\  -*/]:<?VC_X"O\ ,/81/&O^%+>.?^?ZS_\
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M/@K0_&%JL.L6@D9,^7*IVNGT-*]FF'2Q'K7CCPYH.EM?W6JVS1*/D2%PS/Z
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MMZO_ +\?_HE:*_9L'_NE'_!'\CSI?$S9^"O_ "5"\_Z]I_\ T-:]D'_)3_\
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M:7QU /TH6@%]<\9_&GU@^$O$EMXL\/VVKVJ^6LN0\1.3&PZJ?<5O4#"BBB@
MHHHH ***:SA1F@!U%1B0'H?UIP8$9!S]*0#J*0'-+3 **** "BBB@ HHHH *
M*** "BBB@ HHHH *Y?QS_P >&E_]A2W_ /0JZBN7\<_\>&E_]A2W_P#0J /
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MJ3</6F,=13=P]:4,#TH 6BC-% !1110 4444 %%%% !1110 5R_CG_CPTO\
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M!YEX9\1>-?MEI!YVE>)=-<A7N[28++$">&<>N.U=_KOB#2_#FGO>ZK>QVT:
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M#_W2C_@C^1YTOB9L_!7_ )*A>?\ 7M/_ .AK7L@_Y*?_ -PK_P!J5XW\%?\
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M)^O_ %^7'_H9KO;@_P"C2_[A_E7 _!@_\6_3_K\N/_0S0!Z&.E%%% !1110
M8JO>6=O?6[6]U!'-"W5)%W*?J*L4TF@#F[[4]%G\26GA.\L5GFDMS<Q*\0,2
MJIQW[UT4:J@"J,*!@#TKSR__ .2]Z1_V")?_ $*O1ATH 6BBB@ HHHH ****
M "BBB@ HHHH *Y?QS_QX:7_V%+?_ -"KJ*Y?QS_QX:7_ -A2W_\ 0J / ?B?
M_P E;U?_ 'X__1*T4?$__DK>K_[\?_HE:*_9L'_NE'_!'\CSI?$S9^"O_)4+
MS_KVG_\ 0UKV0?\ )3_^X5_[4KQOX*_\E0O/^O:?_P!#6O9!_P E/_[A7_M2
MO@>*?]_7^&/Y,ZJ'PG4T8HHKY<W"BBB@ HHHH *,<T44 %</\7?^28:S_N)_
MZ&*[BN'^+O\ R3#6?]Q/_0Q0!U6C?\@/3_\ KVC_ /015[%4M&_Y =A_U[1_
M^@BKM !1110 4444 %)@4M% !1110 4444 %%%% !1110 4444 %(>E+0: ,
M;1;2_M)]3-[-YBSW;2VXW9V1D# ]N];-(!BEH **** "LO2;"XL/MBW%XUSY
MUR\T>?\ EFIZ)^%:E&!0 B]*6BB@ HHHH *@N[.WOK=[>ZA2>%^&CD7*GZBI
MZ* *%UI&G7MFEI=64$ULF-L3H"HQTP*9/?6UBZ6:C]^86DAMXQ\S*O4*/RK1
M/2N7\8Z%<:I9P:AII\O6M.;S;1]^T-_>0^S 8H T] UVT\0Z:M]9^8$WM&\<
MJ[7C<<%6'8BM:O+]'UQ;+6;37K<+'I'B";R;R$C)M+P<<GI\Q&#^%>F G.,4
M 24'I29XJ-W"#<[!5Z98XH \^\9_$^W\)^*K30[JP=XKI!NN0^!&&.,X]J9X
M*F'A/6(? V1=%HI+\7B_*,,V0N/QK$\9Z%#XG^*LND3  3Z,WEL?X7!RI'XU
MB_#76;K5/B9:V]^C+>Z;ISV<Q;^(J< _E2CJ$MCWU>E+301BG=:8!1110 AZ
M53U&]CTW3[B]FW&*",R,%&20!VJX:P_%Y_XH[6,=1:2?R-1)V0=3AM(U_1O%
M7B!_B!8W4JV^DV4EO/:/'^\.?FW#GI7H6A:Q!K^CVNJ6@<6]RF] XP<>XKYX
MM/\ BBM"L=70$:9K^EO;W"@<+, <&O;/AEQ\.=#SU^SC^=:-(3W.NI:0$9I:
M0PHHHH **** "BBB@ HHHH *Y?QS_P >&E_]A2W_ /0JZBN7\<_\>&E_]A2W
M_P#0J / ?B?_ ,E;U?\ WX__ $2M%'Q/_P"2MZO_ +\?_HE:*_9L'_NE'_!'
M\CSI?$S9^"O_ "5"\_Z]I_\ T-:]D'_)3_\ N%?^U*\;^"O_ "5"\_Z]I_\
MT-:]D'_)3_\ N%?^U*^!XI_W]?X8_DSJH?"=31117RYN%%%% !1110 4A.*6
MFD\T@&LY7DD!>Y)KC/BO')<?#36(X$:5V5-JH,D_./2N:\10W/CGXIOX9DO[
MJUTG3;433K;2;&D<].:O^(_#Y\(_"SQ!:V>HWD\84R0M-(2\0XX#>E%[*X>1
MWNE$IHM@",$6\8(/&/E%7E/KUKP#Q'\1-'O_ (6V&E6.J7!U93 &PKJ201N^
M:O=+.54TZU:215S$G+G&3@4["N7:*:K!NG3UIU PHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  C--*]
MZ=10!YEXBTBTT75YXKV.1_#.N,%N0' %I=$_+(/[H..O8UIW'Q \,^%[2'3#
MJDVJ7=NJQE+93-,PQ]XXX_&NOU'3+/5K":QO[=+BVF&UXW&015/1O"^BZ!"L
M6EZ;;VP4$!E0%L'K\QYH X[_ (2+Q[XC&W1?#\6CVS<&YU)\O@]'5![=C4MM
M\.;J^N8[SQ5XCO=3F5@Y@B;RH-P^Z0H]*]!*@BE*@F@#)/AS37\1IK[0DZBD
M/DK)N. GIBH+3P?HMCXDN/$%O:!-1N%VR2!N"/I6]THH YKQC)XFMM,BN/"\
M4$]U#)OE@G.!)&!R![UG>%?B7H_B.6.PE+Z?K& 'LKI2C%L<[<]17:E037+^
M*?!&C>+(5%[$T5U&VZ*[M_DE1O\ >% '3@G!)J&YO(;.%YKF:.&)>KR-M _$
MUXE;^._&G@RYU;1)]/7Q#;Z/M4W*$AT0C(+^O%:OA[P==_$.RM?$?B_59[FT
MNAYL&F0-LB1<\!O7I0!=OOB'JWBJX?2O FGS2-O"2:M.F((AGDC/WJ[>/2KN
MZ\+'2M8OA<W4T#13W,2;-V>X':M#3]/M--L8K*RMTM[:)=J1QC  JT$ H XZ
M\^'>E7_@.#PG/+,UK"H$<W&]2.AK:TK1O[!\.0:3ILN?L\/EQ23#//8G%; 4
M"@J/2@#RMO&'C#P3<E?&&GQZAI1DQ_:ED,>6"?XU["O0M(US3M=M%NM,O8;J
M C.Z)L_F.U7IH(IX7BFC22-QAD<9!'N*\YU7X:SV&I-K/@>_&C7S#][;XS!.
M<YY':D!Z5FFEF':N)LO$_B+3O"&J:GXJTN&RN+",E3%)N6? Z@=N>U<YX9T?
MQQKUC8^)I_%<D$MRPF^P^6/*$6?N_E0M;@>L;B3P*4$XKS;4O%4FE?&%+&_U
M1+7238!_+F<*A?U^M.\)^)I]:^)WB.V@U-;O2H88S;JC!D4GK@TUKL)Z7/1R
M33@:8"2H-/4YI(8M%%%, KE_'/\ QX:7_P!A2W_]"KJ*Y?QS_P >&E_]A2W_
M /0J / ?B?\ \E;U?_?C_P#1*T4?$_\ Y*WJ_P#OQ_\ HE:*_9L'_NE'_!'\
MCSI?$S9^"O\ R5"\_P"O:?\ ]#6O9!_R4_\ [A7_ +4KQOX*_P#)4+S_ *]I
M_P#T-:]D'_)3_P#N%?\ M2O@>*?]_7^&/Y,ZJ'PG4T445\N;A1110 4444 %
M-*\YIU(: /*?$^FZ]X7^(Z^+]&TN75;.Z@$-W;0D!P1T(J[K5QXA\5_#771<
M:#+97$PVVEH6S*R\<M[UZ0!S2;.<TNE@ZW/*/%?AF\N?A%86%II.[4T^S[XX
MXAO&"-U:_C[1_M_A-&&GM>7=M:'8GVKR?*^49?'<BO0=O.:QM;\*Z1XA9#J=
MLTI12@VR,F5/4'!Y%#8K%?P+=I>>"='GCN9+D&V4&6089B.#FNB-5[2SM["U
MCM;6%8H(E"1QH,!0*L4[C%HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I,
M9I:* /((>/%_Q//_ $XK_P"BS77_  O /PST#_KU'\S7(1?\C=\3_P#KR7_T
M6:[#X7?\DST#_KU'\S0!UP&*6BB@ HHHH 0C((I-H%.I!0!@>,M'DU_PCJFF
M0D"6X@94SZ]J\]\&_$8Z9H=AX>U#0]3;6[8K:^2D!"L <;MW0#%>P%:;Y2[M
MV!N]<<TEH!Y1K&A6NN?'**/5-,%U9?V:#^]C)0-]>F:D\%:/!I'Q9\4V]C9?
M9+(01>4$0A,]\5ZIM'7 SZXICPAE8'^(8)'6FG;03U1YAI%Q?:=\4XM/.I:F
MUM-!(TBZCPLS@\>2/:O4T(Q7+6/@BTM=<@U:YU"^O[BV1DMA<R!EA#=<8'7M
M75 8%'0.K%HHHH&%<OXY_P"/#2_^PI;_ /H5=17+^.?^/#2_^PI;_P#H5 '@
M/Q/_ .2MZO\ [\?_ *)6BCXG_P#)6]7_ -^/_P!$K17[-@_]TH_X(_D>=+XF
M;/P5_P"2H7G_ %[3_P#H:U[(/^2G_P#<*_\ :E>-_!7_ )*A>?\ 7M/_ .AK
M7L@_Y*?_ -PK_P!J5\#Q3_OZ_P ,?R9U4/A.IHHHKY<W"BBB@ HHHH *#S11
M0 F*7%%% "8HQ2T4K )BEHHI@%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M (3BFE\'I2L<52U.=[?2[N>/[\<+LN/4 TF[*X'E%_J&F:+XO\<+J&KV,+ZM
M;+%;*9LD,$(PW]WDUW_P^LY-.\ Z-:2O$\D5N 6B<,I^A'6N*^%GAK2-8\ R
MW^I6-O=WFH2RO/--&&8G)'7M5SX*32CPM?V9):&TOY8H<G.%STJK;KL*YZ>#
MFEIHIU(84444 %%%% !BDQ2T4 )B@"EHI )BEHHI@%%%% !7+^.?^/#2_P#L
M*6__ *%745R_CG_CPTO_ +"EO_Z%0!X#\3_^2MZO_OQ_^B5HH^)__)6]7_WX
M_P#T2M%?LV#_ -TH_P""/Y'G2^)FS\%?^2H7G_7M/_Z&M>R#_DI__<*_]J5X
MW\%?^2H7G_7M/_Z&M>R#_DI__<*_]J5\#Q3_ +^O\,?R9U4/A.IHHHKY<W"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** &M4<L*S(T;J"C JP]C4V*3%(#R>#X?>-/#ZWVF^&=?LX='NI&=5N(R
M9(=W4*:[?P=X5@\(>'XM,@E:9@QDEF?K(YZFNBHIB:N(!2T44#"BBB@ HHHH
M **** "BBB@ HHHH **** "N7\<_\>&E_P#84M__ $*NHKE_'/\ QX:7_P!A
M2W_]"H \!^)__)6]7_WX_P#T2M%'Q/\ ^2MZO_OQ_P#HE:*_9L'_ +I1_P $
M?R/.E\3-GX*_\E0O/^O:?_T-:]D'_)3_ /N%?^U*\:^"W_)4+S_KVG_]#6O9
M1_R4X_\ 8*_]J5\#Q3_OZ_PQ_)G50^$ZFBBBOES<**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y?QS_QX:7_V%+?_ -"KJ*Y;
MQR?^)?IG'_,4M_\ T*@#P+XG_P#)6]7_ -^/_P!$K11\3_\ DK>K_P"_'_Z)
M6BOV;!_[I1_P1_(\Z7Q,D^&OB'2_#7C^\O\ 5[K[-;&&:,/Y;/\ ,74@84$]
MC7IVK>-OA;K=W'=WVJ,]Q&GEK(D%RAVYSCA:\2\<V=OI_CC6+6UC$<$=RX1
M2<<^]<]7%B<CPN9N.*J.2;BMK=O1]RHU90]U'T%_PD/PC_Z"D_\ WS=__$T?
M\)#\(_\ H*3_ /?-W_\ $U\^T5R_ZH8'^:7WK_(KZQ(^@O\ A(?A'_T%)_\
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M^$?_ $%)_P#OF[_^)KY]HH_U0P/\TOO7^0?6)'T%_P )#\(_^@I/_P!\W?\
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M1_PD/PC_ .@I/_WS=_\ Q-?/M%'^J&!_FE]Z_P @^L2/H+_A(?A'_P!!2?\
M[YN__B:/^$A^$?\ T%)_^^;O_P")KY]HH_U0P/\ -+[U_D'UB1]!?\)#\(_^
M@I/_ -\W?_Q-'_"0_"/_ *"D_P#WS=__ !-?/M%'^J&!_FE]Z_R#ZQ(^@O\
MA(?A'_T%)_\ OF[_ /B:/^$A^$?_ $%)_P#OF[_^)KY]HH_U0P/\TOO7^0?6
M)'T%_P )#\(_^@I/_P!\W?\ \33H?$OPDAN8;A=2D:2!Q)'OCNF 8=#@K7SW
M11_JA@?YI?>O\@^L2.N\;ZO8Z[\1M0U+39_/M)V0QR;&7=B)0>& /4'M13_A
M?I5CK/CJUL]0@$]NT<C%"Q )"G'0T5MC<TP^62AA9)NT5VVV\NPHP<_>/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img_016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %S LD# 2(  A$! Q$!_\0
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MZEHVL")I;^;5X099')*+_=7T%:7Q+4WLWAW1W/\ HE]J*K<)V=5&=I]LTO\
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M,[R,]11_K3C^T?\ P%?YA[")E_\ "F/'/_/]9_\ @6__ ,32CX+^.3TOK/\
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MC_6G']H_^ K_ ##V$30_X4MXY_Y_;/\ \"W_ /B:/^%+^.<?\?MG_P"!;_\
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M/]:<?VC_ . K_,/81/G+_A2OCG_G^L__  +?_P")H_X4KXY_Y_K/_P "W_\
MB:^C:*/]:<?VC_X"O\P]A$^<O^%*^.?^?ZS_ / M_P#XFC_A2OCG_G^L_P#P
M+?\ ^)KZ-HH_UIQ_:/\ X"O\P]A$^<O^%*^.?^?ZS_\  M__ (FC_A2OCG_G
M^L__  +?_P")KZ-HH_UIQ_:/_@*_S#V$3YR_X4KXY_Y_K/\ \"W_ /B:/^%*
M^.?^?ZS_ / M_P#XFOHVBC_6G']H_P#@*_S#V$3YR_X4KXY_Y_K/_P "W_\
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MK_:ULYT/3I6DA>3&V7GY0 >Q[T 4?AGX]TWP):)97&@7K:AJ$X62Y8!!@G
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M@!NSFD"8[_2GT4 (!@8K@OC-_P DRU'_ 'XO_0Q7?5P/QF_Y)EJ/^_%_Z&*
M.TT[_D&6O_7%/_015JJVG?\ (,M?^N*?^@BK- !1110 4444 %%%% !1110
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MUM9[^<Q"[N_]7%@9Y]SVKXWBK_?U_AC^3.BA\)@^*/$5KXG\.02:=-?&TCN
M-3M[4%;J)?0KU'/7%1>#WMO^$QB7PS_:_P#9/D,;W[<&\O=_#MW<[O6J8TW4
M;[QF;1];LVUC[.9K?4].0*RXZI.HX9377Z)XDOEU)= \16?V;4RNZ.>!28+D
M#J5/8^QKYFUC8ZWK3Z:,8IU( HHS13 *X'XS?\DRU'_?B_\ 0Q7?5P/QF_Y)
MEJ/^_%_Z&* .UT[_ )!EK_UQ3_T$59JMIW_(,M?^N*?^@BK- !1110 4444
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MD4;01R* .9\)^%[;P?X231[=Q)Y:,9)0,>8Y')Q7G_[/P_T/Q+_V$/Z5[%<
M?9I?]QOY5X[^S]_QY^)?^PA_2@#V>BBB@ HHHH **** "BBB@ HHHH ****
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MO_0Q3 [73O\ D&6O_7%/_015FJNG?\@RU_ZXI_Z"*M4 %%%% !1110 4444
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MM-,N7MKUX3Y,D9PP8<X'UQB@#SW]H7_D2K#_ *_U_D:]1TGC2+$8_P"7>/\
M]!%?*6C:1K?CB&XM-0\1W'GV<OSVUR6?!Z9'-3V>K:KI/CNSTRY\;SBRMW4S
M7)F;8@'5<'J>U 'UG1533K^TU+3X;RRN4N;>104E0Y#>]6Z "BBB@ HHHH *
M*** "BBB@#PO]H?_ %_A[_=N/YQUY;7J7[0_^O\ #W^[<?SCKRVOUC(O^191
M^?YLX:OQL[CX+?\ )4+S_KVG_P#0UKZ,R/6OG+X,?\E/O/\ KVG_ /0UKV#Q
M?K=_IVJ>'K"PEBA;4+SRY9)!D; ,D#W-?&\5/_;[?W8_DSHH? 5+WQEXEMM0
MGM[?P3?7,*.529)E <>HJEH</B;7_'<&OZIH_P#8UG9VSPI$\@:2<MZX["I?
M'>OZK-K.G>$?#=T+?4[TEYYP,FWA'5OK46@2>(/#7C:#PYJVKOJ]G?6S307,
MR@2(Z]5X[5\RC9GHHZ4O- I: $HP:6B@!*X+XR_\DRU'_?B_]#%=]7 _&;_D
MF6H_[\7_ *&* .TT[_D&6O\ UQ3_ -!%6JK:=_R#+7_KBG_H(JS0 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5XK
MXP_Y.+\*_P#7$?\ LU>U5XKXP_Y.+\*_]<1_[-0![51110 4444 %%%% !11
M10!XMXF_Y.1\._\ 7N/Y-7M->+>)O^3D?#O_ %[C^35[30 4444 %%&:* #.
M*0L ,DX%9/B/7(/#VCRZA<123;2$CBB&6DD;A5'U-<_:^&=1\1VL%SXMNY5D
M+^:-.M9"D2+V5\<L1W- ">*-6TZ\UCP[;6U_;33IJB;HHY0S# .<@5U9ZGZU
MQ>K^&]%T"\\.C2M.@M=^K*79%^9B5.<D\UVC=::W X'XFC][X7.T#_B;Q\8%
M3?%2&.XT"R@E13%)J,*L,=B<&M/Q=X<NO$+:.UM/'&+&^6YD\S/S*.WUJ3QC
MH-SXAT^TM[:6.(Q7D=P3)T*J<X&*S6JMYCO9G->&-;7PEH?B#2+QCOT)F: ,
M<EXVYCQ^)Q67X0TN6P\>Z/-=C_3[_3Y;NY/?<YR ?H*Z'Q7\/Y?$/BK3=4AN
ME@MD"K?Q9/\ I"J<J/?FM>ZT"YD\<6NO120I!!9/;B,YW;CT_ 5=]2;:61C>
M,+B;Q'K=MX*TY]B28FU69%'[N#^YGU:NUM+6"RM(K6VC$<$2!(T QM4=!7#^
M'O#_ (M\/+>NL.CWEW>3M-/=2S.'?)X&,<8%=O9FZ-K&;U(4N<?.(6)0'VS0
MM@=[G/ZR2/'WALC_ )XW/\A78Q'*#-<;K7_(^^&S_P!,;G^0KLHON"@8^BBB
M@ HHHH **** "BBB@ HHHH *1NE+0: /G7XM:%>>!?$@\5:$Q2/4MT<Z;!M1
MR.WUZU-H?PRTR#X1:CKVM67G:M-;27,;N2#$,?+QV/>O>KJTM[M0EQ;QS*#D
M"1 P!]>:P_'8 ^'^N 8 %E(,?A0!SOP._P"266& /];+_P"A5Z0.E>;_  ,_
MY);8_P#767_T*O2* "BBB@ HHHH **** "BBB@#PO]H?_7^'O]VX_G'7EM>I
M?M#_ .O\/?[MQ_..O+:_6,B_Y%E'Y_FSAJ_&SM_@Q_R4^\S_ ,^T_P#Z&M>X
M>)?"^G^*]-6SO_,1HW$D,T3;7B<=&4UXA\%O^2H7G_7M/_Z&M?1N*^.XI_W]
M?X8_DS>A\)R7A;P%8>%[J>^6YN+_ %*XXDO+IMSE?3VJZ?#<3^,AXBENY9)H
M[?R(8"/DC!ZD>YKH:3%?,&X#M2T44 %%%% !7 _&;_DF6H_[\7_H8KOJX'XS
M?\DRU'_?B_\ 0Q2N!VNG?\@RU_ZXI_Z"*LU6T[_D&6O_ %Q3_P!!%6:8!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445%<2&&WD
MD",^U2=JC);V'O0!+16)!XBMSH[ZG>6]W80HVUEN8B'^N!GBKMAJEGJL GL;
MF.9.^T\CZCL: +U>*^,/^3B_"O\ UQ'_ +-7M5>*^,/^3B_"O_7$?^S4 >U4
M444 %%%% !1110 4444 >+>)O^3D?#O_ %[C^35[37BWB;_DY'P[_P!>X_DU
M>TT 4M0U"TTRUENKZYC@@C4LSNV, =:XH^*+WQA#LT.\CT?3B1G4+DKYDR$<
M^4A/'U-=!XK\'Z7XPT];/5%D(C8M$\;$%&]??Z&N/.@+X4\Q]=T6QU;2(UPM
MY;6W[^/GC>@X(QW% '51^+?#>EQIIUQX@@FN+9%60E]S$XZMCN:ST^(UI?P,
M^B:1JVI-YGEILMRB,<X^\>@K;T'3?#QLQ>:/I]I'#<#.]( I?'KD9K:2-8UV
MHJJ/11@4 <>VA:YXAUBSO-;GBM=-M'$\6GV[$LTHZ&1N^/05URY.<\U)BEP*
M .?\5Z;->Z6D]I_Q_6$@N;?(SEE[8[Y&1^-4(O'7A\PH;R]^PW#*#):W",LD
M1]",5UV*KRV4$QR\,3,>I9 2: .;'CCPM_T&[;\F_P *7_A.?"W_ $&[;\F_
MPK=_LJV_YX0_]^U_PI?[*M?^?>'_ +]K_A0(P#XY\+?]!RU_)O\ "E_X3GPM
M_P!!NV_)O\*WO[*M/^?:'_OVO^%)_95K_P ^\/\ W[7_  H&8/\ PG/A7_H.
M6OY-_A0/'/A7_H-VOKT;_"M[^RK7_GA#_P!^U_PH_LFU_P">$/\ W[7_  H
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MBA0)%&D:#HJ+@#\!7.^'=)GM)KF[NV#WMW+YLS#D+Z(I_NBNHH 0+CO2T44
M%%%% !7BOC#_ ).+\*_]<1_[-7M!? KQ?Q><_M%>%3_TQ'_LU 'M5%-+X[4G
MF#)'I0 ^BD!S2T %%%% !1110!XMXF_Y.1\._P#7N/Y-7M->+>)N?VD?#O\
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MQ(HD4'##H?K4LT"3PO%+&KQ."KHPR&![5/BB@"I:V=O8VZ6]M D$,:X5(UP
M,>E>0_ K_D,>,/\ K]_JU>SMT/TKQ?X$_P#(8\8?]?O]6H ]JHHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH #TJI=V5O?6DMM=0)-!
M*-KQN,AAZ&K=% %#3-,L]'M$LM.M([6V0DK'&,*,^E>2?!O_ )*!XX_Z^/\
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M;^!;K6-=_LFWC%^_F3F8#:IR3@#/O7:_$#X6^(+GP[+J$WBFYU>XT\&6.&6
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M/4UZ" ,&E"\]30 ( !@#&.U/I@X-+OYZ4 .HI <TM !1110 4444 %)BEHH
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MG_7M/_Z&M?1M?'<4_P"_K_#'\F=%#X0HHHKY<W"BBB@ HHHH **** "BBB@
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ME[X9^(=+\,_$"[O]8NOLUL89HP_EL_S%U(&%!/8U[3_PN'P'_P!!W_R4G_\
MB*^9XDP6)K8U3I4Y27+'5)OH;4914=6=Q17#_P#"X? ?_0=_\E)__B*/^%P^
M _\ H._^2D__ ,17SO\ 9F._Y\R_\!?^1KSQ[G<45P__  N'P'_T'?\ R4G_
M /B*/^%P^ _^@[_Y*3__ !%']F8[_GS+_P !?^0<\>YW%%</_P +A\!_]!W_
M ,E)_P#XBC_A</@/_H._^2D__P 11_9F._Y\R_\  7_D'/'N=Q17#_\ "X?
M?_0=_P#)2?\ ^(H_X7#X#_Z#O_DI/_\ $4?V9CO^?,O_  %_Y!SQ[G<45P__
M  N'P'_T'?\ R4G_ /B*/^%P^ _^@[_Y*3__ !%']F8[_GS+_P !?^0<\>YW
M%%</_P +A\!_]!W_ ,E)_P#XBC_A</@/_H._^2D__P 11_9F._Y\R_\  7_D
M'/'N=Q17#_\ "X? ?_0=_P#)2?\ ^(H_X7#X#_Z#O_DI/_\ $4?V9CO^?,O_
M  %_Y!SQ[G<45P__  N'P'_T'?\ R4G_ /B*/^%P^ _^@[_Y*3__ !%']F8[
M_GS+_P !?^0<\>YW%%</_P +A\!_]!W_ ,E)_P#XBC_A</@/_H._^2D__P 1
M1_9F._Y\R_\  7_D'/'N=Q17#_\ "X? ?_0=_P#)2?\ ^(H_X7#X#_Z#O_DI
M/_\ $4?V9CO^?,O_  %_Y!SQ[G<45P__  N'P'_T'?\ R4G_ /B*/^%P^ _^
M@[_Y*3__ !%']F8[_GS+_P !?^0<\>YW%%</_P +A\!_]!W_ ,E)_P#XBC_A
M</@/_H._^2D__P 11_9F._Y\R_\  7_D'/'N=Q6-XC\.V/BC2)=-U*-FAD(8
M,IPR,.C ]C6!_P +A\!_]!W_ ,E)_P#XBC_A</@/_H._^2D__P 12_LO&_\
M/F7_ ("_\@YX]RL?A1I=PL3:CJ>IW\T#HT$MQ+DQA3T Z<UHZGX!M+[7GUJU
MU"^TZ\EC$<[6LF!*H]0:K?\ "X/ ?_0=_P#)2?\ ^(H_X7!X#_Z#O_DI/_\
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MTO3+:P@+&*WC6-"W4@#'-5/$GA^S\3:/-I=\&\B7!W(<,I'((/K7/?\ "X?
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MQI^[R54_*=W7-8G_  N#P'_T'?\ R4G_ /B*1OB_X$(_Y#O_ )*3_P#Q%/\
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MOO"]EH,[3^58@?9KE7Q+&PZ,#ZU#IOP\LK35H-2U#4+_ %:YMQBW-[)N6+W
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** )[.-9;ZWC<91Y%5AZ@FOJ3_ (5SX2_Z T7_ '\?_P"*HHKX?BNO5I2I
.>SDU>^S:['302=[G_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img_017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )B B,# 2(  A$! Q$!_\0
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M31_PI7QS_P _UG_X%O\ _$U]&T4?ZTX_M'_P%?YA[")\Y?\ "E?'/_/]9_\
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M")\Z?\*J\5?]!K2__ ]O_B:/^%4^*O\ H-:7_P"![?\ Q-?17]F:=T^Q0?\
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M[X:U!(GN1;0W385)22!E<_6O3!TH 6BBB@ HHHH **** "BBB@""\_X\Y_\
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M 7.@M>(E[<3-<RW 7*O(7W?,.XZ ^U7/#/AW4K+7;S6=4:SBFG@2W%M8H5C
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M/_?56?LMO_S[Q?\ ? H^RV__ #[Q?]\"C0"M_;.G?\_L/_?5']LZ=_S^P_\
M?56?LMO_ ,^\7_? H^RV_P#S[Q?]\"C0"M_;.G?\_L/_ 'U1_;.F_P#/[#_W
MU5G[+;_\^\7_ 'P*3[+;_P#/O%_WP*- *_\ ;.F_\_L/_?5']LZ;_P _L/\
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M?[]4%HHHKL/)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(UI@VL\+E982!C*MV..*J/X(T$Z-!IB6K1102F>&:-R)4E/60/UW'UKIL"C
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M_DJ%Y_U[3_\ H:U]&U^;<4_[^O\ #'\F==#X0HHHKY<W"D-+0: .=\5>(H]
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M2_ZK4_\ ?7^5>FKTKRL%_ B?>YU_OU06BBBNP\D**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!K<5S/B
MO[MOW^;^E=,W2N9\5_=M_P#>KIPO\9'AY]I@*GR/-/&7^JT\9[2?TKL_A/\
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M113 **** "N#^,G_ "2[5?\ >A_]&I7>5P?QD_Y)=JO^]#_Z-2O1RK_?J/\
MBC^9$_A9\W6?_'JGX_SHHL_^/5/Q_G17[!+XF<!Z!\%?^2H7G_7M/_Z&M?1M
M?.7P5_Y*A>?]>T__ *&M?1M?FW%/^_K_  Q_)G70^$****^7-PH)P**1N!0
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M"3_5ZG_OK_*O3%Z5\Y@OX$3ZG.O]^J"T445V'DA1110 4444 %%%% !1110
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MCQG_ *K3OI)_,5V?PG_Y%R[_ .OH_P A7&>,_P#5:?\ 23^E=G\*/^1<NO\
MKY/\A7@U/^1E,^OP3_XQ?#_([\4M(*6N\\4****8!1110 5P?QD_Y)=JO^]#
M_P"C4KO*X/XR?\DNU7_>A_\ 1J5Z.5?[]1_Q1_,B?PL^;K/_ (]4_'^=%%G_
M ,>J?C_.BOV"7Q,X#T#X*_\ )4+S_KVG_P#0UKZ-KYR^"O\ R5"\_P"O:?\
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M-?\ =)'CYW_N4SB'^[^%:FE?\>;_ .^/Y5EO]W\*U-*_X\W_ .NG]*^EX?\
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MJ@M%%%=AY(4444 %%)FES0 4444 %%%% !1110 4444 %%%% !1110 4444
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M_*N*\+?\?UQ_UR_K7:V7_'O-_OK_ "KP.-O]\GZ(X<P?_"-(?)6GI7_'H_\
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MJ,U;\,P167C?Q-8V2!+/,,S1I]U)67YL#MD '% '(_'?_F4?^PJ/Z5L_'/\
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MZC 9(6((93M:-AT93U!'J*B\.>&=/\+V,EM8>>_G2&666XE,DDC>K,>M;=%
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MPF3_ *W(X91W'44 =JB!5"CHHP*=C(JO9W$-Y;Q7-M,DT$J!XY$.0P/0BK-
M";:,>YI:* #%%%% "4$4$\5BZW=V4/V2&ZUG^S)9IPL)$BJ96_N\]0:5@&-X
M2TF3Q8GB9H7_ +42/RA)O.-O3I6[BN2M==U#2M>@T7Q%Y+->NWV"]@4JDN.?
M+93]U\?@:ZX=*8"8HQ2T4 )CW-&*6B@ Q28I:0]* $S@UA:#X3TGPU=:A<:;
M"\<E_+YUP6<MEN>GIU-1:G+)-JLEOI7B&&'5O)^2QE*O'QU8H/F_'-.\-^(9
M-7>\L;ZU-KJVGLJ740Y0Y&0Z'NIH Z$<C.:,>] Z4M "8]Z6BB@ Q28I:* $
MJIJ>GV^JZ9<:?=J6M[A#'(H."5/7!JQ*RJ-S$ *,DDX ^M<:^HZE%;/JGA_5
M8=<L8)I#=V[X:7 Y*1,O<=@>OK0!T&@Z'8^'-'@TO38VCM(0=BNV2,\]:TSQ
M6;H6MV7B#1X-4L'+03C@,,,A'!5AV(/!%5O$GB33_#>FF\OY#C^")?O.?04F
M[*[*A"4Y*,5=LW!2XJEI6H1ZIIT%[$DB1S('59%VL/J*O"F)IIV88HHHH$%%
M%% !1110 5P?QD_Y)=JO^]#_ .C4KO*X/XR?\DNU7_>A_P#1J5Z.5?[]1_Q1
M_,B?PL^;K/\ X]4_'^=%%G_QZI^/\Z*_8)?$S@/0/@K_ ,E0O/\ KVG_ /0U
MKZ-KYR^"O_)4+S_KVG_]#6OHVOS;BG_?U_AC^3.NA\(4445\N;A1110 4444
M %%%% !1110 4444 %%%% !114<A559W.U0,DYZ"@"EJ^K0Z/8R7,RR2%02D
M,0!DE(&<(.YQSBN/U#QE:ZS--I-G>VD,-WIGGP23RA&>0MM\H@G@\8(ZC-4=
M5\7V/B&:*#^RYX;3>)-'UBX4I"]TN=HSU4$\9/!J.U\#:1X@U>#Q VG:<TTO
M[G6-/D&Y(YARSH1T?/Y@T 9<5Y;VMU;W7AW1IM U6QC/VY)X_+LYU'6-GSAV
M/\##-=O#_9_ALZGXFFFE@AU58IVM7X*R!><#U/&?I3]>TOPIIVCP2ZI80-:V
M( MHGR0#G("C//-9&EZ3>>,=237-;C,>GQ\VEF3PP_O'_/-:0BOBEL9RET0F
ME:5>>,M177-;1DT]#FTLSP&'J1_G->@QC:,   = .PI$0*,#  X ':I!4SFY
M/R*C&R%HHHJ2A#6!J_BO3M&O8;:=F8/((YY(\$6F1E6E_NJ?6M+5]5L]%TR?
M4;^7RK:!=SMC)]  .Y)KS6Y\1V5]J4NH7>CG3W $.J6U_#@W5DWW&7LS+UV]
M0": ':QXD@\0Q"::RM=0MM+U*5+G35E#230!<+(J9^<@G..])X>U*.UUQ+?3
M;.=/#.KRM;#3;F$I)!)M):14/2(C@^]:&@_#+1]/U:=FTVQO=-<_:+6Z<G[1
M&S'.S(ZH!C%=G:Z!I5IJLFJ0642WTB;'GY+%?3GZ4 2:/IRZ3I\5A&088 5B
M"C&U,\#\*T*** "BBB@ IKD*A). !DTIZ&L#Q#XE@T%(XEMI[[4)PQM[&W&9
M)0/O'V ]: ,^[\>:?;_;T16,UO;FXMRQ CO$'4QMWQW'45QVJWFC/K^HW^LZ
M=_;^G:@B&PFL5^TO:D)AD./N<\@CO4T-KH'BN*30Y9)([34B]QIB^3LEL)1_
MK(S_ '<GG!Z@FNI\,>"M.TRR22[T?3H-3 :.62R!19%Z!L>I'7ZT 87A=M8U
M>PO/#.JR(^HZ489[?4-N_P O=\P0G_GHJ\'ZUZ<.E4=,TFPT>V-MIUK';0%B
MY5!U8]23U)J_0 4444 %%%% %6\NX[&W::9@%R !G!9CP /<GBN;7QII][9H
M?/6P9Y7MKC[4PC>UD Z,#W]/6JGBOQ;I8-QI,MM>RVV1#=ZA;1AH[%S]UF/J
M#@\=*Q/^$;M?%Z17&R&XUG2Y%M[I[N+,.H18&'('!RIR&'0T 8KVVW3%TRRL
M;E?&$3ADUN)!Y=P-V2[3_P!PKPPZUWGAC[7KYTKQ1--##,;>2WN8;?F*8AL!
M@>X&./K6E%X/\/0:7)ID.E0)8R,'> $[2PZ=ZVK6V@L[:*VMHDA@C4*D:#"J
M!V H E%+110 4444 %9>MZQ#HMA)>31RS"-2QA@7=(RCJ57J<=3BM"1P@+,<
M*!DD]!7F.I^+X]8U&WDMM,O+>>VD,NCW=RIBCO''$D6>V1TSUH L:_XIAUV6
M^TJSNK1XHXK:[@B\X*U\I)+Q<GN!C%8MOJ:66OVNI>%-.DTFP55BU"TO8_(A
MD9F&!&O\4O7D<$"MBT^'7A^_UR/7+73K&;3[Y ;JTF7/V>0<DQD=&SD$=*M^
M,KKPWX<2SN)=,@NM4A CT^$Y9D(^Z0.V/6IE)15V:4J4ZLU""NS1U*_L?!%I
MJ5_<SH+>YE$MM:(FTAR/F '<D\FN?\.^&K[Q9J:^)_$ZD1@YLK%ONJO8D5)H
M?@W5-<U.'Q!XNF\V51N@L@/EC/;(_I7HT9XP1CM@5FHN;YI;=CMG4AAHNG1=
MY/=_HOU81GY<'@@=!VJ8=*:,"G5L><%%%% !1110 4444 %<'\9/^27:K_O0
M_P#HU*[RN#^,G_)+M5_WH?\ T:E>CE7^_4?\4?S(G\+/FZS_ ./5/Q_G119_
M\>J?C_.BOV"7Q,X#T#X*_P#)4+S_ *]I_P#T-:^C:^<O@K_R5"\_Z]I__0UK
MZ-K\VXI_W]?X8_DSKH?"%%%%?+FX4444 %%%% !1110 4444 %%%% !116'K
MOB*/29K:SA@:[U&[;$%K&<$J#\SD]E'<T ;$CK%&TCN%1 68GH .M<"?&5WX
MFEU$>%EM[RVLT"O;W :-KS=G=L8] !T/0FNIU:RM?$>C76G&ZV^8A1GMY?FC
M;'M_+O7+6/AS4]0CAAO]]CK&BLL-KJ\*C%S <9PG09 P0>E '/+??9?!%O8W
MK"Z\*22?9]\MM(UXF&_U)C Z@C ;Z&NNT%K+PEX3>]OD, D=I!Y@_?2KT3?Z
MOMP#70ZMJUGHNG/>7CA(U' (&7;T'O7'Z5I5YXRU)=<UQ"FG(<VEF>A']X_Y
MYK2$$_>EL1*71!I.E7?C'4TUS6XVCL(SFTLST(_O'_/->@1J @ 4 #@ = *1
M%PH  4#@ = *D I3GS/R'&-@P*6BFM4%#JHZMJMEHVG2W]_<+!;1#+.?Y =S
M[5EZIXLLM*N;F*6&ZE2S027<L49*P(1D$^OT&:S_ !)HH\::5INHZ1J?DS6T
MJW=I*!N1^,A64^OOR* .:UG7KSQ5X5NK_86\/32%)! A%W9JC?+,%ZL=P!VX
MZ50\5-JVL#3+.],4NK"!GT:2TC<K<,ZA2\I(PGR]0?4UVFBZ-<WFHV_B1K>7
M1;Z8%-3LN'%QM&%R>@ Z@CKFNO4#C@>W'2@"MIT+P:?;0NJJ\<*(RI]T$ 9Q
M[5<HQ10 4444 %(W"FFS2+#"\CG"HI9CZ 5RT?CS2C]DFF2YAL;YUCM+R2(B
M.=CT [K]3B@"QXG\7:;X7M8_ML^VXN#LMX]I;)_O-CHH[DUR-Z=9'BO2KNY:
MR_M549-.U")6-K>1N,M"^.4/=6[ULZYH5[9^*/\ A(],MSJ"W4*V5]I[,,-&
M6_U@)Z;1V'6MKPYX>3P\EQ:VUT\FFLX>TM77BU7NJGJ1GGGI0!P'AVTOKKXF
MR:E;&03><W]N1!"L$3!-L81F&7/N/6O70!Z4!0.@%+0 8HHHH ***S]5U*WT
MFQDO;IW6&/ .Q2Q))P  .Y)% &A7%ZOXR27Q'%X9T6]M4U<D^8]PK&- !G:#
MT9NG'49K4T_Q+9:GJ$VDRQSVFHQQ"1[2<;6V'@$-T/X'(KEK3P9);-=^&KR"
M2YTJXE>]L]55@)K:<G(7UR.H;OTH SXI]3L_[?C@MK6S:56EU>QN$9PA(PUQ
M"1]]6'\)[UL_"W3/[.T.8PS7D^G$JMA+>)L<Q8R<+U5=V< UVUC;26]E!%<3
M?:9TC5))V4 R$#J?K5G ]*  =.>M+110 4444 %1R-L5G9L*HR3[5D:SXCM=
M*OK?3Q'-<ZC<HSPVL(^=D7[S<\8%4YIM*\>^&+RUL[Z6..3,3M'E)8) ?XE/
M(((Z'K0!S:^-[_Q7=ZO#X<M[>ZMM/4*UK<@QR7JMD-MS]T#G![UCS:JDWABQ
MLM7N7U#P_/,8XYEM7-YYBDXBV 84J> _M73V.CW6J30-JT4MAKNCNJ)J5L,)
M=1GKQT(8=5/0]*T/%_B^R\+68VH);^8X@ME'+,>YJ9245=FE*E.K-0@KLQ3K
MUOX"\&65H\(;4Y ?*M5Y=V)X9O?IGWH\)>#[F74#XF\2'SM3F.Z*)N1 O;CU
M_E2^$/!]U)>MXE\2'S]4F.Z.)^1 .W'K_*O0%&.<YK*,7-\TCMJU(8>+HT7=
M]7W\EY?F*@]\T\+BD4<TZMD><&!1113 **** "BBB@ HHHH *X/XR?\ )+M5
M_P!Z'_T:E=Y7!_&3_DEVJ_[T/_HU*]'*O]^H_P"*/YD3^%GS=9_\>J?C_.BB
MS_X]4_'^=%?L$OB9P'H'P5_Y*A>?]>T__H:U]&U\Y?!7_DJ%Y_U[3_\ H:U]
M&U^;<4_[^O\ #'\F==#X0HHHKY<W"BBB@ HHHH **** "BBB@ HHJ-]Q5@A
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M95JPP\71HN[>[[^2\OS'*.#DYIX ]*1:=6VYYH8HHHIC"BBB@ HHHH ****
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MI'YTD<";VCBZ%R/2N#M/#NN7EQ>PPRSM%>PR22ZFUP7CN589B"H3\C*<9]J
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MS2V,Y2=[1$\/>'+O4K\>(?$(WW3G=;V[?=B7MD5W(7N: .<TZHE)R=V5&-@
MI:**DH**** "BBB@ HHHH **** "D)Q2,X7))P!R3Z50_M:W6\NX)I(XC;1B
M8DM_RSQ]_P"G!_*@!;[4889)+6*6)M1,#2PVQ;YI /0>F>*X+16L=;\FWU6S
M/]GZZCRVULZ;39SIQ+&&'(R1N'3H:ZZZL-!\9:6DV8;NWE4^5=6[X=?]UQR*
M3PWX5MO#D5Q%#=W5VLLWG W3[S&<8^4T +X<\*V7AI+Q;.XNY4NG#L+F8R$$
M#'!-;%I96UA;K;VD"0PJ20B# &>M3 8I: "BBB@ HHHH **** "BBB@ HHHH
M ***3/'2@!2<5@ZQXR\/Z#<FVU/4XK>8*'96!.U2< M@< ^]:.J2W,6F7+V7
ME_:5C+1^9]W(]:X,20Z=KD_B6.%=6\/Z]%&MW+$HD%LZ#&XCO&>_H10!UESH
M>FWTMWJ($K2WUG]G>2&0@O%R0%]^>M<QX.T>UTOQ7<-HNGZA9Z2+%8I#<.=D
MDP;LK'.X#J>].\'1M+/K&FZ;-<'PVK)+87JN2Q=CF1%8_P (/Y58\9>,SI!3
M2=*4W6M7/RQQKSY>>YJ)24%=FU&C.M/EA_PWF1>+/%D/AV--$T"W275KACY<
M,:\1ECDL1Z]ZL>"_!G]B*VIZD_VG6KGYI9FY\O/\(I/!?@O^Q%?4]2?[3K5P
M=TLK<^7GL*[, GO6<8W?-+<ZJ]:-./L*.W5]_P#@"[33MM+CBEK8\\****8!
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5P?QD_Y
M)=JO^]#_ .C4KO*X/XR?\DNU7_>A_P#1J5Z.5?[]1_Q1_,B?PL^;K/\ X]4_
M'^=%%G_QZI^/\Z*_8)?$S@.^^"__ "4^\_Z]IO\ T-:[5M&\4P:]JL4>A:>Q
MN]0,RZSJ$BRK'!QM54/(([#IFN+^"_\ R5"\_P"O:?\ ]#6O=_$'A[3?$VF-
MI^JPM+:E@^U7*$,.AR#FOS7BG_?U_AC^3.NA\)S&A6]OKFJZQINL36VMC3'C
MCBNY( LBEAED+#K@XZ5L:KJFD^#=*Q!;P0AB?)M8$"[V/? _G4=]>Z1X#\/1
M6UM"$1%V6]NIRSGW/4_6L[PWX<N]0OU\0^(1YEV_S06[#Y81VX]:^<A%)<TM
MBY2=^5!X=\.W>I7Z^(O$(WW3\P6S#Y85[''K7<!>:%!I]3*3EN5&/*A .:6B
MBI*"BBB@ HHHH **** "BBB@ IDLJPQ/(YPB*68^@'6F3W,5M!+-*VR.)2[L
M>@ &2:PM,\6>'_$SRV-E?"622(L871HV>,C&5W 9'N* .>U[65\46EHNEBZA
M8.MY:--^ZAU!5^]$3VSZ'ZUFV_A^:*&UNM>GELI=0EEL[>VW^9Y2.=\4;L.&
M"E3^!Q70^(_#'A_^Q[&VO=*N[^WM$:"V@B9F*Y''?KV![5J^&=,DB\+:;;7]
ML4>% 5AFP[0X^ZI/=@.,T 5O!_A_4=%&H2ZE+9--=2JPCL8C'$H48SM[$]37
M4#IS0!BEH **** "BBB@ HHHH **** "BBB@ HHH)P* $) '-87BK79M!T<7
M%K;"YNIYDMK>-G"*9'.%W'L/6M'49IA87:V15KY8&:&,D9+8.WCTS7E@LM0\
M2^ 1J!NWOKV+G6-,N#MS*G)"_P#/-UP",<'% '7Z'XCU*+48]!\5VMO;:I-N
M^S26Y+0W:@98K_=(]#UJI<Z1KGA6]:Z\+6\5[I4[[[G2'8(8V/5H3T&>I4\5
M2TV'6_%.A:4CW=O>6)DCNH]94[)656W!?*QP>-I.:O\ C7QF=*9-)TI?M.LW
M/$<:<^7GN:B4N579K1HSK3Y($7BGQNVF6T&F:7:EM;NE 6U&"8"?[V.,U8\%
M>#!H:-J>I/\ :M:N?FEF;GR\_P (I?!7@P:(C:EJ+_:=9N?FFF;G9GL/\:[+
M&16<8MOFD=5:M"G#V%';J^__   "\4X+BE'2EK8X HHHI@%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5P?QD_Y)=JO^]#_
M .C4KO*X/XR?\DNU7_>A_P#1J5Z.5?[]1_Q1_,B?PL^;K/\ X]4_'^=%%G_Q
MZI^/\Z*_8)?$S@/0/@M_R5"\_P"O:?\ ]#6OHJ0,48+C=CC/3-?.OP5_Y*A>
M?]>T_P#Z&M?1M?FO%/\ OZ_PQ_)G70^$XO1_"EW+K4NM>(G2XO Y\B-3E(U[
M8KL0.>:?17S+DWN:J-A!2T44B@HHHH **** "BBB@ HHHH *:S@=:4MZ<UQF
MJ7WB&^\27FG:-JEA8O:P+(EM=0;VGS_'G/"?PY'>@"7Q7/.E[!:75Q'#I&HP
MM;"1_E\JYSF,D^AZ8]JYO5;N:\T>/3M=MI++Q78R 6%U;1'%RX/WHB/X2."I
MQ736%Q:>-]%O]*UO3_*N;=_(OK5CG8^,AT;T[JPJ71M*\1:3J*6LNHVU_HL:
M;8FG4_:H\#@%NC?4T :MKIICOI=0:XN#+/$JO"TF8T(')5>QK2 P*!TI: "B
MBB@ HHHH **** "BBB@ HHHH *.E%(>E  2 *PM1\7:/IVH-I\EPTU^J"1K6
M!"\BI_>('04LWB.V7Q'#HEO#+=W!RURT6"MJ,9!D/;/85S5AK^F>'O%.LKK"
M)9"\F$MMJLH BN5P!L#^J^E !=V(\5:G_P )9X6UR/[7:P"VA4 ["P8EXY%/
MJ./4=:FTW3M*\6R7.IO;WVD:MM-KJ-O%*8SGT;'#\=&]#1X>>UOO'>J:GH$L
M3Z1+;(MT\(_=S7(/WE/0D+U-+XT\9G2732-'C%SK5S\JQH,^7GN?>HE-05V;
M4*$ZT^2'_#$'B/Q+;^%+&U\->'+99-0*"*W@CY$0]3[U<\%>#!H:-J.HN+K6
MKGYI9G.=F?X1_C2>#/!8T-&U+46%UK5S\TTSG.S/\(KL@/YUG&+;YI?(Z:]:
M%.'L*&W5]_\ @"[2.E. IU%;G %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !7!_&3_DEVJ_[T/\ Z-2N\K@_
MC)_R2[5?]Z'_ -&I7HY5_OU'_%'\R)_"SYNL_P#CU3\?YT46?_'JGX_SHK]@
ME\3. ] ^"O\ R5"\_P"O:?\ ]#6OHVOG+X*_\E0O/^O:?_T-:^C:_-N*?]_7
M^&/Y,ZZ'PA1117RYN%%%% !1110 4444 %%%% !3))4BC:21@J*"S,>@ [TD
MUQ%;PO-/(D<2#+NYP%'J37!WGQ"TW4;66S-CJ]I;7GF6R:C+:$0H2,;R<\+S
MU/% $_C2ZL9ET>YOKFY_L&67$EQ92LH5B/E9W4\1^_KBLD^&KFW\2V%D-3N)
M$\MI]*U4.&FBV\M!(?\ EI$<@BK%EHL_@VPM;*"(ZSX6NHUAN(,>886(P9%'
M>-NI';-=3I?A73-(O#=6BSEMNV)992RP(?X8P?NCVH ?H>E7EDUU=ZC=17-_
M=%?,>&/8@"C "CK^9K: I1THH **** "BBB@ HHHH **** "BBB@ HHH)Q0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG]@06\7[J?C'F1L.-YXW9X'6O2-!AU5-/636I(I+^1VD81J-L(/2,'OCU[T
M)X8M)K'POIMI<!EEBMT4J>J<<+^ XK8 P,44M !1110 4444 %%%% !1110
M4444 %%%% "$@=361K6J2V\,MIIC6LNLF$RVUI<2;1*!UIOBO4[C1_#MUJ%N
MJEH &=F&=B9^9L=\#M6=J6E:=XXT*SOK:>2"Z0">POD7;+ ^.#CT/=3VH XJ
MVU?7_'.ERMJ/AN*"YL9B(Y["[ N;*5?5&Y_#H179^$=8OO$6B7-MKNE2V]S
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M@"BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5P?QD_P"27:K_ +T/_HU*[RN#^,G_ "2[
M5?\ >A_]&I7HY5_OU'_%'\R)_"SYNL_^/5/Q_G119_\ 'JGX_P Z*_8)?$S@
M/0/@K_R5"\_Z]I__ $-:^C:^<O@K_P E0O/^O:?_ -#6OHVOS;BG_?U_AC^3
M.NA\(4445\N;A1110 4444 !Z5Q?B3PO<_V@VOZ!'%_:#J([RSEQY.H1?W6'
M0-Z-7:44 8GAO1(M TH6EN;A86<RK!-)O\C=R8U/]T'I6W110 4444 %%%%
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MUG_OS%_\<K.&09E?FE1E?Y?YG77Q=)1]A1?NKKW/4B#BGKG'->6?\+^\*_\
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MB_\ CE']AYE_SYE^'^8>UAW/5:*\J_X7]X5_Z!^L_P#?F+_XY1_PO[PK_P!
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M@VNK')#D]!Z5W9=DV/IXNE.=)I*2;>G?U)G4@XM)GEEG_P >J?C_ #HHL_\
MCU3\?YT5^ER^)G&:'Q ABM_'VM10QI'&MT^%10 .?05S5%%7@G?#4V_Y8_DA
M2^)A111762%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!]-?#C1-*N/A]H\TVF64LKQ,6=[=6).]NI(HHHK\9Q]:HL552D_BEU?=^9Z,
%4N5'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img_018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_018.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )X V4# 2(  A$! Q$!_\0
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MD5S7A'Q?#XKN-62"U>%=.N3;;F;.\CN*/]:<?VC_ . K_,/8Q/&_^%+>.?\
MG^L__ M__B:/^%+>.<X^W6?_ (%O_P#$U]%;UW["Z[^NW//Y4O0YSV[T?ZTX
M_M'_ ,!7^8>QB?.G_"E_''_/]9_^!;__ !-'_"E_'/\ S_6?_@6__P 37K?B
MOQ=<:%XA\.V%M#'-!J<[12/GICTKL#\H.X@*.<T?ZTX_M'_P%?YA[&)\Y_\
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MNP3DD #U-(TBH,NP5?4G%'^M./[1_P# 5_F'L(GSK_PI?QS_ ,_UG_X%O_\
M$T@^#'C@XQ?6?/\ T]O_ /$U[=XSUV7PWX0O]8MXUDDMX]RJ>AJ[H&H/JOA^
MPU"10LMS DK*.@)&:/\ 6G']H_\ @*_S#V,3P0_!CQPO6^L__ M__B:/^%,>
M./\ G^L__ M__B:]?\9^)[W1I=,TS2(8I]7U*<)&CGA$'+,1]*ZE<I&ID8#:
M/F;H,]_PH_UIQ_:/_@*_S#V,3YX_X4MXY_Y_K/\ \"W_ /B:/^%+>.?^?ZS_
M / M_P#XFOHM6#8(8,#TQ2GFC_6G']H_^ K_ ##V,3YS_P"%+^.,9^WV6/\
MK[?_ .)I/^%,>.",_;K/'_7V_P#\37MWB_Q5:^$-"EU.Z1I#D)#"A^:1SP *
MXJ#X@>+-)O;*?Q1X>2VTB_E6.*2%LM"6Z;Q1_K3C^T?_  %?YA[")PW_  IG
MQQ_S_6?_ (%O_P#$TO\ PI;QS_S_ %E_X%O_ /$UZY=^)[S3/'UII%\D?]EZ
ME%_H<ZC!\T<E2?I77J#Q1_K3C^T?_ 5_F'L(GSK_ ,*5\<_\_P!9_P#@6_\
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M">)=$:6&W_MBR::7Y443#+GVH_UIQ_:/_@*_S#V$3PD_!CQP#@WUG_X%O_\
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M)H_X4KXY_P"?ZS_\"W_^)KZ-HH_UIQ_:/_@*_P P]C$^<O\ A2OCG_G^L_\
MP+?_ .)I&^"_CA$+&^L\ 9/^EO\ _$U]'5'/_P >\G^Z?Y4+BG'WVC_X"O\
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M?!83PMX>\<>(;-KB2\TZY>&!7D)7![L.Y]ZZS2=(\57OQ1L/$^HZ)%8V'D/
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M&]JB3P+XC;P#XCEO8TFU[6IUF,"MQ$ W"Y^E S+\3>$9]!^'4/BR/6=0DUZ
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MDBFYH%=$F:/QJG'J=C+>-:1WD#W(&3"'!<#Z59_&EJ-L?0:0'C-'4CTI@-(
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MY\(7OA"PU.VO9XI3<WC3HT?H?6@#F_A^HC^*WC!)V_T@NI4'KL_PJ3XE'/Q
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *CG_X]Y/]T_RJ2HY_^/>3_=/\J:W ^+].
M_P"6GX?UHHT[_EI^']:*_<JOQ,\U'H_P5_Y*A>?]>T__ *&M?1M?.7P5_P"2
MH7G_ %[3_P#H:U]&U^:<4_[^O\,?R9V4?A"BBBOES8**** "C%%% "44M% "
M8I0*** "OG/PW_R<K??]=9/Y5]&5\Z>&_P#DY6^_ZZR?RH ^BZ*** "BBB@
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M/UKW!:];,_AH_P"$QH]0_BIU-_BIU>0C8****8!1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*G/TS3).8WX_A-.XE%+8^>_A0 ?B]KV0,#?Q^->JV0#>*)0   .E>5?"<?\
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MHH **** "BBB@ HHHH **** "BBB@ IDO^J?_=-/IDO^K;_=/\J /GKX3?\
M)7]?_P"!_P Z]5L?^1JFKRKX3?\ )7]>_P"!_P Z]4LO^1JFKKP_PR]#PLV_
MB4?\1V5+2"E/6N0]T\_\>?\ (1L/]\5W%C_QY0_[@KB/'O\ R$=/_P!^NWL?
M^/*'_<%=U?\ @4SU,3_NM+YEFBBBN$\L**** "BBB@ HHHH ::\2^)/_ "5#
M1?\ ?6O;3TKQ+XD?\E0T7_?6O5RK^-+_  LPK_">UQ_ZM?H*>*9'_JU^@IXK
MRGN;+86BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYJ/1O@M_R5"\_P"O:?\ ]#6O8_B#XKE\(>$Y]3MX1+<[UBA1NA8\"O'/@O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_D VW^[63X]_Y H^M:OA7_D 6W^Z*[Y?[JO4]2?^XQ]3:%+2"EK@/+"BBB@
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M9^'/^@S9_P#?P4>QJ_RO[@YX]S=S1FL'_A,_#G_09L_^_@H_X3/PY_T&;/\
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M>EQ^='_"D_#7_/2X_.O2N_2E_"K_ +1Q7\[(]C!]#S3_ (4EX:_YZ7'YT?\
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MN25*I%7E'0X9X>K!7E%I%^EIG&>O-.'2LS$6BBB@ HHHH *3%+10 F*,4M%
M"4<TM% "44M% "<TO-%&: $YHYI<T4 )S1S2YHS0 G-%+1F@!**6C- "44M%
M "44M% "4<TM% "44M% "<TO-%% "<T8-+10!F:XI;1+P 9_=GI4?AY2-!M.
M"#LZ5H7,D<4#R3$"-1EOI3;26*:!)("#$PRN*RY5S\Q=WR\I..*=S3>].K4@
M.:.:** $YHYI:* $HYI:* &,./K63HNF2::;KS'5O-E+C Z"M=JJ6:W8$GVM
ME)WY3;Z5#BKW*3:31<%'-%**LD.:3FEHH 3FCFEHH 2CO2T4 %%%% !1110
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M,0H^II;J\AL[<33/M3(&?K5\R(LRUFC-5KF\AM;4W4K;8E )..U9@\6:0?\
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MF[_.D+].E8R7OHN+]UFL**04M;$!1110 4444 %%%% !1110 4444 %1S_\
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M.?AO_DY6^_ZZR?RKZ,-?.GAO_DY6^_ZZR?RH ^BZ*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *3N:6D[F@#D?%'_'Y
M;?[U=1:_\>L?^Z*Y?Q3_ ,?=M_O5U%J/]%C_ -T5U5?X<3P,!_OU?Y'EWQ^)
M7P&C D$3K@CM6]\,;>*X^'NE2SQ+)(8^6<9)_&L']H _\4 O_7=:Z/X5_P#)
M-=(_ZY5R61]!=I:&KXBL[>/1+ADAC5MO4*,UE^ D67175U##<<@\YK<\2_\
M(!N?]VL7X?\ _(&?_?-=T$OJLO4]2F_]BEZHZUH4="K*&4]01Q2&)"NTJI7I
MM(XJ4?=H XK@LCRRK_9]G_S[0_\ ? I186@.1;Q CH0@JSBC%'*NP<S[D;P1
MR+M=%9?0BAX4D7:ZAE]&%2T4[(+D3PI(FQU#)_=(R*A.GV?_ #[0_P#? JW2
M8I<J!2:V*RV-JC I;Q CD$**E>".0 .BL <C(Z&I *6G9!=O<B>&.0 2(K@=
M-PHD@CE7;(BLOH1Q4E+0TF%RI_9]I_SZP_\ ? IRV-JCADMXE8="%%6:,5/(
M@YF1-#'(070,5.1D=*1H(W/SH&YR-PS@U-0:JR$0O#'(NV15=?1AFHOL-I_S
M[0_]\"K5&*3BF--K8KQV5M&P9((U8="% (J5H49E=E4LO1B.14@&**:207;W
M(C C8RH.#D9&<&DDMXI5VR1JX]&&:FQ1BAI/0+E/^S[/_GTA_P"^!3TM+>)M
MT4,<;>JJ!5C%&T5*BD-RD^I%Y"%][*"PZ$CD4IA1F#,H++]TD<BI,4M59"N0
M2VL,PQ+$C@=F7-1_V=:?\^T7_? JW1BDX1>X*317CL[>%BT4,:$]2J@&GF%-
MX?8-P&-V.14M)0HI;!<C,$9<.44L.C$<BFR6\,O^LB1\?WAFIZ3%%D%V5?L%
MGWM8?^^!4D5K!"28H40GJ57%38HQ1RJ^P.39&(8P_F;!OQC=CFE,,9D#E%W@
M8W8YJ2BG8+E>6UAF*F2-'*]"PSBI!&%&!4E%)12=P;;5A!2T450@HHHH ***
M* "DH[T4@&,,_6J=A'=Q"474XER^4(&,#TJXQY_"JEDEV@E^U2(^6^3:.@I-
M>\AK9EX4M(.E+5""BBB@ HHHH **** "BBB@ HHHH *CG_X]Y/\ =/\ *I*C
MG_X]Y/\ =/\ *FMP/B_3O^6GX?UHHT[_ ):?A_6BOW*K\3/-1Z-\%_\ DI]Y
M_P!>T_\ Z&M>J?%;0[W7_!$\6FQF6Z@D6=(NSA3DC'>O*_@O_P E/O/:VG_]
M#6O4_BQ=ZI8> ;JZTB[^R7,3JQE#[2%SR ?>OS3BG_?U_AC^3.RC\)C:)\:O
M#(TR"'5!<:==01JDD4L1 # 8.*PM0UH_%;QSH4&B6DR:?I4YN);Z12H(] :Z
MG1M?\!>)]"L[W49]+FNC$HF-R%5]X'.0?>NHT[7?"\9CLM-U'35+?*D4+KS]
M *^7-C<!/ISWJ2FJ!U IU !1110 4444 %%%%  :^=/#?_)RM]_UUD_E7T6:
M^<_#?_)RM]_UUD_E0!]&4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4@I&.*:6.<8H Y/Q3_Q^VW^]746O_'M'_NBN
M8\4 _;;8G^]736Q/V6/_ '17757[J#/!P.F-K_(\P_: _P"1!7_KNM='\*O^
M2;:1_P!<ZYSX_9/P_7_KNM='\*VQ\-])_P"N=<A[QN^)/^0%<_[M8WP^_P"0
M,_\ OFM?Q*?^)'<>ZUD> .-&?_?-=T?]TEZGIP_W*7J=>/N_A2CI3-W %.R?
M2N \VXZBF[J-WM3N(=13=U+D^E "T4W=2YHN M%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 )11128(:W )K'T/49M1:[\T*/*E*KCTK7D^X:YWPH 7U CM
M<&LY-\R-(KW6SI12T45J9A1110 4444 %%%% !1110 4444 %1S_ /'O)_NG
M^525'/\ \>\G^Z?Y4UN!\7Z=_P M/P_K11IW_+3\/ZT5^Y5?B9YJ/1O@O_R4
M^\_Z]I__ $-:]N\86>AWWAFZC\1[?[,3$DI9MO(Y%>(?!?\ Y*?>?]>T_P#Z
M&M>D_&BUGN?AY.UO&\L<,\<D\2=70'FOS3BG_?U_AC^3.RA\)YG;S?#S5/$.
MG65IX+N19WDPA6\F=D5O<"NK\.Z9\.8/B'+HL6BRV.KV,I^SO*YVRD=UJIXC
M\0>']5A\"W.FWUM';QW*!H\A3%@<[AVJ;QUJ&G>)OB3X7L?#[)<ZA:3^;<SP
M<A8_0L*^7-CVD'(ZT^HQ@-D#))P:DH **** "BBB@ HHHH #7SGX;_Y.5OO^
MNLG\J^C#7SIX;_Y.5OO^NLG\J /HNB@=** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH 0TT\C/2E-(1Q2OJ!R7BA=MW;'/
M\5;\%[;_ &>-?-7(4=ZK:KHJ:FREG(V^E9__  B<7>>3GWKMO3G346]CYQ1Q
M=#%5)TZ=U+S.,^/%Q%-X! 1@Q$Z]ZW/ACJ5A!\/-+CEOK>-UCY5I "*/$OPS
MMO$6F+9/>RQ*K9SUKAM1^ UCI]DTJZU<?+T4G KGE%7M$]>E7G&DYUU:QZGX
MBU73I=%G":A:DA>@E%9G@*^M!HSYN(N'.<,*\KU/X/VEAX/O-:35[EI((RX3
M/!J]\&_#4>N^%KFXEN)%?S=N U=-.24'2GH>OA,33JT>1NT7K<]S&I69Z7$6
M?]ZE_M.R_P"?F+_OJN0_X5]!C(O)?S-*/A[!WNY?SH]EA_Y_P-O8X7_GY^!U
MW]IV7_/S%_WU2?VE9_\ /S%_WU7)GX>V_P#S]2_G1_PKVW_Y^I/S-'LL/_/^
M >QPO_/S\#K#J5G_ ,_,7_?5)_:5E_S\Q_\ ?5<F/A[;K_R]2_\ ?1H/P^@[
M7,I'^]1[/#_SA[#"_P#/Q_<=;_:5GD#[3$23@?-5I2&7(->4Z[H,>A7]G'%-
M(^]P3EO>O4;,!;6(#^Z*SKT84XJ4'>Y&)P\*48RA*]R<4M(.M+7,<(4444 %
M%%% !1110 4444 %%%% !1110 444E "T9I"33&)#9')["@!X8$D>E+6)X@\
M4:3X8LQ=ZK<B)&.U%4;G<^BJ.34'AKQEH?BQ9CI-WYCPG$D;KL=?JIYH Z'-
M 8'O44LL<$+S3.J1H,L['  KC;3XI^$+[5TTZ+4F$KN41WC*QLP[!NAH [?(
MI:P?$?BO1O"MJEQJUV(A(<1QJ-SO_N@<FF^'/%VC>*[>272+OS#$<21N-KI]
M0>10!T&<TF17%:A\4_"6EZK)I]QJ3>;&XCD9(RR*Q[%AQ743:I90:<=0EO(8
M[3;O\]F 7'UH O45A^'O$^D^*K>6YTB[,\4+F-SC'-;E !1110 4444 %%%%
M !1110 G>BEI*3 8W.1[5G:5IBZ:;@([/YTF_P";M6D>_P!*IV%O/;"03W#3
M%VRN1]T>E1)>\BD]&7Z*3-+6A(4444 %%%% !1110 4444 %%%% !4<__'O)
M_NG^525'/_Q[R?[I_E36X'Q?IW_+3\/ZT4:=_P M/P_K17[E5^)GFH]$^#3!
M/B;>L2 %M9R2>PWK7<:U\;="M[V>PL=.NM3$3&.9XX]R$=_K7FOPZDDB\5Z]
M)$<.NG71!_X$M>G_  ,L;5? 7VCR4:6:X<NY0$GFOS3BG_?U_AC^3.RA\)E>
M'?"/PQ^(BW&H6&GS03J_[ZW\PH5/^[7HOAGP3X?\)Q.ND6"PE_O2,=SGVR>:
M\]\.6T5C^T5K<%M"L,3V>]D3@$G'.*]C48KY<W * !@8Q3J0'-+0(**** "B
MBB@ HHHH *^=/#?_ "<K??\ 763^5?1=?.?AO_DY6^_ZZR?RH&?1@Z4444 %
M%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 3%
M!&12T4 ,P!00#S3L48H : ,5C^(P#I4N?2MH]#6+XC_Y!,OTK6C_ !$<.8_[
MK/T.5\1?\DIU48_Y8&L/]GOGP5=?]?!K=\1?\DIU7_K@:POV>?\ D3+K_KN:
M*S]]AEW^ZP]#U['%&*<*7%8G<,Q13\4E,!M(0<<T[O0?O8H$>?>.AC5+(@\[
MA_.N[L_^/6+_ '17"^.Q_P 3*R/^V/YUW-I_QZPC_9%=N(_@0/4Q7^[TBP*6
MDI:XCS HHHH **** "BBB@ HHHH **** "BBB@ ->8^*/%'BAOB5:^&/#GD*
MK6QEF>9<A >_X5Z;D$5XEIVN:_;?$GQ3KFG:$^KV2R"SW1R ,A7IB@#6T/QK
MJ^@>)-?T7Q5>K?1:=;"[%S%%M;;W&!UI\6N>+OB-#N\/"+1M"D.W[9(0T\B^
MJK_#6GX&\+:B+K5_$'B:"$:GJQVFVX810C@(?6F:G\,C9W+:CX-U.;1;[()A
M#%K=\=05H R1917_ ,9]-TJ^S=1Z/IFZ)I1G>_\ >(]:EU*SBTWX]:'+9HL
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MHVOG+X*_\E0O/^O:?_T-:^C:_-.*?]_7^&/Y,[*/PA1117RYL%%%% !1110
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MT;7SE\%?^2H7G_7M/_Z&M?1M?FG%/^_K_#'\F=E'X0HHHKY<V"BBB@ HHHH
M**** "BBB@!O>OG3P^<?M):@?^FDO_H-?1?>OG/0.?VD-1_WY?\ T&I?PLI;
MGL?@B:2;1[EI96D(NY!D^F:Z8'Y<]?K7+> \'1+C'3[9+_.NH;MQ^%*&D32N
MDJDDB'[9 ;HVPD4S@;MG?%3[B>@Z5Y^NDW,GQ!F9=4N4;9YA QT_N_2I=.;6
M-9\2:E"VJ2V]I:3@((@-S<=#[5,)WW-JF%45=2OHF=YG@$#)I<XKSK7]?D?Q
M!-ILNHW-A#;J"'M8]S.3Z^E7M%UZ]N-#O@T^/LS;([NX0KO7UQZU2G=7(EAI
M))WW.W+ <']:K6]Y;W6XP2K( <$KV->;6^N2?VG#';:U?7:W(:-A+'M"'U'%
M:?@73+F/[3<_VE.\8E9?*;&TGU/O4>U]ZQL\'RTG4DSOL^E&2,5YK'/KVIVN
MM72:O);QV,[B *HR<=F]J=)?:W;:5I^OSW[,[LJ26B#]VP)QGUJO:6:0E@Y/
MKY?A<])Z]N*;QTZ5Y]K_ (C:37Y--?4+BPA@B5RUO'N9R:2#Q'J+^&-2,$TC
M2VKA(;J:,J7SW(-/G(^J5-%?>WXGH8//0U ]W;QW*6[RJLTG*H>K5P]Q-K6C
M7&E:A<:I+/\ :W6.:W.!&"W<4WQ#ILUSXWLBFIW-OO7*[,<>PI.94,+=ZOH_
MP/0E;CD8I]00H41(RS.5&-S=34PK0X^HM%%% !1110 4444 %%%% @HHHH *
M:>M.I,<T -; -9^JV+7]FT*-M)XS6D1FD(IQ;B[HRK4HU8.G/9GG^M>#-1U+
MP_<Z;%>%#+'M'H:\XL?@MXXTV#RK'Q!]F1CEDCE*C]*^AR.*0#(YJISYG=F.
M%PD,-#DA>QX$_P *?B$BLQ\62X'_ $W:J=C\._'E])*B>*I@8^,_:&Y-?0=R
M,VS_ .[7+>&N+R\QZUK3@I0E+L<V*Q<Z6)ITEM(\H^$%_K0^)5[IFIZK<W7V
M=&1E>4LI(-?0X[U\[_"O'_"ZM:^LG\Z^B!UKG/584C#(I](10(Y/Q/X>GUFY
M@E@E",G>LK_A$M<[:G*/HU>@8]J,>U=4,7.$5$[88VI"*@K67<\__P"$2UW_
M *"DW_?5+_PB>N?]!.;_ +ZKO\4;15?7I]E]Q?\ :%7LON. _P"$2US_ *"<
MW_?5'_"):Y_T$YO^^J[_  *,4?7I]E]P?7ZG9?<>?_\ "):[_P!!.;_OJE_X
M1+7/^@I-_P!]5W^*,4?7I]E]P?7ZO9?<<!_PB6N?]!2;_OJC_A$M<_Z"<W_?
M5=_BC H^O3[+[@^OU>R^XX#_ (1+7/\ H*3?]]4?\(EKG_03F_[ZKO\ 'O1B
MCZ]/LON#Z_5[+[C@/^$3US_H)S?]]4?\(GKG_03F_P"^J[_:*-HH^O3[+[@^
MOU>R^XX#_A$M<_Z"<W_?5'_"):Y_T%)O^^J[_%&/>CZ]/LON#^T*O9?<<!_P
MB6N?]!.;_OJC_A$M<_Z"<W_?5=_CWHP*/KT^R^X/K]7LON. _P"$2US_ *"<
MW_?5'_"):Y_T%)O^^J[_ &^]&*/KT^R^X/[0J]E]QP'_  B>N?\ 03F_[ZH_
MX1+7/^@I-_WU7?XHQ[T?7I]E]P?7ZO9?<<!_PB6N?]!.;_OJC_A$M<_Z"<W_
M 'U7?[:,4?7I]E]P?7ZO9?<< ?"6N=M3F_[ZH_X1+7/^@G-_WU7?XHVT?7I]
ME]P?VA5[+[C@/^$2US_H)S?]]4?\(EKG_03F_P"^J[_ %&,T?7I]E]P?VA5[
M+[CS_P#X1/7/^@G-_P!]4O\ PB6N?]!.;_OJN_VT;11]>GV7W!]?J]E]QP'_
M  B6N?\ 04F_[ZH/A+7/^@I-_P!]5W^*,>]'UZ?9?<'U^KV7W'G_ /PB6N?]
M!2;_ +ZK/L6OK#Q7;VLUY-* V&!;@UZABO.+@?\ %P8O]ZNFA7=924TM$=F&
MKNNIJ:6B['H@)R#[5(>E-7M3J\H\,6BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "HY_P#CWD_W3_*I*CG_ ./>3_=/\J:W ^+]._Y:?A_6
MBC3O^6GX?UHK]RJ_$SS4>C_!7_DJ%Y_U[3_^AK7T;7SE\%?^2H7G_7M/_P"A
MK7T;7YIQ3_OZ_P ,?R9V4?A"BBBOES8**** "BBB@ HHHH **** $KYT\.C/
M[2=^/^FDG_H-?19ZBOG7PW_R<K??]=9/Y4#/==#TA='LY+=9-X>9I,X]3TK2
M84\"CO2Z!)N3NSFK[P[=2:_#JUA?BVD VS*R;A(OI[59TG0?[,U'4;L3ES>2
M"3;C&PXQ6UCGKQ0122L:.K)JS9S6I^&;B;4CJ&FWJVEQ(,3%HPP<"FS>&;O4
MM"FL-5U 3N[ADDCCV;<=..]=.5&/6@#BA120>VJ.WD<9%X/U":[M9]1U43?9
MGS&J1! 1[^M7])\/WVDZG<21:B&L96+_ &<IR"?>NC"C-1/<0QS+"\B!W^ZI
M;DTG&*U9?UBK-<KV,.P\-?8K'4[3[26^W2-)DC[F:9<^%OM7AR#2?M;*(F5C
M)CDX.:Z/CGCK2XROI3<5N3[>;W9S>I>&[F34%U#3+Y;2Y*".0O'O#J.G%.;P
M_?WNB36.HZDLTDC B5(@F #TQ71'GCO2]A3L@=6>COL8.J^'1J<&GQ&X*?8Y
M5D!(SNVTS7/#\^I7UK?6=[]DNK<\.4W CTQ718SUS28^:IE%-"]K(CA61(U$
MC!I  &8#&34U)CN*=5F8"BBB@ HHHH **** "BBB@04444 %%%% !1110 TB
MC'O2GI1F@""X&+>3Z5RWAK_C\O/K74W!S#)CT-<IX<EC2[O"\B+R>K"NFE)1
MI3NSP\;!RQM#E7<\G^%?_):=:^LG\Z^B1UKYX^%ZM#\9M9>0%$/F,"PP",]:
M^@OM$0"L94 ;[ISU^E<O-&VY[S33)LTM5Y+N"(XDF13Z$TB7EO(<1S(Q] U1
M[2.UPY7:]BQ147VB+#'S4(7[WS#CZTC7,"H',R!3T);@U7,NXK/L3456^W6V
M['VB+_OH5+YR;@OF+N/09Y-)3B]F%FNA)WHJ'[3$=V)4.W[V#TI@O[7'_'S%
M_P!]"DYP75#L^Q9Q1BH?M4.P/YR;3_%GBE\Z/<%\Q=QZ#/--2B^HM26BJ[7M
MLK$-/&".N6'%.2YADSLF1L=<'I1S1VN-I]B:BH?M$.S>94V=-VX8I'NH(OOS
M(OU-'-%=1)-]">BJPO+=W"K/&6/0!ADU()HR642*2O49Z?6A2B^H6:W1+14'
MVF$)O,R;/[V[BF_;[7I]HB_[Z%#G%=1V;Z%C%%1^?%D#S%RW3GK1Y\98J)%)
M7J,]*.:/<5F2T56^W6^?^/B+_OH4_P"U0F(R"9"@ZMNXI*4>C"S[$V**B,\0
M*@R+EA\O/7Z4Q[RWC;:\Z*WH6%-RBMV.SZ(L45 EW!(=J3QL?0-3OM$6POYL
M>P<%MPP*.:+ZBL^I+14+W,,:@O*B@]"3UI@O;9C@7$9/IN%+G@MV%GV+-%1"
M:(OL$B[\9VYYH^T1;2WFIM!P3D8%/F069+15;[?:_P#/Q%_WT*?]HB"JWFIA
MNAR.:%.+ZCL^Q-14?GQ[]A==_7;GG%1F]M@2#<1 C_:%)S@MV%GV)S7G%P3_
M ,+!B'^U_2O0EN89%+),C =2&S7GD[*WQ A8,"I;KFO1P,D^?7H>EEZ:]IZ'
MHZ]:=35ZTZN(\L!2T@I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *CG_ ./>3_=/\JDJ.?\ X]Y/]T_RIK<#XOT[_EI^']:*-._Y:?A_6BOW
M*K\3/-1Z/\%?^2H7G_7M/_Z&M?1M?.7P5_Y*A>?]>T__ *&M?1M?FG%/^_K_
M  Q_)G91^$****^7-@HHHH **** "BBB@ HHHH #VKYT\-_\G*WW_763^5?1
M9KYT\-_\G*WW_763^5 'T71110 F*#2T4 ,QUHQ2TA) R!F@0=*\^\4@?\+&
MT')/?'-=\6'0D9'.*\_\4M_Q</0F[8(XK"O;E/1P,;U7?L_R/0L#.>]+GG%)
MG(SD4 C\JV21Y[N. I2*.U+3 *,444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 TGM28P#FE/6F$\X/2EU CG"B!B3QM-<1I6CV>H7-T+A6)1
MCM(.*[>Z&;9Q[5RWAKY;N\'N:T5"G5IR<D>1BL14I8RE"#LG<\O\ WDVK?%O
M4K6\*F.&-X4"C'R@U[:^C6DD-M$5;R[<Y3FO"OA;S\:-;^K_ ,Z^A@,5S^SB
MM$CVY5)R?O,R+_PW8:A<_:)U<OC'#8%)8^&]/T^<3PHX<#'+9K9I.I]JS^KT
MD[V#VL^6US/31[,1W"*C8G.9.>M1W.@6-U9QVDBL8HON@-TK5Q^%&*T=.#6P
ME.2ZG.KX/TM9 X63(.>6-:9TRU-U'=E6,L8VJ2>@K0-)MS4PHPBMARJ3ENS-
M31;1!<;58>><OS6?_P (;I()PLF#U^<UT6!FC@4.A3EK8%4FNIE#0++[$EGM
M<PH0R_-S4[:;;&\CNBI\Q%VJ<]JO$4 8'/--4H+1(ESD^I@7'A/3;FXDG=9-
M\ARV&/-6K+0;+3Q(MNC#S1ALMGBM3(S1G&>*E4(*5TBW6DU:YFG0K(V*V>QO
M)5MV,]ZCOO#UAJ)4SJ^5&  V*U0PR,]:4-5>R@UJB54DGHS$M_"NFVUTEQ&L
MGF)TRU74TJUCN+F<!M]P-K\]J;?ZYI6F.L=_J-M;2/\ =620 FKL<T<D:R1.
MLB,,AE.0?QI0HTX_"ARG*6[,TZ#8M8?82K^3G.,U2/@O2CGY9?\ OLULWNHV
M6G0F:^NH;:,?Q2N%'ZTECJ=CJD'GV%W#<Q_WHG#8_*E+#TWN@56:V9$^DVDL
MEM(RL6M_N?-0-(MENIYU5@\XPYS3=2UK2](C#:CJ-M; X_UC@'\JG74+$V0O
M%O(/LI&1-Y@V?G5^SA:UB>:5[W,IO!VE%R^V3).3\YJU%X?L8=/>Q57,#G)!
M:I=/US2]6,@L+^WN6C.&$;@D?A27^NZ5I)4:AJ-M;,WW5DD )_"H6'IIWL4Z
MTWHV*^DVLC6S%6S;?ZLYZ"JMYX8T^^N&N)5?S&ZD,16I!<Q7,"SV\B2PMRKQ
MMD$5..1TIRH0ENA1G..J9CV/AVPTZ=I;=7WE=IRV>*E&AV*V4UJ4;R9FW.-W
M4UID>E)@'K1&E".R!SD]V95[X?LKZ&*&8/MB7:N&QQ5:+PAI<4B.JR;D.0=Y
MK?P/6@8'%2\-2;YK:C56:5KE :9;+?&\PWFE-F<]JC31;);26T",(YB689[F
MM3 HP*T]G'L3S2O>YS9\&:62HVR?*,??-:#:'9M;6]N58I;ME!GH:TQBEP"*
MB%"$=;%2JSEHV9[:5;M?&\VMYVW9UXQ6=)X1TR61I&63<YR?G-;Y7'-+1.A3
MGHT-59QV9DV>@65C%)# K^7+]\%JXJ2UA@\=06J#$0.0,\UZ5P/QKSNX'_%P
MH_\ >_I7H8&E!<R2Z'H8&;;G?^5GHB8&<4[-(HI:Y;6/+'44450@HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "HY_\ CWD_W3_*I*CG_P"/>3_=
M/\J:W ^+]._Y:?A_6BC3O^6GX?UHK]RJ_$SS4>C_  5_Y*A>?]>T_P#Z&M?1
MM?.7P5_Y*A>?]>T__H:U]&U^:<4_[^O\,?R9V4?A"BBBOES8**** "BBB@ H
MHI.] "T9I#THH 4U\Y^&_P#DY6^_ZZR?^@U]%U\Z^&_^3E;[_KK)_P"@T ?1
M=% Z44 %%%% "8IK$@'%/J-N: .,^(,%\VCK=Z?<S0/;ME_+/5>]>3MJ-W-<
M)/)>RO*G^JD8Y85]"7-LES;O!( 4=2I!KP#6M-ETG6KFP(^99/D..&!Z 5Y>
M.A*R<3[#AZM1<94JBU_0[#X>KJVI:R]U<ZE=26]N-NUCPYKU4<]JP?".C#1?
M#T$!7$C#>_U-= !QFNR@I*FN8^>S&M&MB)."LEHAV:6D%+70< 4444 %%%%
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 %1S_ /'O)_NG^525'/\
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M3_"DW?'//WI./9*3BGN:TZLJ3YH/4^@ .!["G#)%?/Q/QS!QN?\ )*,_'/\
MO2?]\I_A3V,CZ#I:^>\_'/\ OR?]\I_A1_Q?/^_)^2?X4 ?0E%?/?_%\_P"_
M)^2?X4?\7S_OR?DG^% 'T)17SW_Q?/\ OR?DG^%'_%\_[\GY)_A0!]"45\]_
M\7S_ +\GY)_A1_Q?/^_)^2?X4 ?0E%?/?_%\_P"_)^2?X49^.?\ ?D_)/\*
M/H.E%?/+2?')%9F>0!02?E3_  K"T/QG\5_$=_<6FEW\DT]O_K5V*-O;TH ^
MHZ*^>\_'/^_)^2?X4?\ %\_[\GY)_A0!]"45\]_\7S_OR?DG^%'_ !?/^_)^
M2?X4 ?0E%?/?_%\_[\GY)_A1_P 7S_OR?DG^% 'T)17SW_Q?/^_)^2?X4?\
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M/CC2KR32KC3] TIO-Q=KAII/85Z^/ITH 6BBB@ HHHH **** "BBB@ HHHH
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M&,8XHW<T;AG% !BEI V:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP?*,]6_*NS\#^'O$/A\7<>MZX=3CE(:+<.4/\7X4 =7-.EO"TTKJD:*6=B>
M*\PN/BOJ&M:E+8^#?#\NI")MK73G$6?K6A\:M3ET[X<7@BW*URPB+*>@K7^&
MFEVND^ -)CMHD0RP"64K_&QZF@#E5^*>L>'K^WL_&_A]K!)V 6[A.^-0?4^M
M>H6\\5Q D\#K)%( R.AR&!Z$53U[0--\2:4^FZK;B:VD()7H0?4'M7$^-_$/
M_"N?#6EZ%X>@47=TPM[/S3E8QGJ<_6@#TKM6%XOU\^&?#%YJXA\XVZY$>>M>
M=R^$_&5K8MJT7CP2:PB>8ULQ7R2>ZU%?^,)/&GP-U:]N(UCNX 8;A5Z%AW'U
MH W=6^)TFF^!='\1+IVYM1F6(Q%ON9[UZ-"_FP1R8QN4-CZBOGOQ5_R1#P>/
M^GN+^M?0-G_QY0?]<U_E0!S'Q#\8OX)\.KJB6HN"TRQ[2<8SWK=T>^;4]&M;
M\Q^6T\8?;Z9KSOX^G_BWR<XS=)_.JOC3Q#J?ASX4Z%?:;<^5,!&",??XZ4 >
MNJ<BLKQ)JESHV@75_9V3WD\*Y6!!DM]*\T?PMX^U?0%UZ?Q8\&HF+SXK.) (
M@,9 )]<4NE^/-:U;X.:KJ\DB1:K8LT)G3HQ!ZXH ](\,ZO<ZWH%KJ%W9/93R
MC+02#E36QGVKR5OB%?Z'\(-.UNX(NM5NR(HF88&\]S[5##X4\9WEB-5G\>+#
MJ[KO6V0KY*GJ%H ]@S1FO+/"_P 3KBX\&:Y>ZQ$C:EH99)_+(VRD< BLO0M$
M\;^/]*37[WQ1+I<5QE[2VME& O;=0!ZWJ-]%I>G7-]<$B"!"[X&3@5B:%XMB
M\0^$Y]>L;63RPKF*,_>DVC^M<#(_C75/ ?B#2_$4DMA-8*S)J"H-MU&.JD>_
MK4'PGL=3T_X<76M+J\C6_P!FE:*SV_+&P!PV: /3/!FNWOB/PY#J5_ITEA<.
M[*8'!! !X//K709.*\>T+XC7VE_!:/Q)JDC7NH23/##N_B;.%S]*=I?A#QYX
MATR/6M1\6SV-_*OFPVL48V(#R U 'K^ZC->3^"_'.M7\6O>'-=,:ZYID3LLZ
M\"0 =?PK!\$'QQ\1=)F:;Q(VG:=;R-$'@0&25L^OI0![MFEKR3P/KWB/2/B%
M=^"-<NUU!$A,UO<D88*.F?J*]:!R* %HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH&%%%% !1110 4444 %,F_U$G^Z?Y4^F3?ZB3_ '3_ "IK<#XNT[_E
MI^']:*-._P"6GX?UHK]RJ_$SS$>C_!7_ )*A>?\ 7M/_ .AK7T;7SE\%?^2H
M7G_7M/\ ^AK7T;7YIQ3_ +^O\,?R9V4/A"BBBOES<**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@04444 %%%% !1110 4444 %%%% "&O#?C3=P6
M7CSPG<W+[((F+.Y[#->Y&LO5?#VD:W(C:GI\%T8QA3*N<4 <Y/\ %KP3;I\^
MMPG '"@DUP-E<7'Q4^*MAJ]K;.FA:0?DF=2/-_R:]1B\">%(V+IH%CN_ZY U
MMVMI;64"PVEO'!$O2.-0H_*@#PWQ'J$GB?XL7?ASQ/K-QI&BPC%O"C^6)O0E
MO>N?^)&G^"-$TBSL/#\[7M^+E7EN?-,H1/0MTKZ USPIH7B-0-6TV&Y8# =E
M^8#TS4=KX+\-V>FG3X-&M%MF'S+Y8.?J: .?\9:#'XM^%/V>W(,BVJ3P,HSR
MHSQ]:\W\':A<?$KQCX=@O+9HH?#]M^^##*R..!GWKTSQCXMD\$V5M9:;H=Q=
MF6,I;"%<JK=@?:H?A1X5N_#^AW-]J<7EZGJDQN)TQ_J\]!0!2^(NM^&(]=T_
M0_%FBF2PN%W1Z@WW8W]!CFO/?%^C:'X+CM-1\$^);@ZE),$CM8I_,#*>V!7T
M#J6D:?K%MY&HV4%U&.0LJYQ]*Q])\!^%]%O!/8Z/!',#N$A7=M/MF@#9TJ2Y
METNTDO$V7+1*91[XKR;X_E/[/T(,1S=C@^F17LW0^N:H:GI&G:ND:ZA917*Q
MMN0.N=IH K6GA_1?LL$BZ7:9,:G/E#GBM'[-%' \4,21*RD810!TQ4RJ%4 #
M"@8 ':FDCTZT >(_#36K;P-XJUOPIKLBV;2W#36\\WRK)[9/%3?%;7K3QA=Z
M7X/T!UOKN2Z2666$[DB ]2*]2UCPUH_B&(+JNG07>.%,B#<![&C1?"^B>'AC
M2]-@MSC!=%^;Z9H \W\2:CX1U/Q6OA;QCI'V66&!4MM2D;:)..H;L/K7)ZC9
M6W@GQAHT7@3Q!<7]S<RA9[02^8I3/<CC%>\ZOX=T?7HC'JFGP70(QF1,D#V-
M5=&\(>'O#[[]+TJW@E QY@7YA^- 'FWC+4[72/CEX:O]3D6WA6S/F2-PJD@]
M_K7L-M<0WEM'<6\JR0R+N1U/!!JAK'AW2-?B5-5T^"ZV]#(F2OT-7;2VALK6
M*UMXQ'#$NV-1T H L#TKQ/X5NK?%7QAAAS,V/?YJ]KZ<]ZH66AZ9I]W/=VEE
M%#<3G=)(JX9C0!P'QSM9Y_ @FA0R);7"R2 =@#5VW^)'AFV\ V]\-2B=OLPC
M6W1LR%]N-NWK7>7$$-Q"T,T2R1./F1ER#6!;> ?"MKJ;ZA!HEJ+ENY3@?0=J
M /&?!<_G?!7QG,,+ON'?#=L\UZC\)-I^&&EE3QY;5TT'A[2+:QN+*'3H([6X
M8M+$J !R>N:M65A;:=:I:6<"0VZC C08 H \G^!Q#7/BM 1_R$&_F:>Q!_:7
M*Y!/]F8^GRUZA8:-IVE-*;"SBMO-;?(8QC<?4TAT;3SJXU4VD1U#9L%QM^;;
MZ9H \A^&^MVO@?Q1K_AGQ PL9KF[-Q!+(<(X/8&D^*NO6GB^_P!(\):#,E[<
M-<K),\/SK&H/J*]7UCPQHOB%=NJZ;!<D#:KLOS ?6C1?"^B>'UQI6FV]L<8+
MHGS'\: /,-=06_QW\(6[/EH;0(<'@$#%>S8X-49=&TZ?4H]2ELHFO8AA)ROS
M ?6KN3W/)H YGX@^'9/%/@O4-+@VBX9-T);IN'.*XKX;_$G3++1X/#?B&0:9
MJ=@/(VS @.HZ'->N>_\ *L36/"/A_72S:EI5M/(>KE &_.@#AOB%\4K.'3&T
MCPM=->ZY=82(V@W>7[US/Q-T/6/^$6\*:GKT<MW]B8?VFT9RR*<9Z?SKUW1O
M"'A_P^P?2]*MH'ZB0+E@?K6Q-##/#)#-$LL;C#(PR&'IB@#Q>;1OA-'H#:V-
M2D,#+D1K=GS"?[NW.<U$1I1^!VNW>DZ/<:7:SD[4G;)D Z,*])7X<^$1J'VX
M:':B7'W=OR_E703Z=9W5B;">VC:U9=IAV_+CTQ0!X#XJ96^"/@\CI]KC_K7T
M':?\>4'_ %S7^54)_#NCW.GP:?-I\#VD#!HH=ORH1T(K44!5  P!QB@#ROX_
M$#X?)GO=)6#\3BH^#_AP%@?FAY_*O9]2TJPU>V%OJ%K'<PA@P209&?6H;O0M
M+OK**SN;&&:VA(*1,/E7'3B@"&U(_P"$3B.>ECU_X!7B'A90WP'\4C@YNI>?
MRKZ"\E(X1$J 1!=H0#C'I7D_Q+U"UT?1+OP?H>@7#7>HJ'3[/%^[R3SD^M '
M*^(='N=4^ WAZYMXI)ULG#S+'R=G<UK6.C_"B[\/KK+:@\:)%F2)KLAPV.1M
MSG->E^!=&ET?P/INFWR RK !(A'3/8U%/\./"-UJ"WTFAVIF4]EPI^HH \RT
MO1]+\1?#/Q,OA;1+RS63F*2=LFYQZ5U'PT\<^'U\"6EE>:C#:7>G1>7<0SML
M92/0'K7I5O;06END%O"D42#"I&,*/PKGM1\ >%M5NUN[S1;5YE;=N"XR??'6
M@#CK?QQ>^.=$\6"UL"-(M[=TMI]I)F//2L[X9:YIL_PEOM+CNH_[0BMY]]NW
M##Y3VKUZRT^ST^S6TL[6*"V'2*-0%]^*S;;PCH%G?3WEKI5O%/.A61D3&X'K
M0!X?::1>:Q^SC:BPC,TMI>M<-&HR2JL<UZGX9^)/AG4/"L-]+J4%JUO"%GAF
M<*Z%1SQWKK+#3;+2;);.PM8[>V&2$0<9/6L2X^'WA2\OENY]#M#.IR<)@'ZB
M@#S'PG++XE\6^+?&21-'IAM'@@9EQY@QUKHO@*0? L^#D"[<#\Z]*ALK2VLQ
M:0VL<=O@KY2* N._%,T_2['2H##I]I';0LQ8I&,#/K0!Y=:LH_:8NAZZ=_2O
M7Q6>-&T\:P=5%I&+YEV&?'S%?3-:(&* "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@84444 %%%% !1110 4R;_42?[I_E3Z9-_J)/]T_RIK<#XNT[_EI
M^']:*-._Y:?A_6BOW*K\3/,1MZ3XBU7P#XPO;NWM8?MBF2!XKM&P 6!/ (.>
M!WKK/^%_>*O^@?HW_?F7_P".445R+ 83&PA7KTDY.*[]EYE<\HNR8?\ "_O%
M7_0/T;_OS+_\<H_X7]XJ_P"@?HW_ 'YE_P#CE%%+^P\M_P"?,?Q_S#VL^X?\
M+^\5?] _1O\ OS+_ /'*/^%_>*O^@?HW_?F7_P".444?V'EO_/F/X_YA[6?<
M/^%_>*O^@?HW_?F7_P".4?\ "_O%7_0/T;_OS+_\<HHH_L/+?^?,?Q_S#VL^
MX?\ "_O%7_0/T;_OS+_\<H_X7]XJ_P"@?HW_ 'YE_P#CE%%']AY;_P ^8_C_
M )A[6?</^%_>*O\ H'Z-_P!^9?\ XY1_PO[Q5_T#]&_[\R__ !RBBC^P\M_Y
M\Q_'_,/:S[A_PO[Q5_T#]&_[\R__ !RC_A?WBK_H'Z-_WYE_^.444?V'EO\
MSYC^/^8>UGW#_A?WBK_H'Z-_WYE_^.4?\+^\5?\ 0/T;_OS+_P#'***/[#RW
M_GS'\?\ ,/:S[A_PO[Q5_P! _1O^_,O_ ,<H_P"%_>*O^@?HW_?F7_XY111_
M8>6_\^8_C_F'M9]P_P"%_>*O^@?HW_?F7_XY1_PO[Q5_T#]&_P"_,O\ \<HH
MH_L/+?\ GS'\?\P]I/N'_"_O%7_0/T;_ +\R_P#QRC_A?WBK_H'Z-_WYE_\
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M\5?] _1O^_,O_P <I?\ A?WBK_H'Z-_WYE_^.444?V'EO_/F/X_YA[2?</\
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M\Q_'_,/:3[A_PO[Q5_T#]&_[\R__ !RC_A?WBK_H'Z-_WYE_^.444?V'EO\
MSYC^/^8>TGW#_A?WBK_H'Z-_WYE_^.4?\+^\5?\ 0/T;_OS+_P#'***/[#RW
M_GS'\?\ ,/:S[A_PO[Q5_P! _1O^_,O_ ,<H_P"%_>*O^@?HW_?F7_XY111_
M8>6_\^8_C_F'M9]P_P"%_>*O^@?HW_?F7_XY1_PO[Q5_T#]&_P"_,O\ \<HH
MH_L/+?\ GS'\?\P]K/N'_"_O%7_0/T;_ +\R_P#QRC_A?WBK_H'Z-_WYE_\
MCE%%']AY;_SYC^/^8>UGW#_A?WBK_H'Z-_WYE_\ CE'_  O[Q5_T#]&_[\R_
M_'***/[#RW_GS'\?\P]K/N'_  O[Q5_T#]&_[\R__'*:WQ\\5.C*;#1L$8_U
M,O\ \<HHH_L/+?\ GS'\?\P]K/N<3X=T/5-76X;3M/N;I8RH<PQE@I.>N***
6*^=S3/ZN%Q<Z,8)I>O9&T*2E%,__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img_019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_019.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (9 V4# 2(  A$! Q$!_\0
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M[[_;6E_]!*T_[_+_ (T?VWI7_02M/^_R_P"-'^LV9?RQ_P# 0]E3[_B>!?\
M"EO'/_/]9_\ @6__ ,31_P *6\<_\_UG_P"!;_\ Q->^_P!M:5_T$K3_ +_+
M_C1_;6E?]!*T_P"_R_XT?ZS9E_+'_P !#V5/O^)X%_PI;QS_ ,_UG_X%O_\
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ML_\ P+?_ .)KWW^V]*_Z"5I_W^7_ !H_MO2O^@E:?]_E_P :/]9<R_EC_P"
MA[*GW_$\#_X4MXY_Y_K/_P "W_\ B:/^%+>.?^?ZS_\  M__ (FO?/[;TO\
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M5_Z"EG_WPU>XX%+Q1_;F-_F7W(/JU,\,_P"%'ZJ#_P A6S_[X:C_ (4?JO\
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M *"EG_WPU ^!^K9S_:EI_P!\-7N?%)@4?VYC?YE]R#ZM3/#?^%'ZK_T%+/\
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MO_04M/\ OAJ]RP*,"C^W,;_,ON0?5J9X:/@AJW_04M/^^&I?^%(:K_T%+/\
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M?]>T_P#Z&M?1M?FG%/\ OZ_PQ_)G90^$****^7-PHHHH **** "BBB@!DO\
MJG_W37@_P!_Y&;Q;_P!=!_Z&U>\2_P"J?_=->$? '_D9_%G_ %T'_H;4 >\B
MEI!TI: "BBB@ HHHH *2EI#TH Q_$O\ R+]W_NU\M^+?^2I67_7:#^8KZD\2
M_P#( N_]VOEOQ;_R5*R_Z[0?S%>?_P QJ_P_J>6_^1@O\+_,^C?B5_R(E]_P
M'^=8OP=_Y %__P!?/]*VOB5_R(E]_P !_G6-\'?^0!?_ /7S_2MW_&7H?:TO
M^1/4_P :/2!TI:0=*6ND^>"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK11IW_+3\/ZT5^Y5?B9YB/1_@M_R5"\_Z]I__0UKZ-KYQ^"__)3[S_KVG_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MTAZT <!\:/\ DEFK_P#;/_T,5Y3\'/\ D&G_ *_5_E7JWQH_Y)9J_P#VS_\
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M",E:%N#V/8-[=*D7IDUR.NZM>:!XBTNYFF#:1>M]EF1O^64I^ZP/H:ZU<T;
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M?PUIVMR:<UT)%_LZ830+$VT!ATS[4>87Z'(^-]*L+?Q?X-FAM(HG6\:,>6@
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M&_F* +_@B]N-1\$Z+>W<IEN)[5'DD/5B1UKH*YCX=?\ ).?#_P#UY1_RKIZ
M"BBB@ HHHH **** "BBB@ HHH- !12#K2T %%%% !3)$#*590P(P01D&GT4
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MW3CL:^91LSOP<# [4X=::M/Q2&%%%%, HHHH 9+_ *I_]TUX1\ ?^1G\6?\
M70?^AM7N\O\ JG_W37A'P!_Y&;Q9_P!=!_Z&U 'O(Z4M(.E+0 4444 %%%%
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M%G#7HN<C@5$MI EPUPD$0F<8:0*-S#W-/K<5NA9'2BBB@85Y9\2O^2C> /\
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MK:6.CQ:3J5C*8KF 1A25S\K<=0:\F/BTV'C/PK=ZCHVI6[:'9-:74:P%LOC
MVXZ@UW_PVL=2U+Q1K_C*^L)+"+5-J6\$OW]B_P 1':OFS5GIZGT[TX]*:O\
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M\JH:AXJT/2[1KJ\U2W$2\$K(&//L*\RU'X-ZQJ&J7=W)J]L_G2M(#(K%@">
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MNCRR*UNA#R_?/'5O>N&^(=A>:WXQ\/:);:O>:;'<+*SR6KX.0,BG2Z-XYO\
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MI] !1110 4444 ,E_P!4_P#NFO"/@#_R,_BS_KH/_0VKW>7_ %3_ .Z:\(^
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M "BBB@ HHHH **** "BBB@ KSGXW_P#)+-1_ZZ1?^A"O1J\Y^.'_ "2S4?\
MKI%_Z$* /,/!7_)#=3_[":_R%=/H/_(C6O\ U^2_RKE_!7_)#M3_ .PFO\A7
M4:!_R(UM_P!?DO\ *O$S-:-^7ZG9FO\ R357_$CU?P[_ ,@2U/\ L"M<5D>'
M?^0%:?\ 7,5KBO5H?PH^B/*PG\"'HOR"BBBMCI"BBB@ HHHH **** "BBB@
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M!#T7Y!1116QTA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD/HS3=U(36IT#\T4P49H&/S29IO>E!YH =1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MDS[49]J %HI,^U&?:@!:*3/M1GVH 6BDS[49]J %HI,^U&?:@!:*3/M1GVH
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MT_\ Q-'_  T3+_T*EQ_W]/\ \37N'V.V_P"?>+_O@4?8[;_GWB_[X% 'A_\
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MWB_[X% 'A_\ PT3+_P!"I<?]_3_A1_PT5+_T*EQ_W]/_ ,37N'V.V_Y]XO\
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M+_O@4?8[;_GWB_[X% 'A_P#PT3+_ -"I<?\ ?T__ !-'_#1,O_0J7'_?T_\
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M/^_I_P#B:/\ AHF7_H5+C_OZ?_B:]P^QVW_/O%_WP*/L=M_S[Q?]\"@#P_\
MX:)E_P"A4N/^_I_^)H_X:)E_Z%2X_P"_I_\ B:]P^QVW_/O%_P!\"C[';?\
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M/_Q-'_#1,O\ T*EQ_P!_3_\ $U[A]DMA_P N\7_? H^R6W_/O#_WP* /#_\
MAHJ7_H5+C_OZ?_B:8?VCBKA&\,3!ST4S<G\,5[G]DML?\>\/_? KA-?^&<6M
M^/M-\3B^6 66S_1A""'VDGK[YH XK_AHF;_H4[C_ +^G_P")H_X:)E_Z%2X_
M[^G_ .)KW#[+;][>'_O@4?9+;_GWB_[X% 'A_P#PT3+_ -"I<?\ ?T__ !-'
M_#1,O_0J7'_?T_\ Q->X?9;;_GWB_P"^!1]CMO\ GWB_[X% 'A__  T3+_T*
MEQ_W]/\ \31_PT3+_P!"I<?]_3_\37N'V.V_Y]XO^^!1]CMO^?>+_O@4 >'_
M /#1,O\ T*EQ_P!_3_\ $T?\-$R_]"I<?]_3_P#$U[A]CMO^?>+_ +X%'V.V
M_P"?>+_O@4 >'_\ #1,O_0J7'_?T_P#Q-'_#1,O_ $*EQ_W]/_Q->X?9+;_G
MWB_[X%'V6V_Y]XO^^!0!X=_PT3*?^93N/^_I_P#B:[#X<_%$>/\ 4KZS&EFR
M-K$'+&3=G)QCI7H!M;<#_CWB_P"^!7#>"/ALO@WQ%J^K+J1N?[0S^[\K;LRV
MZ@#T$=*9-_J)/]T_RIPZ4R?_ %$G^Z?Y4UN!\7Z=_P M/P_K11IW_+3\/ZT5
M^Y5?B9YB/1_@K_R5"\_Z]I__ $-:^C:^<O@K_P E0O/^O:?_ -#6OHVOS3BG
M_?U_AC^3.RA\(4445\N;A1110 4444 (::1P<4XTAZ4@*E]?6NFV4MY?3I!;
M1+EY'. !65H7C/P[XEE>'1]5ANY8QED7(./7!KF?B>G]IZCX8\/R@M9W][FX
M0'&]5&<53\9:+IOA;Q#X7U?1K*&RF%X+67R%V[XFXP1WI(#U)3D4,,BA>II&
M/%4)%>YG6UMIIVZ1H7..I %>=^ /&%WKWB'5(+N3,<A\RWW'!5>@ %6OB?XB
M_LW1ETV%L75WQ\IP53N17D.D:I+HNK6NHPOM:!\GC.5[C\17)6K<LTCZK+,G
M^L8&I5:U>WR/I]?N^]/%5K*Y2]LH;E 0LJ!P#U&15D5UGRS33LQ:*** "JU]
M>VVGVLEU=SQP6\0W/([8"BK-<YXO\*V_BZQMK"\N9HK1)UEEBC_Y; ?PGVI,
M!FB>./#7B.]>TTG5X+J=%R8E)!(]1GK4VO\ C#0/"[0IK6I16C3 F,,"=P'T
MK@O%.CZ$WC/PYI?AFTAM]:MIQ-*]FH'DP#KYA'K[U6\82ZG=?$ZZ%EX3_MUK
M>Q6.);A<0H2<DY/&:!(])T'Q7H?BA)I-%U".\6$XDV C;GIUK;4\5P7P[UZR
MOS?Z;_8,&AZO9L/MEI$@4'/0@CJ*[Q*87%:C-*1FC'- Q,>M+1MHQ0 HI#TI
M:* &$9ZUB:]XGT7PO''-K6H1VB2G;'O!.X_05N8KR3XA2ZA<?$/3(+/PVVM_
M9K.1E@D7$.]CP6)XXJ7<+7W.[T#QGX>\3S2PZ+J<5W)" SJ@(*CUY%07WC[P
MKI>K'3+W6[:&\R 8B3P3ZGH*Y7PEXD@@;6=.N_#-OH'B"UM6N&B@0;9$ X((
MZU7\%>#=%USX<RWNI:?!=7VI"6:6XE7+[CG&#VQ38=+GJD;K*HD1@Z,,JP.0
M1V(J9>E</\*KR>Z\!6:7#EY+:22WS_LJV!^E=P#3:$A:***!A1110 4444 ,
M<A49B< #)-<4_P 6/ T4K(_B" .A*D%6Z_E7;,,J01D>E>;?$*TT30M$5-/\
M/Z;)K&HR_9K16MU.7;JWOCK2Z@=;IOBW0=8TF?5+#48IK&WSYLXR F/6LFV^
M*7@J\NH[:WUZW>:5@B*%898].U<_XBT!?!7P;GTC3;66:>1528PQY:1V/S'
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M/:! OE2#J.*ZQ1CBJ8D.HHHH&%%%% "$ CFF9^F:<PR,5D>(+&_U+2VM=-U
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M*[!"M'DG!/8D<5T<Z-+!+$LAC9U*AQU4D=17F6K^$_!?@OP/>)J\$5[-/O\
MW\R@SW$S= O?.?2@#TF>^M+>P>]EN(TMD3S&E9OE"^N:QM"\;^&_$=T]OI&K
MV]U<(,F-<@X]<'K7FNJ:=?6_P^\'>&M1:4+?WBI<1L?F\O[P0_RK9\=^']+\
M,W'A[6]%LK>QNK>_C@)A3;OC8X(('6I\V!W&O>+="\,I&=8U.&T\S[@?))_
M5;LM6L=9TG[;IUU'<VTB$K)&<CI7GVCZ58^*/BEXEO-7M(KL:>$M;:.9=RJ,
M9)P:?X-M(M!\<>*]"LT$6G[%N8H5^ZA;K@=JJ.DDA/0^>]._Y:?A_6BC3O\
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MV.FSCI1NYI@/S'G\*$93G# _0YJT<VH_-.S3.*7/% #J3BDS1F@8ZBD'2EH
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M3O\ EI^']:*-._Y:?A_6BOW*K\3/,1Z/\%?^2H7G_7M/_P"AK7T;7SE\%?\
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M &F"X;)A^TQ;!,!_=]:\]U2VANO!/PSM[B,26\EVBM&PSD>AKI_B#!#'X_\
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M-V>E+FFBG"@8M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %,F_P!1)_NG^5/IDW^HD_W3_*FMP/B[3O\ EI^']:*-._Y:?A_6BOW*
MK\3/,1T/A/Q:? _C*[U-K W;;98#"9?*QE@<YVGTZ8KT+_AHG_J5O_*A_P#:
MJ\V^(W_)0M<_Z^FKEZ\^>58+'QAB*].\G%=7V\GYE\\H:)GN/_#1/_4K?^5#
M_P"U4?\ #1/_ %*W_E0_^U5X=16?^K>6?\^OQE_F'MI]SW'_ (:)_P"I6_\
M*A_]JH_X:)_ZE;_RH?\ VJO#J*/]6\L_Y]?C+_,/;3[GN/\ PT3_ -2M_P"5
M#_[51_PT3_U*W_E0_P#M5>'44?ZMY9_SZ_&7^8>VGW/<?^&B?^I6_P#*A_\
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M?7XR_P P]M/N>X_\-$_]2M_Y4/\ [51_PT3_ -2M_P"5#_[57AU%'^K>6?\
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M_AHG_J5O_*A_]JH_X:)_ZE;_ ,J'_P!JKPZBC_5O+/\ GU^,O\P]M/N>X_\
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M -JKPZBC_5O+/^?7XR_S#VT^Y[C_ ,-$_P#4K?\ E0_^U4?\-$_]2M_Y4/\
M[57AU%'^K>6?\^OQE_F'MI]SW'_AHG_J5O\ RH?_ &JC_AHG_J5O_*A_]JKP
MZBC_ %;RS_GU^,O\P]M/N>X_\-$_]2M_Y4/_ +51_P -$_\ 4K?^5#_[57AU
M%'^K>6?\^OQE_F'MI]SW'_AHG_J5O_*A_P#:J/\ AHG_ *E;_P J'_VJO#J*
M/]6\L_Y]?C+_ ##VT^Y[C_PT3_U*W_E0_P#M5-?]H;?&R_\ "+XW C/]H?\
MVNO$**?^K>6?\^OQE_F'MI]S1TN*27S?+C9\8SM&<=:*]B^ 7_(,UO\ Z[1?
9R:BO)S+B!X7%3H^SO;K?R7D:0I<T;W/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img_020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_020.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '? V4# 2(  A$! Q$!_\0
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M ,*5\<_\_P!9_P#@6_\ \37T8.E+3_UIQ_:/_@*_S#V$3YR_X4KXY_Y_K/\
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MC$^=/^%+^.?^?VS_ / M_P#XFC_A2_CG_G]L_P#P+?\ ^)KZ+HH_UJQ_:/\
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M_P"%+^.?^?VS_P# M_\ XFC_ (4OXY_Y_;/_ ,"W_P#B:^BZ/SH_UJQ_:/\
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M%+^.?^?VS_\  M__ (FOHOFBC_6K']H_^ K_ ##V,3YT_P"%+^.?^?VS_P#
MM_\ XFC_ (4OXY_Y_;/_ ,"W_P#B:^B^:*/]:L?VC_X"O\P]C$^=/^%+^.?^
M?VS_ / M_P#XFC_A2_CG_G]L_P#P+?\ ^)KZ+YHH_P!:L?VC_P" K_,/8Q/G
M3_A2_CG_ )_;/_P+?_XFC_A2_CG_ )_;/_P+?_XFOHOFC\Z/]:L?VC_X"O\
M,/8Q/G3_ (4OXY_Y_;/_ ,"W_P#B:/\ A2_CG_G]L_\ P+?_ .)KZ+_.BC_6
MK']H_P#@*_S#V,3YT_X4OXY_Y_;/_P "W_\ B:/^%+^.?^?VS_\  M__ (FO
MHO\ .C\Z/]:L?VC_ . K_,/8Q/G3_A2_CG_G]L__  +?_P")H_X4OXY_Y_;/
M_P "W_\ B:^BZ*/]:L?VC_X"O\P]C$^=/^%+^.?^?VS_ / M_P#XFC_A2_CG
M_G]L_P#P+?\ ^)KZ+YHH_P!:L?VC_P" K_,/8Q/G3_A2_CG_ )_;/_P+?_XF
MC_A2_CG_ )_;/_P+?_XFOHO\Z*/]:L?VC_X"O\P]C$^=/^%+^.?^?VS_ / M
M_P#XFC_A2_CG_G]L_P#P+?\ ^)KZ+YH_.C_6K']H_P#@*_S#V,3YT_X4OXY_
MY_;/_P "W_\ B:/^%+^.?^?VS_\  M__ (FOHOFC\Z/]:L?VC_X"O\P]C$^=
M/^%+^.?^?VS_ / M_P#XFC_A2_CG_G]L_P#P+?\ ^)KZ+HYH_P!:L?VC_P"
MK_,/8Q/G3_A2_CG_ )_;/_P+?_XFC_A2_CG_ )_;/_P+?_XFOHNC\Z/]:L?V
MC_X"O\P]C$^=/^%+^.?^?VS_ / M_P#XFC_A2_CG_G]L_P#P+?\ ^)KZ+HYH
M_P!:L?VC_P" K_,/8Q/G3_A2_CG_ )_K/_P+?_XFD_X4QXX_Y_K/_P "W_\
MB:^BSG-<W9>-]$U#Q;=>&;>>4ZG; ^9&8R%&,9Y_&C_6G'_W?_ ?^"'L(GC
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M_L:/^$)^,_\ T-:?^!/_ -C7N^*,4 >$?\(3\9_^AK3_ ,"?_L:/^$)^,_\
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M_K5[%BC%+^U*O\L?_ 4'L8]V>._\(I\5?^ADC_[^_P#UJ/\ A$_BM_T,D?\
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M/_OY_P#6I/\ A$_BK_T,D?\ W\_^M7L6*,4?VI5_EC_X"@]C$\>_X1/XJ_\
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MQB>._P#")_%7_H9(_P#OY_\ 6I?^$4^*O_0R1_\ ?W_ZU>PXHQ1_:E7^6/\
MX"@]C$\=_P"$3^*O_0R1_P#?S_ZU+_PB?Q5_Z&2/_OY_]:O8<44?VI5_EC_X
M"@]C$\>_X1/XJ_\ 0R1_]_/_ *U'_")_%7_H9(_^_G_UJ]AQ1BC^U*O\L?\
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M/_K5[#BBC^U*O\L?_ 4'L8GCW_"*?%7_ *&2/_O[_P#6I/\ A%/BK_T,D?\
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M_P"$4^*O_0R1_P#?W_ZU>Q8HQ2_M2K_+'_P%![&)X]_PBGQ5_P"ADC_[^_\
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MM/\ ^AK7T;7YIQ3_ +^O\,?R9V4/A"BBBOES<**** "BBB@ HHHH \Q^/?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P")_DCS[]HW_D4-*_Z_?_937JVA?\B_IO\ UZQ?^@BO*?VC?^10TK_K]_\
M937JVA?\B_IO_7K%_P"@BMSRC0HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB@!:*3(HR#0 M%)D>M&X9QF@!:*3</6ES0 449HS0 44F<T9% "T4F1ZT9%
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MUR/:OG'5OAI\5]=U&SO]3N[6XNK,Y@E:=08^<]AZUM'0/CGN_P"0U#^$R?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4U>*=6R/)"BBBF 4444 %%%% !1110 4444 %%%% !1110 444G>@ (!ZBC
MH-&:5P @4;1C':DSS2!LTP%P*1D#*58 JPP0>XI<T;A2 \RN?A));W<[>'_%
M6IZ/9SN7:TA.4#'KCTKH-(\":;H?A6]T.REEW7BM]HNG^:1V88+'-=7GZTA'
MYT SFO\ A$8_^$"'A7[9)L%N(/M&T;L=<XJEKW@0:Q#HOV75[BPO-) 6*YA
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M:U@OXK]#UJR?U"EZL]^S1GWI@D&>&6E!!/M6UT>1J.S@=:=30 13J8PHHHH
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M--+&F [F@4W)]:4$G!I7 =13=W/2F[CGV'K18"2BD!R*6F 4"D)IH8__ %Z
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M@5NRC]S)_NG^5>=-*+:3N:Q=SC/AYKMYJ/A"XU+5[LS-%<SAI6&-J*?\*Q?
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M WB/5KV?4-!\11QKK&F$;Y(ONS1G[K@>]=/JNJ1:1I=Q?2Q32I"N2D*;G;V
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_9?^ G:_VWI?_00MO^_HH_MO2_\ H(6W_?T5Q7_"HM'_ .?V\_,4?\*BT?\
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M_E7WB]CE_P#S]E_X"=K_ &WI?_00MO\ OZ*/[;TO_H(6W_?T5Q7_  J+1_\
MG\N_S%'_  J+1_\ G]O/S%'-5_E_$/99=_S]E_X"=K_;>E_]!"V_[^BC^V]+
M_P"@A;?]_17%?\*BT?\ Y_;O\Q1_PJ+1_P#G]O/S%'-5_E_$?LLN_P"?LO\
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M^_HI/[;TK_H(6W_?T5Q?_"HM'_Y_;S\Q1_PJ+1_^?R[_ #%'-5_E_$?LLO\
M^?LO_ 3M?[;TK_H(6W_?T4?VWI7_ $$+;_OZ*XK_ (5%H_\ S^WGYBC_ (5%
MH_\ S^WGYBCFJ_R_B+V67?\ /V7_ ("=K_;>E_\ 00MO^_HH_MO2_P#H(6W_
M ']%<5_PJ+1_^?R[_,4?\*BT?_G]O/S%'-5_E_$?LLO_ .?LO_ 3M/[;TO\
MZ"%M_P!_12_VWI?_ $$+;_OZ*XK_ (5%H_\ S^W?YBC_ (5%H_\ S^WGYBCF
MJ_R_B'LLN_Y^R_\  3M?[;TO_H(6W_?T4G]M:7_T$+;_ +^BN+_X5%H__/Y=
M_F*/^%1:/_S^W?YBCFJ_RK[P]EE__/V7_@)VO]MZ5_T$+;_OZ*/[;TO_ *"%
MM_W]%<5_PJ+1_P#G]O/S%'_"HM'_ .?V[_,4<U7^5?>'LLO_ .?LO_ 3M?[;
MTO\ Z"%M_P!_11_;>E_]!"V_[^BN*_X5%H__ #^W?YBC_A46C_\ /[=_F*.:
MK_+^(>QR_P#Y^R_\!.U_MO2_^@A;?]_11_;>E_\ 00MO^_HKBO\ A46C_P#/
M[>?F*/\ A46C?\_MY^8HYJO\OXB]EEW_ #]E_P" G:_VWI?_ $$+;_OZ*/[;
MTO\ Z"%M_P!_17%?\*BT?_G]O/S%'_"HM'_Y_;S\Q1S5?Y?Q#V67?\_9?^ G
M:_VWI?\ T$+;_OZ*/[;TK_H(6W_?T5Q7_"HM'_Y_;O\ ,4?\*BT?_G]N_P Q
M1S5?Y?Q'[++O^?LO_ 3M?[;TO_H(6W_?T4?VWI7_ $$+;_OZ*XK_ (5%H_\
MS^W?YBC_ (5%H_\ S^W?YBCFJ_R_B'LLN_Y^R_\  3M?[;TO_H(6W_?T4?VW
MI?\ T$+;_OZ*XK_A46C_ //[>?F*/^%0Z/\ \_MY^8HYJO\ +^(>RR[_ )^R
M_P# 3M?[;TO_ *"%M_W]%']MZ7_T$+;_ +^BN*_X5%H__/[>?F*/^%1:.?\
ME]O/S%'-5_E_$7LLN_Y^R_\  3M?[;TO_H(6W_?T4?VWI7_00MO^_HKBO^%1
M:/\ \_MY^8H_X5%H_P#S^WGYBCFJ_P OXC]EEW_/V7_@)VO]MZ5_T$+;_OZ*
M/[;TO_H(6W_?T5Q7_"HM'_Y_;S\Q1_PJ+1_^?R[_ #%'-5_E_$7LLN_Y^R_\
M!.U_MO2_^@A;?]_11_;>E_\ 00MO^_HKBO\ A46C_P#/Y=_F*7_A46C_ //[
M>?F*.:K_ "K[Q^QR_P#Y^R_\!.T_MO2_^@A;?]_11_;>E_\ 00MO^_HKBO\
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MXW_\E#\&?]=!_P"C5KW;O7A/QO\ ^2A^#/\ KH/_ $:M>[=Z %HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\TKF_CW_ ,DNN/\ KYA_G72?#;_DF_A__KS2@#JJ*** "BBB@ HHHH ****
M#M7A/P-_Y'OQE_UU/_HQJ]V[5X3\#?\ D>_&7_74_P#HQJ /=J*** "BBB@
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MX&_\CWXR_P"NI_\ 1C5[M7A/P-_Y'OQE_P!=3_Z,:@#W:BBB@ HHHH ****
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M .!#?XT :O\ PM7P-_T,EG^9_P */^%J^!O^ADL_S/\ A65_PH[P)_T#)?\
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M_P S_A1_PM7P-_T,EG^9_P *RO\ A1W@3_H&2_\ @0W^-'_"CO G_0,E_P#
MAO\ &@#5_P"%J^!O^ADL_P S_A1_PM7P-_T,EG^9_P *RO\ A1W@3_H&2_\
M@0W^-'_"CO G_0,E_P# AO\ &@#5_P"%J^!O^ADL_P S_A1_PM7P-_T,EG^9
M_P *RO\ A1W@3_H&2_\ @0W^-'_"CO G_0,E_P# AO\ &@#5_P"%J^!O^ADL
M_P S_A1_PM7P-_T,EG^9_P *RO\ A1W@3_H&2_\ @0W^-'_"CO G_0,E_P#
MAO\ &@#5_P"%J^!O^ADL_P S_A1_PM7P-_T,EG^9_P *RO\ A1W@3_H&3?\
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MEG^9_P */^%J^!O^ADL_S/\ A65_PH[P)_T#)?\ P(;_ !H_X4=X$_Z!DO\
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M .!#?XT :W_"U? W_0R6?YG_  H_X6KX&_Z&2S_,_P"%97_"CO G_0,E_P#
MAO\ &C_A1W@3_H&2_P#@0W^- &K_ ,+5\#?]#)9_F?\ "C_A:O@;_H9+/\S_
M (5E?\*.\"?] R7_ ,"&_P :/^%'>!/^@9+_ .!#?XT :O\ PM7P-_T,EG^9
M_P */^%J^!O^ADL_S/\ A65_PH[P)_T#)?\ P(;_ !H_X4=X$_Z!DO\ X$-_
MC0!J_P#"U? W_0R6?YG_  H_X6KX&_Z&2S_,_P"%97_"CO G_0,E_P# AO\
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MX1T631-,E2X(^TW5P]S,%Y"LYSM![X]:Z +S[4;>GM0 ZBBB@ HHHH ****
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M#7$[@XE'7 ';BK^H^+F%OIL44D5K+?H6::4_+$ .<>_I6K'HI2[UB;SLG4
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M_P +A\>?]!W_ ,E(/_B*/]4,=_-'[W_D'UB)]545\J_\+A\>?]!W_P E(/\
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M_P#$4?ZH8[^:/WO_ "#ZQ$^JJ*^5?^%P^//^@[_Y*0?_ !%'_"X?'G_0=_\
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M!_\ $4?\+A\>?]!W_P E(/\ XBC_ %0QW\T?O?\ D'UB)]545\J_\+A\>?\
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<:55P3GU/M17W&(QN&IU7"=1)KHV<RC)K1'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img_021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_021.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %5 V4# 2(  A$! Q$!_\0
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M3Z5D>%?B1X?\7WLEEI\D\5VB[Q#<Q%&=?[P]13_UIQ_:/_@*_P Q^P@>1?\
M"EO'/_/]9_\ @6__ ,32_P#"EO'/_/\ 6?\ X%O_ /$U]%@TN:?^M./[1_\
M 5_F+V,3YR_X4MXY_P"?ZS_\"W_^)H_X4MXY_P"?ZS_\"W_^)KZ,S1FC_6G'
M]H_^ K_,/81/G/\ X4MXY_Y_K/\ \"W_ /B:/^%+>.?^?ZS_ / M_P#XFOHS
M-&:7^M./[1_\!7^8>Q@?.?\ PI;QS_S_ %G_ .!;_P#Q-'_"EO'/_/\ 6?\
MX%O_ /$U]&9HS1_K3C^T?_ 5_F'L8'SG_P *6\<_\_UG_P"!;_\ Q-'_  I;
MQS_S_6?_ (%O_P#$U]&9HS3_ -:<?VC_ . K_,/8P/G/_A2WCG_G^L__  +?
M_P")H_X4MXY_Y_K/_P "W_\ B:^C,T9H_P!:<?VC_P" K_,/81/G/_A2WCG_
M )_K/_P+?_XFC_A2WCG_ )_K/_P+?_XFOHS/M1D^E'^M./[1_P# 5_F'L(GS
MG_PI;QS_ ,_UG_X%O_\ $T?\*6\<_P#/]9_^!;__ !-?1F?:C-'^M./[1_\
M 5_F'L(GSG_PI;QS_P _UG_X%O\ _$T?\*6\<_\ /]9_^!;_ /Q-?1F:,GTH
M_P!:<?VC_P" K_,/81/G/_A2WCG_ )_K/_P+?_XFC_A2WCG_ )_K/_P+?_XF
MOHS)]*,T?ZTX_M'_ ,!7^8>PB?.?_"EO'/\ S_6?_@6__P 31_PI;QS_ ,_U
MG_X%O_\ $U]&9HS1_K3C^T?_  %?YA[")\Y_\*6\<_\ /]9_^!;_ /Q-'_"E
MO'/_ #_6?_@6_P#\37T9D^E&3Z4?ZTX_M'_P%?YA[")\Y_\ "EO'/_/]9_\
M@6__ ,31_P *6\<_\_UG_P"!;_\ Q-?1F3Z49H_UIQ_:/_@*_P P]A$^<_\
MA2WCG_G^L_\ P+?_ .)H_P"%+>.?^?ZS_P# M_\ XFOHS-&?:C_6G']H_P#@
M*_S#V$3YS_X4MXY_Y_K/_P "W_\ B:/^%+>.?^?ZS_\  M__ (FOHS)]*,^U
M'^M./[1_\!7^8>PB?.?_  I;QS_S_6?_ (%O_P#$T?\ "EO'/_/]9_\ @6__
M ,37T9FC-'^M./[1_P# 5_F'L(GSG_PI;QS_ ,_UG_X%O_\ $T?\*6\<_P#/
M]9_^!;__ !-?1F3Z49/I1_K3C^T?_ 5_F'L(GSG_ ,*6\<_\_P!9_P#@6_\
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M (%O_P#$U]%Y]J7-'^M./[1_\!7^8>Q@?.?_  I;QS_S_6?_ (%O_P#$T?\
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M_P!9_P#@6_\ \37T9FCM1_K3C^T?_ 5_F'L(GSG_ ,*7\<_\_P!9_P#@6_\
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M_)/(O^OQ/Y&N]\%_\B5HO_7G'_Z"*X+]H7_DGD7_ %^)_(UWO@O_ )$K1?\
MKSC_ /010!NT444 %-[TZF]Z3 \6UC_DX[2_^N:_^@FO:J\5UC_DXW2_^N8_
M]!->U5Z6.VI?X49T^HM%%%><:!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110,**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "F3?ZB3_ '3_ "I],F_U$G^Z?Y4UN!\7:=_RT_#^M%&G?\M/P_K17[E5
M^)GF(]&^"W_)4+S_ *]I_P#T-:^A;VTM[ZTEM;N)9;>5=LD;_=8>AKYZ^"W_
M "5"\_Z]I_\ T-:^BY%#(5894C!'M7YGQ5_OZ_PQ_)G90^$I:=9:=8VZIIMO
M:P0=A;HH!Q].M4=<\8:!X:*+K&K6]H[C*1NWS,/7%<1<^$_$W@2[DU#P7<MJ
M&F2.9)M%NGR>3D^43W]OYUR;:JWB'QY<:[I>@V>L7<ELL%QHVID1SV;KUVAN
M&!]0*^7-SV.QU+P[XQT]VM)K'5;8'#C:' /N#TK3T_3K32[-+.QMX[>WCSLC
M08"YYKSSX=^&M9L_%&KZ]J>C6>B17<*0QV%JP(X.=QQQFO31TIB%HHHH&(>E
M<1XKU'Q]:ZJJ>&M(L+JP\H$RW$P4A^_&>@KMSTKB?BCXD;PWX$OIX7(N[D?9
MK<#KO;C(^@S4L#-^'_CG6O$VDZY>:K96\/\ 9S-'&T!)1V4$D9[]!6;X5\8_
M$;Q*ECJ,>A::=(GEPTWFX;8&P3C/L:Z?P;X<M_#7PYMM-N&6'=;F2[E)QAG&
M6)/MFO-?$.DK\-#HE[X6\47<_GW2Q?V?).)$E1CDE5'0?XU7V@Z'O8//!XIV
M14<;%XE8KM8@$CT-<SXGT_Q=>7EN_A[5K:RMU0B5)8MQ9L\&D(Y#]H7_ ))Y
M%_U^)_(UWO@S_D2M%_Z\X_\ T$5XM\7].\96G@I'U[6K6[M?M*CRHH=K;N<'
M/I7M/@O_ )$K1<_\^<?_ *#3 W:*** "FTO:DY]*3 \3UB1?^&D=,7<-P1>/
M^ &O:\BO)?&_@;58?%USX]T_48H7LK?S$B=-V=JG(_&NB^%OB/4O%7A5M0U1
MT>?SV4%5QA:[JW/5I1J=(V1$;1=CN@:6FBG5Q%A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%)2T %
M%&:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $S2U@:Y
MJE]97]K;621L\X. X[U!]L\3C_ETMOS_ /KT =-17,?;?%'_ #YV_P"?_P!>
MC[;XH_Y\[?\ /_Z] SIZ*YC[;XH_Y\[?\_\ Z]'VWQ1_SYV_Y_\ UZ .GHKF
M/MOBC_GSM_S_ /KT?;?%'_/G;_G_ /7H Z>BN8^V^*/^?.W_ #_^O1]M\4?\
M^=O^?_UZ .GHKF/MOBC_ )\[?\__ *]'VWQ1_P ^=O\ G_\ 7H Z>BN8^V^*
M/^?.W_/_ .O1]M\4?\^=O^?_ ->@#IZ*YC[;XH_Y\[;\_P#Z]'VWQ1_SYV_Y
M_P#UZ .GHKF/MOBC_GSMOS_^O1]M\4?\^=O^?_UZ .GHKF/MOBC_ )\[?\__
M *]'VWQ1_P ^=O\ G_\ 7H Z>BN8^V^*/^?.W_/_ .O1]M\4?\^=O^?_ ->@
M#IZ*YC[;XH_Y\[?\_P#Z]'VWQ1_SYV_Y_P#UZ .GHKF/MOBC_GSM_P __KT?
M;?$__/G;_G_]>@#IZ*YC[;XG_P"?.W_/_P"O1]M\4?\ /G;_ )__ %Z .GHK
MF/MOBC_GSM_S_P#KT?;?%'_/G;_G_P#7H Z>BN8^V^*/^?.W_/\ ^O1]M\4?
M\^=O^?\ ]>@#IZCG/[B3_=/\JYT7OB?/_'G;?G_]>J\VL:U!<007L%O&EP=H
MV\GWIK<#Y9T[_EI^']:*-._Y:?A_6BOW*K\3/,1Z-\%O^2H7G_7M/_Z&M?1;
MGY?Y5\Z_!;_DJ%Y_U[3_ /H:U[WKLNHPZ)>2:1#'/J"1DP12?==NP-?F?%7^
M_K_#'\F=M#X3Y^FOM,NM6U-_'/B3Q%I^LPW4BQ0VP81J@/RE,#'2NN\*^$!X
MZ\#V][K,ES!JL,T@T_50/+NC&#\C/_>_&HV^,3Z=.D7C'P3=6DZC'FK$'!8=
M<;A_6KH_:!\'J@Q;ZD&'1/)'Y=:^8-CI/!\GC+3]1ET7Q,D5[;QQ[[?58N/,
M_P!EQZUVZD8KQZ3XX2ZI*;?POX4U'4)B,!I%VA6/3(&>/QKTKPU<:O=:!:SZ
M[;16NI.N9H8SPASP/RH$;%%)FEH&-(ZUC:SX8TKQ#+9R:I9BX:SD\V ,Q 5O
M7 ZUMXHQ2L!5N;.*]M)K6XC62&9"DB'HRG@BN7TGX7^$=$U!+ZQT>-;F,YC:
M1V<(?8$X%=EBC%,!B@@T^C%% CR7]H7_ ))Y%_U^)_(UWO@O_D2M%_Z\X_\
MT$5P7[0O_)/(O^OQ/Y&N]\%_\B5HO_7G'_Z"* -VBBB@ I,4M% &#XS_ .1)
MUK_KRD_]!-<;\"O^1!/_ %\M_(5V7C/_ )$K6O\ KSD_]!-<;\"O^1 /_7RW
M\A7H4_\ <I_XD0_C1Z>*44@I:\XL****8!1110 4444 %%%% !1110 4444
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M "3R+_K\3^1KO?!?_(E:+_UYQ_\ H(H W:*** "@T44 8/C/_D2=:_Z\Y/\
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M\ZAN_"NEW_B2RU^YA=[^R0I;L7.U >OR],^];0'-"T$Q:6BBF 4444 %%%%
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M0 F*85 .0.O7'>I** & 'TI]%% !1BBB@ Q32*=1BA@-P:7FEHH 0"C%+10
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M^[U/0))[VX>>47#J'?KCTKKA26I%*HJD%-=2EJ^G1ZMI-WI\S,D5S"T3LO4
MC'%<!IWPAM-)M?LVF^(M6M8"=Q2-P 6]:],-<CX_U&[TS0HI[*X>"4W"+N4=
MO2M(594]8L5:<80<WT,O_A6,G_0W:W_W]%<M\0O#5[X2\+2:G:>)=7FE$JH%
MDFXP:]CM29+:)R<DH"3^%>?_ !N_Y)W+_P!?,?\ 6N_"5ZD\1",G=-KHO\@E
M;DNCHOA_/-=> M$N+F5I9WM5+NQR6/J:Z>N5^'/_ "3S0?\ KT6NJ%<-9)59
M6[O\S1;(*;N'K2FLGQ%/+:>'[^>!RDT<+,C@?=..M9BG+EBY/H:NX>M+7/\
M@ZZN+[PK8W-U,TL[J2SMU/-=!0*$U.*DNHM%%%!84444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"KRO@LV,=3U)H;7-(74?[.;5+,7W_/N9AO\ RI]1=+E^BE R=H!)]NU+L?\
MNG\J2ZC&T=ZXCXFZQJVD:+IHT:[^R75Y?QV_G%0=H;V--T_PSX]MM4MYK_QK
M%<VB2 RPBV"^8/3/:A.XWH=R>#@D9/0>M']:XKXIV]R/!TFJV,TD5YI,R7D3
M1L1P#\PP.H(KJ='U%-7T:RU*/&VZA60#ZCFFNI/8N5@>(/\ D(Z3_OFM^L#Q
M!_R$M*_WS36XSY7T[_EI^']:*-._Y:?A_6BOW*K\3/,1Z-\%O^2H7G_7M/\
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M\F=E#X3B?BG=+:^";AGUI]'#RHOVJ-6+#GH-O/-<?X<^"OAO4[6WUC4M5O\
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M "BBB@#FM<_Y&72/QK9/6L;7/^1ETCZFMD]:!B4444#"BBB@D****!H****
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MNE\F/_GFG_?(H\F/_GFG_?(H YK_ (2K3O[ES_WQ1_PE6G?W+G_OBNE\F/\
MYYI_WR*/)C_YYI_WR* .:_X2K3O[ES_WQ1_PE6G?W+G_ +XKI?)C_P">:?\
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M*  ]*3TI3TI/2@#Q<?\ )R+_ /7$?^@U[37BP_Y.1?\ ZXC_ -!KVFO2Q_\
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M!S0!WU%<#_PMWPO_ 'KW_P !S1_PMWPO_>O?_ <T =]17 _\+=\+_P!Z]_\
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MV"S_ .?2#_OV*L44#*_V"S_Y](/^_8H^P6?_ #Z0?]^Q5BB@"L;"S_Y](/\
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M,+,Q26$G.QP>1FNG'2@"O]@L_P#GT@_[]BC[!9_\^D'_ '[%6**!E?[!9_\
M/I!_W[%'V"S_ .?2#_OV*L44 5_L%G_SZ0?]^Q1]@L_^?2#_ +]BK%% %;[!
M9_\ /I!_W[%'V"S_ .?2#_OV*LT4"*WV"S_Y](/^_8H-A9_\^D'_ '[%22R+
M$CR,<*H+$^P%>7:9\7&UOX@V.A66E2QZ9=!PEU< J\FW/S*/[N10M0/1[C3[
M5[65([6WWLA5?W8QDBO/_A7\/]0\()JZZU':2"ZF#Q;,-@<^O2NA\=^,4\':
M/%<+;&[O;B806ML&QYCG^E8'ACX@Z[)XJC\,>+=$33;^YC,MM)"VY6'H>OO0
MM1O0]$^P6?\ SZ0?]^Q1]@L_^?2#_OV*\Z\2_$'7$\4W'ASPCHD>IWEE$);N
M223"I_LCWKH? /C2+QKH;WWV8VMU!*8;BW)SL<>_I0A'2?8+/_GT@_[]BC[!
M9_\ /I!_W[%6*6@97^P6?_/I!_W[%'V"S_Y](/\ OV*L44 5_L%G_P ^D'_?
ML4?8+/\ Y](/^_8JQ10!7^P6?_/I!_W[%'V"S_Y](/\ OV*L44 5_L%G_P ^
MD'_?L4GV"S_Y](/^_8J<G!_"O-/B+\5!X.G>ST_3I;V]B"/.[ B&%6Z9;U-
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MD(I:* $Q1@4M% !@4444 %%%% !1110 4444 %%%% "8HP*6B@!"H-&!2T4
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MHHH **** "@T&O/OC#XCU3PQX(-_I-Q]GN3<)'YF 2 <YZTFP/0:,UX*U_\
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MJ&F75FQPMQ$T9/ID8IR)CH>/? CPGI$F@0>)7@8ZG'-)&LN\X"].E6_#V/\
MAI'Q#T_X\Q_):?\ "[P]X\\)7_\ 8M_;6:^'UDDD,NX,[$]-N#GGW%1>+/"'
MC33/B6_BWP?%;W!N8A'+'*P 4XP003R. <TV]1]"/P_Q^TGKA/\ SZG^2UD:
MOX;M/%7[0]YI=]+*EFULLLL<3%?-"J/E/M6_X(\"^*]'^)=SKVORQ7*W5J?-
MN$8?ZQL?(%ZX'2M2U\):S%\<[GQ,]L@TE[4Q++O&=VT#IUZTK:KT#NSSC2/
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M!VMW_P $;+PW!;(VJQ11*\7F  $'GGI3?%O@S7-5^#.G>';2V5]3@$(DC\P
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MWY%>]J<G->9ZIX2UFZ^-FF>)(K=&TN"#8\ID (.#VZ]Z]+3O0GHAO<?1113
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M3E+=Q7Y();L****Z20HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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$;1__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
